data_2kt8_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2kt8 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 63.2 mttp . . . . . 0 N--CA 1.494 1.771 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 22.9 p -117.61 121.87 42.07 Favored 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.831 0.825 . . . . 0.0 109.631 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -102.03 137.64 13.45 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 27.8 mm -87.11 123.21 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.539 -0.977 . . . . 0.0 109.53 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 70.5 t -74.36 134.08 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.509 -0.744 . . . . 0.0 110.13 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 47.0 t30 -128.53 101.31 6.12 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.6 -0.687 . . . . 0.0 109.401 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 24.5 m -136.71 160.58 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.397 -0.814 . . . . 0.0 109.709 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 99.9 p -84.16 -10.37 57.81 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.498 0.666 . . . . 0.0 109.604 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 62.5 p -147.4 -66.79 0.26 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.13 -0.981 . . . . 0.0 109.503 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.5 p -157.52 165.73 34.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.237 -0.915 . . . . 0.0 109.414 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.0 tp -113.44 130.18 56.37 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 121.672 0.749 . . . . 0.0 109.822 -179.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -85.78 145.84 27.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.518 -0.739 . . . . 0.0 109.678 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.7 t -111.51 130.97 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.483 ' NE ' ' O ' ' A' ' 21' ' ' THR . 84.6 mtt85 -111.14 146.36 36.99 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.788 0.804 . . . . 0.0 109.76 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -88.19 -16.59 32.9 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.458 ' O ' ' CD2' ' A' ' 55' ' ' TYR . . . -96.66 -130.92 6.69 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -152.21 -5.58 0.23 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -1.11 . . . . 0.0 108.581 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.437 ' OG ' ' OG ' ' A' ' 23' ' ' SER . 8.5 p -82.38 172.33 13.19 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.354 -0.841 . . . . 0.0 110.761 -179.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.483 ' O ' ' NE ' ' A' ' 16' ' ' ARG . 52.3 p -66.13 -31.21 71.93 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.603 -0.685 . . . . 0.0 110.219 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 38.0 m -138.39 58.71 1.66 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.029 -1.044 . . . . 0.0 108.896 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.437 ' OG ' ' OG ' ' A' ' 20' ' ' SER . 9.5 m -77.69 -79.1 0.12 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.406 -0.809 . . . . 0.0 109.719 -179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -157.03 112.97 2.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.073 -1.017 . . . . 0.0 109.792 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.0 t -80.67 129.45 37.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.347 -0.846 . . . . 0.0 109.589 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.4 pt -111.16 -5.58 11.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.554 -0.717 . . . . 0.0 109.126 179.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 164.89 -157.98 30.62 Favored Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.189 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.0 p -153.88 164.7 37.96 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.163 -1.198 . . . . 0.0 109.721 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 94.7 mt -126.64 151.56 47.87 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.671 0.748 . . . . 0.0 109.571 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' OG1' ' A' ' 33' ' ' THR . 29.7 t -71.18 160.7 32.38 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-O 121.91 0.862 . . . . 0.0 110.598 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.486 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.54 160.23 49.72 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 57.87 4.09 0.26 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.957 -0.731 . . . . 0.0 109.754 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.486 ' H ' ' C ' ' A' ' 31' ' ' GLY . 86.0 m -70.36 135.94 49.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.22 -0.925 . . . . 0.0 110.275 179.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 10.2 mtpm? -83.59 140.56 32.15 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.577 -0.702 . . . . 0.0 110.251 -179.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.2 m -126.73 130.88 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.619 -0.676 . . . . 0.0 109.341 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 p -79.83 129.31 34.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.537 -0.727 . . . . 0.0 109.719 -179.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 97.0 mt -112.24 129.38 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 CA-C-O 121.482 0.658 . . . . 0.0 109.358 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.2 m -110.18 -2.51 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.01 177.92 47.9 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.307 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.437 ' CD ' ' N ' ' A' ' 41' ' ' GLU . 9.9 tm-20 -133.09 155.4 49.3 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.423 -1.045 . . . . 0.0 109.402 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.437 ' N ' ' CD ' ' A' ' 40' ' ' GLU . 48.6 tp10 -156.31 115.76 3.52 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.493 -0.754 . . . . 0.0 109.149 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 63.68 -142.9 47.32 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.95 20.2 5.04 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.418 -1.048 . . . . 0.0 109.022 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -130.19 150.82 51.27 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.483 -0.761 . . . . 0.0 109.656 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -102.94 140.6 37.01 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.67 0.747 . . . . 0.0 109.988 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -91.16 130.39 37.05 Favored 'General case' 0 N--CA 1.487 1.425 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.2 pt -128.72 157.15 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 CA-C-O 121.766 0.793 . . . . 0.0 110.199 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -82.08 97.3 8.09 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.594 0.711 . . . . 0.0 109.48 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -85.18 144.85 27.91 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.365 -0.834 . . . . 0.0 109.825 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -66.76 100.62 0.72 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.493 -0.754 . . . . 0.0 110.154 -179.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 116.87 -23.4 10.08 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 109.187 -1.565 . . . . 0.0 109.187 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 10.8 t -169.08 -156.08 0.15 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.065 -1.256 . . . . 0.0 110.101 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -108.49 122.77 47.74 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.706 0.765 . . . . 0.0 109.716 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.41 148.76 19.28 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.458 ' CD2' ' O ' ' A' ' 18' ' ' GLY . 87.9 m-85 -127.16 132.27 50.55 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.669 -0.901 . . . . 0.0 109.238 179.306 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.8 m -138.19 153.45 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.396 -0.815 . . . . 0.0 109.923 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.07 151.23 40.22 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-O 121.574 0.702 . . . . 0.0 110.849 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -67.25 -20.34 65.65 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.526 -0.734 . . . . 0.0 110.548 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -65.38 -32.9 74.78 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.213 -0.93 . . . . 0.0 110.565 -178.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -87.91 1.45 54.01 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.854 -1.154 . . . . 0.0 109.396 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.408 HG23 HD12 ' A' ' 61' ' ' ILE . 37.8 mm -108.51 127.25 65.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.411 -0.806 . . . . 0.0 109.346 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 37.5 ttpt -140.58 150.43 43.63 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.815 0.817 . . . . 0.0 110.385 -179.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 54.39 72.3 0.47 Allowed 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.72 0.771 . . . . 0.0 110.254 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.9 mt . . . . . 0 N--CA 1.491 1.607 0 O-C-N 121.287 -0.883 . . . . 0.0 109.402 179.574 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt . . . . . 0 N--CA 1.496 1.826 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 17.4 p -118.36 116.44 26.74 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.513 0.673 . . . . 0.0 109.206 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -93.55 125.62 8.3 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.546 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.7 mp -81.08 124.5 38.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.295 -1.121 . . . . 0.0 109.58 -179.71 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 76.6 t -77.78 132.67 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.343 -0.848 . . . . 0.0 109.956 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -126.92 98.22 5.26 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.5 m -137.23 158.92 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.58 -0.7 . . . . 0.0 109.616 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.9 m -86.06 -12.57 49.79 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.551 -0.718 . . . . 0.0 109.357 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 71.4 m -133.31 -79.51 0.48 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.462 -0.774 . . . . 0.0 109.204 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.3 p -158.29 165.1 35.62 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.173 -0.954 . . . . 0.0 109.725 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 34.0 tp -112.8 131.58 55.63 Favored 'General case' 0 N--CA 1.498 1.963 0 CA-C-O 121.545 0.688 . . . . 0.0 109.561 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -92.17 143.69 26.17 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.503 -0.748 . . . . 0.0 110.063 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 71.1 t -92.57 132.02 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.479 -0.763 . . . . 0.0 109.122 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -102.16 130.53 48.81 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.395 -0.816 . . . . 0.0 110.102 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -70.41 -41.55 72.8 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.719 -0.613 . . . . 0.0 109.821 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -105.7 -171.62 23.65 Favored Glycine 0 N--CA 1.497 2.766 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.106 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.05 57.99 0.76 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.699 -0.883 . . . . 0.0 109.124 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.437 ' HG ' ' N ' ' A' ' 21' ' ' THR . 40.7 t -161.33 154.9 21.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.244 -0.91 . . . . 0.0 109.821 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.437 ' N ' ' HG ' ' A' ' 20' ' ' SER . 75.2 p -66.15 -33.09 74.99 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.627 -0.67 . . . . 0.0 109.806 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 47.1 t -79.07 9.18 4.64 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.195 -0.94 . . . . 0.0 108.979 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 94.2 p -69.36 159.46 33.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.492 -0.755 . . . . 0.0 110.427 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -84.16 138.68 32.87 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.471 -0.768 . . . . 0.0 110.837 -179.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.0 t -89.69 130.99 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.541 -0.724 . . . . 0.0 109.792 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 36.8 pt -102.8 -6.59 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.574 -0.703 . . . . 0.0 109.177 179.428 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 169.22 -179.83 41.62 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 119.489 -1.339 . . . . 0.0 110.05 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 63.1 m -133.95 157.03 47.07 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.643 -0.916 . . . . 0.0 109.445 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.1 mt -122.59 148.96 44.61 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 121.544 0.687 . . . . 0.0 109.705 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.0 m -71.18 150.2 45.59 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-O 121.705 0.764 . . . . 0.0 110.519 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.575 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -64.13 163.33 34.45 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 111.099 -0.801 . . . . 0.0 111.099 -179.275 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 37.6 t-20 66.74 -19.64 0.11 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.942 -0.74 . . . . 0.0 110.135 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.575 ' H ' ' C ' ' A' ' 31' ' ' GLY . 33.0 m -67.31 136.4 54.8 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.047 -1.033 . . . . 0.0 110.209 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -90.42 148.81 22.55 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.502 -0.749 . . . . 0.0 109.605 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.5 m -123.51 131.53 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 CA-C-O 121.579 0.704 . . . . 0.0 109.188 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 28.5 m -66.63 130.5 43.39 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.86 -0.525 . . . . 0.0 110.025 -179.166 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.0 mt -110.53 129.78 65.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 19.0 m -112.92 -0.12 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -179.61 -179.31 48.76 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.43 -1.367 . . . . 0.0 110.307 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -139.87 154.08 47.19 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.462 -1.023 . . . . 0.0 109.75 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -153.98 109.05 3.13 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -0.854 . . . . 0.0 109.402 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 59.14 -142.22 46.74 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -83.2 17.85 1.91 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.487 -1.008 . . . . 0.0 109.278 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -129.83 145.57 51.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.615 -0.678 . . . . 0.0 109.514 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 50.4 m-85 -107.68 147.69 30.38 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.605 0.716 . . . . 0.0 109.833 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -90.84 139.29 30.88 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.537 -0.727 . . . . 0.0 109.044 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.4 pt -134.45 158.45 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 CA-C-O 121.665 0.745 . . . . 0.0 110.519 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -84.22 93.59 8.22 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.674 -0.641 . . . . 0.0 109.426 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 82.4 t80 -98.37 135.31 40.14 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.358 -0.839 . . . . 0.0 109.278 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.9 ttpt -49.77 106.72 0.12 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.383 -0.823 . . . . 0.0 110.568 -179.162 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 123.31 -51.76 0.79 Allowed Glycine 0 N--CA 1.496 2.647 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 179.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 22.8 p -158.86 -166.2 1.81 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.132 -1.216 . . . . 0.0 110.124 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 78.3 m80 -90.41 116.87 28.68 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.366 -0.834 . . . . 0.0 109.865 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -86.29 160.75 33.57 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -123.96 136.36 54.26 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.665 -0.903 . . . . 0.0 109.423 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.8 m -136.81 137.24 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.506 -0.746 . . . . 0.0 109.337 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.97 143.67 57.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.599 -0.688 . . . . 0.0 110.632 -179.216 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.9 pttt -62.01 -13.35 24.92 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.544 -0.722 . . . . 0.0 109.422 179.377 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -68.25 -31.0 70.17 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.434 -0.791 . . . . 0.0 110.95 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -93.1 -11.05 33.87 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.792 -1.192 . . . . 0.0 109.769 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.513 ' N ' ' CD1' ' A' ' 61' ' ' ILE . 1.4 mp -94.73 131.63 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.361 -0.837 . . . . 0.0 109.207 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.471 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 65.8 tttm -135.43 155.41 50.59 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.653 -0.655 . . . . 0.0 109.828 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.471 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 11.7 t0 79.39 -66.78 0.17 Allowed 'General case' 0 N--CA 1.495 1.799 0 CA-C-O 121.268 0.556 . . . . 0.0 109.535 179.753 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 91.5 mt . . . . . 0 N--CA 1.488 1.463 0 O-C-N 121.634 -0.666 . . . . 0.0 109.488 -179.442 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.8 mttt . . . . . 0 N--CA 1.493 1.685 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -114.46 126.61 55.16 Favored 'General case' 0 N--CA 1.498 1.975 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.31 140.75 15.2 Favored Glycine 0 N--CA 1.497 2.754 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 23.7 mm -94.33 116.33 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.364 -1.08 . . . . 0.0 108.904 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.3 t -80.35 132.63 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.376 -0.828 . . . . 0.0 109.99 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.6 t30 -132.99 106.9 7.94 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.428 -0.795 . . . . 0.0 109.34 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 11' ' ' SER . 19.6 m -151.65 -12.87 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 24.0 p 43.87 17.79 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.724 -0.61 . . . . 0.0 109.729 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.525 ' N ' ' O ' ' A' ' 9' ' ' VAL . 23.7 m -151.55 35.85 0.57 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.1 t 60.63 145.31 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.793 -0.567 . . . . 0.0 110.437 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 35.9 tp -116.16 133.13 56.36 Favored 'General case' 0 N--CA 1.503 2.209 0 CA-C-O 121.572 0.701 . . . . 0.0 109.613 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 18.9 p30 -80.65 137.34 36.33 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.429 -0.794 . . . . 0.0 109.62 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 73.7 t -90.95 131.25 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.361 -0.837 . . . . 0.0 108.84 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 96.7 mtt-85 -95.9 138.81 33.0 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.001 . . . . 0.0 109.981 -179.123 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 50.4 tp10 -67.5 -43.67 80.31 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.424 -0.797 . . . . 0.0 109.777 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -119.52 -166.6 13.4 Favored Glycine 0 N--CA 1.499 2.856 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 -178.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.69 56.03 0.88 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.62 -0.929 . . . . 0.0 109.225 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 28.8 t -152.8 151.09 30.05 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.264 -0.898 . . . . 0.0 109.725 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 41.7 p -68.06 -23.12 64.92 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.394 -0.816 . . . . 0.0 109.438 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 86.1 p -83.65 -0.48 50.83 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.423 -0.798 . . . . 0.0 109.429 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 99.8 p -64.84 159.42 22.61 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.222 -0.924 . . . . 0.0 110.387 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 22.6 pttp -92.6 140.18 29.81 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.49 -0.756 . . . . 0.0 110.407 -179.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 22.6 t -86.69 129.81 37.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.383 -0.823 . . . . 0.0 109.909 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 36.3 pt -102.39 -7.4 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.512 -0.743 . . . . 0.0 109.157 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.77 -162.81 35.22 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 24.8 p -152.78 164.04 38.57 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.299 -1.118 . . . . 0.0 109.433 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.3 mt -124.26 148.48 47.35 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.546 -0.721 . . . . 0.0 109.39 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.9 t -69.94 152.02 44.95 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.493 -0.755 . . . . 0.0 110.622 -179.016 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.46 160.55 32.24 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 12.3 m120 57.31 33.22 22.99 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.653 -0.91 . . . . 0.0 109.563 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 35.1 m -105.02 137.02 43.41 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.57 -0.706 . . . . 0.0 109.832 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -79.76 140.32 36.95 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 109.057 -0.719 . . . . 0.0 109.057 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.8 m -126.77 130.5 71.53 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.416 -0.803 . . . . 0.0 109.397 179.565 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 54.6 m -72.84 126.39 29.81 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.41 -0.806 . . . . 0.0 109.628 -179.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 93.1 mt -107.33 126.71 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.639 -0.663 . . . . 0.0 109.65 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 30.9 m -111.13 -3.26 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 177.21 -174.14 46.78 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -141.05 155.16 46.21 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.323 -1.104 . . . . 0.0 109.441 179.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -151.27 112.06 4.25 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 109.598 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.461 ' O ' ' NZ ' ' A' ' 58' ' ' LYS . . . 61.92 -144.93 49.19 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.504 ' C ' ' HZ1' ' A' ' 58' ' ' LYS . . . -84.36 24.96 0.91 Allowed 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.657 -0.908 . . . . 0.0 109.384 -179.8 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 -131.58 152.68 50.59 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.602 -0.686 . . . . 0.0 109.341 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 9.1 m-85 -103.16 139.08 39.12 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.413 -0.804 . . . . 0.0 108.855 179.592 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -90.71 129.72 36.78 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 33.3 pt -130.72 154.47 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.483 -0.761 . . . . 0.0 109.588 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -83.22 100.3 10.5 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.455 -0.778 . . . . 0.0 109.341 -179.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -83.64 147.1 27.9 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.351 -0.843 . . . . 0.0 109.797 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 8.0 mtmp? -62.21 102.96 0.34 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.267 -0.895 . . . . 0.0 110.861 -179.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.43 ' O ' ' OG ' ' A' ' 52' ' ' SER . . . 101.63 -10.28 57.5 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.43 ' OG ' ' O ' ' A' ' 51' ' ' GLY . 50.4 m -168.29 -166.09 0.67 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.861 -1.376 . . . . 0.0 110.035 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -110.28 115.92 30.55 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.52 -0.737 . . . . 0.0 109.085 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.2 152.08 21.07 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.371 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -126.55 137.79 53.39 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.639 -0.918 . . . . 0.0 109.021 179.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.3 m -135.59 139.56 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.339 -0.85 . . . . 0.0 109.753 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.09 149.58 49.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.575 -0.703 . . . . 0.0 110.593 -179.378 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.504 ' HZ1' ' C ' ' A' ' 43' ' ' ALA . 64.2 mttp -62.23 -33.73 75.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.463 -0.773 . . . . 0.0 109.772 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 58.7 mp0 -55.1 -30.98 60.84 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.354 -0.841 . . . . 0.0 110.086 -178.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -92.84 -3.98 53.73 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.966 -1.084 . . . . 0.0 109.353 -179.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.1 mm -114.46 129.18 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 121.541 -0.724 . . . . 0.0 109.516 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.577 ' O ' ' N ' ' A' ' 64' ' ' ILE . 21.7 ptmt -141.14 -174.16 3.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.418 -0.801 . . . . 0.0 109.581 179.852 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.458 ' O ' ' O ' ' A' ' 64' ' ' ILE . 91.1 m-20 56.69 -75.48 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.577 ' N ' ' O ' ' A' ' 62' ' ' LYS . 97.7 mt . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.393 0.616 . . . . 0.0 110.01 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.5 mtmp? . . . . . 0 N--CA 1.492 1.642 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.459 ' CG2' ' HZ2' ' A' ' 34' ' ' LYS . 62.0 p -121.35 125.21 46.42 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.567 -0.708 . . . . 0.0 109.464 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -102.86 137.32 13.34 Favored Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.43 HD13 HG21 ' A' ' 6' ' ' ILE . 17.4 mm -95.5 120.07 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.275 -1.133 . . . . 0.0 109.449 179.617 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 74.1 t -75.67 134.2 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.566 -0.709 . . . . 0.0 110.321 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' A' ' 60' ' ' TYR . 3.6 p-10 -138.72 99.74 3.88 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.437 -0.789 . . . . 0.0 109.385 179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 5.7 m -134.98 135.73 52.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.577 -0.702 . . . . 0.0 109.682 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 78.2 p -62.52 -40.49 96.94 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.614 -0.679 . . . . 0.0 109.638 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 68.9 m -101.8 -79.19 0.52 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.447 -0.783 . . . . 0.0 109.877 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 45.5 m -161.51 167.06 26.13 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.334 -0.854 . . . . 0.0 109.596 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 38.6 tp -116.95 130.17 56.53 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.64 -0.662 . . . . 0.0 109.789 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . 0.404 HD21 ' HG ' ' A' ' 28' ' ' SER . 9.2 m120 -91.16 142.29 27.89 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.397 -0.814 . . . . 0.0 109.686 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 96.3 t -88.89 128.08 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.324 -0.86 . . . . 0.0 109.21 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.714 HH21 ' H ' ' A' ' 20' ' ' SER . 67.5 mtp180 -107.52 133.16 52.39 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.549 -0.719 . . . . 0.0 109.962 -179.357 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.3 pt-20 -70.7 -35.01 72.55 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.488 -0.757 . . . . 0.0 109.879 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -120.95 -148.8 8.05 Favored Glycine 0 N--CA 1.498 2.774 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 -178.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -147.27 75.05 1.36 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.574 -0.957 . . . . 0.0 108.834 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.714 ' H ' HH21 ' A' ' 16' ' ' ARG . 15.2 m -141.85 44.95 1.7 Allowed 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.633 ' N ' ' NH2' ' A' ' 16' ' ' ARG . 59.0 p 50.37 -84.81 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.769 0 CA-C-O 121.319 0.58 . . . . 0.0 110.471 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.527 ' N ' ' O ' ' A' ' 20' ' ' SER . 23.0 t -71.39 44.4 0.09 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.354 -0.841 . . . . 0.0 109.002 -179.45 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.477 ' H ' ' C ' ' A' ' 21' ' ' THR . 15.4 p -78.58 165.22 23.94 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.355 -0.84 . . . . 0.0 110.411 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -77.3 138.54 39.42 Favored 'General case' 0 N--CA 1.488 1.473 0 CA-C-O 121.721 0.772 . . . . 0.0 110.637 -179.583 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 76.5 t -93.49 129.9 43.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 39.4 pt -109.19 -7.1 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.6 -0.687 . . . . 0.0 109.556 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 179.12 -173.53 45.65 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 119.287 -1.435 . . . . 0.0 110.349 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.404 ' HG ' HD21 ' A' ' 14' ' ' ASN . 54.8 m -144.0 154.06 42.87 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.405 -1.056 . . . . 0.0 109.789 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.7 mt -124.89 148.78 48.12 Favored 'General case' 0 N--CA 1.497 1.884 0 CA-C-O 121.546 0.689 . . . . 0.0 109.63 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 90.6 p -79.08 165.06 23.78 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 121.72 0.772 . . . . 0.0 110.854 -179.148 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -65.78 155.27 50.4 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 12.0 m120 57.41 31.59 20.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.73 -0.865 . . . . 0.0 109.86 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 37.0 m -91.73 129.94 37.61 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.216 -0.928 . . . . 0.0 109.835 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.459 ' HZ2' ' CG2' ' A' ' 4' ' ' THR . 63.9 tttm -80.11 133.33 36.08 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.514 -0.741 . . . . 0.0 109.639 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 m -128.1 133.29 67.4 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.303 -0.873 . . . . 0.0 110.037 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 21.6 m -81.56 131.23 35.27 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.685 -0.634 . . . . 0.0 109.451 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 91.1 mt -104.91 126.0 59.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.593 -0.692 . . . . 0.0 109.785 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 15.8 m -109.66 -1.43 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.46 -177.79 48.42 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -142.23 160.84 39.45 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.342 -1.093 . . . . 0.0 109.631 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -152.84 112.57 3.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.241 -0.912 . . . . 0.0 109.546 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.22 -135.16 47.88 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.82 25.91 1.94 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.462 -1.022 . . . . 0.0 109.006 -179.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 65.3 m-85 -132.4 151.33 51.92 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.685 -0.634 . . . . 0.0 109.452 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 31.5 m-85 -107.84 139.49 42.35 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.528 0.68 . . . . 0.0 109.894 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -92.42 132.63 36.61 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 36.7 pt -128.4 156.88 40.9 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.556 -0.715 . . . . 0.0 110.205 -179.638 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -82.15 97.56 8.27 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.66 -0.65 . . . . 0.0 109.483 -179.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.411 ' CG ' ' N ' ' A' ' 50' ' ' LYS . 90.0 t80 -85.49 161.46 19.36 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.525 -0.734 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.411 ' N ' ' CG ' ' A' ' 49' ' ' TYR . 98.6 mttt -70.91 107.81 4.22 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.415 -0.803 . . . . 0.0 110.267 -179.543 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 98.84 -14.46 61.64 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 81.0 p -169.46 -161.61 0.3 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.942 -1.328 . . . . 0.0 110.145 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -116.43 121.47 41.98 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.628 -0.67 . . . . 0.0 109.571 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.84 163.57 30.84 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.597 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 81.9 m-85 -132.23 137.35 47.52 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.62 -0.929 . . . . 0.0 109.431 179.507 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 30.2 m -138.73 156.49 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.916 0 O-C-N 121.518 -0.739 . . . . 0.0 109.82 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.86 145.54 42.69 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.508 -0.745 . . . . 0.0 110.314 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 10.3 ptmm? -68.71 -13.79 62.6 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.597 -0.69 . . . . 0.0 110.064 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -67.21 -35.99 80.77 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.195 -0.941 . . . . 0.0 110.149 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.424 ' O ' ' OD1' ' A' ' 8' ' ' ASN . 75.7 m-85 -92.14 1.33 57.27 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.079 -1.013 . . . . 0.0 109.602 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.0 mm -113.68 125.49 70.96 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.561 -0.712 . . . . 0.0 109.601 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -142.42 169.83 16.85 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.477 -0.765 . . . . 0.0 109.856 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 47.9 t0 62.28 52.38 3.14 Favored 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.575 0.703 . . . . 0.0 109.787 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt . . . . . 0 N--CA 1.488 1.466 0 O-C-N 121.463 -0.773 . . . . 0.0 109.188 179.571 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 64.5 mttp . . . . . 0 N--CA 1.494 1.77 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 10.1 p -122.86 114.45 20.5 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.506 -0.746 . . . . 0.0 109.315 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -97.3 141.42 15.6 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.425 HD11 HG22 ' A' ' 6' ' ' ILE . 24.4 mm -94.71 119.48 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.381 -1.07 . . . . 0.0 109.225 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.3 t -79.04 125.1 38.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.305 -0.872 . . . . 0.0 109.774 -179.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.4 t30 -105.52 94.95 5.48 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.453 -0.779 . . . . 0.0 109.387 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 2.2 p -144.42 135.49 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.361 -0.837 . . . . 0.0 109.174 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 77.3 p -84.71 -13.73 50.51 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.558 -0.714 . . . . 0.0 109.562 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 66.3 m -117.44 -89.26 0.59 Allowed 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.463 -0.773 . . . . 0.0 109.841 -179.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.9 p -158.58 163.51 36.93 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.914 -1.116 . . . . 0.0 109.751 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 40.2 tp -120.52 131.21 54.59 Favored 'General case' 0 N--CA 1.498 1.968 0 CA-C-O 121.666 0.746 . . . . 0.0 109.626 179.74 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -87.04 146.61 26.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.457 -0.777 . . . . 0.0 109.82 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 74.3 t -104.98 129.0 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.455 -0.778 . . . . 0.0 109.125 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.651 HH22 ' N ' ' A' ' 57' ' ' ALA . 0.6 OUTLIER -107.87 138.71 43.64 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.655 0.741 . . . . 0.0 109.372 -179.617 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -93.3 -21.84 19.34 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.554 -0.716 . . . . 0.0 109.35 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.542 ' C ' ' H ' ' A' ' 20' ' ' SER . . . -101.97 7.52 55.05 Favored Glycine 0 N--CA 1.497 2.748 0 N-CA-C 108.897 -1.681 . . . . 0.0 108.897 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . 56.83 3.97 0.15 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.478 -1.013 . . . . 0.0 109.392 -179.44 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.542 ' H ' ' C ' ' A' ' 18' ' ' GLY . 7.6 m -80.87 156.81 25.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.316 -0.865 . . . . 0.0 110.327 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.456 ' O ' ' CB ' ' A' ' 22' ' ' SER . 43.1 p -61.29 101.53 0.17 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.531 -0.731 . . . . 0.0 110.171 -179.852 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.456 ' CB ' ' O ' ' A' ' 21' ' ' THR . 0.7 OUTLIER 79.06 27.65 0.41 Allowed 'General case' 0 N--CA 1.496 1.852 0 CA-C-O 121.639 0.733 . . . . 0.0 109.519 179.587 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.42 ' O ' ' O ' ' A' ' 22' ' ' SER . 0.2 OUTLIER -56.64 -159.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.915 0.864 . . . . 0.0 110.763 -179.747 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 38.1 ttmt -64.32 128.6 36.51 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.616 0.722 . . . . 0.0 109.785 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 91.1 t -92.14 115.26 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 CA-C-O 121.58 0.705 . . . . 0.0 109.277 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.9 pt -103.66 -3.98 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.57 -163.11 36.73 Favored Glycine 0 N--CA 1.488 2.15 0 C-N-CA 119.405 -1.378 . . . . 0.0 110.53 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.5 p -154.02 163.54 39.91 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.311 -1.111 . . . . 0.0 109.221 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.2 mt -124.63 146.39 49.11 Favored 'General case' 0 N--CA 1.497 1.9 0 CA-C-O 121.725 0.774 . . . . 0.0 110.013 -179.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 12.9 m -83.32 162.12 21.21 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-O 121.837 0.827 . . . . 0.0 110.404 -179.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.515 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -65.45 158.35 46.35 Favored Glycine 0 N--CA 1.49 2.296 0 CA-C-O 121.817 0.676 . . . . 0.0 111.583 -179.467 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 59.43 0.04 0.19 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.966 -0.726 . . . . 0.0 110.032 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.515 ' H ' ' C ' ' A' ' 31' ' ' GLY . 30.2 m -72.09 140.88 49.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.244 -0.91 . . . . 0.0 110.505 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -87.41 144.74 26.6 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.528 -0.733 . . . . 0.0 109.592 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.6 m -125.87 132.1 71.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 121.456 -0.777 . . . . 0.0 109.96 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 26.6 m -73.11 104.06 4.06 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.68 -0.637 . . . . 0.0 109.362 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.3 mt -101.73 131.1 50.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.553 0.692 . . . . 0.0 109.521 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.474 ' CG2' ' N ' ' A' ' 39' ' ' GLY . 23.8 m -140.32 -46.51 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.474 ' N ' ' CG2' ' A' ' 38' ' ' VAL . . . -95.41 164.74 24.59 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -179.338 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.447 ' CD ' ' N ' ' A' ' 41' ' ' GLU . 15.8 tm-20 -135.28 146.0 48.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.369 -1.077 . . . . 0.0 109.594 179.63 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.447 ' N ' ' CD ' ' A' ' 40' ' ' GLU . 84.4 tt0 -153.57 109.1 3.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.458 -0.776 . . . . 0.0 109.408 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.431 ' C ' ' H ' ' A' ' 44' ' ' PHE . . . 48.58 -142.28 8.76 Favored Glycine 0 N--CA 1.494 2.509 0 CA-C-O 121.967 0.759 . . . . 0.0 111.269 179.175 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -81.9 28.51 0.42 Allowed 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.435 -1.038 . . . . 0.0 108.738 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.431 ' H ' ' C ' ' A' ' 42' ' ' GLY . 91.0 m-85 -134.01 140.22 46.56 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.516 -0.74 . . . . 0.0 109.137 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -100.7 142.81 31.64 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.495 -0.753 . . . . 0.0 109.276 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.616 ' NZ ' ' ND1' ' A' ' 53' ' ' HIS . 65.1 tttm -90.45 129.03 36.68 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -179.582 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.411 HG22 HD13 ' A' ' 47' ' ' ILE . 32.0 pt -126.57 152.24 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 CA-C-O 121.699 0.761 . . . . 0.0 110.164 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -84.39 92.2 7.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.511 -0.743 . . . . 0.0 109.658 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -79.3 142.11 36.43 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.331 -0.856 . . . . 0.0 110.134 -179.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -58.18 96.46 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.547 -0.721 . . . . 0.0 110.408 -179.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 123.19 -35.83 3.25 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 67.8 p -158.96 -162.96 1.15 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.986 -1.302 . . . . 0.0 109.759 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.616 ' ND1' ' NZ ' ' A' ' 46' ' ' LYS . 97.5 m-70 -106.31 118.26 36.18 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.492 -0.755 . . . . 0.0 109.347 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.15 162.39 22.8 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -126.54 136.56 52.73 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.526 -0.985 . . . . 0.0 109.514 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.8 m -133.67 137.15 53.21 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 CA-C-O 121.477 0.656 . . . . 0.0 109.619 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.651 ' N ' HH22 ' A' ' 16' ' ' ARG . . . -68.85 147.21 52.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.395 -0.816 . . . . 0.0 110.352 -179.61 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.474 ' CB ' ' HZ3' ' A' ' 58' ' ' LYS . 6.4 mtmp? -63.8 -9.03 12.51 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.567 -0.708 . . . . 0.0 109.736 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -68.83 -35.99 77.64 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.108 -0.995 . . . . 0.0 110.096 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -92.96 4.99 53.0 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.052 -1.03 . . . . 0.0 109.203 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 44.8 mm -103.88 129.16 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.39 -0.819 . . . . 0.0 109.513 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 26.2 ttpp -149.88 157.34 43.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.306 -0.872 . . . . 0.0 110.439 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 55.81 52.97 9.98 Favored 'General case' 0 N--CA 1.49 1.57 0 CA-C-O 121.59 0.709 . . . . 0.0 109.498 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt . . . . . 0 N--CA 1.489 1.487 0 O-C-N 121.497 -0.752 . . . . 0.0 109.554 179.904 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.4 mttm . . . . . 0 N--CA 1.494 1.754 0 N-CA-C 109.592 -0.521 . . . . 0.0 109.592 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 67.2 p -134.22 152.32 51.76 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.569 -0.707 . . . . 0.0 109.476 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -135.1 128.67 4.83 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.543 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 2.0 mp -81.99 124.52 39.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.669 -0.901 . . . . 0.0 109.579 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 91.8 t -85.33 116.75 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.506 -0.746 . . . . 0.0 109.732 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -110.19 107.38 17.15 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.521 -0.737 . . . . 0.0 109.663 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 14.9 m -139.33 156.72 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.386 -0.821 . . . . 0.0 109.616 179.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 82.0 p -73.18 -13.81 61.23 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.502 ' OG ' ' N ' ' A' ' 12' ' ' SER . 77.0 p -152.95 -118.61 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.327 -0.858 . . . . 0.0 110.096 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.502 ' N ' ' OG ' ' A' ' 11' ' ' SER . 21.5 m -101.37 161.26 13.75 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.382 -0.824 . . . . 0.0 110.246 -178.835 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 61.6 tp -120.99 133.4 55.27 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.632 0.729 . . . . 0.0 109.653 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -88.95 129.46 35.62 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.633 -0.667 . . . . 0.0 109.866 179.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 80.7 t -89.89 132.56 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.423 -0.798 . . . . 0.0 109.23 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -101.69 134.08 45.39 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.421 -0.799 . . . . 0.0 110.533 -178.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 11.4 tm-20 -69.21 -43.18 74.61 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.315 0.578 . . . . 0.0 109.548 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -101.42 -178.48 28.59 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -178.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -93.24 -2.22 55.34 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.591 -0.947 . . . . 0.0 109.365 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.7 m -82.37 150.79 26.97 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.187 -0.946 . . . . 0.0 110.368 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.473 ' C ' ' H ' ' A' ' 23' ' ' SER . 19.0 m -64.91 -45.4 86.05 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.501 -0.75 . . . . 0.0 109.534 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 8.7 t -77.24 24.39 0.18 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.607 -0.683 . . . . 0.0 109.161 -179.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.473 ' H ' ' C ' ' A' ' 21' ' ' THR . 14.8 m -71.18 151.14 44.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.477 -0.764 . . . . 0.0 110.291 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -73.37 136.65 44.39 Favored 'General case' 0 N--CA 1.491 1.582 0 CA-C-O 121.789 0.804 . . . . 0.0 110.995 -179.181 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 82.2 t -85.62 131.58 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 CA-C-O 121.372 0.605 . . . . 0.0 109.822 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.4 pt -125.33 -44.31 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.722 -0.611 . . . . 0.0 109.378 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -101.29 171.89 22.71 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 -178.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.8 p -158.42 155.58 28.86 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.583 -0.951 . . . . 0.0 109.55 179.072 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 91.9 mt -133.92 150.57 51.32 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.452 -0.78 . . . . 0.0 109.72 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.9 t -82.11 -1.53 49.02 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.535 ' C ' ' H ' ' A' ' 33' ' ' THR . . . 97.83 164.83 31.52 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.272 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.0 m120 52.78 5.22 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.746 -0.855 . . . . 0.0 110.014 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.535 ' H ' ' C ' ' A' ' 31' ' ' GLY . 24.9 m -78.9 141.44 37.61 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.101 -0.999 . . . . 0.0 110.312 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -88.74 132.99 34.37 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.643 -0.661 . . . . 0.0 109.493 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.7 m -124.12 133.79 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 CA-C-O 121.785 0.802 . . . . 0.0 109.854 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 5.8 p -76.8 133.92 39.25 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.722 -0.611 . . . . 0.0 110.141 -179.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.0 mt -111.54 128.9 67.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 121.448 0.642 . . . . 0.0 109.362 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 29.7 m -111.21 -3.34 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -174.99 175.92 47.1 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.662 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -136.51 153.44 51.02 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.667 -0.902 . . . . 0.0 109.46 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -155.11 113.19 3.45 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.195 -0.94 . . . . 0.0 109.996 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 57.48 -137.52 49.38 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 178.695 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.9 24.2 2.86 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.602 -0.94 . . . . 0.0 109.073 -179.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -133.2 147.54 52.01 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.576 -0.702 . . . . 0.0 109.571 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 24.9 m-85 -106.35 147.93 28.65 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.559 -0.713 . . . . 0.0 109.782 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.673 ' HZ2' ' HD1' ' A' ' 53' ' ' HIS . 64.8 tttm -95.53 124.9 39.79 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 13.8 pt -131.51 154.26 40.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 CA-C-O 121.762 0.791 . . . . 0.0 110.217 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -90.89 106.29 18.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.695 -0.628 . . . . 0.0 109.958 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 88.7 t80 -112.45 115.37 28.57 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.572 0.701 . . . . 0.0 109.172 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.1 mmtp 52.27 31.07 8.73 Favored 'General case' 0 N--CA 1.493 1.689 0 CA-C-O 121.3 0.571 . . . . 0.0 110.193 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 85.64 -11.22 62.27 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 178.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 38.4 t -90.2 170.05 10.62 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.25 -1.147 . . . . 0.0 110.203 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.673 ' HD1' ' HZ2' ' A' ' 46' ' ' LYS . 90.6 m-70 -100.28 93.41 5.67 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.429 -0.794 . . . . 0.0 109.231 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.26 136.1 12.73 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.696 -1.361 . . . . 0.0 109.696 -179.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -112.95 138.58 49.59 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.689 -0.889 . . . . 0.0 109.562 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.1 m -135.89 156.13 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.544 -0.723 . . . . 0.0 109.997 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.21 152.06 45.55 Favored 'General case' 0 N--CA 1.491 1.588 0 CA-C-O 121.76 0.791 . . . . 0.0 110.767 -179.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.562 ' C ' ' H ' ' A' ' 60' ' ' TYR . 47.9 mtmt -63.41 -38.69 92.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.698 -0.626 . . . . 0.0 109.49 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -49.64 -7.42 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.401 -0.812 . . . . 0.0 110.222 -179.382 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.562 ' H ' ' C ' ' A' ' 58' ' ' LYS . 59.0 m-85 -105.26 -25.05 12.59 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.289 -0.882 . . . . 0.0 109.236 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.542 ' N ' ' CD1' ' A' ' 61' ' ' ILE . 1.5 mp -89.13 129.09 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.365 -0.835 . . . . 0.0 109.828 -179.51 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 65.2 tttm -146.37 152.55 39.27 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.546 -0.721 . . . . 0.0 109.857 179.228 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 57.47 57.11 4.55 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.496 0.665 . . . . 0.0 109.803 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.4 HG21 HD11 ' A' ' 64' ' ' ILE . 96.9 mt . . . . . 0 N--CA 1.489 1.48 0 O-C-N 121.382 -0.824 . . . . 0.0 109.533 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 62.9 mttp . . . . . 0 N--CA 1.497 1.88 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.0 p -126.8 126.65 43.76 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.519 -0.738 . . . . 0.0 109.23 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -94.32 130.58 10.36 Favored Glycine 0 N--CA 1.495 2.611 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.555 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.5 mp -93.64 120.5 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.294 -1.121 . . . . 0.0 109.392 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 70.7 t -76.34 132.91 32.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.427 -0.796 . . . . 0.0 109.335 179.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -134.87 85.82 2.21 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.439 -0.788 . . . . 0.0 109.246 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.3 m -130.73 132.97 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.578 -0.701 . . . . 0.0 109.52 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 46.7 m -62.42 -41.56 98.79 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.453 -0.779 . . . . 0.0 109.907 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.417 ' OG ' ' N ' ' A' ' 12' ' ' SER . 77.6 p -91.81 -82.09 0.32 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.216 -0.928 . . . . 0.0 109.628 -179.399 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.417 ' N ' ' OG ' ' A' ' 11' ' ' SER . 43.1 t -165.98 167.25 16.76 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.383 -0.823 . . . . 0.0 109.111 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 51.0 tp -119.87 132.45 55.57 Favored 'General case' 0 N--CA 1.498 1.97 0 CA-C-O 121.595 0.712 . . . . 0.0 109.61 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -91.28 152.79 20.34 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.628 -0.67 . . . . 0.0 109.858 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.3 t -103.41 131.02 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.665 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 92.1 mtm-85 -110.5 134.69 52.13 Favored 'General case' 0 N--CA 1.492 1.664 0 CA-C-O 121.689 0.757 . . . . 0.0 110.178 -179.569 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -70.91 -36.4 72.68 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.716 -0.615 . . . . 0.0 109.487 179.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.54 -175.88 31.21 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -179.191 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -109.24 24.48 13.05 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.6 -0.941 . . . . 0.0 108.723 179.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.462 ' OG ' ' OG ' ' A' ' 23' ' ' SER . 6.4 p -83.84 171.49 13.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 110.201 -179.524 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 15.9 m -62.72 -43.51 98.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.53 -0.731 . . . . 0.0 109.417 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.8 p -136.12 66.18 1.5 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.457 -0.777 . . . . 0.0 108.956 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.462 ' OG ' ' OG ' ' A' ' 20' ' ' SER . 1.9 m -77.26 -178.08 4.92 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.866 0.841 . . . . 0.0 110.353 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -63.67 139.14 58.74 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.663 0.744 . . . . 0.0 110.656 -179.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 65.6 t -98.27 124.95 51.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.439 -0.788 . . . . 0.0 108.924 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 40.1 pt -104.65 -4.1 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.61 -0.681 . . . . 0.0 109.272 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.81 -168.22 41.23 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.191 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 40.3 t -153.87 154.61 34.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.51 -0.994 . . . . 0.0 109.353 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.7 mt -123.67 151.39 43.14 Favored 'General case' 0 N--CA 1.497 1.923 0 CA-C-O 121.566 0.698 . . . . 0.0 109.652 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.403 ' O ' ' OG1' ' A' ' 33' ' ' THR . 30.7 t -79.17 166.62 22.02 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.627 0.727 . . . . 0.0 110.606 -179.046 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -64.79 158.55 44.12 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -179.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 66.8 m-20 57.39 32.94 22.57 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.711 -0.876 . . . . 0.0 109.685 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.403 ' OG1' ' O ' ' A' ' 30' ' ' SER . 23.2 m -94.53 129.07 41.48 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.281 -0.887 . . . . 0.0 109.456 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -82.92 132.82 35.14 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.426 -0.796 . . . . 0.0 109.822 -179.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 m -127.23 134.52 65.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 O-C-N 121.535 -0.728 . . . . 0.0 109.498 179.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 33.6 m -78.49 129.31 34.73 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.462 -0.774 . . . . 0.0 109.732 -179.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.417 HD13 HG21 ' A' ' 37' ' ' ILE . 96.3 mt -106.7 126.03 62.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.593 -0.692 . . . . 0.0 109.612 179.787 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 28.5 m -118.77 8.48 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.03 174.47 45.89 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -135.28 155.64 50.3 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.372 -1.075 . . . . 0.0 109.904 -179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.417 ' O ' ' O ' ' A' ' 44' ' ' PHE . 76.3 mm-40 -138.86 153.65 48.34 Favored 'General case' 0 N--CA 1.494 1.73 0 CA-C-O 121.435 0.636 . . . . 0.0 109.759 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.49 ' O ' ' CB ' ' A' ' 43' ' ' ALA . . . -64.36 108.02 2.09 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.124 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.49 ' CB ' ' O ' ' A' ' 42' ' ' GLY . . . 80.67 4.03 1.69 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.663 -0.904 . . . . 0.0 109.151 179.488 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.417 ' O ' ' O ' ' A' ' 41' ' ' GLU . 95.6 m-85 -149.39 159.6 44.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 109.736 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -118.25 147.45 43.41 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.574 ' HZ2' ' CG ' ' A' ' 53' ' ' HIS . 0.1 OUTLIER -91.6 118.1 30.32 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 179.674 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.6 pt -126.57 153.13 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 CA-C-O 121.644 0.735 . . . . 0.0 109.702 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -86.06 118.2 25.38 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.531 -0.731 . . . . 0.0 109.61 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.55 ' O ' ' N ' ' A' ' 51' ' ' GLY . 89.6 t80 -111.58 121.7 45.86 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.554 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.418 ' C ' ' O ' ' A' ' 49' ' ' TYR . 37.3 ttpt 39.52 -90.38 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.261 0.553 . . . . 0.0 110.311 -179.669 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -130.2 -22.64 1.09 Allowed Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.914 -1.675 . . . . 0.0 108.914 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 22.5 m -91.19 163.41 14.27 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.217 -1.167 . . . . 0.0 110.532 -179.355 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.574 ' CG ' ' HZ2' ' A' ' 46' ' ' LYS . 56.9 m170 -83.37 113.12 20.52 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.382 -0.824 . . . . 0.0 109.357 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.64 141.95 15.83 Favored Glycine 0 N--CA 1.495 2.576 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -120.81 139.54 52.99 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.672 -0.899 . . . . 0.0 109.427 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.4 m -132.57 137.83 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.662 -0.649 . . . . 0.0 109.525 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.665 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -61.48 143.72 55.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.548 -0.72 . . . . 0.0 110.805 -179.02 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -66.76 -12.31 58.22 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.505 -0.747 . . . . 0.0 109.899 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 47.3 tp10 -67.15 -36.54 82.06 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.169 -0.957 . . . . 0.0 110.256 -179.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -95.62 -5.03 43.39 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.173 -0.955 . . . . 0.0 109.842 -178.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 36.5 mm -110.22 128.94 66.07 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 O-C-N 121.511 -0.743 . . . . 0.0 109.37 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.43 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 21.2 ptmt -140.45 173.23 11.7 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.546 -0.721 . . . . 0.0 110.266 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.43 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 14.7 t0 77.36 -72.21 0.1 Allowed 'General case' 0 N--CA 1.495 1.781 0 CA-C-O 121.114 0.483 . . . . 0.0 109.748 179.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 27.3 mt . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.624 -0.673 . . . . 0.0 109.332 -179.651 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt . . . . . 0 N--CA 1.496 1.828 0 CA-C-O 121.633 0.73 . . . . 0.0 109.889 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 44.1 p -115.72 121.78 43.52 Favored 'General case' 0 N--CA 1.499 1.987 0 CA-C-O 121.833 0.825 . . . . 0.0 109.79 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -100.79 142.27 15.73 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.594 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.408 HD12 HG23 ' A' ' 6' ' ' ILE . 22.6 mm -92.69 120.89 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 CA-C-O 121.684 0.754 . . . . 0.0 109.378 179.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.2 t -80.58 105.03 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 CA-C-O 121.668 0.746 . . . . 0.0 109.59 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -99.43 103.88 15.7 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-O 121.747 0.784 . . . . 0.0 109.61 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 26.8 m -137.93 160.58 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 CA-C-O 121.727 0.775 . . . . 0.0 109.918 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 88.0 p -85.73 -12.83 50.15 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.0 m -142.1 -76.01 0.28 Allowed 'General case' 0 N--CA 1.497 1.884 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 25.9 p -155.81 166.56 33.12 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.518 -0.739 . . . . 0.0 109.735 -179.385 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.8 tp -114.18 133.1 55.83 Favored 'General case' 0 N--CA 1.496 1.849 0 CA-C-O 121.841 0.829 . . . . 0.0 110.34 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -91.29 142.3 27.85 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-O 121.719 0.771 . . . . 0.0 109.991 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.9 t -99.11 129.51 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 CA-C-O 121.634 0.731 . . . . 0.0 109.662 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.7 mtt85 -92.87 153.44 18.82 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 121.793 0.806 . . . . 0.0 110.049 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -64.68 -44.37 90.58 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 19' ' ' ALA . . . -157.88 102.92 0.22 Allowed Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.549 ' H ' ' CB ' ' A' ' 55' ' ' TYR . . . 38.8 -114.51 0.14 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 122.001 -0.705 . . . . 0.0 110.292 179.476 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 19' ' ' ALA . 4.9 m 56.35 152.53 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 121.8 0.81 . . . . 0.0 110.508 179.678 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 97.8 m -67.82 -45.5 74.53 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.822 -0.549 . . . . 0.0 109.907 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 39.5 p -153.05 61.05 0.78 Allowed 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 121.836 0.827 . . . . 0.0 109.222 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 5.2 p -75.04 -171.38 1.34 Allowed 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.76 0.79 . . . . 0.0 110.634 179.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt -66.29 142.91 57.5 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-O 121.743 0.782 . . . . 0.0 110.411 -178.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 68.4 t -98.52 127.31 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 CA-C-O 121.732 0.777 . . . . 0.0 109.305 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 27.8 pt -103.26 -4.12 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 173.34 -173.9 45.86 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 24.1 p -154.35 161.69 41.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.81 -0.818 . . . . 0.0 109.711 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.8 mt -126.99 151.49 48.51 Favored 'General case' 0 N--CA 1.499 2.007 0 CA-C-O 121.947 0.879 . . . . 0.0 109.984 -179.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.436 ' OG ' ' OG1' ' A' ' 33' ' ' THR . 84.1 p -72.7 165.87 23.94 Favored 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 121.812 0.815 . . . . 0.0 110.261 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.519 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.85 165.02 45.63 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 56.33 2.88 0.09 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 122.335 -0.509 . . . . 0.0 110.116 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.519 ' H ' ' C ' ' A' ' 31' ' ' GLY . 47.5 m -71.24 136.14 47.83 Favored 'General case' 0 N--CA 1.496 1.851 0 CA-C-O 121.916 0.865 . . . . 0.0 110.391 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -88.9 143.04 27.15 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.34 0.591 . . . . 0.0 109.866 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 35.4 m -126.26 130.46 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 CA-C-O 121.821 0.82 . . . . 0.0 110.08 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 82.7 m -80.01 125.7 30.11 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.517 0.675 . . . . 0.0 109.739 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.6 mt -104.87 128.09 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 CA-C-O 121.554 0.693 . . . . 0.0 109.83 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.8 m -123.92 7.5 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.488 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.04 169.6 42.75 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -129.84 152.77 48.95 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.789 -0.83 . . . . 0.0 109.553 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 53.3 tp10 -153.29 108.33 3.19 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.936 0.874 . . . . 0.0 110.068 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 49.73 -138.14 20.1 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 178.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -84.67 20.3 1.79 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 122.005 -0.703 . . . . 0.0 109.226 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -128.35 151.0 49.85 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-O 121.688 0.756 . . . . 0.0 109.582 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 51.9 m-85 -102.98 141.87 35.04 Favored 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.945 0.878 . . . . 0.0 109.968 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.566 ' NZ ' ' CD2' ' A' ' 53' ' ' HIS . 65.4 tttm -94.29 122.53 36.93 Favored 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.493 0.663 . . . . 0.0 109.384 -179.505 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 34.6 pt -129.25 154.99 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 CA-C-O 121.806 0.813 . . . . 0.0 110.316 179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -83.45 114.4 21.44 Favored 'General case' 0 N--CA 1.494 1.73 0 CA-C-O 121.568 0.699 . . . . 0.0 109.915 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.569 ' O ' ' N ' ' A' ' 51' ' ' GLY . 86.1 t80 -106.28 114.85 29.22 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.694 0.759 . . . . 0.0 109.588 179.77 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.1 mttp 40.96 -87.54 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.754 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.105 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -115.63 -39.38 0.92 Allowed Glycine 0 N--CA 1.495 2.58 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 16.7 p -89.54 169.37 11.41 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.804 -0.821 . . . . 0.0 110.45 -179.184 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.566 ' CD2' ' NZ ' ' A' ' 46' ' ' LYS . 73.2 m80 -96.52 111.19 23.4 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.914 0.864 . . . . 0.0 109.952 -179.61 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.64 144.08 23.97 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.549 ' CB ' ' H ' ' A' ' 19' ' ' ALA . 75.8 m-85 -119.63 135.76 54.67 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-O 121.751 0.786 . . . . 0.0 109.515 179.346 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 20.1 m -137.38 156.12 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 CA-C-O 121.913 0.863 . . . . 0.0 110.318 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.07 154.36 33.42 Favored 'General case' 0 N--CA 1.492 1.667 0 CA-C-O 121.681 0.753 . . . . 0.0 110.107 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -69.67 -17.6 63.5 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.529 ' OE2' ' CE2' ' A' ' 60' ' ' TYR . 9.7 pt-20 -65.0 -34.92 79.58 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.786 -0.572 . . . . 0.0 109.893 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.529 ' CE2' ' OE2' ' A' ' 59' ' ' GLU . 66.8 m-85 -91.98 -10.16 40.33 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.451 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 36.0 mm -110.46 120.73 61.94 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.121 0 CA-C-O 121.847 0.832 . . . . 0.0 110.021 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -149.72 173.47 13.67 Favored 'General case' 0 N--CA 1.494 1.734 0 CA-C-O 121.616 0.722 . . . . 0.0 110.21 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 57.6 47.98 15.01 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 121.353 0.596 . . . . 0.0 109.405 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt . . . . . 0 N--CA 1.495 1.788 0 CA-C-O 121.699 0.762 . . . . 0.0 110.055 -179.647 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.5 mttt . . . . . 0 N--CA 1.496 1.83 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.603 ' HG1' ' HZ2' ' A' ' 34' ' ' LYS . 70.4 p -127.73 131.14 49.73 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.524 -0.735 . . . . 0.0 109.144 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -120.02 135.18 10.91 Favored Glycine 0 N--CA 1.5 2.918 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.553 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.9 mp -86.72 129.02 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.434 -1.039 . . . . 0.0 109.675 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.3 t -82.13 104.8 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.181 -0.949 . . . . 0.0 109.665 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -108.29 106.45 16.61 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.481 -0.762 . . . . 0.0 109.054 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 27.7 m -138.47 162.4 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.27 -0.894 . . . . 0.0 110.016 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 t -61.99 -43.57 98.55 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.55 -0.719 . . . . 0.0 109.46 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 12' ' ' SER . 70.5 m -161.09 108.9 1.52 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.006 -1.059 . . . . 0.0 110.262 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 11' ' ' SER . 22.7 t 54.0 159.19 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.849 0.833 . . . . 0.0 111.509 179.126 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 35.1 tp -133.22 133.03 42.19 Favored 'General case' 0 N--CA 1.498 1.971 0 CA-C-O 121.485 0.66 . . . . 0.0 109.652 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 46.0 p-10 -80.69 141.81 34.52 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.391 -0.818 . . . . 0.0 109.914 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 78.2 t -93.45 133.12 35.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.201 -0.937 . . . . 0.0 109.666 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -102.38 130.54 49.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.384 -0.823 . . . . 0.0 109.909 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -73.75 -41.31 62.67 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.468 -0.77 . . . . 0.0 109.763 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.479 ' O ' ' CG ' ' A' ' 55' ' ' TYR . . . -95.93 -129.42 5.96 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.934 -1.266 . . . . 0.0 109.934 -179.111 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -137.13 -12.85 1.63 Allowed 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.519 -0.989 . . . . 0.0 109.073 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 12.0 m -72.72 152.36 41.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.198 -0.939 . . . . 0.0 110.688 -179.094 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.7 m -63.15 -46.08 88.87 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.376 -0.828 . . . . 0.0 109.34 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 58.7 m -88.75 34.74 0.77 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.152 -0.967 . . . . 0.0 108.604 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.2 p -73.78 161.95 29.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.405 -0.81 . . . . 0.0 110.376 -179.2 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -66.28 136.11 55.37 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.348 -0.845 . . . . 0.0 110.299 -179.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 53.4 t -100.72 127.98 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.416 -0.802 . . . . 0.0 109.355 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.5 pt -101.11 -3.07 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.04 -164.22 37.6 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.458 -1.353 . . . . 0.0 110.325 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 40.4 t -155.31 158.87 39.43 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.268 -1.136 . . . . 0.0 109.373 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.0 mt -122.96 149.96 43.59 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.508 -0.745 . . . . 0.0 109.769 -179.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 29.6 t -69.23 154.62 41.75 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-O 121.834 0.826 . . . . 0.0 111.02 -178.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.46 157.25 37.53 Favored Glycine 0 N--CA 1.492 2.413 0 O-C-N 121.637 -0.664 . . . . 0.0 111.475 -179.418 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.3 t-20 58.75 33.88 23.37 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.809 -0.818 . . . . 0.0 109.741 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.7 m -97.02 129.52 44.46 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.314 -0.866 . . . . 0.0 109.594 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.603 ' HZ2' ' HG1' ' A' ' 4' ' ' THR . 54.1 tttp -79.8 131.13 35.82 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.352 -0.843 . . . . 0.0 109.344 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 21.6 m -128.77 136.6 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.392 -0.817 . . . . 0.0 109.697 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 18.8 m -80.99 129.46 34.54 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.613 -0.679 . . . . 0.0 109.586 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.6 mt -110.45 129.56 65.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.686 -0.633 . . . . 0.0 109.446 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 24.4 m -128.62 -49.37 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -91.57 166.84 30.64 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 -179.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -139.0 146.87 41.42 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.337 -1.096 . . . . 0.0 109.559 179.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.5 tm-20 -154.31 110.02 3.19 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.321 -0.862 . . . . 0.0 109.07 179.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 53.13 -138.82 34.79 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 111.044 -0.822 . . . . 0.0 111.044 179.186 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.02 10.65 13.57 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.366 -1.079 . . . . 0.0 109.113 -179.411 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -111.62 144.45 40.85 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.502 -0.748 . . . . 0.0 109.447 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 47.2 m-85 -104.03 141.33 36.38 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.544 -0.723 . . . . 0.0 109.702 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -90.28 137.91 31.96 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.266 -0.897 . . . . 0.0 108.751 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.421 HD13 HG21 ' A' ' 47' ' ' ILE . 17.3 pt -127.81 154.38 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.0 0 O-C-N 121.468 -0.77 . . . . 0.0 110.087 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 50.8 tp10 -82.95 106.87 15.13 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.532 ' O ' ' N ' ' A' ' 51' ' ' GLY . 80.1 t80 -109.21 124.69 51.27 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.52 -0.737 . . . . 0.0 110.134 -179.722 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.443 ' C ' ' O ' ' A' ' 49' ' ' TYR . 67.8 mttm 33.62 -88.97 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.103 0.478 . . . . 0.0 111.246 179.504 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -119.83 -29.3 1.71 Allowed Glycine 0 N--CA 1.498 2.807 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 -179.251 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 66.6 m -100.58 176.86 5.18 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.088 -1.242 . . . . 0.0 110.478 -179.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -107.68 119.91 40.75 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.527 -0.733 . . . . 0.0 109.682 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.7 159.03 25.56 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.479 ' CG ' ' O ' ' A' ' 18' ' ' GLY . 91.0 m-85 -115.98 137.32 52.22 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.444 -1.033 . . . . 0.0 109.64 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.8 m -136.11 137.19 48.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.627 -0.671 . . . . 0.0 109.431 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.32 148.08 51.25 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.498 -0.751 . . . . 0.0 110.611 -179.278 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.3 ptpm? -62.84 -16.55 58.92 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.376 -0.827 . . . . 0.0 109.368 179.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -67.58 -35.84 79.77 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.292 -0.88 . . . . 0.0 109.89 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -92.34 -5.02 53.01 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.018 -1.051 . . . . 0.0 109.236 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.403 HG22 HD13 ' A' ' 61' ' ' ILE . 36.7 mm -112.11 123.87 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 121.374 -0.829 . . . . 0.0 109.21 179.735 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 20.5 ptmt -141.63 171.17 14.43 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.479 -0.763 . . . . 0.0 110.068 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 58.72 40.86 22.73 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-O 121.477 0.656 . . . . 0.0 109.487 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.404 HG21 HD13 ' A' ' 64' ' ' ILE . 96.6 mt . . . . . 0 N--CA 1.493 1.708 0 O-C-N 121.285 -0.884 . . . . 0.0 110.042 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 99.1 mttt . . . . . 0 N--CA 1.497 1.923 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.577 ' CB ' ' HZ3' ' A' ' 34' ' ' LYS . 59.2 p -128.41 124.78 37.14 Favored 'General case' 0 N--CA 1.497 1.893 0 CA-C-O 121.643 0.735 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -99.91 137.25 13.15 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.567 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.8 mp -93.95 119.16 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.536 -0.979 . . . . 0.0 109.673 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 71.9 t -79.09 133.2 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 CA-C-O 121.494 0.664 . . . . 0.0 109.791 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.533 ' CB ' ' NZ ' ' A' ' 62' ' ' LYS . 46.1 t30 -140.34 106.98 5.33 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.404 -0.81 . . . . 0.0 109.648 -179.813 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 m -138.3 151.68 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.603 -0.686 . . . . 0.0 109.634 179.8 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 73.5 m -72.26 -42.9 65.06 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 121.477 0.656 . . . . 0.0 109.828 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 69.0 m -103.85 -76.67 0.59 Allowed 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.446 -0.784 . . . . 0.0 109.625 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 41.2 t -160.03 168.27 25.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.325 -0.86 . . . . 0.0 109.687 -179.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 41.8 tp -116.58 130.21 56.62 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 121.592 0.71 . . . . 0.0 109.984 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -91.92 138.38 31.59 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.771 0.796 . . . . 0.0 110.158 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.3 t -89.5 130.01 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 CA-C-O 121.497 0.665 . . . . 0.0 109.802 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.404 ' CZ ' ' O ' ' A' ' 21' ' ' THR . 38.4 mmt180 -107.67 131.15 54.71 Favored 'General case' 0 N--CA 1.496 1.835 0 CA-C-O 121.872 0.844 . . . . 0.0 109.565 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -71.22 -40.18 71.27 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-O 121.532 0.682 . . . . 0.0 109.549 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.502 ' N ' ' OG ' ' A' ' 23' ' ' SER . . . -93.69 177.09 37.07 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.34 39.51 0.87 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.501 -0.999 . . . . 0.0 109.104 179.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.9 p -151.91 154.88 36.97 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.398 -0.814 . . . . 0.0 109.686 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.404 ' O ' ' CZ ' ' A' ' 16' ' ' ARG . 60.5 p -71.29 -28.03 63.84 Favored 'General case' 0 N--CA 1.493 1.724 0 CA-C-O 121.675 0.75 . . . . 0.0 109.379 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 91.9 p -82.35 -3.71 55.94 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.502 ' OG ' ' N ' ' A' ' 18' ' ' GLY . 24.0 t -51.73 -97.08 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.619 -0.675 . . . . 0.0 110.188 -179.746 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.443 ' N ' ' HG ' ' A' ' 23' ' ' SER . 88.5 tttt -169.33 131.58 1.2 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.311 -0.868 . . . . 0.0 110.011 -179.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 84.2 t -81.67 132.17 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.73 -0.606 . . . . 0.0 109.939 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 45.0 pt -117.6 -10.28 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.69 -175.01 45.23 Favored Glycine 0 N--CA 1.494 2.554 0 C-N-CA 119.402 -1.38 . . . . 0.0 110.252 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 65.8 m -133.04 156.18 47.84 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.714 -0.874 . . . . 0.0 109.814 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 92.2 mt -122.9 147.91 46.04 Favored 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.83 0.824 . . . . 0.0 109.941 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.574 ' HG ' ' N ' ' A' ' 31' ' ' GLY . 30.6 t -74.77 157.85 34.5 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-O 121.937 0.875 . . . . 0.0 110.63 -179.328 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.574 ' N ' ' HG ' ' A' ' 30' ' ' SER . . . -66.6 156.52 51.04 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 11.5 m120 57.36 33.09 22.8 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 122.075 -0.662 . . . . 0.0 109.461 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.417 ' OG1' ' O ' ' A' ' 30' ' ' SER . 43.3 m -94.42 125.07 38.84 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.843 0.83 . . . . 0.0 110.331 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.577 ' HZ3' ' CB ' ' A' ' 4' ' ' THR . 63.3 tttp -79.24 132.14 36.4 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-O 121.306 0.574 . . . . 0.0 109.677 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.1 m -129.5 134.13 64.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 121.804 0.811 . . . . 0.0 109.763 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 52.7 m -79.09 127.63 32.25 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-O 121.6 0.714 . . . . 0.0 109.901 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.7 mt -102.76 124.2 56.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 CA-C-O 121.499 0.666 . . . . 0.0 109.508 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.76 -0.8 9.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.3 176.31 46.0 Favored Glycine 0 N--CA 1.494 2.551 0 C-N-CA 119.681 -1.247 . . . . 0.0 110.538 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -143.94 155.3 44.01 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.65 -0.912 . . . . 0.0 109.475 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -153.27 107.28 3.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.456 -0.777 . . . . 0.0 109.78 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.3 -135.96 49.75 Favored Glycine 0 N--CA 1.493 2.493 0 CA-C-O 121.98 0.766 . . . . 0.0 111.626 178.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -88.28 28.19 1.12 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.554 -0.968 . . . . 0.0 109.122 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -136.11 150.26 49.03 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.641 -0.662 . . . . 0.0 109.58 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.626 ' CZ ' ' NZ ' ' A' ' 58' ' ' LYS . 12.5 m-85 -107.17 146.04 31.82 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-O 121.882 0.849 . . . . 0.0 109.925 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -98.67 124.77 43.69 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.7 pt -129.73 157.79 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 121.651 0.738 . . . . 0.0 110.187 -179.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -87.5 101.79 13.95 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.43 0.634 . . . . 0.0 109.811 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.8 t80 -109.85 118.64 37.03 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-O 121.618 0.723 . . . . 0.0 109.45 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.6 mmtt 51.43 29.8 5.6 Favored 'General case' 0 N--CA 1.492 1.668 0 CA-C-O 121.763 0.792 . . . . 0.0 109.754 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.97 -23.45 23.55 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 179.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.3 m -86.53 165.34 16.31 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.281 -1.129 . . . . 0.0 110.576 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -94.51 101.63 13.54 Favored 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 121.73 0.776 . . . . 0.0 109.667 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.1 147.93 19.9 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -115.51 134.08 55.42 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.699 -0.883 . . . . 0.0 109.425 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.6 m -136.14 139.58 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 CA-C-O 121.573 0.702 . . . . 0.0 109.902 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.53 144.71 55.75 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.889 0.852 . . . . 0.0 110.387 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.626 ' NZ ' ' CZ ' ' A' ' 45' ' ' TYR . 67.1 mttm -63.74 -36.84 85.19 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-O 121.421 0.629 . . . . 0.0 110.468 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -46.83 -16.34 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.238 -0.914 . . . . 0.0 110.675 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.45 ' N ' ' O ' ' A' ' 58' ' ' LYS . 36.1 m-85 -108.37 -30.65 8.2 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.162 -0.961 . . . . 0.0 109.132 179.488 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.528 ' N ' ' CD1' ' A' ' 61' ' ' ILE . 1.5 mp -93.54 123.22 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.424 -0.798 . . . . 0.0 109.741 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.533 ' NZ ' ' CB ' ' A' ' 8' ' ' ASN . 26.6 pttm -148.78 174.73 11.89 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.585 0.707 . . . . 0.0 109.952 179.527 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.5 m-20 58.11 51.28 8.87 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-O 121.68 0.752 . . . . 0.0 109.765 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.9 mt . . . . . 0 N--CA 1.494 1.757 0 O-C-N 121.51 -0.744 . . . . 0.0 109.722 179.949 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt . . . . . 0 N--CA 1.495 1.825 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 46.9 p -115.13 123.13 48.16 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.679 -0.638 . . . . 0.0 109.372 -179.673 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -96.04 131.45 10.66 Favored Glycine 0 N--CA 1.496 2.674 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.536 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.4 mp -80.81 126.41 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.332 -1.099 . . . . 0.0 109.251 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 74.9 t -80.61 132.78 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.542 -0.724 . . . . 0.0 109.645 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 24.2 t-20 -131.24 103.41 6.46 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.547 -0.721 . . . . 0.0 109.271 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 27.9 m -135.46 156.45 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.492 -0.755 . . . . 0.0 109.434 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 95.6 p -83.7 -10.96 57.8 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.488 -0.758 . . . . 0.0 109.3 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.501 ' OG ' ' N ' ' A' ' 12' ' ' SER . 86.4 p -138.37 -73.1 0.4 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.359 -0.838 . . . . 0.0 109.154 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.501 ' N ' ' OG ' ' A' ' 11' ' ' SER . 31.9 p -158.71 165.04 35.29 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.369 -0.832 . . . . 0.0 109.249 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.9 tp -113.83 131.47 56.23 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.482 -0.761 . . . . 0.0 109.028 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -91.07 146.43 23.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.406 -0.809 . . . . 0.0 109.885 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 65.1 t -99.3 130.1 48.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.504 ' NH1' ' O ' ' A' ' 21' ' ' THR . 93.0 mtt-85 -110.97 136.85 49.36 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.587 -0.695 . . . . 0.0 109.95 -179.346 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 66.3 mm-40 -80.58 -35.73 33.84 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.453 -0.779 . . . . 0.0 109.655 179.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -95.57 177.17 34.4 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.68 -5.42 42.31 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.402 -1.058 . . . . 0.0 109.083 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 33.5 t -86.16 153.67 21.89 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -0.852 . . . . 0.0 109.951 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.515 ' C ' ' H ' ' A' ' 23' ' ' SER . 15.3 m -63.67 -44.77 92.79 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.433 -0.792 . . . . 0.0 109.725 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 76.7 p -73.11 17.83 0.12 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.212 -0.93 . . . . 0.0 109.408 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.515 ' H ' ' C ' ' A' ' 21' ' ' THR . 17.3 m -64.65 149.22 49.4 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.239 -0.913 . . . . 0.0 109.788 -179.723 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 24.9 pttm -70.79 143.53 51.14 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.395 -0.815 . . . . 0.0 110.367 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 55.6 t -103.24 131.28 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.528 -0.732 . . . . 0.0 109.641 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 24.7 pt -99.01 -6.58 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.441 -0.787 . . . . 0.0 109.538 179.712 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.3 -159.81 33.27 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.8 m -152.92 167.11 30.23 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.436 -1.037 . . . . 0.0 109.571 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.9 mt -127.23 153.89 45.53 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.525 -0.734 . . . . 0.0 109.576 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.6 p -73.25 162.08 29.79 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.505 -0.747 . . . . 0.0 110.721 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.574 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -69.07 163.71 50.6 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -179.509 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 35.2 t-20 65.45 -13.95 0.12 Allowed 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.81 -0.818 . . . . 0.0 110.012 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.574 ' H ' ' C ' ' A' ' 31' ' ' GLY . 38.2 m -67.83 133.7 49.64 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.055 -1.028 . . . . 0.0 109.503 179.568 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.5 pttp -93.81 146.57 23.78 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.353 -0.842 . . . . 0.0 109.651 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.1 m -122.86 131.46 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.618 -0.677 . . . . 0.0 109.424 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 33.6 m -66.13 128.85 37.73 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.526 -0.733 . . . . 0.0 110.352 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 94.2 mt -107.95 127.81 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.399 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 17.1 m -111.57 -1.06 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 O-C-N 121.567 -0.708 . . . . 0.0 109.468 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 178.75 -175.27 47.25 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -140.69 153.63 46.03 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.369 -1.077 . . . . 0.0 109.432 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 47.9 tp10 -151.64 112.06 4.15 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.326 -0.859 . . . . 0.0 109.506 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.96 -143.35 48.58 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.63 17.2 3.41 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.635 -0.92 . . . . 0.0 109.874 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -127.21 148.1 50.2 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.415 -0.803 . . . . 0.0 109.34 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -98.99 147.42 25.03 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.432 -0.792 . . . . 0.0 109.734 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.669 ' HZ2' ' HD1' ' A' ' 53' ' ' HIS . 65.0 tttm -96.37 126.79 41.81 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.603 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.6 pt -128.95 156.36 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.503 -0.748 . . . . 0.0 109.952 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -90.27 117.69 29.2 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.488 -0.757 . . . . 0.0 109.418 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.537 ' O ' ' N ' ' A' ' 51' ' ' GLY . 53.1 t80 -106.49 101.96 11.39 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.551 -0.718 . . . . 0.0 109.358 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 7.7 mtmp? 43.51 -88.69 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.59 -0.693 . . . . 0.0 110.655 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.537 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -128.39 42.61 1.42 Allowed Glycine 0 N--CA 1.501 2.993 0 N-CA-C 109.784 -1.327 . . . . 0.0 109.784 -179.329 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 93.9 p -161.43 163.59 30.38 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.196 -1.179 . . . . 0.0 109.172 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.669 ' HD1' ' HZ2' ' A' ' 46' ' ' LYS . 99.3 m-70 -94.91 111.18 22.99 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.22 -0.925 . . . . 0.0 109.559 -179.639 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.11 150.22 19.56 Favored Glycine 0 N--CA 1.494 2.546 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -128.41 139.6 52.28 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.627 -0.925 . . . . 0.0 109.473 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 28.8 m -136.19 156.21 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.436 -0.79 . . . . 0.0 109.826 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 147.18 39.49 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.484 -0.76 . . . . 0.0 110.465 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -69.18 -12.53 61.76 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.485 -0.76 . . . . 0.0 109.593 179.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -67.88 -35.27 78.22 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.22 -0.925 . . . . 0.0 110.499 -179.352 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 19.8 m-85 -94.35 -4.49 48.47 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.906 -1.121 . . . . 0.0 110.336 -179.17 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.401 ' CD1' ' N ' ' A' ' 61' ' ' ILE . 1.6 mp -107.82 130.6 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.237 -0.914 . . . . 0.0 108.88 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.563 ' O ' ' N ' ' A' ' 64' ' ' ILE . 64.3 pttt -142.34 -168.11 2.65 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.478 -0.764 . . . . 0.0 109.077 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 56.26 -75.16 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 CA-C-O 120.986 0.422 . . . . 0.0 110.262 179.655 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.563 ' N ' ' O ' ' A' ' 62' ' ' LYS . 90.3 mt . . . . . 0 N--CA 1.491 1.62 0 O-C-N 121.445 -0.785 . . . . 0.0 109.369 -179.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.498 1.936 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 42.5 p -107.22 114.93 29.29 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.777 0.798 . . . . 0.0 109.289 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.45 136.2 12.57 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.523 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.56 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.8 mp -86.38 120.84 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.568 -0.96 . . . . 0.0 109.445 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 99.5 t -82.58 104.35 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 CA-C-O 121.581 0.705 . . . . 0.0 109.354 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 -102.26 103.79 14.29 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.51 -0.744 . . . . 0.0 109.762 -179.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 34.7 m -137.46 164.05 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.57 -0.706 . . . . 0.0 109.832 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 79.8 p -63.25 -39.88 95.85 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.348 0.594 . . . . 0.0 109.755 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.442 ' O ' ' O ' ' A' ' 12' ' ' SER . 29.6 p -163.89 109.16 1.04 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.94 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.442 ' O ' ' O ' ' A' ' 11' ' ' SER . 1.4 m 52.48 166.82 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 CA-C-O 121.938 0.875 . . . . 0.0 111.156 179.634 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 37.1 tp -139.46 131.53 27.96 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.583 0.706 . . . . 0.0 109.853 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -79.52 141.86 36.29 Favored 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.516 0.674 . . . . 0.0 109.933 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 75.3 t -98.78 130.62 47.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.54 -0.725 . . . . 0.0 109.718 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.509 ' NE ' ' O ' ' A' ' 21' ' ' THR . 85.1 mtt85 -103.58 134.09 47.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.468 -0.77 . . . . 0.0 109.73 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.1 tm-20 -71.58 -38.98 70.85 Favored 'General case' 0 N--CA 1.491 1.575 0 CA-C-O 121.596 0.713 . . . . 0.0 109.617 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -90.96 173.66 38.2 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.123 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -90.36 5.35 47.71 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.367 -1.079 . . . . 0.0 109.385 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.436 ' OG ' ' OG ' ' A' ' 23' ' ' SER . 7.2 p -78.66 166.64 22.28 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.319 -0.863 . . . . 0.0 110.38 -179.389 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.509 ' O ' ' NE ' ' A' ' 16' ' ' ARG . 0.7 OUTLIER -69.85 -20.71 63.4 Favored 'General case' 0 N--CA 1.491 1.596 0 CA-C-O 121.509 0.671 . . . . 0.0 109.664 179.807 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.7 t -151.11 63.76 0.9 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.009 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.436 ' OG ' ' OG ' ' A' ' 20' ' ' SER . 18.1 m -75.13 -79.42 0.09 Allowed 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.636 0.732 . . . . 0.0 109.447 179.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -160.56 121.17 2.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.218 -0.926 . . . . 0.0 109.935 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 75.7 t -74.97 129.3 36.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.496 0.665 . . . . 0.0 109.623 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 34.8 pt -119.6 -10.22 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.483 0.658 . . . . 0.0 109.24 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 179.47 -168.73 39.47 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.633 -1.27 . . . . 0.0 110.163 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 39.4 t -154.31 154.5 33.47 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.576 -0.955 . . . . 0.0 109.831 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.0 mt -122.71 150.56 42.57 Favored 'General case' 0 N--CA 1.495 1.806 0 CA-C-O 121.622 0.725 . . . . 0.0 109.544 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 17.1 m -69.45 151.31 46.24 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.851 0.834 . . . . 0.0 110.354 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.431 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.2 166.04 41.91 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 57.11 8.52 0.54 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 122.012 -0.699 . . . . 0.0 109.575 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.431 ' H ' ' C ' ' A' ' 31' ' ' GLY . 34.6 m -88.47 134.33 33.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.44 -0.788 . . . . 0.0 110.243 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -78.14 146.66 34.98 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.641 -0.662 . . . . 0.0 110.094 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.7 m -126.33 132.58 70.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 CA-C-O 121.621 0.724 . . . . 0.0 109.567 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 39.6 m -65.12 128.89 37.65 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.547 0.689 . . . . 0.0 110.116 -179.509 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 5.4 mm -102.8 125.2 57.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 CA-C-O 121.442 0.639 . . . . 0.0 109.426 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 6.3 m -122.11 -11.83 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.55 -173.81 45.6 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.544 -1.312 . . . . 0.0 110.659 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -148.56 163.15 38.09 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.577 -0.955 . . . . 0.0 109.827 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -156.08 114.06 3.33 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.504 -0.748 . . . . 0.0 109.503 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 61.17 -136.5 48.14 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 179.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.545 ' C ' ' HZ2' ' A' ' 58' ' ' LYS . . . -92.34 28.91 1.8 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.527 -0.984 . . . . 0.0 108.719 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -134.5 150.35 50.78 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.621 -0.674 . . . . 0.0 109.435 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -105.37 139.63 39.7 Favored 'General case' 0 N--CA 1.493 1.715 0 CA-C-O 121.798 0.809 . . . . 0.0 109.703 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -96.86 129.19 44.33 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.9 pt -129.29 164.22 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 CA-C-O 121.727 0.775 . . . . 0.0 110.212 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -77.72 99.75 5.97 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-O 121.619 0.723 . . . . 0.0 109.94 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -90.36 134.77 34.1 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.515 -0.741 . . . . 0.0 109.484 179.521 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 56.6 mtpt -52.1 97.8 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.452 0.644 . . . . 0.0 110.422 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 121.46 -35.58 3.56 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.604 ' HG ' ' N ' ' A' ' 53' ' ' HIS . 23.4 p -163.31 -153.96 0.26 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.141 -1.211 . . . . 0.0 110.076 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.604 ' N ' ' HG ' ' A' ' 52' ' ' SER . 97.9 m-70 -106.4 118.6 37.08 Favored 'General case' 0 N--CA 1.496 1.835 0 CA-C-O 121.698 0.761 . . . . 0.0 109.999 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.83 145.55 17.67 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -115.86 136.86 52.64 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.807 -0.819 . . . . 0.0 109.781 179.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.6 m -138.09 154.57 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 CA-C-O 121.425 0.631 . . . . 0.0 109.679 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.97 149.52 43.27 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.845 0.831 . . . . 0.0 110.899 -179.492 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.545 ' HZ2' ' C ' ' A' ' 43' ' ' ALA . 57.1 mttp -63.1 -34.5 77.73 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.486 0.66 . . . . 0.0 109.99 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -53.67 -30.12 41.87 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.418 -0.801 . . . . 0.0 110.111 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -90.03 -2.22 58.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.989 -1.069 . . . . 0.0 109.236 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.0 mm -107.64 127.41 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 CA-C-O 121.796 0.807 . . . . 0.0 109.854 -179.788 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -141.22 150.72 43.04 Favored 'General case' 0 N--CA 1.49 1.563 0 CA-C-O 121.77 0.795 . . . . 0.0 110.133 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.1 t0 56.62 59.5 3.54 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 121.652 0.739 . . . . 0.0 109.965 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.408 HD13 HG21 ' A' ' 64' ' ' ILE . 97.2 mt . . . . . 0 N--CA 1.488 1.47 0 O-C-N 121.409 -0.807 . . . . 0.0 109.505 179.804 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt . . . . . 0 N--CA 1.496 1.829 0 CA-C-O 121.12 0.486 . . . . 0.0 109.762 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.8 p -116.21 118.32 32.49 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.556 -0.715 . . . . 0.0 109.367 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -105.52 131.5 10.68 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 -179.351 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.56 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.7 mp -84.91 126.04 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.41 -1.053 . . . . 0.0 109.477 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 74.0 t -75.2 129.03 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 O-C-N 121.318 -0.864 . . . . 0.0 109.938 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 65.0 t-20 -120.38 102.61 8.59 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.1 m -137.09 160.75 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.455 -0.778 . . . . 0.0 109.826 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 87.3 p -82.8 -13.09 56.88 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.524 -0.735 . . . . 0.0 109.266 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.7 m -145.69 -69.41 0.28 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.277 -0.889 . . . . 0.0 109.297 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 58.3 m -156.84 168.86 26.19 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.062 -1.024 . . . . 0.0 109.825 -179.564 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 49.8 tp -116.46 129.76 56.39 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-O 121.656 0.741 . . . . 0.0 109.838 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 14' ' ' ASN . 15.1 p30 -89.1 122.12 32.1 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.433 -0.792 . . . . 0.0 109.778 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.0 t -76.49 153.54 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.364 -0.835 . . . . 0.0 109.864 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.442 HH21 ' N ' ' A' ' 57' ' ' ALA . 88.9 mtm180 -128.54 136.47 50.8 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.567 -0.708 . . . . 0.0 109.809 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 12.6 tm-20 -69.95 -38.8 76.23 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.548 -0.72 . . . . 0.0 109.138 179.464 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -104.78 -178.86 24.6 Favored Glycine 0 N--CA 1.496 2.652 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 -179.236 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -94.5 -0.88 54.32 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.493 -1.004 . . . . 0.0 108.569 179.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.2 m -84.69 151.53 24.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.307 -0.871 . . . . 0.0 110.022 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 59.0 p -68.96 -29.08 67.23 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.55 -0.719 . . . . 0.0 109.612 179.421 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 96.7 p -85.65 7.47 23.25 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.278 -0.889 . . . . 0.0 109.257 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.0 t -62.42 146.44 51.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.434 -0.791 . . . . 0.0 110.759 -179.278 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -68.77 137.45 54.02 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-O 121.723 0.773 . . . . 0.0 110.954 -179.339 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 69.9 t -80.37 131.59 33.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 121.595 -0.691 . . . . 0.0 110.049 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 23.1 pt -102.21 -4.27 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.507 -0.746 . . . . 0.0 109.029 179.518 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 161.72 -177.09 38.12 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.483 -1.342 . . . . 0.0 109.959 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 57.8 m -132.91 159.55 39.58 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.47 -1.018 . . . . 0.0 109.732 -179.674 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 95.9 mt -120.07 149.55 42.0 Favored 'General case' 0 N--CA 1.496 1.87 0 CA-C-O 121.661 0.743 . . . . 0.0 109.884 -179.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.8 m -74.24 161.42 29.95 Favored 'General case' 0 N--CA 1.489 1.488 0 CA-C-O 121.863 0.839 . . . . 0.0 110.739 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -63.09 149.41 49.79 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 111.339 -0.704 . . . . 0.0 111.339 -179.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.9 m-20 57.09 32.93 22.53 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.792 -0.828 . . . . 0.0 109.73 179.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 25.3 m -90.77 126.63 36.06 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.241 -0.912 . . . . 0.0 109.772 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.5 ttmt -80.3 132.89 35.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.428 -0.795 . . . . 0.0 109.716 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.1 m -124.03 131.96 72.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.579 -0.701 . . . . 0.0 109.734 179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 61.1 m -80.04 128.21 33.21 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-O 121.426 0.631 . . . . 0.0 109.979 -179.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.7 mt -97.37 124.68 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.56 -0.712 . . . . 0.0 109.875 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 34.4 m -110.18 -0.84 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.477 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -175.2 178.01 47.01 Favored Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.637 -1.268 . . . . 0.0 110.2 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -142.74 153.58 43.45 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.08 -1.247 . . . . 0.0 109.527 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.408 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 12.9 tm-20 -151.9 107.6 3.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.47 179.367 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.37 -137.39 45.19 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 179.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -84.64 26.01 0.85 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.437 -1.037 . . . . 0.0 109.098 -179.341 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -132.02 145.19 51.29 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.559 -0.713 . . . . 0.0 109.412 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -106.95 139.46 41.31 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.615 0.722 . . . . 0.0 109.455 179.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -93.09 130.44 38.71 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.557 -0.714 . . . . 0.0 109.174 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 37.2 pt -131.26 154.22 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.611 -0.681 . . . . 0.0 110.044 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -90.86 96.57 10.7 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.519 -0.738 . . . . 0.0 109.127 179.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -107.33 123.54 48.49 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.507 -0.746 . . . . 0.0 109.953 -179.728 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.401 ' C ' ' H ' ' A' ' 52' ' ' SER . 74.3 tttt 51.49 34.54 12.44 Favored 'General case' 0 N--CA 1.493 1.678 0 CA-C-O 121.292 0.568 . . . . 0.0 109.944 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.41 -11.84 11.84 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 178.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.401 ' H ' ' C ' ' A' ' 50' ' ' LYS . 26.4 t -91.84 174.02 7.55 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.256 -1.144 . . . . 0.0 110.333 -179.513 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -97.37 101.53 13.09 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.36 -0.837 . . . . 0.0 109.639 -179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.26 137.79 13.52 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -119.73 137.39 53.97 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.411 -1.052 . . . . 0.0 109.585 179.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.2 m -139.45 154.76 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.276 -0.89 . . . . 0.0 109.822 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.442 ' N ' HH21 ' A' ' 16' ' ' ARG . . . -73.83 146.98 43.76 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.406 -0.809 . . . . 0.0 110.584 -179.762 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -66.21 -11.37 49.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.62 -0.675 . . . . 0.0 109.682 179.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -67.35 -34.57 77.59 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.222 -0.924 . . . . 0.0 109.779 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -90.71 3.3 54.64 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.209 -0.932 . . . . 0.0 109.487 -179.197 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 38.3 mm -103.47 129.68 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.346 -0.846 . . . . 0.0 109.939 -179.52 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -146.24 154.91 42.26 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.42 -0.8 . . . . 0.0 109.912 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.6 t0 63.11 52.8 2.43 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 121.555 0.693 . . . . 0.0 109.42 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt . . . . . 0 N--CA 1.487 1.392 0 O-C-N 121.524 -0.735 . . . . 0.0 109.649 -179.834 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt . . . . . 0 N--CA 1.495 1.776 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 70.2 p -132.16 133.55 44.37 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.576 -0.703 . . . . 0.0 109.643 -179.539 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -121.61 131.71 8.66 Favored Glycine 0 N--CA 1.499 2.876 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.56 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.8 mp -86.35 127.65 40.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.075 -1.25 . . . . 0.0 110.005 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 71.5 t -75.61 131.09 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 110.186 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.6 t-20 -123.74 108.23 12.3 Favored 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.52 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 29.3 m -152.96 -19.47 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.8 t 67.97 -52.84 0.52 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.79 -0.569 . . . . 0.0 109.677 -179.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 74.0 m -77.92 -79.41 0.12 Allowed 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.382 -0.824 . . . . 0.0 109.751 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 31.2 t -168.45 156.06 7.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.43 -0.794 . . . . 0.0 109.332 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 49.5 tp -123.58 130.28 52.43 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.56 -0.713 . . . . 0.0 109.317 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -84.16 154.48 23.08 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.361 -0.837 . . . . 0.0 109.79 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 54.4 t -105.95 130.14 57.97 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.445 -0.784 . . . . 0.0 109.276 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.708 HH21 ' N ' ' A' ' 20' ' ' SER . 42.4 mtp180 -104.64 128.05 52.57 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.476 -0.765 . . . . 0.0 109.699 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -72.06 -43.16 65.35 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.479 -0.763 . . . . 0.0 109.612 179.68 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -100.32 -175.48 30.1 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.125 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.473 ' C ' HH21 ' A' ' 16' ' ' ARG . . . -97.01 39.59 1.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.505 -0.997 . . . . 0.0 108.944 179.589 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.708 ' N ' HH21 ' A' ' 16' ' ' ARG . 33.0 t -131.86 149.87 52.32 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.554 -0.716 . . . . 0.0 109.72 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 53.1 p -65.11 -31.27 72.39 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.507 -0.746 . . . . 0.0 109.64 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.477 ' HG ' ' HG ' ' A' ' 20' ' ' SER . 96.6 p -86.55 13.34 8.63 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.262 -0.899 . . . . 0.0 108.993 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.9 m -62.2 151.13 36.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.442 -0.786 . . . . 0.0 110.442 -179.209 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 17.7 ttmm -64.97 136.83 57.27 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.503 -0.748 . . . . 0.0 110.941 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 97.4 t -90.86 116.73 32.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.3 pt -103.73 -4.76 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.514 -0.741 . . . . 0.0 109.699 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -178.69 -175.5 45.81 Favored Glycine 0 N--CA 1.49 2.253 0 C-N-CA 119.316 -1.421 . . . . 0.0 110.615 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.9 p -158.55 166.1 32.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.558 -0.966 . . . . 0.0 109.004 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.3 mt -123.21 153.92 39.45 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.446 -0.784 . . . . 0.0 109.926 -179.552 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.5 m -80.53 -3.54 50.53 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.663 -0.648 . . . . 0.0 109.334 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.533 ' C ' ' H ' ' A' ' 33' ' ' THR . . . 95.19 164.27 34.91 Favored Glycine 0 N--CA 1.498 2.772 0 O-C-N 121.304 -0.872 . . . . 0.0 111.031 178.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 55.7 2.37 0.07 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.753 -0.851 . . . . 0.0 110.033 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.533 ' H ' ' C ' ' A' ' 31' ' ' GLY . 54.0 m -85.01 133.1 34.26 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.122 -0.986 . . . . 0.0 109.578 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 8.3 ttpm? -80.4 136.79 36.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.341 -0.849 . . . . 0.0 109.964 -179.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.9 m -121.24 130.6 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 CA-C-O 121.506 0.669 . . . . 0.0 109.298 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 53.9 m -73.48 133.12 43.58 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.629 -0.669 . . . . 0.0 110.092 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.417 HG22 HD13 ' A' ' 37' ' ' ILE . 97.6 mt -109.66 127.7 66.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 CA-C-O 121.362 0.601 . . . . 0.0 109.491 179.744 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.54 -1.12 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.42 176.08 45.44 Favored Glycine 0 N--CA 1.49 2.289 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.244 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 -140.13 153.14 46.59 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.346 -1.091 . . . . 0.0 109.828 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.413 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 12.5 tm-20 -151.08 106.93 3.4 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.229 -0.919 . . . . 0.0 109.385 179.71 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 58.82 -138.69 49.23 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.214 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -83.45 5.05 25.13 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.594 -0.945 . . . . 0.0 109.271 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.448 ' CE1' ' NH1' ' A' ' 16' ' ' ARG . 96.6 m-85 -114.5 141.76 47.28 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.69 -0.631 . . . . 0.0 109.539 -179.636 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -107.86 150.72 26.69 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.664 -0.648 . . . . 0.0 109.666 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.5 mtpm? -91.35 139.16 30.99 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.501 -0.749 . . . . 0.0 109.024 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 38.8 pt -134.05 149.82 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.515 -0.741 . . . . 0.0 109.852 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -86.8 95.03 9.71 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.372 -0.83 . . . . 0.0 108.919 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 84.0 t80 -104.6 116.07 31.44 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.382 -0.824 . . . . 0.0 109.196 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 49.2 tttm 52.39 32.19 10.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.614 -0.679 . . . . 0.0 109.695 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 88.36 -20.92 27.71 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 87.2 p -83.3 166.18 18.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.237 -1.155 . . . . 0.0 110.228 -179.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 61.9 m170 -101.62 95.72 6.63 Favored 'General case' 0 N--CA 1.495 1.788 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -88.19 162.9 32.62 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 -179.163 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -122.18 138.02 54.62 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.768 -0.843 . . . . 0.0 109.227 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 20.7 m -137.29 153.61 29.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.333 -0.854 . . . . 0.0 109.647 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.01 139.77 46.87 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.509 -0.744 . . . . 0.0 110.274 -179.475 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -69.2 -12.43 61.67 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.37 -0.831 . . . . 0.0 109.604 179.336 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -63.09 -32.14 73.45 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.44 -0.788 . . . . 0.0 110.353 -179.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -99.17 5.91 46.61 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 109.828 -179.37 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.5 mm -105.18 128.59 58.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.934 0 O-C-N 121.296 -0.877 . . . . 0.0 109.515 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -141.65 164.29 30.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.466 -0.771 . . . . 0.0 110.17 -179.39 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 56.32 52.03 10.71 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.191 0.519 . . . . 0.0 110.137 179.714 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt . . . . . 0 N--CA 1.489 1.493 0 O-C-N 121.249 -0.907 . . . . 0.0 109.319 179.352 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 64.3 mttp . . . . . 0 N--CA 1.495 1.79 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 52.8 p -131.55 115.02 15.58 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.619 0.724 . . . . 0.0 109.363 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -91.18 137.65 13.94 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 -179.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.565 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.5 mp -92.22 122.22 43.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.618 -0.931 . . . . 0.0 109.398 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.0 t -78.22 132.46 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 O-C-N 121.512 -0.743 . . . . 0.0 110.045 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.6 t-20 -137.72 110.16 7.45 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.519 -0.738 . . . . 0.0 109.351 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.3 m -144.62 149.89 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.394 -0.816 . . . . 0.0 109.607 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 39.8 t -63.66 -43.85 95.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.546 -0.721 . . . . 0.0 110.05 179.837 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 24.6 t -109.43 -76.15 0.62 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.555 -0.715 . . . . 0.0 110.09 -179.204 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 92.1 p -156.73 165.54 35.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 -179.244 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.3 tp -115.17 128.28 56.09 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.761 0.791 . . . . 0.0 109.952 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -84.16 149.9 25.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.586 -0.696 . . . . 0.0 110.055 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.0 t -99.91 131.23 47.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.318 -0.864 . . . . 0.0 109.261 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.432 ' CZ ' ' O ' ' A' ' 21' ' ' THR . 99.7 mtt180 -103.84 135.25 45.74 Favored 'General case' 0 N--CA 1.494 1.758 0 CA-C-O 121.777 0.799 . . . . 0.0 110.099 -179.282 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 46.5 tp10 -70.87 -45.33 64.59 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.554 0.693 . . . . 0.0 109.508 179.715 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.653 ' H ' ' HG ' ' A' ' 23' ' ' SER . . . -99.08 172.93 26.01 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 -179.303 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -91.59 11.22 24.96 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.472 -1.016 . . . . 0.0 108.727 179.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.1 m -73.87 170.86 14.48 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.333 -0.855 . . . . 0.0 110.305 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.432 ' O ' ' CZ ' ' A' ' 16' ' ' ARG . 18.3 m -62.94 -44.82 95.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.576 -0.702 . . . . 0.0 109.996 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.3 t -131.12 71.12 1.46 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.352 -0.843 . . . . 0.0 109.235 -179.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.653 ' HG ' ' H ' ' A' ' 18' ' ' GLY . 3.7 t -83.14 176.66 9.03 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-O 121.659 0.742 . . . . 0.0 110.419 -179.592 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 65.7 tttm -63.72 133.76 54.12 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-O 121.797 0.808 . . . . 0.0 110.569 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 67.0 t -97.62 128.91 48.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.515 -0.74 . . . . 0.0 109.413 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 39.8 pt -105.19 -4.44 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.673 -0.642 . . . . 0.0 109.342 179.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.91 -156.84 27.36 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.368 -1.396 . . . . 0.0 110.491 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 92.9 p -157.43 164.92 36.96 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.425 -1.044 . . . . 0.0 109.515 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 97.4 mt -126.65 148.69 49.79 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.746 0.784 . . . . 0.0 110.021 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 19.4 m -73.59 156.6 37.9 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-O 121.807 0.813 . . . . 0.0 110.55 -179.4 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.17 156.19 38.09 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 65.3 t30 58.14 33.9 23.63 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.688 -0.889 . . . . 0.0 109.873 179.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 24.1 m -97.55 132.39 43.27 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.333 -0.855 . . . . 0.0 109.761 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -80.93 128.73 34.01 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.525 -0.734 . . . . 0.0 110.096 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.8 m -128.24 134.19 65.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.589 -0.694 . . . . 0.0 109.504 179.466 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 34.4 m -82.27 124.98 30.44 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.486 -0.758 . . . . 0.0 109.426 -179.662 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.424 HG21 HD11 ' A' ' 37' ' ' ILE . 96.8 mt -99.41 136.15 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 CA-C-O 121.608 0.718 . . . . 0.0 110.433 -179.517 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 34.1 m -110.44 -6.93 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 165.79 -174.67 41.49 Favored Glycine 0 N--CA 1.489 2.189 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.359 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -140.91 147.2 38.5 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.459 -1.024 . . . . 0.0 109.205 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.513 ' OE1' ' N ' ' A' ' 41' ' ' GLU . 56.9 mp0 -145.87 120.67 9.91 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.29 -0.881 . . . . 0.0 110.153 -179.454 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.482 ' O ' ' CB ' ' A' ' 43' ' ' ALA . . . 70.19 31.08 69.13 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.482 ' CB ' ' O ' ' A' ' 42' ' ' GLY . . . 77.4 11.03 2.28 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.524 -0.986 . . . . 0.0 109.136 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.464 ' CD2' ' O ' ' A' ' 42' ' ' GLY . 99.2 m-85 -114.03 131.6 56.3 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.653 -0.654 . . . . 0.0 109.319 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -79.47 139.71 37.54 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.615 -0.678 . . . . 0.0 109.963 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -100.56 120.05 39.44 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.495 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.5 pt -125.07 161.63 28.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 CA-C-O 121.748 0.785 . . . . 0.0 110.45 -179.076 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.17 124.31 34.72 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.269 0.557 . . . . 0.0 109.649 -179.588 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 81.9 t80 -132.99 120.82 21.88 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.459 -0.776 . . . . 0.0 109.861 179.611 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 76.5 tttt 39.03 47.38 1.26 Allowed 'General case' 0 N--CA 1.496 1.846 0 CA-C-O 121.687 0.756 . . . . 0.0 110.427 179.424 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 86.3 -50.67 4.28 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 179.615 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 16.7 m -74.46 145.16 43.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -1.132 . . . . 0.0 110.51 -179.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -83.94 120.54 26.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.393 -0.817 . . . . 0.0 109.915 -179.665 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.12 148.45 18.99 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -115.23 142.68 46.34 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.689 -0.889 . . . . 0.0 109.846 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.4 m -140.94 153.6 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.491 -0.756 . . . . 0.0 109.525 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.85 140.23 43.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.408 -0.808 . . . . 0.0 110.247 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 7.2 ptmm? -65.45 -9.23 23.82 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.516 -0.74 . . . . 0.0 109.744 179.615 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.53 -21.09 62.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.797 . . . . 0.0 110.164 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 -104.97 -23.26 13.0 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.268 -0.895 . . . . 0.0 109.582 -179.435 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.518 ' N ' ' CD1' ' A' ' 61' ' ' ILE . 1.6 mp -97.07 130.87 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.26 -0.9 . . . . 0.0 109.841 -179.706 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.473 ' O ' ' N ' ' A' ' 64' ' ' ILE . 23.0 pttp -134.98 -165.35 1.66 Allowed 'General case' 0 N--CA 1.494 1.739 0 CA-C-O 121.474 0.654 . . . . 0.0 109.697 179.579 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 59.17 -78.27 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.771 0 CA-C-O 121.151 0.5 . . . . 0.0 109.986 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.473 ' N ' ' O ' ' A' ' 62' ' ' LYS . 97.2 mt . . . . . 0 N--CA 1.493 1.684 0 CA-C-O 121.44 0.638 . . . . 0.0 109.842 -179.35 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.8 mttt . . . . . 0 N--CA 1.496 1.854 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 25.7 p -123.57 128.61 49.98 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.519 -0.738 . . . . 0.0 109.682 -179.474 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.97 129.87 9.82 Favored Glycine 0 N--CA 1.497 2.746 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.542 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.6 mp -80.14 126.3 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.185 -1.185 . . . . 0.0 109.292 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.2 t -81.74 131.62 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.274 -0.891 . . . . 0.0 110.186 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.2 m120 -120.2 100.07 6.97 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.476 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.7 m -141.01 136.27 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.875 0 O-C-N 121.302 -0.874 . . . . 0.0 109.577 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 t -61.99 -44.86 95.85 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.576 -0.702 . . . . 0.0 109.707 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 68.0 m -99.3 -79.72 0.48 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.557 -0.715 . . . . 0.0 109.456 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 59.9 m -158.92 172.29 18.48 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.359 -0.838 . . . . 0.0 109.389 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.0 tp -116.27 131.48 56.93 Favored 'General case' 0 N--CA 1.5 2.055 0 CA-C-O 121.479 0.657 . . . . 0.0 109.516 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.5 p30 -90.86 153.86 19.9 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.393 -0.817 . . . . 0.0 109.655 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 53.7 t -105.3 130.28 56.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.39 -0.819 . . . . 0.0 108.842 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.453 HH22 ' H ' ' A' ' 57' ' ' ALA . 91.0 mtm-85 -112.11 137.94 49.47 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.533 -0.729 . . . . 0.0 109.502 -179.538 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 69.8 mm-40 -86.48 -29.35 22.83 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.463 -0.773 . . . . 0.0 109.193 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.683 ' H ' ' HG ' ' A' ' 23' ' ' SER . . . -98.46 148.39 18.85 Favored Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.701 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -82.63 73.17 9.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.313 -1.11 . . . . 0.0 109.325 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.1 m -159.15 -169.43 2.65 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.127 -0.983 . . . . 0.0 109.55 179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 65.9 p -80.71 101.56 9.36 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.277 -0.889 . . . . 0.0 109.785 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.408 ' OG ' ' O ' ' A' ' 22' ' ' SER . 6.6 t 56.6 52.36 9.86 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.77 -0.582 . . . . 0.0 109.854 179.398 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.683 ' HG ' ' H ' ' A' ' 18' ' ' GLY . 77.9 p -62.31 -42.97 99.81 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.301 -0.875 . . . . 0.0 109.313 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 33.2 ttpt -170.6 115.94 0.48 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.262 -0.899 . . . . 0.0 109.443 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.3 t -90.45 130.22 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.527 -0.733 . . . . 0.0 109.737 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.9 pt -117.37 -11.63 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.32 -162.54 31.36 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.187 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 36.9 t -155.44 168.49 26.95 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.321 -1.105 . . . . 0.0 109.868 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 95.2 mt -127.3 152.74 47.04 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.607 -0.683 . . . . 0.0 109.721 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.6 m -71.4 152.95 42.66 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.609 -0.682 . . . . 0.0 110.368 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -61.86 160.45 29.91 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 -179.176 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 64.4 t30 62.06 4.92 1.29 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.941 -0.741 . . . . 0.0 109.874 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 66.7 m -82.74 130.81 35.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.077 -1.014 . . . . 0.0 109.958 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -86.81 147.46 25.81 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.316 -0.865 . . . . 0.0 109.576 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.3 m -123.34 132.97 70.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.431 -0.793 . . . . 0.0 109.458 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 36.2 m -69.92 130.68 42.87 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.744 -0.598 . . . . 0.0 110.065 -179.352 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.2 mt -109.34 129.17 64.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 29.3 m -120.59 5.24 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 179.591 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.68 177.4 45.25 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 119.531 -1.318 . . . . 0.0 110.463 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -126.69 153.74 45.04 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.676 -0.896 . . . . 0.0 109.247 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 8.1 tm-20 -151.03 93.47 1.93 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.158 -0.963 . . . . 0.0 109.892 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 51.97 -133.27 36.82 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 178.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.81 25.38 1.11 Allowed 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.623 -0.928 . . . . 0.0 108.941 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -138.07 134.62 34.95 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.691 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 44.7 m-85 -89.08 144.89 25.82 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.18 -0.95 . . . . 0.0 109.803 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -90.88 129.49 36.92 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.444 -0.785 . . . . 0.0 109.031 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 39.2 pt -128.46 154.26 39.01 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.592 -0.693 . . . . 0.0 110.06 -179.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -87.52 93.74 9.51 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.518 -0.739 . . . . 0.0 109.099 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -92.92 152.74 19.2 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.232 -0.917 . . . . 0.0 110.009 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 41.2 tttp -55.46 119.87 6.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.332 -0.855 . . . . 0.0 110.462 -179.37 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 104.4 -46.3 1.2 Allowed Glycine 0 N--CA 1.496 2.66 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.665 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 95.9 p -163.34 177.92 8.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.121 -1.223 . . . . 0.0 109.953 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -81.08 119.74 23.93 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.2 -0.937 . . . . 0.0 109.452 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.72 165.49 32.17 Favored Glycine 0 N--CA 1.496 2.697 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 -179.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -123.42 138.22 54.64 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.762 -0.846 . . . . 0.0 109.455 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.1 m -137.35 140.76 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.535 -0.728 . . . . 0.0 109.534 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.453 ' H ' HH22 ' A' ' 16' ' ' ARG . . . -68.41 151.0 47.47 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.517 -0.739 . . . . 0.0 110.794 -179.291 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 45.3 mtmt -62.6 -28.91 70.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.573 -0.704 . . . . 0.0 109.184 179.49 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -58.95 -34.43 71.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.474 -0.766 . . . . 0.0 110.418 -178.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -89.73 -1.99 58.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.019 -1.051 . . . . 0.0 109.466 -179.345 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 43.7 mm -112.59 130.29 66.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.616 -0.678 . . . . 0.0 109.828 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -136.47 142.17 43.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.65 -0.656 . . . . 0.0 109.694 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 44.6 t0 62.43 77.99 0.31 Allowed 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.296 0.57 . . . . 0.0 109.899 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 82.2 mt . . . . . 0 N--CA 1.491 1.623 0 O-C-N 121.457 -0.777 . . . . 0.0 109.158 179.716 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.495 1.782 0 CA-C-O 121.292 0.568 . . . . 0.0 109.786 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 69.3 p -117.05 113.96 23.07 Favored 'General case' 0 N--CA 1.498 1.973 0 CA-C-O 121.898 0.856 . . . . 0.0 110.038 -179.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -103.06 130.73 10.35 Favored Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.4 mm -87.53 127.66 40.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.901 -0.764 . . . . 0.0 109.957 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.2 t -71.93 130.56 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 CA-C-O 121.467 0.651 . . . . 0.0 109.725 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.486 ' CG ' ' HZ2' ' A' ' 62' ' ' LYS . 56.0 t30 -123.39 101.93 7.62 Favored 'General case' 0 N--CA 1.497 1.894 0 CA-C-O 121.311 0.577 . . . . 0.0 109.642 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 30.5 m -148.18 158.19 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 121.611 0.719 . . . . 0.0 110.146 179.001 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 58.6 m -87.94 -16.81 32.81 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.859 -0.525 . . . . 0.0 109.976 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 12' ' ' SER . 66.4 m -155.38 87.79 1.12 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.422 -0.799 . . . . 0.0 110.326 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 11' ' ' SER . 1.3 m 46.73 -179.99 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 CA-C-O 121.724 0.773 . . . . 0.0 110.99 178.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 37.8 tp -144.59 130.55 19.34 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.681 0.753 . . . . 0.0 109.846 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -83.31 132.37 35.02 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-O 121.721 0.772 . . . . 0.0 110.053 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 86.7 t -81.18 131.99 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 CA-C-O 121.708 0.766 . . . . 0.0 109.73 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.582 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 93.5 mtm-85 -106.42 135.15 48.42 Favored 'General case' 0 N--CA 1.493 1.688 0 CA-C-O 121.762 0.791 . . . . 0.0 109.897 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.513 ' N ' ' OG ' ' A' ' 23' ' ' SER . 82.8 tt0 -99.52 77.4 2.09 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.645 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.38 170.89 16.7 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 179.413 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -88.66 4.87 45.63 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.7 -0.882 . . . . 0.0 109.199 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.3 m -74.68 155.94 37.2 Favored 'General case' 0 N--CA 1.495 1.779 0 CA-C-O 121.637 0.732 . . . . 0.0 109.966 179.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 51.0 p -66.77 -29.97 70.06 Favored 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.7 t -136.59 68.32 1.43 Allowed 'General case' 0 N--CA 1.497 1.893 0 CA-C-O 121.429 0.633 . . . . 0.0 109.443 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 17' ' ' GLU . 5.1 p -82.83 176.79 9.03 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.805 0.812 . . . . 0.0 110.6 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -58.5 130.85 48.75 Favored 'General case' 0 N--CA 1.491 1.58 0 CA-C-O 121.991 0.901 . . . . 0.0 111.11 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.4 t -84.31 129.18 38.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 42.1 pt -115.87 -6.39 11.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 168.83 -166.05 39.36 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.996 -1.097 . . . . 0.0 110.66 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 47.4 t -151.84 153.82 34.97 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.825 -0.809 . . . . 0.0 109.935 -179.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.0 mt -123.26 149.76 44.35 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.794 0.807 . . . . 0.0 109.65 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 23.4 p -74.73 160.61 30.53 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.752 0.787 . . . . 0.0 110.451 -179.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -68.62 155.72 53.36 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 58.15 34.69 24.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 122.046 -0.679 . . . . 0.0 109.889 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 53.2 m -102.4 127.16 49.53 Favored 'General case' 0 N--CA 1.498 1.949 0 CA-C-O 121.968 0.889 . . . . 0.0 109.936 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.6 ttpt -77.0 130.33 37.32 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.535 0.684 . . . . 0.0 109.881 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.2 m -129.96 130.89 66.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 CA-C-O 121.75 0.786 . . . . 0.0 109.674 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 11.1 p -77.19 134.29 38.68 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.455 0.645 . . . . 0.0 109.879 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.5 mt -106.23 127.64 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 CA-C-O 121.481 0.658 . . . . 0.0 109.473 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -112.05 -1.06 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.99 171.85 44.72 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.789 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 10.0 tm-20 -137.96 146.65 43.44 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.848 -0.795 . . . . 0.0 109.935 -179.499 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 68.7 mm-40 -144.05 109.4 5.11 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-O 121.97 0.891 . . . . 0.0 109.851 179.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.12 -135.11 47.73 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.464 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.36 30.52 0.98 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.765 -0.844 . . . . 0.0 108.746 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -134.49 143.42 47.47 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-O 121.531 0.681 . . . . 0.0 109.821 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -108.82 140.46 42.23 Favored 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.898 0.856 . . . . 0.0 109.59 179.342 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 51.1 mtmt -93.59 143.97 25.81 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.686 0.755 . . . . 0.0 109.717 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 41.5 pt -132.94 152.37 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 CA-C-O 121.646 0.736 . . . . 0.0 110.056 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -75.46 93.78 3.02 Favored 'General case' 0 N--CA 1.489 1.506 0 CA-C-O 121.42 0.629 . . . . 0.0 109.787 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -108.78 142.39 39.4 Favored 'General case' 0 N--CA 1.491 1.611 0 CA-C-O 121.828 0.823 . . . . 0.0 109.589 179.624 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 18.5 ptmt -55.03 119.63 5.73 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 121.845 0.831 . . . . 0.0 110.318 -179.697 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.453 ' O ' ' OG ' ' A' ' 52' ' ' SER . . . 110.63 -47.98 0.98 Allowed Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.286 -1.525 . . . . 0.0 109.286 179.58 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.453 ' OG ' ' O ' ' A' ' 51' ' ' GLY . 24.7 m -167.77 -162.44 0.44 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.739 -0.859 . . . . 0.0 110.386 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -100.11 120.2 39.5 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.832 0.825 . . . . 0.0 109.926 -179.157 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -83.03 145.24 23.24 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -108.54 137.33 46.67 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.615 0.721 . . . . 0.0 109.703 179.724 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.6 m -140.67 143.99 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 CA-C-O 121.735 0.779 . . . . 0.0 110.237 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.582 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -66.66 146.76 54.12 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.64 0.734 . . . . 0.0 110.329 -179.716 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 48.3 mtmt -62.94 -34.4 77.4 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 121.318 0.58 . . . . 0.0 109.468 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -51.47 -33.79 32.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.851 -0.53 . . . . 0.0 110.169 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -89.57 0.7 56.74 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.567 -0.708 . . . . 0.0 109.831 -179.367 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 5.6 mm -108.84 125.95 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 CA-C-O 121.685 0.755 . . . . 0.0 110.215 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.486 ' HZ2' ' CG ' ' A' ' 8' ' ' ASN . 64.0 pttt -145.92 163.49 34.97 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.757 0.789 . . . . 0.0 110.536 -179.741 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 57.94 55.02 5.6 Favored 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 121.444 0.64 . . . . 0.0 109.614 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt . . . . . 0 N--CA 1.489 1.481 0 CA-C-O 121.646 0.736 . . . . 0.0 109.554 -179.837 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt . . . . . 0 N--CA 1.479 1.013 1 N-CA-C 99.335 -4.32 . . . . 0.0 99.335 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.06 135.32 29.05 Favored 'General case' 0 N--CA 1.506 2.357 0 C-N-CA 114.944 -2.702 . . . . 0.0 116.574 -173.512 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -105.02 135.82 12.77 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 106.493 -2.643 . . . . 0.0 106.493 177.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 37.1 mm -97.91 121.67 48.7 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.191 -1.182 . . . . 0.0 108.444 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 76.4 t -80.88 132.34 31.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.248 -0.907 . . . . 0.0 109.619 -179.089 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.651 HD21 ' NZ ' ' A' ' 62' ' ' LYS . 43.9 t-20 -144.91 108.38 4.63 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.245 -0.909 . . . . 0.0 109.216 179.753 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 28.5 m -135.84 162.25 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.169 -0.957 . . . . 0.0 110.168 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.6 t -61.65 -43.15 99.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.549 -0.72 . . . . 0.0 110.017 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 57.9 m -123.75 -90.63 0.56 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.432 -0.792 . . . . 0.0 110.245 -179.387 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.9 m -129.71 157.32 42.48 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.539 -0.726 . . . . 0.0 109.771 -179.258 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.9 tp -114.01 130.9 56.51 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.454 -0.778 . . . . 0.0 109.009 179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -88.29 144.7 26.27 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.421 -0.8 . . . . 0.0 109.614 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 70.8 t -92.35 131.32 39.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.28 -0.888 . . . . 0.0 108.901 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.653 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 84.4 mtm-85 -107.61 136.39 47.45 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.472 -0.767 . . . . 0.0 109.572 -179.464 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -93.48 90.12 6.57 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.162 -0.961 . . . . 0.0 110.049 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 130.16 -174.09 19.7 Favored Glycine 0 N--CA 1.499 2.841 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 179.289 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -105.01 31.19 4.99 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.574 -0.957 . . . . 0.0 109.22 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 36.0 m -134.02 148.87 51.15 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.363 -0.836 . . . . 0.0 109.674 -179.794 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 40.2 p -67.78 -30.87 70.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.302 -0.874 . . . . 0.0 110.285 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 35.9 t -75.5 7.22 3.81 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.273 -0.892 . . . . 0.0 109.605 -179.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.8 m -65.17 148.95 50.77 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.363 -0.835 . . . . 0.0 110.091 -179.43 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -71.46 142.86 50.21 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.488 -0.757 . . . . 0.0 110.343 -179.578 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 20.4 t -85.64 128.32 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.449 -0.782 . . . . 0.0 109.293 179.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 23.9 pt -107.7 -2.89 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 121.312 -0.867 . . . . 0.0 109.908 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.13 178.87 39.23 Favored Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.007 179.662 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -134.23 153.42 51.86 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.542 -0.975 . . . . 0.0 109.248 179.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 91.7 mt -123.98 146.4 48.53 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 121.321 -0.862 . . . . 0.0 109.497 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 28.0 t -79.75 163.53 24.4 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.435 -0.791 . . . . 0.0 110.635 -179.07 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -66.03 161.7 43.83 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.524 -1.031 . . . . 0.0 110.524 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 54.75 31.96 16.51 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.578 -0.954 . . . . 0.0 109.595 -179.762 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.2 m -100.09 126.25 46.29 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.432 -0.793 . . . . 0.0 108.957 179.609 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -79.49 132.2 36.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.32 -0.862 . . . . 0.0 109.501 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 14.9 m -127.03 131.86 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.394 -0.816 . . . . 0.0 108.991 179.451 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 45.9 p -75.4 134.45 40.92 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-O 121.243 0.545 . . . . 0.0 109.87 -179.184 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.425 HG21 HD12 ' A' ' 37' ' ' ILE . 95.3 mt -111.35 128.89 67.54 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 CA-C-O 121.391 0.615 . . . . 0.0 109.379 179.508 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 35.3 m -113.29 -1.57 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.706 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -179.48 -178.67 48.51 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -142.84 159.45 42.22 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.256 -1.144 . . . . 0.0 109.676 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -154.53 113.0 3.56 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.137 -0.977 . . . . 0.0 109.759 179.496 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 59.97 -141.94 47.57 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.414 -1.075 . . . . 0.0 110.414 179.312 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.44 24.92 1.53 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.572 -0.958 . . . . 0.0 109.324 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -129.75 147.78 51.57 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.545 -0.722 . . . . 0.0 109.087 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -103.94 142.8 33.78 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.465 -0.772 . . . . 0.0 109.607 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -91.69 128.0 37.35 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 14.2 pt -129.89 154.02 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.296 -0.878 . . . . 0.0 109.391 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.413 ' OE1' ' CD2' ' A' ' 53' ' ' HIS . 49.0 tp10 -82.88 110.99 18.36 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.464 -0.772 . . . . 0.0 109.148 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.577 ' O ' ' N ' ' A' ' 51' ' ' GLY . 79.1 t80 -107.35 117.49 34.21 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.398 -0.814 . . . . 0.0 109.464 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt 44.23 -87.44 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.549 -0.72 . . . . 0.0 110.106 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -123.51 -34.0 0.78 Allowed Glycine 0 N--CA 1.497 2.741 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 15.6 p -89.43 169.43 11.39 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.335 -1.097 . . . . 0.0 109.822 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . 0.413 ' CD2' ' OE1' ' A' ' 48' ' ' GLU . 73.2 m80 -96.46 115.63 27.75 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.533 -0.729 . . . . 0.0 109.124 179.645 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.96 153.12 26.56 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -121.01 138.66 54.06 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.708 -0.877 . . . . 0.0 109.073 179.661 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -136.58 152.59 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.307 -0.87 . . . . 0.0 109.495 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.653 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -75.03 147.26 40.86 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.523 -0.736 . . . . 0.0 110.65 -179.363 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -70.98 -14.11 62.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.431 -0.793 . . . . 0.0 109.444 179.187 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -65.47 -37.9 88.2 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.447 -0.783 . . . . 0.0 110.292 -179.222 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 74.1 m-85 -96.81 -7.55 33.35 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.24 -0.912 . . . . 0.0 110.397 -179.068 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 1.5 mp -108.17 129.08 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.062 0 O-C-N 121.366 -0.834 . . . . 0.0 108.931 -179.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.651 ' NZ ' HD21 ' A' ' 8' ' ' ASN . 26.7 pttm -145.86 -178.81 6.3 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.201 -0.937 . . . . 0.0 109.708 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 43.2 t0 60.73 46.67 8.82 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.609 -0.682 . . . . 0.0 109.368 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt . . . . . 0 N--CA 1.489 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.02 179.667 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.3 mppt? . . . . . 0 N--CA 1.494 1.76 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 68.9 p -122.74 137.68 54.84 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.621 -0.674 . . . . 0.0 109.765 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -119.49 131.09 8.81 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 5.6 mm -86.87 122.53 38.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.411 -1.052 . . . . 0.0 109.431 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 80.7 t -79.13 131.46 34.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.449 -0.782 . . . . 0.0 110.071 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 96.2 m-20 -121.48 101.77 7.83 Favored 'General case' 0 N--CA 1.497 1.925 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 29.4 m -139.98 160.95 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.425 -0.797 . . . . 0.0 110.025 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 80.6 p -81.63 -11.65 59.02 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.0 p -149.07 -70.21 0.21 Allowed 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.455 -0.778 . . . . 0.0 109.267 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 98.6 p -153.95 168.89 24.89 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.904 . . . . 0.0 110.116 -179.598 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.7 tp -115.47 131.03 57.06 Favored 'General case' 0 N--CA 1.498 1.925 0 CA-C-O 121.479 0.657 . . . . 0.0 109.495 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -83.92 135.25 34.55 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.484 -0.76 . . . . 0.0 110.196 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 87.3 t -90.36 131.74 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.478 -0.764 . . . . 0.0 109.218 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.595 HH21 ' N ' ' A' ' 57' ' ' ALA . 87.5 mtm180 -105.55 133.89 49.56 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.493 -0.754 . . . . 0.0 110.187 -179.601 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -67.53 -46.76 71.86 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.561 -0.712 . . . . 0.0 109.673 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.52 178.68 30.23 Favored Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.182 -1.167 . . . . 0.0 110.182 -179.311 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -92.95 21.28 5.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.616 -0.932 . . . . 0.0 108.681 179.536 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.1 m -79.59 165.2 23.18 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.543 -0.723 . . . . 0.0 110.407 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.7 m -63.19 -46.17 88.34 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.691 -0.631 . . . . 0.0 109.976 -179.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.8 m -129.44 71.13 1.43 Allowed 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.484 -0.76 . . . . 0.0 109.014 -179.553 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.46 -180.0 7.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.639 -0.663 . . . . 0.0 110.136 -179.545 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -67.05 133.12 49.26 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.617 0.723 . . . . 0.0 110.389 -179.453 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 74.8 t -81.15 129.19 37.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.482 -0.762 . . . . 0.0 109.536 179.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.1 pt -109.99 -5.09 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.723 -0.611 . . . . 0.0 109.489 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.09 177.39 38.15 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.489 -1.339 . . . . 0.0 110.284 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -132.23 155.71 47.78 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.73 -0.865 . . . . 0.0 109.397 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.6 mt -123.55 150.3 44.18 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-O 121.456 0.646 . . . . 0.0 109.801 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.4 m -71.82 152.54 42.59 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 121.522 0.677 . . . . 0.0 110.195 -179.537 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.495 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -68.07 162.83 48.61 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 11.8 m120 56.46 5.0 0.17 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.979 -0.719 . . . . 0.0 109.854 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.495 ' H ' ' C ' ' A' ' 31' ' ' GLY . 35.3 m -81.26 137.1 35.85 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.898 . . . . 0.0 110.138 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -84.96 139.88 31.49 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.498 -0.751 . . . . 0.0 110.176 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 19.8 m -127.0 132.16 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.625 -0.672 . . . . 0.0 109.403 179.562 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 44.5 m -65.67 128.21 35.03 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.725 -0.609 . . . . 0.0 110.047 -179.496 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 97.1 mt -115.55 125.13 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 CA-C-O 121.391 0.615 . . . . 0.0 109.631 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.426 ' CG2' ' N ' ' A' ' 39' ' ' GLY . 34.6 m -112.96 -47.88 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 179.39 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.426 ' N ' ' CG2' ' A' ' 38' ' ' VAL . . . -95.06 162.58 23.95 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -142.01 125.63 16.85 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.494 -1.003 . . . . 0.0 109.298 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.467 ' O ' ' N ' ' A' ' 43' ' ' ALA . 83.1 tt0 -114.91 142.95 45.89 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.507 ' O ' ' CB ' ' A' ' 43' ' ' ALA . . . -65.71 59.52 0.13 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.487 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.507 ' CB ' ' O ' ' A' ' 42' ' ' GLY . . . 160.58 -31.7 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.711 -0.876 . . . . 0.0 108.715 179.707 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -134.68 160.91 36.67 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.534 -0.729 . . . . 0.0 110.204 -178.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.7 m-85 -114.13 140.25 48.67 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.589 -0.694 . . . . 0.0 109.688 179.679 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -90.68 129.95 36.73 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 -179.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.9 pt -127.9 157.04 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 CA-C-O 121.571 0.701 . . . . 0.0 110.1 -179.685 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -86.93 93.98 9.47 Favored 'General case' 0 N--CA 1.49 1.561 0 CA-C-O 121.431 0.634 . . . . 0.0 109.927 -179.485 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 91.5 t80 -86.89 140.07 30.0 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.399 -0.813 . . . . 0.0 109.467 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.8 tttm -54.63 100.53 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.422 -0.799 . . . . 0.0 110.05 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 124.51 -33.94 3.63 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 20.7 t -171.11 -168.58 0.66 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.214 -1.168 . . . . 0.0 109.942 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 5.9 m170 -100.69 120.16 39.66 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.519 -0.738 . . . . 0.0 109.641 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.09 161.37 20.85 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -118.09 147.06 43.64 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.737 -0.86 . . . . 0.0 109.626 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.2 m -139.27 153.32 24.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.699 -0.626 . . . . 0.0 109.794 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.595 ' N ' HH21 ' A' ' 16' ' ' ARG . . . -73.68 141.34 46.44 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.574 -0.704 . . . . 0.0 110.59 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -64.61 -12.25 43.65 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.681 -0.637 . . . . 0.0 110.016 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 45.1 tp10 -68.87 -35.97 77.54 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -0.9 . . . . 0.0 110.546 -179.228 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -93.52 2.25 56.48 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.103 -0.998 . . . . 0.0 110.147 -178.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.8 mm -105.67 128.91 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.483 -0.761 . . . . 0.0 109.616 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -143.63 157.09 44.67 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.56 -0.712 . . . . 0.0 109.993 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 37.5 t0 64.39 45.68 3.7 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.615 0.721 . . . . 0.0 109.675 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.407 HD12 HG22 ' A' ' 64' ' ' ILE . 97.1 mt . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.68 -0.638 . . . . 0.0 110.071 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 52.4 mtmt . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 50.6 p -122.8 124.54 43.55 Favored 'General case' 0 N--CA 1.496 1.872 0 CA-C-O 121.829 0.823 . . . . 0.0 109.357 179.52 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -101.78 133.69 11.45 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 -179.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 34.4 mm -84.29 126.62 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.7 -0.882 . . . . 0.0 110.009 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.1 t -82.89 98.6 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.376 -0.827 . . . . 0.0 109.317 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -101.47 107.24 18.49 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.508 -0.745 . . . . 0.0 109.889 -179.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 m -141.09 144.3 26.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.299 -0.876 . . . . 0.0 109.575 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 27.5 t -66.97 -13.78 62.19 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-O 121.44 0.638 . . . . 0.0 109.497 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.422 ' OG ' ' N ' ' A' ' 12' ' ' SER . 91.1 p -141.3 -103.84 0.14 Allowed 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.161 -0.962 . . . . 0.0 110.231 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.422 ' N ' ' OG ' ' A' ' 11' ' ' SER . 57.8 m -127.49 157.38 40.24 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.464 -0.773 . . . . 0.0 110.191 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 36.5 tp -113.39 128.81 56.58 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 121.723 0.773 . . . . 0.0 109.875 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.9 m-20 -85.07 150.8 24.61 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.479 0.657 . . . . 0.0 110.025 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.4 t -104.41 129.94 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.423 -0.798 . . . . 0.0 109.276 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -105.28 132.81 51.01 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.546 0.688 . . . . 0.0 109.816 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -71.23 -37.22 72.01 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-O 121.819 0.818 . . . . 0.0 109.433 179.635 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -100.73 179.44 29.02 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -179.392 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -94.31 -1.44 53.87 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.193 -1.18 . . . . 0.0 108.825 179.393 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.9 m -83.36 149.82 26.48 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.312 -0.867 . . . . 0.0 110.196 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.424 ' C ' ' H ' ' A' ' 23' ' ' SER . 97.7 m -65.0 -44.33 89.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.415 -0.803 . . . . 0.0 110.078 179.489 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 76.5 p -78.49 16.66 0.78 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.078 -1.014 . . . . 0.0 109.529 -179.448 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.424 ' H ' ' C ' ' A' ' 21' ' ' THR . 18.8 m -63.64 149.65 46.03 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.212 -0.93 . . . . 0.0 110.251 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -70.96 138.25 49.86 Favored 'General case' 0 N--CA 1.488 1.47 0 CA-C-O 121.981 0.895 . . . . 0.0 110.528 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 75.0 t -87.37 130.17 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 CA-C-O 121.697 0.761 . . . . 0.0 109.925 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 37.4 pt -103.61 -4.57 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.007 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.91 -163.96 36.48 Favored Glycine 0 N--CA 1.493 2.451 0 C-N-CA 119.497 -1.335 . . . . 0.0 110.434 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 95.3 p -156.6 163.03 39.81 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.469 -1.019 . . . . 0.0 109.663 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 89.7 mt -124.79 150.86 45.87 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-O 121.694 0.759 . . . . 0.0 109.903 -179.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 12.3 p -76.19 164.72 25.81 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.062 0.934 . . . . 0.0 111.038 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.23 152.81 43.48 Favored Glycine 0 N--CA 1.489 2.222 0 CA-C-O 122.105 0.836 . . . . 0.0 111.665 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 67.1 t30 57.89 32.19 21.6 Favored 'General case' 0 N--CA 1.494 1.744 0 CA-C-O 121.635 0.731 . . . . 0.0 110.147 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 24.6 m -89.98 126.95 35.93 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.154 -0.966 . . . . 0.0 109.539 179.044 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -82.77 133.17 35.15 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.337 -0.852 . . . . 0.0 109.624 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.0 m -125.85 133.62 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 CA-C-O 121.791 0.805 . . . . 0.0 110.03 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 85.5 m -80.37 127.53 32.49 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.413 0.625 . . . . 0.0 109.78 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.401 HG22 HD12 ' A' ' 37' ' ' ILE . 92.8 mt -105.41 126.72 60.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 CA-C-O 121.466 0.65 . . . . 0.0 109.602 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 18.5 m -112.68 -1.97 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.56 177.82 45.75 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.613 -1.279 . . . . 0.0 110.364 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -141.72 159.63 41.83 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.356 -1.084 . . . . 0.0 109.871 -179.786 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -154.32 109.42 3.11 Favored 'General case' 0 N--CA 1.489 1.497 0 CA-C-O 121.684 0.754 . . . . 0.0 109.158 179.37 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.34 -137.47 45.0 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.06 23.28 1.26 Allowed 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.458 -1.024 . . . . 0.0 108.979 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -130.44 145.3 51.8 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.415 -0.803 . . . . 0.0 109.79 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.4 m-85 -108.5 139.66 42.94 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.611 0.719 . . . . 0.0 109.41 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -90.65 129.95 36.71 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.558 -0.714 . . . . 0.0 109.304 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.7 pt -129.03 153.53 38.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 CA-C-O 121.708 0.765 . . . . 0.0 109.804 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -81.02 99.66 8.56 Favored 'General case' 0 N--CA 1.49 1.531 0 CA-C-O 121.674 0.75 . . . . 0.0 109.857 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.404 ' CD2' ' N ' ' A' ' 51' ' ' GLY . 88.0 t80 -81.2 144.13 31.83 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.559 -0.713 . . . . 0.0 110.021 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 51.9 mtmt -46.85 -47.22 21.26 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.461 -0.775 . . . . 0.0 110.144 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.404 ' N ' ' CD2' ' A' ' 49' ' ' TYR . . . -69.34 -39.93 80.81 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 179.797 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 21.4 m -171.62 -110.78 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.152 -1.205 . . . . 0.0 109.325 -179.536 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 73.2 m80 -127.56 112.56 15.04 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-O 121.801 0.81 . . . . 0.0 109.352 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.84 154.29 19.94 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 -179.681 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -120.87 139.96 52.45 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.606 -0.938 . . . . 0.0 109.712 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.2 m -135.96 152.55 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.55 -0.719 . . . . 0.0 109.195 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 149.8 37.93 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-O 121.861 0.839 . . . . 0.0 110.667 -179.528 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 62.2 pttt -65.8 -15.43 62.87 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.57 0.7 . . . . 0.0 109.977 179.4 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.443 ' OE2' ' CE2' ' A' ' 60' ' ' TYR . 14.4 pt-20 -67.28 -35.73 80.1 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.243 -0.911 . . . . 0.0 110.199 -179.563 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.443 ' CE2' ' OE2' ' A' ' 59' ' ' GLU . 54.9 m-85 -90.79 -1.69 57.84 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.07 -1.019 . . . . 0.0 109.26 -179.407 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 39.3 mm -110.86 131.72 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.397 -0.815 . . . . 0.0 109.428 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.486 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 63.8 tttp -130.45 158.05 40.96 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.486 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 11.7 t0 79.81 -59.02 0.35 Allowed 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.393 0.616 . . . . 0.0 109.529 179.518 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.403 ' C ' ' O ' ' A' ' 63' ' ' ASP . 82.1 mt . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.741 0.782 . . . . 0.0 109.268 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.677 0.751 . . . . 0.0 109.393 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -70.82 151.21 45.03 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.356 -0.84 . . . . 0.0 110.076 -179.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -127.01 144.2 51.09 Favored 'General case' 0 N--CA 1.494 1.771 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 22.9 p -117.61 121.87 42.07 Favored 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.831 0.825 . . . . 0.0 109.631 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -102.03 137.64 13.45 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 27.8 mm -87.11 123.21 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.539 -0.977 . . . . 0.0 109.53 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 70.5 t -74.36 134.08 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.509 -0.744 . . . . 0.0 110.13 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 47.0 t30 -128.53 101.31 6.12 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.6 -0.687 . . . . 0.0 109.401 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 24.5 m -136.71 160.58 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.397 -0.814 . . . . 0.0 109.709 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 99.9 p -84.16 -10.37 57.81 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.498 0.666 . . . . 0.0 109.604 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 62.5 p -147.4 -66.79 0.26 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.13 -0.981 . . . . 0.0 109.503 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.5 p -157.52 165.73 34.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.237 -0.915 . . . . 0.0 109.414 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.0 tp -113.44 130.18 56.37 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 121.672 0.749 . . . . 0.0 109.822 -179.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -85.78 145.84 27.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.518 -0.739 . . . . 0.0 109.678 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.7 t -111.51 130.97 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.483 ' NE ' ' O ' ' A' ' 21' ' ' THR . 84.6 mtt85 -111.14 146.36 36.99 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.788 0.804 . . . . 0.0 109.76 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -88.19 -16.59 32.9 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.458 ' O ' ' CD2' ' A' ' 55' ' ' TYR . . . -96.66 -130.92 6.69 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -152.21 -5.58 0.23 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -1.11 . . . . 0.0 108.581 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.437 ' OG ' ' OG ' ' A' ' 23' ' ' SER . 8.5 p -82.38 172.33 13.19 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.354 -0.841 . . . . 0.0 110.761 -179.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.483 ' O ' ' NE ' ' A' ' 16' ' ' ARG . 52.3 p -66.13 -31.21 71.93 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.603 -0.685 . . . . 0.0 110.219 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 38.0 m -138.39 58.71 1.66 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.029 -1.044 . . . . 0.0 108.896 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.437 ' OG ' ' OG ' ' A' ' 20' ' ' SER . 9.5 m -77.69 -79.1 0.12 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.406 -0.809 . . . . 0.0 109.719 -179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -157.03 112.97 2.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.073 -1.017 . . . . 0.0 109.792 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.0 t -80.67 129.45 37.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.347 -0.846 . . . . 0.0 109.589 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.4 pt -111.16 -5.58 11.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.554 -0.717 . . . . 0.0 109.126 179.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 164.89 -157.98 30.62 Favored Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.189 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.0 p -153.88 164.7 37.96 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.163 -1.198 . . . . 0.0 109.721 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 94.7 mt -126.64 151.56 47.87 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.671 0.748 . . . . 0.0 109.571 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' OG1' ' A' ' 33' ' ' THR . 29.7 t -71.18 160.7 32.38 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-O 121.91 0.862 . . . . 0.0 110.598 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.486 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.54 160.23 49.72 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 57.87 4.09 0.26 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.957 -0.731 . . . . 0.0 109.754 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.486 ' H ' ' C ' ' A' ' 31' ' ' GLY . 86.0 m -70.36 135.94 49.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.22 -0.925 . . . . 0.0 110.275 179.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 10.2 mtpm? -83.59 140.56 32.15 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.577 -0.702 . . . . 0.0 110.251 -179.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.2 m -126.73 130.88 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.619 -0.676 . . . . 0.0 109.341 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 p -79.83 129.31 34.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.537 -0.727 . . . . 0.0 109.719 -179.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 97.0 mt -112.24 129.38 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 CA-C-O 121.482 0.658 . . . . 0.0 109.358 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.2 m -110.18 -2.51 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.01 177.92 47.9 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.307 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.437 ' CD ' ' N ' ' A' ' 41' ' ' GLU . 9.9 tm-20 -133.09 155.4 49.3 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.423 -1.045 . . . . 0.0 109.402 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.437 ' N ' ' CD ' ' A' ' 40' ' ' GLU . 48.6 tp10 -156.31 115.76 3.52 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.493 -0.754 . . . . 0.0 109.149 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 63.68 -142.9 47.32 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.95 20.2 5.04 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.418 -1.048 . . . . 0.0 109.022 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -130.19 150.82 51.27 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.483 -0.761 . . . . 0.0 109.656 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -102.94 140.6 37.01 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.67 0.747 . . . . 0.0 109.988 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -91.16 130.39 37.05 Favored 'General case' 0 N--CA 1.487 1.425 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.2 pt -128.72 157.15 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 CA-C-O 121.766 0.793 . . . . 0.0 110.199 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -82.08 97.3 8.09 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.594 0.711 . . . . 0.0 109.48 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -85.18 144.85 27.91 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.365 -0.834 . . . . 0.0 109.825 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -66.76 100.62 0.72 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.493 -0.754 . . . . 0.0 110.154 -179.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 116.87 -23.4 10.08 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 109.187 -1.565 . . . . 0.0 109.187 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 10.8 t -169.08 -156.08 0.15 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.065 -1.256 . . . . 0.0 110.101 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -108.49 122.77 47.74 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.706 0.765 . . . . 0.0 109.716 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.41 148.76 19.28 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.458 ' CD2' ' O ' ' A' ' 18' ' ' GLY . 87.9 m-85 -127.16 132.27 50.55 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.669 -0.901 . . . . 0.0 109.238 179.306 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.8 m -138.19 153.45 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.396 -0.815 . . . . 0.0 109.923 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.07 151.23 40.22 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-O 121.574 0.702 . . . . 0.0 110.849 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -67.25 -20.34 65.65 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.526 -0.734 . . . . 0.0 110.548 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -65.38 -32.9 74.78 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.213 -0.93 . . . . 0.0 110.565 -178.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -87.91 1.45 54.01 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.854 -1.154 . . . . 0.0 109.396 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.408 HG23 HD12 ' A' ' 61' ' ' ILE . 37.8 mm -108.51 127.25 65.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.411 -0.806 . . . . 0.0 109.346 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 37.5 ttpt -140.58 150.43 43.63 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.815 0.817 . . . . 0.0 110.385 -179.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 54.39 72.3 0.47 Allowed 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.72 0.771 . . . . 0.0 110.254 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.9 mt -90.46 115.14 29.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.287 -0.883 . . . . 0.0 109.402 179.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -142.21 149.79 40.13 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.352 -0.842 . . . . 0.0 110.004 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -67.44 141.76 56.89 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 121.644 0.735 . . . . 0.0 110.357 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -166.84 76.81 0.18 Allowed 'General case' 0 N--CA 1.487 1.384 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.9 t -94.93 -7.87 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.193 -0.942 . . . . 0.0 109.257 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 60.2 mt 60.27 120.22 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.884 0 CA-C-O 122.045 0.926 . . . . 0.0 110.791 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -61.1 148.51 40.22 Favored 'General case' 0 N--CA 1.489 1.522 0 CA-C-O 121.875 0.845 . . . . 0.0 110.575 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.509 ' ND1' ' N ' ' A' ' 72' ' ' HIS . 57.4 t-80 -66.88 170.93 5.9 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-O 121.952 0.882 . . . . 0.0 111.028 -179.387 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.509 ' N ' ' ND1' ' A' ' 71' ' ' HIS . 84.6 t60 53.26 81.02 0.1 Allowed 'General case' 0 N--CA 1.488 1.455 0 CA-C-O 121.956 0.884 . . . . 0.0 109.547 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -67.11 -38.18 85.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.493 -0.755 . . . . 0.0 109.594 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . 0.456 ' O ' ' NE2' ' A' ' 72' ' ' HIS . 63.0 t-80 -57.87 123.27 15.2 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.29 -0.881 . . . . 0.0 110.284 -179.167 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -81.76 129.97 34.91 Favored 'General case' 0 N--CA 1.488 1.446 0 CA-C-O 121.746 0.784 . . . . 0.0 110.007 -179.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 62.2 m170 . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.018 -0.992 . . . . 0.0 109.987 179.761 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -73.12 150.31 42.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.402 -0.811 . . . . 0.0 110.301 -179.424 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -119.22 151.14 38.89 Favored 'General case' 0 N--CA 1.496 1.826 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 17.4 p -118.36 116.44 26.74 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.513 0.673 . . . . 0.0 109.206 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -93.55 125.62 8.3 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.546 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.7 mp -81.08 124.5 38.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.295 -1.121 . . . . 0.0 109.58 -179.71 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 76.6 t -77.78 132.67 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.343 -0.848 . . . . 0.0 109.956 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -126.92 98.22 5.26 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.5 m -137.23 158.92 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.58 -0.7 . . . . 0.0 109.616 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.9 m -86.06 -12.57 49.79 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.551 -0.718 . . . . 0.0 109.357 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 71.4 m -133.31 -79.51 0.48 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.462 -0.774 . . . . 0.0 109.204 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.3 p -158.29 165.1 35.62 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.173 -0.954 . . . . 0.0 109.725 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 34.0 tp -112.8 131.58 55.63 Favored 'General case' 0 N--CA 1.498 1.963 0 CA-C-O 121.545 0.688 . . . . 0.0 109.561 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -92.17 143.69 26.17 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.503 -0.748 . . . . 0.0 110.063 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 71.1 t -92.57 132.02 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.479 -0.763 . . . . 0.0 109.122 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -102.16 130.53 48.81 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.395 -0.816 . . . . 0.0 110.102 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -70.41 -41.55 72.8 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.719 -0.613 . . . . 0.0 109.821 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -105.7 -171.62 23.65 Favored Glycine 0 N--CA 1.497 2.766 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.106 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.05 57.99 0.76 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.699 -0.883 . . . . 0.0 109.124 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.437 ' HG ' ' N ' ' A' ' 21' ' ' THR . 40.7 t -161.33 154.9 21.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.244 -0.91 . . . . 0.0 109.821 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.437 ' N ' ' HG ' ' A' ' 20' ' ' SER . 75.2 p -66.15 -33.09 74.99 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.627 -0.67 . . . . 0.0 109.806 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 47.1 t -79.07 9.18 4.64 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.195 -0.94 . . . . 0.0 108.979 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 94.2 p -69.36 159.46 33.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.492 -0.755 . . . . 0.0 110.427 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -84.16 138.68 32.87 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.471 -0.768 . . . . 0.0 110.837 -179.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.0 t -89.69 130.99 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.541 -0.724 . . . . 0.0 109.792 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 36.8 pt -102.8 -6.59 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.574 -0.703 . . . . 0.0 109.177 179.428 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 169.22 -179.83 41.62 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 119.489 -1.339 . . . . 0.0 110.05 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 63.1 m -133.95 157.03 47.07 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.643 -0.916 . . . . 0.0 109.445 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.1 mt -122.59 148.96 44.61 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 121.544 0.687 . . . . 0.0 109.705 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.0 m -71.18 150.2 45.59 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-O 121.705 0.764 . . . . 0.0 110.519 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.575 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -64.13 163.33 34.45 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 111.099 -0.801 . . . . 0.0 111.099 -179.275 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 37.6 t-20 66.74 -19.64 0.11 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.942 -0.74 . . . . 0.0 110.135 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.575 ' H ' ' C ' ' A' ' 31' ' ' GLY . 33.0 m -67.31 136.4 54.8 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.047 -1.033 . . . . 0.0 110.209 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -90.42 148.81 22.55 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.502 -0.749 . . . . 0.0 109.605 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.5 m -123.51 131.53 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 CA-C-O 121.579 0.704 . . . . 0.0 109.188 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 28.5 m -66.63 130.5 43.39 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.86 -0.525 . . . . 0.0 110.025 -179.166 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.0 mt -110.53 129.78 65.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 19.0 m -112.92 -0.12 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -179.61 -179.31 48.76 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.43 -1.367 . . . . 0.0 110.307 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -139.87 154.08 47.19 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.462 -1.023 . . . . 0.0 109.75 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -153.98 109.05 3.13 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -0.854 . . . . 0.0 109.402 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 59.14 -142.22 46.74 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -83.2 17.85 1.91 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.487 -1.008 . . . . 0.0 109.278 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -129.83 145.57 51.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.615 -0.678 . . . . 0.0 109.514 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 50.4 m-85 -107.68 147.69 30.38 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.605 0.716 . . . . 0.0 109.833 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -90.84 139.29 30.88 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.537 -0.727 . . . . 0.0 109.044 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.4 pt -134.45 158.45 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 CA-C-O 121.665 0.745 . . . . 0.0 110.519 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -84.22 93.59 8.22 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.674 -0.641 . . . . 0.0 109.426 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 82.4 t80 -98.37 135.31 40.14 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.358 -0.839 . . . . 0.0 109.278 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.9 ttpt -49.77 106.72 0.12 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.383 -0.823 . . . . 0.0 110.568 -179.162 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 123.31 -51.76 0.79 Allowed Glycine 0 N--CA 1.496 2.647 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 179.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 22.8 p -158.86 -166.2 1.81 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.132 -1.216 . . . . 0.0 110.124 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 78.3 m80 -90.41 116.87 28.68 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.366 -0.834 . . . . 0.0 109.865 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -86.29 160.75 33.57 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -123.96 136.36 54.26 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.665 -0.903 . . . . 0.0 109.423 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.8 m -136.81 137.24 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.506 -0.746 . . . . 0.0 109.337 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.97 143.67 57.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.599 -0.688 . . . . 0.0 110.632 -179.216 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.9 pttt -62.01 -13.35 24.92 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.544 -0.722 . . . . 0.0 109.422 179.377 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -68.25 -31.0 70.17 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.434 -0.791 . . . . 0.0 110.95 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -93.1 -11.05 33.87 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.792 -1.192 . . . . 0.0 109.769 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.513 ' N ' ' CD1' ' A' ' 61' ' ' ILE . 1.4 mp -94.73 131.63 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.361 -0.837 . . . . 0.0 109.207 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.471 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 65.8 tttm -135.43 155.41 50.59 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.653 -0.655 . . . . 0.0 109.828 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.471 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 11.7 t0 79.39 -66.78 0.17 Allowed 'General case' 0 N--CA 1.495 1.799 0 CA-C-O 121.268 0.556 . . . . 0.0 109.535 179.753 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 91.5 mt 56.46 83.95 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.634 -0.666 . . . . 0.0 109.488 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -142.16 152.29 43.05 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.533 -0.729 . . . . 0.0 109.826 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -79.34 110.01 14.22 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.422 -0.799 . . . . 0.0 109.674 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 49.6 tp10 -87.55 143.18 27.33 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.357 -0.839 . . . . 0.0 109.739 -179.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 27.9 m -75.84 144.9 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.452 -0.78 . . . . 0.0 110.159 -179.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.411 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 10.8 mp -84.0 -4.27 58.62 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.292 -0.88 . . . . 0.0 109.022 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 10.8 tm-20 -100.72 120.83 40.66 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.334 -0.854 . . . . 0.0 109.793 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -155.85 48.89 0.51 Allowed 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.373 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.609 ' NE2' ' CE1' ' A' ' 73' ' ' HIS . 6.9 t-80 -148.52 145.9 28.09 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.373 -0.829 . . . . 0.0 109.722 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.609 ' CE1' ' NE2' ' A' ' 72' ' ' HIS . 5.8 p-80 -72.36 -14.08 61.63 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.594 -0.691 . . . . 0.0 109.457 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 13.8 m80 -132.21 144.21 50.48 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.446 -0.784 . . . . 0.0 109.573 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -87.91 140.73 29.21 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.594 -0.691 . . . . 0.0 110.394 -179.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 . . . . . 0 N--CA 1.493 1.696 0 CA-C-O 118.081 -0.962 . . . . 0.0 110.021 179.849 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.464 ' O ' ' O ' ' A' ' 1' ' ' ALA . 50.7 mt-10 57.5 144.94 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 121.581 0.705 . . . . 0.0 110.372 -179.87 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -139.19 154.62 48.08 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.431 -0.793 . . . . 0.0 109.133 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -114.46 126.61 55.16 Favored 'General case' 0 N--CA 1.498 1.975 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.31 140.75 15.2 Favored Glycine 0 N--CA 1.497 2.754 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 23.7 mm -94.33 116.33 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.364 -1.08 . . . . 0.0 108.904 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.3 t -80.35 132.63 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.376 -0.828 . . . . 0.0 109.99 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.6 t30 -132.99 106.9 7.94 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.428 -0.795 . . . . 0.0 109.34 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 11' ' ' SER . 19.6 m -151.65 -12.87 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 24.0 p 43.87 17.79 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.724 -0.61 . . . . 0.0 109.729 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.525 ' N ' ' O ' ' A' ' 9' ' ' VAL . 23.7 m -151.55 35.85 0.57 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.1 t 60.63 145.31 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.793 -0.567 . . . . 0.0 110.437 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 35.9 tp -116.16 133.13 56.36 Favored 'General case' 0 N--CA 1.503 2.209 0 CA-C-O 121.572 0.701 . . . . 0.0 109.613 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 18.9 p30 -80.65 137.34 36.33 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.429 -0.794 . . . . 0.0 109.62 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 73.7 t -90.95 131.25 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.361 -0.837 . . . . 0.0 108.84 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 96.7 mtt-85 -95.9 138.81 33.0 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.001 . . . . 0.0 109.981 -179.123 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 50.4 tp10 -67.5 -43.67 80.31 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.424 -0.797 . . . . 0.0 109.777 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -119.52 -166.6 13.4 Favored Glycine 0 N--CA 1.499 2.856 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 -178.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.69 56.03 0.88 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.62 -0.929 . . . . 0.0 109.225 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 28.8 t -152.8 151.09 30.05 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.264 -0.898 . . . . 0.0 109.725 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 41.7 p -68.06 -23.12 64.92 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.394 -0.816 . . . . 0.0 109.438 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 86.1 p -83.65 -0.48 50.83 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.423 -0.798 . . . . 0.0 109.429 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 99.8 p -64.84 159.42 22.61 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.222 -0.924 . . . . 0.0 110.387 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 22.6 pttp -92.6 140.18 29.81 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.49 -0.756 . . . . 0.0 110.407 -179.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 22.6 t -86.69 129.81 37.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.383 -0.823 . . . . 0.0 109.909 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 36.3 pt -102.39 -7.4 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.512 -0.743 . . . . 0.0 109.157 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.77 -162.81 35.22 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 24.8 p -152.78 164.04 38.57 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.299 -1.118 . . . . 0.0 109.433 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.3 mt -124.26 148.48 47.35 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.546 -0.721 . . . . 0.0 109.39 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.9 t -69.94 152.02 44.95 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.493 -0.755 . . . . 0.0 110.622 -179.016 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.46 160.55 32.24 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 12.3 m120 57.31 33.22 22.99 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.653 -0.91 . . . . 0.0 109.563 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 35.1 m -105.02 137.02 43.41 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.57 -0.706 . . . . 0.0 109.832 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -79.76 140.32 36.95 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 109.057 -0.719 . . . . 0.0 109.057 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.8 m -126.77 130.5 71.53 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.416 -0.803 . . . . 0.0 109.397 179.565 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 54.6 m -72.84 126.39 29.81 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.41 -0.806 . . . . 0.0 109.628 -179.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 93.1 mt -107.33 126.71 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.639 -0.663 . . . . 0.0 109.65 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 30.9 m -111.13 -3.26 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 177.21 -174.14 46.78 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -141.05 155.16 46.21 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.323 -1.104 . . . . 0.0 109.441 179.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -151.27 112.06 4.25 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 109.598 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.461 ' O ' ' NZ ' ' A' ' 58' ' ' LYS . . . 61.92 -144.93 49.19 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.504 ' C ' ' HZ1' ' A' ' 58' ' ' LYS . . . -84.36 24.96 0.91 Allowed 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.657 -0.908 . . . . 0.0 109.384 -179.8 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 -131.58 152.68 50.59 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.602 -0.686 . . . . 0.0 109.341 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 9.1 m-85 -103.16 139.08 39.12 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.413 -0.804 . . . . 0.0 108.855 179.592 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -90.71 129.72 36.78 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 33.3 pt -130.72 154.47 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.483 -0.761 . . . . 0.0 109.588 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -83.22 100.3 10.5 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.455 -0.778 . . . . 0.0 109.341 -179.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -83.64 147.1 27.9 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.351 -0.843 . . . . 0.0 109.797 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 8.0 mtmp? -62.21 102.96 0.34 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.267 -0.895 . . . . 0.0 110.861 -179.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.43 ' O ' ' OG ' ' A' ' 52' ' ' SER . . . 101.63 -10.28 57.5 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.43 ' OG ' ' O ' ' A' ' 51' ' ' GLY . 50.4 m -168.29 -166.09 0.67 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.861 -1.376 . . . . 0.0 110.035 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -110.28 115.92 30.55 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.52 -0.737 . . . . 0.0 109.085 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.2 152.08 21.07 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.371 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -126.55 137.79 53.39 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.639 -0.918 . . . . 0.0 109.021 179.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.3 m -135.59 139.56 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.339 -0.85 . . . . 0.0 109.753 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.09 149.58 49.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.575 -0.703 . . . . 0.0 110.593 -179.378 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.504 ' HZ1' ' C ' ' A' ' 43' ' ' ALA . 64.2 mttp -62.23 -33.73 75.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.463 -0.773 . . . . 0.0 109.772 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 58.7 mp0 -55.1 -30.98 60.84 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.354 -0.841 . . . . 0.0 110.086 -178.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -92.84 -3.98 53.73 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.966 -1.084 . . . . 0.0 109.353 -179.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.1 mm -114.46 129.18 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 121.541 -0.724 . . . . 0.0 109.516 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.577 ' O ' ' N ' ' A' ' 64' ' ' ILE . 21.7 ptmt -141.14 -174.16 3.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.418 -0.801 . . . . 0.0 109.581 179.852 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.458 ' O ' ' O ' ' A' ' 64' ' ' ILE . 91.1 m-20 56.69 -75.48 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.577 ' N ' ' O ' ' A' ' 62' ' ' LYS . 97.7 mt 57.71 150.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 CA-C-O 121.393 0.616 . . . . 0.0 110.01 -179.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -117.52 108.71 15.83 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.619 -0.676 . . . . 0.0 109.473 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -88.87 113.71 24.71 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.335 -0.853 . . . . 0.0 109.309 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -87.61 -2.11 58.4 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.231 -0.918 . . . . 0.0 109.234 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 3.4 p -155.84 114.89 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.344 -0.847 . . . . 0.0 109.36 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 88.5 mt -80.41 141.39 35.36 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.324 -0.86 . . . . 0.0 110.159 -179.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.513 ' C ' ' H ' ' A' ' 72' ' ' HIS . 96.0 mt-10 -84.09 162.34 20.34 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.385 -0.822 . . . . 0.0 110.669 -179.317 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 28.8 t60 66.43 -8.51 0.37 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.812 -0.555 . . . . 0.0 109.889 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.513 ' H ' ' C ' ' A' ' 70' ' ' GLU . 74.8 m80 -89.31 -7.62 54.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.223 -0.923 . . . . 0.0 109.045 179.523 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 74.2 m80 -71.4 142.61 50.31 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.428 -0.795 . . . . 0.0 110.036 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . 0.508 ' CD2' ' H ' ' A' ' 74' ' ' HIS . 0.2 OUTLIER -132.99 89.65 2.65 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.419 -0.801 . . . . 0.0 109.171 179.577 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 86.4 t60 40.03 86.35 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.947 0 CA-C-O 121.379 0.609 . . . . 0.0 110.318 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 61.1 t-80 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.644 179.764 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.449 0.642 . . . . 0.0 109.625 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -80.48 126.69 31.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.258 -0.901 . . . . 0.0 110.214 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.5 mtmp? -143.13 157.74 44.24 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.512 -0.742 . . . . 0.0 109.051 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.459 ' CG2' ' HZ2' ' A' ' 34' ' ' LYS . 62.0 p -121.35 125.21 46.42 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.567 -0.708 . . . . 0.0 109.464 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -102.86 137.32 13.34 Favored Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.43 HG21 HD13 ' A' ' 6' ' ' ILE . 17.4 mm -95.5 120.07 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.275 -1.133 . . . . 0.0 109.449 179.617 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 74.1 t -75.67 134.2 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.566 -0.709 . . . . 0.0 110.321 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' A' ' 60' ' ' TYR . 3.6 p-10 -138.72 99.74 3.88 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.437 -0.789 . . . . 0.0 109.385 179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 5.7 m -134.98 135.73 52.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.577 -0.702 . . . . 0.0 109.682 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 78.2 p -62.52 -40.49 96.94 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.614 -0.679 . . . . 0.0 109.638 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 68.9 m -101.8 -79.19 0.52 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.447 -0.783 . . . . 0.0 109.877 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 45.5 m -161.51 167.06 26.13 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.334 -0.854 . . . . 0.0 109.596 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 38.6 tp -116.95 130.17 56.53 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.64 -0.662 . . . . 0.0 109.789 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . 0.404 HD21 ' HG ' ' A' ' 28' ' ' SER . 9.2 m120 -91.16 142.29 27.89 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.397 -0.814 . . . . 0.0 109.686 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 96.3 t -88.89 128.08 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.324 -0.86 . . . . 0.0 109.21 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.714 HH21 ' H ' ' A' ' 20' ' ' SER . 67.5 mtp180 -107.52 133.16 52.39 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.549 -0.719 . . . . 0.0 109.962 -179.357 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.3 pt-20 -70.7 -35.01 72.55 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.488 -0.757 . . . . 0.0 109.879 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -120.95 -148.8 8.05 Favored Glycine 0 N--CA 1.498 2.774 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 -178.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -147.27 75.05 1.36 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.574 -0.957 . . . . 0.0 108.834 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.714 ' H ' HH21 ' A' ' 16' ' ' ARG . 15.2 m -141.85 44.95 1.7 Allowed 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.633 ' N ' ' NH2' ' A' ' 16' ' ' ARG . 59.0 p 50.37 -84.81 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.769 0 CA-C-O 121.319 0.58 . . . . 0.0 110.471 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.527 ' N ' ' O ' ' A' ' 20' ' ' SER . 23.0 t -71.39 44.4 0.09 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.354 -0.841 . . . . 0.0 109.002 -179.45 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.477 ' H ' ' C ' ' A' ' 21' ' ' THR . 15.4 p -78.58 165.22 23.94 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.355 -0.84 . . . . 0.0 110.411 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -77.3 138.54 39.42 Favored 'General case' 0 N--CA 1.488 1.473 0 CA-C-O 121.721 0.772 . . . . 0.0 110.637 -179.583 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 76.5 t -93.49 129.9 43.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 39.4 pt -109.19 -7.1 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.6 -0.687 . . . . 0.0 109.556 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 179.12 -173.53 45.65 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 119.287 -1.435 . . . . 0.0 110.349 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.404 ' HG ' HD21 ' A' ' 14' ' ' ASN . 54.8 m -144.0 154.06 42.87 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.405 -1.056 . . . . 0.0 109.789 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.7 mt -124.89 148.78 48.12 Favored 'General case' 0 N--CA 1.497 1.884 0 CA-C-O 121.546 0.689 . . . . 0.0 109.63 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 90.6 p -79.08 165.06 23.78 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 121.72 0.772 . . . . 0.0 110.854 -179.148 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -65.78 155.27 50.4 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 12.0 m120 57.41 31.59 20.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.73 -0.865 . . . . 0.0 109.86 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 37.0 m -91.73 129.94 37.61 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.216 -0.928 . . . . 0.0 109.835 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.459 ' HZ2' ' CG2' ' A' ' 4' ' ' THR . 63.9 tttm -80.11 133.33 36.08 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.514 -0.741 . . . . 0.0 109.639 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 m -128.1 133.29 67.4 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.303 -0.873 . . . . 0.0 110.037 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 21.6 m -81.56 131.23 35.27 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.685 -0.634 . . . . 0.0 109.451 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 91.1 mt -104.91 126.0 59.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.593 -0.692 . . . . 0.0 109.785 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 15.8 m -109.66 -1.43 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.46 -177.79 48.42 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -142.23 160.84 39.45 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.342 -1.093 . . . . 0.0 109.631 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -152.84 112.57 3.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.241 -0.912 . . . . 0.0 109.546 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.22 -135.16 47.88 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.82 25.91 1.94 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.462 -1.022 . . . . 0.0 109.006 -179.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 65.3 m-85 -132.4 151.33 51.92 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.685 -0.634 . . . . 0.0 109.452 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 31.5 m-85 -107.84 139.49 42.35 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.528 0.68 . . . . 0.0 109.894 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -92.42 132.63 36.61 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 36.7 pt -128.4 156.88 40.9 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.556 -0.715 . . . . 0.0 110.205 -179.638 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -82.15 97.56 8.27 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.66 -0.65 . . . . 0.0 109.483 -179.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.411 ' CG ' ' N ' ' A' ' 50' ' ' LYS . 90.0 t80 -85.49 161.46 19.36 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.525 -0.734 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.411 ' N ' ' CG ' ' A' ' 49' ' ' TYR . 98.6 mttt -70.91 107.81 4.22 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.415 -0.803 . . . . 0.0 110.267 -179.543 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 98.84 -14.46 61.64 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 81.0 p -169.46 -161.61 0.3 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.942 -1.328 . . . . 0.0 110.145 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -116.43 121.47 41.98 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.628 -0.67 . . . . 0.0 109.571 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.84 163.57 30.84 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.597 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 81.9 m-85 -132.23 137.35 47.52 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.62 -0.929 . . . . 0.0 109.431 179.507 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 30.2 m -138.73 156.49 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.916 0 O-C-N 121.518 -0.739 . . . . 0.0 109.82 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.86 145.54 42.69 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.508 -0.745 . . . . 0.0 110.314 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 10.3 ptmm? -68.71 -13.79 62.6 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.597 -0.69 . . . . 0.0 110.064 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -67.21 -35.99 80.77 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.195 -0.941 . . . . 0.0 110.149 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.424 ' O ' ' OD1' ' A' ' 8' ' ' ASN . 75.7 m-85 -92.14 1.33 57.27 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.079 -1.013 . . . . 0.0 109.602 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.0 mm -113.68 125.49 70.96 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.561 -0.712 . . . . 0.0 109.601 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -142.42 169.83 16.85 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.477 -0.765 . . . . 0.0 109.856 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 47.9 t0 62.28 52.38 3.14 Favored 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.575 0.703 . . . . 0.0 109.787 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt -74.62 131.04 35.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.463 -0.773 . . . . 0.0 109.188 179.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -114.0 134.37 54.89 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.547 -0.72 . . . . 0.0 110.038 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.411 ' O ' ' OD1' ' A' ' 66' ' ' ASP . 43.3 p-10 -104.28 125.76 50.81 Favored 'General case' 0 N--CA 1.494 1.727 0 CA-C-O 121.472 0.653 . . . . 0.0 109.461 179.71 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.551 ' OE1' ' N ' ' A' ' 67' ' ' GLU . 56.8 mp0 -98.97 -16.36 18.77 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 16.8 m -94.06 140.13 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.335 -0.853 . . . . 0.0 110.274 -179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.448 ' O ' ' N ' ' A' ' 71' ' ' HIS . 10.6 mp -85.08 -1.41 56.82 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 52.96 -90.6 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.391 -0.818 . . . . 0.0 110.205 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.448 ' N ' ' O ' ' A' ' 69' ' ' LEU . 44.6 m80 -143.14 153.3 42.74 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.188 -0.945 . . . . 0.0 109.646 -179.148 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.442 ' CG ' ' N ' ' A' ' 73' ' ' HIS . 86.3 t60 -78.14 162.34 26.7 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.561 -0.712 . . . . 0.0 110.622 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.442 ' N ' ' CG ' ' A' ' 72' ' ' HIS . 75.4 m80 -70.58 132.58 45.7 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.454 -0.779 . . . . 0.0 110.492 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 51.6 p-80 -84.94 -14.13 48.59 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.512 -0.742 . . . . 0.0 109.337 179.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 74.8 m80 -66.0 -39.76 90.56 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.345 -0.847 . . . . 0.0 109.242 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 75.0 m-70 . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 118.076 -0.964 . . . . 0.0 109.558 -179.674 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -65.05 134.17 53.25 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.434 -0.791 . . . . 0.0 110.02 -179.507 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -137.33 149.98 47.41 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.421 -0.799 . . . . 0.0 109.285 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 10.1 p -122.86 114.45 20.5 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.506 -0.746 . . . . 0.0 109.315 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -97.3 141.42 15.6 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.425 HD11 HG22 ' A' ' 6' ' ' ILE . 24.4 mm -94.71 119.48 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.381 -1.07 . . . . 0.0 109.225 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.3 t -79.04 125.1 38.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.305 -0.872 . . . . 0.0 109.774 -179.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.4 t30 -105.52 94.95 5.48 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.453 -0.779 . . . . 0.0 109.387 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 2.2 p -144.42 135.49 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.361 -0.837 . . . . 0.0 109.174 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 77.3 p -84.71 -13.73 50.51 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.558 -0.714 . . . . 0.0 109.562 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 66.3 m -117.44 -89.26 0.59 Allowed 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.463 -0.773 . . . . 0.0 109.841 -179.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.9 p -158.58 163.51 36.93 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.914 -1.116 . . . . 0.0 109.751 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 40.2 tp -120.52 131.21 54.59 Favored 'General case' 0 N--CA 1.498 1.968 0 CA-C-O 121.666 0.746 . . . . 0.0 109.626 179.74 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -87.04 146.61 26.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.457 -0.777 . . . . 0.0 109.82 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 74.3 t -104.98 129.0 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.455 -0.778 . . . . 0.0 109.125 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.651 HH22 ' N ' ' A' ' 57' ' ' ALA . 0.6 OUTLIER -107.87 138.71 43.64 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.655 0.741 . . . . 0.0 109.372 -179.617 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -93.3 -21.84 19.34 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.554 -0.716 . . . . 0.0 109.35 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.542 ' C ' ' H ' ' A' ' 20' ' ' SER . . . -101.97 7.52 55.05 Favored Glycine 0 N--CA 1.497 2.748 0 N-CA-C 108.897 -1.681 . . . . 0.0 108.897 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . 56.83 3.97 0.15 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.478 -1.013 . . . . 0.0 109.392 -179.44 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.542 ' H ' ' C ' ' A' ' 18' ' ' GLY . 7.6 m -80.87 156.81 25.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.316 -0.865 . . . . 0.0 110.327 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.456 ' O ' ' CB ' ' A' ' 22' ' ' SER . 43.1 p -61.29 101.53 0.17 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.531 -0.731 . . . . 0.0 110.171 -179.852 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.456 ' CB ' ' O ' ' A' ' 21' ' ' THR . 0.7 OUTLIER 79.06 27.65 0.41 Allowed 'General case' 0 N--CA 1.496 1.852 0 CA-C-O 121.639 0.733 . . . . 0.0 109.519 179.587 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.42 ' O ' ' O ' ' A' ' 22' ' ' SER . 0.2 OUTLIER -56.64 -159.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.915 0.864 . . . . 0.0 110.763 -179.747 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 38.1 ttmt -64.32 128.6 36.51 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.616 0.722 . . . . 0.0 109.785 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 91.1 t -92.14 115.26 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 CA-C-O 121.58 0.705 . . . . 0.0 109.277 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.9 pt -103.66 -3.98 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.57 -163.11 36.73 Favored Glycine 0 N--CA 1.488 2.15 0 C-N-CA 119.405 -1.378 . . . . 0.0 110.53 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.5 p -154.02 163.54 39.91 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.311 -1.111 . . . . 0.0 109.221 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.2 mt -124.63 146.39 49.11 Favored 'General case' 0 N--CA 1.497 1.9 0 CA-C-O 121.725 0.774 . . . . 0.0 110.013 -179.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 12.9 m -83.32 162.12 21.21 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-O 121.837 0.827 . . . . 0.0 110.404 -179.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.515 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -65.45 158.35 46.35 Favored Glycine 0 N--CA 1.49 2.296 0 CA-C-O 121.817 0.676 . . . . 0.0 111.583 -179.467 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 59.43 0.04 0.19 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.966 -0.726 . . . . 0.0 110.032 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.515 ' H ' ' C ' ' A' ' 31' ' ' GLY . 30.2 m -72.09 140.88 49.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.244 -0.91 . . . . 0.0 110.505 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -87.41 144.74 26.6 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.528 -0.733 . . . . 0.0 109.592 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.6 m -125.87 132.1 71.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 121.456 -0.777 . . . . 0.0 109.96 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 26.6 m -73.11 104.06 4.06 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.68 -0.637 . . . . 0.0 109.362 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.3 mt -101.73 131.1 50.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.553 0.692 . . . . 0.0 109.521 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.474 ' CG2' ' N ' ' A' ' 39' ' ' GLY . 23.8 m -140.32 -46.51 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.474 ' N ' ' CG2' ' A' ' 38' ' ' VAL . . . -95.41 164.74 24.59 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -179.338 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.447 ' CD ' ' N ' ' A' ' 41' ' ' GLU . 15.8 tm-20 -135.28 146.0 48.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.369 -1.077 . . . . 0.0 109.594 179.63 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.447 ' N ' ' CD ' ' A' ' 40' ' ' GLU . 84.4 tt0 -153.57 109.1 3.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.458 -0.776 . . . . 0.0 109.408 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.431 ' C ' ' H ' ' A' ' 44' ' ' PHE . . . 48.58 -142.28 8.76 Favored Glycine 0 N--CA 1.494 2.509 0 CA-C-O 121.967 0.759 . . . . 0.0 111.269 179.175 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -81.9 28.51 0.42 Allowed 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.435 -1.038 . . . . 0.0 108.738 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.431 ' H ' ' C ' ' A' ' 42' ' ' GLY . 91.0 m-85 -134.01 140.22 46.56 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.516 -0.74 . . . . 0.0 109.137 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -100.7 142.81 31.64 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.495 -0.753 . . . . 0.0 109.276 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.616 ' NZ ' ' ND1' ' A' ' 53' ' ' HIS . 65.1 tttm -90.45 129.03 36.68 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -179.582 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.411 HG22 HD13 ' A' ' 47' ' ' ILE . 32.0 pt -126.57 152.24 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 CA-C-O 121.699 0.761 . . . . 0.0 110.164 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -84.39 92.2 7.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.511 -0.743 . . . . 0.0 109.658 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -79.3 142.11 36.43 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.331 -0.856 . . . . 0.0 110.134 -179.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -58.18 96.46 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.547 -0.721 . . . . 0.0 110.408 -179.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 123.19 -35.83 3.25 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 67.8 p -158.96 -162.96 1.15 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.986 -1.302 . . . . 0.0 109.759 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.616 ' ND1' ' NZ ' ' A' ' 46' ' ' LYS . 97.5 m-70 -106.31 118.26 36.18 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.492 -0.755 . . . . 0.0 109.347 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.15 162.39 22.8 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -126.54 136.56 52.73 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.526 -0.985 . . . . 0.0 109.514 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.8 m -133.67 137.15 53.21 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 CA-C-O 121.477 0.656 . . . . 0.0 109.619 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.651 ' N ' HH22 ' A' ' 16' ' ' ARG . . . -68.85 147.21 52.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.395 -0.816 . . . . 0.0 110.352 -179.61 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.474 ' CB ' ' HZ3' ' A' ' 58' ' ' LYS . 6.4 mtmp? -63.8 -9.03 12.51 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.567 -0.708 . . . . 0.0 109.736 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -68.83 -35.99 77.64 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.108 -0.995 . . . . 0.0 110.096 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -92.96 4.99 53.0 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.052 -1.03 . . . . 0.0 109.203 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 44.8 mm -103.88 129.16 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.39 -0.819 . . . . 0.0 109.513 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 26.2 ttpp -149.88 157.34 43.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.306 -0.872 . . . . 0.0 110.439 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 55.81 52.97 9.98 Favored 'General case' 0 N--CA 1.49 1.57 0 CA-C-O 121.59 0.709 . . . . 0.0 109.498 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt -69.9 130.8 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.497 -0.752 . . . . 0.0 109.554 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 18.2 tptm -133.05 137.54 46.47 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.815 0.817 . . . . 0.0 110.173 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -89.33 114.63 26.06 Favored 'General case' 0 N--CA 1.488 1.461 0 CA-C-O 121.694 0.759 . . . . 0.0 109.744 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -56.43 156.27 6.2 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.699 0.762 . . . . 0.0 110.844 -179.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 4.9 t 62.1 77.83 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.77 0.795 . . . . 0.0 109.639 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -85.08 157.3 20.75 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 121.773 0.797 . . . . 0.0 110.064 -179.243 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 73.5 mm-40 -59.98 140.61 56.64 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 121.729 0.776 . . . . 0.0 110.435 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.411 ' O ' ' O ' ' A' ' 72' ' ' HIS . 59.2 t-80 -80.64 -15.13 57.35 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 179.38 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.411 ' O ' ' O ' ' A' ' 71' ' ' HIS . 96.9 m-70 54.45 106.21 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.662 0.744 . . . . 0.0 110.174 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -148.4 159.08 44.38 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.114 -0.991 . . . . 0.0 109.562 179.645 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -102.82 133.26 48.18 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.301 -0.875 . . . . 0.0 110.217 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 58.6 t-80 -66.12 -42.86 88.58 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.475 -0.766 . . . . 0.0 109.797 179.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 67.5 m-70 . . . . . 0 N--CA 1.495 1.788 0 CA-C-O 118.198 -0.906 . . . . 0.0 109.947 -179.538 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -74.17 152.42 39.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.486 -0.758 . . . . 0.0 110.192 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -112.0 156.92 21.37 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.694 -0.629 . . . . 0.0 109.592 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 67.2 p -134.22 152.32 51.76 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.569 -0.707 . . . . 0.0 109.476 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -135.1 128.67 4.83 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.543 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 2.0 mp -81.99 124.52 39.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.669 -0.901 . . . . 0.0 109.579 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 91.8 t -85.33 116.75 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.506 -0.746 . . . . 0.0 109.732 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -110.19 107.38 17.15 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.521 -0.737 . . . . 0.0 109.663 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 14.9 m -139.33 156.72 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.386 -0.821 . . . . 0.0 109.616 179.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 82.0 p -73.18 -13.81 61.23 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.502 ' OG ' ' N ' ' A' ' 12' ' ' SER . 77.0 p -152.95 -118.61 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.327 -0.858 . . . . 0.0 110.096 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.502 ' N ' ' OG ' ' A' ' 11' ' ' SER . 21.5 m -101.37 161.26 13.75 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.382 -0.824 . . . . 0.0 110.246 -178.835 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 61.6 tp -120.99 133.4 55.27 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.632 0.729 . . . . 0.0 109.653 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -88.95 129.46 35.62 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.633 -0.667 . . . . 0.0 109.866 179.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 80.7 t -89.89 132.56 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.423 -0.798 . . . . 0.0 109.23 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -101.69 134.08 45.39 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.421 -0.799 . . . . 0.0 110.533 -178.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 11.4 tm-20 -69.21 -43.18 74.61 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.315 0.578 . . . . 0.0 109.548 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -101.42 -178.48 28.59 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -178.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -93.24 -2.22 55.34 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.591 -0.947 . . . . 0.0 109.365 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.7 m -82.37 150.79 26.97 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.187 -0.946 . . . . 0.0 110.368 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.473 ' C ' ' H ' ' A' ' 23' ' ' SER . 19.0 m -64.91 -45.4 86.05 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.501 -0.75 . . . . 0.0 109.534 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 8.7 t -77.24 24.39 0.18 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.607 -0.683 . . . . 0.0 109.161 -179.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.473 ' H ' ' C ' ' A' ' 21' ' ' THR . 14.8 m -71.18 151.14 44.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.477 -0.764 . . . . 0.0 110.291 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -73.37 136.65 44.39 Favored 'General case' 0 N--CA 1.491 1.582 0 CA-C-O 121.789 0.804 . . . . 0.0 110.995 -179.181 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 82.2 t -85.62 131.58 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 CA-C-O 121.372 0.605 . . . . 0.0 109.822 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.4 pt -125.33 -44.31 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.722 -0.611 . . . . 0.0 109.378 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -101.29 171.89 22.71 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 -178.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.8 p -158.42 155.58 28.86 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.583 -0.951 . . . . 0.0 109.55 179.072 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 91.9 mt -133.92 150.57 51.32 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.452 -0.78 . . . . 0.0 109.72 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.9 t -82.11 -1.53 49.02 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.535 ' C ' ' H ' ' A' ' 33' ' ' THR . . . 97.83 164.83 31.52 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.272 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.0 m120 52.78 5.22 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.746 -0.855 . . . . 0.0 110.014 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.535 ' H ' ' C ' ' A' ' 31' ' ' GLY . 24.9 m -78.9 141.44 37.61 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.101 -0.999 . . . . 0.0 110.312 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -88.74 132.99 34.37 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.643 -0.661 . . . . 0.0 109.493 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.7 m -124.12 133.79 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 CA-C-O 121.785 0.802 . . . . 0.0 109.854 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 5.8 p -76.8 133.92 39.25 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.722 -0.611 . . . . 0.0 110.141 -179.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.0 mt -111.54 128.9 67.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 121.448 0.642 . . . . 0.0 109.362 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 29.7 m -111.21 -3.34 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -174.99 175.92 47.1 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.662 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -136.51 153.44 51.02 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.667 -0.902 . . . . 0.0 109.46 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -155.11 113.19 3.45 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.195 -0.94 . . . . 0.0 109.996 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 57.48 -137.52 49.38 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 178.695 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.9 24.2 2.86 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.602 -0.94 . . . . 0.0 109.073 -179.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -133.2 147.54 52.01 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.576 -0.702 . . . . 0.0 109.571 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 24.9 m-85 -106.35 147.93 28.65 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.559 -0.713 . . . . 0.0 109.782 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.673 ' HZ2' ' HD1' ' A' ' 53' ' ' HIS . 64.8 tttm -95.53 124.9 39.79 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 13.8 pt -131.51 154.26 40.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 CA-C-O 121.762 0.791 . . . . 0.0 110.217 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -90.89 106.29 18.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.695 -0.628 . . . . 0.0 109.958 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 88.7 t80 -112.45 115.37 28.57 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.572 0.701 . . . . 0.0 109.172 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.1 mmtp 52.27 31.07 8.73 Favored 'General case' 0 N--CA 1.493 1.689 0 CA-C-O 121.3 0.571 . . . . 0.0 110.193 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 85.64 -11.22 62.27 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 178.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 38.4 t -90.2 170.05 10.62 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.25 -1.147 . . . . 0.0 110.203 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.673 ' HD1' ' HZ2' ' A' ' 46' ' ' LYS . 90.6 m-70 -100.28 93.41 5.67 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.429 -0.794 . . . . 0.0 109.231 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.26 136.1 12.73 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.696 -1.361 . . . . 0.0 109.696 -179.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -112.95 138.58 49.59 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.689 -0.889 . . . . 0.0 109.562 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.1 m -135.89 156.13 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.544 -0.723 . . . . 0.0 109.997 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.21 152.06 45.55 Favored 'General case' 0 N--CA 1.491 1.588 0 CA-C-O 121.76 0.791 . . . . 0.0 110.767 -179.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.562 ' C ' ' H ' ' A' ' 60' ' ' TYR . 47.9 mtmt -63.41 -38.69 92.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.698 -0.626 . . . . 0.0 109.49 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -49.64 -7.42 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.401 -0.812 . . . . 0.0 110.222 -179.382 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.562 ' H ' ' C ' ' A' ' 58' ' ' LYS . 59.0 m-85 -105.26 -25.05 12.59 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.289 -0.882 . . . . 0.0 109.236 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.542 ' N ' ' CD1' ' A' ' 61' ' ' ILE . 1.5 mp -89.13 129.09 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.365 -0.835 . . . . 0.0 109.828 -179.51 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 65.2 tttm -146.37 152.55 39.27 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.546 -0.721 . . . . 0.0 109.857 179.228 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 57.47 57.11 4.55 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.496 0.665 . . . . 0.0 109.803 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.4 HG21 HD11 ' A' ' 64' ' ' ILE . 96.9 mt -70.73 131.7 34.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.382 -0.824 . . . . 0.0 109.533 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -130.71 139.9 50.32 Favored 'General case' 0 N--CA 1.494 1.755 0 CA-C-O 121.511 0.672 . . . . 0.0 109.346 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 41.0 p-10 -93.46 116.21 28.74 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.467 -0.771 . . . . 0.0 110.428 -179.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.428 ' OE2' ' O ' ' A' ' 69' ' ' LEU . 4.7 tm-20 54.56 95.93 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 CA-C-O 121.644 0.735 . . . . 0.0 110.114 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.453 ' O ' ' O ' ' A' ' 69' ' ' LEU . 14.8 t -87.32 104.81 14.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.51 -0.744 . . . . 0.0 110.119 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.453 ' O ' ' O ' ' A' ' 68' ' ' VAL . 10.7 mp 55.85 148.28 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 122.045 0.926 . . . . 0.0 111.076 179.196 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 14.7 tm-20 -155.86 114.37 3.43 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.41 -0.806 . . . . 0.0 109.404 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 7.8 p80 -77.68 119.7 21.58 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.549 -0.719 . . . . 0.0 109.866 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 28.5 p80 -100.26 -10.13 21.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.502 -0.749 . . . . 0.0 109.023 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -65.96 -36.74 84.17 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.526 -0.734 . . . . 0.0 109.327 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . 0.592 ' CD2' ' CE1' ' A' ' 75' ' ' HIS . 79.1 t60 -60.03 -44.16 94.83 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.454 -0.779 . . . . 0.0 109.655 -179.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.592 ' CE1' ' CD2' ' A' ' 74' ' ' HIS . 26.1 m170 -144.69 142.7 30.27 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.314 -0.866 . . . . 0.0 109.84 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . 0.521 ' CG ' ' O ' ' A' ' 76' ' ' HIS . 54.2 p-80 . . . . . 0 N--CA 1.489 1.479 0 CA-C-O 118.081 -0.962 . . . . 0.0 109.724 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.432 ' O ' ' O ' ' A' ' 1' ' ' ALA . 79.8 tt0 58.35 121.49 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.389 0.614 . . . . 0.0 110.27 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -136.44 155.74 49.58 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.494 -0.754 . . . . 0.0 109.283 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.0 p -126.8 126.65 43.76 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.519 -0.738 . . . . 0.0 109.23 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -94.32 130.58 10.36 Favored Glycine 0 N--CA 1.495 2.611 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.555 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.5 mp -93.64 120.5 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.294 -1.121 . . . . 0.0 109.392 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 70.7 t -76.34 132.91 32.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.427 -0.796 . . . . 0.0 109.335 179.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -134.87 85.82 2.21 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.439 -0.788 . . . . 0.0 109.246 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.3 m -130.73 132.97 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.578 -0.701 . . . . 0.0 109.52 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 46.7 m -62.42 -41.56 98.79 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.453 -0.779 . . . . 0.0 109.907 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.417 ' OG ' ' N ' ' A' ' 12' ' ' SER . 77.6 p -91.81 -82.09 0.32 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.216 -0.928 . . . . 0.0 109.628 -179.399 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.417 ' N ' ' OG ' ' A' ' 11' ' ' SER . 43.1 t -165.98 167.25 16.76 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.383 -0.823 . . . . 0.0 109.111 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 51.0 tp -119.87 132.45 55.57 Favored 'General case' 0 N--CA 1.498 1.97 0 CA-C-O 121.595 0.712 . . . . 0.0 109.61 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -91.28 152.79 20.34 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.628 -0.67 . . . . 0.0 109.858 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.3 t -103.41 131.02 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.665 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 92.1 mtm-85 -110.5 134.69 52.13 Favored 'General case' 0 N--CA 1.492 1.664 0 CA-C-O 121.689 0.757 . . . . 0.0 110.178 -179.569 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -70.91 -36.4 72.68 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.716 -0.615 . . . . 0.0 109.487 179.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.54 -175.88 31.21 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -179.191 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -109.24 24.48 13.05 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.6 -0.941 . . . . 0.0 108.723 179.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.462 ' OG ' ' OG ' ' A' ' 23' ' ' SER . 6.4 p -83.84 171.49 13.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 110.201 -179.524 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 15.9 m -62.72 -43.51 98.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.53 -0.731 . . . . 0.0 109.417 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.8 p -136.12 66.18 1.5 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.457 -0.777 . . . . 0.0 108.956 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.462 ' OG ' ' OG ' ' A' ' 20' ' ' SER . 1.9 m -77.26 -178.08 4.92 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.866 0.841 . . . . 0.0 110.353 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -63.67 139.14 58.74 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.663 0.744 . . . . 0.0 110.656 -179.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 65.6 t -98.27 124.95 51.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.439 -0.788 . . . . 0.0 108.924 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 40.1 pt -104.65 -4.1 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.61 -0.681 . . . . 0.0 109.272 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.81 -168.22 41.23 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.191 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 40.3 t -153.87 154.61 34.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.51 -0.994 . . . . 0.0 109.353 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.7 mt -123.67 151.39 43.14 Favored 'General case' 0 N--CA 1.497 1.923 0 CA-C-O 121.566 0.698 . . . . 0.0 109.652 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.403 ' O ' ' OG1' ' A' ' 33' ' ' THR . 30.7 t -79.17 166.62 22.02 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.627 0.727 . . . . 0.0 110.606 -179.046 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -64.79 158.55 44.12 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -179.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 66.8 m-20 57.39 32.94 22.57 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.711 -0.876 . . . . 0.0 109.685 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.403 ' OG1' ' O ' ' A' ' 30' ' ' SER . 23.2 m -94.53 129.07 41.48 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.281 -0.887 . . . . 0.0 109.456 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -82.92 132.82 35.14 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.426 -0.796 . . . . 0.0 109.822 -179.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 m -127.23 134.52 65.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 O-C-N 121.535 -0.728 . . . . 0.0 109.498 179.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 33.6 m -78.49 129.31 34.73 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.462 -0.774 . . . . 0.0 109.732 -179.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.417 HD13 HG21 ' A' ' 37' ' ' ILE . 96.3 mt -106.7 126.03 62.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.593 -0.692 . . . . 0.0 109.612 179.787 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 28.5 m -118.77 8.48 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.03 174.47 45.89 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -135.28 155.64 50.3 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.372 -1.075 . . . . 0.0 109.904 -179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.417 ' O ' ' O ' ' A' ' 44' ' ' PHE . 76.3 mm-40 -138.86 153.65 48.34 Favored 'General case' 0 N--CA 1.494 1.73 0 CA-C-O 121.435 0.636 . . . . 0.0 109.759 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.49 ' O ' ' CB ' ' A' ' 43' ' ' ALA . . . -64.36 108.02 2.09 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.124 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.49 ' CB ' ' O ' ' A' ' 42' ' ' GLY . . . 80.67 4.03 1.69 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.663 -0.904 . . . . 0.0 109.151 179.488 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.417 ' O ' ' O ' ' A' ' 41' ' ' GLU . 95.6 m-85 -149.39 159.6 44.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 109.736 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -118.25 147.45 43.41 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.574 ' HZ2' ' CG ' ' A' ' 53' ' ' HIS . 0.1 OUTLIER -91.6 118.1 30.32 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 179.674 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.6 pt -126.57 153.13 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 CA-C-O 121.644 0.735 . . . . 0.0 109.702 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -86.06 118.2 25.38 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.531 -0.731 . . . . 0.0 109.61 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.55 ' O ' ' N ' ' A' ' 51' ' ' GLY . 89.6 t80 -111.58 121.7 45.86 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.554 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.418 ' C ' ' O ' ' A' ' 49' ' ' TYR . 37.3 ttpt 39.52 -90.38 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.261 0.553 . . . . 0.0 110.311 -179.669 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -130.2 -22.64 1.09 Allowed Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.914 -1.675 . . . . 0.0 108.914 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 22.5 m -91.19 163.41 14.27 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.217 -1.167 . . . . 0.0 110.532 -179.355 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.574 ' CG ' ' HZ2' ' A' ' 46' ' ' LYS . 56.9 m170 -83.37 113.12 20.52 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.382 -0.824 . . . . 0.0 109.357 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.64 141.95 15.83 Favored Glycine 0 N--CA 1.495 2.576 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -120.81 139.54 52.99 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.672 -0.899 . . . . 0.0 109.427 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.4 m -132.57 137.83 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.662 -0.649 . . . . 0.0 109.525 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.665 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -61.48 143.72 55.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.548 -0.72 . . . . 0.0 110.805 -179.02 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -66.76 -12.31 58.22 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.505 -0.747 . . . . 0.0 109.899 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 47.3 tp10 -67.15 -36.54 82.06 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.169 -0.957 . . . . 0.0 110.256 -179.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -95.62 -5.03 43.39 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.173 -0.955 . . . . 0.0 109.842 -178.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 36.5 mm -110.22 128.94 66.07 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 O-C-N 121.511 -0.743 . . . . 0.0 109.37 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.43 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 21.2 ptmt -140.45 173.23 11.7 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.546 -0.721 . . . . 0.0 110.266 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.43 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 14.7 t0 77.36 -72.21 0.1 Allowed 'General case' 0 N--CA 1.495 1.781 0 CA-C-O 121.114 0.483 . . . . 0.0 109.748 179.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 27.3 mt 62.04 59.59 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.624 -0.673 . . . . 0.0 109.332 -179.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -142.89 135.68 27.89 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.509 -0.744 . . . . 0.0 109.587 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.438 ' OD1' ' N ' ' A' ' 67' ' ' GLU . 67.9 t0 -67.68 134.22 50.72 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.465 -0.772 . . . . 0.0 109.926 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.438 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 98.0 mt-10 -72.56 95.64 1.85 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.35 -0.844 . . . . 0.0 109.829 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 14.6 m -122.0 131.43 73.15 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 O-C-N 121.653 -0.655 . . . . 0.0 109.489 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.521 ' N ' ' CD2' ' A' ' 69' ' ' LEU . 3.8 mm? -78.31 142.76 37.53 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.513 -0.742 . . . . 0.0 110.341 -179.264 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -157.12 110.61 2.59 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 73.6 m80 -76.02 -73.54 0.26 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.579 -0.701 . . . . 0.0 109.806 -179.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -82.5 132.69 35.2 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.271 -0.893 . . . . 0.0 110.14 -179.218 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.537 ' O ' ' CG ' ' A' ' 74' ' ' HIS . 92.6 m-70 -67.33 -39.09 85.79 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.431 -0.793 . . . . 0.0 109.494 179.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . 0.537 ' CG ' ' O ' ' A' ' 73' ' ' HIS . 98.0 m-70 -158.49 -126.36 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.261 -0.899 . . . . 0.0 110.023 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -66.41 -39.31 88.93 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.538 -0.726 . . . . 0.0 109.605 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 92.4 m-70 . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.147 -0.97 . . . . 0.0 109.71 -179.871 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.54 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 57.4 mp0 -81.41 148.98 29.03 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 121.979 0.895 . . . . 0.0 110.462 -179.522 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt -132.21 153.13 50.9 Favored 'General case' 0 N--CA 1.496 1.828 0 CA-C-O 121.633 0.73 . . . . 0.0 109.889 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 44.1 p -115.72 121.78 43.52 Favored 'General case' 0 N--CA 1.499 1.987 0 CA-C-O 121.833 0.825 . . . . 0.0 109.79 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -100.79 142.27 15.73 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.594 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.408 HD12 HG23 ' A' ' 6' ' ' ILE . 22.6 mm -92.69 120.89 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 CA-C-O 121.684 0.754 . . . . 0.0 109.378 179.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.2 t -80.58 105.03 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 CA-C-O 121.668 0.746 . . . . 0.0 109.59 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -99.43 103.88 15.7 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-O 121.747 0.784 . . . . 0.0 109.61 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 26.8 m -137.93 160.58 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 CA-C-O 121.727 0.775 . . . . 0.0 109.918 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 88.0 p -85.73 -12.83 50.15 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.0 m -142.1 -76.01 0.28 Allowed 'General case' 0 N--CA 1.497 1.884 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 25.9 p -155.81 166.56 33.12 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.518 -0.739 . . . . 0.0 109.735 -179.385 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.8 tp -114.18 133.1 55.83 Favored 'General case' 0 N--CA 1.496 1.849 0 CA-C-O 121.841 0.829 . . . . 0.0 110.34 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -91.29 142.3 27.85 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-O 121.719 0.771 . . . . 0.0 109.991 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.9 t -99.11 129.51 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 CA-C-O 121.634 0.731 . . . . 0.0 109.662 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.7 mtt85 -92.87 153.44 18.82 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 121.793 0.806 . . . . 0.0 110.049 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -64.68 -44.37 90.58 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 19' ' ' ALA . . . -157.88 102.92 0.22 Allowed Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.549 ' H ' ' CB ' ' A' ' 55' ' ' TYR . . . 38.8 -114.51 0.14 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 122.001 -0.705 . . . . 0.0 110.292 179.476 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 19' ' ' ALA . 4.9 m 56.35 152.53 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 121.8 0.81 . . . . 0.0 110.508 179.678 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 97.8 m -67.82 -45.5 74.53 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.822 -0.549 . . . . 0.0 109.907 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 39.5 p -153.05 61.05 0.78 Allowed 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 121.836 0.827 . . . . 0.0 109.222 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 5.2 p -75.04 -171.38 1.34 Allowed 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.76 0.79 . . . . 0.0 110.634 179.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt -66.29 142.91 57.5 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-O 121.743 0.782 . . . . 0.0 110.411 -178.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 68.4 t -98.52 127.31 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 CA-C-O 121.732 0.777 . . . . 0.0 109.305 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 27.8 pt -103.26 -4.12 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 173.34 -173.9 45.86 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 24.1 p -154.35 161.69 41.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.81 -0.818 . . . . 0.0 109.711 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.8 mt -126.99 151.49 48.51 Favored 'General case' 0 N--CA 1.499 2.007 0 CA-C-O 121.947 0.879 . . . . 0.0 109.984 -179.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.436 ' OG ' ' OG1' ' A' ' 33' ' ' THR . 84.1 p -72.7 165.87 23.94 Favored 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 121.812 0.815 . . . . 0.0 110.261 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.519 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.85 165.02 45.63 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 56.33 2.88 0.09 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 122.335 -0.509 . . . . 0.0 110.116 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.519 ' H ' ' C ' ' A' ' 31' ' ' GLY . 47.5 m -71.24 136.14 47.83 Favored 'General case' 0 N--CA 1.496 1.851 0 CA-C-O 121.916 0.865 . . . . 0.0 110.391 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -88.9 143.04 27.15 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.34 0.591 . . . . 0.0 109.866 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 35.4 m -126.26 130.46 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 CA-C-O 121.821 0.82 . . . . 0.0 110.08 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 82.7 m -80.01 125.7 30.11 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.517 0.675 . . . . 0.0 109.739 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.6 mt -104.87 128.09 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 CA-C-O 121.554 0.693 . . . . 0.0 109.83 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.8 m -123.92 7.5 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.488 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.04 169.6 42.75 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -129.84 152.77 48.95 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.789 -0.83 . . . . 0.0 109.553 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 53.3 tp10 -153.29 108.33 3.19 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.936 0.874 . . . . 0.0 110.068 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 49.73 -138.14 20.1 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 178.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -84.67 20.3 1.79 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 122.005 -0.703 . . . . 0.0 109.226 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -128.35 151.0 49.85 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-O 121.688 0.756 . . . . 0.0 109.582 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 51.9 m-85 -102.98 141.87 35.04 Favored 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.945 0.878 . . . . 0.0 109.968 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.566 ' NZ ' ' CD2' ' A' ' 53' ' ' HIS . 65.4 tttm -94.29 122.53 36.93 Favored 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.493 0.663 . . . . 0.0 109.384 -179.505 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 34.6 pt -129.25 154.99 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 CA-C-O 121.806 0.813 . . . . 0.0 110.316 179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -83.45 114.4 21.44 Favored 'General case' 0 N--CA 1.494 1.73 0 CA-C-O 121.568 0.699 . . . . 0.0 109.915 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.569 ' O ' ' N ' ' A' ' 51' ' ' GLY . 86.1 t80 -106.28 114.85 29.22 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.694 0.759 . . . . 0.0 109.588 179.77 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.1 mttp 40.96 -87.54 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.754 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.105 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -115.63 -39.38 0.92 Allowed Glycine 0 N--CA 1.495 2.58 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 16.7 p -89.54 169.37 11.41 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.804 -0.821 . . . . 0.0 110.45 -179.184 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.566 ' CD2' ' NZ ' ' A' ' 46' ' ' LYS . 73.2 m80 -96.52 111.19 23.4 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.914 0.864 . . . . 0.0 109.952 -179.61 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.64 144.08 23.97 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.549 ' CB ' ' H ' ' A' ' 19' ' ' ALA . 75.8 m-85 -119.63 135.76 54.67 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-O 121.751 0.786 . . . . 0.0 109.515 179.346 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 20.1 m -137.38 156.12 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 CA-C-O 121.913 0.863 . . . . 0.0 110.318 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.07 154.36 33.42 Favored 'General case' 0 N--CA 1.492 1.667 0 CA-C-O 121.681 0.753 . . . . 0.0 110.107 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -69.67 -17.6 63.5 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.529 ' OE2' ' CE2' ' A' ' 60' ' ' TYR . 9.7 pt-20 -65.0 -34.92 79.58 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.786 -0.572 . . . . 0.0 109.893 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.529 ' CE2' ' OE2' ' A' ' 59' ' ' GLU . 66.8 m-85 -91.98 -10.16 40.33 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.451 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 36.0 mm -110.46 120.73 61.94 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.121 0 CA-C-O 121.847 0.832 . . . . 0.0 110.021 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -149.72 173.47 13.67 Favored 'General case' 0 N--CA 1.494 1.734 0 CA-C-O 121.616 0.722 . . . . 0.0 110.21 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 57.6 47.98 15.01 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 121.353 0.596 . . . . 0.0 109.405 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt -72.0 129.91 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 CA-C-O 121.699 0.762 . . . . 0.0 110.055 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -103.61 140.59 37.35 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-O 121.924 0.869 . . . . 0.0 110.148 -179.018 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -97.66 113.53 25.29 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.703 0.764 . . . . 0.0 109.697 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.532 ' N ' ' OE1' ' A' ' 67' ' ' GLU . 57.3 mp0 -84.2 -6.48 59.41 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 75.0 t -84.34 134.29 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 CA-C-O 121.704 0.764 . . . . 0.0 110.21 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 65.4 mt -64.57 134.74 55.0 Favored 'General case' 0 N--CA 1.495 1.791 0 CA-C-O 121.814 0.816 . . . . 0.0 110.088 -179.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -74.11 141.88 45.61 Favored 'General case' 0 N--CA 1.491 1.603 0 CA-C-O 121.695 0.76 . . . . 0.0 110.207 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.409 ' CD2' ' O ' ' A' ' 72' ' ' HIS . 85.9 t60 -71.76 149.81 45.02 Favored 'General case' 0 N--CA 1.491 1.594 0 CA-C-O 121.777 0.799 . . . . 0.0 110.464 -179.302 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.409 ' O ' ' CD2' ' A' ' 71' ' ' HIS . 99.3 m-70 -70.05 138.91 52.51 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.773 0.797 . . . . 0.0 110.553 -179.308 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 46.62 77.0 0.09 Allowed 'General case' 0 N--CA 1.491 1.576 0 CA-C-O 121.575 0.703 . . . . 0.0 109.496 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -62.27 -42.9 99.74 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -147.08 140.07 25.17 Favored 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 121.884 0.85 . . . . 0.0 109.885 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 47.1 p-80 . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 118.135 -0.936 . . . . 0.0 109.325 179.687 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.685 0 CA-C-O 121.624 0.726 . . . . 0.0 110.303 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.427 ' OE1' ' OE1' ' A' ' 67' ' ' GLU . 96.9 mt-10 -66.12 142.22 57.84 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.288 -0.882 . . . . 0.0 110.512 -179.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -136.48 151.34 49.35 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.535 -0.728 . . . . 0.0 109.478 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.603 ' HG1' ' HZ2' ' A' ' 34' ' ' LYS . 70.4 p -127.73 131.14 49.73 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.524 -0.735 . . . . 0.0 109.144 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -120.02 135.18 10.91 Favored Glycine 0 N--CA 1.5 2.918 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.553 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.9 mp -86.72 129.02 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.434 -1.039 . . . . 0.0 109.675 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.3 t -82.13 104.8 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.181 -0.949 . . . . 0.0 109.665 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -108.29 106.45 16.61 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.481 -0.762 . . . . 0.0 109.054 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 27.7 m -138.47 162.4 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.27 -0.894 . . . . 0.0 110.016 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 t -61.99 -43.57 98.55 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.55 -0.719 . . . . 0.0 109.46 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 12' ' ' SER . 70.5 m -161.09 108.9 1.52 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.006 -1.059 . . . . 0.0 110.262 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 11' ' ' SER . 22.7 t 54.0 159.19 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.849 0.833 . . . . 0.0 111.509 179.126 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 35.1 tp -133.22 133.03 42.19 Favored 'General case' 0 N--CA 1.498 1.971 0 CA-C-O 121.485 0.66 . . . . 0.0 109.652 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 46.0 p-10 -80.69 141.81 34.52 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.391 -0.818 . . . . 0.0 109.914 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 78.2 t -93.45 133.12 35.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.201 -0.937 . . . . 0.0 109.666 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -102.38 130.54 49.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.384 -0.823 . . . . 0.0 109.909 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -73.75 -41.31 62.67 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.468 -0.77 . . . . 0.0 109.763 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.479 ' O ' ' CG ' ' A' ' 55' ' ' TYR . . . -95.93 -129.42 5.96 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.934 -1.266 . . . . 0.0 109.934 -179.111 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -137.13 -12.85 1.63 Allowed 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.519 -0.989 . . . . 0.0 109.073 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 12.0 m -72.72 152.36 41.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.198 -0.939 . . . . 0.0 110.688 -179.094 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.7 m -63.15 -46.08 88.87 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.376 -0.828 . . . . 0.0 109.34 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 58.7 m -88.75 34.74 0.77 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.152 -0.967 . . . . 0.0 108.604 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.2 p -73.78 161.95 29.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.405 -0.81 . . . . 0.0 110.376 -179.2 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -66.28 136.11 55.37 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.348 -0.845 . . . . 0.0 110.299 -179.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 53.4 t -100.72 127.98 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.416 -0.802 . . . . 0.0 109.355 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.5 pt -101.11 -3.07 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.04 -164.22 37.6 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.458 -1.353 . . . . 0.0 110.325 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 40.4 t -155.31 158.87 39.43 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.268 -1.136 . . . . 0.0 109.373 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.0 mt -122.96 149.96 43.59 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.508 -0.745 . . . . 0.0 109.769 -179.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 29.6 t -69.23 154.62 41.75 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-O 121.834 0.826 . . . . 0.0 111.02 -178.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.46 157.25 37.53 Favored Glycine 0 N--CA 1.492 2.413 0 O-C-N 121.637 -0.664 . . . . 0.0 111.475 -179.418 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.3 t-20 58.75 33.88 23.37 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.809 -0.818 . . . . 0.0 109.741 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.7 m -97.02 129.52 44.46 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.314 -0.866 . . . . 0.0 109.594 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.603 ' HZ2' ' HG1' ' A' ' 4' ' ' THR . 54.1 tttp -79.8 131.13 35.82 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.352 -0.843 . . . . 0.0 109.344 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 21.6 m -128.77 136.6 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.392 -0.817 . . . . 0.0 109.697 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 18.8 m -80.99 129.46 34.54 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.613 -0.679 . . . . 0.0 109.586 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.6 mt -110.45 129.56 65.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.686 -0.633 . . . . 0.0 109.446 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 24.4 m -128.62 -49.37 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -91.57 166.84 30.64 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 -179.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -139.0 146.87 41.42 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.337 -1.096 . . . . 0.0 109.559 179.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.5 tm-20 -154.31 110.02 3.19 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.321 -0.862 . . . . 0.0 109.07 179.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 53.13 -138.82 34.79 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 111.044 -0.822 . . . . 0.0 111.044 179.186 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.02 10.65 13.57 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.366 -1.079 . . . . 0.0 109.113 -179.411 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -111.62 144.45 40.85 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.502 -0.748 . . . . 0.0 109.447 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 47.2 m-85 -104.03 141.33 36.38 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.544 -0.723 . . . . 0.0 109.702 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -90.28 137.91 31.96 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.266 -0.897 . . . . 0.0 108.751 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.421 HD13 HG21 ' A' ' 47' ' ' ILE . 17.3 pt -127.81 154.38 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.0 0 O-C-N 121.468 -0.77 . . . . 0.0 110.087 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 50.8 tp10 -82.95 106.87 15.13 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.532 ' O ' ' N ' ' A' ' 51' ' ' GLY . 80.1 t80 -109.21 124.69 51.27 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.52 -0.737 . . . . 0.0 110.134 -179.722 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.443 ' C ' ' O ' ' A' ' 49' ' ' TYR . 67.8 mttm 33.62 -88.97 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.103 0.478 . . . . 0.0 111.246 179.504 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -119.83 -29.3 1.71 Allowed Glycine 0 N--CA 1.498 2.807 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 -179.251 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 66.6 m -100.58 176.86 5.18 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.088 -1.242 . . . . 0.0 110.478 -179.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -107.68 119.91 40.75 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.527 -0.733 . . . . 0.0 109.682 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.7 159.03 25.56 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.479 ' CG ' ' O ' ' A' ' 18' ' ' GLY . 91.0 m-85 -115.98 137.32 52.22 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.444 -1.033 . . . . 0.0 109.64 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.8 m -136.11 137.19 48.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.627 -0.671 . . . . 0.0 109.431 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.32 148.08 51.25 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.498 -0.751 . . . . 0.0 110.611 -179.278 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.3 ptpm? -62.84 -16.55 58.92 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.376 -0.827 . . . . 0.0 109.368 179.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -67.58 -35.84 79.77 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.292 -0.88 . . . . 0.0 109.89 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -92.34 -5.02 53.01 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.018 -1.051 . . . . 0.0 109.236 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.403 HG22 HD13 ' A' ' 61' ' ' ILE . 36.7 mm -112.11 123.87 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 121.374 -0.829 . . . . 0.0 109.21 179.735 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 20.5 ptmt -141.63 171.17 14.43 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.479 -0.763 . . . . 0.0 110.068 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 58.72 40.86 22.73 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-O 121.477 0.656 . . . . 0.0 109.487 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.404 HG21 HD13 ' A' ' 64' ' ' ILE . 96.6 mt -75.8 129.87 36.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.285 -0.884 . . . . 0.0 110.042 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.9 mtpt -135.42 147.13 48.88 Favored 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 121.752 0.787 . . . . 0.0 110.215 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 65.1 t0 -82.92 122.19 27.94 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.565 -0.709 . . . . 0.0 110.251 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.427 ' OE1' ' OE1' ' A' ' 2' ' ' GLU . 96.2 mt-10 -47.43 152.15 0.68 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.263 -0.898 . . . . 0.0 110.76 -179.535 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 19.5 m -66.62 130.56 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 CA-C-O 121.881 0.848 . . . . 0.0 110.56 -179.093 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.426 ' O ' ' O ' ' A' ' 70' ' ' GLU . 5.6 tp -104.11 -18.6 14.47 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.426 ' O ' ' O ' ' A' ' 69' ' ' LEU . 73.8 mm-40 58.28 119.45 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.923 0 CA-C-O 121.925 0.869 . . . . 0.0 110.467 -179.736 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.423 ' O ' ' O ' ' A' ' 72' ' ' HIS . 96.7 m-70 -74.65 147.92 41.12 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.609 0.718 . . . . 0.0 110.82 -179.463 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.423 ' O ' ' O ' ' A' ' 71' ' ' HIS . 71.1 m80 58.61 123.42 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.779 0 CA-C-O 121.713 0.768 . . . . 0.0 110.418 179.526 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 58.8 t-80 -79.99 106.33 11.93 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.486 -0.759 . . . . 0.0 109.926 -179.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 78.3 m80 -151.86 64.05 0.85 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 179.497 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -61.97 -42.04 98.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.397 -0.814 . . . . 0.0 109.221 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 33.9 p-80 . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 117.945 -1.026 . . . . 0.0 109.699 -179.711 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.448 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.527 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 56.2 mp0 44.02 97.47 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.668 0.747 . . . . 0.0 110.205 179.819 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -119.62 154.95 33.22 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.577 ' CB ' ' HZ3' ' A' ' 34' ' ' LYS . 59.2 p -128.41 124.78 37.14 Favored 'General case' 0 N--CA 1.497 1.893 0 CA-C-O 121.643 0.735 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -99.91 137.25 13.15 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.567 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.8 mp -93.95 119.16 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.536 -0.979 . . . . 0.0 109.673 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 71.9 t -79.09 133.2 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 CA-C-O 121.494 0.664 . . . . 0.0 109.791 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.533 ' CB ' ' NZ ' ' A' ' 62' ' ' LYS . 46.1 t30 -140.34 106.98 5.33 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.404 -0.81 . . . . 0.0 109.648 -179.813 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 m -138.3 151.68 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.603 -0.686 . . . . 0.0 109.634 179.8 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 73.5 m -72.26 -42.9 65.06 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 121.477 0.656 . . . . 0.0 109.828 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 69.0 m -103.85 -76.67 0.59 Allowed 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.446 -0.784 . . . . 0.0 109.625 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 41.2 t -160.03 168.27 25.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.325 -0.86 . . . . 0.0 109.687 -179.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 41.8 tp -116.58 130.21 56.62 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 121.592 0.71 . . . . 0.0 109.984 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -91.92 138.38 31.59 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.771 0.796 . . . . 0.0 110.158 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.3 t -89.5 130.01 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 CA-C-O 121.497 0.665 . . . . 0.0 109.802 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.404 ' CZ ' ' O ' ' A' ' 21' ' ' THR . 38.4 mmt180 -107.67 131.15 54.71 Favored 'General case' 0 N--CA 1.496 1.835 0 CA-C-O 121.872 0.844 . . . . 0.0 109.565 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -71.22 -40.18 71.27 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-O 121.532 0.682 . . . . 0.0 109.549 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.502 ' N ' ' OG ' ' A' ' 23' ' ' SER . . . -93.69 177.09 37.07 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.34 39.51 0.87 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.501 -0.999 . . . . 0.0 109.104 179.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.9 p -151.91 154.88 36.97 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.398 -0.814 . . . . 0.0 109.686 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.404 ' O ' ' CZ ' ' A' ' 16' ' ' ARG . 60.5 p -71.29 -28.03 63.84 Favored 'General case' 0 N--CA 1.493 1.724 0 CA-C-O 121.675 0.75 . . . . 0.0 109.379 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 91.9 p -82.35 -3.71 55.94 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.502 ' OG ' ' N ' ' A' ' 18' ' ' GLY . 24.0 t -51.73 -97.08 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.619 -0.675 . . . . 0.0 110.188 -179.746 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.443 ' N ' ' HG ' ' A' ' 23' ' ' SER . 88.5 tttt -169.33 131.58 1.2 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.311 -0.868 . . . . 0.0 110.011 -179.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 84.2 t -81.67 132.17 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.73 -0.606 . . . . 0.0 109.939 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 45.0 pt -117.6 -10.28 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.69 -175.01 45.23 Favored Glycine 0 N--CA 1.494 2.554 0 C-N-CA 119.402 -1.38 . . . . 0.0 110.252 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 65.8 m -133.04 156.18 47.84 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.714 -0.874 . . . . 0.0 109.814 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 92.2 mt -122.9 147.91 46.04 Favored 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.83 0.824 . . . . 0.0 109.941 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.574 ' HG ' ' N ' ' A' ' 31' ' ' GLY . 30.6 t -74.77 157.85 34.5 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-O 121.937 0.875 . . . . 0.0 110.63 -179.328 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.574 ' N ' ' HG ' ' A' ' 30' ' ' SER . . . -66.6 156.52 51.04 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 11.5 m120 57.36 33.09 22.8 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 122.075 -0.662 . . . . 0.0 109.461 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.417 ' OG1' ' O ' ' A' ' 30' ' ' SER . 43.3 m -94.42 125.07 38.84 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.843 0.83 . . . . 0.0 110.331 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.577 ' HZ3' ' CB ' ' A' ' 4' ' ' THR . 63.3 tttp -79.24 132.14 36.4 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-O 121.306 0.574 . . . . 0.0 109.677 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.1 m -129.5 134.13 64.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 121.804 0.811 . . . . 0.0 109.763 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 52.7 m -79.09 127.63 32.25 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-O 121.6 0.714 . . . . 0.0 109.901 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.7 mt -102.76 124.2 56.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 CA-C-O 121.499 0.666 . . . . 0.0 109.508 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.76 -0.8 9.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.3 176.31 46.0 Favored Glycine 0 N--CA 1.494 2.551 0 C-N-CA 119.681 -1.247 . . . . 0.0 110.538 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -143.94 155.3 44.01 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.65 -0.912 . . . . 0.0 109.475 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -153.27 107.28 3.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.456 -0.777 . . . . 0.0 109.78 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.3 -135.96 49.75 Favored Glycine 0 N--CA 1.493 2.493 0 CA-C-O 121.98 0.766 . . . . 0.0 111.626 178.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -88.28 28.19 1.12 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.554 -0.968 . . . . 0.0 109.122 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -136.11 150.26 49.03 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.641 -0.662 . . . . 0.0 109.58 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.626 ' CZ ' ' NZ ' ' A' ' 58' ' ' LYS . 12.5 m-85 -107.17 146.04 31.82 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-O 121.882 0.849 . . . . 0.0 109.925 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -98.67 124.77 43.69 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.7 pt -129.73 157.79 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 121.651 0.738 . . . . 0.0 110.187 -179.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -87.5 101.79 13.95 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.43 0.634 . . . . 0.0 109.811 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.8 t80 -109.85 118.64 37.03 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-O 121.618 0.723 . . . . 0.0 109.45 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.6 mmtt 51.43 29.8 5.6 Favored 'General case' 0 N--CA 1.492 1.668 0 CA-C-O 121.763 0.792 . . . . 0.0 109.754 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.97 -23.45 23.55 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 179.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.3 m -86.53 165.34 16.31 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.281 -1.129 . . . . 0.0 110.576 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -94.51 101.63 13.54 Favored 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 121.73 0.776 . . . . 0.0 109.667 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.1 147.93 19.9 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -115.51 134.08 55.42 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.699 -0.883 . . . . 0.0 109.425 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.6 m -136.14 139.58 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 CA-C-O 121.573 0.702 . . . . 0.0 109.902 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.53 144.71 55.75 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.889 0.852 . . . . 0.0 110.387 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.626 ' NZ ' ' CZ ' ' A' ' 45' ' ' TYR . 67.1 mttm -63.74 -36.84 85.19 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-O 121.421 0.629 . . . . 0.0 110.468 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -46.83 -16.34 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.238 -0.914 . . . . 0.0 110.675 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.45 ' N ' ' O ' ' A' ' 58' ' ' LYS . 36.1 m-85 -108.37 -30.65 8.2 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.162 -0.961 . . . . 0.0 109.132 179.488 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.528 ' CD1' ' N ' ' A' ' 61' ' ' ILE . 1.5 mp -93.54 123.22 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.424 -0.798 . . . . 0.0 109.741 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.533 ' NZ ' ' CB ' ' A' ' 8' ' ' ASN . 26.6 pttm -148.78 174.73 11.89 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.585 0.707 . . . . 0.0 109.952 179.527 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.5 m-20 58.11 51.28 8.87 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-O 121.68 0.752 . . . . 0.0 109.765 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.9 mt -71.08 133.53 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.51 -0.744 . . . . 0.0 109.722 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 15.0 ttmm -112.87 132.25 55.37 Favored 'General case' 0 N--CA 1.496 1.825 0 CA-C-O 121.841 0.829 . . . . 0.0 110.258 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -85.91 117.68 24.92 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.739 0.78 . . . . 0.0 109.672 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -60.31 135.73 57.82 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.846 0.832 . . . . 0.0 110.117 -179.583 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.417 HG23 ' H ' ' A' ' 70' ' ' GLU . 9.0 p -99.45 125.44 53.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 CA-C-O 121.673 0.749 . . . . 0.0 109.581 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 87.0 mt -93.42 -5.23 49.81 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.542 -0.724 . . . . 0.0 109.116 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.417 ' H ' HG23 ' A' ' 68' ' ' VAL . 97.8 mt-10 -59.23 136.01 57.83 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.309 -0.869 . . . . 0.0 110.051 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 86.6 t60 -67.17 -40.41 86.59 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.75 0.786 . . . . 0.0 109.506 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -68.25 145.53 54.18 Favored 'General case' 0 N--CA 1.49 1.531 0 CA-C-O 121.677 0.751 . . . . 0.0 110.156 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.531 ' O ' ' CG ' ' A' ' 74' ' ' HIS . 59.4 t-80 -132.95 164.53 26.74 Favored 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.576 0.703 . . . . 0.0 109.811 -179.565 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . 0.631 ' HD1' ' N ' ' A' ' 75' ' ' HIS . 18.7 p80 41.7 -158.98 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.579 0.705 . . . . 0.0 110.589 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.631 ' N ' ' HD1' ' A' ' 74' ' ' HIS . 99.1 m-70 -138.88 147.66 42.66 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.422 -0.799 . . . . 0.0 110.072 -179.139 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . 0.455 ' O ' ' CG ' ' A' ' 76' ' ' HIS . 85.8 t60 . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 118.145 -0.931 . . . . 0.0 109.065 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -69.48 140.51 54.02 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.342 -0.849 . . . . 0.0 110.265 -179.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt -137.42 153.28 50.16 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.482 -0.761 . . . . 0.0 109.384 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 46.9 p -115.13 123.13 48.16 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.679 -0.638 . . . . 0.0 109.372 -179.673 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -96.04 131.45 10.66 Favored Glycine 0 N--CA 1.496 2.674 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.536 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.4 mp -80.81 126.41 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.332 -1.099 . . . . 0.0 109.251 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 74.9 t -80.61 132.78 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.542 -0.724 . . . . 0.0 109.645 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 24.2 t-20 -131.24 103.41 6.46 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.547 -0.721 . . . . 0.0 109.271 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 27.9 m -135.46 156.45 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.492 -0.755 . . . . 0.0 109.434 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 95.6 p -83.7 -10.96 57.8 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.488 -0.758 . . . . 0.0 109.3 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.501 ' OG ' ' N ' ' A' ' 12' ' ' SER . 86.4 p -138.37 -73.1 0.4 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.359 -0.838 . . . . 0.0 109.154 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.501 ' N ' ' OG ' ' A' ' 11' ' ' SER . 31.9 p -158.71 165.04 35.29 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.369 -0.832 . . . . 0.0 109.249 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.9 tp -113.83 131.47 56.23 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.482 -0.761 . . . . 0.0 109.028 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -91.07 146.43 23.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.406 -0.809 . . . . 0.0 109.885 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 65.1 t -99.3 130.1 48.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.504 ' NH1' ' O ' ' A' ' 21' ' ' THR . 93.0 mtt-85 -110.97 136.85 49.36 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.587 -0.695 . . . . 0.0 109.95 -179.346 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 66.3 mm-40 -80.58 -35.73 33.84 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.453 -0.779 . . . . 0.0 109.655 179.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -95.57 177.17 34.4 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.68 -5.42 42.31 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.402 -1.058 . . . . 0.0 109.083 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 33.5 t -86.16 153.67 21.89 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -0.852 . . . . 0.0 109.951 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.515 ' C ' ' H ' ' A' ' 23' ' ' SER . 15.3 m -63.67 -44.77 92.79 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.433 -0.792 . . . . 0.0 109.725 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 76.7 p -73.11 17.83 0.12 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.212 -0.93 . . . . 0.0 109.408 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.515 ' H ' ' C ' ' A' ' 21' ' ' THR . 17.3 m -64.65 149.22 49.4 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.239 -0.913 . . . . 0.0 109.788 -179.723 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 24.9 pttm -70.79 143.53 51.14 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.395 -0.815 . . . . 0.0 110.367 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 55.6 t -103.24 131.28 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.528 -0.732 . . . . 0.0 109.641 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 24.7 pt -99.01 -6.58 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.441 -0.787 . . . . 0.0 109.538 179.712 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.3 -159.81 33.27 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.8 m -152.92 167.11 30.23 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.436 -1.037 . . . . 0.0 109.571 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.9 mt -127.23 153.89 45.53 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.525 -0.734 . . . . 0.0 109.576 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.6 p -73.25 162.08 29.79 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.505 -0.747 . . . . 0.0 110.721 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.574 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -69.07 163.71 50.6 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -179.509 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 35.2 t-20 65.45 -13.95 0.12 Allowed 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.81 -0.818 . . . . 0.0 110.012 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.574 ' H ' ' C ' ' A' ' 31' ' ' GLY . 38.2 m -67.83 133.7 49.64 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.055 -1.028 . . . . 0.0 109.503 179.568 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.5 pttp -93.81 146.57 23.78 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.353 -0.842 . . . . 0.0 109.651 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.1 m -122.86 131.46 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.618 -0.677 . . . . 0.0 109.424 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 33.6 m -66.13 128.85 37.73 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.526 -0.733 . . . . 0.0 110.352 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 94.2 mt -107.95 127.81 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.399 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 17.1 m -111.57 -1.06 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 O-C-N 121.567 -0.708 . . . . 0.0 109.468 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 178.75 -175.27 47.25 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -140.69 153.63 46.03 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.369 -1.077 . . . . 0.0 109.432 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 47.9 tp10 -151.64 112.06 4.15 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.326 -0.859 . . . . 0.0 109.506 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.96 -143.35 48.58 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.63 17.2 3.41 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.635 -0.92 . . . . 0.0 109.874 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -127.21 148.1 50.2 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.415 -0.803 . . . . 0.0 109.34 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -98.99 147.42 25.03 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.432 -0.792 . . . . 0.0 109.734 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.669 ' HZ2' ' HD1' ' A' ' 53' ' ' HIS . 65.0 tttm -96.37 126.79 41.81 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.603 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.6 pt -128.95 156.36 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.503 -0.748 . . . . 0.0 109.952 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -90.27 117.69 29.2 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.488 -0.757 . . . . 0.0 109.418 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.537 ' O ' ' N ' ' A' ' 51' ' ' GLY . 53.1 t80 -106.49 101.96 11.39 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.551 -0.718 . . . . 0.0 109.358 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 7.7 mtmp? 43.51 -88.69 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.59 -0.693 . . . . 0.0 110.655 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.537 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -128.39 42.61 1.42 Allowed Glycine 0 N--CA 1.501 2.993 0 N-CA-C 109.784 -1.327 . . . . 0.0 109.784 -179.329 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 93.9 p -161.43 163.59 30.38 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.196 -1.179 . . . . 0.0 109.172 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.669 ' HD1' ' HZ2' ' A' ' 46' ' ' LYS . 99.3 m-70 -94.91 111.18 22.99 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.22 -0.925 . . . . 0.0 109.559 -179.639 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.11 150.22 19.56 Favored Glycine 0 N--CA 1.494 2.546 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -128.41 139.6 52.28 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.627 -0.925 . . . . 0.0 109.473 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 28.8 m -136.19 156.21 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.436 -0.79 . . . . 0.0 109.826 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 147.18 39.49 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.484 -0.76 . . . . 0.0 110.465 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -69.18 -12.53 61.76 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.485 -0.76 . . . . 0.0 109.593 179.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -67.88 -35.27 78.22 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.22 -0.925 . . . . 0.0 110.499 -179.352 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 19.8 m-85 -94.35 -4.49 48.47 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.906 -1.121 . . . . 0.0 110.336 -179.17 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.401 ' CD1' ' N ' ' A' ' 61' ' ' ILE . 1.6 mp -107.82 130.6 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.237 -0.914 . . . . 0.0 108.88 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.563 ' O ' ' N ' ' A' ' 64' ' ' ILE . 64.3 pttt -142.34 -168.11 2.65 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.478 -0.764 . . . . 0.0 109.077 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 56.26 -75.16 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 CA-C-O 120.986 0.422 . . . . 0.0 110.262 179.655 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.563 ' N ' ' O ' ' A' ' 62' ' ' LYS . 90.3 mt 57.49 81.08 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.445 -0.785 . . . . 0.0 109.369 -179.667 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -139.15 154.74 48.14 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.518 -0.739 . . . . 0.0 109.359 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -81.19 108.4 14.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.298 -0.876 . . . . 0.0 109.813 -179.527 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -103.67 -10.74 18.14 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.476 -0.765 . . . . 0.0 109.157 179.556 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.6 t -92.16 -21.19 6.37 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.239 -0.913 . . . . 0.0 109.396 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 70' ' ' GLU . 86.6 mt -89.91 137.49 32.3 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.357 -0.839 . . . . 0.0 109.917 -179.627 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.421 ' C ' ' O ' ' A' ' 69' ' ' LEU . 15.0 pt-20 35.16 -150.99 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.971 0 CA-C-O 121.661 0.743 . . . . 0.0 111.504 179.146 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 69.8 t60 54.82 92.29 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.392 -0.818 . . . . 0.0 109.451 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.571 ' O ' ' N ' ' A' ' 74' ' ' HIS . 59.0 t-80 -70.14 105.87 3.08 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.455 -0.778 . . . . 0.0 110.063 -179.718 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.601 ' ND1' ' ND1' ' A' ' 74' ' ' HIS . 62.4 t-80 51.3 -80.12 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.65 -0.656 . . . . 0.0 110.814 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . 0.601 ' ND1' ' ND1' ' A' ' 73' ' ' HIS . 21.2 p-80 -146.99 168.44 21.5 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.922 -1.111 . . . . 0.0 109.635 -179.293 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.432 ' H ' ' CD2' ' A' ' 75' ' ' HIS . 5.9 p80 -66.06 141.08 58.27 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.448 -0.782 . . . . 0.0 110.348 -179.177 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.5 m-70 . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 118.151 -0.928 . . . . 0.0 109.97 179.622 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.665 0.745 . . . . 0.0 109.938 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -71.74 155.28 40.63 Favored 'General case' 0 N--CA 1.491 1.583 0 CA-C-O 121.543 0.687 . . . . 0.0 110.237 -179.503 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -136.54 154.9 50.58 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.486 -0.758 . . . . 0.0 109.566 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.667 ' HG1' ' H ' ' A' ' 67' ' ' GLU . 42.5 p -107.22 114.93 29.29 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.777 0.798 . . . . 0.0 109.289 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.45 136.2 12.57 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.523 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.56 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.8 mp -86.38 120.84 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.568 -0.96 . . . . 0.0 109.445 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 99.5 t -82.58 104.35 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 CA-C-O 121.581 0.705 . . . . 0.0 109.354 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 -102.26 103.79 14.29 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.51 -0.744 . . . . 0.0 109.762 -179.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 34.7 m -137.46 164.05 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.57 -0.706 . . . . 0.0 109.832 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 79.8 p -63.25 -39.88 95.85 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.348 0.594 . . . . 0.0 109.755 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.442 ' O ' ' O ' ' A' ' 12' ' ' SER . 29.6 p -163.89 109.16 1.04 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.94 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.442 ' O ' ' O ' ' A' ' 11' ' ' SER . 1.4 m 52.48 166.82 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 CA-C-O 121.938 0.875 . . . . 0.0 111.156 179.634 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 37.1 tp -139.46 131.53 27.96 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.583 0.706 . . . . 0.0 109.853 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -79.52 141.86 36.29 Favored 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.516 0.674 . . . . 0.0 109.933 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 75.3 t -98.78 130.62 47.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.54 -0.725 . . . . 0.0 109.718 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.509 ' NE ' ' O ' ' A' ' 21' ' ' THR . 85.1 mtt85 -103.58 134.09 47.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.468 -0.77 . . . . 0.0 109.73 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.1 tm-20 -71.58 -38.98 70.85 Favored 'General case' 0 N--CA 1.491 1.575 0 CA-C-O 121.596 0.713 . . . . 0.0 109.617 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -90.96 173.66 38.2 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.123 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -90.36 5.35 47.71 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.367 -1.079 . . . . 0.0 109.385 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.436 ' OG ' ' OG ' ' A' ' 23' ' ' SER . 7.2 p -78.66 166.64 22.28 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.319 -0.863 . . . . 0.0 110.38 -179.389 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.509 ' O ' ' NE ' ' A' ' 16' ' ' ARG . 0.7 OUTLIER -69.85 -20.71 63.4 Favored 'General case' 0 N--CA 1.491 1.596 0 CA-C-O 121.509 0.671 . . . . 0.0 109.664 179.807 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.7 t -151.11 63.76 0.9 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.009 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.436 ' OG ' ' OG ' ' A' ' 20' ' ' SER . 18.1 m -75.13 -79.42 0.09 Allowed 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.636 0.732 . . . . 0.0 109.447 179.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -160.56 121.17 2.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.218 -0.926 . . . . 0.0 109.935 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 75.7 t -74.97 129.3 36.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.496 0.665 . . . . 0.0 109.623 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 34.8 pt -119.6 -10.22 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.483 0.658 . . . . 0.0 109.24 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 179.47 -168.73 39.47 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.633 -1.27 . . . . 0.0 110.163 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 39.4 t -154.31 154.5 33.47 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.576 -0.955 . . . . 0.0 109.831 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.0 mt -122.71 150.56 42.57 Favored 'General case' 0 N--CA 1.495 1.806 0 CA-C-O 121.622 0.725 . . . . 0.0 109.544 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 17.1 m -69.45 151.31 46.24 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.851 0.834 . . . . 0.0 110.354 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.431 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.2 166.04 41.91 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 57.11 8.52 0.54 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 122.012 -0.699 . . . . 0.0 109.575 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.431 ' H ' ' C ' ' A' ' 31' ' ' GLY . 34.6 m -88.47 134.33 33.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.44 -0.788 . . . . 0.0 110.243 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -78.14 146.66 34.98 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.641 -0.662 . . . . 0.0 110.094 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.7 m -126.33 132.58 70.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 CA-C-O 121.621 0.724 . . . . 0.0 109.567 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 39.6 m -65.12 128.89 37.65 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.547 0.689 . . . . 0.0 110.116 -179.509 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 5.4 mm -102.8 125.2 57.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 CA-C-O 121.442 0.639 . . . . 0.0 109.426 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 6.3 m -122.11 -11.83 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.55 -173.81 45.6 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.544 -1.312 . . . . 0.0 110.659 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -148.56 163.15 38.09 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.577 -0.955 . . . . 0.0 109.827 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -156.08 114.06 3.33 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.504 -0.748 . . . . 0.0 109.503 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 61.17 -136.5 48.14 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 179.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.545 ' C ' ' HZ2' ' A' ' 58' ' ' LYS . . . -92.34 28.91 1.8 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.527 -0.984 . . . . 0.0 108.719 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -134.5 150.35 50.78 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.621 -0.674 . . . . 0.0 109.435 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -105.37 139.63 39.7 Favored 'General case' 0 N--CA 1.493 1.715 0 CA-C-O 121.798 0.809 . . . . 0.0 109.703 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -96.86 129.19 44.33 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.9 pt -129.29 164.22 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 CA-C-O 121.727 0.775 . . . . 0.0 110.212 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -77.72 99.75 5.97 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-O 121.619 0.723 . . . . 0.0 109.94 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -90.36 134.77 34.1 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.515 -0.741 . . . . 0.0 109.484 179.521 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 56.6 mtpt -52.1 97.8 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.452 0.644 . . . . 0.0 110.422 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 121.46 -35.58 3.56 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.604 ' HG ' ' N ' ' A' ' 53' ' ' HIS . 23.4 p -163.31 -153.96 0.26 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.141 -1.211 . . . . 0.0 110.076 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.604 ' N ' ' HG ' ' A' ' 52' ' ' SER . 97.9 m-70 -106.4 118.6 37.08 Favored 'General case' 0 N--CA 1.496 1.835 0 CA-C-O 121.698 0.761 . . . . 0.0 109.999 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.83 145.55 17.67 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -115.86 136.86 52.64 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.807 -0.819 . . . . 0.0 109.781 179.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.6 m -138.09 154.57 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 CA-C-O 121.425 0.631 . . . . 0.0 109.679 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.97 149.52 43.27 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.845 0.831 . . . . 0.0 110.899 -179.492 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.545 ' HZ2' ' C ' ' A' ' 43' ' ' ALA . 57.1 mttp -63.1 -34.5 77.73 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.486 0.66 . . . . 0.0 109.99 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -53.67 -30.12 41.87 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.418 -0.801 . . . . 0.0 110.111 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -90.03 -2.22 58.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.989 -1.069 . . . . 0.0 109.236 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.0 mm -107.64 127.41 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 CA-C-O 121.796 0.807 . . . . 0.0 109.854 -179.788 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -141.22 150.72 43.04 Favored 'General case' 0 N--CA 1.49 1.563 0 CA-C-O 121.77 0.795 . . . . 0.0 110.133 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.1 t0 56.62 59.5 3.54 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 121.652 0.739 . . . . 0.0 109.965 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.408 HD13 HG21 ' A' ' 64' ' ' ILE . 97.2 mt -75.4 98.63 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.409 -0.807 . . . . 0.0 109.505 179.804 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.424 ' O ' ' OG1' ' A' ' 4' ' ' THR . 98.5 mttt -141.85 155.95 45.54 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.608 0.718 . . . . 0.0 109.988 -179.542 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -83.88 112.58 20.26 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.667 ' H ' ' HG1' ' A' ' 4' ' ' THR . 48.6 tp10 -76.9 98.8 5.0 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.479 -0.763 . . . . 0.0 109.822 -179.47 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.2 m -152.37 -8.31 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -90.88 152.65 20.66 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.383 -0.823 . . . . 0.0 110.332 -179.706 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -57.37 152.29 14.57 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.699 0.761 . . . . 0.0 110.796 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 36.1 p-80 -148.02 165.33 31.07 Favored 'General case' 0 N--CA 1.491 1.622 0 CA-C-O 121.733 0.778 . . . . 0.0 110.279 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 84.9 t60 43.25 92.55 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.721 0 CA-C-O 121.94 0.876 . . . . 0.0 110.058 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 55.6 p-80 -72.3 128.57 36.05 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-O 121.495 0.664 . . . . 0.0 110.173 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . 0.466 ' CG ' ' O ' ' A' ' 74' ' ' HIS . 55.1 p-80 -103.07 112.53 25.41 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.52 -0.738 . . . . 0.0 109.666 -179.778 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 75.0 m80 -144.0 148.65 35.55 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.553 -0.717 . . . . 0.0 109.935 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.211 -0.9 . . . . 0.0 109.827 179.678 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.431 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 1' ' ' ALA . 97.3 mt-10 56.16 114.23 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.539 0.685 . . . . 0.0 110.33 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -132.85 151.0 52.1 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.596 -0.69 . . . . 0.0 109.762 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.8 p -116.21 118.32 32.49 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.556 -0.715 . . . . 0.0 109.367 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -105.52 131.5 10.68 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 -179.351 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.56 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.7 mp -84.91 126.04 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.41 -1.053 . . . . 0.0 109.477 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 74.0 t -75.2 129.03 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 O-C-N 121.318 -0.864 . . . . 0.0 109.938 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 65.0 t-20 -120.38 102.61 8.59 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.1 m -137.09 160.75 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.455 -0.778 . . . . 0.0 109.826 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 87.3 p -82.8 -13.09 56.88 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.524 -0.735 . . . . 0.0 109.266 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.7 m -145.69 -69.41 0.28 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.277 -0.889 . . . . 0.0 109.297 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 58.3 m -156.84 168.86 26.19 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.062 -1.024 . . . . 0.0 109.825 -179.564 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 49.8 tp -116.46 129.76 56.39 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-O 121.656 0.741 . . . . 0.0 109.838 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . 0.436 ' O ' ' OD1' ' A' ' 14' ' ' ASN . 15.1 p30 -89.1 122.12 32.1 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.433 -0.792 . . . . 0.0 109.778 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.0 t -76.49 153.54 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.364 -0.835 . . . . 0.0 109.864 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.442 HH21 ' N ' ' A' ' 57' ' ' ALA . 88.9 mtm180 -128.54 136.47 50.8 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.567 -0.708 . . . . 0.0 109.809 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 12.6 tm-20 -69.95 -38.8 76.23 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.548 -0.72 . . . . 0.0 109.138 179.464 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -104.78 -178.86 24.6 Favored Glycine 0 N--CA 1.496 2.652 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 -179.236 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -94.5 -0.88 54.32 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.493 -1.004 . . . . 0.0 108.569 179.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.2 m -84.69 151.53 24.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.307 -0.871 . . . . 0.0 110.022 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 59.0 p -68.96 -29.08 67.23 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.55 -0.719 . . . . 0.0 109.612 179.421 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 96.7 p -85.65 7.47 23.25 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.278 -0.889 . . . . 0.0 109.257 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.0 t -62.42 146.44 51.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.434 -0.791 . . . . 0.0 110.759 -179.278 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -68.77 137.45 54.02 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-O 121.723 0.773 . . . . 0.0 110.954 -179.339 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 69.9 t -80.37 131.59 33.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 121.595 -0.691 . . . . 0.0 110.049 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 23.1 pt -102.21 -4.27 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.507 -0.746 . . . . 0.0 109.029 179.518 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 161.72 -177.09 38.12 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.483 -1.342 . . . . 0.0 109.959 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 57.8 m -132.91 159.55 39.58 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.47 -1.018 . . . . 0.0 109.732 -179.674 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 95.9 mt -120.07 149.55 42.0 Favored 'General case' 0 N--CA 1.496 1.87 0 CA-C-O 121.661 0.743 . . . . 0.0 109.884 -179.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.8 m -74.24 161.42 29.95 Favored 'General case' 0 N--CA 1.489 1.488 0 CA-C-O 121.863 0.839 . . . . 0.0 110.739 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -63.09 149.41 49.79 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 111.339 -0.704 . . . . 0.0 111.339 -179.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.9 m-20 57.09 32.93 22.53 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.792 -0.828 . . . . 0.0 109.73 179.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 25.3 m -90.77 126.63 36.06 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.241 -0.912 . . . . 0.0 109.772 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.419 ' NZ ' ' OE2' ' A' ' 67' ' ' GLU . 38.5 ttmt -80.3 132.89 35.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.428 -0.795 . . . . 0.0 109.716 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.1 m -124.03 131.96 72.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.579 -0.701 . . . . 0.0 109.734 179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 61.1 m -80.04 128.21 33.21 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-O 121.426 0.631 . . . . 0.0 109.979 -179.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.7 mt -97.37 124.68 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.56 -0.712 . . . . 0.0 109.875 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 34.4 m -110.18 -0.84 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.477 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -175.2 178.01 47.01 Favored Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.637 -1.268 . . . . 0.0 110.2 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -142.74 153.58 43.45 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.08 -1.247 . . . . 0.0 109.527 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.408 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 12.9 tm-20 -151.9 107.6 3.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.47 179.367 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.37 -137.39 45.19 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 179.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -84.64 26.01 0.85 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.437 -1.037 . . . . 0.0 109.098 -179.341 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -132.02 145.19 51.29 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.559 -0.713 . . . . 0.0 109.412 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -106.95 139.46 41.31 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.615 0.722 . . . . 0.0 109.455 179.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -93.09 130.44 38.71 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.557 -0.714 . . . . 0.0 109.174 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 37.2 pt -131.26 154.22 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.611 -0.681 . . . . 0.0 110.044 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -90.86 96.57 10.7 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.519 -0.738 . . . . 0.0 109.127 179.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -107.33 123.54 48.49 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.507 -0.746 . . . . 0.0 109.953 -179.728 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.401 ' C ' ' H ' ' A' ' 52' ' ' SER . 74.3 tttt 51.49 34.54 12.44 Favored 'General case' 0 N--CA 1.493 1.678 0 CA-C-O 121.292 0.568 . . . . 0.0 109.944 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.41 -11.84 11.84 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 178.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.401 ' H ' ' C ' ' A' ' 50' ' ' LYS . 26.4 t -91.84 174.02 7.55 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.256 -1.144 . . . . 0.0 110.333 -179.513 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -97.37 101.53 13.09 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.36 -0.837 . . . . 0.0 109.639 -179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.26 137.79 13.52 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -119.73 137.39 53.97 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.411 -1.052 . . . . 0.0 109.585 179.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.2 m -139.45 154.76 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.276 -0.89 . . . . 0.0 109.822 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.442 ' N ' HH21 ' A' ' 16' ' ' ARG . . . -73.83 146.98 43.76 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.406 -0.809 . . . . 0.0 110.584 -179.762 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -66.21 -11.37 49.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.62 -0.675 . . . . 0.0 109.682 179.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -67.35 -34.57 77.59 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.222 -0.924 . . . . 0.0 109.779 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -90.71 3.3 54.64 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.209 -0.932 . . . . 0.0 109.487 -179.197 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 38.3 mm -103.47 129.68 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.346 -0.846 . . . . 0.0 109.939 -179.52 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -146.24 154.91 42.26 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.42 -0.8 . . . . 0.0 109.912 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.6 t0 63.11 52.8 2.43 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 121.555 0.693 . . . . 0.0 109.42 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt -78.09 123.37 34.78 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 121.524 -0.735 . . . . 0.0 109.649 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 19.2 tptm -140.43 142.61 35.39 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.35 -0.844 . . . . 0.0 109.742 179.734 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.526 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 1.9 m-20 -85.14 118.29 24.61 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.414 -0.804 . . . . 0.0 110.29 -179.516 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.428 ' O ' ' O ' ' A' ' 68' ' ' VAL . 97.5 mt-10 -94.86 -14.5 24.51 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 179.365 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.449 ' CG1' ' N ' ' A' ' 69' ' ' LEU . 43.5 t 52.01 169.28 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 CA-C-O 121.884 0.849 . . . . 0.0 110.889 179.345 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.449 ' N ' ' CG1' ' A' ' 68' ' ' VAL . 4.2 tt -68.58 105.14 2.15 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.381 -0.824 . . . . 0.0 109.781 -179.13 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.406 ' C ' ' O ' ' A' ' 69' ' ' LEU . 93.3 mt-10 40.28 85.45 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.85 0 CA-C-O 121.623 0.725 . . . . 0.0 110.471 179.581 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.562 ' H ' ' HD1' ' A' ' 71' ' ' HIS . 0.0 OUTLIER -90.76 164.45 14.1 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.449 -0.782 . . . . 0.0 109.923 -179.731 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.479 ' CD2' ' N ' ' A' ' 72' ' ' HIS . 2.8 p80 -146.89 133.43 19.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.07 179.49 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.522 ' C ' ' H ' ' A' ' 75' ' ' HIS . 95.9 m-70 -112.44 109.01 18.36 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.433 -0.792 . . . . 0.0 109.626 -179.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . 0.472 ' ND1' ' O ' ' A' ' 74' ' ' HIS . 60.9 t-80 53.62 6.04 0.07 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.626 -0.672 . . . . 0.0 109.762 -179.803 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.522 ' H ' ' C ' ' A' ' 73' ' ' HIS . 81.0 t60 -89.88 135.79 33.42 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.239 -0.913 . . . . 0.0 109.746 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 86.3 t60 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.156 -179.635 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.488 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -75.86 137.29 40.35 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.48 -0.763 . . . . 0.0 110.343 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt -130.29 145.96 51.83 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 70.2 p -132.16 133.55 44.37 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.576 -0.703 . . . . 0.0 109.643 -179.539 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -121.61 131.71 8.66 Favored Glycine 0 N--CA 1.499 2.876 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.56 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.8 mp -86.35 127.65 40.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.075 -1.25 . . . . 0.0 110.005 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 71.5 t -75.61 131.09 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 110.186 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.6 t-20 -123.74 108.23 12.3 Favored 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.52 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 29.3 m -152.96 -19.47 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.8 t 67.97 -52.84 0.52 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.79 -0.569 . . . . 0.0 109.677 -179.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 74.0 m -77.92 -79.41 0.12 Allowed 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.382 -0.824 . . . . 0.0 109.751 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 31.2 t -168.45 156.06 7.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.43 -0.794 . . . . 0.0 109.332 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 49.5 tp -123.58 130.28 52.43 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.56 -0.713 . . . . 0.0 109.317 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -84.16 154.48 23.08 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.361 -0.837 . . . . 0.0 109.79 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 54.4 t -105.95 130.14 57.97 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.445 -0.784 . . . . 0.0 109.276 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.708 HH21 ' N ' ' A' ' 20' ' ' SER . 42.4 mtp180 -104.64 128.05 52.57 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.476 -0.765 . . . . 0.0 109.699 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -72.06 -43.16 65.35 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.479 -0.763 . . . . 0.0 109.612 179.68 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -100.32 -175.48 30.1 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.125 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.473 ' C ' HH21 ' A' ' 16' ' ' ARG . . . -97.01 39.59 1.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.505 -0.997 . . . . 0.0 108.944 179.589 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.708 ' N ' HH21 ' A' ' 16' ' ' ARG . 33.0 t -131.86 149.87 52.32 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.554 -0.716 . . . . 0.0 109.72 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 53.1 p -65.11 -31.27 72.39 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.507 -0.746 . . . . 0.0 109.64 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.477 ' HG ' ' HG ' ' A' ' 20' ' ' SER . 96.6 p -86.55 13.34 8.63 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.262 -0.899 . . . . 0.0 108.993 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.9 m -62.2 151.13 36.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.442 -0.786 . . . . 0.0 110.442 -179.209 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 17.7 ttmm -64.97 136.83 57.27 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.503 -0.748 . . . . 0.0 110.941 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 97.4 t -90.86 116.73 32.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.3 pt -103.73 -4.76 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.514 -0.741 . . . . 0.0 109.699 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -178.69 -175.5 45.81 Favored Glycine 0 N--CA 1.49 2.253 0 C-N-CA 119.316 -1.421 . . . . 0.0 110.615 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.9 p -158.55 166.1 32.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.558 -0.966 . . . . 0.0 109.004 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.3 mt -123.21 153.92 39.45 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.446 -0.784 . . . . 0.0 109.926 -179.552 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.5 m -80.53 -3.54 50.53 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.663 -0.648 . . . . 0.0 109.334 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.533 ' C ' ' H ' ' A' ' 33' ' ' THR . . . 95.19 164.27 34.91 Favored Glycine 0 N--CA 1.498 2.772 0 O-C-N 121.304 -0.872 . . . . 0.0 111.031 178.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 55.7 2.37 0.07 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.753 -0.851 . . . . 0.0 110.033 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.533 ' H ' ' C ' ' A' ' 31' ' ' GLY . 54.0 m -85.01 133.1 34.26 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.122 -0.986 . . . . 0.0 109.578 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 8.3 ttpm? -80.4 136.79 36.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.341 -0.849 . . . . 0.0 109.964 -179.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.9 m -121.24 130.6 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 CA-C-O 121.506 0.669 . . . . 0.0 109.298 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 53.9 m -73.48 133.12 43.58 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.629 -0.669 . . . . 0.0 110.092 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.417 HG22 HD13 ' A' ' 37' ' ' ILE . 97.6 mt -109.66 127.7 66.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 CA-C-O 121.362 0.601 . . . . 0.0 109.491 179.744 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.54 -1.12 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.42 176.08 45.44 Favored Glycine 0 N--CA 1.49 2.289 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.244 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 -140.13 153.14 46.59 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.346 -1.091 . . . . 0.0 109.828 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.413 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 12.5 tm-20 -151.08 106.93 3.4 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.229 -0.919 . . . . 0.0 109.385 179.71 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 58.82 -138.69 49.23 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.214 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -83.45 5.05 25.13 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.594 -0.945 . . . . 0.0 109.271 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.448 ' CE1' ' NH1' ' A' ' 16' ' ' ARG . 96.6 m-85 -114.5 141.76 47.28 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.69 -0.631 . . . . 0.0 109.539 -179.636 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -107.86 150.72 26.69 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.664 -0.648 . . . . 0.0 109.666 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.5 mtpm? -91.35 139.16 30.99 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.501 -0.749 . . . . 0.0 109.024 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 38.8 pt -134.05 149.82 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.515 -0.741 . . . . 0.0 109.852 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -86.8 95.03 9.71 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.372 -0.83 . . . . 0.0 108.919 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 84.0 t80 -104.6 116.07 31.44 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.382 -0.824 . . . . 0.0 109.196 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 49.2 tttm 52.39 32.19 10.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.614 -0.679 . . . . 0.0 109.695 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 88.36 -20.92 27.71 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 87.2 p -83.3 166.18 18.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.237 -1.155 . . . . 0.0 110.228 -179.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 61.9 m170 -101.62 95.72 6.63 Favored 'General case' 0 N--CA 1.495 1.788 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -88.19 162.9 32.62 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 -179.163 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -122.18 138.02 54.62 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.768 -0.843 . . . . 0.0 109.227 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 20.7 m -137.29 153.61 29.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.333 -0.854 . . . . 0.0 109.647 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.01 139.77 46.87 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.509 -0.744 . . . . 0.0 110.274 -179.475 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -69.2 -12.43 61.67 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.37 -0.831 . . . . 0.0 109.604 179.336 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -63.09 -32.14 73.45 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.44 -0.788 . . . . 0.0 110.353 -179.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -99.17 5.91 46.61 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 109.828 -179.37 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.5 mm -105.18 128.59 58.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.934 0 O-C-N 121.296 -0.877 . . . . 0.0 109.515 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -141.65 164.29 30.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.466 -0.771 . . . . 0.0 110.17 -179.39 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 56.32 52.03 10.71 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.191 0.519 . . . . 0.0 110.137 179.714 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt -79.43 122.08 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.249 -0.907 . . . . 0.0 109.319 179.352 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.9 ptpp? -142.85 150.72 40.26 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.288 -0.882 . . . . 0.0 109.885 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -69.27 140.54 54.45 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.502 -0.749 . . . . 0.0 110.351 -179.406 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.445 ' O ' ' O ' ' A' ' 68' ' ' VAL . 39.9 tp10 -80.08 61.91 4.09 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.333 -0.854 . . . . 0.0 109.365 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.445 ' O ' ' O ' ' A' ' 67' ' ' GLU . 5.3 t 58.55 127.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 CA-C-O 121.654 0.74 . . . . 0.0 110.731 179.807 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 83.6 mt -72.31 142.31 48.84 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.459 -0.776 . . . . 0.0 109.551 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -156.79 86.04 0.98 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.355 -0.841 . . . . 0.0 108.902 179.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 59.9 m170 42.09 90.29 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.652 -0.655 . . . . 0.0 110.108 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 9.3 p80 -67.76 138.4 56.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.352 -0.843 . . . . 0.0 110.074 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -74.51 132.36 41.79 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.3 -0.875 . . . . 0.0 110.433 -179.313 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 81.4 t60 -152.0 139.51 19.6 Favored 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.549 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 97.8 m-70 -106.67 136.5 46.37 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.344 -0.847 . . . . 0.0 109.858 -179.531 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 76.2 m80 . . . . . 0 N--CA 1.488 1.47 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.658 179.942 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.639 0.733 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.577 ' H ' ' CD ' ' A' ' 2' ' ' GLU . 1.0 OUTLIER -86.88 154.16 21.06 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.397 -0.814 . . . . 0.0 110.133 -179.401 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -123.4 157.14 34.04 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.729 -0.607 . . . . 0.0 109.496 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 52.8 p -131.55 115.02 15.58 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.619 0.724 . . . . 0.0 109.363 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -91.18 137.65 13.94 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 -179.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.565 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.5 mp -92.22 122.22 43.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.618 -0.931 . . . . 0.0 109.398 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.0 t -78.22 132.46 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 O-C-N 121.512 -0.743 . . . . 0.0 110.045 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.6 t-20 -137.72 110.16 7.45 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.519 -0.738 . . . . 0.0 109.351 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.3 m -144.62 149.89 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.394 -0.816 . . . . 0.0 109.607 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 39.8 t -63.66 -43.85 95.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.546 -0.721 . . . . 0.0 110.05 179.837 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 24.6 t -109.43 -76.15 0.62 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.555 -0.715 . . . . 0.0 110.09 -179.204 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 92.1 p -156.73 165.54 35.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 -179.244 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.3 tp -115.17 128.28 56.09 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.761 0.791 . . . . 0.0 109.952 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -84.16 149.9 25.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.586 -0.696 . . . . 0.0 110.055 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.0 t -99.91 131.23 47.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.318 -0.864 . . . . 0.0 109.261 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.432 ' CZ ' ' O ' ' A' ' 21' ' ' THR . 99.7 mtt180 -103.84 135.25 45.74 Favored 'General case' 0 N--CA 1.494 1.758 0 CA-C-O 121.777 0.799 . . . . 0.0 110.099 -179.282 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 46.5 tp10 -70.87 -45.33 64.59 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.554 0.693 . . . . 0.0 109.508 179.715 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.653 ' H ' ' HG ' ' A' ' 23' ' ' SER . . . -99.08 172.93 26.01 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 -179.303 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -91.59 11.22 24.96 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.472 -1.016 . . . . 0.0 108.727 179.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.1 m -73.87 170.86 14.48 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.333 -0.855 . . . . 0.0 110.305 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.432 ' O ' ' CZ ' ' A' ' 16' ' ' ARG . 18.3 m -62.94 -44.82 95.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.576 -0.702 . . . . 0.0 109.996 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.3 t -131.12 71.12 1.46 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.352 -0.843 . . . . 0.0 109.235 -179.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.653 ' HG ' ' H ' ' A' ' 18' ' ' GLY . 3.7 t -83.14 176.66 9.03 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-O 121.659 0.742 . . . . 0.0 110.419 -179.592 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 65.7 tttm -63.72 133.76 54.12 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-O 121.797 0.808 . . . . 0.0 110.569 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 67.0 t -97.62 128.91 48.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.515 -0.74 . . . . 0.0 109.413 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 39.8 pt -105.19 -4.44 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.673 -0.642 . . . . 0.0 109.342 179.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.91 -156.84 27.36 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.368 -1.396 . . . . 0.0 110.491 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 92.9 p -157.43 164.92 36.96 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.425 -1.044 . . . . 0.0 109.515 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 97.4 mt -126.65 148.69 49.79 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.746 0.784 . . . . 0.0 110.021 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 19.4 m -73.59 156.6 37.9 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-O 121.807 0.813 . . . . 0.0 110.55 -179.4 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.17 156.19 38.09 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 65.3 t30 58.14 33.9 23.63 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.688 -0.889 . . . . 0.0 109.873 179.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 24.1 m -97.55 132.39 43.27 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.333 -0.855 . . . . 0.0 109.761 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -80.93 128.73 34.01 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.525 -0.734 . . . . 0.0 110.096 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.8 m -128.24 134.19 65.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.589 -0.694 . . . . 0.0 109.504 179.466 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 34.4 m -82.27 124.98 30.44 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.486 -0.758 . . . . 0.0 109.426 -179.662 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.424 HG21 HD11 ' A' ' 37' ' ' ILE . 96.8 mt -99.41 136.15 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 CA-C-O 121.608 0.718 . . . . 0.0 110.433 -179.517 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 34.1 m -110.44 -6.93 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 165.79 -174.67 41.49 Favored Glycine 0 N--CA 1.489 2.189 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.359 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -140.91 147.2 38.5 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.459 -1.024 . . . . 0.0 109.205 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.513 ' OE1' ' N ' ' A' ' 41' ' ' GLU . 56.9 mp0 -145.87 120.67 9.91 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.29 -0.881 . . . . 0.0 110.153 -179.454 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.482 ' O ' ' CB ' ' A' ' 43' ' ' ALA . . . 70.19 31.08 69.13 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.482 ' CB ' ' O ' ' A' ' 42' ' ' GLY . . . 77.4 11.03 2.28 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.524 -0.986 . . . . 0.0 109.136 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.464 ' CD2' ' O ' ' A' ' 42' ' ' GLY . 99.2 m-85 -114.03 131.6 56.3 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.653 -0.654 . . . . 0.0 109.319 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -79.47 139.71 37.54 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.615 -0.678 . . . . 0.0 109.963 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -100.56 120.05 39.44 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.495 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.5 pt -125.07 161.63 28.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 CA-C-O 121.748 0.785 . . . . 0.0 110.45 -179.076 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.17 124.31 34.72 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.269 0.557 . . . . 0.0 109.649 -179.588 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 81.9 t80 -132.99 120.82 21.88 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.459 -0.776 . . . . 0.0 109.861 179.611 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 76.5 tttt 39.03 47.38 1.26 Allowed 'General case' 0 N--CA 1.496 1.846 0 CA-C-O 121.687 0.756 . . . . 0.0 110.427 179.424 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 86.3 -50.67 4.28 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 179.615 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 16.7 m -74.46 145.16 43.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -1.132 . . . . 0.0 110.51 -179.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -83.94 120.54 26.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.393 -0.817 . . . . 0.0 109.915 -179.665 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.12 148.45 18.99 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -115.23 142.68 46.34 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.689 -0.889 . . . . 0.0 109.846 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.4 m -140.94 153.6 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.491 -0.756 . . . . 0.0 109.525 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.85 140.23 43.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.408 -0.808 . . . . 0.0 110.247 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 7.2 ptmm? -65.45 -9.23 23.82 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.516 -0.74 . . . . 0.0 109.744 179.615 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.53 -21.09 62.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.797 . . . . 0.0 110.164 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 -104.97 -23.26 13.0 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.268 -0.895 . . . . 0.0 109.582 -179.435 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.518 ' N ' ' CD1' ' A' ' 61' ' ' ILE . 1.6 mp -97.07 130.87 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.26 -0.9 . . . . 0.0 109.841 -179.706 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.473 ' O ' ' N ' ' A' ' 64' ' ' ILE . 23.0 pttp -134.98 -165.35 1.66 Allowed 'General case' 0 N--CA 1.494 1.739 0 CA-C-O 121.474 0.654 . . . . 0.0 109.697 179.579 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 59.17 -78.27 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.771 0 CA-C-O 121.151 0.5 . . . . 0.0 109.986 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.473 ' N ' ' O ' ' A' ' 62' ' ' LYS . 97.2 mt 57.42 87.63 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 CA-C-O 121.44 0.638 . . . . 0.0 109.842 -179.35 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 63.3 tttp -139.56 133.61 31.02 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.379 -0.826 . . . . 0.0 109.752 179.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.407 ' OD1' ' O ' ' A' ' 66' ' ' ASP . 40.9 p-10 -67.12 122.82 18.65 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 121.577 0.703 . . . . 0.0 110.183 -179.759 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 32.6 tp10 -99.18 -13.77 19.6 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.417 -0.802 . . . . 0.0 109.061 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 11.2 t -88.9 99.38 9.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.231 -0.918 . . . . 0.0 109.487 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.413 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 10.4 mp -100.13 11.47 39.28 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.516 -0.74 . . . . 0.0 109.17 -179.685 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 71.8 mm-40 57.66 92.87 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.673 0.749 . . . . 0.0 109.86 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 34.6 p80 -68.44 140.21 55.75 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 121.711 0.767 . . . . 0.0 110.736 -179.425 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.625 ' CE1' ' NE2' ' A' ' 73' ' ' HIS . 14.2 t-160 -159.24 -29.23 0.07 Allowed 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.405 -0.809 . . . . 0.0 109.306 179.209 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.625 ' NE2' ' CE1' ' A' ' 72' ' ' HIS . 95.9 m-70 -150.97 159.86 44.3 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.092 -1.005 . . . . 0.0 110.302 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 32.6 p-80 -151.5 162.16 41.45 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.265 -0.897 . . . . 0.0 109.945 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 35.1 p-80 -136.61 89.57 2.47 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.462 -0.773 . . . . 0.0 109.564 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 . . . . . 0 N--CA 1.493 1.725 0 CA-C-O 118.119 -0.944 . . . . 0.0 110.355 179.685 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -66.96 137.38 56.48 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.422 -0.799 . . . . 0.0 110.386 -179.493 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -136.69 151.35 49.16 Favored 'General case' 0 N--CA 1.496 1.854 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.654 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.422 ' OG1' ' O ' ' A' ' 65' ' ' LYS . 25.7 p -123.57 128.61 49.98 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.519 -0.738 . . . . 0.0 109.682 -179.474 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.97 129.87 9.82 Favored Glycine 0 N--CA 1.497 2.746 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.542 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.6 mp -80.14 126.3 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.185 -1.185 . . . . 0.0 109.292 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.2 t -81.74 131.62 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.274 -0.891 . . . . 0.0 110.186 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.2 m120 -120.2 100.07 6.97 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.476 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.7 m -141.01 136.27 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.875 0 O-C-N 121.302 -0.874 . . . . 0.0 109.577 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 t -61.99 -44.86 95.85 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.576 -0.702 . . . . 0.0 109.707 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 68.0 m -99.3 -79.72 0.48 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.557 -0.715 . . . . 0.0 109.456 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 59.9 m -158.92 172.29 18.48 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.359 -0.838 . . . . 0.0 109.389 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.0 tp -116.27 131.48 56.93 Favored 'General case' 0 N--CA 1.5 2.055 0 CA-C-O 121.479 0.657 . . . . 0.0 109.516 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.5 p30 -90.86 153.86 19.9 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.393 -0.817 . . . . 0.0 109.655 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 53.7 t -105.3 130.28 56.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.39 -0.819 . . . . 0.0 108.842 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.453 HH22 ' H ' ' A' ' 57' ' ' ALA . 91.0 mtm-85 -112.11 137.94 49.47 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.533 -0.729 . . . . 0.0 109.502 -179.538 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 69.8 mm-40 -86.48 -29.35 22.83 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.463 -0.773 . . . . 0.0 109.193 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.683 ' H ' ' HG ' ' A' ' 23' ' ' SER . . . -98.46 148.39 18.85 Favored Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.701 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -82.63 73.17 9.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.313 -1.11 . . . . 0.0 109.325 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.1 m -159.15 -169.43 2.65 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.127 -0.983 . . . . 0.0 109.55 179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 65.9 p -80.71 101.56 9.36 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.277 -0.889 . . . . 0.0 109.785 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.408 ' OG ' ' O ' ' A' ' 22' ' ' SER . 6.6 t 56.6 52.36 9.86 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.77 -0.582 . . . . 0.0 109.854 179.398 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.683 ' HG ' ' H ' ' A' ' 18' ' ' GLY . 77.9 p -62.31 -42.97 99.81 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.301 -0.875 . . . . 0.0 109.313 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 33.2 ttpt -170.6 115.94 0.48 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.262 -0.899 . . . . 0.0 109.443 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.3 t -90.45 130.22 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.527 -0.733 . . . . 0.0 109.737 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.9 pt -117.37 -11.63 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.32 -162.54 31.36 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.187 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 36.9 t -155.44 168.49 26.95 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.321 -1.105 . . . . 0.0 109.868 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 95.2 mt -127.3 152.74 47.04 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.607 -0.683 . . . . 0.0 109.721 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.6 m -71.4 152.95 42.66 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.609 -0.682 . . . . 0.0 110.368 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -61.86 160.45 29.91 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 -179.176 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 64.4 t30 62.06 4.92 1.29 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.941 -0.741 . . . . 0.0 109.874 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 66.7 m -82.74 130.81 35.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.077 -1.014 . . . . 0.0 109.958 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -86.81 147.46 25.81 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.316 -0.865 . . . . 0.0 109.576 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.3 m -123.34 132.97 70.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.431 -0.793 . . . . 0.0 109.458 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 36.2 m -69.92 130.68 42.87 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.744 -0.598 . . . . 0.0 110.065 -179.352 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.2 mt -109.34 129.17 64.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 29.3 m -120.59 5.24 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 179.591 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.68 177.4 45.25 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 119.531 -1.318 . . . . 0.0 110.463 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -126.69 153.74 45.04 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.676 -0.896 . . . . 0.0 109.247 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 8.1 tm-20 -151.03 93.47 1.93 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.158 -0.963 . . . . 0.0 109.892 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 51.97 -133.27 36.82 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 178.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.81 25.38 1.11 Allowed 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.623 -0.928 . . . . 0.0 108.941 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -138.07 134.62 34.95 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.691 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 44.7 m-85 -89.08 144.89 25.82 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.18 -0.95 . . . . 0.0 109.803 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -90.88 129.49 36.92 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.444 -0.785 . . . . 0.0 109.031 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 39.2 pt -128.46 154.26 39.01 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.592 -0.693 . . . . 0.0 110.06 -179.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -87.52 93.74 9.51 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.518 -0.739 . . . . 0.0 109.099 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -92.92 152.74 19.2 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.232 -0.917 . . . . 0.0 110.009 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 41.2 tttp -55.46 119.87 6.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.332 -0.855 . . . . 0.0 110.462 -179.37 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 104.4 -46.3 1.2 Allowed Glycine 0 N--CA 1.496 2.66 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.665 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 95.9 p -163.34 177.92 8.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.121 -1.223 . . . . 0.0 109.953 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -81.08 119.74 23.93 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.2 -0.937 . . . . 0.0 109.452 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.72 165.49 32.17 Favored Glycine 0 N--CA 1.496 2.697 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 -179.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -123.42 138.22 54.64 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.762 -0.846 . . . . 0.0 109.455 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.1 m -137.35 140.76 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.535 -0.728 . . . . 0.0 109.534 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.453 ' H ' HH22 ' A' ' 16' ' ' ARG . . . -68.41 151.0 47.47 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.517 -0.739 . . . . 0.0 110.794 -179.291 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 45.3 mtmt -62.6 -28.91 70.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.573 -0.704 . . . . 0.0 109.184 179.49 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -58.95 -34.43 71.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.474 -0.766 . . . . 0.0 110.418 -178.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -89.73 -1.99 58.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.019 -1.051 . . . . 0.0 109.466 -179.345 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 43.7 mm -112.59 130.29 66.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.616 -0.678 . . . . 0.0 109.828 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -136.47 142.17 43.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.65 -0.656 . . . . 0.0 109.694 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 44.6 t0 62.43 77.99 0.31 Allowed 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.296 0.57 . . . . 0.0 109.899 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 82.2 mt -81.95 77.68 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.457 -0.777 . . . . 0.0 109.158 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.422 ' O ' ' OG1' ' A' ' 4' ' ' THR . 63.9 mttp -143.08 157.58 44.4 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.297 -0.877 . . . . 0.0 109.723 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -86.24 109.48 18.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.451 -0.78 . . . . 0.0 109.33 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 45.6 tp10 -90.21 -77.35 0.4 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.331 -0.856 . . . . 0.0 109.48 -179.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 13.7 p -172.29 152.83 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.297 -0.877 . . . . 0.0 109.767 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 78.7 mt -66.49 145.0 56.14 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.356 -0.84 . . . . 0.0 110.346 -179.163 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -55.18 136.88 48.11 Favored 'General case' 0 N--CA 1.491 1.581 0 CA-C-O 121.565 0.698 . . . . 0.0 110.332 -179.244 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.56 ' CD2' ' H ' ' A' ' 73' ' ' HIS . 49.0 t60 -80.77 165.11 22.21 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.452 -0.78 . . . . 0.0 110.438 -179.539 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.501 ' N ' ' CG ' ' A' ' 71' ' ' HIS . 76.5 m80 -65.8 -39.93 91.41 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.581 -0.699 . . . . 0.0 109.812 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.56 ' H ' ' CD2' ' A' ' 71' ' ' HIS . 80.3 m80 -105.18 137.63 42.65 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.446 -0.784 . . . . 0.0 109.775 -179.335 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 62.4 m170 -48.48 172.13 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.668 0 CA-C-O 121.788 0.804 . . . . 0.0 111.473 -178.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 47.5 p-80 -59.38 -41.3 89.01 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.645 -0.659 . . . . 0.0 109.741 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 56.8 t-80 . . . . . 0 N--CA 1.488 1.469 0 CA-C-O 117.916 -1.04 . . . . 0.0 109.248 179.939 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.431 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.486 0 CA-C-O 121.542 0.686 . . . . 0.0 110.01 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 1' ' ' ALA . 44.7 tt0 58.76 147.47 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 CA-C-O 121.577 0.703 . . . . 0.0 110.138 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.513 ' NZ ' ' OD1' ' A' ' 66' ' ' ASP . 68.6 mttm -137.56 151.64 48.59 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.759 -0.588 . . . . 0.0 109.786 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 69.3 p -117.05 113.96 23.07 Favored 'General case' 0 N--CA 1.498 1.973 0 CA-C-O 121.898 0.856 . . . . 0.0 110.038 -179.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -103.06 130.73 10.35 Favored Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.4 mm -87.53 127.66 40.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.901 -0.764 . . . . 0.0 109.957 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.2 t -71.93 130.56 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 CA-C-O 121.467 0.651 . . . . 0.0 109.725 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.486 ' CG ' ' HZ2' ' A' ' 62' ' ' LYS . 56.0 t30 -123.39 101.93 7.62 Favored 'General case' 0 N--CA 1.497 1.894 0 CA-C-O 121.311 0.577 . . . . 0.0 109.642 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 30.5 m -148.18 158.19 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 121.611 0.719 . . . . 0.0 110.146 179.001 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 58.6 m -87.94 -16.81 32.81 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.859 -0.525 . . . . 0.0 109.976 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 12' ' ' SER . 66.4 m -155.38 87.79 1.12 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.422 -0.799 . . . . 0.0 110.326 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 11' ' ' SER . 1.3 m 46.73 -179.99 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 CA-C-O 121.724 0.773 . . . . 0.0 110.99 178.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 37.8 tp -144.59 130.55 19.34 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.681 0.753 . . . . 0.0 109.846 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -83.31 132.37 35.02 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-O 121.721 0.772 . . . . 0.0 110.053 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 86.7 t -81.18 131.99 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 CA-C-O 121.708 0.766 . . . . 0.0 109.73 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.582 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 93.5 mtm-85 -106.42 135.15 48.42 Favored 'General case' 0 N--CA 1.493 1.688 0 CA-C-O 121.762 0.791 . . . . 0.0 109.897 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.513 ' N ' ' OG ' ' A' ' 23' ' ' SER . 82.8 tt0 -99.52 77.4 2.09 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.645 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.38 170.89 16.7 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 179.413 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -88.66 4.87 45.63 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.7 -0.882 . . . . 0.0 109.199 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.3 m -74.68 155.94 37.2 Favored 'General case' 0 N--CA 1.495 1.779 0 CA-C-O 121.637 0.732 . . . . 0.0 109.966 179.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 51.0 p -66.77 -29.97 70.06 Favored 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.7 t -136.59 68.32 1.43 Allowed 'General case' 0 N--CA 1.497 1.893 0 CA-C-O 121.429 0.633 . . . . 0.0 109.443 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 17' ' ' GLU . 5.1 p -82.83 176.79 9.03 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.805 0.812 . . . . 0.0 110.6 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -58.5 130.85 48.75 Favored 'General case' 0 N--CA 1.491 1.58 0 CA-C-O 121.991 0.901 . . . . 0.0 111.11 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.4 t -84.31 129.18 38.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 42.1 pt -115.87 -6.39 11.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 168.83 -166.05 39.36 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.996 -1.097 . . . . 0.0 110.66 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 47.4 t -151.84 153.82 34.97 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.825 -0.809 . . . . 0.0 109.935 -179.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.0 mt -123.26 149.76 44.35 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.794 0.807 . . . . 0.0 109.65 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 23.4 p -74.73 160.61 30.53 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.752 0.787 . . . . 0.0 110.451 -179.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -68.62 155.72 53.36 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 58.15 34.69 24.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 122.046 -0.679 . . . . 0.0 109.889 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 53.2 m -102.4 127.16 49.53 Favored 'General case' 0 N--CA 1.498 1.949 0 CA-C-O 121.968 0.889 . . . . 0.0 109.936 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.6 ttpt -77.0 130.33 37.32 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.535 0.684 . . . . 0.0 109.881 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.2 m -129.96 130.89 66.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 CA-C-O 121.75 0.786 . . . . 0.0 109.674 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 11.1 p -77.19 134.29 38.68 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.455 0.645 . . . . 0.0 109.879 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.5 mt -106.23 127.64 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 CA-C-O 121.481 0.658 . . . . 0.0 109.473 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -112.05 -1.06 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.99 171.85 44.72 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.789 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 10.0 tm-20 -137.96 146.65 43.44 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.848 -0.795 . . . . 0.0 109.935 -179.499 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 68.7 mm-40 -144.05 109.4 5.11 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-O 121.97 0.891 . . . . 0.0 109.851 179.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.12 -135.11 47.73 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.464 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.36 30.52 0.98 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.765 -0.844 . . . . 0.0 108.746 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -134.49 143.42 47.47 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-O 121.531 0.681 . . . . 0.0 109.821 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -108.82 140.46 42.23 Favored 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.898 0.856 . . . . 0.0 109.59 179.342 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 51.1 mtmt -93.59 143.97 25.81 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.686 0.755 . . . . 0.0 109.717 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 41.5 pt -132.94 152.37 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 CA-C-O 121.646 0.736 . . . . 0.0 110.056 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -75.46 93.78 3.02 Favored 'General case' 0 N--CA 1.489 1.506 0 CA-C-O 121.42 0.629 . . . . 0.0 109.787 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -108.78 142.39 39.4 Favored 'General case' 0 N--CA 1.491 1.611 0 CA-C-O 121.828 0.823 . . . . 0.0 109.589 179.624 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 18.5 ptmt -55.03 119.63 5.73 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 121.845 0.831 . . . . 0.0 110.318 -179.697 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.453 ' O ' ' OG ' ' A' ' 52' ' ' SER . . . 110.63 -47.98 0.98 Allowed Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.286 -1.525 . . . . 0.0 109.286 179.58 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.453 ' OG ' ' O ' ' A' ' 51' ' ' GLY . 24.7 m -167.77 -162.44 0.44 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.739 -0.859 . . . . 0.0 110.386 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -100.11 120.2 39.5 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.832 0.825 . . . . 0.0 109.926 -179.157 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -83.03 145.24 23.24 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -108.54 137.33 46.67 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.615 0.721 . . . . 0.0 109.703 179.724 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.6 m -140.67 143.99 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 CA-C-O 121.735 0.779 . . . . 0.0 110.237 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.582 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -66.66 146.76 54.12 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.64 0.734 . . . . 0.0 110.329 -179.716 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 48.3 mtmt -62.94 -34.4 77.4 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 121.318 0.58 . . . . 0.0 109.468 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -51.47 -33.79 32.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.851 -0.53 . . . . 0.0 110.169 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -89.57 0.7 56.74 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.567 -0.708 . . . . 0.0 109.831 -179.367 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 5.6 mm -108.84 125.95 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 CA-C-O 121.685 0.755 . . . . 0.0 110.215 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.486 ' HZ2' ' CG ' ' A' ' 8' ' ' ASN . 64.0 pttt -145.92 163.49 34.97 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.757 0.789 . . . . 0.0 110.536 -179.741 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 57.94 55.02 5.6 Favored 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 121.444 0.64 . . . . 0.0 109.614 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt -76.02 126.23 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 CA-C-O 121.646 0.736 . . . . 0.0 109.554 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -129.32 145.81 51.31 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.726 0.774 . . . . 0.0 110.169 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.513 ' OD1' ' NZ ' ' A' ' 3' ' ' LYS . 85.5 m-20 -89.89 105.76 18.02 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.705 -0.479 . . . . 0.0 109.705 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.452 ' C ' ' O ' ' A' ' 66' ' ' ASP . 52.3 tp10 34.09 79.25 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 CA-C-O 121.277 0.561 . . . . 0.0 110.153 179.615 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 7.5 p -104.99 114.48 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 CA-C-O 121.618 0.723 . . . . 0.0 109.951 -179.481 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.47 ' N ' ' CD2' ' A' ' 69' ' ' LEU . 4.0 mm? -97.6 -6.62 32.97 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.684 -0.635 . . . . 0.0 109.414 179.56 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 52.5 tp10 57.9 78.18 0.25 Allowed 'General case' 0 N--CA 1.491 1.622 0 CA-C-O 121.689 0.757 . . . . 0.0 109.764 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 72.3 m80 -81.21 145.48 30.96 Favored 'General case' 0 N--CA 1.488 1.472 0 CA-C-O 121.76 0.791 . . . . 0.0 110.123 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 79.8 m80 39.82 83.28 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.634 0 CA-C-O 121.712 0.767 . . . . 0.0 110.057 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 54.0 p-80 -86.57 -16.15 37.71 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 61.6 t-80 -66.35 -44.72 82.46 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.829 -0.544 . . . . 0.0 109.54 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -79.47 142.67 35.65 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-O 121.793 0.806 . . . . 0.0 110.267 -179.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . 0.459 ' H ' ' CD2' ' A' ' 76' ' ' HIS . 4.9 p80 . . . . . 0 N--CA 1.489 1.478 0 CA-C-O 117.844 -1.074 . . . . 0.0 109.686 -179.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.41 0 CA-C-O 122.109 0.957 . . . . 0.0 108.566 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -158.18 102.48 1.78 Allowed 'General case' 0 C--N 1.29 -1.996 0 CA-C-O 122.417 1.103 . . . . 0.0 109.868 179.258 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -113.63 156.36 23.83 Favored 'General case' 0 C--N 1.282 -2.357 1 N-CA-C 99.335 -4.32 . . . . 0.0 99.335 174.36 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.06 135.32 29.05 Favored 'General case' 0 N--CA 1.506 2.357 0 C-N-CA 114.944 -2.702 . . . . 0.0 116.574 -173.512 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -105.02 135.82 12.77 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 106.493 -2.643 . . . . 0.0 106.493 177.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 37.1 mm -97.91 121.67 48.7 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.191 -1.182 . . . . 0.0 108.444 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 76.4 t -80.88 132.34 31.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.248 -0.907 . . . . 0.0 109.619 -179.089 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.651 HD21 ' NZ ' ' A' ' 62' ' ' LYS . 43.9 t-20 -144.91 108.38 4.63 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.245 -0.909 . . . . 0.0 109.216 179.753 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 28.5 m -135.84 162.25 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.169 -0.957 . . . . 0.0 110.168 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.6 t -61.65 -43.15 99.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.549 -0.72 . . . . 0.0 110.017 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 57.9 m -123.75 -90.63 0.56 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.432 -0.792 . . . . 0.0 110.245 -179.387 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.9 m -129.71 157.32 42.48 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.539 -0.726 . . . . 0.0 109.771 -179.258 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.9 tp -114.01 130.9 56.51 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.454 -0.778 . . . . 0.0 109.009 179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -88.29 144.7 26.27 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.421 -0.8 . . . . 0.0 109.614 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 70.8 t -92.35 131.32 39.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.28 -0.888 . . . . 0.0 108.901 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.653 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 84.4 mtm-85 -107.61 136.39 47.45 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.472 -0.767 . . . . 0.0 109.572 -179.464 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -93.48 90.12 6.57 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.162 -0.961 . . . . 0.0 110.049 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 130.16 -174.09 19.7 Favored Glycine 0 N--CA 1.499 2.841 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 179.289 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -105.01 31.19 4.99 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.574 -0.957 . . . . 0.0 109.22 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 36.0 m -134.02 148.87 51.15 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.363 -0.836 . . . . 0.0 109.674 -179.794 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 40.2 p -67.78 -30.87 70.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.302 -0.874 . . . . 0.0 110.285 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 35.9 t -75.5 7.22 3.81 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.273 -0.892 . . . . 0.0 109.605 -179.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.8 m -65.17 148.95 50.77 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.363 -0.835 . . . . 0.0 110.091 -179.43 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -71.46 142.86 50.21 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.488 -0.757 . . . . 0.0 110.343 -179.578 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 20.4 t -85.64 128.32 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.449 -0.782 . . . . 0.0 109.293 179.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 23.9 pt -107.7 -2.89 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 121.312 -0.867 . . . . 0.0 109.908 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.13 178.87 39.23 Favored Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.007 179.662 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -134.23 153.42 51.86 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.542 -0.975 . . . . 0.0 109.248 179.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 91.7 mt -123.98 146.4 48.53 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 121.321 -0.862 . . . . 0.0 109.497 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 28.0 t -79.75 163.53 24.4 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.435 -0.791 . . . . 0.0 110.635 -179.07 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -66.03 161.7 43.83 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.524 -1.031 . . . . 0.0 110.524 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 54.75 31.96 16.51 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.578 -0.954 . . . . 0.0 109.595 -179.762 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.2 m -100.09 126.25 46.29 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.432 -0.793 . . . . 0.0 108.957 179.609 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -79.49 132.2 36.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.32 -0.862 . . . . 0.0 109.501 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 14.9 m -127.03 131.86 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.394 -0.816 . . . . 0.0 108.991 179.451 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 45.9 p -75.4 134.45 40.92 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-O 121.243 0.545 . . . . 0.0 109.87 -179.184 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.425 HG21 HD12 ' A' ' 37' ' ' ILE . 95.3 mt -111.35 128.89 67.54 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 CA-C-O 121.391 0.615 . . . . 0.0 109.379 179.508 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 35.3 m -113.29 -1.57 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.706 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -179.48 -178.67 48.51 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -142.84 159.45 42.22 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.256 -1.144 . . . . 0.0 109.676 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -154.53 113.0 3.56 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.137 -0.977 . . . . 0.0 109.759 179.496 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 59.97 -141.94 47.57 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.414 -1.075 . . . . 0.0 110.414 179.312 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.44 24.92 1.53 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.572 -0.958 . . . . 0.0 109.324 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -129.75 147.78 51.57 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.545 -0.722 . . . . 0.0 109.087 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -103.94 142.8 33.78 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.465 -0.772 . . . . 0.0 109.607 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -91.69 128.0 37.35 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 14.2 pt -129.89 154.02 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.296 -0.878 . . . . 0.0 109.391 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.413 ' OE1' ' CD2' ' A' ' 53' ' ' HIS . 49.0 tp10 -82.88 110.99 18.36 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.464 -0.772 . . . . 0.0 109.148 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.577 ' O ' ' N ' ' A' ' 51' ' ' GLY . 79.1 t80 -107.35 117.49 34.21 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.398 -0.814 . . . . 0.0 109.464 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt 44.23 -87.44 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.549 -0.72 . . . . 0.0 110.106 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -123.51 -34.0 0.78 Allowed Glycine 0 N--CA 1.497 2.741 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 15.6 p -89.43 169.43 11.39 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.335 -1.097 . . . . 0.0 109.822 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . 0.413 ' CD2' ' OE1' ' A' ' 48' ' ' GLU . 73.2 m80 -96.46 115.63 27.75 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.533 -0.729 . . . . 0.0 109.124 179.645 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.96 153.12 26.56 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -121.01 138.66 54.06 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.708 -0.877 . . . . 0.0 109.073 179.661 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -136.58 152.59 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.307 -0.87 . . . . 0.0 109.495 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.653 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -75.03 147.26 40.86 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.523 -0.736 . . . . 0.0 110.65 -179.363 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -70.98 -14.11 62.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.431 -0.793 . . . . 0.0 109.444 179.187 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -65.47 -37.9 88.2 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.447 -0.783 . . . . 0.0 110.292 -179.222 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 74.1 m-85 -96.81 -7.55 33.35 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.24 -0.912 . . . . 0.0 110.397 -179.068 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 1.5 mp -108.17 129.08 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.062 0 O-C-N 121.366 -0.834 . . . . 0.0 108.931 -179.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.651 ' NZ ' HD21 ' A' ' 8' ' ' ASN . 26.7 pttm -145.86 -178.81 6.3 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.201 -0.937 . . . . 0.0 109.708 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 43.2 t0 60.73 46.67 8.82 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.609 -0.682 . . . . 0.0 109.368 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt -75.56 131.37 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.02 179.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.8 mtpm? -107.32 146.01 32.09 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.443 -0.786 . . . . 0.0 110.144 -179.198 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -73.03 149.62 43.08 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.587 -0.696 . . . . 0.0 110.033 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 50.1 tp10 -60.65 -81.13 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.474 -0.766 . . . . 0.0 109.755 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.2 m -84.16 132.76 30.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.183 -0.948 . . . . 0.0 110.271 -179.242 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.465 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 8.9 mp -88.14 -2.31 58.53 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.517 -0.74 . . . . 0.0 109.442 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -77.0 135.04 38.67 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.28 -0.887 . . . . 0.0 109.992 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.526 ' C ' ' H ' ' A' ' 73' ' ' HIS . 97.8 m-70 -104.87 13.44 31.17 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.555 -0.716 . . . . 0.0 109.079 179.584 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 54.88 4.81 0.08 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.771 -0.581 . . . . 0.0 109.911 -179.581 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.526 ' H ' ' C ' ' A' ' 71' ' ' HIS . 62.0 t-80 -142.18 116.48 9.53 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.279 -0.888 . . . . 0.0 109.399 179.62 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . 0.472 ' NE2' ' OXT' ' A' ' 76' ' ' HIS . 84.4 t60 -166.94 85.12 0.26 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.229 -0.92 . . . . 0.0 109.043 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.428 ' O ' ' O ' ' A' ' 76' ' ' HIS . 59.5 t-80 -65.86 -43.06 89.51 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.515 -0.741 . . . . 0.0 109.963 -179.47 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . 0.472 ' OXT' ' NE2' ' A' ' 74' ' ' HIS . 63.3 t-80 . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 118.064 -0.97 . . . . 0.0 109.901 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.1 tm-20 -89.11 133.05 34.53 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.375 -0.828 . . . . 0.0 110.026 -179.356 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.3 mppt? -137.04 151.88 49.44 Favored 'General case' 0 N--CA 1.494 1.76 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.326 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 68.9 p -122.74 137.68 54.84 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.621 -0.674 . . . . 0.0 109.765 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -119.49 131.09 8.81 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 5.6 mm -86.87 122.53 38.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.411 -1.052 . . . . 0.0 109.431 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 80.7 t -79.13 131.46 34.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.449 -0.782 . . . . 0.0 110.071 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 96.2 m-20 -121.48 101.77 7.83 Favored 'General case' 0 N--CA 1.497 1.925 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 29.4 m -139.98 160.95 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.425 -0.797 . . . . 0.0 110.025 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 80.6 p -81.63 -11.65 59.02 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.0 p -149.07 -70.21 0.21 Allowed 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.455 -0.778 . . . . 0.0 109.267 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 98.6 p -153.95 168.89 24.89 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.904 . . . . 0.0 110.116 -179.598 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.7 tp -115.47 131.03 57.06 Favored 'General case' 0 N--CA 1.498 1.925 0 CA-C-O 121.479 0.657 . . . . 0.0 109.495 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -83.92 135.25 34.55 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.484 -0.76 . . . . 0.0 110.196 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 87.3 t -90.36 131.74 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.478 -0.764 . . . . 0.0 109.218 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.595 HH21 ' N ' ' A' ' 57' ' ' ALA . 87.5 mtm180 -105.55 133.89 49.56 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.493 -0.754 . . . . 0.0 110.187 -179.601 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -67.53 -46.76 71.86 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.561 -0.712 . . . . 0.0 109.673 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.52 178.68 30.23 Favored Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.182 -1.167 . . . . 0.0 110.182 -179.311 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -92.95 21.28 5.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.616 -0.932 . . . . 0.0 108.681 179.536 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.1 m -79.59 165.2 23.18 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.543 -0.723 . . . . 0.0 110.407 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.7 m -63.19 -46.17 88.34 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.691 -0.631 . . . . 0.0 109.976 -179.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.8 m -129.44 71.13 1.43 Allowed 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.484 -0.76 . . . . 0.0 109.014 -179.553 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.46 -180.0 7.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.639 -0.663 . . . . 0.0 110.136 -179.545 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -67.05 133.12 49.26 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.617 0.723 . . . . 0.0 110.389 -179.453 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 74.8 t -81.15 129.19 37.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.482 -0.762 . . . . 0.0 109.536 179.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.1 pt -109.99 -5.09 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.723 -0.611 . . . . 0.0 109.489 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.09 177.39 38.15 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.489 -1.339 . . . . 0.0 110.284 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -132.23 155.71 47.78 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.73 -0.865 . . . . 0.0 109.397 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.6 mt -123.55 150.3 44.18 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-O 121.456 0.646 . . . . 0.0 109.801 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.4 m -71.82 152.54 42.59 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 121.522 0.677 . . . . 0.0 110.195 -179.537 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.495 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -68.07 162.83 48.61 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 11.8 m120 56.46 5.0 0.17 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.979 -0.719 . . . . 0.0 109.854 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.495 ' H ' ' C ' ' A' ' 31' ' ' GLY . 35.3 m -81.26 137.1 35.85 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.898 . . . . 0.0 110.138 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -84.96 139.88 31.49 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.498 -0.751 . . . . 0.0 110.176 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 19.8 m -127.0 132.16 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.625 -0.672 . . . . 0.0 109.403 179.562 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 44.5 m -65.67 128.21 35.03 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.725 -0.609 . . . . 0.0 110.047 -179.496 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 97.1 mt -115.55 125.13 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 CA-C-O 121.391 0.615 . . . . 0.0 109.631 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.426 ' CG2' ' N ' ' A' ' 39' ' ' GLY . 34.6 m -112.96 -47.88 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 179.39 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.426 ' N ' ' CG2' ' A' ' 38' ' ' VAL . . . -95.06 162.58 23.95 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -142.01 125.63 16.85 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.494 -1.003 . . . . 0.0 109.298 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.467 ' O ' ' N ' ' A' ' 43' ' ' ALA . 83.1 tt0 -114.91 142.95 45.89 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.507 ' O ' ' CB ' ' A' ' 43' ' ' ALA . . . -65.71 59.52 0.13 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.487 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.507 ' CB ' ' O ' ' A' ' 42' ' ' GLY . . . 160.58 -31.7 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.711 -0.876 . . . . 0.0 108.715 179.707 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -134.68 160.91 36.67 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.534 -0.729 . . . . 0.0 110.204 -178.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.7 m-85 -114.13 140.25 48.67 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.589 -0.694 . . . . 0.0 109.688 179.679 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -90.68 129.95 36.73 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 -179.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.9 pt -127.9 157.04 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 CA-C-O 121.571 0.701 . . . . 0.0 110.1 -179.685 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -86.93 93.98 9.47 Favored 'General case' 0 N--CA 1.49 1.561 0 CA-C-O 121.431 0.634 . . . . 0.0 109.927 -179.485 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 91.5 t80 -86.89 140.07 30.0 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.399 -0.813 . . . . 0.0 109.467 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.8 tttm -54.63 100.53 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.422 -0.799 . . . . 0.0 110.05 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 124.51 -33.94 3.63 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 20.7 t -171.11 -168.58 0.66 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.214 -1.168 . . . . 0.0 109.942 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 5.9 m170 -100.69 120.16 39.66 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.519 -0.738 . . . . 0.0 109.641 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.09 161.37 20.85 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -118.09 147.06 43.64 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.737 -0.86 . . . . 0.0 109.626 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.2 m -139.27 153.32 24.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.699 -0.626 . . . . 0.0 109.794 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.595 ' N ' HH21 ' A' ' 16' ' ' ARG . . . -73.68 141.34 46.44 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.574 -0.704 . . . . 0.0 110.59 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -64.61 -12.25 43.65 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.681 -0.637 . . . . 0.0 110.016 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 45.1 tp10 -68.87 -35.97 77.54 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -0.9 . . . . 0.0 110.546 -179.228 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -93.52 2.25 56.48 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.103 -0.998 . . . . 0.0 110.147 -178.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.8 mm -105.67 128.91 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.483 -0.761 . . . . 0.0 109.616 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -143.63 157.09 44.67 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.56 -0.712 . . . . 0.0 109.993 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 37.5 t0 64.39 45.68 3.7 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.615 0.721 . . . . 0.0 109.675 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.407 HD12 HG22 ' A' ' 64' ' ' ILE . 97.1 mt -67.83 147.12 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.68 -0.638 . . . . 0.0 110.071 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -80.61 140.19 35.86 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.433 -0.792 . . . . 0.0 110.548 -178.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -62.57 145.21 54.96 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.46 0.648 . . . . 0.0 110.746 -179.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.521 ' CD ' ' H ' ' A' ' 68' ' ' VAL . 0.0 OUTLIER -132.19 -83.66 0.49 Allowed 'General case' 0 N--CA 1.498 1.927 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.881 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.521 ' H ' ' CD ' ' A' ' 67' ' ' GLU . 7.9 p -167.66 131.76 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.47 -0.768 . . . . 0.0 109.787 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.487 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 9.3 mp -79.27 141.62 36.9 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.517 -0.74 . . . . 0.0 110.41 -179.447 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.44 ' O ' ' CD2' ' A' ' 72' ' ' HIS . 96.7 mt-10 55.37 103.11 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 CA-C-O 121.662 0.744 . . . . 0.0 110.181 179.612 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 26.9 p-80 -75.22 -11.34 60.05 Favored 'General case' 0 N--CA 1.487 1.416 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.694 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.44 ' CD2' ' O ' ' A' ' 70' ' ' GLU . 70.4 m-70 60.96 99.02 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 CA-C-O 121.463 0.649 . . . . 0.0 109.943 179.509 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.547 ' CE1' ' HD1' ' A' ' 74' ' ' HIS . 8.2 p80 -81.57 1.37 34.03 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . 0.547 ' HD1' ' CE1' ' A' ' 73' ' ' HIS . 44.9 p-80 -149.24 163.37 37.86 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.233 -0.917 . . . . 0.0 110.026 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 -113.81 139.03 49.48 Favored 'General case' 0 N--CA 1.493 1.692 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 83.9 t60 . . . . . 0 N--CA 1.489 1.497 0 CA-C-O 117.847 -1.073 . . . . 0.0 109.043 -179.981 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -67.81 137.54 55.44 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.764 0.792 . . . . 0.0 110.423 -179.208 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 52.4 mtmt -137.66 152.93 49.82 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.53 -0.732 . . . . 0.0 109.253 179.584 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 50.6 p -122.8 124.54 43.55 Favored 'General case' 0 N--CA 1.496 1.872 0 CA-C-O 121.829 0.823 . . . . 0.0 109.357 179.52 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -101.78 133.69 11.45 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 -179.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 34.4 mm -84.29 126.62 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.7 -0.882 . . . . 0.0 110.009 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.1 t -82.89 98.6 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.376 -0.827 . . . . 0.0 109.317 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -101.47 107.24 18.49 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.508 -0.745 . . . . 0.0 109.889 -179.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 m -141.09 144.3 26.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.299 -0.876 . . . . 0.0 109.575 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 27.5 t -66.97 -13.78 62.19 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-O 121.44 0.638 . . . . 0.0 109.497 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.422 ' OG ' ' N ' ' A' ' 12' ' ' SER . 91.1 p -141.3 -103.84 0.14 Allowed 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.161 -0.962 . . . . 0.0 110.231 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.422 ' N ' ' OG ' ' A' ' 11' ' ' SER . 57.8 m -127.49 157.38 40.24 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.464 -0.773 . . . . 0.0 110.191 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 36.5 tp -113.39 128.81 56.58 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 121.723 0.773 . . . . 0.0 109.875 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.9 m-20 -85.07 150.8 24.61 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.479 0.657 . . . . 0.0 110.025 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.4 t -104.41 129.94 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.423 -0.798 . . . . 0.0 109.276 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -105.28 132.81 51.01 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.546 0.688 . . . . 0.0 109.816 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -71.23 -37.22 72.01 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-O 121.819 0.818 . . . . 0.0 109.433 179.635 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -100.73 179.44 29.02 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -179.392 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -94.31 -1.44 53.87 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.193 -1.18 . . . . 0.0 108.825 179.393 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.9 m -83.36 149.82 26.48 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.312 -0.867 . . . . 0.0 110.196 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.424 ' C ' ' H ' ' A' ' 23' ' ' SER . 97.7 m -65.0 -44.33 89.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.415 -0.803 . . . . 0.0 110.078 179.489 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 76.5 p -78.49 16.66 0.78 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.078 -1.014 . . . . 0.0 109.529 -179.448 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.424 ' H ' ' C ' ' A' ' 21' ' ' THR . 18.8 m -63.64 149.65 46.03 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.212 -0.93 . . . . 0.0 110.251 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -70.96 138.25 49.86 Favored 'General case' 0 N--CA 1.488 1.47 0 CA-C-O 121.981 0.895 . . . . 0.0 110.528 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 75.0 t -87.37 130.17 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 CA-C-O 121.697 0.761 . . . . 0.0 109.925 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 37.4 pt -103.61 -4.57 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.007 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.91 -163.96 36.48 Favored Glycine 0 N--CA 1.493 2.451 0 C-N-CA 119.497 -1.335 . . . . 0.0 110.434 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 95.3 p -156.6 163.03 39.81 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.469 -1.019 . . . . 0.0 109.663 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 89.7 mt -124.79 150.86 45.87 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-O 121.694 0.759 . . . . 0.0 109.903 -179.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 12.3 p -76.19 164.72 25.81 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.062 0.934 . . . . 0.0 111.038 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.23 152.81 43.48 Favored Glycine 0 N--CA 1.489 2.222 0 CA-C-O 122.105 0.836 . . . . 0.0 111.665 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 67.1 t30 57.89 32.19 21.6 Favored 'General case' 0 N--CA 1.494 1.744 0 CA-C-O 121.635 0.731 . . . . 0.0 110.147 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 24.6 m -89.98 126.95 35.93 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.154 -0.966 . . . . 0.0 109.539 179.044 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -82.77 133.17 35.15 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.337 -0.852 . . . . 0.0 109.624 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.0 m -125.85 133.62 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 CA-C-O 121.791 0.805 . . . . 0.0 110.03 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 85.5 m -80.37 127.53 32.49 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.413 0.625 . . . . 0.0 109.78 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.401 HG22 HD12 ' A' ' 37' ' ' ILE . 92.8 mt -105.41 126.72 60.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 CA-C-O 121.466 0.65 . . . . 0.0 109.602 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 18.5 m -112.68 -1.97 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.56 177.82 45.75 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.613 -1.279 . . . . 0.0 110.364 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -141.72 159.63 41.83 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.356 -1.084 . . . . 0.0 109.871 -179.786 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -154.32 109.42 3.11 Favored 'General case' 0 N--CA 1.489 1.497 0 CA-C-O 121.684 0.754 . . . . 0.0 109.158 179.37 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.34 -137.47 45.0 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.06 23.28 1.26 Allowed 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.458 -1.024 . . . . 0.0 108.979 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -130.44 145.3 51.8 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.415 -0.803 . . . . 0.0 109.79 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.4 m-85 -108.5 139.66 42.94 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.611 0.719 . . . . 0.0 109.41 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -90.65 129.95 36.71 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.558 -0.714 . . . . 0.0 109.304 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.7 pt -129.03 153.53 38.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 CA-C-O 121.708 0.765 . . . . 0.0 109.804 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -81.02 99.66 8.56 Favored 'General case' 0 N--CA 1.49 1.531 0 CA-C-O 121.674 0.75 . . . . 0.0 109.857 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.404 ' CD2' ' N ' ' A' ' 51' ' ' GLY . 88.0 t80 -81.2 144.13 31.83 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.559 -0.713 . . . . 0.0 110.021 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 51.9 mtmt -46.85 -47.22 21.26 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.461 -0.775 . . . . 0.0 110.144 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.404 ' N ' ' CD2' ' A' ' 49' ' ' TYR . . . -69.34 -39.93 80.81 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 179.797 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 21.4 m -171.62 -110.78 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.152 -1.205 . . . . 0.0 109.325 -179.536 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 73.2 m80 -127.56 112.56 15.04 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-O 121.801 0.81 . . . . 0.0 109.352 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.84 154.29 19.94 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 -179.681 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -120.87 139.96 52.45 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.606 -0.938 . . . . 0.0 109.712 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.2 m -135.96 152.55 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.55 -0.719 . . . . 0.0 109.195 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 149.8 37.93 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-O 121.861 0.839 . . . . 0.0 110.667 -179.528 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 62.2 pttt -65.8 -15.43 62.87 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.57 0.7 . . . . 0.0 109.977 179.4 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.443 ' OE2' ' CE2' ' A' ' 60' ' ' TYR . 14.4 pt-20 -67.28 -35.73 80.1 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.243 -0.911 . . . . 0.0 110.199 -179.563 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.443 ' CE2' ' OE2' ' A' ' 59' ' ' GLU . 54.9 m-85 -90.79 -1.69 57.84 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.07 -1.019 . . . . 0.0 109.26 -179.407 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 39.3 mm -110.86 131.72 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.397 -0.815 . . . . 0.0 109.428 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.486 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 63.8 tttp -130.45 158.05 40.96 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.486 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 11.7 t0 79.81 -59.02 0.35 Allowed 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.393 0.616 . . . . 0.0 109.529 179.518 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.403 ' C ' ' O ' ' A' ' 63' ' ' ASP . 82.1 mt 43.77 65.91 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 CA-C-O 121.741 0.782 . . . . 0.0 109.268 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 38.0 ttmt -142.55 144.45 32.92 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.258 -0.901 . . . . 0.0 110.065 -179.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.478 ' OD1' ' N ' ' A' ' 67' ' ' GLU . 68.1 t0 -63.04 137.63 58.32 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 121.787 0.803 . . . . 0.0 110.316 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.478 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 20.3 pt-20 -50.95 143.35 10.34 Favored 'General case' 0 N--CA 1.494 1.745 0 CA-C-O 121.589 0.709 . . . . 0.0 110.569 -179.489 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 6.9 m -103.25 131.08 52.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 CA-C-O 121.739 0.781 . . . . 0.0 110.266 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.503 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 9.2 mp -76.39 149.29 36.94 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.773 0.797 . . . . 0.0 110.235 -179.7 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -44.97 146.39 0.82 Allowed 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.951 0.881 . . . . 0.0 110.858 -179.407 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -72.85 127.25 31.99 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.694 0.759 . . . . 0.0 110.735 -179.412 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.514 ' CG ' ' H ' ' A' ' 73' ' ' HIS . 80.9 t60 -160.59 172.78 16.55 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.559 -0.713 . . . . 0.0 109.539 179.767 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.514 ' H ' ' CG ' ' A' ' 72' ' ' HIS . 95.1 m-70 -61.52 -36.87 81.76 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.433 -0.792 . . . . 0.0 109.639 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 58.6 t-80 -65.07 -39.32 93.06 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.207 -0.933 . . . . 0.0 109.379 179.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 24.9 t-80 -69.44 130.02 41.35 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.889 . . . . 0.0 109.919 -179.457 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 . . . . . 0 C--N 1.302 -1.475 0 CA-C-O 118.102 -0.951 . . . . 0.0 109.634 179.985 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 63.2 mttp . . . . . 0 N--CA 1.494 1.771 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 22.9 p -117.61 121.87 42.07 Favored 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.831 0.825 . . . . 0.0 109.631 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -102.03 137.64 13.45 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 27.8 mm -87.11 123.21 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.539 -0.977 . . . . 0.0 109.53 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 33' ' ' THR . 70.5 t -74.36 134.08 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.509 -0.744 . . . . 0.0 110.13 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 47.0 t30 -128.53 101.31 6.12 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.6 -0.687 . . . . 0.0 109.401 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 24.5 m -136.71 160.58 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.397 -0.814 . . . . 0.0 109.709 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 99.9 p -84.16 -10.37 57.81 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.498 0.666 . . . . 0.0 109.604 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 62.5 p -147.4 -66.79 0.26 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.13 -0.981 . . . . 0.0 109.503 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.5 p -157.52 165.73 34.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.237 -0.915 . . . . 0.0 109.414 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.0 tp -113.44 130.18 56.37 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 121.672 0.749 . . . . 0.0 109.822 -179.676 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -85.78 145.84 27.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.518 -0.739 . . . . 0.0 109.678 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.7 t -111.51 130.97 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.483 ' NE ' ' O ' ' A' ' 21' ' ' THR . 84.6 mtt85 -111.14 146.36 36.99 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.788 0.804 . . . . 0.0 109.76 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -88.19 -16.59 32.9 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.458 ' O ' ' CD2' ' A' ' 55' ' ' TYR . . . -96.66 -130.92 6.69 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -152.21 -5.58 0.23 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -1.11 . . . . 0.0 108.581 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 8.5 p -82.38 172.33 13.19 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.354 -0.841 . . . . 0.0 110.761 -179.509 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.483 ' O ' ' NE ' ' A' ' 16' ' ' ARG . 52.3 p -66.13 -31.21 71.93 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.603 -0.685 . . . . 0.0 110.219 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 38.0 m -138.39 58.71 1.66 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.029 -1.044 . . . . 0.0 108.896 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.5 m -77.69 -79.1 0.12 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.406 -0.809 . . . . 0.0 109.719 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -157.03 112.97 2.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.073 -1.017 . . . . 0.0 109.792 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.0 t -80.67 129.45 37.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.347 -0.846 . . . . 0.0 109.589 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.4 pt -111.16 -5.58 11.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.554 -0.717 . . . . 0.0 109.126 179.658 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 164.89 -157.98 30.62 Favored Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.189 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.0 p -153.88 164.7 37.96 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.163 -1.198 . . . . 0.0 109.721 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 94.7 mt -126.64 151.56 47.87 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.671 0.748 . . . . 0.0 109.571 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' OG1' ' A' ' 33' ' ' THR . 29.7 t -71.18 160.7 32.38 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-O 121.91 0.862 . . . . 0.0 110.598 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.459 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.54 160.23 49.72 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 57.87 4.09 0.26 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.957 -0.731 . . . . 0.0 109.754 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.459 ' H ' ' C ' ' A' ' 31' ' ' GLY . 86.0 m -70.36 135.94 49.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.22 -0.925 . . . . 0.0 110.275 179.603 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 10.2 mtpm? -83.59 140.56 32.15 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.577 -0.702 . . . . 0.0 110.251 -179.689 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.2 m -126.73 130.88 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.619 -0.676 . . . . 0.0 109.341 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 p -79.83 129.31 34.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.537 -0.727 . . . . 0.0 109.719 -179.486 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 97.0 mt -112.24 129.38 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 CA-C-O 121.482 0.658 . . . . 0.0 109.358 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.2 m -110.18 -2.51 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.01 177.92 47.9 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.307 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.437 ' CD ' ' N ' ' A' ' 41' ' ' GLU . 9.9 tm-20 -133.09 155.4 49.3 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.423 -1.045 . . . . 0.0 109.402 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.437 ' N ' ' CD ' ' A' ' 40' ' ' GLU . 48.6 tp10 -156.31 115.76 3.52 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.493 -0.754 . . . . 0.0 109.149 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 63.68 -142.9 47.32 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.495 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.95 20.2 5.04 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.418 -1.048 . . . . 0.0 109.022 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -130.19 150.82 51.27 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.483 -0.761 . . . . 0.0 109.656 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -102.94 140.6 37.01 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.67 0.747 . . . . 0.0 109.988 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -91.16 130.39 37.05 Favored 'General case' 0 N--CA 1.487 1.425 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.2 pt -128.72 157.15 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 CA-C-O 121.766 0.793 . . . . 0.0 110.199 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -82.08 97.3 8.09 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.594 0.711 . . . . 0.0 109.48 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -85.18 144.85 27.91 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.365 -0.834 . . . . 0.0 109.825 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -66.76 100.62 0.72 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.493 -0.754 . . . . 0.0 110.154 -179.416 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 116.87 -23.4 10.08 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 109.187 -1.565 . . . . 0.0 109.187 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 10.8 t -169.08 -156.08 0.15 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.065 -1.256 . . . . 0.0 110.101 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -108.49 122.77 47.74 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.706 0.765 . . . . 0.0 109.716 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.41 148.76 19.28 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.458 ' CD2' ' O ' ' A' ' 18' ' ' GLY . 87.9 m-85 -127.16 132.27 50.55 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.669 -0.901 . . . . 0.0 109.238 179.306 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.8 m -138.19 153.45 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.396 -0.815 . . . . 0.0 109.923 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.07 151.23 40.22 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-O 121.574 0.702 . . . . 0.0 110.849 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -67.25 -20.34 65.65 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.526 -0.734 . . . . 0.0 110.548 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -65.38 -32.9 74.78 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.213 -0.93 . . . . 0.0 110.565 -178.885 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -87.91 1.45 54.01 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.854 -1.154 . . . . 0.0 109.396 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 37.8 mm -108.51 127.25 65.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.411 -0.806 . . . . 0.0 109.346 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 37.5 ttpt -140.58 150.43 43.63 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.815 0.817 . . . . 0.0 110.385 -179.215 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 54.39 72.3 0.47 Allowed 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.72 0.771 . . . . 0.0 110.254 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.9 mt . . . . . 0 N--CA 1.491 1.607 0 O-C-N 121.287 -0.883 . . . . 0.0 109.402 179.574 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt . . . . . 0 N--CA 1.496 1.826 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 17.4 p -118.36 116.44 26.74 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.513 0.673 . . . . 0.0 109.206 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -93.55 125.62 8.3 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.677 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.7 mp -81.08 124.5 38.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.295 -1.121 . . . . 0.0 109.58 -179.71 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 76.6 t -77.78 132.67 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.343 -0.848 . . . . 0.0 109.956 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -126.92 98.22 5.26 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.5 m -137.23 158.92 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.58 -0.7 . . . . 0.0 109.616 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.9 m -86.06 -12.57 49.79 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.551 -0.718 . . . . 0.0 109.357 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 71.4 m -133.31 -79.51 0.48 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.462 -0.774 . . . . 0.0 109.204 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.3 p -158.29 165.1 35.62 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.173 -0.954 . . . . 0.0 109.725 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 34.0 tp -112.8 131.58 55.63 Favored 'General case' 0 N--CA 1.498 1.963 0 CA-C-O 121.545 0.688 . . . . 0.0 109.561 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -92.17 143.69 26.17 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.503 -0.748 . . . . 0.0 110.063 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 71.1 t -92.57 132.02 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.479 -0.763 . . . . 0.0 109.122 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -102.16 130.53 48.81 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.395 -0.816 . . . . 0.0 110.102 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -70.41 -41.55 72.8 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.719 -0.613 . . . . 0.0 109.821 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.45 ' H ' ' HB2' ' A' ' 23' ' ' SER . . . -105.7 -171.62 23.65 Favored Glycine 0 N--CA 1.497 2.766 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.106 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.05 57.99 0.76 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.699 -0.883 . . . . 0.0 109.124 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 40.7 t -161.33 154.9 21.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.244 -0.91 . . . . 0.0 109.821 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 75.2 p -66.15 -33.09 74.99 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.627 -0.67 . . . . 0.0 109.806 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 47.1 t -79.07 9.18 4.64 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.195 -0.94 . . . . 0.0 108.979 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.45 ' HB2' ' H ' ' A' ' 18' ' ' GLY . 94.2 p -69.36 159.46 33.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.492 -0.755 . . . . 0.0 110.427 -179.304 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -84.16 138.68 32.87 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.471 -0.768 . . . . 0.0 110.837 -179.198 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.0 t -89.69 130.99 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.541 -0.724 . . . . 0.0 109.792 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.41 HD12 ' CE2' ' A' ' 49' ' ' TYR . 36.8 pt -102.8 -6.59 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.574 -0.703 . . . . 0.0 109.177 179.428 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 169.22 -179.83 41.62 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 119.489 -1.339 . . . . 0.0 110.05 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 63.1 m -133.95 157.03 47.07 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.643 -0.916 . . . . 0.0 109.445 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.1 mt -122.59 148.96 44.61 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 121.544 0.687 . . . . 0.0 109.705 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.0 m -71.18 150.2 45.59 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-O 121.705 0.764 . . . . 0.0 110.519 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.543 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -64.13 163.33 34.45 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 111.099 -0.801 . . . . 0.0 111.099 -179.275 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 37.6 t-20 66.74 -19.64 0.11 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.942 -0.74 . . . . 0.0 110.135 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.543 ' H ' ' C ' ' A' ' 31' ' ' GLY . 33.0 m -67.31 136.4 54.8 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.047 -1.033 . . . . 0.0 110.209 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -90.42 148.81 22.55 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.502 -0.749 . . . . 0.0 109.605 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.5 m -123.51 131.53 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 CA-C-O 121.579 0.704 . . . . 0.0 109.188 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 28.5 m -66.63 130.5 43.39 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.86 -0.525 . . . . 0.0 110.025 -179.166 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.0 mt -110.53 129.78 65.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 19.0 m -112.92 -0.12 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -179.61 -179.31 48.76 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.43 -1.367 . . . . 0.0 110.307 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -139.87 154.08 47.19 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.462 -1.023 . . . . 0.0 109.75 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -153.98 109.05 3.13 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -0.854 . . . . 0.0 109.402 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 59.14 -142.22 46.74 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -83.2 17.85 1.91 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.487 -1.008 . . . . 0.0 109.278 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -129.83 145.57 51.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.615 -0.678 . . . . 0.0 109.514 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 50.4 m-85 -107.68 147.69 30.38 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.605 0.716 . . . . 0.0 109.833 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -90.84 139.29 30.88 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.537 -0.727 . . . . 0.0 109.044 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.4 pt -134.45 158.45 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 CA-C-O 121.665 0.745 . . . . 0.0 110.519 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -84.22 93.59 8.22 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.674 -0.641 . . . . 0.0 109.426 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.41 ' CE2' HD12 ' A' ' 26' ' ' ILE . 82.4 t80 -98.37 135.31 40.14 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.358 -0.839 . . . . 0.0 109.278 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.9 ttpt -49.77 106.72 0.12 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.383 -0.823 . . . . 0.0 110.568 -179.162 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 123.31 -51.76 0.79 Allowed Glycine 0 N--CA 1.496 2.647 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 179.317 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 22.8 p -158.86 -166.2 1.81 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.132 -1.216 . . . . 0.0 110.124 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 78.3 m80 -90.41 116.87 28.68 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.366 -0.834 . . . . 0.0 109.865 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -86.29 160.75 33.57 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -123.96 136.36 54.26 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.665 -0.903 . . . . 0.0 109.423 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.8 m -136.81 137.24 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.506 -0.746 . . . . 0.0 109.337 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.97 143.67 57.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.599 -0.688 . . . . 0.0 110.632 -179.216 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.9 pttt -62.01 -13.35 24.92 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.544 -0.722 . . . . 0.0 109.422 179.377 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -68.25 -31.0 70.17 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.434 -0.791 . . . . 0.0 110.95 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.402 ' C ' HD12 ' A' ' 61' ' ' ILE . 61.2 m-85 -93.1 -11.05 33.87 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.792 -1.192 . . . . 0.0 109.769 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.533 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.4 mp -94.73 131.63 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.361 -0.837 . . . . 0.0 109.207 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.471 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 65.8 tttm -135.43 155.41 50.59 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.653 -0.655 . . . . 0.0 109.828 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.471 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 11.7 t0 79.39 -66.78 0.17 Allowed 'General case' 0 N--CA 1.495 1.799 0 CA-C-O 121.268 0.556 . . . . 0.0 109.535 179.753 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 91.5 mt . . . . . 0 N--CA 1.488 1.463 0 O-C-N 121.634 -0.666 . . . . 0.0 109.488 -179.442 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.8 mttt . . . . . 0 N--CA 1.493 1.685 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -114.46 126.61 55.16 Favored 'General case' 0 N--CA 1.498 1.975 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.31 140.75 15.2 Favored Glycine 0 N--CA 1.497 2.754 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.309 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 23.7 mm -94.33 116.33 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.364 -1.08 . . . . 0.0 108.904 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.3 t -80.35 132.63 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.376 -0.828 . . . . 0.0 109.99 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.6 t30 -132.99 106.9 7.94 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.428 -0.795 . . . . 0.0 109.34 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 11' ' ' SER . 19.6 m -151.65 -12.87 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.416 ' H ' ' H ' ' A' ' 9' ' ' VAL . 24.0 p 43.87 17.79 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.724 -0.61 . . . . 0.0 109.729 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.525 ' N ' ' O ' ' A' ' 9' ' ' VAL . 23.7 m -151.55 35.85 0.57 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.1 t 60.63 145.31 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.793 -0.567 . . . . 0.0 110.437 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 35.9 tp -116.16 133.13 56.36 Favored 'General case' 0 N--CA 1.503 2.209 0 CA-C-O 121.572 0.701 . . . . 0.0 109.613 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 18.9 p30 -80.65 137.34 36.33 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.429 -0.794 . . . . 0.0 109.62 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 73.7 t -90.95 131.25 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.361 -0.837 . . . . 0.0 108.84 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 96.7 mtt-85 -95.9 138.81 33.0 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.001 . . . . 0.0 109.981 -179.123 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 50.4 tp10 -67.5 -43.67 80.31 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.424 -0.797 . . . . 0.0 109.777 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.43 ' H ' ' HB2' ' A' ' 23' ' ' SER . . . -119.52 -166.6 13.4 Favored Glycine 0 N--CA 1.499 2.856 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 -178.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.69 56.03 0.88 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.62 -0.929 . . . . 0.0 109.225 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 28.8 t -152.8 151.09 30.05 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.264 -0.898 . . . . 0.0 109.725 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 41.7 p -68.06 -23.12 64.92 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.394 -0.816 . . . . 0.0 109.438 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 86.1 p -83.65 -0.48 50.83 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.423 -0.798 . . . . 0.0 109.429 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.43 ' HB2' ' H ' ' A' ' 18' ' ' GLY . 99.8 p -64.84 159.42 22.61 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.222 -0.924 . . . . 0.0 110.387 -179.323 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 22.6 pttp -92.6 140.18 29.81 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.49 -0.756 . . . . 0.0 110.407 -179.458 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 22.6 t -86.69 129.81 37.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.383 -0.823 . . . . 0.0 109.909 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 36.3 pt -102.39 -7.4 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.512 -0.743 . . . . 0.0 109.157 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.77 -162.81 35.22 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 24.8 p -152.78 164.04 38.57 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.299 -1.118 . . . . 0.0 109.433 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.3 mt -124.26 148.48 47.35 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.546 -0.721 . . . . 0.0 109.39 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.9 t -69.94 152.02 44.95 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.493 -0.755 . . . . 0.0 110.622 -179.016 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.46 160.55 32.24 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 12.3 m120 57.31 33.22 22.99 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.653 -0.91 . . . . 0.0 109.563 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 35.1 m -105.02 137.02 43.41 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.57 -0.706 . . . . 0.0 109.832 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -79.76 140.32 36.95 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 109.057 -0.719 . . . . 0.0 109.057 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.8 m -126.77 130.5 71.53 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.416 -0.803 . . . . 0.0 109.397 179.565 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 54.6 m -72.84 126.39 29.81 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.41 -0.806 . . . . 0.0 109.628 -179.542 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 93.1 mt -107.33 126.71 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.639 -0.663 . . . . 0.0 109.65 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 30.9 m -111.13 -3.26 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.468 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 177.21 -174.14 46.78 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -141.05 155.16 46.21 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.323 -1.104 . . . . 0.0 109.441 179.844 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -151.27 112.06 4.25 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 109.598 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.461 ' O ' ' NZ ' ' A' ' 58' ' ' LYS . . . 61.92 -144.93 49.19 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.501 ' C ' ' HZ2' ' A' ' 58' ' ' LYS . . . -84.36 24.96 0.91 Allowed 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.657 -0.908 . . . . 0.0 109.384 -179.8 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 -131.58 152.68 50.59 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.602 -0.686 . . . . 0.0 109.341 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 9.1 m-85 -103.16 139.08 39.12 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.413 -0.804 . . . . 0.0 108.855 179.592 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.535 ' HZ2' ' HB3' ' A' ' 53' ' ' HIS . 63.5 tttp -90.71 129.72 36.78 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 33.3 pt -130.72 154.47 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.483 -0.761 . . . . 0.0 109.588 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -83.22 100.3 10.5 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.455 -0.778 . . . . 0.0 109.341 -179.294 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -83.64 147.1 27.9 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.351 -0.843 . . . . 0.0 109.797 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 8.0 mtmp? -62.21 102.96 0.34 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.267 -0.895 . . . . 0.0 110.861 -179.169 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 101.63 -10.28 57.5 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 179.106 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 50.4 m -168.29 -166.09 0.67 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.861 -1.376 . . . . 0.0 110.035 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.535 ' HB3' ' HZ2' ' A' ' 46' ' ' LYS . 96.9 m-70 -110.28 115.92 30.55 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.52 -0.737 . . . . 0.0 109.085 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.2 152.08 21.07 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.371 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -126.55 137.79 53.39 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.639 -0.918 . . . . 0.0 109.021 179.488 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.3 m -135.59 139.56 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.339 -0.85 . . . . 0.0 109.753 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.574 ' HB1' ' OE1' ' A' ' 59' ' ' GLU . . . -68.09 149.58 49.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.575 -0.703 . . . . 0.0 110.593 -179.378 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.501 ' HZ2' ' C ' ' A' ' 43' ' ' ALA . 64.2 mttp -62.23 -33.73 75.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.463 -0.773 . . . . 0.0 109.772 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.574 ' OE1' ' HB1' ' A' ' 57' ' ' ALA . 58.7 mp0 -55.1 -30.98 60.84 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.354 -0.841 . . . . 0.0 110.086 -178.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.478 ' CD2' ' HB3' ' A' ' 57' ' ' ALA . 40.0 m-85 -92.84 -3.98 53.73 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.966 -1.084 . . . . 0.0 109.353 -179.631 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.1 mm -114.46 129.18 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 121.541 -0.724 . . . . 0.0 109.516 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.577 ' O ' ' N ' ' A' ' 64' ' ' ILE . 21.7 ptmt -141.14 -174.16 3.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.418 -0.801 . . . . 0.0 109.581 179.852 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.458 ' O ' ' O ' ' A' ' 64' ' ' ILE . 91.1 m-20 56.69 -75.48 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.577 ' N ' ' O ' ' A' ' 62' ' ' LYS . 97.7 mt . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.393 0.616 . . . . 0.0 110.01 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.5 mtmp? . . . . . 0 N--CA 1.492 1.642 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 62.0 p -121.35 125.21 46.42 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.567 -0.708 . . . . 0.0 109.464 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -102.86 137.32 13.34 Favored Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.666 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.4 mm -95.5 120.07 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.275 -1.133 . . . . 0.0 109.449 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 74.1 t -75.67 134.2 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.566 -0.709 . . . . 0.0 110.321 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' A' ' 60' ' ' TYR . 3.6 p-10 -138.72 99.74 3.88 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.437 -0.789 . . . . 0.0 109.385 179.592 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 5.7 m -134.98 135.73 52.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.577 -0.702 . . . . 0.0 109.682 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 78.2 p -62.52 -40.49 96.94 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.614 -0.679 . . . . 0.0 109.638 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 68.9 m -101.8 -79.19 0.52 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.447 -0.783 . . . . 0.0 109.877 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 45.5 m -161.51 167.06 26.13 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.334 -0.854 . . . . 0.0 109.596 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 38.6 tp -116.95 130.17 56.53 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.64 -0.662 . . . . 0.0 109.789 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -91.16 142.29 27.89 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.397 -0.814 . . . . 0.0 109.686 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 96.3 t -88.89 128.08 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.324 -0.86 . . . . 0.0 109.21 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.758 HH21 ' H ' ' A' ' 20' ' ' SER . 67.5 mtp180 -107.52 133.16 52.39 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.549 -0.719 . . . . 0.0 109.962 -179.357 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.3 pt-20 -70.7 -35.01 72.55 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.488 -0.757 . . . . 0.0 109.879 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -120.95 -148.8 8.05 Favored Glycine 0 N--CA 1.498 2.774 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 -178.537 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -147.27 75.05 1.36 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.574 -0.957 . . . . 0.0 108.834 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.758 ' H ' HH21 ' A' ' 16' ' ' ARG . 15.2 m -141.85 44.95 1.7 Allowed 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.633 ' N ' ' NH2' ' A' ' 16' ' ' ARG . 59.0 p 50.37 -84.81 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.769 0 CA-C-O 121.319 0.58 . . . . 0.0 110.471 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.527 ' N ' ' O ' ' A' ' 20' ' ' SER . 23.0 t -71.39 44.4 0.09 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.354 -0.841 . . . . 0.0 109.002 -179.45 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.43 ' H ' ' C ' ' A' ' 21' ' ' THR . 15.4 p -78.58 165.22 23.94 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.355 -0.84 . . . . 0.0 110.411 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -77.3 138.54 39.42 Favored 'General case' 0 N--CA 1.488 1.473 0 CA-C-O 121.721 0.772 . . . . 0.0 110.637 -179.583 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 76.5 t -93.49 129.9 43.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 39.4 pt -109.19 -7.1 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.6 -0.687 . . . . 0.0 109.556 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 179.12 -173.53 45.65 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 119.287 -1.435 . . . . 0.0 110.349 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 54.8 m -144.0 154.06 42.87 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.405 -1.056 . . . . 0.0 109.789 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.7 mt -124.89 148.78 48.12 Favored 'General case' 0 N--CA 1.497 1.884 0 CA-C-O 121.546 0.689 . . . . 0.0 109.63 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 90.6 p -79.08 165.06 23.78 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 121.72 0.772 . . . . 0.0 110.854 -179.148 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -65.78 155.27 50.4 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 12.0 m120 57.41 31.59 20.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.73 -0.865 . . . . 0.0 109.86 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 37.0 m -91.73 129.94 37.61 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.216 -0.928 . . . . 0.0 109.835 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -80.11 133.33 36.08 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.514 -0.741 . . . . 0.0 109.639 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 m -128.1 133.29 67.4 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.303 -0.873 . . . . 0.0 110.037 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 21.6 m -81.56 131.23 35.27 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.685 -0.634 . . . . 0.0 109.451 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 91.1 mt -104.91 126.0 59.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.593 -0.692 . . . . 0.0 109.785 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 15.8 m -109.66 -1.43 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.46 -177.79 48.42 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -142.23 160.84 39.45 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.342 -1.093 . . . . 0.0 109.631 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -152.84 112.57 3.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.241 -0.912 . . . . 0.0 109.546 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.22 -135.16 47.88 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.011 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.82 25.91 1.94 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.462 -1.022 . . . . 0.0 109.006 -179.456 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 65.3 m-85 -132.4 151.33 51.92 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.685 -0.634 . . . . 0.0 109.452 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 31.5 m-85 -107.84 139.49 42.35 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.528 0.68 . . . . 0.0 109.894 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -92.42 132.63 36.61 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 36.7 pt -128.4 156.88 40.9 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.556 -0.715 . . . . 0.0 110.205 -179.638 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -82.15 97.56 8.27 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.66 -0.65 . . . . 0.0 109.483 -179.697 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.418 ' H ' ' HA ' ' A' ' 53' ' ' HIS . 90.0 t80 -85.49 161.46 19.36 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.525 -0.734 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.411 ' N ' ' CG ' ' A' ' 49' ' ' TYR . 98.6 mttt -70.91 107.81 4.22 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.415 -0.803 . . . . 0.0 110.267 -179.543 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 98.84 -14.46 61.64 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 81.0 p -169.46 -161.61 0.3 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.942 -1.328 . . . . 0.0 110.145 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.418 ' HA ' ' H ' ' A' ' 49' ' ' TYR . 77.4 m80 -116.43 121.47 41.98 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.628 -0.67 . . . . 0.0 109.571 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.84 163.57 30.84 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.597 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 81.9 m-85 -132.23 137.35 47.52 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.62 -0.929 . . . . 0.0 109.431 179.507 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 30.2 m -138.73 156.49 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.916 0 O-C-N 121.518 -0.739 . . . . 0.0 109.82 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.86 145.54 42.69 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.508 -0.745 . . . . 0.0 110.314 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 10.3 ptmm? -68.71 -13.79 62.6 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.597 -0.69 . . . . 0.0 110.064 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -67.21 -35.99 80.77 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.195 -0.941 . . . . 0.0 110.149 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.424 ' O ' ' OD1' ' A' ' 8' ' ' ASN . 75.7 m-85 -92.14 1.33 57.27 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.079 -1.013 . . . . 0.0 109.602 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.0 mm -113.68 125.49 70.96 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.561 -0.712 . . . . 0.0 109.601 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -142.42 169.83 16.85 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.477 -0.765 . . . . 0.0 109.856 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 47.9 t0 62.28 52.38 3.14 Favored 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.575 0.703 . . . . 0.0 109.787 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt . . . . . 0 N--CA 1.488 1.466 0 O-C-N 121.463 -0.773 . . . . 0.0 109.188 179.571 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 64.5 mttp . . . . . 0 N--CA 1.494 1.77 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 10.1 p -122.86 114.45 20.5 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.506 -0.746 . . . . 0.0 109.315 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -97.3 141.42 15.6 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.437 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.4 mm -94.71 119.48 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.381 -1.07 . . . . 0.0 109.225 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.3 t -79.04 125.1 38.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.305 -0.872 . . . . 0.0 109.774 -179.478 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.4 t30 -105.52 94.95 5.48 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.453 -0.779 . . . . 0.0 109.387 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.616 HG22 ' H ' ' A' ' 11' ' ' SER . 2.2 p -144.42 135.49 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.361 -0.837 . . . . 0.0 109.174 179.474 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 77.3 p -84.71 -13.73 50.51 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.558 -0.714 . . . . 0.0 109.562 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.616 ' H ' HG22 ' A' ' 9' ' ' VAL . 66.3 m -117.44 -89.26 0.59 Allowed 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.463 -0.773 . . . . 0.0 109.841 -179.686 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.9 p -158.58 163.51 36.93 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.914 -1.116 . . . . 0.0 109.751 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 40.2 tp -120.52 131.21 54.59 Favored 'General case' 0 N--CA 1.498 1.968 0 CA-C-O 121.666 0.746 . . . . 0.0 109.626 179.74 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -87.04 146.61 26.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.457 -0.777 . . . . 0.0 109.82 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 74.3 t -104.98 129.0 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.455 -0.778 . . . . 0.0 109.125 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.67 HH22 ' N ' ' A' ' 57' ' ' ALA . 0.6 OUTLIER -107.87 138.71 43.64 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.655 0.741 . . . . 0.0 109.372 -179.617 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -93.3 -21.84 19.34 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.554 -0.716 . . . . 0.0 109.35 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.493 ' C ' ' H ' ' A' ' 20' ' ' SER . . . -101.97 7.52 55.05 Favored Glycine 0 N--CA 1.497 2.748 0 N-CA-C 108.897 -1.681 . . . . 0.0 108.897 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . 56.83 3.97 0.15 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.478 -1.013 . . . . 0.0 109.392 -179.44 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.493 ' H ' ' C ' ' A' ' 18' ' ' GLY . 7.6 m -80.87 156.81 25.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.316 -0.865 . . . . 0.0 110.327 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.456 ' O ' ' CB ' ' A' ' 22' ' ' SER . 43.1 p -61.29 101.53 0.17 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.531 -0.731 . . . . 0.0 110.171 -179.852 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.456 ' CB ' ' O ' ' A' ' 21' ' ' THR . 0.7 OUTLIER 79.06 27.65 0.41 Allowed 'General case' 0 N--CA 1.496 1.852 0 CA-C-O 121.639 0.733 . . . . 0.0 109.519 179.587 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.42 ' O ' ' O ' ' A' ' 22' ' ' SER . 0.2 OUTLIER -56.64 -159.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.915 0.864 . . . . 0.0 110.763 -179.747 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 38.1 ttmt -64.32 128.6 36.51 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.616 0.722 . . . . 0.0 109.785 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 91.1 t -92.14 115.26 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 CA-C-O 121.58 0.705 . . . . 0.0 109.277 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.9 pt -103.66 -3.98 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.7 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.57 -163.11 36.73 Favored Glycine 0 N--CA 1.488 2.15 0 C-N-CA 119.405 -1.378 . . . . 0.0 110.53 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.5 p -154.02 163.54 39.91 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.311 -1.111 . . . . 0.0 109.221 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.2 mt -124.63 146.39 49.11 Favored 'General case' 0 N--CA 1.497 1.9 0 CA-C-O 121.725 0.774 . . . . 0.0 110.013 -179.477 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.412 ' C ' ' HG1' ' A' ' 33' ' ' THR . 12.9 m -83.32 162.12 21.21 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-O 121.837 0.827 . . . . 0.0 110.404 -179.533 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.478 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -65.45 158.35 46.35 Favored Glycine 0 N--CA 1.49 2.296 0 CA-C-O 121.817 0.676 . . . . 0.0 111.583 -179.467 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 59.43 0.04 0.19 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.966 -0.726 . . . . 0.0 110.032 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.478 ' H ' ' C ' ' A' ' 31' ' ' GLY . 30.2 m -72.09 140.88 49.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.244 -0.91 . . . . 0.0 110.505 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -87.41 144.74 26.6 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.528 -0.733 . . . . 0.0 109.592 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.6 m -125.87 132.1 71.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 121.456 -0.777 . . . . 0.0 109.96 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 26.6 m -73.11 104.06 4.06 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.68 -0.637 . . . . 0.0 109.362 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.3 mt -101.73 131.1 50.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.553 0.692 . . . . 0.0 109.521 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.612 HG23 ' N ' ' A' ' 39' ' ' GLY . 23.8 m -140.32 -46.51 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.612 ' N ' HG23 ' A' ' 38' ' ' VAL . . . -95.41 164.74 24.59 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -179.338 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.447 ' CD ' ' N ' ' A' ' 41' ' ' GLU . 15.8 tm-20 -135.28 146.0 48.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.369 -1.077 . . . . 0.0 109.594 179.63 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.447 ' N ' ' CD ' ' A' ' 40' ' ' GLU . 84.4 tt0 -153.57 109.1 3.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.458 -0.776 . . . . 0.0 109.408 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.401 ' C ' ' H ' ' A' ' 44' ' ' PHE . . . 48.58 -142.28 8.76 Favored Glycine 0 N--CA 1.494 2.509 0 CA-C-O 121.967 0.759 . . . . 0.0 111.269 179.175 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -81.9 28.51 0.42 Allowed 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.435 -1.038 . . . . 0.0 108.738 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.401 ' H ' ' C ' ' A' ' 42' ' ' GLY . 91.0 m-85 -134.01 140.22 46.56 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.516 -0.74 . . . . 0.0 109.137 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -100.7 142.81 31.64 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.495 -0.753 . . . . 0.0 109.276 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.615 ' HZ3' ' CG ' ' A' ' 53' ' ' HIS . 65.1 tttm -90.45 129.03 36.68 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -179.582 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.0 pt -126.57 152.24 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 CA-C-O 121.699 0.761 . . . . 0.0 110.164 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -84.39 92.2 7.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.511 -0.743 . . . . 0.0 109.658 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -79.3 142.11 36.43 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.331 -0.856 . . . . 0.0 110.134 -179.504 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -58.18 96.46 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.547 -0.721 . . . . 0.0 110.408 -179.058 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 123.19 -35.83 3.25 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.459 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 67.8 p -158.96 -162.96 1.15 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.986 -1.302 . . . . 0.0 109.759 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.615 ' CG ' ' HZ3' ' A' ' 46' ' ' LYS . 97.5 m-70 -106.31 118.26 36.18 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.492 -0.755 . . . . 0.0 109.347 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.15 162.39 22.8 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -126.54 136.56 52.73 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.526 -0.985 . . . . 0.0 109.514 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.8 m -133.67 137.15 53.21 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 CA-C-O 121.477 0.656 . . . . 0.0 109.619 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.67 ' N ' HH22 ' A' ' 16' ' ' ARG . . . -68.85 147.21 52.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.395 -0.816 . . . . 0.0 110.352 -179.61 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.4 mtmp? -63.8 -9.03 12.51 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.567 -0.708 . . . . 0.0 109.736 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -68.83 -35.99 77.64 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.108 -0.995 . . . . 0.0 110.096 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -92.96 4.99 53.0 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.052 -1.03 . . . . 0.0 109.203 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 44.8 mm -103.88 129.16 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.39 -0.819 . . . . 0.0 109.513 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 26.2 ttpp -149.88 157.34 43.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.306 -0.872 . . . . 0.0 110.439 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 55.81 52.97 9.98 Favored 'General case' 0 N--CA 1.49 1.57 0 CA-C-O 121.59 0.709 . . . . 0.0 109.498 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt . . . . . 0 N--CA 1.489 1.487 0 O-C-N 121.497 -0.752 . . . . 0.0 109.554 179.904 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.4 mttm . . . . . 0 N--CA 1.494 1.754 0 N-CA-C 109.592 -0.521 . . . . 0.0 109.592 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 67.2 p -134.22 152.32 51.76 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.569 -0.707 . . . . 0.0 109.476 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -135.1 128.67 4.83 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.75 ' N ' HD12 ' A' ' 6' ' ' ILE . 2.0 mp -81.99 124.52 39.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.669 -0.901 . . . . 0.0 109.579 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 91.8 t -85.33 116.75 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.506 -0.746 . . . . 0.0 109.732 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.403 HD22 ' HD3' ' A' ' 62' ' ' LYS . 98.0 m-20 -110.19 107.38 17.15 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.521 -0.737 . . . . 0.0 109.663 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 14.9 m -139.33 156.72 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.386 -0.821 . . . . 0.0 109.616 179.183 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 82.0 p -73.18 -13.81 61.23 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.502 ' OG ' ' N ' ' A' ' 12' ' ' SER . 77.0 p -152.95 -118.61 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.327 -0.858 . . . . 0.0 110.096 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.502 ' N ' ' OG ' ' A' ' 11' ' ' SER . 21.5 m -101.37 161.26 13.75 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.382 -0.824 . . . . 0.0 110.246 -178.835 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 61.6 tp -120.99 133.4 55.27 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.632 0.729 . . . . 0.0 109.653 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -88.95 129.46 35.62 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.633 -0.667 . . . . 0.0 109.866 179.778 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 80.7 t -89.89 132.56 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.423 -0.798 . . . . 0.0 109.23 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -101.69 134.08 45.39 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.421 -0.799 . . . . 0.0 110.533 -178.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 11.4 tm-20 -69.21 -43.18 74.61 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.315 0.578 . . . . 0.0 109.548 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -101.42 -178.48 28.59 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -178.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -93.24 -2.22 55.34 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.591 -0.947 . . . . 0.0 109.365 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.7 m -82.37 150.79 26.97 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.187 -0.946 . . . . 0.0 110.368 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.458 ' C ' ' H ' ' A' ' 23' ' ' SER . 19.0 m -64.91 -45.4 86.05 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.501 -0.75 . . . . 0.0 109.534 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 8.7 t -77.24 24.39 0.18 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.607 -0.683 . . . . 0.0 109.161 -179.562 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.458 ' H ' ' C ' ' A' ' 21' ' ' THR . 14.8 m -71.18 151.14 44.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.477 -0.764 . . . . 0.0 110.291 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -73.37 136.65 44.39 Favored 'General case' 0 N--CA 1.491 1.582 0 CA-C-O 121.789 0.804 . . . . 0.0 110.995 -179.181 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 82.2 t -85.62 131.58 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 CA-C-O 121.372 0.605 . . . . 0.0 109.822 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.403 HG13 ' N ' ' A' ' 27' ' ' GLY . 8.4 pt -125.33 -44.31 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.722 -0.611 . . . . 0.0 109.378 179.779 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.403 ' N ' HG13 ' A' ' 26' ' ' ILE . . . -101.29 171.89 22.71 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 -178.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.8 p -158.42 155.58 28.86 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.583 -0.951 . . . . 0.0 109.55 179.072 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 91.9 mt -133.92 150.57 51.32 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.452 -0.78 . . . . 0.0 109.72 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.9 t -82.11 -1.53 49.02 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.497 ' C ' ' H ' ' A' ' 33' ' ' THR . . . 97.83 164.83 31.52 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.272 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 52.78 5.22 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.746 -0.855 . . . . 0.0 110.014 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.497 ' H ' ' C ' ' A' ' 31' ' ' GLY . 24.9 m -78.9 141.44 37.61 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.101 -0.999 . . . . 0.0 110.312 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -88.74 132.99 34.37 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.643 -0.661 . . . . 0.0 109.493 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.7 m -124.12 133.79 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 CA-C-O 121.785 0.802 . . . . 0.0 109.854 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 5.8 p -76.8 133.92 39.25 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.722 -0.611 . . . . 0.0 110.141 -179.397 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.0 mt -111.54 128.9 67.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 121.448 0.642 . . . . 0.0 109.362 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 29.7 m -111.21 -3.34 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -174.99 175.92 47.1 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.662 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -136.51 153.44 51.02 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.667 -0.902 . . . . 0.0 109.46 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -155.11 113.19 3.45 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.195 -0.94 . . . . 0.0 109.996 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 57.48 -137.52 49.38 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 178.695 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.9 24.2 2.86 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.602 -0.94 . . . . 0.0 109.073 -179.258 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -133.2 147.54 52.01 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.576 -0.702 . . . . 0.0 109.571 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 24.9 m-85 -106.35 147.93 28.65 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.559 -0.713 . . . . 0.0 109.782 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -95.53 124.9 39.79 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 13.8 pt -131.51 154.26 40.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 CA-C-O 121.762 0.791 . . . . 0.0 110.217 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -90.89 106.29 18.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.695 -0.628 . . . . 0.0 109.958 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 88.7 t80 -112.45 115.37 28.57 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.572 0.701 . . . . 0.0 109.172 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.1 mmtp 52.27 31.07 8.73 Favored 'General case' 0 N--CA 1.493 1.689 0 CA-C-O 121.3 0.571 . . . . 0.0 110.193 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 85.64 -11.22 62.27 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 178.759 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 38.4 t -90.2 170.05 10.62 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.25 -1.147 . . . . 0.0 110.203 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -100.28 93.41 5.67 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.429 -0.794 . . . . 0.0 109.231 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.26 136.1 12.73 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.696 -1.361 . . . . 0.0 109.696 -179.649 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -112.95 138.58 49.59 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.689 -0.889 . . . . 0.0 109.562 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.1 m -135.89 156.13 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.544 -0.723 . . . . 0.0 109.997 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.548 ' HB3' ' CE2' ' A' ' 60' ' ' TYR . . . -69.21 152.06 45.55 Favored 'General case' 0 N--CA 1.491 1.588 0 CA-C-O 121.76 0.791 . . . . 0.0 110.767 -179.374 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 60' ' ' TYR . 47.9 mtmt -63.41 -38.69 92.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.698 -0.626 . . . . 0.0 109.49 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -49.64 -7.42 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.401 -0.812 . . . . 0.0 110.222 -179.382 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.548 ' CE2' ' HB3' ' A' ' 57' ' ' ALA . 59.0 m-85 -105.26 -25.05 12.59 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.289 -0.882 . . . . 0.0 109.236 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.629 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.5 mp -89.13 129.09 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.365 -0.835 . . . . 0.0 109.828 -179.51 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.403 ' HD3' HD22 ' A' ' 8' ' ' ASN . 65.2 tttm -146.37 152.55 39.27 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.546 -0.721 . . . . 0.0 109.857 179.228 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 57.47 57.11 4.55 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.496 0.665 . . . . 0.0 109.803 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.9 mt . . . . . 0 N--CA 1.489 1.48 0 O-C-N 121.382 -0.824 . . . . 0.0 109.533 179.902 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 62.9 mttp . . . . . 0 N--CA 1.497 1.88 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.0 p -126.8 126.65 43.76 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.519 -0.738 . . . . 0.0 109.23 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLY . . . . . 0.459 ' C ' HD12 ' A' ' 6' ' ' ILE . . . -94.32 130.58 10.36 Favored Glycine 0 N--CA 1.495 2.611 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.694 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.5 mp -93.64 120.5 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.294 -1.121 . . . . 0.0 109.392 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 70.7 t -76.34 132.91 32.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.427 -0.796 . . . . 0.0 109.335 179.47 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -134.87 85.82 2.21 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.439 -0.788 . . . . 0.0 109.246 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.3 m -130.73 132.97 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.578 -0.701 . . . . 0.0 109.52 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 46.7 m -62.42 -41.56 98.79 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.453 -0.779 . . . . 0.0 109.907 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.42 ' OG ' ' N ' ' A' ' 12' ' ' SER . 77.6 p -91.81 -82.09 0.32 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.216 -0.928 . . . . 0.0 109.628 -179.399 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.42 ' N ' ' OG ' ' A' ' 11' ' ' SER . 43.1 t -165.98 167.25 16.76 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.383 -0.823 . . . . 0.0 109.111 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 51.0 tp -119.87 132.45 55.57 Favored 'General case' 0 N--CA 1.498 1.97 0 CA-C-O 121.595 0.712 . . . . 0.0 109.61 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -91.28 152.79 20.34 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.628 -0.67 . . . . 0.0 109.858 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.3 t -103.41 131.02 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.702 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 92.1 mtm-85 -110.5 134.69 52.13 Favored 'General case' 0 N--CA 1.492 1.664 0 CA-C-O 121.689 0.757 . . . . 0.0 110.178 -179.569 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -70.91 -36.4 72.68 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.716 -0.615 . . . . 0.0 109.487 179.594 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.54 -175.88 31.21 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -179.191 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -109.24 24.48 13.05 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.6 -0.941 . . . . 0.0 108.723 179.594 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.462 ' OG ' ' OG ' ' A' ' 23' ' ' SER . 6.4 p -83.84 171.49 13.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 110.201 -179.524 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 15.9 m -62.72 -43.51 98.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.53 -0.731 . . . . 0.0 109.417 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.8 p -136.12 66.18 1.5 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.457 -0.777 . . . . 0.0 108.956 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.462 ' OG ' ' OG ' ' A' ' 20' ' ' SER . 1.9 m -77.26 -178.08 4.92 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.866 0.841 . . . . 0.0 110.353 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -63.67 139.14 58.74 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.663 0.744 . . . . 0.0 110.656 -179.44 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 65.6 t -98.27 124.95 51.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.439 -0.788 . . . . 0.0 108.924 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 40.1 pt -104.65 -4.1 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.61 -0.681 . . . . 0.0 109.272 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.81 -168.22 41.23 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.191 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 40.3 t -153.87 154.61 34.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.51 -0.994 . . . . 0.0 109.353 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.7 mt -123.67 151.39 43.14 Favored 'General case' 0 N--CA 1.497 1.923 0 CA-C-O 121.566 0.698 . . . . 0.0 109.652 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.7 t -79.17 166.62 22.02 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.627 0.727 . . . . 0.0 110.606 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -64.79 158.55 44.12 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -179.234 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 66.8 m-20 57.39 32.94 22.57 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.711 -0.876 . . . . 0.0 109.685 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.2 m -94.53 129.07 41.48 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.281 -0.887 . . . . 0.0 109.456 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -82.92 132.82 35.14 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.426 -0.796 . . . . 0.0 109.822 -179.735 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 m -127.23 134.52 65.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 O-C-N 121.535 -0.728 . . . . 0.0 109.498 179.692 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 33.6 m -78.49 129.31 34.73 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.462 -0.774 . . . . 0.0 109.732 -179.346 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.3 mt -106.7 126.03 62.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.593 -0.692 . . . . 0.0 109.612 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 28.5 m -118.77 8.48 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.469 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.03 174.47 45.89 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -135.28 155.64 50.3 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.372 -1.075 . . . . 0.0 109.904 -179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.417 ' O ' ' O ' ' A' ' 44' ' ' PHE . 76.3 mm-40 -138.86 153.65 48.34 Favored 'General case' 0 N--CA 1.494 1.73 0 CA-C-O 121.435 0.636 . . . . 0.0 109.759 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.663 ' O ' ' HB3' ' A' ' 43' ' ' ALA . . . -64.36 108.02 2.09 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.124 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.663 ' HB3' ' O ' ' A' ' 42' ' ' GLY . . . 80.67 4.03 1.69 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.663 -0.904 . . . . 0.0 109.151 179.488 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.417 ' O ' ' O ' ' A' ' 41' ' ' GLU . 95.6 m-85 -149.39 159.6 44.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 109.736 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -118.25 147.45 43.41 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.435 ' HZ2' ' HB3' ' A' ' 53' ' ' HIS . 0.1 OUTLIER -91.6 118.1 30.32 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 179.674 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.6 pt -126.57 153.13 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 CA-C-O 121.644 0.735 . . . . 0.0 109.702 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -86.06 118.2 25.38 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.531 -0.731 . . . . 0.0 109.61 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.55 ' O ' ' N ' ' A' ' 51' ' ' GLY . 89.6 t80 -111.58 121.7 45.86 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.554 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.418 ' C ' ' O ' ' A' ' 49' ' ' TYR . 37.3 ttpt 39.52 -90.38 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.261 0.553 . . . . 0.0 110.311 -179.669 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -130.2 -22.64 1.09 Allowed Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.914 -1.675 . . . . 0.0 108.914 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 22.5 m -91.19 163.41 14.27 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.217 -1.167 . . . . 0.0 110.532 -179.355 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.435 ' HB3' ' HZ2' ' A' ' 46' ' ' LYS . 56.9 m170 -83.37 113.12 20.52 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.382 -0.824 . . . . 0.0 109.357 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.64 141.95 15.83 Favored Glycine 0 N--CA 1.495 2.576 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -120.81 139.54 52.99 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.672 -0.899 . . . . 0.0 109.427 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.4 m -132.57 137.83 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.662 -0.649 . . . . 0.0 109.525 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.702 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -61.48 143.72 55.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.548 -0.72 . . . . 0.0 110.805 -179.02 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -66.76 -12.31 58.22 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.505 -0.747 . . . . 0.0 109.899 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 47.3 tp10 -67.15 -36.54 82.06 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.169 -0.957 . . . . 0.0 110.256 -179.494 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -95.62 -5.03 43.39 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.173 -0.955 . . . . 0.0 109.842 -178.879 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 36.5 mm -110.22 128.94 66.07 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 O-C-N 121.511 -0.743 . . . . 0.0 109.37 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.43 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 21.2 ptmt -140.45 173.23 11.7 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.546 -0.721 . . . . 0.0 110.266 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.43 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 14.7 t0 77.36 -72.21 0.1 Allowed 'General case' 0 N--CA 1.495 1.781 0 CA-C-O 121.114 0.483 . . . . 0.0 109.748 179.644 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 27.3 mt . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.624 -0.673 . . . . 0.0 109.332 -179.651 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt . . . . . 0 N--CA 1.496 1.828 0 CA-C-O 121.633 0.73 . . . . 0.0 109.889 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 44.1 p -115.72 121.78 43.52 Favored 'General case' 0 N--CA 1.499 1.987 0 CA-C-O 121.833 0.825 . . . . 0.0 109.79 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -100.79 142.27 15.73 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.594 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 22.6 mm -92.69 120.89 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 CA-C-O 121.684 0.754 . . . . 0.0 109.378 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.2 t -80.58 105.03 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 CA-C-O 121.668 0.746 . . . . 0.0 109.59 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.42 HD21 ' HA ' ' A' ' 8' ' ' ASN . 3.0 t-20 -99.43 103.88 15.7 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-O 121.747 0.784 . . . . 0.0 109.61 179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 26.8 m -137.93 160.58 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 CA-C-O 121.727 0.775 . . . . 0.0 109.918 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 88.0 p -85.73 -12.83 50.15 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.0 m -142.1 -76.01 0.28 Allowed 'General case' 0 N--CA 1.497 1.884 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 25.9 p -155.81 166.56 33.12 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.518 -0.739 . . . . 0.0 109.735 -179.385 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.8 tp -114.18 133.1 55.83 Favored 'General case' 0 N--CA 1.496 1.849 0 CA-C-O 121.841 0.829 . . . . 0.0 110.34 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -91.29 142.3 27.85 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-O 121.719 0.771 . . . . 0.0 109.991 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.9 t -99.11 129.51 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 CA-C-O 121.634 0.731 . . . . 0.0 109.662 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.7 mtt85 -92.87 153.44 18.82 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 121.793 0.806 . . . . 0.0 110.049 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -64.68 -44.37 90.58 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 19' ' ' ALA . . . -157.88 102.92 0.22 Allowed Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.614 ' H ' ' CB ' ' A' ' 55' ' ' TYR . . . 38.8 -114.51 0.14 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 122.001 -0.705 . . . . 0.0 110.292 179.476 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 19' ' ' ALA . 4.9 m 56.35 152.53 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 121.8 0.81 . . . . 0.0 110.508 179.678 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 97.8 m -67.82 -45.5 74.53 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.822 -0.549 . . . . 0.0 109.907 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 39.5 p -153.05 61.05 0.78 Allowed 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 121.836 0.827 . . . . 0.0 109.222 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 5.2 p -75.04 -171.38 1.34 Allowed 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.76 0.79 . . . . 0.0 110.634 179.583 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt -66.29 142.91 57.5 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-O 121.743 0.782 . . . . 0.0 110.411 -178.83 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 68.4 t -98.52 127.31 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 CA-C-O 121.732 0.777 . . . . 0.0 109.305 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 27.8 pt -103.26 -4.12 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 173.34 -173.9 45.86 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 24.1 p -154.35 161.69 41.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.81 -0.818 . . . . 0.0 109.711 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.8 mt -126.99 151.49 48.51 Favored 'General case' 0 N--CA 1.499 2.007 0 CA-C-O 121.947 0.879 . . . . 0.0 109.984 -179.665 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.412 ' O ' ' OG1' ' A' ' 33' ' ' THR . 84.1 p -72.7 165.87 23.94 Favored 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 121.812 0.815 . . . . 0.0 110.261 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.479 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.85 165.02 45.63 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 56.33 2.88 0.09 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 122.335 -0.509 . . . . 0.0 110.116 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.479 ' H ' ' C ' ' A' ' 31' ' ' GLY . 47.5 m -71.24 136.14 47.83 Favored 'General case' 0 N--CA 1.496 1.851 0 CA-C-O 121.916 0.865 . . . . 0.0 110.391 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -88.9 143.04 27.15 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.34 0.591 . . . . 0.0 109.866 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 35.4 m -126.26 130.46 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 CA-C-O 121.821 0.82 . . . . 0.0 110.08 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 82.7 m -80.01 125.7 30.11 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.517 0.675 . . . . 0.0 109.739 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.6 mt -104.87 128.09 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 CA-C-O 121.554 0.693 . . . . 0.0 109.83 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.8 m -123.92 7.5 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.488 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.04 169.6 42.75 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -129.84 152.77 48.95 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.789 -0.83 . . . . 0.0 109.553 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 53.3 tp10 -153.29 108.33 3.19 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.936 0.874 . . . . 0.0 110.068 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 49.73 -138.14 20.1 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 178.645 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -84.67 20.3 1.79 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 122.005 -0.703 . . . . 0.0 109.226 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -128.35 151.0 49.85 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-O 121.688 0.756 . . . . 0.0 109.582 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 51.9 m-85 -102.98 141.87 35.04 Favored 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.945 0.878 . . . . 0.0 109.968 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 65.4 tttm -94.29 122.53 36.93 Favored 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.493 0.663 . . . . 0.0 109.384 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 34.6 pt -129.25 154.99 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 CA-C-O 121.806 0.813 . . . . 0.0 110.316 179.839 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -83.45 114.4 21.44 Favored 'General case' 0 N--CA 1.494 1.73 0 CA-C-O 121.568 0.699 . . . . 0.0 109.915 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.569 ' O ' ' N ' ' A' ' 51' ' ' GLY . 86.1 t80 -106.28 114.85 29.22 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.694 0.759 . . . . 0.0 109.588 179.77 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.1 mttp 40.96 -87.54 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.754 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.105 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -115.63 -39.38 0.92 Allowed Glycine 0 N--CA 1.495 2.58 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 16.7 p -89.54 169.37 11.41 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.804 -0.821 . . . . 0.0 110.45 -179.184 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 96.0 m-70 -96.52 111.19 23.4 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.914 0.864 . . . . 0.0 109.952 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.64 144.08 23.97 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.614 ' CB ' ' H ' ' A' ' 19' ' ' ALA . 75.8 m-85 -119.63 135.76 54.67 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-O 121.751 0.786 . . . . 0.0 109.515 179.346 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 20.1 m -137.38 156.12 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 CA-C-O 121.913 0.863 . . . . 0.0 110.318 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.07 154.36 33.42 Favored 'General case' 0 N--CA 1.492 1.667 0 CA-C-O 121.681 0.753 . . . . 0.0 110.107 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -69.67 -17.6 63.5 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.529 ' OE2' ' CE2' ' A' ' 60' ' ' TYR . 9.7 pt-20 -65.0 -34.92 79.58 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.786 -0.572 . . . . 0.0 109.893 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.529 ' CE2' ' OE2' ' A' ' 59' ' ' GLU . 66.8 m-85 -91.98 -10.16 40.33 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.451 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 36.0 mm -110.46 120.73 61.94 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.121 0 CA-C-O 121.847 0.832 . . . . 0.0 110.021 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -149.72 173.47 13.67 Favored 'General case' 0 N--CA 1.494 1.734 0 CA-C-O 121.616 0.722 . . . . 0.0 110.21 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 57.6 47.98 15.01 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 121.353 0.596 . . . . 0.0 109.405 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt . . . . . 0 N--CA 1.495 1.788 0 CA-C-O 121.699 0.762 . . . . 0.0 110.055 -179.647 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.5 mttt . . . . . 0 N--CA 1.496 1.83 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 70.4 p -127.73 131.14 49.73 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.524 -0.735 . . . . 0.0 109.144 179.644 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -120.02 135.18 10.91 Favored Glycine 0 N--CA 1.5 2.918 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.757 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.9 mp -86.72 129.02 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.434 -1.039 . . . . 0.0 109.675 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.3 t -82.13 104.8 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.181 -0.949 . . . . 0.0 109.665 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -108.29 106.45 16.61 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.481 -0.762 . . . . 0.0 109.054 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 27.7 m -138.47 162.4 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.27 -0.894 . . . . 0.0 110.016 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 t -61.99 -43.57 98.55 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.55 -0.719 . . . . 0.0 109.46 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 12' ' ' SER . 70.5 m -161.09 108.9 1.52 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.006 -1.059 . . . . 0.0 110.262 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 11' ' ' SER . 22.7 t 54.0 159.19 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.849 0.833 . . . . 0.0 111.509 179.126 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 35.1 tp -133.22 133.03 42.19 Favored 'General case' 0 N--CA 1.498 1.971 0 CA-C-O 121.485 0.66 . . . . 0.0 109.652 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 46.0 p-10 -80.69 141.81 34.52 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.391 -0.818 . . . . 0.0 109.914 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 78.2 t -93.45 133.12 35.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.201 -0.937 . . . . 0.0 109.666 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -102.38 130.54 49.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.384 -0.823 . . . . 0.0 109.909 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -73.75 -41.31 62.67 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.468 -0.77 . . . . 0.0 109.763 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.479 ' O ' ' CG ' ' A' ' 55' ' ' TYR . . . -95.93 -129.42 5.96 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.934 -1.266 . . . . 0.0 109.934 -179.111 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -137.13 -12.85 1.63 Allowed 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.519 -0.989 . . . . 0.0 109.073 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 12.0 m -72.72 152.36 41.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.198 -0.939 . . . . 0.0 110.688 -179.094 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.7 m -63.15 -46.08 88.87 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.376 -0.828 . . . . 0.0 109.34 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 58.7 m -88.75 34.74 0.77 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.152 -0.967 . . . . 0.0 108.604 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.2 p -73.78 161.95 29.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.405 -0.81 . . . . 0.0 110.376 -179.2 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -66.28 136.11 55.37 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.348 -0.845 . . . . 0.0 110.299 -179.307 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 53.4 t -100.72 127.98 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.416 -0.802 . . . . 0.0 109.355 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.5 pt -101.11 -3.07 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.04 -164.22 37.6 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.458 -1.353 . . . . 0.0 110.325 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 40.4 t -155.31 158.87 39.43 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.268 -1.136 . . . . 0.0 109.373 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.0 mt -122.96 149.96 43.59 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.508 -0.745 . . . . 0.0 109.769 -179.693 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 29.6 t -69.23 154.62 41.75 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-O 121.834 0.826 . . . . 0.0 111.02 -178.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.46 157.25 37.53 Favored Glycine 0 N--CA 1.492 2.413 0 O-C-N 121.637 -0.664 . . . . 0.0 111.475 -179.418 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.3 t-20 58.75 33.88 23.37 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.809 -0.818 . . . . 0.0 109.741 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.7 m -97.02 129.52 44.46 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.314 -0.866 . . . . 0.0 109.594 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 54.1 tttp -79.8 131.13 35.82 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.352 -0.843 . . . . 0.0 109.344 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 21.6 m -128.77 136.6 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.392 -0.817 . . . . 0.0 109.697 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 18.8 m -80.99 129.46 34.54 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.613 -0.679 . . . . 0.0 109.586 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.6 mt -110.45 129.56 65.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.686 -0.633 . . . . 0.0 109.446 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.583 HG23 ' N ' ' A' ' 39' ' ' GLY . 24.4 m -128.62 -49.37 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.583 ' N ' HG23 ' A' ' 38' ' ' VAL . . . -91.57 166.84 30.64 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 -179.112 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -139.0 146.87 41.42 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.337 -1.096 . . . . 0.0 109.559 179.572 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.5 tm-20 -154.31 110.02 3.19 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.321 -0.862 . . . . 0.0 109.07 179.387 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 53.13 -138.82 34.79 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 111.044 -0.822 . . . . 0.0 111.044 179.186 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.02 10.65 13.57 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.366 -1.079 . . . . 0.0 109.113 -179.411 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -111.62 144.45 40.85 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.502 -0.748 . . . . 0.0 109.447 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 47.2 m-85 -104.03 141.33 36.38 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.544 -0.723 . . . . 0.0 109.702 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -90.28 137.91 31.96 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.266 -0.897 . . . . 0.0 108.751 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 17.3 pt -127.81 154.38 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.0 0 O-C-N 121.468 -0.77 . . . . 0.0 110.087 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 50.8 tp10 -82.95 106.87 15.13 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.532 ' O ' ' N ' ' A' ' 51' ' ' GLY . 80.1 t80 -109.21 124.69 51.27 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.52 -0.737 . . . . 0.0 110.134 -179.722 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.443 ' C ' ' O ' ' A' ' 49' ' ' TYR . 67.8 mttm 33.62 -88.97 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.103 0.478 . . . . 0.0 111.246 179.504 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -119.83 -29.3 1.71 Allowed Glycine 0 N--CA 1.498 2.807 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 -179.251 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 66.6 m -100.58 176.86 5.18 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.088 -1.242 . . . . 0.0 110.478 -179.276 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -107.68 119.91 40.75 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.527 -0.733 . . . . 0.0 109.682 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.7 159.03 25.56 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.479 ' CG ' ' O ' ' A' ' 18' ' ' GLY . 91.0 m-85 -115.98 137.32 52.22 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.444 -1.033 . . . . 0.0 109.64 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.8 m -136.11 137.19 48.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.627 -0.671 . . . . 0.0 109.431 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.32 148.08 51.25 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.498 -0.751 . . . . 0.0 110.611 -179.278 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.3 ptpm? -62.84 -16.55 58.92 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.376 -0.827 . . . . 0.0 109.368 179.511 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -67.58 -35.84 79.77 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.292 -0.88 . . . . 0.0 109.89 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -92.34 -5.02 53.01 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.018 -1.051 . . . . 0.0 109.236 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 36.7 mm -112.11 123.87 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 121.374 -0.829 . . . . 0.0 109.21 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 20.5 ptmt -141.63 171.17 14.43 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.479 -0.763 . . . . 0.0 110.068 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 58.72 40.86 22.73 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-O 121.477 0.656 . . . . 0.0 109.487 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt . . . . . 0 N--CA 1.493 1.708 0 O-C-N 121.285 -0.884 . . . . 0.0 110.042 -179.95 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 99.1 mttt . . . . . 0 N--CA 1.497 1.923 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.448 ' CB ' ' HZ1' ' A' ' 34' ' ' LYS . 59.2 p -128.41 124.78 37.14 Favored 'General case' 0 N--CA 1.497 1.893 0 CA-C-O 121.643 0.735 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLY . . . . . 0.454 ' C ' HD12 ' A' ' 6' ' ' ILE . . . -99.91 137.25 13.15 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -179.745 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.776 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.8 mp -93.95 119.16 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.536 -0.979 . . . . 0.0 109.673 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 71.9 t -79.09 133.2 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 CA-C-O 121.494 0.664 . . . . 0.0 109.791 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.533 ' CB ' ' NZ ' ' A' ' 62' ' ' LYS . 4.0 t-20 -140.34 106.98 5.33 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.404 -0.81 . . . . 0.0 109.648 -179.813 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 m -138.3 151.68 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.603 -0.686 . . . . 0.0 109.634 179.8 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 73.5 m -72.26 -42.9 65.06 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 121.477 0.656 . . . . 0.0 109.828 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 69.0 m -103.85 -76.67 0.59 Allowed 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.446 -0.784 . . . . 0.0 109.625 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 41.2 t -160.03 168.27 25.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.325 -0.86 . . . . 0.0 109.687 -179.565 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 41.8 tp -116.58 130.21 56.62 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 121.592 0.71 . . . . 0.0 109.984 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -91.92 138.38 31.59 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.771 0.796 . . . . 0.0 110.158 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.3 t -89.5 130.01 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 CA-C-O 121.497 0.665 . . . . 0.0 109.802 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.425 ' NH1' HG23 ' A' ' 25' ' ' VAL . 38.4 mmt180 -107.67 131.15 54.71 Favored 'General case' 0 N--CA 1.496 1.835 0 CA-C-O 121.872 0.844 . . . . 0.0 109.565 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -71.22 -40.18 71.27 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-O 121.532 0.682 . . . . 0.0 109.549 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.502 ' N ' ' OG ' ' A' ' 23' ' ' SER . . . -93.69 177.09 37.07 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.34 39.51 0.87 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.501 -0.999 . . . . 0.0 109.104 179.744 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.9 p -151.91 154.88 36.97 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.398 -0.814 . . . . 0.0 109.686 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.404 ' O ' ' CZ ' ' A' ' 16' ' ' ARG . 60.5 p -71.29 -28.03 63.84 Favored 'General case' 0 N--CA 1.493 1.724 0 CA-C-O 121.675 0.75 . . . . 0.0 109.379 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 91.9 p -82.35 -3.71 55.94 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.502 ' OG ' ' N ' ' A' ' 18' ' ' GLY . 24.0 t -51.73 -97.08 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.619 -0.675 . . . . 0.0 110.188 -179.746 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.33 131.58 1.2 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.311 -0.868 . . . . 0.0 110.011 -179.445 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.425 HG23 ' NH1' ' A' ' 16' ' ' ARG . 84.2 t -81.67 132.17 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.73 -0.606 . . . . 0.0 109.939 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 45.0 pt -117.6 -10.28 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.69 -175.01 45.23 Favored Glycine 0 N--CA 1.494 2.554 0 C-N-CA 119.402 -1.38 . . . . 0.0 110.252 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 65.8 m -133.04 156.18 47.84 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.714 -0.874 . . . . 0.0 109.814 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 92.2 mt -122.9 147.91 46.04 Favored 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.83 0.824 . . . . 0.0 109.941 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.6 t -74.77 157.85 34.5 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-O 121.937 0.875 . . . . 0.0 110.63 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -66.6 156.52 51.04 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 57.36 33.09 22.8 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 122.075 -0.662 . . . . 0.0 109.461 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 43.3 m -94.42 125.07 38.84 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.843 0.83 . . . . 0.0 110.331 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.448 ' HZ1' ' CB ' ' A' ' 4' ' ' THR . 63.3 tttp -79.24 132.14 36.4 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-O 121.306 0.574 . . . . 0.0 109.677 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.1 m -129.5 134.13 64.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 121.804 0.811 . . . . 0.0 109.763 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 52.7 m -79.09 127.63 32.25 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-O 121.6 0.714 . . . . 0.0 109.901 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.7 mt -102.76 124.2 56.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 CA-C-O 121.499 0.666 . . . . 0.0 109.508 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.76 -0.8 9.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.3 176.31 46.0 Favored Glycine 0 N--CA 1.494 2.551 0 C-N-CA 119.681 -1.247 . . . . 0.0 110.538 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -143.94 155.3 44.01 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.65 -0.912 . . . . 0.0 109.475 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -153.27 107.28 3.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.456 -0.777 . . . . 0.0 109.78 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.3 -135.96 49.75 Favored Glycine 0 N--CA 1.493 2.493 0 CA-C-O 121.98 0.766 . . . . 0.0 111.626 178.952 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -88.28 28.19 1.12 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.554 -0.968 . . . . 0.0 109.122 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -136.11 150.26 49.03 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.641 -0.662 . . . . 0.0 109.58 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.626 ' CZ ' ' NZ ' ' A' ' 58' ' ' LYS . 12.5 m-85 -107.17 146.04 31.82 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-O 121.882 0.849 . . . . 0.0 109.925 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -98.67 124.77 43.69 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.7 pt -129.73 157.79 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 121.651 0.738 . . . . 0.0 110.187 -179.77 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -87.5 101.79 13.95 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.43 0.634 . . . . 0.0 109.811 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.8 t80 -109.85 118.64 37.03 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-O 121.618 0.723 . . . . 0.0 109.45 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.6 mmtt 51.43 29.8 5.6 Favored 'General case' 0 N--CA 1.492 1.668 0 CA-C-O 121.763 0.792 . . . . 0.0 109.754 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.97 -23.45 23.55 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 179.346 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.3 m -86.53 165.34 16.31 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.281 -1.129 . . . . 0.0 110.576 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -94.51 101.63 13.54 Favored 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 121.73 0.776 . . . . 0.0 109.667 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.1 147.93 19.9 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.742 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -115.51 134.08 55.42 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.699 -0.883 . . . . 0.0 109.425 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.6 m -136.14 139.58 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 CA-C-O 121.573 0.702 . . . . 0.0 109.902 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.53 144.71 55.75 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.889 0.852 . . . . 0.0 110.387 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.626 ' NZ ' ' CZ ' ' A' ' 45' ' ' TYR . 67.1 mttm -63.74 -36.84 85.19 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-O 121.421 0.629 . . . . 0.0 110.468 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -46.83 -16.34 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.238 -0.914 . . . . 0.0 110.675 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.45 ' N ' ' O ' ' A' ' 58' ' ' LYS . 36.1 m-85 -108.37 -30.65 8.2 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.162 -0.961 . . . . 0.0 109.132 179.488 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.627 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.5 mp -93.54 123.22 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.424 -0.798 . . . . 0.0 109.741 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.533 ' NZ ' ' CB ' ' A' ' 8' ' ' ASN . 26.6 pttm -148.78 174.73 11.89 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.585 0.707 . . . . 0.0 109.952 179.527 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.551 ' O ' HD13 ' A' ' 6' ' ' ILE . 97.5 m-20 58.11 51.28 8.87 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-O 121.68 0.752 . . . . 0.0 109.765 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.411 HD11 ' CE2' ' A' ' 45' ' ' TYR . 96.9 mt . . . . . 0 N--CA 1.494 1.757 0 O-C-N 121.51 -0.744 . . . . 0.0 109.722 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt . . . . . 0 N--CA 1.495 1.825 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 46.9 p -115.13 123.13 48.16 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.679 -0.638 . . . . 0.0 109.372 -179.673 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -96.04 131.45 10.66 Favored Glycine 0 N--CA 1.496 2.674 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.585 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.4 mp -80.81 126.41 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.332 -1.099 . . . . 0.0 109.251 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.441 HG13 HD22 ' A' ' 13' ' ' LEU . 74.9 t -80.61 132.78 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.542 -0.724 . . . . 0.0 109.645 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 24.2 t-20 -131.24 103.41 6.46 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.547 -0.721 . . . . 0.0 109.271 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 27.9 m -135.46 156.45 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.492 -0.755 . . . . 0.0 109.434 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 95.6 p -83.7 -10.96 57.8 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.488 -0.758 . . . . 0.0 109.3 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.501 ' OG ' ' N ' ' A' ' 12' ' ' SER . 86.4 p -138.37 -73.1 0.4 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.359 -0.838 . . . . 0.0 109.154 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.501 ' N ' ' OG ' ' A' ' 11' ' ' SER . 31.9 p -158.71 165.04 35.29 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.369 -0.832 . . . . 0.0 109.249 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.441 HD22 HG13 ' A' ' 7' ' ' VAL . 44.9 tp -113.83 131.47 56.23 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.482 -0.761 . . . . 0.0 109.028 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -91.07 146.43 23.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.406 -0.809 . . . . 0.0 109.885 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 65.1 t -99.3 130.1 48.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.504 ' NH1' ' O ' ' A' ' 21' ' ' THR . 93.0 mtt-85 -110.97 136.85 49.36 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.587 -0.695 . . . . 0.0 109.95 -179.346 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.5 ' OE2' HD13 ' A' ' 26' ' ' ILE . 66.3 mm-40 -80.58 -35.73 33.84 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.453 -0.779 . . . . 0.0 109.655 179.592 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -95.57 177.17 34.4 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.538 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.68 -5.42 42.31 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.402 -1.058 . . . . 0.0 109.083 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 33.5 t -86.16 153.67 21.89 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -0.852 . . . . 0.0 109.951 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.504 ' O ' ' NH1' ' A' ' 16' ' ' ARG . 15.3 m -63.67 -44.77 92.79 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.433 -0.792 . . . . 0.0 109.725 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 76.7 p -73.11 17.83 0.12 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.212 -0.93 . . . . 0.0 109.408 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.487 ' H ' ' C ' ' A' ' 21' ' ' THR . 17.3 m -64.65 149.22 49.4 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.239 -0.913 . . . . 0.0 109.788 -179.723 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 24.9 pttm -70.79 143.53 51.14 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.395 -0.815 . . . . 0.0 110.367 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 55.6 t -103.24 131.28 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.528 -0.732 . . . . 0.0 109.641 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.5 HD13 ' OE2' ' A' ' 17' ' ' GLU . 24.7 pt -99.01 -6.58 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.441 -0.787 . . . . 0.0 109.538 179.712 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.3 -159.81 33.27 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.8 m -152.92 167.11 30.23 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.436 -1.037 . . . . 0.0 109.571 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.9 mt -127.23 153.89 45.53 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.525 -0.734 . . . . 0.0 109.576 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.6 p -73.25 162.08 29.79 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.505 -0.747 . . . . 0.0 110.721 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.537 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -69.07 163.71 50.6 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -179.509 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 35.2 t-20 65.45 -13.95 0.12 Allowed 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.81 -0.818 . . . . 0.0 110.012 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.537 ' H ' ' C ' ' A' ' 31' ' ' GLY . 38.2 m -67.83 133.7 49.64 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.055 -1.028 . . . . 0.0 109.503 179.568 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.405 ' H ' ' HG2' ' A' ' 34' ' ' LYS . 19.5 pttp -93.81 146.57 23.78 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.353 -0.842 . . . . 0.0 109.651 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.1 m -122.86 131.46 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.618 -0.677 . . . . 0.0 109.424 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 33.6 m -66.13 128.85 37.73 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.526 -0.733 . . . . 0.0 110.352 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 94.2 mt -107.95 127.81 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.399 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 17.1 m -111.57 -1.06 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 O-C-N 121.567 -0.708 . . . . 0.0 109.468 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 178.75 -175.27 47.25 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -140.69 153.63 46.03 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.369 -1.077 . . . . 0.0 109.432 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 47.9 tp10 -151.64 112.06 4.15 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.326 -0.859 . . . . 0.0 109.506 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.96 -143.35 48.58 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.63 17.2 3.41 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.635 -0.92 . . . . 0.0 109.874 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -127.21 148.1 50.2 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.415 -0.803 . . . . 0.0 109.34 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -98.99 147.42 25.03 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.432 -0.792 . . . . 0.0 109.734 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -96.37 126.79 41.81 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.6 pt -128.95 156.36 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.503 -0.748 . . . . 0.0 109.952 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -90.27 117.69 29.2 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.488 -0.757 . . . . 0.0 109.418 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.537 ' O ' ' N ' ' A' ' 51' ' ' GLY . 53.1 t80 -106.49 101.96 11.39 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.551 -0.718 . . . . 0.0 109.358 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 7.7 mtmp? 43.51 -88.69 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.59 -0.693 . . . . 0.0 110.655 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.537 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -128.39 42.61 1.42 Allowed Glycine 0 N--CA 1.501 2.993 0 N-CA-C 109.784 -1.327 . . . . 0.0 109.784 -179.329 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 93.9 p -161.43 163.59 30.38 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.196 -1.179 . . . . 0.0 109.172 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -94.91 111.18 22.99 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.22 -0.925 . . . . 0.0 109.559 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.11 150.22 19.56 Favored Glycine 0 N--CA 1.494 2.546 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -128.41 139.6 52.28 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.627 -0.925 . . . . 0.0 109.473 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 28.8 m -136.19 156.21 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.436 -0.79 . . . . 0.0 109.826 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 147.18 39.49 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.484 -0.76 . . . . 0.0 110.465 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -69.18 -12.53 61.76 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.485 -0.76 . . . . 0.0 109.593 179.456 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -67.88 -35.27 78.22 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.22 -0.925 . . . . 0.0 110.499 -179.352 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.541 ' C ' HD12 ' A' ' 61' ' ' ILE . 19.8 m-85 -94.35 -4.49 48.47 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.906 -1.121 . . . . 0.0 110.336 -179.17 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.541 HD12 ' C ' ' A' ' 60' ' ' TYR . 1.6 mp -107.82 130.6 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.237 -0.914 . . . . 0.0 108.88 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.563 ' O ' ' N ' ' A' ' 64' ' ' ILE . 64.3 pttt -142.34 -168.11 2.65 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.478 -0.764 . . . . 0.0 109.077 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 56.26 -75.16 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 CA-C-O 120.986 0.422 . . . . 0.0 110.262 179.655 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.563 ' N ' ' O ' ' A' ' 62' ' ' LYS . 90.3 mt . . . . . 0 N--CA 1.491 1.62 0 O-C-N 121.445 -0.785 . . . . 0.0 109.369 -179.667 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.498 1.936 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 42.5 p -107.22 114.93 29.29 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.777 0.798 . . . . 0.0 109.289 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.45 136.2 12.57 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.523 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.771 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.8 mp -86.38 120.84 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.568 -0.96 . . . . 0.0 109.445 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 99.5 t -82.58 104.35 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 CA-C-O 121.581 0.705 . . . . 0.0 109.354 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 -102.26 103.79 14.29 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.51 -0.744 . . . . 0.0 109.762 -179.57 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 34.7 m -137.46 164.05 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.57 -0.706 . . . . 0.0 109.832 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 79.8 p -63.25 -39.88 95.85 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.348 0.594 . . . . 0.0 109.755 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.442 ' O ' ' O ' ' A' ' 12' ' ' SER . 29.6 p -163.89 109.16 1.04 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.94 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.442 ' O ' ' O ' ' A' ' 11' ' ' SER . 1.4 m 52.48 166.82 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 CA-C-O 121.938 0.875 . . . . 0.0 111.156 179.634 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 37.1 tp -139.46 131.53 27.96 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.583 0.706 . . . . 0.0 109.853 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -79.52 141.86 36.29 Favored 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.516 0.674 . . . . 0.0 109.933 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 75.3 t -98.78 130.62 47.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.54 -0.725 . . . . 0.0 109.718 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.509 ' NE ' ' O ' ' A' ' 21' ' ' THR . 85.1 mtt85 -103.58 134.09 47.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.468 -0.77 . . . . 0.0 109.73 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.1 tm-20 -71.58 -38.98 70.85 Favored 'General case' 0 N--CA 1.491 1.575 0 CA-C-O 121.596 0.713 . . . . 0.0 109.617 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -90.96 173.66 38.2 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.123 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -90.36 5.35 47.71 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.367 -1.079 . . . . 0.0 109.385 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.438 ' CB ' ' HG ' ' A' ' 23' ' ' SER . 7.2 p -78.66 166.64 22.28 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.319 -0.863 . . . . 0.0 110.38 -179.389 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.509 ' O ' ' NE ' ' A' ' 16' ' ' ARG . 0.7 OUTLIER -69.85 -20.71 63.4 Favored 'General case' 0 N--CA 1.491 1.596 0 CA-C-O 121.509 0.671 . . . . 0.0 109.664 179.807 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.7 t -151.11 63.76 0.9 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.009 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.438 ' HG ' ' CB ' ' A' ' 20' ' ' SER . 18.1 m -75.13 -79.42 0.09 Allowed 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.636 0.732 . . . . 0.0 109.447 179.839 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -160.56 121.17 2.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.218 -0.926 . . . . 0.0 109.935 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 75.7 t -74.97 129.3 36.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.496 0.665 . . . . 0.0 109.623 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 34.8 pt -119.6 -10.22 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.483 0.658 . . . . 0.0 109.24 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 179.47 -168.73 39.47 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.633 -1.27 . . . . 0.0 110.163 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 39.4 t -154.31 154.5 33.47 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.576 -0.955 . . . . 0.0 109.831 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.0 mt -122.71 150.56 42.57 Favored 'General case' 0 N--CA 1.495 1.806 0 CA-C-O 121.622 0.725 . . . . 0.0 109.544 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 17.1 m -69.45 151.31 46.24 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.851 0.834 . . . . 0.0 110.354 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.403 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.2 166.04 41.91 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 57.11 8.52 0.54 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 122.012 -0.699 . . . . 0.0 109.575 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.403 ' H ' ' C ' ' A' ' 31' ' ' GLY . 34.6 m -88.47 134.33 33.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.44 -0.788 . . . . 0.0 110.243 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -78.14 146.66 34.98 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.641 -0.662 . . . . 0.0 110.094 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.7 m -126.33 132.58 70.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 CA-C-O 121.621 0.724 . . . . 0.0 109.567 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 39.6 m -65.12 128.89 37.65 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.547 0.689 . . . . 0.0 110.116 -179.509 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 5.4 mm -102.8 125.2 57.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 CA-C-O 121.442 0.639 . . . . 0.0 109.426 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 6.3 m -122.11 -11.83 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.55 -173.81 45.6 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.544 -1.312 . . . . 0.0 110.659 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -148.56 163.15 38.09 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.577 -0.955 . . . . 0.0 109.827 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -156.08 114.06 3.33 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.504 -0.748 . . . . 0.0 109.503 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 61.17 -136.5 48.14 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 179.582 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.418 ' C ' ' HZ2' ' A' ' 58' ' ' LYS . . . -92.34 28.91 1.8 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.527 -0.984 . . . . 0.0 108.719 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -134.5 150.35 50.78 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.621 -0.674 . . . . 0.0 109.435 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -105.37 139.63 39.7 Favored 'General case' 0 N--CA 1.493 1.715 0 CA-C-O 121.798 0.809 . . . . 0.0 109.703 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -96.86 129.19 44.33 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.9 pt -129.29 164.22 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 CA-C-O 121.727 0.775 . . . . 0.0 110.212 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -77.72 99.75 5.97 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-O 121.619 0.723 . . . . 0.0 109.94 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -90.36 134.77 34.1 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.515 -0.741 . . . . 0.0 109.484 179.521 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 56.6 mtpt -52.1 97.8 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.452 0.644 . . . . 0.0 110.422 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 121.46 -35.58 3.56 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 23.4 p -163.31 -153.96 0.26 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.141 -1.211 . . . . 0.0 110.076 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -106.4 118.6 37.08 Favored 'General case' 0 N--CA 1.496 1.835 0 CA-C-O 121.698 0.761 . . . . 0.0 109.999 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.83 145.55 17.67 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -115.86 136.86 52.64 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.807 -0.819 . . . . 0.0 109.781 179.837 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.6 m -138.09 154.57 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 CA-C-O 121.425 0.631 . . . . 0.0 109.679 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.5 ' HB3' ' CD2' ' A' ' 60' ' ' TYR . . . -72.97 149.52 43.27 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.845 0.831 . . . . 0.0 110.899 -179.492 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.418 ' HZ2' ' C ' ' A' ' 43' ' ' ALA . 57.1 mttp -63.1 -34.5 77.73 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.486 0.66 . . . . 0.0 109.99 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -53.67 -30.12 41.87 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.418 -0.801 . . . . 0.0 110.111 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.5 ' CD2' ' HB3' ' A' ' 57' ' ' ALA . 36.5 m-85 -90.03 -2.22 58.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.989 -1.069 . . . . 0.0 109.236 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.0 mm -107.64 127.41 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 CA-C-O 121.796 0.807 . . . . 0.0 109.854 -179.788 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -141.22 150.72 43.04 Favored 'General case' 0 N--CA 1.49 1.563 0 CA-C-O 121.77 0.795 . . . . 0.0 110.133 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.1 t0 56.62 59.5 3.54 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 121.652 0.739 . . . . 0.0 109.965 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 97.2 mt . . . . . 0 N--CA 1.488 1.47 0 O-C-N 121.409 -0.807 . . . . 0.0 109.505 179.804 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt . . . . . 0 N--CA 1.496 1.829 0 CA-C-O 121.12 0.486 . . . . 0.0 109.762 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.8 p -116.21 118.32 32.49 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.556 -0.715 . . . . 0.0 109.367 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -105.52 131.5 10.68 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 -179.351 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.749 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.7 mp -84.91 126.04 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.41 -1.053 . . . . 0.0 109.477 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 74.0 t -75.2 129.03 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 O-C-N 121.318 -0.864 . . . . 0.0 109.938 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 65.0 t-20 -120.38 102.61 8.59 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.1 m -137.09 160.75 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.455 -0.778 . . . . 0.0 109.826 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 87.3 p -82.8 -13.09 56.88 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.524 -0.735 . . . . 0.0 109.266 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.7 m -145.69 -69.41 0.28 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.277 -0.889 . . . . 0.0 109.297 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 58.3 m -156.84 168.86 26.19 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.062 -1.024 . . . . 0.0 109.825 -179.564 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 49.8 tp -116.46 129.76 56.39 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-O 121.656 0.741 . . . . 0.0 109.838 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 14' ' ' ASN . 15.1 p30 -89.1 122.12 32.1 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.433 -0.792 . . . . 0.0 109.778 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.0 t -76.49 153.54 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.364 -0.835 . . . . 0.0 109.864 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.562 HH22 ' HB2' ' A' ' 57' ' ' ALA . 88.9 mtm180 -128.54 136.47 50.8 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.567 -0.708 . . . . 0.0 109.809 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 12.6 tm-20 -69.95 -38.8 76.23 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.548 -0.72 . . . . 0.0 109.138 179.464 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -104.78 -178.86 24.6 Favored Glycine 0 N--CA 1.496 2.652 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 -179.236 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -94.5 -0.88 54.32 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.493 -1.004 . . . . 0.0 108.569 179.261 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.2 m -84.69 151.53 24.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.307 -0.871 . . . . 0.0 110.022 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 59.0 p -68.96 -29.08 67.23 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.55 -0.719 . . . . 0.0 109.612 179.421 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 96.7 p -85.65 7.47 23.25 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.278 -0.889 . . . . 0.0 109.257 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.0 t -62.42 146.44 51.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.434 -0.791 . . . . 0.0 110.759 -179.278 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -68.77 137.45 54.02 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-O 121.723 0.773 . . . . 0.0 110.954 -179.339 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 69.9 t -80.37 131.59 33.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 121.595 -0.691 . . . . 0.0 110.049 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 23.1 pt -102.21 -4.27 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.507 -0.746 . . . . 0.0 109.029 179.518 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 161.72 -177.09 38.12 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.483 -1.342 . . . . 0.0 109.959 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 57.8 m -132.91 159.55 39.58 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.47 -1.018 . . . . 0.0 109.732 -179.674 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.536 HD21 ' CE1' ' A' ' 49' ' ' TYR . 95.9 mt -120.07 149.55 42.0 Favored 'General case' 0 N--CA 1.496 1.87 0 CA-C-O 121.661 0.743 . . . . 0.0 109.884 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.8 m -74.24 161.42 29.95 Favored 'General case' 0 N--CA 1.489 1.488 0 CA-C-O 121.863 0.839 . . . . 0.0 110.739 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -63.09 149.41 49.79 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 111.339 -0.704 . . . . 0.0 111.339 -179.42 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.9 m-20 57.09 32.93 22.53 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.792 -0.828 . . . . 0.0 109.73 179.709 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 25.3 m -90.77 126.63 36.06 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.241 -0.912 . . . . 0.0 109.772 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.5 ttmt -80.3 132.89 35.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.428 -0.795 . . . . 0.0 109.716 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.1 m -124.03 131.96 72.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.579 -0.701 . . . . 0.0 109.734 179.794 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 61.1 m -80.04 128.21 33.21 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-O 121.426 0.631 . . . . 0.0 109.979 -179.301 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.7 mt -97.37 124.68 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.56 -0.712 . . . . 0.0 109.875 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 34.4 m -110.18 -0.84 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.477 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -175.2 178.01 47.01 Favored Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.637 -1.268 . . . . 0.0 110.2 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -142.74 153.58 43.45 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.08 -1.247 . . . . 0.0 109.527 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.408 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 12.9 tm-20 -151.9 107.6 3.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.47 179.367 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.37 -137.39 45.19 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 179.002 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -84.64 26.01 0.85 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.437 -1.037 . . . . 0.0 109.098 -179.341 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -132.02 145.19 51.29 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.559 -0.713 . . . . 0.0 109.412 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -106.95 139.46 41.31 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.615 0.722 . . . . 0.0 109.455 179.66 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -93.09 130.44 38.71 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.557 -0.714 . . . . 0.0 109.174 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 37.2 pt -131.26 154.22 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.611 -0.681 . . . . 0.0 110.044 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -90.86 96.57 10.7 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.519 -0.738 . . . . 0.0 109.127 179.718 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.536 ' CE1' HD21 ' A' ' 29' ' ' LEU . 73.4 t80 -107.33 123.54 48.49 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.507 -0.746 . . . . 0.0 109.953 -179.728 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 74.3 tttt 51.49 34.54 12.44 Favored 'General case' 0 N--CA 1.493 1.678 0 CA-C-O 121.292 0.568 . . . . 0.0 109.944 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.41 -11.84 11.84 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 178.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 26.4 t -91.84 174.02 7.55 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.256 -1.144 . . . . 0.0 110.333 -179.513 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -97.37 101.53 13.09 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.36 -0.837 . . . . 0.0 109.639 -179.811 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.26 137.79 13.52 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.755 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -119.73 137.39 53.97 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.411 -1.052 . . . . 0.0 109.585 179.741 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.2 m -139.45 154.76 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.276 -0.89 . . . . 0.0 109.822 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.562 ' HB2' HH22 ' A' ' 16' ' ' ARG . . . -73.83 146.98 43.76 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.406 -0.809 . . . . 0.0 110.584 -179.762 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -66.21 -11.37 49.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.62 -0.675 . . . . 0.0 109.682 179.42 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -67.35 -34.57 77.59 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.222 -0.924 . . . . 0.0 109.779 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -90.71 3.3 54.64 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.209 -0.932 . . . . 0.0 109.487 -179.197 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 38.3 mm -103.47 129.68 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.346 -0.846 . . . . 0.0 109.939 -179.52 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -146.24 154.91 42.26 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.42 -0.8 . . . . 0.0 109.912 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.6 t0 63.11 52.8 2.43 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 121.555 0.693 . . . . 0.0 109.42 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt . . . . . 0 N--CA 1.487 1.392 0 O-C-N 121.524 -0.735 . . . . 0.0 109.649 -179.834 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt . . . . . 0 N--CA 1.495 1.776 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 70.2 p -132.16 133.55 44.37 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.576 -0.703 . . . . 0.0 109.643 -179.539 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -121.61 131.71 8.66 Favored Glycine 0 N--CA 1.499 2.876 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.751 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.8 mp -86.35 127.65 40.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.075 -1.25 . . . . 0.0 110.005 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 71.5 t -75.61 131.09 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 110.186 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 34.1 t30 -123.74 108.23 12.3 Favored 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.52 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' A' ' 11' ' ' SER . 29.3 m -152.96 -19.47 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 179.618 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.8 t 67.97 -52.84 0.52 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.79 -0.569 . . . . 0.0 109.677 -179.648 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.448 ' N ' ' O ' ' A' ' 9' ' ' VAL . 74.0 m -77.92 -79.41 0.12 Allowed 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.382 -0.824 . . . . 0.0 109.751 -179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 31.2 t -168.45 156.06 7.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.43 -0.794 . . . . 0.0 109.332 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 49.5 tp -123.58 130.28 52.43 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.56 -0.713 . . . . 0.0 109.317 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -84.16 154.48 23.08 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.361 -0.837 . . . . 0.0 109.79 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 54.4 t -105.95 130.14 57.97 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.445 -0.784 . . . . 0.0 109.276 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.723 HH21 ' N ' ' A' ' 20' ' ' SER . 42.4 mtp180 -104.64 128.05 52.57 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.476 -0.765 . . . . 0.0 109.699 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -72.06 -43.16 65.35 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.479 -0.763 . . . . 0.0 109.612 179.68 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -100.32 -175.48 30.1 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.125 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.488 ' C ' HH21 ' A' ' 16' ' ' ARG . . . -97.01 39.59 1.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.505 -0.997 . . . . 0.0 108.944 179.589 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.723 ' N ' HH21 ' A' ' 16' ' ' ARG . 33.0 t -131.86 149.87 52.32 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.554 -0.716 . . . . 0.0 109.72 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 53.1 p -65.11 -31.27 72.39 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.507 -0.746 . . . . 0.0 109.64 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 96.6 p -86.55 13.34 8.63 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.262 -0.899 . . . . 0.0 108.993 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.9 m -62.2 151.13 36.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.442 -0.786 . . . . 0.0 110.442 -179.209 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 17.7 ttmm -64.97 136.83 57.27 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.503 -0.748 . . . . 0.0 110.941 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 97.4 t -90.86 116.73 32.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.3 pt -103.73 -4.76 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.514 -0.741 . . . . 0.0 109.699 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -178.69 -175.5 45.81 Favored Glycine 0 N--CA 1.49 2.253 0 C-N-CA 119.316 -1.421 . . . . 0.0 110.615 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.9 p -158.55 166.1 32.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.558 -0.966 . . . . 0.0 109.004 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.3 mt -123.21 153.92 39.45 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.446 -0.784 . . . . 0.0 109.926 -179.552 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.5 m -80.53 -3.54 50.53 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.663 -0.648 . . . . 0.0 109.334 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.488 ' C ' ' H ' ' A' ' 33' ' ' THR . . . 95.19 164.27 34.91 Favored Glycine 0 N--CA 1.498 2.772 0 O-C-N 121.304 -0.872 . . . . 0.0 111.031 178.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 55.7 2.37 0.07 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.753 -0.851 . . . . 0.0 110.033 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.488 ' H ' ' C ' ' A' ' 31' ' ' GLY . 54.0 m -85.01 133.1 34.26 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.122 -0.986 . . . . 0.0 109.578 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 8.3 ttpm? -80.4 136.79 36.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.341 -0.849 . . . . 0.0 109.964 -179.757 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.9 m -121.24 130.6 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 CA-C-O 121.506 0.669 . . . . 0.0 109.298 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 53.9 m -73.48 133.12 43.58 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.629 -0.669 . . . . 0.0 110.092 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 97.6 mt -109.66 127.7 66.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 CA-C-O 121.362 0.601 . . . . 0.0 109.491 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.54 -1.12 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.42 176.08 45.44 Favored Glycine 0 N--CA 1.49 2.289 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.244 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 -140.13 153.14 46.59 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.346 -1.091 . . . . 0.0 109.828 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.413 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 12.5 tm-20 -151.08 106.93 3.4 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.229 -0.919 . . . . 0.0 109.385 179.71 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 58.82 -138.69 49.23 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.214 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -83.45 5.05 25.13 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.594 -0.945 . . . . 0.0 109.271 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.448 ' CE1' ' NH1' ' A' ' 16' ' ' ARG . 96.6 m-85 -114.5 141.76 47.28 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.69 -0.631 . . . . 0.0 109.539 -179.636 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -107.86 150.72 26.69 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.664 -0.648 . . . . 0.0 109.666 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.5 mtpm? -91.35 139.16 30.99 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.501 -0.749 . . . . 0.0 109.024 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 38.8 pt -134.05 149.82 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.515 -0.741 . . . . 0.0 109.852 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -86.8 95.03 9.71 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.372 -0.83 . . . . 0.0 108.919 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 84.0 t80 -104.6 116.07 31.44 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.382 -0.824 . . . . 0.0 109.196 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 49.2 tttm 52.39 32.19 10.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.614 -0.679 . . . . 0.0 109.695 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 88.36 -20.92 27.71 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.528 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 87.2 p -83.3 166.18 18.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.237 -1.155 . . . . 0.0 110.228 -179.513 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 61.9 m170 -101.62 95.72 6.63 Favored 'General case' 0 N--CA 1.495 1.788 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -88.19 162.9 32.62 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 -179.163 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -122.18 138.02 54.62 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.768 -0.843 . . . . 0.0 109.227 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 20.7 m -137.29 153.61 29.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.333 -0.854 . . . . 0.0 109.647 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.01 139.77 46.87 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.509 -0.744 . . . . 0.0 110.274 -179.475 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -69.2 -12.43 61.67 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.37 -0.831 . . . . 0.0 109.604 179.336 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -63.09 -32.14 73.45 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.44 -0.788 . . . . 0.0 110.353 -179.276 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -99.17 5.91 46.61 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 109.828 -179.37 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.5 mm -105.18 128.59 58.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.934 0 O-C-N 121.296 -0.877 . . . . 0.0 109.515 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -141.65 164.29 30.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.466 -0.771 . . . . 0.0 110.17 -179.39 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 56.32 52.03 10.71 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.191 0.519 . . . . 0.0 110.137 179.714 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt . . . . . 0 N--CA 1.489 1.493 0 O-C-N 121.249 -0.907 . . . . 0.0 109.319 179.352 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 64.3 mttp . . . . . 0 N--CA 1.495 1.79 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 52.8 p -131.55 115.02 15.58 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.619 0.724 . . . . 0.0 109.363 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' GLY . . . . . 0.455 ' C ' HD12 ' A' ' 6' ' ' ILE . . . -91.18 137.65 13.94 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 -179.491 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.698 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.5 mp -92.22 122.22 43.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.618 -0.931 . . . . 0.0 109.398 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.0 t -78.22 132.46 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 O-C-N 121.512 -0.743 . . . . 0.0 110.045 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.6 t-20 -137.72 110.16 7.45 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.519 -0.738 . . . . 0.0 109.351 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.3 m -144.62 149.89 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.394 -0.816 . . . . 0.0 109.607 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 39.8 t -63.66 -43.85 95.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.546 -0.721 . . . . 0.0 110.05 179.837 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 24.6 t -109.43 -76.15 0.62 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.555 -0.715 . . . . 0.0 110.09 -179.204 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 92.1 p -156.73 165.54 35.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 -179.244 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.3 tp -115.17 128.28 56.09 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.761 0.791 . . . . 0.0 109.952 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -84.16 149.9 25.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.586 -0.696 . . . . 0.0 110.055 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.0 t -99.91 131.23 47.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.318 -0.864 . . . . 0.0 109.261 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.432 ' CZ ' ' O ' ' A' ' 21' ' ' THR . 99.7 mtt180 -103.84 135.25 45.74 Favored 'General case' 0 N--CA 1.494 1.758 0 CA-C-O 121.777 0.799 . . . . 0.0 110.099 -179.282 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 46.5 tp10 -70.87 -45.33 64.59 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.554 0.693 . . . . 0.0 109.508 179.715 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.08 172.93 26.01 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 -179.303 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -91.59 11.22 24.96 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.472 -1.016 . . . . 0.0 108.727 179.391 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.1 m -73.87 170.86 14.48 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.333 -0.855 . . . . 0.0 110.305 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.432 ' O ' ' CZ ' ' A' ' 16' ' ' ARG . 18.3 m -62.94 -44.82 95.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.576 -0.702 . . . . 0.0 109.996 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.3 t -131.12 71.12 1.46 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.352 -0.843 . . . . 0.0 109.235 -179.648 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.7 t -83.14 176.66 9.03 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-O 121.659 0.742 . . . . 0.0 110.419 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 65.7 tttm -63.72 133.76 54.12 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-O 121.797 0.808 . . . . 0.0 110.569 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 67.0 t -97.62 128.91 48.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.515 -0.74 . . . . 0.0 109.413 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 39.8 pt -105.19 -4.44 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.673 -0.642 . . . . 0.0 109.342 179.601 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.91 -156.84 27.36 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.368 -1.396 . . . . 0.0 110.491 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 92.9 p -157.43 164.92 36.96 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.425 -1.044 . . . . 0.0 109.515 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.404 HD21 ' CE1' ' A' ' 49' ' ' TYR . 97.4 mt -126.65 148.69 49.79 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.746 0.784 . . . . 0.0 110.021 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 19.4 m -73.59 156.6 37.9 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-O 121.807 0.813 . . . . 0.0 110.55 -179.4 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.17 156.19 38.09 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 65.3 t30 58.14 33.9 23.63 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.688 -0.889 . . . . 0.0 109.873 179.789 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 24.1 m -97.55 132.39 43.27 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.333 -0.855 . . . . 0.0 109.761 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -80.93 128.73 34.01 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.525 -0.734 . . . . 0.0 110.096 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.8 m -128.24 134.19 65.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.589 -0.694 . . . . 0.0 109.504 179.466 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 34.4 m -82.27 124.98 30.44 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.486 -0.758 . . . . 0.0 109.426 -179.662 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.8 mt -99.41 136.15 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 CA-C-O 121.608 0.718 . . . . 0.0 110.433 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 34.1 m -110.44 -6.93 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.758 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 165.79 -174.67 41.49 Favored Glycine 0 N--CA 1.489 2.189 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.359 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -140.91 147.2 38.5 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.459 -1.024 . . . . 0.0 109.205 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.513 ' OE1' ' N ' ' A' ' 41' ' ' GLU . 56.9 mp0 -145.87 120.67 9.91 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.29 -0.881 . . . . 0.0 110.153 -179.454 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.654 ' O ' ' HB3' ' A' ' 43' ' ' ALA . . . 70.19 31.08 69.13 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.654 ' HB3' ' O ' ' A' ' 42' ' ' GLY . . . 77.4 11.03 2.28 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.524 -0.986 . . . . 0.0 109.136 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.464 ' CD2' ' O ' ' A' ' 42' ' ' GLY . 99.2 m-85 -114.03 131.6 56.3 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.653 -0.654 . . . . 0.0 109.319 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -79.47 139.71 37.54 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.615 -0.678 . . . . 0.0 109.963 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -100.56 120.05 39.44 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.495 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.5 pt -125.07 161.63 28.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 CA-C-O 121.748 0.785 . . . . 0.0 110.45 -179.076 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.474 ' CD ' ' H ' ' A' ' 48' ' ' GLU . 0.0 OUTLIER -90.17 124.31 34.72 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.269 0.557 . . . . 0.0 109.649 -179.588 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.404 ' CE1' HD21 ' A' ' 29' ' ' LEU . 81.9 t80 -132.99 120.82 21.88 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.459 -0.776 . . . . 0.0 109.861 179.611 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 76.5 tttt 39.03 47.38 1.26 Allowed 'General case' 0 N--CA 1.496 1.846 0 CA-C-O 121.687 0.756 . . . . 0.0 110.427 179.424 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 86.3 -50.67 4.28 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 179.615 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 16.7 m -74.46 145.16 43.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -1.132 . . . . 0.0 110.51 -179.197 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -83.94 120.54 26.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.393 -0.817 . . . . 0.0 109.915 -179.665 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.12 148.45 18.99 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -115.23 142.68 46.34 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.689 -0.889 . . . . 0.0 109.846 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.4 m -140.94 153.6 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.491 -0.756 . . . . 0.0 109.525 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.85 140.23 43.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.408 -0.808 . . . . 0.0 110.247 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 7.2 ptmm? -65.45 -9.23 23.82 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.516 -0.74 . . . . 0.0 109.744 179.615 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.53 -21.09 62.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.797 . . . . 0.0 110.164 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.489 ' C ' HD12 ' A' ' 61' ' ' ILE . 65.5 m-85 -104.97 -23.26 13.0 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.268 -0.895 . . . . 0.0 109.582 -179.435 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.668 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.6 mp -97.07 130.87 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.26 -0.9 . . . . 0.0 109.841 -179.706 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.473 ' O ' ' N ' ' A' ' 64' ' ' ILE . 23.0 pttp -134.98 -165.35 1.66 Allowed 'General case' 0 N--CA 1.494 1.739 0 CA-C-O 121.474 0.654 . . . . 0.0 109.697 179.579 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 59.17 -78.27 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.771 0 CA-C-O 121.151 0.5 . . . . 0.0 109.986 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.473 ' N ' ' O ' ' A' ' 62' ' ' LYS . 97.2 mt . . . . . 0 N--CA 1.493 1.684 0 CA-C-O 121.44 0.638 . . . . 0.0 109.842 -179.35 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.8 mttt . . . . . 0 N--CA 1.496 1.854 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 25.7 p -123.57 128.61 49.98 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.519 -0.738 . . . . 0.0 109.682 -179.474 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.97 129.87 9.82 Favored Glycine 0 N--CA 1.497 2.746 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.676 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.6 mp -80.14 126.3 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.185 -1.185 . . . . 0.0 109.292 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.2 t -81.74 131.62 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.274 -0.891 . . . . 0.0 110.186 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.2 m120 -120.2 100.07 6.97 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.476 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.7 m -141.01 136.27 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.875 0 O-C-N 121.302 -0.874 . . . . 0.0 109.577 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 t -61.99 -44.86 95.85 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.576 -0.702 . . . . 0.0 109.707 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 68.0 m -99.3 -79.72 0.48 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.557 -0.715 . . . . 0.0 109.456 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 59.9 m -158.92 172.29 18.48 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.359 -0.838 . . . . 0.0 109.389 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.0 tp -116.27 131.48 56.93 Favored 'General case' 0 N--CA 1.5 2.055 0 CA-C-O 121.479 0.657 . . . . 0.0 109.516 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.5 p30 -90.86 153.86 19.9 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.393 -0.817 . . . . 0.0 109.655 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 53.7 t -105.3 130.28 56.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.39 -0.819 . . . . 0.0 108.842 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.489 HH22 ' H ' ' A' ' 57' ' ' ALA . 91.0 mtm-85 -112.11 137.94 49.47 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.533 -0.729 . . . . 0.0 109.502 -179.538 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 69.8 mm-40 -86.48 -29.35 22.83 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.463 -0.773 . . . . 0.0 109.193 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -98.46 148.39 18.85 Favored Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.701 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -82.63 73.17 9.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.313 -1.11 . . . . 0.0 109.325 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.1 m -159.15 -169.43 2.65 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.127 -0.983 . . . . 0.0 109.55 179.854 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 65.9 p -80.71 101.56 9.36 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.277 -0.889 . . . . 0.0 109.785 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.6 t 56.6 52.36 9.86 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.77 -0.582 . . . . 0.0 109.854 179.398 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 77.9 p -62.31 -42.97 99.81 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.301 -0.875 . . . . 0.0 109.313 179.551 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 33.2 ttpt -170.6 115.94 0.48 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.262 -0.899 . . . . 0.0 109.443 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.3 t -90.45 130.22 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.527 -0.733 . . . . 0.0 109.737 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.9 pt -117.37 -11.63 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.32 -162.54 31.36 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.187 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 36.9 t -155.44 168.49 26.95 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.321 -1.105 . . . . 0.0 109.868 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 95.2 mt -127.3 152.74 47.04 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.607 -0.683 . . . . 0.0 109.721 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.6 m -71.4 152.95 42.66 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.609 -0.682 . . . . 0.0 110.368 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -61.86 160.45 29.91 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 -179.176 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 64.4 t30 62.06 4.92 1.29 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.941 -0.741 . . . . 0.0 109.874 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 66.7 m -82.74 130.81 35.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.077 -1.014 . . . . 0.0 109.958 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -86.81 147.46 25.81 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.316 -0.865 . . . . 0.0 109.576 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.3 m -123.34 132.97 70.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.431 -0.793 . . . . 0.0 109.458 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 36.2 m -69.92 130.68 42.87 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.744 -0.598 . . . . 0.0 110.065 -179.352 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.2 mt -109.34 129.17 64.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 29.3 m -120.59 5.24 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 179.591 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.68 177.4 45.25 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 119.531 -1.318 . . . . 0.0 110.463 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -126.69 153.74 45.04 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.676 -0.896 . . . . 0.0 109.247 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 8.1 tm-20 -151.03 93.47 1.93 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.158 -0.963 . . . . 0.0 109.892 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 51.97 -133.27 36.82 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 178.842 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.81 25.38 1.11 Allowed 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.623 -0.928 . . . . 0.0 108.941 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -138.07 134.62 34.95 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.691 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 44.7 m-85 -89.08 144.89 25.82 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.18 -0.95 . . . . 0.0 109.803 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -90.88 129.49 36.92 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.444 -0.785 . . . . 0.0 109.031 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 39.2 pt -128.46 154.26 39.01 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.592 -0.693 . . . . 0.0 110.06 -179.699 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -87.52 93.74 9.51 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.518 -0.739 . . . . 0.0 109.099 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -92.92 152.74 19.2 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.232 -0.917 . . . . 0.0 110.009 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 41.2 tttp -55.46 119.87 6.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.332 -0.855 . . . . 0.0 110.462 -179.37 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 104.4 -46.3 1.2 Allowed Glycine 0 N--CA 1.496 2.66 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.665 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 95.9 p -163.34 177.92 8.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.121 -1.223 . . . . 0.0 109.953 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -81.08 119.74 23.93 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.2 -0.937 . . . . 0.0 109.452 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.72 165.49 32.17 Favored Glycine 0 N--CA 1.496 2.697 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 -179.329 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -123.42 138.22 54.64 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.762 -0.846 . . . . 0.0 109.455 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.1 m -137.35 140.76 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.535 -0.728 . . . . 0.0 109.534 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.489 ' H ' HH22 ' A' ' 16' ' ' ARG . . . -68.41 151.0 47.47 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.517 -0.739 . . . . 0.0 110.794 -179.291 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 45.3 mtmt -62.6 -28.91 70.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.573 -0.704 . . . . 0.0 109.184 179.49 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -58.95 -34.43 71.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.474 -0.766 . . . . 0.0 110.418 -178.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -89.73 -1.99 58.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.019 -1.051 . . . . 0.0 109.466 -179.345 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 43.7 mm -112.59 130.29 66.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.616 -0.678 . . . . 0.0 109.828 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -136.47 142.17 43.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.65 -0.656 . . . . 0.0 109.694 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 44.6 t0 62.43 77.99 0.31 Allowed 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.296 0.57 . . . . 0.0 109.899 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 82.2 mt . . . . . 0 N--CA 1.491 1.623 0 O-C-N 121.457 -0.777 . . . . 0.0 109.158 179.716 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.495 1.782 0 CA-C-O 121.292 0.568 . . . . 0.0 109.786 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 69.3 p -117.05 113.96 23.07 Favored 'General case' 0 N--CA 1.498 1.973 0 CA-C-O 121.898 0.856 . . . . 0.0 110.038 -179.611 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -103.06 130.73 10.35 Favored Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.4 mm -87.53 127.66 40.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.901 -0.764 . . . . 0.0 109.957 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.2 t -71.93 130.56 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 CA-C-O 121.467 0.651 . . . . 0.0 109.725 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.413 ' OD1' ' NZ ' ' A' ' 62' ' ' LYS . 56.0 t30 -123.39 101.93 7.62 Favored 'General case' 0 N--CA 1.497 1.894 0 CA-C-O 121.311 0.577 . . . . 0.0 109.642 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 30.5 m -148.18 158.19 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 121.611 0.719 . . . . 0.0 110.146 179.001 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 58.6 m -87.94 -16.81 32.81 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.859 -0.525 . . . . 0.0 109.976 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 12' ' ' SER . 66.4 m -155.38 87.79 1.12 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.422 -0.799 . . . . 0.0 110.326 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 11' ' ' SER . 1.3 m 46.73 -179.99 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 CA-C-O 121.724 0.773 . . . . 0.0 110.99 178.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 37.8 tp -144.59 130.55 19.34 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.681 0.753 . . . . 0.0 109.846 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -83.31 132.37 35.02 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-O 121.721 0.772 . . . . 0.0 110.053 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 86.7 t -81.18 131.99 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 CA-C-O 121.708 0.766 . . . . 0.0 109.73 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.594 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 93.5 mtm-85 -106.42 135.15 48.42 Favored 'General case' 0 N--CA 1.493 1.688 0 CA-C-O 121.762 0.791 . . . . 0.0 109.897 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.513 ' N ' ' OG ' ' A' ' 23' ' ' SER . 82.8 tt0 -99.52 77.4 2.09 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.645 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.38 170.89 16.7 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 179.413 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -88.66 4.87 45.63 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.7 -0.882 . . . . 0.0 109.199 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.3 m -74.68 155.94 37.2 Favored 'General case' 0 N--CA 1.495 1.779 0 CA-C-O 121.637 0.732 . . . . 0.0 109.966 179.753 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 51.0 p -66.77 -29.97 70.06 Favored 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.7 t -136.59 68.32 1.43 Allowed 'General case' 0 N--CA 1.497 1.893 0 CA-C-O 121.429 0.633 . . . . 0.0 109.443 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 17' ' ' GLU . 5.1 p -82.83 176.79 9.03 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.805 0.812 . . . . 0.0 110.6 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -58.5 130.85 48.75 Favored 'General case' 0 N--CA 1.491 1.58 0 CA-C-O 121.991 0.901 . . . . 0.0 111.11 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.4 t -84.31 129.18 38.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.715 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 42.1 pt -115.87 -6.39 11.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 168.83 -166.05 39.36 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.996 -1.097 . . . . 0.0 110.66 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 47.4 t -151.84 153.82 34.97 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.825 -0.809 . . . . 0.0 109.935 -179.748 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.0 mt -123.26 149.76 44.35 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.794 0.807 . . . . 0.0 109.65 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 23.4 p -74.73 160.61 30.53 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.752 0.787 . . . . 0.0 110.451 -179.311 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -68.62 155.72 53.36 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 58.15 34.69 24.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 122.046 -0.679 . . . . 0.0 109.889 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 53.2 m -102.4 127.16 49.53 Favored 'General case' 0 N--CA 1.498 1.949 0 CA-C-O 121.968 0.889 . . . . 0.0 109.936 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.6 ttpt -77.0 130.33 37.32 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.535 0.684 . . . . 0.0 109.881 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.2 m -129.96 130.89 66.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 CA-C-O 121.75 0.786 . . . . 0.0 109.674 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 11.1 p -77.19 134.29 38.68 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.455 0.645 . . . . 0.0 109.879 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.5 mt -106.23 127.64 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 CA-C-O 121.481 0.658 . . . . 0.0 109.473 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -112.05 -1.06 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.99 171.85 44.72 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.789 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 10.0 tm-20 -137.96 146.65 43.44 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.848 -0.795 . . . . 0.0 109.935 -179.499 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 68.7 mm-40 -144.05 109.4 5.11 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-O 121.97 0.891 . . . . 0.0 109.851 179.706 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.12 -135.11 47.73 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.464 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.36 30.52 0.98 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.765 -0.844 . . . . 0.0 108.746 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -134.49 143.42 47.47 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-O 121.531 0.681 . . . . 0.0 109.821 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -108.82 140.46 42.23 Favored 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.898 0.856 . . . . 0.0 109.59 179.342 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 51.1 mtmt -93.59 143.97 25.81 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.686 0.755 . . . . 0.0 109.717 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 41.5 pt -132.94 152.37 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 CA-C-O 121.646 0.736 . . . . 0.0 110.056 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -75.46 93.78 3.02 Favored 'General case' 0 N--CA 1.489 1.506 0 CA-C-O 121.42 0.629 . . . . 0.0 109.787 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -108.78 142.39 39.4 Favored 'General case' 0 N--CA 1.491 1.611 0 CA-C-O 121.828 0.823 . . . . 0.0 109.589 179.624 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 18.5 ptmt -55.03 119.63 5.73 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 121.845 0.831 . . . . 0.0 110.318 -179.697 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.432 ' O ' ' OG ' ' A' ' 52' ' ' SER . . . 110.63 -47.98 0.98 Allowed Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.286 -1.525 . . . . 0.0 109.286 179.58 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.432 ' OG ' ' O ' ' A' ' 51' ' ' GLY . 24.7 m -167.77 -162.44 0.44 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.739 -0.859 . . . . 0.0 110.386 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -100.11 120.2 39.5 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.832 0.825 . . . . 0.0 109.926 -179.157 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -83.03 145.24 23.24 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -108.54 137.33 46.67 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.615 0.721 . . . . 0.0 109.703 179.724 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.6 m -140.67 143.99 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 CA-C-O 121.735 0.779 . . . . 0.0 110.237 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.594 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -66.66 146.76 54.12 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.64 0.734 . . . . 0.0 110.329 -179.716 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 48.3 mtmt -62.94 -34.4 77.4 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 121.318 0.58 . . . . 0.0 109.468 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -51.47 -33.79 32.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.851 -0.53 . . . . 0.0 110.169 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.428 ' CD2' ' HB3' ' A' ' 57' ' ' ALA . 37.9 m-85 -89.57 0.7 56.74 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.567 -0.708 . . . . 0.0 109.831 -179.367 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 5.6 mm -108.84 125.95 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 CA-C-O 121.685 0.755 . . . . 0.0 110.215 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.413 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 64.0 pttt -145.92 163.49 34.97 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.757 0.789 . . . . 0.0 110.536 -179.741 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 57.94 55.02 5.6 Favored 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 121.444 0.64 . . . . 0.0 109.614 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt . . . . . 0 N--CA 1.489 1.481 0 CA-C-O 121.646 0.736 . . . . 0.0 109.554 -179.837 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt . . . . . 0 N--CA 1.479 1.013 1 N-CA-C 99.335 -4.32 . . . . 0.0 99.335 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.06 135.32 29.05 Favored 'General case' 0 N--CA 1.506 2.357 0 C-N-CA 114.944 -2.702 . . . . 0.0 116.574 -173.512 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -105.02 135.82 12.77 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 106.493 -2.643 . . . . 0.0 106.493 177.604 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 37.1 mm -97.91 121.67 48.7 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.191 -1.182 . . . . 0.0 108.444 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 76.4 t -80.88 132.34 31.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.248 -0.907 . . . . 0.0 109.619 -179.089 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.782 ' C ' HD21 ' A' ' 8' ' ' ASN . 0.1 OUTLIER -144.91 108.38 4.63 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.245 -0.909 . . . . 0.0 109.216 179.753 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.566 ' N ' HD21 ' A' ' 8' ' ' ASN . 28.5 m -135.84 162.25 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.169 -0.957 . . . . 0.0 110.168 -179.761 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.6 t -61.65 -43.15 99.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.549 -0.72 . . . . 0.0 110.017 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 57.9 m -123.75 -90.63 0.56 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.432 -0.792 . . . . 0.0 110.245 -179.387 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.9 m -129.71 157.32 42.48 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.539 -0.726 . . . . 0.0 109.771 -179.258 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.9 tp -114.01 130.9 56.51 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.454 -0.778 . . . . 0.0 109.009 179.815 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -88.29 144.7 26.27 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.421 -0.8 . . . . 0.0 109.614 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 70.8 t -92.35 131.32 39.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.28 -0.888 . . . . 0.0 108.901 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.658 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 84.4 mtm-85 -107.61 136.39 47.45 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.472 -0.767 . . . . 0.0 109.572 -179.464 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -93.48 90.12 6.57 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.162 -0.961 . . . . 0.0 110.049 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 130.16 -174.09 19.7 Favored Glycine 0 N--CA 1.499 2.841 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 179.289 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -105.01 31.19 4.99 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.574 -0.957 . . . . 0.0 109.22 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 36.0 m -134.02 148.87 51.15 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.363 -0.836 . . . . 0.0 109.674 -179.794 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 40.2 p -67.78 -30.87 70.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.302 -0.874 . . . . 0.0 110.285 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 35.9 t -75.5 7.22 3.81 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.273 -0.892 . . . . 0.0 109.605 -179.631 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.8 m -65.17 148.95 50.77 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.363 -0.835 . . . . 0.0 110.091 -179.43 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -71.46 142.86 50.21 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.488 -0.757 . . . . 0.0 110.343 -179.578 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 20.4 t -85.64 128.32 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.449 -0.782 . . . . 0.0 109.293 179.493 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 23.9 pt -107.7 -2.89 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 121.312 -0.867 . . . . 0.0 109.908 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.13 178.87 39.23 Favored Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.007 179.662 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -134.23 153.42 51.86 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.542 -0.975 . . . . 0.0 109.248 179.84 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 91.7 mt -123.98 146.4 48.53 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 121.321 -0.862 . . . . 0.0 109.497 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 28.0 t -79.75 163.53 24.4 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.435 -0.791 . . . . 0.0 110.635 -179.07 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -66.03 161.7 43.83 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.524 -1.031 . . . . 0.0 110.524 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 54.75 31.96 16.51 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.578 -0.954 . . . . 0.0 109.595 -179.762 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.2 m -100.09 126.25 46.29 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.432 -0.793 . . . . 0.0 108.957 179.609 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -79.49 132.2 36.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.32 -0.862 . . . . 0.0 109.501 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 14.9 m -127.03 131.86 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.394 -0.816 . . . . 0.0 108.991 179.451 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 45.9 p -75.4 134.45 40.92 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-O 121.243 0.545 . . . . 0.0 109.87 -179.184 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 95.3 mt -111.35 128.89 67.54 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 CA-C-O 121.391 0.615 . . . . 0.0 109.379 179.508 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 35.3 m -113.29 -1.57 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.706 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -179.48 -178.67 48.51 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -142.84 159.45 42.22 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.256 -1.144 . . . . 0.0 109.676 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -154.53 113.0 3.56 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.137 -0.977 . . . . 0.0 109.759 179.496 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 59.97 -141.94 47.57 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.414 -1.075 . . . . 0.0 110.414 179.312 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.44 24.92 1.53 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.572 -0.958 . . . . 0.0 109.324 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -129.75 147.78 51.57 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.545 -0.722 . . . . 0.0 109.087 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -103.94 142.8 33.78 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.465 -0.772 . . . . 0.0 109.607 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -91.69 128.0 37.35 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 14.2 pt -129.89 154.02 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.296 -0.878 . . . . 0.0 109.391 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.413 ' OE1' ' CD2' ' A' ' 53' ' ' HIS . 49.0 tp10 -82.88 110.99 18.36 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.464 -0.772 . . . . 0.0 109.148 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.577 ' O ' ' N ' ' A' ' 51' ' ' GLY . 79.1 t80 -107.35 117.49 34.21 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.398 -0.814 . . . . 0.0 109.464 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt 44.23 -87.44 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.549 -0.72 . . . . 0.0 110.106 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -123.51 -34.0 0.78 Allowed Glycine 0 N--CA 1.497 2.741 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 15.6 p -89.43 169.43 11.39 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.335 -1.097 . . . . 0.0 109.822 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.413 ' CD2' ' OE1' ' A' ' 48' ' ' GLU . 73.2 m80 -96.46 115.63 27.75 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.533 -0.729 . . . . 0.0 109.124 179.645 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.96 153.12 26.56 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.403 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -121.01 138.66 54.06 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.708 -0.877 . . . . 0.0 109.073 179.661 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -136.58 152.59 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.307 -0.87 . . . . 0.0 109.495 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.658 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -75.03 147.26 40.86 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.523 -0.736 . . . . 0.0 110.65 -179.363 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -70.98 -14.11 62.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.431 -0.793 . . . . 0.0 109.444 179.187 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -65.47 -37.9 88.2 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.447 -0.783 . . . . 0.0 110.292 -179.222 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.519 ' C ' HD12 ' A' ' 61' ' ' ILE . 74.1 m-85 -96.81 -7.55 33.35 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.24 -0.912 . . . . 0.0 110.397 -179.068 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.519 HD12 ' C ' ' A' ' 60' ' ' TYR . 1.5 mp -108.17 129.08 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.062 0 O-C-N 121.366 -0.834 . . . . 0.0 108.931 -179.502 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.566 ' NZ ' ' CB ' ' A' ' 8' ' ' ASN . 26.7 pttm -145.86 -178.81 6.3 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.201 -0.937 . . . . 0.0 109.708 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 43.2 t0 60.73 46.67 8.82 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.609 -0.682 . . . . 0.0 109.368 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt . . . . . 0 N--CA 1.489 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.02 179.667 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.3 mppt? . . . . . 0 N--CA 1.494 1.76 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 68.9 p -122.74 137.68 54.84 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.621 -0.674 . . . . 0.0 109.765 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -119.49 131.09 8.81 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 5.6 mm -86.87 122.53 38.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.411 -1.052 . . . . 0.0 109.431 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 80.7 t -79.13 131.46 34.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.449 -0.782 . . . . 0.0 110.071 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 96.2 m-20 -121.48 101.77 7.83 Favored 'General case' 0 N--CA 1.497 1.925 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 29.4 m -139.98 160.95 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.425 -0.797 . . . . 0.0 110.025 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 80.6 p -81.63 -11.65 59.02 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.0 p -149.07 -70.21 0.21 Allowed 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.455 -0.778 . . . . 0.0 109.267 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 98.6 p -153.95 168.89 24.89 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.904 . . . . 0.0 110.116 -179.598 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.7 tp -115.47 131.03 57.06 Favored 'General case' 0 N--CA 1.498 1.925 0 CA-C-O 121.479 0.657 . . . . 0.0 109.495 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -83.92 135.25 34.55 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.484 -0.76 . . . . 0.0 110.196 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 87.3 t -90.36 131.74 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.478 -0.764 . . . . 0.0 109.218 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.602 HH21 ' N ' ' A' ' 57' ' ' ALA . 87.5 mtm180 -105.55 133.89 49.56 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.493 -0.754 . . . . 0.0 110.187 -179.601 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -67.53 -46.76 71.86 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.561 -0.712 . . . . 0.0 109.673 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.52 178.68 30.23 Favored Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.182 -1.167 . . . . 0.0 110.182 -179.311 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -92.95 21.28 5.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.616 -0.932 . . . . 0.0 108.681 179.536 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.1 m -79.59 165.2 23.18 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.543 -0.723 . . . . 0.0 110.407 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.7 m -63.19 -46.17 88.34 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.691 -0.631 . . . . 0.0 109.976 -179.83 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.8 m -129.44 71.13 1.43 Allowed 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.484 -0.76 . . . . 0.0 109.014 -179.553 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.46 -180.0 7.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.639 -0.663 . . . . 0.0 110.136 -179.545 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -67.05 133.12 49.26 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.617 0.723 . . . . 0.0 110.389 -179.453 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 74.8 t -81.15 129.19 37.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.482 -0.762 . . . . 0.0 109.536 179.696 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.407 HD12 ' CD2' ' A' ' 49' ' ' TYR . 41.1 pt -109.99 -5.09 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.723 -0.611 . . . . 0.0 109.489 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.09 177.39 38.15 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.489 -1.339 . . . . 0.0 110.284 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -132.23 155.71 47.78 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.73 -0.865 . . . . 0.0 109.397 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.6 mt -123.55 150.3 44.18 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-O 121.456 0.646 . . . . 0.0 109.801 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.4 m -71.82 152.54 42.59 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 121.522 0.677 . . . . 0.0 110.195 -179.537 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.451 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -68.07 162.83 48.61 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 56.46 5.0 0.17 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.979 -0.719 . . . . 0.0 109.854 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.451 ' H ' ' C ' ' A' ' 31' ' ' GLY . 35.3 m -81.26 137.1 35.85 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.898 . . . . 0.0 110.138 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -84.96 139.88 31.49 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.498 -0.751 . . . . 0.0 110.176 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 19.8 m -127.0 132.16 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.625 -0.672 . . . . 0.0 109.403 179.562 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 44.5 m -65.67 128.21 35.03 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.725 -0.609 . . . . 0.0 110.047 -179.496 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 97.1 mt -115.55 125.13 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 CA-C-O 121.391 0.615 . . . . 0.0 109.631 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.61 HG23 ' N ' ' A' ' 39' ' ' GLY . 34.6 m -112.96 -47.88 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 179.39 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.61 ' N ' HG23 ' A' ' 38' ' ' VAL . . . -95.06 162.58 23.95 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -142.01 125.63 16.85 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.494 -1.003 . . . . 0.0 109.298 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.518 ' O ' ' N ' ' A' ' 43' ' ' ALA . 83.1 tt0 -114.91 142.95 45.89 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.674 ' O ' ' HB2' ' A' ' 43' ' ' ALA . . . -65.71 59.52 0.13 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.487 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.674 ' HB2' ' O ' ' A' ' 42' ' ' GLY . . . 160.58 -31.7 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.711 -0.876 . . . . 0.0 108.715 179.707 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -134.68 160.91 36.67 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.534 -0.729 . . . . 0.0 110.204 -178.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.7 m-85 -114.13 140.25 48.67 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.589 -0.694 . . . . 0.0 109.688 179.679 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -90.68 129.95 36.73 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 -179.743 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.9 pt -127.9 157.04 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 CA-C-O 121.571 0.701 . . . . 0.0 110.1 -179.685 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -86.93 93.98 9.47 Favored 'General case' 0 N--CA 1.49 1.561 0 CA-C-O 121.431 0.634 . . . . 0.0 109.927 -179.485 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.407 ' CD2' HD12 ' A' ' 26' ' ' ILE . 91.5 t80 -86.89 140.07 30.0 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.399 -0.813 . . . . 0.0 109.467 179.771 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.8 tttm -54.63 100.53 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.422 -0.799 . . . . 0.0 110.05 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 124.51 -33.94 3.63 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 20.7 t -171.11 -168.58 0.66 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.214 -1.168 . . . . 0.0 109.942 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 5.9 m170 -100.69 120.16 39.66 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.519 -0.738 . . . . 0.0 109.641 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.09 161.37 20.85 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -118.09 147.06 43.64 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.737 -0.86 . . . . 0.0 109.626 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.2 m -139.27 153.32 24.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.699 -0.626 . . . . 0.0 109.794 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.602 ' N ' HH21 ' A' ' 16' ' ' ARG . . . -73.68 141.34 46.44 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.574 -0.704 . . . . 0.0 110.59 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -64.61 -12.25 43.65 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.681 -0.637 . . . . 0.0 110.016 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 45.1 tp10 -68.87 -35.97 77.54 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -0.9 . . . . 0.0 110.546 -179.228 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -93.52 2.25 56.48 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.103 -0.998 . . . . 0.0 110.147 -178.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.8 mm -105.67 128.91 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.483 -0.761 . . . . 0.0 109.616 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -143.63 157.09 44.67 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.56 -0.712 . . . . 0.0 109.993 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 37.5 t0 64.39 45.68 3.7 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.615 0.721 . . . . 0.0 109.675 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 97.1 mt . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.68 -0.638 . . . . 0.0 110.071 179.916 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 52.4 mtmt . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 50.6 p -122.8 124.54 43.55 Favored 'General case' 0 N--CA 1.496 1.872 0 CA-C-O 121.829 0.823 . . . . 0.0 109.357 179.52 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -101.78 133.69 11.45 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 -179.365 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 34.4 mm -84.29 126.62 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.7 -0.882 . . . . 0.0 110.009 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.1 t -82.89 98.6 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.376 -0.827 . . . . 0.0 109.317 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -101.47 107.24 18.49 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.508 -0.745 . . . . 0.0 109.889 -179.603 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 m -141.09 144.3 26.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.299 -0.876 . . . . 0.0 109.575 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 27.5 t -66.97 -13.78 62.19 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-O 121.44 0.638 . . . . 0.0 109.497 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.484 ' OG ' ' N ' ' A' ' 12' ' ' SER . 91.1 p -141.3 -103.84 0.14 Allowed 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.161 -0.962 . . . . 0.0 110.231 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.484 ' N ' ' OG ' ' A' ' 11' ' ' SER . 57.8 m -127.49 157.38 40.24 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.464 -0.773 . . . . 0.0 110.191 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 36.5 tp -113.39 128.81 56.58 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 121.723 0.773 . . . . 0.0 109.875 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.9 m-20 -85.07 150.8 24.61 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.479 0.657 . . . . 0.0 110.025 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.4 t -104.41 129.94 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.423 -0.798 . . . . 0.0 109.276 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -105.28 132.81 51.01 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.546 0.688 . . . . 0.0 109.816 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -71.23 -37.22 72.01 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-O 121.819 0.818 . . . . 0.0 109.433 179.635 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -100.73 179.44 29.02 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -179.392 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -94.31 -1.44 53.87 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.193 -1.18 . . . . 0.0 108.825 179.393 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.9 m -83.36 149.82 26.48 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.312 -0.867 . . . . 0.0 110.196 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 97.7 m -65.0 -44.33 89.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.415 -0.803 . . . . 0.0 110.078 179.489 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 76.5 p -78.49 16.66 0.78 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.078 -1.014 . . . . 0.0 109.529 -179.448 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.8 m -63.64 149.65 46.03 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.212 -0.93 . . . . 0.0 110.251 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -70.96 138.25 49.86 Favored 'General case' 0 N--CA 1.488 1.47 0 CA-C-O 121.981 0.895 . . . . 0.0 110.528 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 75.0 t -87.37 130.17 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 CA-C-O 121.697 0.761 . . . . 0.0 109.925 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 37.4 pt -103.61 -4.57 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.007 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.91 -163.96 36.48 Favored Glycine 0 N--CA 1.493 2.451 0 C-N-CA 119.497 -1.335 . . . . 0.0 110.434 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 95.3 p -156.6 163.03 39.81 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.469 -1.019 . . . . 0.0 109.663 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 89.7 mt -124.79 150.86 45.87 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-O 121.694 0.759 . . . . 0.0 109.903 -179.601 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 12.3 p -76.19 164.72 25.81 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.062 0.934 . . . . 0.0 111.038 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.23 152.81 43.48 Favored Glycine 0 N--CA 1.489 2.222 0 CA-C-O 122.105 0.836 . . . . 0.0 111.665 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 67.1 t30 57.89 32.19 21.6 Favored 'General case' 0 N--CA 1.494 1.744 0 CA-C-O 121.635 0.731 . . . . 0.0 110.147 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 24.6 m -89.98 126.95 35.93 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.154 -0.966 . . . . 0.0 109.539 179.044 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -82.77 133.17 35.15 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.337 -0.852 . . . . 0.0 109.624 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.0 m -125.85 133.62 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 CA-C-O 121.791 0.805 . . . . 0.0 110.03 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 85.5 m -80.37 127.53 32.49 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.413 0.625 . . . . 0.0 109.78 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.8 mt -105.41 126.72 60.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 CA-C-O 121.466 0.65 . . . . 0.0 109.602 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 18.5 m -112.68 -1.97 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.56 177.82 45.75 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.613 -1.279 . . . . 0.0 110.364 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -141.72 159.63 41.83 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.356 -1.084 . . . . 0.0 109.871 -179.786 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -154.32 109.42 3.11 Favored 'General case' 0 N--CA 1.489 1.497 0 CA-C-O 121.684 0.754 . . . . 0.0 109.158 179.37 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.34 -137.47 45.0 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.06 23.28 1.26 Allowed 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.458 -1.024 . . . . 0.0 108.979 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -130.44 145.3 51.8 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.415 -0.803 . . . . 0.0 109.79 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.4 m-85 -108.5 139.66 42.94 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.611 0.719 . . . . 0.0 109.41 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -90.65 129.95 36.71 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.558 -0.714 . . . . 0.0 109.304 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.7 pt -129.03 153.53 38.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 CA-C-O 121.708 0.765 . . . . 0.0 109.804 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -81.02 99.66 8.56 Favored 'General case' 0 N--CA 1.49 1.531 0 CA-C-O 121.674 0.75 . . . . 0.0 109.857 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.404 ' CD2' ' N ' ' A' ' 51' ' ' GLY . 88.0 t80 -81.2 144.13 31.83 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.559 -0.713 . . . . 0.0 110.021 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 51.9 mtmt -46.85 -47.22 21.26 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.461 -0.775 . . . . 0.0 110.144 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.404 ' N ' ' CD2' ' A' ' 49' ' ' TYR . . . -69.34 -39.93 80.81 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 179.797 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 21.4 m -171.62 -110.78 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.152 -1.205 . . . . 0.0 109.325 -179.536 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 73.2 m80 -127.56 112.56 15.04 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-O 121.801 0.81 . . . . 0.0 109.352 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.84 154.29 19.94 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 -179.681 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -120.87 139.96 52.45 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.606 -0.938 . . . . 0.0 109.712 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.2 m -135.96 152.55 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.55 -0.719 . . . . 0.0 109.195 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 149.8 37.93 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-O 121.861 0.839 . . . . 0.0 110.667 -179.528 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 62.2 pttt -65.8 -15.43 62.87 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.57 0.7 . . . . 0.0 109.977 179.4 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.443 ' OE2' ' CE2' ' A' ' 60' ' ' TYR . 14.4 pt-20 -67.28 -35.73 80.1 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.243 -0.911 . . . . 0.0 110.199 -179.563 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.443 ' CE2' ' OE2' ' A' ' 59' ' ' GLU . 54.9 m-85 -90.79 -1.69 57.84 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.07 -1.019 . . . . 0.0 109.26 -179.407 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 39.3 mm -110.86 131.72 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.397 -0.815 . . . . 0.0 109.428 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.486 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 63.8 tttp -130.45 158.05 40.96 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.486 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 11.7 t0 79.81 -59.02 0.35 Allowed 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.393 0.616 . . . . 0.0 109.529 179.518 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.414 ' O ' HG22 ' A' ' 64' ' ' ILE . 82.1 mt . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.741 0.782 . . . . 0.0 109.268 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.677 0.751 . . . . 0.0 109.393 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -70.82 151.21 45.03 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.356 -0.84 . . . . 0.0 110.076 -179.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -127.01 144.2 51.09 Favored 'General case' 0 N--CA 1.494 1.771 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 22.9 p -117.61 121.87 42.07 Favored 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.831 0.825 . . . . 0.0 109.631 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -102.03 137.64 13.45 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 27.8 mm -87.11 123.21 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.539 -0.977 . . . . 0.0 109.53 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 33' ' ' THR . 70.5 t -74.36 134.08 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.509 -0.744 . . . . 0.0 110.13 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 47.0 t30 -128.53 101.31 6.12 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.6 -0.687 . . . . 0.0 109.401 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 24.5 m -136.71 160.58 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.397 -0.814 . . . . 0.0 109.709 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 99.9 p -84.16 -10.37 57.81 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.498 0.666 . . . . 0.0 109.604 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 62.5 p -147.4 -66.79 0.26 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.13 -0.981 . . . . 0.0 109.503 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.5 p -157.52 165.73 34.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.237 -0.915 . . . . 0.0 109.414 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.0 tp -113.44 130.18 56.37 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 121.672 0.749 . . . . 0.0 109.822 -179.676 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -85.78 145.84 27.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.518 -0.739 . . . . 0.0 109.678 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.7 t -111.51 130.97 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.483 ' NE ' ' O ' ' A' ' 21' ' ' THR . 84.6 mtt85 -111.14 146.36 36.99 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.788 0.804 . . . . 0.0 109.76 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -88.19 -16.59 32.9 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.458 ' O ' ' CD2' ' A' ' 55' ' ' TYR . . . -96.66 -130.92 6.69 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -152.21 -5.58 0.23 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -1.11 . . . . 0.0 108.581 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 8.5 p -82.38 172.33 13.19 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.354 -0.841 . . . . 0.0 110.761 -179.509 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.483 ' O ' ' NE ' ' A' ' 16' ' ' ARG . 52.3 p -66.13 -31.21 71.93 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.603 -0.685 . . . . 0.0 110.219 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 38.0 m -138.39 58.71 1.66 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.029 -1.044 . . . . 0.0 108.896 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.5 m -77.69 -79.1 0.12 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.406 -0.809 . . . . 0.0 109.719 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -157.03 112.97 2.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.073 -1.017 . . . . 0.0 109.792 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.0 t -80.67 129.45 37.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.347 -0.846 . . . . 0.0 109.589 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.4 pt -111.16 -5.58 11.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.554 -0.717 . . . . 0.0 109.126 179.658 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 164.89 -157.98 30.62 Favored Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.189 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.0 p -153.88 164.7 37.96 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.163 -1.198 . . . . 0.0 109.721 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 94.7 mt -126.64 151.56 47.87 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.671 0.748 . . . . 0.0 109.571 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' OG1' ' A' ' 33' ' ' THR . 29.7 t -71.18 160.7 32.38 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-O 121.91 0.862 . . . . 0.0 110.598 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.459 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.54 160.23 49.72 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 57.87 4.09 0.26 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.957 -0.731 . . . . 0.0 109.754 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.459 ' H ' ' C ' ' A' ' 31' ' ' GLY . 86.0 m -70.36 135.94 49.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.22 -0.925 . . . . 0.0 110.275 179.603 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 10.2 mtpm? -83.59 140.56 32.15 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.577 -0.702 . . . . 0.0 110.251 -179.689 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.2 m -126.73 130.88 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.619 -0.676 . . . . 0.0 109.341 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 p -79.83 129.31 34.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.537 -0.727 . . . . 0.0 109.719 -179.486 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 97.0 mt -112.24 129.38 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 CA-C-O 121.482 0.658 . . . . 0.0 109.358 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.2 m -110.18 -2.51 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.01 177.92 47.9 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.307 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.437 ' CD ' ' N ' ' A' ' 41' ' ' GLU . 9.9 tm-20 -133.09 155.4 49.3 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.423 -1.045 . . . . 0.0 109.402 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.437 ' N ' ' CD ' ' A' ' 40' ' ' GLU . 48.6 tp10 -156.31 115.76 3.52 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.493 -0.754 . . . . 0.0 109.149 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 63.68 -142.9 47.32 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.495 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.95 20.2 5.04 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.418 -1.048 . . . . 0.0 109.022 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -130.19 150.82 51.27 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.483 -0.761 . . . . 0.0 109.656 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -102.94 140.6 37.01 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.67 0.747 . . . . 0.0 109.988 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -91.16 130.39 37.05 Favored 'General case' 0 N--CA 1.487 1.425 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.2 pt -128.72 157.15 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 CA-C-O 121.766 0.793 . . . . 0.0 110.199 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -82.08 97.3 8.09 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.594 0.711 . . . . 0.0 109.48 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -85.18 144.85 27.91 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.365 -0.834 . . . . 0.0 109.825 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -66.76 100.62 0.72 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.493 -0.754 . . . . 0.0 110.154 -179.416 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 116.87 -23.4 10.08 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 109.187 -1.565 . . . . 0.0 109.187 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 10.8 t -169.08 -156.08 0.15 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.065 -1.256 . . . . 0.0 110.101 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -108.49 122.77 47.74 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.706 0.765 . . . . 0.0 109.716 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.41 148.76 19.28 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.458 ' CD2' ' O ' ' A' ' 18' ' ' GLY . 87.9 m-85 -127.16 132.27 50.55 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.669 -0.901 . . . . 0.0 109.238 179.306 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.8 m -138.19 153.45 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.396 -0.815 . . . . 0.0 109.923 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.07 151.23 40.22 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-O 121.574 0.702 . . . . 0.0 110.849 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -67.25 -20.34 65.65 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.526 -0.734 . . . . 0.0 110.548 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -65.38 -32.9 74.78 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.213 -0.93 . . . . 0.0 110.565 -178.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -87.91 1.45 54.01 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.854 -1.154 . . . . 0.0 109.396 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 37.8 mm -108.51 127.25 65.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.411 -0.806 . . . . 0.0 109.346 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 37.5 ttpt -140.58 150.43 43.63 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.815 0.817 . . . . 0.0 110.385 -179.215 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 54.39 72.3 0.47 Allowed 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.72 0.771 . . . . 0.0 110.254 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.9 mt -90.46 115.14 29.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.287 -0.883 . . . . 0.0 109.402 179.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -142.21 149.79 40.13 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.352 -0.842 . . . . 0.0 110.004 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -67.44 141.76 56.89 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 121.644 0.735 . . . . 0.0 110.357 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -166.84 76.81 0.18 Allowed 'General case' 0 N--CA 1.487 1.384 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.507 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.428 HG12 ' O ' ' A' ' 68' ' ' VAL . 46.9 t -94.93 -7.87 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.193 -0.942 . . . . 0.0 109.257 -179.814 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 60.2 mt 60.27 120.22 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.884 0 CA-C-O 122.045 0.926 . . . . 0.0 110.791 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -61.1 148.51 40.22 Favored 'General case' 0 N--CA 1.489 1.522 0 CA-C-O 121.875 0.845 . . . . 0.0 110.575 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.509 ' ND1' ' N ' ' A' ' 72' ' ' HIS . 57.4 t-80 -66.88 170.93 5.9 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-O 121.952 0.882 . . . . 0.0 111.028 -179.387 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.509 ' N ' ' ND1' ' A' ' 71' ' ' HIS . 84.6 t60 53.26 81.02 0.1 Allowed 'General case' 0 N--CA 1.488 1.455 0 CA-C-O 121.956 0.884 . . . . 0.0 109.547 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -67.11 -38.18 85.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.493 -0.755 . . . . 0.0 109.594 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' HIS . . . . . 0.456 ' O ' ' NE2' ' A' ' 72' ' ' HIS . 63.0 t-80 -57.87 123.27 15.2 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.29 -0.881 . . . . 0.0 110.284 -179.167 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -81.76 129.97 34.91 Favored 'General case' 0 N--CA 1.488 1.446 0 CA-C-O 121.746 0.784 . . . . 0.0 110.007 -179.717 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.018 -0.992 . . . . 0.0 109.987 179.761 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -73.12 150.31 42.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.402 -0.811 . . . . 0.0 110.301 -179.424 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -119.22 151.14 38.89 Favored 'General case' 0 N--CA 1.496 1.826 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 17.4 p -118.36 116.44 26.74 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.513 0.673 . . . . 0.0 109.206 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -93.55 125.62 8.3 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.677 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.7 mp -81.08 124.5 38.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.295 -1.121 . . . . 0.0 109.58 -179.71 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 76.6 t -77.78 132.67 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.343 -0.848 . . . . 0.0 109.956 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -126.92 98.22 5.26 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.5 m -137.23 158.92 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.58 -0.7 . . . . 0.0 109.616 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.9 m -86.06 -12.57 49.79 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.551 -0.718 . . . . 0.0 109.357 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 71.4 m -133.31 -79.51 0.48 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.462 -0.774 . . . . 0.0 109.204 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.3 p -158.29 165.1 35.62 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.173 -0.954 . . . . 0.0 109.725 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 34.0 tp -112.8 131.58 55.63 Favored 'General case' 0 N--CA 1.498 1.963 0 CA-C-O 121.545 0.688 . . . . 0.0 109.561 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -92.17 143.69 26.17 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.503 -0.748 . . . . 0.0 110.063 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 71.1 t -92.57 132.02 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.479 -0.763 . . . . 0.0 109.122 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -102.16 130.53 48.81 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.395 -0.816 . . . . 0.0 110.102 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -70.41 -41.55 72.8 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.719 -0.613 . . . . 0.0 109.821 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.45 ' H ' ' HB2' ' A' ' 23' ' ' SER . . . -105.7 -171.62 23.65 Favored Glycine 0 N--CA 1.497 2.766 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.106 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.05 57.99 0.76 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.699 -0.883 . . . . 0.0 109.124 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 40.7 t -161.33 154.9 21.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.244 -0.91 . . . . 0.0 109.821 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 75.2 p -66.15 -33.09 74.99 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.627 -0.67 . . . . 0.0 109.806 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 47.1 t -79.07 9.18 4.64 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.195 -0.94 . . . . 0.0 108.979 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.45 ' HB2' ' H ' ' A' ' 18' ' ' GLY . 94.2 p -69.36 159.46 33.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.492 -0.755 . . . . 0.0 110.427 -179.304 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -84.16 138.68 32.87 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.471 -0.768 . . . . 0.0 110.837 -179.198 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.0 t -89.69 130.99 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.541 -0.724 . . . . 0.0 109.792 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.41 HD12 ' CE2' ' A' ' 49' ' ' TYR . 36.8 pt -102.8 -6.59 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.574 -0.703 . . . . 0.0 109.177 179.428 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 169.22 -179.83 41.62 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 119.489 -1.339 . . . . 0.0 110.05 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 63.1 m -133.95 157.03 47.07 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.643 -0.916 . . . . 0.0 109.445 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.1 mt -122.59 148.96 44.61 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 121.544 0.687 . . . . 0.0 109.705 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.0 m -71.18 150.2 45.59 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-O 121.705 0.764 . . . . 0.0 110.519 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.543 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -64.13 163.33 34.45 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 111.099 -0.801 . . . . 0.0 111.099 -179.275 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 37.6 t-20 66.74 -19.64 0.11 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.942 -0.74 . . . . 0.0 110.135 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.543 ' H ' ' C ' ' A' ' 31' ' ' GLY . 33.0 m -67.31 136.4 54.8 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.047 -1.033 . . . . 0.0 110.209 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -90.42 148.81 22.55 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.502 -0.749 . . . . 0.0 109.605 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.5 m -123.51 131.53 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 CA-C-O 121.579 0.704 . . . . 0.0 109.188 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 28.5 m -66.63 130.5 43.39 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.86 -0.525 . . . . 0.0 110.025 -179.166 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.0 mt -110.53 129.78 65.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 19.0 m -112.92 -0.12 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -179.61 -179.31 48.76 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.43 -1.367 . . . . 0.0 110.307 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -139.87 154.08 47.19 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.462 -1.023 . . . . 0.0 109.75 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -153.98 109.05 3.13 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -0.854 . . . . 0.0 109.402 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 59.14 -142.22 46.74 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -83.2 17.85 1.91 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.487 -1.008 . . . . 0.0 109.278 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -129.83 145.57 51.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.615 -0.678 . . . . 0.0 109.514 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 50.4 m-85 -107.68 147.69 30.38 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.605 0.716 . . . . 0.0 109.833 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -90.84 139.29 30.88 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.537 -0.727 . . . . 0.0 109.044 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.4 pt -134.45 158.45 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 CA-C-O 121.665 0.745 . . . . 0.0 110.519 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -84.22 93.59 8.22 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.674 -0.641 . . . . 0.0 109.426 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.41 ' CE2' HD12 ' A' ' 26' ' ' ILE . 82.4 t80 -98.37 135.31 40.14 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.358 -0.839 . . . . 0.0 109.278 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.9 ttpt -49.77 106.72 0.12 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.383 -0.823 . . . . 0.0 110.568 -179.162 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 123.31 -51.76 0.79 Allowed Glycine 0 N--CA 1.496 2.647 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 179.317 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 22.8 p -158.86 -166.2 1.81 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.132 -1.216 . . . . 0.0 110.124 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 78.3 m80 -90.41 116.87 28.68 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.366 -0.834 . . . . 0.0 109.865 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -86.29 160.75 33.57 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -123.96 136.36 54.26 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.665 -0.903 . . . . 0.0 109.423 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.8 m -136.81 137.24 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.506 -0.746 . . . . 0.0 109.337 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.97 143.67 57.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.599 -0.688 . . . . 0.0 110.632 -179.216 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.9 pttt -62.01 -13.35 24.92 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.544 -0.722 . . . . 0.0 109.422 179.377 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -68.25 -31.0 70.17 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.434 -0.791 . . . . 0.0 110.95 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.402 ' C ' HD12 ' A' ' 61' ' ' ILE . 61.2 m-85 -93.1 -11.05 33.87 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.792 -1.192 . . . . 0.0 109.769 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.533 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.4 mp -94.73 131.63 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.361 -0.837 . . . . 0.0 109.207 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.471 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 65.8 tttm -135.43 155.41 50.59 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.653 -0.655 . . . . 0.0 109.828 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.471 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 11.7 t0 79.39 -66.78 0.17 Allowed 'General case' 0 N--CA 1.495 1.799 0 CA-C-O 121.268 0.556 . . . . 0.0 109.535 179.753 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 91.5 mt 56.46 83.95 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.634 -0.666 . . . . 0.0 109.488 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -142.16 152.29 43.05 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.533 -0.729 . . . . 0.0 109.826 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -79.34 110.01 14.22 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.422 -0.799 . . . . 0.0 109.674 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 49.6 tp10 -87.55 143.18 27.33 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.357 -0.839 . . . . 0.0 109.739 -179.516 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 27.9 m -75.84 144.9 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.452 -0.78 . . . . 0.0 110.159 -179.766 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.536 HD12 ' N ' ' A' ' 69' ' ' LEU . 10.8 mp -84.0 -4.27 58.62 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.292 -0.88 . . . . 0.0 109.022 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 10.8 tm-20 -100.72 120.83 40.66 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.334 -0.854 . . . . 0.0 109.793 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -155.85 48.89 0.51 Allowed 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.373 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.609 ' NE2' ' CE1' ' A' ' 73' ' ' HIS . 6.9 t-80 -148.52 145.9 28.09 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.373 -0.829 . . . . 0.0 109.722 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.609 ' CE1' ' NE2' ' A' ' 72' ' ' HIS . 5.8 p-80 -72.36 -14.08 61.63 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.594 -0.691 . . . . 0.0 109.457 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 13.8 m80 -132.21 144.21 50.48 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.446 -0.784 . . . . 0.0 109.573 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -87.91 140.73 29.21 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.594 -0.691 . . . . 0.0 110.394 -179.588 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 . . . . . 0 N--CA 1.493 1.696 0 CA-C-O 118.081 -0.962 . . . . 0.0 110.021 179.849 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.464 ' O ' ' O ' ' A' ' 1' ' ' ALA . 50.7 mt-10 57.5 144.94 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 121.581 0.705 . . . . 0.0 110.372 -179.87 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -139.19 154.62 48.08 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.431 -0.793 . . . . 0.0 109.133 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -114.46 126.61 55.16 Favored 'General case' 0 N--CA 1.498 1.975 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.31 140.75 15.2 Favored Glycine 0 N--CA 1.497 2.754 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.309 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 23.7 mm -94.33 116.33 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.364 -1.08 . . . . 0.0 108.904 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.3 t -80.35 132.63 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.376 -0.828 . . . . 0.0 109.99 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.6 t30 -132.99 106.9 7.94 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.428 -0.795 . . . . 0.0 109.34 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 11' ' ' SER . 19.6 m -151.65 -12.87 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.416 ' H ' ' H ' ' A' ' 9' ' ' VAL . 24.0 p 43.87 17.79 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.724 -0.61 . . . . 0.0 109.729 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.525 ' N ' ' O ' ' A' ' 9' ' ' VAL . 23.7 m -151.55 35.85 0.57 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.1 t 60.63 145.31 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.793 -0.567 . . . . 0.0 110.437 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 35.9 tp -116.16 133.13 56.36 Favored 'General case' 0 N--CA 1.503 2.209 0 CA-C-O 121.572 0.701 . . . . 0.0 109.613 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 18.9 p30 -80.65 137.34 36.33 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.429 -0.794 . . . . 0.0 109.62 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 73.7 t -90.95 131.25 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.361 -0.837 . . . . 0.0 108.84 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 96.7 mtt-85 -95.9 138.81 33.0 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.001 . . . . 0.0 109.981 -179.123 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 50.4 tp10 -67.5 -43.67 80.31 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.424 -0.797 . . . . 0.0 109.777 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.43 ' H ' ' HB2' ' A' ' 23' ' ' SER . . . -119.52 -166.6 13.4 Favored Glycine 0 N--CA 1.499 2.856 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 -178.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.69 56.03 0.88 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.62 -0.929 . . . . 0.0 109.225 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 28.8 t -152.8 151.09 30.05 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.264 -0.898 . . . . 0.0 109.725 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 41.7 p -68.06 -23.12 64.92 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.394 -0.816 . . . . 0.0 109.438 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 86.1 p -83.65 -0.48 50.83 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.423 -0.798 . . . . 0.0 109.429 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.43 ' HB2' ' H ' ' A' ' 18' ' ' GLY . 99.8 p -64.84 159.42 22.61 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.222 -0.924 . . . . 0.0 110.387 -179.323 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 22.6 pttp -92.6 140.18 29.81 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.49 -0.756 . . . . 0.0 110.407 -179.458 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 22.6 t -86.69 129.81 37.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.383 -0.823 . . . . 0.0 109.909 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 36.3 pt -102.39 -7.4 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.512 -0.743 . . . . 0.0 109.157 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.77 -162.81 35.22 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 24.8 p -152.78 164.04 38.57 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.299 -1.118 . . . . 0.0 109.433 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.3 mt -124.26 148.48 47.35 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.546 -0.721 . . . . 0.0 109.39 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.9 t -69.94 152.02 44.95 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.493 -0.755 . . . . 0.0 110.622 -179.016 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.46 160.55 32.24 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 12.3 m120 57.31 33.22 22.99 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.653 -0.91 . . . . 0.0 109.563 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 35.1 m -105.02 137.02 43.41 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.57 -0.706 . . . . 0.0 109.832 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -79.76 140.32 36.95 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 109.057 -0.719 . . . . 0.0 109.057 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.8 m -126.77 130.5 71.53 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.416 -0.803 . . . . 0.0 109.397 179.565 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 54.6 m -72.84 126.39 29.81 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.41 -0.806 . . . . 0.0 109.628 -179.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 93.1 mt -107.33 126.71 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.639 -0.663 . . . . 0.0 109.65 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 30.9 m -111.13 -3.26 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.468 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 177.21 -174.14 46.78 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -141.05 155.16 46.21 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.323 -1.104 . . . . 0.0 109.441 179.844 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -151.27 112.06 4.25 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 109.598 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.461 ' O ' ' NZ ' ' A' ' 58' ' ' LYS . . . 61.92 -144.93 49.19 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.501 ' C ' ' HZ2' ' A' ' 58' ' ' LYS . . . -84.36 24.96 0.91 Allowed 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.657 -0.908 . . . . 0.0 109.384 -179.8 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 -131.58 152.68 50.59 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.602 -0.686 . . . . 0.0 109.341 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 9.1 m-85 -103.16 139.08 39.12 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.413 -0.804 . . . . 0.0 108.855 179.592 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.535 ' HZ2' ' HB3' ' A' ' 53' ' ' HIS . 63.5 tttp -90.71 129.72 36.78 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 33.3 pt -130.72 154.47 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.483 -0.761 . . . . 0.0 109.588 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -83.22 100.3 10.5 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.455 -0.778 . . . . 0.0 109.341 -179.294 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -83.64 147.1 27.9 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.351 -0.843 . . . . 0.0 109.797 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 8.0 mtmp? -62.21 102.96 0.34 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.267 -0.895 . . . . 0.0 110.861 -179.169 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 101.63 -10.28 57.5 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 179.106 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 50.4 m -168.29 -166.09 0.67 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.861 -1.376 . . . . 0.0 110.035 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.535 ' HB3' ' HZ2' ' A' ' 46' ' ' LYS . 96.9 m-70 -110.28 115.92 30.55 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.52 -0.737 . . . . 0.0 109.085 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.2 152.08 21.07 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.371 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -126.55 137.79 53.39 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.639 -0.918 . . . . 0.0 109.021 179.488 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.3 m -135.59 139.56 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.339 -0.85 . . . . 0.0 109.753 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.574 ' HB1' ' OE1' ' A' ' 59' ' ' GLU . . . -68.09 149.58 49.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.575 -0.703 . . . . 0.0 110.593 -179.378 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.501 ' HZ2' ' C ' ' A' ' 43' ' ' ALA . 64.2 mttp -62.23 -33.73 75.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.463 -0.773 . . . . 0.0 109.772 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.574 ' OE1' ' HB1' ' A' ' 57' ' ' ALA . 58.7 mp0 -55.1 -30.98 60.84 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.354 -0.841 . . . . 0.0 110.086 -178.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.478 ' CD2' ' HB3' ' A' ' 57' ' ' ALA . 40.0 m-85 -92.84 -3.98 53.73 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.966 -1.084 . . . . 0.0 109.353 -179.631 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.1 mm -114.46 129.18 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 121.541 -0.724 . . . . 0.0 109.516 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.577 ' O ' ' N ' ' A' ' 64' ' ' ILE . 21.7 ptmt -141.14 -174.16 3.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.418 -0.801 . . . . 0.0 109.581 179.852 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.458 ' O ' ' O ' ' A' ' 64' ' ' ILE . 91.1 m-20 56.69 -75.48 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.577 ' N ' ' O ' ' A' ' 62' ' ' LYS . 97.7 mt 57.71 150.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 CA-C-O 121.393 0.616 . . . . 0.0 110.01 -179.855 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -117.52 108.71 15.83 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.619 -0.676 . . . . 0.0 109.473 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -88.87 113.71 24.71 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.335 -0.853 . . . . 0.0 109.309 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -87.61 -2.11 58.4 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.231 -0.918 . . . . 0.0 109.234 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.414 HG13 ' O ' ' A' ' 68' ' ' VAL . 3.4 p -155.84 114.89 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.344 -0.847 . . . . 0.0 109.36 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 88.5 mt -80.41 141.39 35.36 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.324 -0.86 . . . . 0.0 110.159 -179.46 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.481 ' C ' ' H ' ' A' ' 72' ' ' HIS . 96.0 mt-10 -84.09 162.34 20.34 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.385 -0.822 . . . . 0.0 110.669 -179.317 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 28.8 t60 66.43 -8.51 0.37 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.812 -0.555 . . . . 0.0 109.889 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.481 ' H ' ' C ' ' A' ' 70' ' ' GLU . 74.8 m80 -89.31 -7.62 54.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.223 -0.923 . . . . 0.0 109.045 179.523 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 74.2 m80 -71.4 142.61 50.31 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.428 -0.795 . . . . 0.0 110.036 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -132.99 89.65 2.65 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.419 -0.801 . . . . 0.0 109.171 179.577 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 86.4 t60 40.03 86.35 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.947 0 CA-C-O 121.379 0.609 . . . . 0.0 110.318 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 61.1 t-80 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.644 179.764 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.449 0.642 . . . . 0.0 109.625 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -80.48 126.69 31.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.258 -0.901 . . . . 0.0 110.214 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.5 mtmp? -143.13 157.74 44.24 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.512 -0.742 . . . . 0.0 109.051 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 62.0 p -121.35 125.21 46.42 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.567 -0.708 . . . . 0.0 109.464 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -102.86 137.32 13.34 Favored Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.666 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.4 mm -95.5 120.07 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.275 -1.133 . . . . 0.0 109.449 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 74.1 t -75.67 134.2 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.566 -0.709 . . . . 0.0 110.321 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' A' ' 60' ' ' TYR . 3.6 p-10 -138.72 99.74 3.88 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.437 -0.789 . . . . 0.0 109.385 179.592 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 5.7 m -134.98 135.73 52.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.577 -0.702 . . . . 0.0 109.682 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 78.2 p -62.52 -40.49 96.94 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.614 -0.679 . . . . 0.0 109.638 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 68.9 m -101.8 -79.19 0.52 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.447 -0.783 . . . . 0.0 109.877 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 45.5 m -161.51 167.06 26.13 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.334 -0.854 . . . . 0.0 109.596 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 38.6 tp -116.95 130.17 56.53 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.64 -0.662 . . . . 0.0 109.789 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -91.16 142.29 27.89 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.397 -0.814 . . . . 0.0 109.686 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 96.3 t -88.89 128.08 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.324 -0.86 . . . . 0.0 109.21 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.758 HH21 ' H ' ' A' ' 20' ' ' SER . 67.5 mtp180 -107.52 133.16 52.39 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.549 -0.719 . . . . 0.0 109.962 -179.357 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.3 pt-20 -70.7 -35.01 72.55 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.488 -0.757 . . . . 0.0 109.879 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -120.95 -148.8 8.05 Favored Glycine 0 N--CA 1.498 2.774 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 -178.537 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -147.27 75.05 1.36 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.574 -0.957 . . . . 0.0 108.834 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.758 ' H ' HH21 ' A' ' 16' ' ' ARG . 15.2 m -141.85 44.95 1.7 Allowed 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.633 ' N ' ' NH2' ' A' ' 16' ' ' ARG . 59.0 p 50.37 -84.81 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.769 0 CA-C-O 121.319 0.58 . . . . 0.0 110.471 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.527 ' N ' ' O ' ' A' ' 20' ' ' SER . 23.0 t -71.39 44.4 0.09 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.354 -0.841 . . . . 0.0 109.002 -179.45 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.43 ' H ' ' C ' ' A' ' 21' ' ' THR . 15.4 p -78.58 165.22 23.94 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.355 -0.84 . . . . 0.0 110.411 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -77.3 138.54 39.42 Favored 'General case' 0 N--CA 1.488 1.473 0 CA-C-O 121.721 0.772 . . . . 0.0 110.637 -179.583 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 76.5 t -93.49 129.9 43.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 39.4 pt -109.19 -7.1 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.6 -0.687 . . . . 0.0 109.556 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 179.12 -173.53 45.65 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 119.287 -1.435 . . . . 0.0 110.349 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 54.8 m -144.0 154.06 42.87 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.405 -1.056 . . . . 0.0 109.789 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.7 mt -124.89 148.78 48.12 Favored 'General case' 0 N--CA 1.497 1.884 0 CA-C-O 121.546 0.689 . . . . 0.0 109.63 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 90.6 p -79.08 165.06 23.78 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 121.72 0.772 . . . . 0.0 110.854 -179.148 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -65.78 155.27 50.4 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 12.0 m120 57.41 31.59 20.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.73 -0.865 . . . . 0.0 109.86 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 37.0 m -91.73 129.94 37.61 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.216 -0.928 . . . . 0.0 109.835 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -80.11 133.33 36.08 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.514 -0.741 . . . . 0.0 109.639 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 m -128.1 133.29 67.4 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.303 -0.873 . . . . 0.0 110.037 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 21.6 m -81.56 131.23 35.27 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.685 -0.634 . . . . 0.0 109.451 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 91.1 mt -104.91 126.0 59.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.593 -0.692 . . . . 0.0 109.785 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 15.8 m -109.66 -1.43 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.46 -177.79 48.42 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -142.23 160.84 39.45 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.342 -1.093 . . . . 0.0 109.631 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -152.84 112.57 3.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.241 -0.912 . . . . 0.0 109.546 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.22 -135.16 47.88 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.011 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.82 25.91 1.94 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.462 -1.022 . . . . 0.0 109.006 -179.456 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 65.3 m-85 -132.4 151.33 51.92 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.685 -0.634 . . . . 0.0 109.452 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 31.5 m-85 -107.84 139.49 42.35 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.528 0.68 . . . . 0.0 109.894 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -92.42 132.63 36.61 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 36.7 pt -128.4 156.88 40.9 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.556 -0.715 . . . . 0.0 110.205 -179.638 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -82.15 97.56 8.27 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.66 -0.65 . . . . 0.0 109.483 -179.697 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.418 ' H ' ' HA ' ' A' ' 53' ' ' HIS . 90.0 t80 -85.49 161.46 19.36 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.525 -0.734 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.411 ' N ' ' CG ' ' A' ' 49' ' ' TYR . 98.6 mttt -70.91 107.81 4.22 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.415 -0.803 . . . . 0.0 110.267 -179.543 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 98.84 -14.46 61.64 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 81.0 p -169.46 -161.61 0.3 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.942 -1.328 . . . . 0.0 110.145 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.418 ' HA ' ' H ' ' A' ' 49' ' ' TYR . 77.4 m80 -116.43 121.47 41.98 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.628 -0.67 . . . . 0.0 109.571 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.84 163.57 30.84 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.597 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 81.9 m-85 -132.23 137.35 47.52 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.62 -0.929 . . . . 0.0 109.431 179.507 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 30.2 m -138.73 156.49 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.916 0 O-C-N 121.518 -0.739 . . . . 0.0 109.82 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.86 145.54 42.69 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.508 -0.745 . . . . 0.0 110.314 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 10.3 ptmm? -68.71 -13.79 62.6 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.597 -0.69 . . . . 0.0 110.064 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -67.21 -35.99 80.77 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.195 -0.941 . . . . 0.0 110.149 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.424 ' O ' ' OD1' ' A' ' 8' ' ' ASN . 75.7 m-85 -92.14 1.33 57.27 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.079 -1.013 . . . . 0.0 109.602 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.0 mm -113.68 125.49 70.96 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.561 -0.712 . . . . 0.0 109.601 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -142.42 169.83 16.85 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.477 -0.765 . . . . 0.0 109.856 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 47.9 t0 62.28 52.38 3.14 Favored 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.575 0.703 . . . . 0.0 109.787 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt -74.62 131.04 35.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.463 -0.773 . . . . 0.0 109.188 179.571 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -114.0 134.37 54.89 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.547 -0.72 . . . . 0.0 110.038 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.411 ' OD1' ' O ' ' A' ' 66' ' ' ASP . 43.3 p-10 -104.28 125.76 50.81 Favored 'General case' 0 N--CA 1.494 1.727 0 CA-C-O 121.472 0.653 . . . . 0.0 109.461 179.71 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.551 ' N ' ' OE1' ' A' ' 67' ' ' GLU . 56.8 mp0 -98.97 -16.36 18.77 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 16.8 m -94.06 140.13 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.335 -0.853 . . . . 0.0 110.274 -179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.573 HD12 ' N ' ' A' ' 69' ' ' LEU . 10.6 mp -85.08 -1.41 56.82 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 52.96 -90.6 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.391 -0.818 . . . . 0.0 110.205 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.448 ' N ' ' O ' ' A' ' 69' ' ' LEU . 44.6 m80 -143.14 153.3 42.74 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.188 -0.945 . . . . 0.0 109.646 -179.148 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.442 ' CG ' ' N ' ' A' ' 73' ' ' HIS . 86.3 t60 -78.14 162.34 26.7 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.561 -0.712 . . . . 0.0 110.622 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.442 ' N ' ' CG ' ' A' ' 72' ' ' HIS . 75.4 m80 -70.58 132.58 45.7 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.454 -0.779 . . . . 0.0 110.492 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 51.6 p-80 -84.94 -14.13 48.59 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.512 -0.742 . . . . 0.0 109.337 179.711 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -66.0 -39.76 90.56 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.345 -0.847 . . . . 0.0 109.242 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 75.0 m-70 . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 118.076 -0.964 . . . . 0.0 109.558 -179.674 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -65.05 134.17 53.25 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.434 -0.791 . . . . 0.0 110.02 -179.507 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -137.33 149.98 47.41 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.421 -0.799 . . . . 0.0 109.285 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 10.1 p -122.86 114.45 20.5 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.506 -0.746 . . . . 0.0 109.315 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -97.3 141.42 15.6 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.437 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.4 mm -94.71 119.48 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.381 -1.07 . . . . 0.0 109.225 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.3 t -79.04 125.1 38.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.305 -0.872 . . . . 0.0 109.774 -179.478 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.4 t30 -105.52 94.95 5.48 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.453 -0.779 . . . . 0.0 109.387 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.616 HG22 ' H ' ' A' ' 11' ' ' SER . 2.2 p -144.42 135.49 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.361 -0.837 . . . . 0.0 109.174 179.474 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 77.3 p -84.71 -13.73 50.51 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.558 -0.714 . . . . 0.0 109.562 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.616 ' H ' HG22 ' A' ' 9' ' ' VAL . 66.3 m -117.44 -89.26 0.59 Allowed 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.463 -0.773 . . . . 0.0 109.841 -179.686 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.9 p -158.58 163.51 36.93 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.914 -1.116 . . . . 0.0 109.751 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 40.2 tp -120.52 131.21 54.59 Favored 'General case' 0 N--CA 1.498 1.968 0 CA-C-O 121.666 0.746 . . . . 0.0 109.626 179.74 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -87.04 146.61 26.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.457 -0.777 . . . . 0.0 109.82 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 74.3 t -104.98 129.0 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.455 -0.778 . . . . 0.0 109.125 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.67 HH22 ' N ' ' A' ' 57' ' ' ALA . 0.6 OUTLIER -107.87 138.71 43.64 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.655 0.741 . . . . 0.0 109.372 -179.617 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -93.3 -21.84 19.34 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.554 -0.716 . . . . 0.0 109.35 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.493 ' C ' ' H ' ' A' ' 20' ' ' SER . . . -101.97 7.52 55.05 Favored Glycine 0 N--CA 1.497 2.748 0 N-CA-C 108.897 -1.681 . . . . 0.0 108.897 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . 56.83 3.97 0.15 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.478 -1.013 . . . . 0.0 109.392 -179.44 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.493 ' H ' ' C ' ' A' ' 18' ' ' GLY . 7.6 m -80.87 156.81 25.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.316 -0.865 . . . . 0.0 110.327 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.456 ' O ' ' CB ' ' A' ' 22' ' ' SER . 43.1 p -61.29 101.53 0.17 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.531 -0.731 . . . . 0.0 110.171 -179.852 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.456 ' CB ' ' O ' ' A' ' 21' ' ' THR . 0.7 OUTLIER 79.06 27.65 0.41 Allowed 'General case' 0 N--CA 1.496 1.852 0 CA-C-O 121.639 0.733 . . . . 0.0 109.519 179.587 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.42 ' O ' ' O ' ' A' ' 22' ' ' SER . 0.2 OUTLIER -56.64 -159.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.915 0.864 . . . . 0.0 110.763 -179.747 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 38.1 ttmt -64.32 128.6 36.51 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.616 0.722 . . . . 0.0 109.785 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 91.1 t -92.14 115.26 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 CA-C-O 121.58 0.705 . . . . 0.0 109.277 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.9 pt -103.66 -3.98 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.7 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.57 -163.11 36.73 Favored Glycine 0 N--CA 1.488 2.15 0 C-N-CA 119.405 -1.378 . . . . 0.0 110.53 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.5 p -154.02 163.54 39.91 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.311 -1.111 . . . . 0.0 109.221 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.2 mt -124.63 146.39 49.11 Favored 'General case' 0 N--CA 1.497 1.9 0 CA-C-O 121.725 0.774 . . . . 0.0 110.013 -179.477 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.412 ' C ' ' HG1' ' A' ' 33' ' ' THR . 12.9 m -83.32 162.12 21.21 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-O 121.837 0.827 . . . . 0.0 110.404 -179.533 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.478 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -65.45 158.35 46.35 Favored Glycine 0 N--CA 1.49 2.296 0 CA-C-O 121.817 0.676 . . . . 0.0 111.583 -179.467 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 59.43 0.04 0.19 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.966 -0.726 . . . . 0.0 110.032 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.478 ' H ' ' C ' ' A' ' 31' ' ' GLY . 30.2 m -72.09 140.88 49.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.244 -0.91 . . . . 0.0 110.505 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -87.41 144.74 26.6 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.528 -0.733 . . . . 0.0 109.592 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.6 m -125.87 132.1 71.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 121.456 -0.777 . . . . 0.0 109.96 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 26.6 m -73.11 104.06 4.06 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.68 -0.637 . . . . 0.0 109.362 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.3 mt -101.73 131.1 50.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.553 0.692 . . . . 0.0 109.521 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.612 HG23 ' N ' ' A' ' 39' ' ' GLY . 23.8 m -140.32 -46.51 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.612 ' N ' HG23 ' A' ' 38' ' ' VAL . . . -95.41 164.74 24.59 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -179.338 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.447 ' CD ' ' N ' ' A' ' 41' ' ' GLU . 15.8 tm-20 -135.28 146.0 48.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.369 -1.077 . . . . 0.0 109.594 179.63 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.447 ' N ' ' CD ' ' A' ' 40' ' ' GLU . 84.4 tt0 -153.57 109.1 3.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.458 -0.776 . . . . 0.0 109.408 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.401 ' C ' ' H ' ' A' ' 44' ' ' PHE . . . 48.58 -142.28 8.76 Favored Glycine 0 N--CA 1.494 2.509 0 CA-C-O 121.967 0.759 . . . . 0.0 111.269 179.175 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -81.9 28.51 0.42 Allowed 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.435 -1.038 . . . . 0.0 108.738 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.401 ' H ' ' C ' ' A' ' 42' ' ' GLY . 91.0 m-85 -134.01 140.22 46.56 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.516 -0.74 . . . . 0.0 109.137 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -100.7 142.81 31.64 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.495 -0.753 . . . . 0.0 109.276 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.615 ' HZ3' ' CG ' ' A' ' 53' ' ' HIS . 65.1 tttm -90.45 129.03 36.68 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -179.582 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.0 pt -126.57 152.24 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 CA-C-O 121.699 0.761 . . . . 0.0 110.164 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -84.39 92.2 7.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.511 -0.743 . . . . 0.0 109.658 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -79.3 142.11 36.43 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.331 -0.856 . . . . 0.0 110.134 -179.504 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -58.18 96.46 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.547 -0.721 . . . . 0.0 110.408 -179.058 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 123.19 -35.83 3.25 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.459 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 67.8 p -158.96 -162.96 1.15 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.986 -1.302 . . . . 0.0 109.759 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.615 ' CG ' ' HZ3' ' A' ' 46' ' ' LYS . 97.5 m-70 -106.31 118.26 36.18 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.492 -0.755 . . . . 0.0 109.347 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.15 162.39 22.8 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -126.54 136.56 52.73 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.526 -0.985 . . . . 0.0 109.514 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.8 m -133.67 137.15 53.21 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 CA-C-O 121.477 0.656 . . . . 0.0 109.619 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.67 ' N ' HH22 ' A' ' 16' ' ' ARG . . . -68.85 147.21 52.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.395 -0.816 . . . . 0.0 110.352 -179.61 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.4 mtmp? -63.8 -9.03 12.51 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.567 -0.708 . . . . 0.0 109.736 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -68.83 -35.99 77.64 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.108 -0.995 . . . . 0.0 110.096 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -92.96 4.99 53.0 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.052 -1.03 . . . . 0.0 109.203 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 44.8 mm -103.88 129.16 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.39 -0.819 . . . . 0.0 109.513 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 26.2 ttpp -149.88 157.34 43.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.306 -0.872 . . . . 0.0 110.439 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 55.81 52.97 9.98 Favored 'General case' 0 N--CA 1.49 1.57 0 CA-C-O 121.59 0.709 . . . . 0.0 109.498 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt -69.9 130.8 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.497 -0.752 . . . . 0.0 109.554 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 18.2 tptm -133.05 137.54 46.47 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.815 0.817 . . . . 0.0 110.173 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -89.33 114.63 26.06 Favored 'General case' 0 N--CA 1.488 1.461 0 CA-C-O 121.694 0.759 . . . . 0.0 109.744 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -56.43 156.27 6.2 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.699 0.762 . . . . 0.0 110.844 -179.241 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 4.9 t 62.1 77.83 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.77 0.795 . . . . 0.0 109.639 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.454 HD23 ' H ' ' A' ' 69' ' ' LEU . 0.1 OUTLIER -85.08 157.3 20.75 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 121.773 0.797 . . . . 0.0 110.064 -179.243 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 73.5 mm-40 -59.98 140.61 56.64 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 121.729 0.776 . . . . 0.0 110.435 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.411 ' O ' ' O ' ' A' ' 72' ' ' HIS . 59.2 t-80 -80.64 -15.13 57.35 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 179.38 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.411 ' O ' ' O ' ' A' ' 71' ' ' HIS . 96.9 m-70 54.45 106.21 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.662 0.744 . . . . 0.0 110.174 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -148.4 159.08 44.38 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.114 -0.991 . . . . 0.0 109.562 179.645 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -102.82 133.26 48.18 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.301 -0.875 . . . . 0.0 110.217 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 58.6 t-80 -66.12 -42.86 88.58 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.475 -0.766 . . . . 0.0 109.797 179.69 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 67.5 m-70 . . . . . 0 N--CA 1.495 1.788 0 CA-C-O 118.198 -0.906 . . . . 0.0 109.947 -179.538 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -74.17 152.42 39.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.486 -0.758 . . . . 0.0 110.192 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -112.0 156.92 21.37 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.694 -0.629 . . . . 0.0 109.592 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 67.2 p -134.22 152.32 51.76 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.569 -0.707 . . . . 0.0 109.476 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -135.1 128.67 4.83 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.75 ' N ' HD12 ' A' ' 6' ' ' ILE . 2.0 mp -81.99 124.52 39.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.669 -0.901 . . . . 0.0 109.579 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 91.8 t -85.33 116.75 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.506 -0.746 . . . . 0.0 109.732 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.403 HD22 ' HD3' ' A' ' 62' ' ' LYS . 98.0 m-20 -110.19 107.38 17.15 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.521 -0.737 . . . . 0.0 109.663 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 14.9 m -139.33 156.72 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.386 -0.821 . . . . 0.0 109.616 179.183 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 82.0 p -73.18 -13.81 61.23 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.502 ' OG ' ' N ' ' A' ' 12' ' ' SER . 77.0 p -152.95 -118.61 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.327 -0.858 . . . . 0.0 110.096 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.502 ' N ' ' OG ' ' A' ' 11' ' ' SER . 21.5 m -101.37 161.26 13.75 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.382 -0.824 . . . . 0.0 110.246 -178.835 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 61.6 tp -120.99 133.4 55.27 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.632 0.729 . . . . 0.0 109.653 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -88.95 129.46 35.62 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.633 -0.667 . . . . 0.0 109.866 179.778 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 80.7 t -89.89 132.56 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.423 -0.798 . . . . 0.0 109.23 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -101.69 134.08 45.39 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.421 -0.799 . . . . 0.0 110.533 -178.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 11.4 tm-20 -69.21 -43.18 74.61 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.315 0.578 . . . . 0.0 109.548 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -101.42 -178.48 28.59 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -178.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -93.24 -2.22 55.34 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.591 -0.947 . . . . 0.0 109.365 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.7 m -82.37 150.79 26.97 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.187 -0.946 . . . . 0.0 110.368 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.458 ' C ' ' H ' ' A' ' 23' ' ' SER . 19.0 m -64.91 -45.4 86.05 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.501 -0.75 . . . . 0.0 109.534 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 8.7 t -77.24 24.39 0.18 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.607 -0.683 . . . . 0.0 109.161 -179.562 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.458 ' H ' ' C ' ' A' ' 21' ' ' THR . 14.8 m -71.18 151.14 44.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.477 -0.764 . . . . 0.0 110.291 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -73.37 136.65 44.39 Favored 'General case' 0 N--CA 1.491 1.582 0 CA-C-O 121.789 0.804 . . . . 0.0 110.995 -179.181 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 82.2 t -85.62 131.58 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 CA-C-O 121.372 0.605 . . . . 0.0 109.822 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.403 HG13 ' N ' ' A' ' 27' ' ' GLY . 8.4 pt -125.33 -44.31 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.722 -0.611 . . . . 0.0 109.378 179.779 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.403 ' N ' HG13 ' A' ' 26' ' ' ILE . . . -101.29 171.89 22.71 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 -178.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.8 p -158.42 155.58 28.86 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.583 -0.951 . . . . 0.0 109.55 179.072 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 91.9 mt -133.92 150.57 51.32 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.452 -0.78 . . . . 0.0 109.72 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.9 t -82.11 -1.53 49.02 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.497 ' C ' ' H ' ' A' ' 33' ' ' THR . . . 97.83 164.83 31.52 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.272 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 52.78 5.22 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.746 -0.855 . . . . 0.0 110.014 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.497 ' H ' ' C ' ' A' ' 31' ' ' GLY . 24.9 m -78.9 141.44 37.61 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.101 -0.999 . . . . 0.0 110.312 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -88.74 132.99 34.37 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.643 -0.661 . . . . 0.0 109.493 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.7 m -124.12 133.79 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 CA-C-O 121.785 0.802 . . . . 0.0 109.854 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 5.8 p -76.8 133.92 39.25 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.722 -0.611 . . . . 0.0 110.141 -179.397 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.0 mt -111.54 128.9 67.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 121.448 0.642 . . . . 0.0 109.362 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 29.7 m -111.21 -3.34 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -174.99 175.92 47.1 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.662 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -136.51 153.44 51.02 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.667 -0.902 . . . . 0.0 109.46 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -155.11 113.19 3.45 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.195 -0.94 . . . . 0.0 109.996 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 57.48 -137.52 49.38 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 178.695 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.9 24.2 2.86 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.602 -0.94 . . . . 0.0 109.073 -179.258 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -133.2 147.54 52.01 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.576 -0.702 . . . . 0.0 109.571 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 24.9 m-85 -106.35 147.93 28.65 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.559 -0.713 . . . . 0.0 109.782 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -95.53 124.9 39.79 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 13.8 pt -131.51 154.26 40.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 CA-C-O 121.762 0.791 . . . . 0.0 110.217 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -90.89 106.29 18.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.695 -0.628 . . . . 0.0 109.958 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 88.7 t80 -112.45 115.37 28.57 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.572 0.701 . . . . 0.0 109.172 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.1 mmtp 52.27 31.07 8.73 Favored 'General case' 0 N--CA 1.493 1.689 0 CA-C-O 121.3 0.571 . . . . 0.0 110.193 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 85.64 -11.22 62.27 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 178.759 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 38.4 t -90.2 170.05 10.62 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.25 -1.147 . . . . 0.0 110.203 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -100.28 93.41 5.67 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.429 -0.794 . . . . 0.0 109.231 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.26 136.1 12.73 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.696 -1.361 . . . . 0.0 109.696 -179.649 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -112.95 138.58 49.59 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.689 -0.889 . . . . 0.0 109.562 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.1 m -135.89 156.13 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.544 -0.723 . . . . 0.0 109.997 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.548 ' HB3' ' CE2' ' A' ' 60' ' ' TYR . . . -69.21 152.06 45.55 Favored 'General case' 0 N--CA 1.491 1.588 0 CA-C-O 121.76 0.791 . . . . 0.0 110.767 -179.374 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 60' ' ' TYR . 47.9 mtmt -63.41 -38.69 92.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.698 -0.626 . . . . 0.0 109.49 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -49.64 -7.42 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.401 -0.812 . . . . 0.0 110.222 -179.382 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.548 ' CE2' ' HB3' ' A' ' 57' ' ' ALA . 59.0 m-85 -105.26 -25.05 12.59 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.289 -0.882 . . . . 0.0 109.236 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.629 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.5 mp -89.13 129.09 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.365 -0.835 . . . . 0.0 109.828 -179.51 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.403 ' HD3' HD22 ' A' ' 8' ' ' ASN . 65.2 tttm -146.37 152.55 39.27 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.546 -0.721 . . . . 0.0 109.857 179.228 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 57.47 57.11 4.55 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.496 0.665 . . . . 0.0 109.803 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.9 mt -70.73 131.7 34.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.382 -0.824 . . . . 0.0 109.533 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -130.71 139.9 50.32 Favored 'General case' 0 N--CA 1.494 1.755 0 CA-C-O 121.511 0.672 . . . . 0.0 109.346 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 41.0 p-10 -93.46 116.21 28.74 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.467 -0.771 . . . . 0.0 110.428 -179.421 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.428 ' OE2' ' O ' ' A' ' 69' ' ' LEU . 4.7 tm-20 54.56 95.93 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 CA-C-O 121.644 0.735 . . . . 0.0 110.114 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.453 ' O ' ' O ' ' A' ' 69' ' ' LEU . 14.8 t -87.32 104.81 14.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.51 -0.744 . . . . 0.0 110.119 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.469 ' N ' HD12 ' A' ' 69' ' ' LEU . 10.7 mp 55.85 148.28 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 122.045 0.926 . . . . 0.0 111.076 179.196 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 14.7 tm-20 -155.86 114.37 3.43 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.41 -0.806 . . . . 0.0 109.404 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 7.8 p80 -77.68 119.7 21.58 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.549 -0.719 . . . . 0.0 109.866 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 28.5 p80 -100.26 -10.13 21.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.502 -0.749 . . . . 0.0 109.023 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -65.96 -36.74 84.17 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.526 -0.734 . . . . 0.0 109.327 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' HIS . . . . . 0.522 ' CE1' ' NE2' ' A' ' 75' ' ' HIS . 25.8 t-80 -60.03 -44.16 94.83 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.454 -0.779 . . . . 0.0 109.655 -179.712 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' HIS . . . . . 0.522 ' NE2' ' CE1' ' A' ' 74' ' ' HIS . 32.9 m-70 -144.69 142.7 30.27 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.314 -0.866 . . . . 0.0 109.84 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' HIS . . . . . 0.521 ' O ' ' CG ' ' A' ' 76' ' ' HIS . 54.2 p-80 . . . . . 0 N--CA 1.489 1.479 0 CA-C-O 118.081 -0.962 . . . . 0.0 109.724 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.432 ' O ' ' O ' ' A' ' 1' ' ' ALA . 79.8 tt0 58.35 121.49 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.389 0.614 . . . . 0.0 110.27 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -136.44 155.74 49.58 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.494 -0.754 . . . . 0.0 109.283 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.0 p -126.8 126.65 43.76 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.519 -0.738 . . . . 0.0 109.23 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.459 ' C ' HD12 ' A' ' 6' ' ' ILE . . . -94.32 130.58 10.36 Favored Glycine 0 N--CA 1.495 2.611 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.694 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.5 mp -93.64 120.5 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.294 -1.121 . . . . 0.0 109.392 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 70.7 t -76.34 132.91 32.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.427 -0.796 . . . . 0.0 109.335 179.47 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -134.87 85.82 2.21 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.439 -0.788 . . . . 0.0 109.246 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.3 m -130.73 132.97 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.578 -0.701 . . . . 0.0 109.52 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 46.7 m -62.42 -41.56 98.79 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.453 -0.779 . . . . 0.0 109.907 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.42 ' OG ' ' N ' ' A' ' 12' ' ' SER . 77.6 p -91.81 -82.09 0.32 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.216 -0.928 . . . . 0.0 109.628 -179.399 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.42 ' N ' ' OG ' ' A' ' 11' ' ' SER . 43.1 t -165.98 167.25 16.76 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.383 -0.823 . . . . 0.0 109.111 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 51.0 tp -119.87 132.45 55.57 Favored 'General case' 0 N--CA 1.498 1.97 0 CA-C-O 121.595 0.712 . . . . 0.0 109.61 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -91.28 152.79 20.34 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.628 -0.67 . . . . 0.0 109.858 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.3 t -103.41 131.02 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.702 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 92.1 mtm-85 -110.5 134.69 52.13 Favored 'General case' 0 N--CA 1.492 1.664 0 CA-C-O 121.689 0.757 . . . . 0.0 110.178 -179.569 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -70.91 -36.4 72.68 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.716 -0.615 . . . . 0.0 109.487 179.594 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.54 -175.88 31.21 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -179.191 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -109.24 24.48 13.05 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.6 -0.941 . . . . 0.0 108.723 179.594 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.462 ' OG ' ' OG ' ' A' ' 23' ' ' SER . 6.4 p -83.84 171.49 13.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 110.201 -179.524 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 15.9 m -62.72 -43.51 98.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.53 -0.731 . . . . 0.0 109.417 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.8 p -136.12 66.18 1.5 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.457 -0.777 . . . . 0.0 108.956 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.462 ' OG ' ' OG ' ' A' ' 20' ' ' SER . 1.9 m -77.26 -178.08 4.92 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.866 0.841 . . . . 0.0 110.353 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -63.67 139.14 58.74 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.663 0.744 . . . . 0.0 110.656 -179.44 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 65.6 t -98.27 124.95 51.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.439 -0.788 . . . . 0.0 108.924 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 40.1 pt -104.65 -4.1 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.61 -0.681 . . . . 0.0 109.272 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.81 -168.22 41.23 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.191 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 40.3 t -153.87 154.61 34.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.51 -0.994 . . . . 0.0 109.353 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.7 mt -123.67 151.39 43.14 Favored 'General case' 0 N--CA 1.497 1.923 0 CA-C-O 121.566 0.698 . . . . 0.0 109.652 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.7 t -79.17 166.62 22.02 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.627 0.727 . . . . 0.0 110.606 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -64.79 158.55 44.12 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -179.234 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 66.8 m-20 57.39 32.94 22.57 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.711 -0.876 . . . . 0.0 109.685 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.2 m -94.53 129.07 41.48 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.281 -0.887 . . . . 0.0 109.456 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -82.92 132.82 35.14 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.426 -0.796 . . . . 0.0 109.822 -179.735 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 m -127.23 134.52 65.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 O-C-N 121.535 -0.728 . . . . 0.0 109.498 179.692 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 33.6 m -78.49 129.31 34.73 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.462 -0.774 . . . . 0.0 109.732 -179.346 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.3 mt -106.7 126.03 62.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.593 -0.692 . . . . 0.0 109.612 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 28.5 m -118.77 8.48 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.469 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.03 174.47 45.89 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -135.28 155.64 50.3 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.372 -1.075 . . . . 0.0 109.904 -179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.417 ' O ' ' O ' ' A' ' 44' ' ' PHE . 76.3 mm-40 -138.86 153.65 48.34 Favored 'General case' 0 N--CA 1.494 1.73 0 CA-C-O 121.435 0.636 . . . . 0.0 109.759 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.663 ' O ' ' HB3' ' A' ' 43' ' ' ALA . . . -64.36 108.02 2.09 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.124 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.663 ' HB3' ' O ' ' A' ' 42' ' ' GLY . . . 80.67 4.03 1.69 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.663 -0.904 . . . . 0.0 109.151 179.488 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.417 ' O ' ' O ' ' A' ' 41' ' ' GLU . 95.6 m-85 -149.39 159.6 44.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 109.736 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -118.25 147.45 43.41 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.435 ' HZ2' ' HB3' ' A' ' 53' ' ' HIS . 0.1 OUTLIER -91.6 118.1 30.32 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 179.674 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.6 pt -126.57 153.13 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 CA-C-O 121.644 0.735 . . . . 0.0 109.702 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -86.06 118.2 25.38 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.531 -0.731 . . . . 0.0 109.61 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.55 ' O ' ' N ' ' A' ' 51' ' ' GLY . 89.6 t80 -111.58 121.7 45.86 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.554 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.418 ' C ' ' O ' ' A' ' 49' ' ' TYR . 37.3 ttpt 39.52 -90.38 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.261 0.553 . . . . 0.0 110.311 -179.669 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -130.2 -22.64 1.09 Allowed Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.914 -1.675 . . . . 0.0 108.914 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 22.5 m -91.19 163.41 14.27 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.217 -1.167 . . . . 0.0 110.532 -179.355 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.435 ' HB3' ' HZ2' ' A' ' 46' ' ' LYS . 56.9 m170 -83.37 113.12 20.52 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.382 -0.824 . . . . 0.0 109.357 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.64 141.95 15.83 Favored Glycine 0 N--CA 1.495 2.576 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -120.81 139.54 52.99 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.672 -0.899 . . . . 0.0 109.427 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.4 m -132.57 137.83 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.662 -0.649 . . . . 0.0 109.525 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.702 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -61.48 143.72 55.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.548 -0.72 . . . . 0.0 110.805 -179.02 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -66.76 -12.31 58.22 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.505 -0.747 . . . . 0.0 109.899 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 47.3 tp10 -67.15 -36.54 82.06 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.169 -0.957 . . . . 0.0 110.256 -179.494 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -95.62 -5.03 43.39 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.173 -0.955 . . . . 0.0 109.842 -178.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 36.5 mm -110.22 128.94 66.07 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 O-C-N 121.511 -0.743 . . . . 0.0 109.37 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.43 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 21.2 ptmt -140.45 173.23 11.7 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.546 -0.721 . . . . 0.0 110.266 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.43 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 14.7 t0 77.36 -72.21 0.1 Allowed 'General case' 0 N--CA 1.495 1.781 0 CA-C-O 121.114 0.483 . . . . 0.0 109.748 179.644 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 27.3 mt 62.04 59.59 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.624 -0.673 . . . . 0.0 109.332 -179.651 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -142.89 135.68 27.89 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.509 -0.744 . . . . 0.0 109.587 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.438 ' OD1' ' N ' ' A' ' 67' ' ' GLU . 67.9 t0 -67.68 134.22 50.72 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.465 -0.772 . . . . 0.0 109.926 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.438 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 98.0 mt-10 -72.56 95.64 1.85 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.35 -0.844 . . . . 0.0 109.829 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 14.6 m -122.0 131.43 73.15 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 O-C-N 121.653 -0.655 . . . . 0.0 109.489 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.565 ' N ' HD22 ' A' ' 69' ' ' LEU . 3.8 mm? -78.31 142.76 37.53 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.513 -0.742 . . . . 0.0 110.341 -179.264 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -157.12 110.61 2.59 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 73.6 m80 -76.02 -73.54 0.26 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.579 -0.701 . . . . 0.0 109.806 -179.527 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -82.5 132.69 35.2 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.271 -0.893 . . . . 0.0 110.14 -179.218 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.537 ' O ' ' CG ' ' A' ' 74' ' ' HIS . 92.6 m-70 -67.33 -39.09 85.79 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.431 -0.793 . . . . 0.0 109.494 179.615 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' HIS . . . . . 0.537 ' CG ' ' O ' ' A' ' 73' ' ' HIS . 98.0 m-70 -158.49 -126.36 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.261 -0.899 . . . . 0.0 110.023 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -66.41 -39.31 88.93 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.538 -0.726 . . . . 0.0 109.605 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 92.4 m-70 . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.147 -0.97 . . . . 0.0 109.71 -179.871 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.54 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 57.4 mp0 -81.41 148.98 29.03 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 121.979 0.895 . . . . 0.0 110.462 -179.522 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt -132.21 153.13 50.9 Favored 'General case' 0 N--CA 1.496 1.828 0 CA-C-O 121.633 0.73 . . . . 0.0 109.889 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 44.1 p -115.72 121.78 43.52 Favored 'General case' 0 N--CA 1.499 1.987 0 CA-C-O 121.833 0.825 . . . . 0.0 109.79 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -100.79 142.27 15.73 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.594 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 22.6 mm -92.69 120.89 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 CA-C-O 121.684 0.754 . . . . 0.0 109.378 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.2 t -80.58 105.03 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 CA-C-O 121.668 0.746 . . . . 0.0 109.59 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.42 HD21 ' HA ' ' A' ' 8' ' ' ASN . 3.0 t-20 -99.43 103.88 15.7 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-O 121.747 0.784 . . . . 0.0 109.61 179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 26.8 m -137.93 160.58 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 CA-C-O 121.727 0.775 . . . . 0.0 109.918 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 88.0 p -85.73 -12.83 50.15 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.0 m -142.1 -76.01 0.28 Allowed 'General case' 0 N--CA 1.497 1.884 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 25.9 p -155.81 166.56 33.12 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.518 -0.739 . . . . 0.0 109.735 -179.385 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.8 tp -114.18 133.1 55.83 Favored 'General case' 0 N--CA 1.496 1.849 0 CA-C-O 121.841 0.829 . . . . 0.0 110.34 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -91.29 142.3 27.85 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-O 121.719 0.771 . . . . 0.0 109.991 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.9 t -99.11 129.51 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 CA-C-O 121.634 0.731 . . . . 0.0 109.662 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.7 mtt85 -92.87 153.44 18.82 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 121.793 0.806 . . . . 0.0 110.049 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -64.68 -44.37 90.58 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 19' ' ' ALA . . . -157.88 102.92 0.22 Allowed Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.614 ' H ' ' CB ' ' A' ' 55' ' ' TYR . . . 38.8 -114.51 0.14 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 122.001 -0.705 . . . . 0.0 110.292 179.476 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 19' ' ' ALA . 4.9 m 56.35 152.53 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 121.8 0.81 . . . . 0.0 110.508 179.678 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 97.8 m -67.82 -45.5 74.53 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.822 -0.549 . . . . 0.0 109.907 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 39.5 p -153.05 61.05 0.78 Allowed 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 121.836 0.827 . . . . 0.0 109.222 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 5.2 p -75.04 -171.38 1.34 Allowed 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.76 0.79 . . . . 0.0 110.634 179.583 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt -66.29 142.91 57.5 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-O 121.743 0.782 . . . . 0.0 110.411 -178.83 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 68.4 t -98.52 127.31 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 CA-C-O 121.732 0.777 . . . . 0.0 109.305 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 27.8 pt -103.26 -4.12 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 173.34 -173.9 45.86 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 24.1 p -154.35 161.69 41.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.81 -0.818 . . . . 0.0 109.711 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.8 mt -126.99 151.49 48.51 Favored 'General case' 0 N--CA 1.499 2.007 0 CA-C-O 121.947 0.879 . . . . 0.0 109.984 -179.665 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.412 ' O ' ' OG1' ' A' ' 33' ' ' THR . 84.1 p -72.7 165.87 23.94 Favored 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 121.812 0.815 . . . . 0.0 110.261 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.479 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.85 165.02 45.63 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 56.33 2.88 0.09 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 122.335 -0.509 . . . . 0.0 110.116 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.479 ' H ' ' C ' ' A' ' 31' ' ' GLY . 47.5 m -71.24 136.14 47.83 Favored 'General case' 0 N--CA 1.496 1.851 0 CA-C-O 121.916 0.865 . . . . 0.0 110.391 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -88.9 143.04 27.15 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.34 0.591 . . . . 0.0 109.866 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 35.4 m -126.26 130.46 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 CA-C-O 121.821 0.82 . . . . 0.0 110.08 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 82.7 m -80.01 125.7 30.11 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.517 0.675 . . . . 0.0 109.739 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.6 mt -104.87 128.09 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 CA-C-O 121.554 0.693 . . . . 0.0 109.83 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.8 m -123.92 7.5 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.488 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.04 169.6 42.75 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -129.84 152.77 48.95 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.789 -0.83 . . . . 0.0 109.553 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 53.3 tp10 -153.29 108.33 3.19 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.936 0.874 . . . . 0.0 110.068 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 49.73 -138.14 20.1 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 178.645 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -84.67 20.3 1.79 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 122.005 -0.703 . . . . 0.0 109.226 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -128.35 151.0 49.85 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-O 121.688 0.756 . . . . 0.0 109.582 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 51.9 m-85 -102.98 141.87 35.04 Favored 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.945 0.878 . . . . 0.0 109.968 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 65.4 tttm -94.29 122.53 36.93 Favored 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.493 0.663 . . . . 0.0 109.384 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 34.6 pt -129.25 154.99 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 CA-C-O 121.806 0.813 . . . . 0.0 110.316 179.839 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -83.45 114.4 21.44 Favored 'General case' 0 N--CA 1.494 1.73 0 CA-C-O 121.568 0.699 . . . . 0.0 109.915 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.569 ' O ' ' N ' ' A' ' 51' ' ' GLY . 86.1 t80 -106.28 114.85 29.22 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.694 0.759 . . . . 0.0 109.588 179.77 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.1 mttp 40.96 -87.54 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.754 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.105 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -115.63 -39.38 0.92 Allowed Glycine 0 N--CA 1.495 2.58 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 16.7 p -89.54 169.37 11.41 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.804 -0.821 . . . . 0.0 110.45 -179.184 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 96.0 m-70 -96.52 111.19 23.4 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.914 0.864 . . . . 0.0 109.952 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.64 144.08 23.97 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.614 ' CB ' ' H ' ' A' ' 19' ' ' ALA . 75.8 m-85 -119.63 135.76 54.67 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-O 121.751 0.786 . . . . 0.0 109.515 179.346 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 20.1 m -137.38 156.12 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 CA-C-O 121.913 0.863 . . . . 0.0 110.318 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.07 154.36 33.42 Favored 'General case' 0 N--CA 1.492 1.667 0 CA-C-O 121.681 0.753 . . . . 0.0 110.107 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -69.67 -17.6 63.5 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.529 ' OE2' ' CE2' ' A' ' 60' ' ' TYR . 9.7 pt-20 -65.0 -34.92 79.58 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.786 -0.572 . . . . 0.0 109.893 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.529 ' CE2' ' OE2' ' A' ' 59' ' ' GLU . 66.8 m-85 -91.98 -10.16 40.33 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.451 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 36.0 mm -110.46 120.73 61.94 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.121 0 CA-C-O 121.847 0.832 . . . . 0.0 110.021 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -149.72 173.47 13.67 Favored 'General case' 0 N--CA 1.494 1.734 0 CA-C-O 121.616 0.722 . . . . 0.0 110.21 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 57.6 47.98 15.01 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 121.353 0.596 . . . . 0.0 109.405 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt -72.0 129.91 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 CA-C-O 121.699 0.762 . . . . 0.0 110.055 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -103.61 140.59 37.35 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-O 121.924 0.869 . . . . 0.0 110.148 -179.018 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -97.66 113.53 25.29 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.703 0.764 . . . . 0.0 109.697 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.532 ' N ' ' OE1' ' A' ' 67' ' ' GLU . 57.3 mp0 -84.2 -6.48 59.41 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 75.0 t -84.34 134.29 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 CA-C-O 121.704 0.764 . . . . 0.0 110.21 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 65.4 mt -64.57 134.74 55.0 Favored 'General case' 0 N--CA 1.495 1.791 0 CA-C-O 121.814 0.816 . . . . 0.0 110.088 -179.364 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -74.11 141.88 45.61 Favored 'General case' 0 N--CA 1.491 1.603 0 CA-C-O 121.695 0.76 . . . . 0.0 110.207 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 49.4 t-80 -71.76 149.81 45.02 Favored 'General case' 0 N--CA 1.491 1.594 0 CA-C-O 121.777 0.799 . . . . 0.0 110.464 -179.302 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -70.05 138.91 52.51 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.773 0.797 . . . . 0.0 110.553 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 46.62 77.0 0.09 Allowed 'General case' 0 N--CA 1.491 1.576 0 CA-C-O 121.575 0.703 . . . . 0.0 109.496 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -62.27 -42.9 99.74 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -147.08 140.07 25.17 Favored 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 121.884 0.85 . . . . 0.0 109.885 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 47.1 p-80 . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 118.135 -0.936 . . . . 0.0 109.325 179.687 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.685 0 CA-C-O 121.624 0.726 . . . . 0.0 110.303 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.427 ' OE1' ' OE1' ' A' ' 67' ' ' GLU . 96.9 mt-10 -66.12 142.22 57.84 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.288 -0.882 . . . . 0.0 110.512 -179.228 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -136.48 151.34 49.35 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.535 -0.728 . . . . 0.0 109.478 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 70.4 p -127.73 131.14 49.73 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.524 -0.735 . . . . 0.0 109.144 179.644 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -120.02 135.18 10.91 Favored Glycine 0 N--CA 1.5 2.918 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.757 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.9 mp -86.72 129.02 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.434 -1.039 . . . . 0.0 109.675 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.3 t -82.13 104.8 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.181 -0.949 . . . . 0.0 109.665 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -108.29 106.45 16.61 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.481 -0.762 . . . . 0.0 109.054 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 27.7 m -138.47 162.4 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.27 -0.894 . . . . 0.0 110.016 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 t -61.99 -43.57 98.55 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.55 -0.719 . . . . 0.0 109.46 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 12' ' ' SER . 70.5 m -161.09 108.9 1.52 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.006 -1.059 . . . . 0.0 110.262 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 11' ' ' SER . 22.7 t 54.0 159.19 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.849 0.833 . . . . 0.0 111.509 179.126 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 35.1 tp -133.22 133.03 42.19 Favored 'General case' 0 N--CA 1.498 1.971 0 CA-C-O 121.485 0.66 . . . . 0.0 109.652 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 46.0 p-10 -80.69 141.81 34.52 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.391 -0.818 . . . . 0.0 109.914 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 78.2 t -93.45 133.12 35.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.201 -0.937 . . . . 0.0 109.666 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -102.38 130.54 49.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.384 -0.823 . . . . 0.0 109.909 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -73.75 -41.31 62.67 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.468 -0.77 . . . . 0.0 109.763 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.479 ' O ' ' CG ' ' A' ' 55' ' ' TYR . . . -95.93 -129.42 5.96 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.934 -1.266 . . . . 0.0 109.934 -179.111 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -137.13 -12.85 1.63 Allowed 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.519 -0.989 . . . . 0.0 109.073 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 12.0 m -72.72 152.36 41.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.198 -0.939 . . . . 0.0 110.688 -179.094 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.7 m -63.15 -46.08 88.87 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.376 -0.828 . . . . 0.0 109.34 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 58.7 m -88.75 34.74 0.77 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.152 -0.967 . . . . 0.0 108.604 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.2 p -73.78 161.95 29.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.405 -0.81 . . . . 0.0 110.376 -179.2 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -66.28 136.11 55.37 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.348 -0.845 . . . . 0.0 110.299 -179.307 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 53.4 t -100.72 127.98 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.416 -0.802 . . . . 0.0 109.355 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.5 pt -101.11 -3.07 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.04 -164.22 37.6 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.458 -1.353 . . . . 0.0 110.325 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 40.4 t -155.31 158.87 39.43 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.268 -1.136 . . . . 0.0 109.373 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.0 mt -122.96 149.96 43.59 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.508 -0.745 . . . . 0.0 109.769 -179.693 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 29.6 t -69.23 154.62 41.75 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-O 121.834 0.826 . . . . 0.0 111.02 -178.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.46 157.25 37.53 Favored Glycine 0 N--CA 1.492 2.413 0 O-C-N 121.637 -0.664 . . . . 0.0 111.475 -179.418 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.3 t-20 58.75 33.88 23.37 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.809 -0.818 . . . . 0.0 109.741 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.7 m -97.02 129.52 44.46 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.314 -0.866 . . . . 0.0 109.594 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 54.1 tttp -79.8 131.13 35.82 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.352 -0.843 . . . . 0.0 109.344 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 21.6 m -128.77 136.6 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.392 -0.817 . . . . 0.0 109.697 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 18.8 m -80.99 129.46 34.54 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.613 -0.679 . . . . 0.0 109.586 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.6 mt -110.45 129.56 65.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.686 -0.633 . . . . 0.0 109.446 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.583 HG23 ' N ' ' A' ' 39' ' ' GLY . 24.4 m -128.62 -49.37 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.583 ' N ' HG23 ' A' ' 38' ' ' VAL . . . -91.57 166.84 30.64 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 -179.112 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -139.0 146.87 41.42 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.337 -1.096 . . . . 0.0 109.559 179.572 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.5 tm-20 -154.31 110.02 3.19 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.321 -0.862 . . . . 0.0 109.07 179.387 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 53.13 -138.82 34.79 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 111.044 -0.822 . . . . 0.0 111.044 179.186 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.02 10.65 13.57 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.366 -1.079 . . . . 0.0 109.113 -179.411 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -111.62 144.45 40.85 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.502 -0.748 . . . . 0.0 109.447 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 47.2 m-85 -104.03 141.33 36.38 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.544 -0.723 . . . . 0.0 109.702 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -90.28 137.91 31.96 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.266 -0.897 . . . . 0.0 108.751 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 17.3 pt -127.81 154.38 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.0 0 O-C-N 121.468 -0.77 . . . . 0.0 110.087 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 50.8 tp10 -82.95 106.87 15.13 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.532 ' O ' ' N ' ' A' ' 51' ' ' GLY . 80.1 t80 -109.21 124.69 51.27 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.52 -0.737 . . . . 0.0 110.134 -179.722 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.443 ' C ' ' O ' ' A' ' 49' ' ' TYR . 67.8 mttm 33.62 -88.97 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.103 0.478 . . . . 0.0 111.246 179.504 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -119.83 -29.3 1.71 Allowed Glycine 0 N--CA 1.498 2.807 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 -179.251 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 66.6 m -100.58 176.86 5.18 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.088 -1.242 . . . . 0.0 110.478 -179.276 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -107.68 119.91 40.75 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.527 -0.733 . . . . 0.0 109.682 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.7 159.03 25.56 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.479 ' CG ' ' O ' ' A' ' 18' ' ' GLY . 91.0 m-85 -115.98 137.32 52.22 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.444 -1.033 . . . . 0.0 109.64 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.8 m -136.11 137.19 48.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.627 -0.671 . . . . 0.0 109.431 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.32 148.08 51.25 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.498 -0.751 . . . . 0.0 110.611 -179.278 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.3 ptpm? -62.84 -16.55 58.92 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.376 -0.827 . . . . 0.0 109.368 179.511 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -67.58 -35.84 79.77 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.292 -0.88 . . . . 0.0 109.89 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -92.34 -5.02 53.01 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.018 -1.051 . . . . 0.0 109.236 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 36.7 mm -112.11 123.87 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 121.374 -0.829 . . . . 0.0 109.21 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 20.5 ptmt -141.63 171.17 14.43 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.479 -0.763 . . . . 0.0 110.068 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 58.72 40.86 22.73 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-O 121.477 0.656 . . . . 0.0 109.487 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt -75.8 129.87 36.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.285 -0.884 . . . . 0.0 110.042 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.9 mtpt -135.42 147.13 48.88 Favored 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 121.752 0.787 . . . . 0.0 110.215 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 65.1 t0 -82.92 122.19 27.94 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.565 -0.709 . . . . 0.0 110.251 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.427 ' OE1' ' OE1' ' A' ' 2' ' ' GLU . 96.2 mt-10 -47.43 152.15 0.68 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.263 -0.898 . . . . 0.0 110.76 -179.535 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.415 HG23 ' O ' ' A' ' 68' ' ' VAL . 19.5 m -66.62 130.56 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 CA-C-O 121.881 0.848 . . . . 0.0 110.56 -179.093 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.426 ' O ' ' O ' ' A' ' 70' ' ' GLU . 5.6 tp -104.11 -18.6 14.47 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.426 ' O ' ' O ' ' A' ' 69' ' ' LEU . 73.8 mm-40 58.28 119.45 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.923 0 CA-C-O 121.925 0.869 . . . . 0.0 110.467 -179.736 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.423 ' O ' ' O ' ' A' ' 72' ' ' HIS . 96.7 m-70 -74.65 147.92 41.12 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.609 0.718 . . . . 0.0 110.82 -179.463 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.423 ' O ' ' O ' ' A' ' 71' ' ' HIS . 71.1 m80 58.61 123.42 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.779 0 CA-C-O 121.713 0.768 . . . . 0.0 110.418 179.526 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 58.8 t-80 -79.99 106.33 11.93 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.486 -0.759 . . . . 0.0 109.926 -179.704 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 78.3 m80 -151.86 64.05 0.85 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 179.497 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -61.97 -42.04 98.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.397 -0.814 . . . . 0.0 109.221 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 33.9 p-80 . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 117.945 -1.026 . . . . 0.0 109.699 -179.711 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.448 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.527 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 56.2 mp0 44.02 97.47 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.668 0.747 . . . . 0.0 110.205 179.819 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -119.62 154.95 33.22 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.448 ' CB ' ' HZ1' ' A' ' 34' ' ' LYS . 59.2 p -128.41 124.78 37.14 Favored 'General case' 0 N--CA 1.497 1.893 0 CA-C-O 121.643 0.735 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.454 ' C ' HD12 ' A' ' 6' ' ' ILE . . . -99.91 137.25 13.15 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -179.745 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.776 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.8 mp -93.95 119.16 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.536 -0.979 . . . . 0.0 109.673 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 71.9 t -79.09 133.2 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 CA-C-O 121.494 0.664 . . . . 0.0 109.791 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.533 ' CB ' ' NZ ' ' A' ' 62' ' ' LYS . 4.0 t-20 -140.34 106.98 5.33 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.404 -0.81 . . . . 0.0 109.648 -179.813 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 m -138.3 151.68 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.603 -0.686 . . . . 0.0 109.634 179.8 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 73.5 m -72.26 -42.9 65.06 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 121.477 0.656 . . . . 0.0 109.828 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 69.0 m -103.85 -76.67 0.59 Allowed 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.446 -0.784 . . . . 0.0 109.625 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 41.2 t -160.03 168.27 25.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.325 -0.86 . . . . 0.0 109.687 -179.565 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 41.8 tp -116.58 130.21 56.62 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 121.592 0.71 . . . . 0.0 109.984 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -91.92 138.38 31.59 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.771 0.796 . . . . 0.0 110.158 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.3 t -89.5 130.01 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 CA-C-O 121.497 0.665 . . . . 0.0 109.802 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.425 ' NH1' HG23 ' A' ' 25' ' ' VAL . 38.4 mmt180 -107.67 131.15 54.71 Favored 'General case' 0 N--CA 1.496 1.835 0 CA-C-O 121.872 0.844 . . . . 0.0 109.565 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -71.22 -40.18 71.27 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-O 121.532 0.682 . . . . 0.0 109.549 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.502 ' N ' ' OG ' ' A' ' 23' ' ' SER . . . -93.69 177.09 37.07 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.34 39.51 0.87 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.501 -0.999 . . . . 0.0 109.104 179.744 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.9 p -151.91 154.88 36.97 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.398 -0.814 . . . . 0.0 109.686 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.404 ' O ' ' CZ ' ' A' ' 16' ' ' ARG . 60.5 p -71.29 -28.03 63.84 Favored 'General case' 0 N--CA 1.493 1.724 0 CA-C-O 121.675 0.75 . . . . 0.0 109.379 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 91.9 p -82.35 -3.71 55.94 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.502 ' OG ' ' N ' ' A' ' 18' ' ' GLY . 24.0 t -51.73 -97.08 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.619 -0.675 . . . . 0.0 110.188 -179.746 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.33 131.58 1.2 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.311 -0.868 . . . . 0.0 110.011 -179.445 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.425 HG23 ' NH1' ' A' ' 16' ' ' ARG . 84.2 t -81.67 132.17 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.73 -0.606 . . . . 0.0 109.939 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 45.0 pt -117.6 -10.28 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.69 -175.01 45.23 Favored Glycine 0 N--CA 1.494 2.554 0 C-N-CA 119.402 -1.38 . . . . 0.0 110.252 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 65.8 m -133.04 156.18 47.84 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.714 -0.874 . . . . 0.0 109.814 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 92.2 mt -122.9 147.91 46.04 Favored 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.83 0.824 . . . . 0.0 109.941 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.6 t -74.77 157.85 34.5 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-O 121.937 0.875 . . . . 0.0 110.63 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -66.6 156.52 51.04 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 57.36 33.09 22.8 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 122.075 -0.662 . . . . 0.0 109.461 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 43.3 m -94.42 125.07 38.84 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.843 0.83 . . . . 0.0 110.331 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.448 ' HZ1' ' CB ' ' A' ' 4' ' ' THR . 63.3 tttp -79.24 132.14 36.4 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-O 121.306 0.574 . . . . 0.0 109.677 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.1 m -129.5 134.13 64.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 121.804 0.811 . . . . 0.0 109.763 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 52.7 m -79.09 127.63 32.25 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-O 121.6 0.714 . . . . 0.0 109.901 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.7 mt -102.76 124.2 56.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 CA-C-O 121.499 0.666 . . . . 0.0 109.508 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.76 -0.8 9.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.3 176.31 46.0 Favored Glycine 0 N--CA 1.494 2.551 0 C-N-CA 119.681 -1.247 . . . . 0.0 110.538 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -143.94 155.3 44.01 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.65 -0.912 . . . . 0.0 109.475 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -153.27 107.28 3.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.456 -0.777 . . . . 0.0 109.78 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.3 -135.96 49.75 Favored Glycine 0 N--CA 1.493 2.493 0 CA-C-O 121.98 0.766 . . . . 0.0 111.626 178.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -88.28 28.19 1.12 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.554 -0.968 . . . . 0.0 109.122 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -136.11 150.26 49.03 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.641 -0.662 . . . . 0.0 109.58 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.626 ' CZ ' ' NZ ' ' A' ' 58' ' ' LYS . 12.5 m-85 -107.17 146.04 31.82 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-O 121.882 0.849 . . . . 0.0 109.925 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -98.67 124.77 43.69 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.7 pt -129.73 157.79 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 121.651 0.738 . . . . 0.0 110.187 -179.77 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -87.5 101.79 13.95 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.43 0.634 . . . . 0.0 109.811 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.8 t80 -109.85 118.64 37.03 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-O 121.618 0.723 . . . . 0.0 109.45 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.6 mmtt 51.43 29.8 5.6 Favored 'General case' 0 N--CA 1.492 1.668 0 CA-C-O 121.763 0.792 . . . . 0.0 109.754 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.97 -23.45 23.55 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 179.346 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.3 m -86.53 165.34 16.31 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.281 -1.129 . . . . 0.0 110.576 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -94.51 101.63 13.54 Favored 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 121.73 0.776 . . . . 0.0 109.667 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.1 147.93 19.9 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.742 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -115.51 134.08 55.42 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.699 -0.883 . . . . 0.0 109.425 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.6 m -136.14 139.58 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 CA-C-O 121.573 0.702 . . . . 0.0 109.902 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.53 144.71 55.75 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.889 0.852 . . . . 0.0 110.387 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.626 ' NZ ' ' CZ ' ' A' ' 45' ' ' TYR . 67.1 mttm -63.74 -36.84 85.19 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-O 121.421 0.629 . . . . 0.0 110.468 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -46.83 -16.34 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.238 -0.914 . . . . 0.0 110.675 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.45 ' N ' ' O ' ' A' ' 58' ' ' LYS . 36.1 m-85 -108.37 -30.65 8.2 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.162 -0.961 . . . . 0.0 109.132 179.488 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.627 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.5 mp -93.54 123.22 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.424 -0.798 . . . . 0.0 109.741 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.533 ' NZ ' ' CB ' ' A' ' 8' ' ' ASN . 26.6 pttm -148.78 174.73 11.89 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.585 0.707 . . . . 0.0 109.952 179.527 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.551 ' O ' HD13 ' A' ' 6' ' ' ILE . 97.5 m-20 58.11 51.28 8.87 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-O 121.68 0.752 . . . . 0.0 109.765 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.411 HD11 ' CE2' ' A' ' 45' ' ' TYR . 96.9 mt -71.08 133.53 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.51 -0.744 . . . . 0.0 109.722 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 15.0 ttmm -112.87 132.25 55.37 Favored 'General case' 0 N--CA 1.496 1.825 0 CA-C-O 121.841 0.829 . . . . 0.0 110.258 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -85.91 117.68 24.92 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.739 0.78 . . . . 0.0 109.672 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -60.31 135.73 57.82 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.846 0.832 . . . . 0.0 110.117 -179.583 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.456 ' O ' HG13 ' A' ' 68' ' ' VAL . 9.0 p -99.45 125.44 53.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 CA-C-O 121.673 0.749 . . . . 0.0 109.581 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 87.0 mt -93.42 -5.23 49.81 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.542 -0.724 . . . . 0.0 109.116 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.427 ' H ' HG22 ' A' ' 68' ' ' VAL . 97.8 mt-10 -59.23 136.01 57.83 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.309 -0.869 . . . . 0.0 110.051 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 86.6 t60 -67.17 -40.41 86.59 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.75 0.786 . . . . 0.0 109.506 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -68.25 145.53 54.18 Favored 'General case' 0 N--CA 1.49 1.531 0 CA-C-O 121.677 0.751 . . . . 0.0 110.156 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.531 ' O ' ' CG ' ' A' ' 74' ' ' HIS . 59.4 t-80 -132.95 164.53 26.74 Favored 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.576 0.703 . . . . 0.0 109.811 -179.565 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' HIS . . . . . 0.531 ' CG ' ' O ' ' A' ' 73' ' ' HIS . 18.7 p80 41.7 -158.98 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.579 0.705 . . . . 0.0 110.589 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' HIS . . . . . 0.443 ' N ' ' ND1' ' A' ' 74' ' ' HIS . 99.1 m-70 -138.88 147.66 42.66 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.422 -0.799 . . . . 0.0 110.072 -179.139 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' HIS . . . . . 0.455 ' O ' ' CG ' ' A' ' 76' ' ' HIS . 85.8 t60 . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 118.145 -0.931 . . . . 0.0 109.065 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -69.48 140.51 54.02 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.342 -0.849 . . . . 0.0 110.265 -179.557 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt -137.42 153.28 50.16 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.482 -0.761 . . . . 0.0 109.384 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 46.9 p -115.13 123.13 48.16 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.679 -0.638 . . . . 0.0 109.372 -179.673 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -96.04 131.45 10.66 Favored Glycine 0 N--CA 1.496 2.674 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.585 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.4 mp -80.81 126.41 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.332 -1.099 . . . . 0.0 109.251 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.441 HG13 HD22 ' A' ' 13' ' ' LEU . 74.9 t -80.61 132.78 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.542 -0.724 . . . . 0.0 109.645 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 24.2 t-20 -131.24 103.41 6.46 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.547 -0.721 . . . . 0.0 109.271 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 27.9 m -135.46 156.45 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.492 -0.755 . . . . 0.0 109.434 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 95.6 p -83.7 -10.96 57.8 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.488 -0.758 . . . . 0.0 109.3 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.501 ' OG ' ' N ' ' A' ' 12' ' ' SER . 86.4 p -138.37 -73.1 0.4 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.359 -0.838 . . . . 0.0 109.154 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.501 ' N ' ' OG ' ' A' ' 11' ' ' SER . 31.9 p -158.71 165.04 35.29 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.369 -0.832 . . . . 0.0 109.249 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.441 HD22 HG13 ' A' ' 7' ' ' VAL . 44.9 tp -113.83 131.47 56.23 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.482 -0.761 . . . . 0.0 109.028 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -91.07 146.43 23.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.406 -0.809 . . . . 0.0 109.885 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 65.1 t -99.3 130.1 48.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.504 ' NH1' ' O ' ' A' ' 21' ' ' THR . 93.0 mtt-85 -110.97 136.85 49.36 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.587 -0.695 . . . . 0.0 109.95 -179.346 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.5 ' OE2' HD13 ' A' ' 26' ' ' ILE . 66.3 mm-40 -80.58 -35.73 33.84 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.453 -0.779 . . . . 0.0 109.655 179.592 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -95.57 177.17 34.4 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.538 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.68 -5.42 42.31 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.402 -1.058 . . . . 0.0 109.083 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 33.5 t -86.16 153.67 21.89 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -0.852 . . . . 0.0 109.951 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.504 ' O ' ' NH1' ' A' ' 16' ' ' ARG . 15.3 m -63.67 -44.77 92.79 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.433 -0.792 . . . . 0.0 109.725 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 76.7 p -73.11 17.83 0.12 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.212 -0.93 . . . . 0.0 109.408 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.487 ' H ' ' C ' ' A' ' 21' ' ' THR . 17.3 m -64.65 149.22 49.4 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.239 -0.913 . . . . 0.0 109.788 -179.723 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 24.9 pttm -70.79 143.53 51.14 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.395 -0.815 . . . . 0.0 110.367 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 55.6 t -103.24 131.28 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.528 -0.732 . . . . 0.0 109.641 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.5 HD13 ' OE2' ' A' ' 17' ' ' GLU . 24.7 pt -99.01 -6.58 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.441 -0.787 . . . . 0.0 109.538 179.712 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.3 -159.81 33.27 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.8 m -152.92 167.11 30.23 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.436 -1.037 . . . . 0.0 109.571 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.9 mt -127.23 153.89 45.53 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.525 -0.734 . . . . 0.0 109.576 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.6 p -73.25 162.08 29.79 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.505 -0.747 . . . . 0.0 110.721 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.537 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -69.07 163.71 50.6 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -179.509 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 35.2 t-20 65.45 -13.95 0.12 Allowed 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.81 -0.818 . . . . 0.0 110.012 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.537 ' H ' ' C ' ' A' ' 31' ' ' GLY . 38.2 m -67.83 133.7 49.64 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.055 -1.028 . . . . 0.0 109.503 179.568 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.405 ' H ' ' HG2' ' A' ' 34' ' ' LYS . 19.5 pttp -93.81 146.57 23.78 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.353 -0.842 . . . . 0.0 109.651 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.1 m -122.86 131.46 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.618 -0.677 . . . . 0.0 109.424 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 33.6 m -66.13 128.85 37.73 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.526 -0.733 . . . . 0.0 110.352 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 94.2 mt -107.95 127.81 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.399 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 17.1 m -111.57 -1.06 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 O-C-N 121.567 -0.708 . . . . 0.0 109.468 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 178.75 -175.27 47.25 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -140.69 153.63 46.03 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.369 -1.077 . . . . 0.0 109.432 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 47.9 tp10 -151.64 112.06 4.15 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.326 -0.859 . . . . 0.0 109.506 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.96 -143.35 48.58 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.63 17.2 3.41 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.635 -0.92 . . . . 0.0 109.874 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -127.21 148.1 50.2 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.415 -0.803 . . . . 0.0 109.34 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -98.99 147.42 25.03 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.432 -0.792 . . . . 0.0 109.734 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -96.37 126.79 41.81 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.6 pt -128.95 156.36 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.503 -0.748 . . . . 0.0 109.952 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -90.27 117.69 29.2 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.488 -0.757 . . . . 0.0 109.418 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.537 ' O ' ' N ' ' A' ' 51' ' ' GLY . 53.1 t80 -106.49 101.96 11.39 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.551 -0.718 . . . . 0.0 109.358 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 7.7 mtmp? 43.51 -88.69 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.59 -0.693 . . . . 0.0 110.655 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.537 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -128.39 42.61 1.42 Allowed Glycine 0 N--CA 1.501 2.993 0 N-CA-C 109.784 -1.327 . . . . 0.0 109.784 -179.329 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 93.9 p -161.43 163.59 30.38 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.196 -1.179 . . . . 0.0 109.172 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -94.91 111.18 22.99 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.22 -0.925 . . . . 0.0 109.559 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.11 150.22 19.56 Favored Glycine 0 N--CA 1.494 2.546 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -128.41 139.6 52.28 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.627 -0.925 . . . . 0.0 109.473 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 28.8 m -136.19 156.21 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.436 -0.79 . . . . 0.0 109.826 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 147.18 39.49 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.484 -0.76 . . . . 0.0 110.465 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -69.18 -12.53 61.76 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.485 -0.76 . . . . 0.0 109.593 179.456 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -67.88 -35.27 78.22 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.22 -0.925 . . . . 0.0 110.499 -179.352 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.541 ' C ' HD12 ' A' ' 61' ' ' ILE . 19.8 m-85 -94.35 -4.49 48.47 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.906 -1.121 . . . . 0.0 110.336 -179.17 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.541 HD12 ' C ' ' A' ' 60' ' ' TYR . 1.6 mp -107.82 130.6 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.237 -0.914 . . . . 0.0 108.88 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.563 ' O ' ' N ' ' A' ' 64' ' ' ILE . 64.3 pttt -142.34 -168.11 2.65 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.478 -0.764 . . . . 0.0 109.077 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 56.26 -75.16 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 CA-C-O 120.986 0.422 . . . . 0.0 110.262 179.655 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.563 ' N ' ' O ' ' A' ' 62' ' ' LYS . 90.3 mt 57.49 81.08 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.445 -0.785 . . . . 0.0 109.369 -179.667 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -139.15 154.74 48.14 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.518 -0.739 . . . . 0.0 109.359 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -81.19 108.4 14.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.298 -0.876 . . . . 0.0 109.813 -179.527 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -103.67 -10.74 18.14 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.476 -0.765 . . . . 0.0 109.157 179.556 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.6 t -92.16 -21.19 6.37 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.239 -0.913 . . . . 0.0 109.396 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 70' ' ' GLU . 86.6 mt -89.91 137.49 32.3 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.357 -0.839 . . . . 0.0 109.917 -179.627 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.421 ' C ' ' O ' ' A' ' 69' ' ' LEU . 15.0 pt-20 35.16 -150.99 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.971 0 CA-C-O 121.661 0.743 . . . . 0.0 111.504 179.146 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 69.8 t60 54.82 92.29 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.392 -0.818 . . . . 0.0 109.451 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.571 ' O ' ' N ' ' A' ' 74' ' ' HIS . 59.0 t-80 -70.14 105.87 3.08 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.455 -0.778 . . . . 0.0 110.063 -179.718 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.601 ' ND1' ' ND1' ' A' ' 74' ' ' HIS . 62.4 t-80 51.3 -80.12 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.65 -0.656 . . . . 0.0 110.814 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' HIS . . . . . 0.601 ' ND1' ' ND1' ' A' ' 73' ' ' HIS . 21.2 p-80 -146.99 168.44 21.5 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.922 -1.111 . . . . 0.0 109.635 -179.293 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 8.9 p-80 -66.06 141.08 58.27 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.448 -0.782 . . . . 0.0 110.348 -179.177 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.5 m-70 . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 118.151 -0.928 . . . . 0.0 109.97 179.622 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.665 0.745 . . . . 0.0 109.938 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -71.74 155.28 40.63 Favored 'General case' 0 N--CA 1.491 1.583 0 CA-C-O 121.543 0.687 . . . . 0.0 110.237 -179.503 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.445 ' H ' ' HB ' ' A' ' 37' ' ' ILE . 68.6 mttm -136.54 154.9 50.58 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.486 -0.758 . . . . 0.0 109.566 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 42.5 p -107.22 114.93 29.29 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.777 0.798 . . . . 0.0 109.289 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.45 136.2 12.57 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.523 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.771 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.8 mp -86.38 120.84 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.568 -0.96 . . . . 0.0 109.445 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 99.5 t -82.58 104.35 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 CA-C-O 121.581 0.705 . . . . 0.0 109.354 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 -102.26 103.79 14.29 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.51 -0.744 . . . . 0.0 109.762 -179.57 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 34.7 m -137.46 164.05 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.57 -0.706 . . . . 0.0 109.832 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 79.8 p -63.25 -39.88 95.85 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.348 0.594 . . . . 0.0 109.755 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.442 ' O ' ' O ' ' A' ' 12' ' ' SER . 29.6 p -163.89 109.16 1.04 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.94 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.442 ' O ' ' O ' ' A' ' 11' ' ' SER . 1.4 m 52.48 166.82 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 CA-C-O 121.938 0.875 . . . . 0.0 111.156 179.634 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 37.1 tp -139.46 131.53 27.96 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.583 0.706 . . . . 0.0 109.853 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -79.52 141.86 36.29 Favored 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.516 0.674 . . . . 0.0 109.933 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 75.3 t -98.78 130.62 47.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.54 -0.725 . . . . 0.0 109.718 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.509 ' NE ' ' O ' ' A' ' 21' ' ' THR . 85.1 mtt85 -103.58 134.09 47.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.468 -0.77 . . . . 0.0 109.73 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.1 tm-20 -71.58 -38.98 70.85 Favored 'General case' 0 N--CA 1.491 1.575 0 CA-C-O 121.596 0.713 . . . . 0.0 109.617 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -90.96 173.66 38.2 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.123 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -90.36 5.35 47.71 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.367 -1.079 . . . . 0.0 109.385 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.438 ' CB ' ' HG ' ' A' ' 23' ' ' SER . 7.2 p -78.66 166.64 22.28 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.319 -0.863 . . . . 0.0 110.38 -179.389 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.509 ' O ' ' NE ' ' A' ' 16' ' ' ARG . 0.7 OUTLIER -69.85 -20.71 63.4 Favored 'General case' 0 N--CA 1.491 1.596 0 CA-C-O 121.509 0.671 . . . . 0.0 109.664 179.807 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.7 t -151.11 63.76 0.9 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.009 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.438 ' HG ' ' CB ' ' A' ' 20' ' ' SER . 18.1 m -75.13 -79.42 0.09 Allowed 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.636 0.732 . . . . 0.0 109.447 179.839 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -160.56 121.17 2.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.218 -0.926 . . . . 0.0 109.935 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 75.7 t -74.97 129.3 36.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.496 0.665 . . . . 0.0 109.623 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 34.8 pt -119.6 -10.22 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.483 0.658 . . . . 0.0 109.24 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 179.47 -168.73 39.47 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.633 -1.27 . . . . 0.0 110.163 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 39.4 t -154.31 154.5 33.47 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.576 -0.955 . . . . 0.0 109.831 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.0 mt -122.71 150.56 42.57 Favored 'General case' 0 N--CA 1.495 1.806 0 CA-C-O 121.622 0.725 . . . . 0.0 109.544 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 17.1 m -69.45 151.31 46.24 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.851 0.834 . . . . 0.0 110.354 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.403 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.2 166.04 41.91 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 57.11 8.52 0.54 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 122.012 -0.699 . . . . 0.0 109.575 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.403 ' H ' ' C ' ' A' ' 31' ' ' GLY . 34.6 m -88.47 134.33 33.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.44 -0.788 . . . . 0.0 110.243 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -78.14 146.66 34.98 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.641 -0.662 . . . . 0.0 110.094 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.7 m -126.33 132.58 70.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 CA-C-O 121.621 0.724 . . . . 0.0 109.567 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 39.6 m -65.12 128.89 37.65 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.547 0.689 . . . . 0.0 110.116 -179.509 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.445 ' HB ' ' H ' ' A' ' 3' ' ' LYS . 5.4 mm -102.8 125.2 57.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 CA-C-O 121.442 0.639 . . . . 0.0 109.426 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 6.3 m -122.11 -11.83 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.55 -173.81 45.6 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.544 -1.312 . . . . 0.0 110.659 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -148.56 163.15 38.09 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.577 -0.955 . . . . 0.0 109.827 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -156.08 114.06 3.33 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.504 -0.748 . . . . 0.0 109.503 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 61.17 -136.5 48.14 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 179.582 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.418 ' C ' ' HZ2' ' A' ' 58' ' ' LYS . . . -92.34 28.91 1.8 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.527 -0.984 . . . . 0.0 108.719 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -134.5 150.35 50.78 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.621 -0.674 . . . . 0.0 109.435 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -105.37 139.63 39.7 Favored 'General case' 0 N--CA 1.493 1.715 0 CA-C-O 121.798 0.809 . . . . 0.0 109.703 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -96.86 129.19 44.33 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.9 pt -129.29 164.22 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 CA-C-O 121.727 0.775 . . . . 0.0 110.212 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -77.72 99.75 5.97 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-O 121.619 0.723 . . . . 0.0 109.94 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -90.36 134.77 34.1 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.515 -0.741 . . . . 0.0 109.484 179.521 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 56.6 mtpt -52.1 97.8 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.452 0.644 . . . . 0.0 110.422 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 121.46 -35.58 3.56 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 23.4 p -163.31 -153.96 0.26 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.141 -1.211 . . . . 0.0 110.076 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -106.4 118.6 37.08 Favored 'General case' 0 N--CA 1.496 1.835 0 CA-C-O 121.698 0.761 . . . . 0.0 109.999 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.83 145.55 17.67 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -115.86 136.86 52.64 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.807 -0.819 . . . . 0.0 109.781 179.837 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.6 m -138.09 154.57 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 CA-C-O 121.425 0.631 . . . . 0.0 109.679 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.5 ' HB3' ' CD2' ' A' ' 60' ' ' TYR . . . -72.97 149.52 43.27 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.845 0.831 . . . . 0.0 110.899 -179.492 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.418 ' HZ2' ' C ' ' A' ' 43' ' ' ALA . 57.1 mttp -63.1 -34.5 77.73 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.486 0.66 . . . . 0.0 109.99 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -53.67 -30.12 41.87 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.418 -0.801 . . . . 0.0 110.111 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.5 ' CD2' ' HB3' ' A' ' 57' ' ' ALA . 36.5 m-85 -90.03 -2.22 58.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.989 -1.069 . . . . 0.0 109.236 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.0 mm -107.64 127.41 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 CA-C-O 121.796 0.807 . . . . 0.0 109.854 -179.788 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -141.22 150.72 43.04 Favored 'General case' 0 N--CA 1.49 1.563 0 CA-C-O 121.77 0.795 . . . . 0.0 110.133 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.1 t0 56.62 59.5 3.54 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 121.652 0.739 . . . . 0.0 109.965 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 97.2 mt -75.4 98.63 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.409 -0.807 . . . . 0.0 109.505 179.804 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -141.85 155.95 45.54 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.608 0.718 . . . . 0.0 109.988 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -83.88 112.58 20.26 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -76.9 98.8 5.0 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.479 -0.763 . . . . 0.0 109.822 -179.47 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.2 m -152.37 -8.31 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -90.88 152.65 20.66 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.383 -0.823 . . . . 0.0 110.332 -179.706 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -57.37 152.29 14.57 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.699 0.761 . . . . 0.0 110.796 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 36.1 p-80 -148.02 165.33 31.07 Favored 'General case' 0 N--CA 1.491 1.622 0 CA-C-O 121.733 0.778 . . . . 0.0 110.279 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 84.9 t60 43.25 92.55 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.721 0 CA-C-O 121.94 0.876 . . . . 0.0 110.058 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 55.6 p-80 -72.3 128.57 36.05 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-O 121.495 0.664 . . . . 0.0 110.173 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' HIS . . . . . 0.466 ' CG ' ' O ' ' A' ' 74' ' ' HIS . 55.1 p-80 -103.07 112.53 25.41 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.52 -0.738 . . . . 0.0 109.666 -179.778 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 75.0 m80 -144.0 148.65 35.55 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.553 -0.717 . . . . 0.0 109.935 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.211 -0.9 . . . . 0.0 109.827 179.678 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.431 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 1' ' ' ALA . 97.3 mt-10 56.16 114.23 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.539 0.685 . . . . 0.0 110.33 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -132.85 151.0 52.1 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.596 -0.69 . . . . 0.0 109.762 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.8 p -116.21 118.32 32.49 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.556 -0.715 . . . . 0.0 109.367 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -105.52 131.5 10.68 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 -179.351 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.749 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.7 mp -84.91 126.04 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.41 -1.053 . . . . 0.0 109.477 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 74.0 t -75.2 129.03 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 O-C-N 121.318 -0.864 . . . . 0.0 109.938 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 65.0 t-20 -120.38 102.61 8.59 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.1 m -137.09 160.75 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.455 -0.778 . . . . 0.0 109.826 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 87.3 p -82.8 -13.09 56.88 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.524 -0.735 . . . . 0.0 109.266 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.7 m -145.69 -69.41 0.28 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.277 -0.889 . . . . 0.0 109.297 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 58.3 m -156.84 168.86 26.19 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.062 -1.024 . . . . 0.0 109.825 -179.564 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 49.8 tp -116.46 129.76 56.39 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-O 121.656 0.741 . . . . 0.0 109.838 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ASN . . . . . 0.436 ' O ' ' OD1' ' A' ' 14' ' ' ASN . 15.1 p30 -89.1 122.12 32.1 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.433 -0.792 . . . . 0.0 109.778 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.0 t -76.49 153.54 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.364 -0.835 . . . . 0.0 109.864 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.562 HH22 ' HB2' ' A' ' 57' ' ' ALA . 88.9 mtm180 -128.54 136.47 50.8 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.567 -0.708 . . . . 0.0 109.809 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 12.6 tm-20 -69.95 -38.8 76.23 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.548 -0.72 . . . . 0.0 109.138 179.464 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -104.78 -178.86 24.6 Favored Glycine 0 N--CA 1.496 2.652 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 -179.236 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -94.5 -0.88 54.32 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.493 -1.004 . . . . 0.0 108.569 179.261 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.2 m -84.69 151.53 24.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.307 -0.871 . . . . 0.0 110.022 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 59.0 p -68.96 -29.08 67.23 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.55 -0.719 . . . . 0.0 109.612 179.421 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 96.7 p -85.65 7.47 23.25 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.278 -0.889 . . . . 0.0 109.257 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.0 t -62.42 146.44 51.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.434 -0.791 . . . . 0.0 110.759 -179.278 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -68.77 137.45 54.02 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-O 121.723 0.773 . . . . 0.0 110.954 -179.339 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 69.9 t -80.37 131.59 33.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 121.595 -0.691 . . . . 0.0 110.049 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 23.1 pt -102.21 -4.27 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.507 -0.746 . . . . 0.0 109.029 179.518 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 161.72 -177.09 38.12 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.483 -1.342 . . . . 0.0 109.959 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 57.8 m -132.91 159.55 39.58 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.47 -1.018 . . . . 0.0 109.732 -179.674 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.536 HD21 ' CE1' ' A' ' 49' ' ' TYR . 95.9 mt -120.07 149.55 42.0 Favored 'General case' 0 N--CA 1.496 1.87 0 CA-C-O 121.661 0.743 . . . . 0.0 109.884 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.8 m -74.24 161.42 29.95 Favored 'General case' 0 N--CA 1.489 1.488 0 CA-C-O 121.863 0.839 . . . . 0.0 110.739 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -63.09 149.41 49.79 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 111.339 -0.704 . . . . 0.0 111.339 -179.42 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.9 m-20 57.09 32.93 22.53 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.792 -0.828 . . . . 0.0 109.73 179.709 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 25.3 m -90.77 126.63 36.06 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.241 -0.912 . . . . 0.0 109.772 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.5 ttmt -80.3 132.89 35.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.428 -0.795 . . . . 0.0 109.716 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.1 m -124.03 131.96 72.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.579 -0.701 . . . . 0.0 109.734 179.794 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 61.1 m -80.04 128.21 33.21 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-O 121.426 0.631 . . . . 0.0 109.979 -179.301 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.7 mt -97.37 124.68 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.56 -0.712 . . . . 0.0 109.875 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 34.4 m -110.18 -0.84 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.477 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -175.2 178.01 47.01 Favored Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.637 -1.268 . . . . 0.0 110.2 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -142.74 153.58 43.45 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.08 -1.247 . . . . 0.0 109.527 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.408 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 12.9 tm-20 -151.9 107.6 3.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.47 179.367 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.37 -137.39 45.19 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 179.002 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -84.64 26.01 0.85 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.437 -1.037 . . . . 0.0 109.098 -179.341 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -132.02 145.19 51.29 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.559 -0.713 . . . . 0.0 109.412 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -106.95 139.46 41.31 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.615 0.722 . . . . 0.0 109.455 179.66 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -93.09 130.44 38.71 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.557 -0.714 . . . . 0.0 109.174 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 37.2 pt -131.26 154.22 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.611 -0.681 . . . . 0.0 110.044 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -90.86 96.57 10.7 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.519 -0.738 . . . . 0.0 109.127 179.718 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.536 ' CE1' HD21 ' A' ' 29' ' ' LEU . 73.4 t80 -107.33 123.54 48.49 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.507 -0.746 . . . . 0.0 109.953 -179.728 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 74.3 tttt 51.49 34.54 12.44 Favored 'General case' 0 N--CA 1.493 1.678 0 CA-C-O 121.292 0.568 . . . . 0.0 109.944 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.41 -11.84 11.84 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 178.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 26.4 t -91.84 174.02 7.55 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.256 -1.144 . . . . 0.0 110.333 -179.513 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -97.37 101.53 13.09 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.36 -0.837 . . . . 0.0 109.639 -179.811 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.26 137.79 13.52 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.755 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -119.73 137.39 53.97 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.411 -1.052 . . . . 0.0 109.585 179.741 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.2 m -139.45 154.76 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.276 -0.89 . . . . 0.0 109.822 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.562 ' HB2' HH22 ' A' ' 16' ' ' ARG . . . -73.83 146.98 43.76 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.406 -0.809 . . . . 0.0 110.584 -179.762 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -66.21 -11.37 49.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.62 -0.675 . . . . 0.0 109.682 179.42 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -67.35 -34.57 77.59 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.222 -0.924 . . . . 0.0 109.779 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -90.71 3.3 54.64 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.209 -0.932 . . . . 0.0 109.487 -179.197 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 38.3 mm -103.47 129.68 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.346 -0.846 . . . . 0.0 109.939 -179.52 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -146.24 154.91 42.26 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.42 -0.8 . . . . 0.0 109.912 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.6 t0 63.11 52.8 2.43 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 121.555 0.693 . . . . 0.0 109.42 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt -78.09 123.37 34.78 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 121.524 -0.735 . . . . 0.0 109.649 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 19.2 tptm -140.43 142.61 35.39 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.35 -0.844 . . . . 0.0 109.742 179.734 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.526 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 1.9 m-20 -85.14 118.29 24.61 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.414 -0.804 . . . . 0.0 110.29 -179.516 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.428 ' O ' ' O ' ' A' ' 68' ' ' VAL . 97.5 mt-10 -94.86 -14.5 24.51 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 179.365 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.624 HG12 ' N ' ' A' ' 69' ' ' LEU . 43.5 t 52.01 169.28 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 CA-C-O 121.884 0.849 . . . . 0.0 110.889 179.345 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.624 ' N ' HG12 ' A' ' 68' ' ' VAL . 4.2 tt -68.58 105.14 2.15 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.381 -0.824 . . . . 0.0 109.781 -179.13 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.406 ' C ' ' O ' ' A' ' 69' ' ' LEU . 93.3 mt-10 40.28 85.45 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.85 0 CA-C-O 121.623 0.725 . . . . 0.0 110.471 179.581 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.405 ' ND1' ' N ' ' A' ' 71' ' ' HIS . 0.0 OUTLIER -90.76 164.45 14.1 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.449 -0.782 . . . . 0.0 109.923 -179.731 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 6.3 p-80 -146.89 133.43 19.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.07 179.49 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.495 ' C ' ' H ' ' A' ' 75' ' ' HIS . 95.9 m-70 -112.44 109.01 18.36 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.433 -0.792 . . . . 0.0 109.626 -179.871 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' HIS . . . . . 0.472 ' ND1' ' O ' ' A' ' 74' ' ' HIS . 60.9 t-80 53.62 6.04 0.07 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.626 -0.672 . . . . 0.0 109.762 -179.803 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' HIS . . . . . 0.495 ' H ' ' C ' ' A' ' 73' ' ' HIS . 81.0 t60 -89.88 135.79 33.42 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.239 -0.913 . . . . 0.0 109.746 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 86.3 t60 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.156 -179.635 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.488 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -75.86 137.29 40.35 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.48 -0.763 . . . . 0.0 110.343 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt -130.29 145.96 51.83 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 70.2 p -132.16 133.55 44.37 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.576 -0.703 . . . . 0.0 109.643 -179.539 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -121.61 131.71 8.66 Favored Glycine 0 N--CA 1.499 2.876 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.751 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.8 mp -86.35 127.65 40.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.075 -1.25 . . . . 0.0 110.005 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 71.5 t -75.61 131.09 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 110.186 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 34.1 t30 -123.74 108.23 12.3 Favored 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.52 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' A' ' 11' ' ' SER . 29.3 m -152.96 -19.47 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 179.618 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.8 t 67.97 -52.84 0.52 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.79 -0.569 . . . . 0.0 109.677 -179.648 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.448 ' N ' ' O ' ' A' ' 9' ' ' VAL . 74.0 m -77.92 -79.41 0.12 Allowed 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.382 -0.824 . . . . 0.0 109.751 -179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 31.2 t -168.45 156.06 7.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.43 -0.794 . . . . 0.0 109.332 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 49.5 tp -123.58 130.28 52.43 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.56 -0.713 . . . . 0.0 109.317 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -84.16 154.48 23.08 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.361 -0.837 . . . . 0.0 109.79 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 54.4 t -105.95 130.14 57.97 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.445 -0.784 . . . . 0.0 109.276 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.723 HH21 ' N ' ' A' ' 20' ' ' SER . 42.4 mtp180 -104.64 128.05 52.57 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.476 -0.765 . . . . 0.0 109.699 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -72.06 -43.16 65.35 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.479 -0.763 . . . . 0.0 109.612 179.68 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -100.32 -175.48 30.1 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.125 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.488 ' C ' HH21 ' A' ' 16' ' ' ARG . . . -97.01 39.59 1.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.505 -0.997 . . . . 0.0 108.944 179.589 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.723 ' N ' HH21 ' A' ' 16' ' ' ARG . 33.0 t -131.86 149.87 52.32 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.554 -0.716 . . . . 0.0 109.72 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 53.1 p -65.11 -31.27 72.39 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.507 -0.746 . . . . 0.0 109.64 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 96.6 p -86.55 13.34 8.63 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.262 -0.899 . . . . 0.0 108.993 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.9 m -62.2 151.13 36.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.442 -0.786 . . . . 0.0 110.442 -179.209 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 17.7 ttmm -64.97 136.83 57.27 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.503 -0.748 . . . . 0.0 110.941 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 97.4 t -90.86 116.73 32.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.3 pt -103.73 -4.76 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.514 -0.741 . . . . 0.0 109.699 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -178.69 -175.5 45.81 Favored Glycine 0 N--CA 1.49 2.253 0 C-N-CA 119.316 -1.421 . . . . 0.0 110.615 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.9 p -158.55 166.1 32.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.558 -0.966 . . . . 0.0 109.004 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.3 mt -123.21 153.92 39.45 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.446 -0.784 . . . . 0.0 109.926 -179.552 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.5 m -80.53 -3.54 50.53 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.663 -0.648 . . . . 0.0 109.334 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.488 ' C ' ' H ' ' A' ' 33' ' ' THR . . . 95.19 164.27 34.91 Favored Glycine 0 N--CA 1.498 2.772 0 O-C-N 121.304 -0.872 . . . . 0.0 111.031 178.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 55.7 2.37 0.07 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.753 -0.851 . . . . 0.0 110.033 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.488 ' H ' ' C ' ' A' ' 31' ' ' GLY . 54.0 m -85.01 133.1 34.26 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.122 -0.986 . . . . 0.0 109.578 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 8.3 ttpm? -80.4 136.79 36.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.341 -0.849 . . . . 0.0 109.964 -179.757 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.9 m -121.24 130.6 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 CA-C-O 121.506 0.669 . . . . 0.0 109.298 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 53.9 m -73.48 133.12 43.58 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.629 -0.669 . . . . 0.0 110.092 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 97.6 mt -109.66 127.7 66.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 CA-C-O 121.362 0.601 . . . . 0.0 109.491 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.54 -1.12 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.42 176.08 45.44 Favored Glycine 0 N--CA 1.49 2.289 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.244 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 -140.13 153.14 46.59 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.346 -1.091 . . . . 0.0 109.828 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.413 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 12.5 tm-20 -151.08 106.93 3.4 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.229 -0.919 . . . . 0.0 109.385 179.71 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 58.82 -138.69 49.23 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.214 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -83.45 5.05 25.13 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.594 -0.945 . . . . 0.0 109.271 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.448 ' CE1' ' NH1' ' A' ' 16' ' ' ARG . 96.6 m-85 -114.5 141.76 47.28 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.69 -0.631 . . . . 0.0 109.539 -179.636 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -107.86 150.72 26.69 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.664 -0.648 . . . . 0.0 109.666 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.5 mtpm? -91.35 139.16 30.99 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.501 -0.749 . . . . 0.0 109.024 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 38.8 pt -134.05 149.82 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.515 -0.741 . . . . 0.0 109.852 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -86.8 95.03 9.71 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.372 -0.83 . . . . 0.0 108.919 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 84.0 t80 -104.6 116.07 31.44 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.382 -0.824 . . . . 0.0 109.196 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 49.2 tttm 52.39 32.19 10.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.614 -0.679 . . . . 0.0 109.695 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 88.36 -20.92 27.71 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.528 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 87.2 p -83.3 166.18 18.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.237 -1.155 . . . . 0.0 110.228 -179.513 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 61.9 m170 -101.62 95.72 6.63 Favored 'General case' 0 N--CA 1.495 1.788 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -88.19 162.9 32.62 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 -179.163 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -122.18 138.02 54.62 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.768 -0.843 . . . . 0.0 109.227 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 20.7 m -137.29 153.61 29.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.333 -0.854 . . . . 0.0 109.647 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.01 139.77 46.87 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.509 -0.744 . . . . 0.0 110.274 -179.475 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -69.2 -12.43 61.67 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.37 -0.831 . . . . 0.0 109.604 179.336 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -63.09 -32.14 73.45 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.44 -0.788 . . . . 0.0 110.353 -179.276 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -99.17 5.91 46.61 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 109.828 -179.37 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.5 mm -105.18 128.59 58.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.934 0 O-C-N 121.296 -0.877 . . . . 0.0 109.515 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -141.65 164.29 30.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.466 -0.771 . . . . 0.0 110.17 -179.39 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 56.32 52.03 10.71 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.191 0.519 . . . . 0.0 110.137 179.714 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt -79.43 122.08 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.249 -0.907 . . . . 0.0 109.319 179.352 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.9 ptpp? -142.85 150.72 40.26 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.288 -0.882 . . . . 0.0 109.885 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -69.27 140.54 54.45 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.502 -0.749 . . . . 0.0 110.351 -179.406 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.445 ' O ' ' O ' ' A' ' 68' ' ' VAL . 39.9 tp10 -80.08 61.91 4.09 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.333 -0.854 . . . . 0.0 109.365 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.445 ' O ' ' O ' ' A' ' 67' ' ' GLU . 5.3 t 58.55 127.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 CA-C-O 121.654 0.74 . . . . 0.0 110.731 179.807 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 83.6 mt -72.31 142.31 48.84 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.459 -0.776 . . . . 0.0 109.551 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -156.79 86.04 0.98 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.355 -0.841 . . . . 0.0 108.902 179.665 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 59.9 m170 42.09 90.29 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.652 -0.655 . . . . 0.0 110.108 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 47.7 p-80 -67.76 138.4 56.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.352 -0.843 . . . . 0.0 110.074 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 1.7 p-80 -74.51 132.36 41.79 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.3 -0.875 . . . . 0.0 110.433 -179.313 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 81.4 t60 -152.0 139.51 19.6 Favored 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.549 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 97.8 m-70 -106.67 136.5 46.37 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.344 -0.847 . . . . 0.0 109.858 -179.531 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 76.2 m80 . . . . . 0 N--CA 1.488 1.47 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.658 179.942 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.639 0.733 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.621 ' H ' ' CD ' ' A' ' 2' ' ' GLU . 1.0 OUTLIER -86.88 154.16 21.06 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.397 -0.814 . . . . 0.0 110.133 -179.401 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -123.4 157.14 34.04 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.729 -0.607 . . . . 0.0 109.496 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 52.8 p -131.55 115.02 15.58 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.619 0.724 . . . . 0.0 109.363 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.455 ' C ' HD12 ' A' ' 6' ' ' ILE . . . -91.18 137.65 13.94 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 -179.491 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.698 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.5 mp -92.22 122.22 43.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.618 -0.931 . . . . 0.0 109.398 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.0 t -78.22 132.46 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 O-C-N 121.512 -0.743 . . . . 0.0 110.045 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.6 t-20 -137.72 110.16 7.45 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.519 -0.738 . . . . 0.0 109.351 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.3 m -144.62 149.89 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.394 -0.816 . . . . 0.0 109.607 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 39.8 t -63.66 -43.85 95.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.546 -0.721 . . . . 0.0 110.05 179.837 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 24.6 t -109.43 -76.15 0.62 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.555 -0.715 . . . . 0.0 110.09 -179.204 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 92.1 p -156.73 165.54 35.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 -179.244 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.3 tp -115.17 128.28 56.09 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.761 0.791 . . . . 0.0 109.952 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -84.16 149.9 25.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.586 -0.696 . . . . 0.0 110.055 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.0 t -99.91 131.23 47.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.318 -0.864 . . . . 0.0 109.261 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.432 ' CZ ' ' O ' ' A' ' 21' ' ' THR . 99.7 mtt180 -103.84 135.25 45.74 Favored 'General case' 0 N--CA 1.494 1.758 0 CA-C-O 121.777 0.799 . . . . 0.0 110.099 -179.282 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 46.5 tp10 -70.87 -45.33 64.59 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.554 0.693 . . . . 0.0 109.508 179.715 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.08 172.93 26.01 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 -179.303 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -91.59 11.22 24.96 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.472 -1.016 . . . . 0.0 108.727 179.391 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.1 m -73.87 170.86 14.48 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.333 -0.855 . . . . 0.0 110.305 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.432 ' O ' ' CZ ' ' A' ' 16' ' ' ARG . 18.3 m -62.94 -44.82 95.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.576 -0.702 . . . . 0.0 109.996 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.3 t -131.12 71.12 1.46 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.352 -0.843 . . . . 0.0 109.235 -179.648 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.7 t -83.14 176.66 9.03 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-O 121.659 0.742 . . . . 0.0 110.419 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 65.7 tttm -63.72 133.76 54.12 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-O 121.797 0.808 . . . . 0.0 110.569 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 67.0 t -97.62 128.91 48.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.515 -0.74 . . . . 0.0 109.413 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 39.8 pt -105.19 -4.44 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.673 -0.642 . . . . 0.0 109.342 179.601 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.91 -156.84 27.36 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.368 -1.396 . . . . 0.0 110.491 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 92.9 p -157.43 164.92 36.96 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.425 -1.044 . . . . 0.0 109.515 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.404 HD21 ' CE1' ' A' ' 49' ' ' TYR . 97.4 mt -126.65 148.69 49.79 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.746 0.784 . . . . 0.0 110.021 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 19.4 m -73.59 156.6 37.9 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-O 121.807 0.813 . . . . 0.0 110.55 -179.4 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.17 156.19 38.09 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 65.3 t30 58.14 33.9 23.63 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.688 -0.889 . . . . 0.0 109.873 179.789 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 24.1 m -97.55 132.39 43.27 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.333 -0.855 . . . . 0.0 109.761 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -80.93 128.73 34.01 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.525 -0.734 . . . . 0.0 110.096 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.8 m -128.24 134.19 65.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.589 -0.694 . . . . 0.0 109.504 179.466 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 34.4 m -82.27 124.98 30.44 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.486 -0.758 . . . . 0.0 109.426 -179.662 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.8 mt -99.41 136.15 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 CA-C-O 121.608 0.718 . . . . 0.0 110.433 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 34.1 m -110.44 -6.93 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 165.79 -174.67 41.49 Favored Glycine 0 N--CA 1.489 2.189 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.359 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -140.91 147.2 38.5 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.459 -1.024 . . . . 0.0 109.205 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.513 ' OE1' ' N ' ' A' ' 41' ' ' GLU . 56.9 mp0 -145.87 120.67 9.91 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.29 -0.881 . . . . 0.0 110.153 -179.454 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.654 ' O ' ' HB3' ' A' ' 43' ' ' ALA . . . 70.19 31.08 69.13 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.654 ' HB3' ' O ' ' A' ' 42' ' ' GLY . . . 77.4 11.03 2.28 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.524 -0.986 . . . . 0.0 109.136 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.464 ' CD2' ' O ' ' A' ' 42' ' ' GLY . 99.2 m-85 -114.03 131.6 56.3 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.653 -0.654 . . . . 0.0 109.319 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -79.47 139.71 37.54 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.615 -0.678 . . . . 0.0 109.963 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -100.56 120.05 39.44 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.495 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.5 pt -125.07 161.63 28.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 CA-C-O 121.748 0.785 . . . . 0.0 110.45 -179.076 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.474 ' CD ' ' H ' ' A' ' 48' ' ' GLU . 0.0 OUTLIER -90.17 124.31 34.72 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.269 0.557 . . . . 0.0 109.649 -179.588 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.404 ' CE1' HD21 ' A' ' 29' ' ' LEU . 81.9 t80 -132.99 120.82 21.88 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.459 -0.776 . . . . 0.0 109.861 179.611 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 76.5 tttt 39.03 47.38 1.26 Allowed 'General case' 0 N--CA 1.496 1.846 0 CA-C-O 121.687 0.756 . . . . 0.0 110.427 179.424 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 86.3 -50.67 4.28 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 179.615 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 16.7 m -74.46 145.16 43.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -1.132 . . . . 0.0 110.51 -179.197 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -83.94 120.54 26.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.393 -0.817 . . . . 0.0 109.915 -179.665 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.12 148.45 18.99 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -115.23 142.68 46.34 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.689 -0.889 . . . . 0.0 109.846 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.4 m -140.94 153.6 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.491 -0.756 . . . . 0.0 109.525 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.85 140.23 43.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.408 -0.808 . . . . 0.0 110.247 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 7.2 ptmm? -65.45 -9.23 23.82 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.516 -0.74 . . . . 0.0 109.744 179.615 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.53 -21.09 62.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.797 . . . . 0.0 110.164 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.489 ' C ' HD12 ' A' ' 61' ' ' ILE . 65.5 m-85 -104.97 -23.26 13.0 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.268 -0.895 . . . . 0.0 109.582 -179.435 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.668 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.6 mp -97.07 130.87 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.26 -0.9 . . . . 0.0 109.841 -179.706 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.473 ' O ' ' N ' ' A' ' 64' ' ' ILE . 23.0 pttp -134.98 -165.35 1.66 Allowed 'General case' 0 N--CA 1.494 1.739 0 CA-C-O 121.474 0.654 . . . . 0.0 109.697 179.579 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 59.17 -78.27 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.771 0 CA-C-O 121.151 0.5 . . . . 0.0 109.986 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.473 ' N ' ' O ' ' A' ' 62' ' ' LYS . 97.2 mt 57.42 87.63 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 CA-C-O 121.44 0.638 . . . . 0.0 109.842 -179.35 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 63.3 tttp -139.56 133.61 31.02 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.379 -0.826 . . . . 0.0 109.752 179.814 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.407 ' OD1' ' O ' ' A' ' 66' ' ' ASP . 40.9 p-10 -67.12 122.82 18.65 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 121.577 0.703 . . . . 0.0 110.183 -179.759 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 32.6 tp10 -99.18 -13.77 19.6 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.417 -0.802 . . . . 0.0 109.061 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.418 ' C ' HD12 ' A' ' 69' ' ' LEU . 11.2 t -88.9 99.38 9.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.231 -0.918 . . . . 0.0 109.487 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.562 HD12 ' N ' ' A' ' 69' ' ' LEU . 10.4 mp -100.13 11.47 39.28 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.516 -0.74 . . . . 0.0 109.17 -179.685 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 71.8 mm-40 57.66 92.87 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.673 0.749 . . . . 0.0 109.86 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 34.6 p80 -68.44 140.21 55.75 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 121.711 0.767 . . . . 0.0 110.736 -179.425 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.594 ' CD2' ' CD2' ' A' ' 73' ' ' HIS . 6.8 t60 -159.24 -29.23 0.07 Allowed 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.405 -0.809 . . . . 0.0 109.306 179.209 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.594 ' CD2' ' CD2' ' A' ' 72' ' ' HIS . 95.9 m-70 -150.97 159.86 44.3 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.092 -1.005 . . . . 0.0 110.302 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 32.6 p-80 -151.5 162.16 41.45 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.265 -0.897 . . . . 0.0 109.945 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 35.1 p-80 -136.61 89.57 2.47 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.462 -0.773 . . . . 0.0 109.564 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 . . . . . 0 N--CA 1.493 1.725 0 CA-C-O 118.119 -0.944 . . . . 0.0 110.355 179.685 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -66.96 137.38 56.48 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.422 -0.799 . . . . 0.0 110.386 -179.493 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -136.69 151.35 49.16 Favored 'General case' 0 N--CA 1.496 1.854 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.654 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.419 ' OG1' ' O ' ' A' ' 65' ' ' LYS . 25.7 p -123.57 128.61 49.98 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.519 -0.738 . . . . 0.0 109.682 -179.474 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.97 129.87 9.82 Favored Glycine 0 N--CA 1.497 2.746 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.676 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.6 mp -80.14 126.3 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.185 -1.185 . . . . 0.0 109.292 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.2 t -81.74 131.62 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.274 -0.891 . . . . 0.0 110.186 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.2 m120 -120.2 100.07 6.97 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.476 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.7 m -141.01 136.27 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.875 0 O-C-N 121.302 -0.874 . . . . 0.0 109.577 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 t -61.99 -44.86 95.85 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.576 -0.702 . . . . 0.0 109.707 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 68.0 m -99.3 -79.72 0.48 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.557 -0.715 . . . . 0.0 109.456 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 59.9 m -158.92 172.29 18.48 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.359 -0.838 . . . . 0.0 109.389 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.0 tp -116.27 131.48 56.93 Favored 'General case' 0 N--CA 1.5 2.055 0 CA-C-O 121.479 0.657 . . . . 0.0 109.516 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.5 p30 -90.86 153.86 19.9 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.393 -0.817 . . . . 0.0 109.655 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 53.7 t -105.3 130.28 56.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.39 -0.819 . . . . 0.0 108.842 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.489 HH22 ' H ' ' A' ' 57' ' ' ALA . 91.0 mtm-85 -112.11 137.94 49.47 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.533 -0.729 . . . . 0.0 109.502 -179.538 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 69.8 mm-40 -86.48 -29.35 22.83 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.463 -0.773 . . . . 0.0 109.193 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -98.46 148.39 18.85 Favored Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.701 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -82.63 73.17 9.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.313 -1.11 . . . . 0.0 109.325 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.1 m -159.15 -169.43 2.65 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.127 -0.983 . . . . 0.0 109.55 179.854 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 65.9 p -80.71 101.56 9.36 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.277 -0.889 . . . . 0.0 109.785 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.6 t 56.6 52.36 9.86 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.77 -0.582 . . . . 0.0 109.854 179.398 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 77.9 p -62.31 -42.97 99.81 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.301 -0.875 . . . . 0.0 109.313 179.551 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 33.2 ttpt -170.6 115.94 0.48 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.262 -0.899 . . . . 0.0 109.443 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.3 t -90.45 130.22 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.527 -0.733 . . . . 0.0 109.737 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.9 pt -117.37 -11.63 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.32 -162.54 31.36 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.187 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 36.9 t -155.44 168.49 26.95 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.321 -1.105 . . . . 0.0 109.868 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 95.2 mt -127.3 152.74 47.04 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.607 -0.683 . . . . 0.0 109.721 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.6 m -71.4 152.95 42.66 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.609 -0.682 . . . . 0.0 110.368 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -61.86 160.45 29.91 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 -179.176 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 64.4 t30 62.06 4.92 1.29 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.941 -0.741 . . . . 0.0 109.874 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 66.7 m -82.74 130.81 35.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.077 -1.014 . . . . 0.0 109.958 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -86.81 147.46 25.81 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.316 -0.865 . . . . 0.0 109.576 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.3 m -123.34 132.97 70.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.431 -0.793 . . . . 0.0 109.458 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 36.2 m -69.92 130.68 42.87 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.744 -0.598 . . . . 0.0 110.065 -179.352 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.2 mt -109.34 129.17 64.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 29.3 m -120.59 5.24 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 179.591 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.68 177.4 45.25 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 119.531 -1.318 . . . . 0.0 110.463 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -126.69 153.74 45.04 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.676 -0.896 . . . . 0.0 109.247 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 8.1 tm-20 -151.03 93.47 1.93 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.158 -0.963 . . . . 0.0 109.892 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 51.97 -133.27 36.82 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 178.842 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.81 25.38 1.11 Allowed 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.623 -0.928 . . . . 0.0 108.941 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -138.07 134.62 34.95 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.691 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 44.7 m-85 -89.08 144.89 25.82 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.18 -0.95 . . . . 0.0 109.803 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -90.88 129.49 36.92 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.444 -0.785 . . . . 0.0 109.031 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 39.2 pt -128.46 154.26 39.01 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.592 -0.693 . . . . 0.0 110.06 -179.699 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -87.52 93.74 9.51 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.518 -0.739 . . . . 0.0 109.099 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -92.92 152.74 19.2 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.232 -0.917 . . . . 0.0 110.009 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 41.2 tttp -55.46 119.87 6.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.332 -0.855 . . . . 0.0 110.462 -179.37 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 104.4 -46.3 1.2 Allowed Glycine 0 N--CA 1.496 2.66 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.665 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 95.9 p -163.34 177.92 8.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.121 -1.223 . . . . 0.0 109.953 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -81.08 119.74 23.93 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.2 -0.937 . . . . 0.0 109.452 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.72 165.49 32.17 Favored Glycine 0 N--CA 1.496 2.697 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 -179.329 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -123.42 138.22 54.64 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.762 -0.846 . . . . 0.0 109.455 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.1 m -137.35 140.76 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.535 -0.728 . . . . 0.0 109.534 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.489 ' H ' HH22 ' A' ' 16' ' ' ARG . . . -68.41 151.0 47.47 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.517 -0.739 . . . . 0.0 110.794 -179.291 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 45.3 mtmt -62.6 -28.91 70.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.573 -0.704 . . . . 0.0 109.184 179.49 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -58.95 -34.43 71.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.474 -0.766 . . . . 0.0 110.418 -178.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -89.73 -1.99 58.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.019 -1.051 . . . . 0.0 109.466 -179.345 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 43.7 mm -112.59 130.29 66.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.616 -0.678 . . . . 0.0 109.828 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -136.47 142.17 43.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.65 -0.656 . . . . 0.0 109.694 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 44.6 t0 62.43 77.99 0.31 Allowed 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.296 0.57 . . . . 0.0 109.899 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 82.2 mt -81.95 77.68 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.457 -0.777 . . . . 0.0 109.158 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.419 ' O ' ' OG1' ' A' ' 4' ' ' THR . 63.9 mttp -143.08 157.58 44.4 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.297 -0.877 . . . . 0.0 109.723 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -86.24 109.48 18.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.451 -0.78 . . . . 0.0 109.33 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 45.6 tp10 -90.21 -77.35 0.4 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.331 -0.856 . . . . 0.0 109.48 -179.722 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 13.7 p -172.29 152.83 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.297 -0.877 . . . . 0.0 109.767 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 78.7 mt -66.49 145.0 56.14 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.356 -0.84 . . . . 0.0 110.346 -179.163 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -55.18 136.88 48.11 Favored 'General case' 0 N--CA 1.491 1.581 0 CA-C-O 121.565 0.698 . . . . 0.0 110.332 -179.244 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.617 ' CD2' ' H ' ' A' ' 73' ' ' HIS . 49.0 t60 -80.77 165.11 22.21 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.452 -0.78 . . . . 0.0 110.438 -179.539 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.501 ' N ' ' CG ' ' A' ' 71' ' ' HIS . 76.5 m80 -65.8 -39.93 91.41 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.581 -0.699 . . . . 0.0 109.812 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.617 ' H ' ' CD2' ' A' ' 71' ' ' HIS . 80.3 m80 -105.18 137.63 42.65 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.446 -0.784 . . . . 0.0 109.775 -179.335 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 62.4 m170 -48.48 172.13 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.668 0 CA-C-O 121.788 0.804 . . . . 0.0 111.473 -178.918 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 47.5 p-80 -59.38 -41.3 89.01 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.645 -0.659 . . . . 0.0 109.741 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 56.8 t-80 . . . . . 0 N--CA 1.488 1.469 0 CA-C-O 117.916 -1.04 . . . . 0.0 109.248 179.939 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.431 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.486 0 CA-C-O 121.542 0.686 . . . . 0.0 110.01 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 1' ' ' ALA . 44.7 tt0 58.76 147.47 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 CA-C-O 121.577 0.703 . . . . 0.0 110.138 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.49 ' NZ ' ' OD1' ' A' ' 66' ' ' ASP . 68.6 mttm -137.56 151.64 48.59 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.759 -0.588 . . . . 0.0 109.786 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 69.3 p -117.05 113.96 23.07 Favored 'General case' 0 N--CA 1.498 1.973 0 CA-C-O 121.898 0.856 . . . . 0.0 110.038 -179.611 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -103.06 130.73 10.35 Favored Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.4 mm -87.53 127.66 40.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.901 -0.764 . . . . 0.0 109.957 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.2 t -71.93 130.56 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 CA-C-O 121.467 0.651 . . . . 0.0 109.725 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.413 ' OD1' ' NZ ' ' A' ' 62' ' ' LYS . 56.0 t30 -123.39 101.93 7.62 Favored 'General case' 0 N--CA 1.497 1.894 0 CA-C-O 121.311 0.577 . . . . 0.0 109.642 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 30.5 m -148.18 158.19 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 121.611 0.719 . . . . 0.0 110.146 179.001 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 58.6 m -87.94 -16.81 32.81 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.859 -0.525 . . . . 0.0 109.976 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 12' ' ' SER . 66.4 m -155.38 87.79 1.12 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.422 -0.799 . . . . 0.0 110.326 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 11' ' ' SER . 1.3 m 46.73 -179.99 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 CA-C-O 121.724 0.773 . . . . 0.0 110.99 178.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 37.8 tp -144.59 130.55 19.34 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.681 0.753 . . . . 0.0 109.846 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -83.31 132.37 35.02 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-O 121.721 0.772 . . . . 0.0 110.053 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 86.7 t -81.18 131.99 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 CA-C-O 121.708 0.766 . . . . 0.0 109.73 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.594 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 93.5 mtm-85 -106.42 135.15 48.42 Favored 'General case' 0 N--CA 1.493 1.688 0 CA-C-O 121.762 0.791 . . . . 0.0 109.897 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.513 ' N ' ' OG ' ' A' ' 23' ' ' SER . 82.8 tt0 -99.52 77.4 2.09 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.645 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.38 170.89 16.7 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 179.413 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -88.66 4.87 45.63 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.7 -0.882 . . . . 0.0 109.199 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.3 m -74.68 155.94 37.2 Favored 'General case' 0 N--CA 1.495 1.779 0 CA-C-O 121.637 0.732 . . . . 0.0 109.966 179.753 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 51.0 p -66.77 -29.97 70.06 Favored 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.7 t -136.59 68.32 1.43 Allowed 'General case' 0 N--CA 1.497 1.893 0 CA-C-O 121.429 0.633 . . . . 0.0 109.443 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 17' ' ' GLU . 5.1 p -82.83 176.79 9.03 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.805 0.812 . . . . 0.0 110.6 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -58.5 130.85 48.75 Favored 'General case' 0 N--CA 1.491 1.58 0 CA-C-O 121.991 0.901 . . . . 0.0 111.11 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.4 t -84.31 129.18 38.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.715 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 42.1 pt -115.87 -6.39 11.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 168.83 -166.05 39.36 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.996 -1.097 . . . . 0.0 110.66 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 47.4 t -151.84 153.82 34.97 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.825 -0.809 . . . . 0.0 109.935 -179.748 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.0 mt -123.26 149.76 44.35 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.794 0.807 . . . . 0.0 109.65 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 23.4 p -74.73 160.61 30.53 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.752 0.787 . . . . 0.0 110.451 -179.311 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -68.62 155.72 53.36 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 58.15 34.69 24.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 122.046 -0.679 . . . . 0.0 109.889 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 53.2 m -102.4 127.16 49.53 Favored 'General case' 0 N--CA 1.498 1.949 0 CA-C-O 121.968 0.889 . . . . 0.0 109.936 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.6 ttpt -77.0 130.33 37.32 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.535 0.684 . . . . 0.0 109.881 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.2 m -129.96 130.89 66.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 CA-C-O 121.75 0.786 . . . . 0.0 109.674 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 11.1 p -77.19 134.29 38.68 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.455 0.645 . . . . 0.0 109.879 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.5 mt -106.23 127.64 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 CA-C-O 121.481 0.658 . . . . 0.0 109.473 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -112.05 -1.06 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.99 171.85 44.72 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.789 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 10.0 tm-20 -137.96 146.65 43.44 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.848 -0.795 . . . . 0.0 109.935 -179.499 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 68.7 mm-40 -144.05 109.4 5.11 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-O 121.97 0.891 . . . . 0.0 109.851 179.706 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.12 -135.11 47.73 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.464 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.36 30.52 0.98 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.765 -0.844 . . . . 0.0 108.746 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -134.49 143.42 47.47 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-O 121.531 0.681 . . . . 0.0 109.821 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -108.82 140.46 42.23 Favored 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.898 0.856 . . . . 0.0 109.59 179.342 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 51.1 mtmt -93.59 143.97 25.81 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.686 0.755 . . . . 0.0 109.717 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 41.5 pt -132.94 152.37 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 CA-C-O 121.646 0.736 . . . . 0.0 110.056 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -75.46 93.78 3.02 Favored 'General case' 0 N--CA 1.489 1.506 0 CA-C-O 121.42 0.629 . . . . 0.0 109.787 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -108.78 142.39 39.4 Favored 'General case' 0 N--CA 1.491 1.611 0 CA-C-O 121.828 0.823 . . . . 0.0 109.589 179.624 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 18.5 ptmt -55.03 119.63 5.73 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 121.845 0.831 . . . . 0.0 110.318 -179.697 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.432 ' O ' ' OG ' ' A' ' 52' ' ' SER . . . 110.63 -47.98 0.98 Allowed Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.286 -1.525 . . . . 0.0 109.286 179.58 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.432 ' OG ' ' O ' ' A' ' 51' ' ' GLY . 24.7 m -167.77 -162.44 0.44 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.739 -0.859 . . . . 0.0 110.386 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -100.11 120.2 39.5 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.832 0.825 . . . . 0.0 109.926 -179.157 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -83.03 145.24 23.24 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -108.54 137.33 46.67 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.615 0.721 . . . . 0.0 109.703 179.724 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.6 m -140.67 143.99 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 CA-C-O 121.735 0.779 . . . . 0.0 110.237 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.594 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -66.66 146.76 54.12 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.64 0.734 . . . . 0.0 110.329 -179.716 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 48.3 mtmt -62.94 -34.4 77.4 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 121.318 0.58 . . . . 0.0 109.468 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -51.47 -33.79 32.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.851 -0.53 . . . . 0.0 110.169 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.428 ' CD2' ' HB3' ' A' ' 57' ' ' ALA . 37.9 m-85 -89.57 0.7 56.74 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.567 -0.708 . . . . 0.0 109.831 -179.367 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 5.6 mm -108.84 125.95 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 CA-C-O 121.685 0.755 . . . . 0.0 110.215 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.413 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 64.0 pttt -145.92 163.49 34.97 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.757 0.789 . . . . 0.0 110.536 -179.741 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 57.94 55.02 5.6 Favored 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 121.444 0.64 . . . . 0.0 109.614 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt -76.02 126.23 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 CA-C-O 121.646 0.736 . . . . 0.0 109.554 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -129.32 145.81 51.31 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.726 0.774 . . . . 0.0 110.169 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.49 ' OD1' ' NZ ' ' A' ' 3' ' ' LYS . 85.5 m-20 -89.89 105.76 18.02 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.705 -0.479 . . . . 0.0 109.705 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.452 ' C ' ' O ' ' A' ' 66' ' ' ASP . 52.3 tp10 34.09 79.25 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 CA-C-O 121.277 0.561 . . . . 0.0 110.153 179.615 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.568 HG13 ' O ' ' A' ' 68' ' ' VAL . 7.5 p -104.99 114.48 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 CA-C-O 121.618 0.723 . . . . 0.0 109.951 -179.481 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.496 ' N ' HD22 ' A' ' 69' ' ' LEU . 4.0 mm? -97.6 -6.62 32.97 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.684 -0.635 . . . . 0.0 109.414 179.56 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 52.5 tp10 57.9 78.18 0.25 Allowed 'General case' 0 N--CA 1.491 1.622 0 CA-C-O 121.689 0.757 . . . . 0.0 109.764 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 72.3 m80 -81.21 145.48 30.96 Favored 'General case' 0 N--CA 1.488 1.472 0 CA-C-O 121.76 0.791 . . . . 0.0 110.123 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 79.8 m80 39.82 83.28 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.634 0 CA-C-O 121.712 0.767 . . . . 0.0 110.057 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 54.0 p-80 -86.57 -16.15 37.71 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 61.6 t-80 -66.35 -44.72 82.46 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.829 -0.544 . . . . 0.0 109.54 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -79.47 142.67 35.65 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-O 121.793 0.806 . . . . 0.0 110.267 -179.636 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 9.8 p-80 . . . . . 0 N--CA 1.489 1.478 0 CA-C-O 117.844 -1.074 . . . . 0.0 109.686 -179.623 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.41 0 CA-C-O 122.109 0.957 . . . . 0.0 108.566 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -158.18 102.48 1.78 Allowed 'General case' 0 C--N 1.29 -1.996 0 CA-C-O 122.417 1.103 . . . . 0.0 109.868 179.258 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -113.63 156.36 23.83 Favored 'General case' 0 C--N 1.282 -2.357 1 N-CA-C 99.335 -4.32 . . . . 0.0 99.335 174.36 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.06 135.32 29.05 Favored 'General case' 0 N--CA 1.506 2.357 0 C-N-CA 114.944 -2.702 . . . . 0.0 116.574 -173.512 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -105.02 135.82 12.77 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 106.493 -2.643 . . . . 0.0 106.493 177.604 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 37.1 mm -97.91 121.67 48.7 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.191 -1.182 . . . . 0.0 108.444 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 76.4 t -80.88 132.34 31.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.248 -0.907 . . . . 0.0 109.619 -179.089 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.782 ' C ' HD21 ' A' ' 8' ' ' ASN . 0.1 OUTLIER -144.91 108.38 4.63 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.245 -0.909 . . . . 0.0 109.216 179.753 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.566 ' N ' HD21 ' A' ' 8' ' ' ASN . 28.5 m -135.84 162.25 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.169 -0.957 . . . . 0.0 110.168 -179.761 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.6 t -61.65 -43.15 99.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.549 -0.72 . . . . 0.0 110.017 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 57.9 m -123.75 -90.63 0.56 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.432 -0.792 . . . . 0.0 110.245 -179.387 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.9 m -129.71 157.32 42.48 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.539 -0.726 . . . . 0.0 109.771 -179.258 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.9 tp -114.01 130.9 56.51 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.454 -0.778 . . . . 0.0 109.009 179.815 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -88.29 144.7 26.27 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.421 -0.8 . . . . 0.0 109.614 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 70.8 t -92.35 131.32 39.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.28 -0.888 . . . . 0.0 108.901 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.658 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 84.4 mtm-85 -107.61 136.39 47.45 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.472 -0.767 . . . . 0.0 109.572 -179.464 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -93.48 90.12 6.57 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.162 -0.961 . . . . 0.0 110.049 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 130.16 -174.09 19.7 Favored Glycine 0 N--CA 1.499 2.841 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 179.289 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -105.01 31.19 4.99 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.574 -0.957 . . . . 0.0 109.22 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 36.0 m -134.02 148.87 51.15 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.363 -0.836 . . . . 0.0 109.674 -179.794 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 40.2 p -67.78 -30.87 70.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.302 -0.874 . . . . 0.0 110.285 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 35.9 t -75.5 7.22 3.81 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.273 -0.892 . . . . 0.0 109.605 -179.631 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.8 m -65.17 148.95 50.77 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.363 -0.835 . . . . 0.0 110.091 -179.43 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -71.46 142.86 50.21 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.488 -0.757 . . . . 0.0 110.343 -179.578 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 20.4 t -85.64 128.32 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.449 -0.782 . . . . 0.0 109.293 179.493 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 23.9 pt -107.7 -2.89 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 121.312 -0.867 . . . . 0.0 109.908 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.13 178.87 39.23 Favored Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.007 179.662 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -134.23 153.42 51.86 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.542 -0.975 . . . . 0.0 109.248 179.84 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 91.7 mt -123.98 146.4 48.53 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 121.321 -0.862 . . . . 0.0 109.497 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 28.0 t -79.75 163.53 24.4 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.435 -0.791 . . . . 0.0 110.635 -179.07 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -66.03 161.7 43.83 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.524 -1.031 . . . . 0.0 110.524 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 54.75 31.96 16.51 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.578 -0.954 . . . . 0.0 109.595 -179.762 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.2 m -100.09 126.25 46.29 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.432 -0.793 . . . . 0.0 108.957 179.609 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -79.49 132.2 36.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.32 -0.862 . . . . 0.0 109.501 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 14.9 m -127.03 131.86 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.394 -0.816 . . . . 0.0 108.991 179.451 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 45.9 p -75.4 134.45 40.92 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-O 121.243 0.545 . . . . 0.0 109.87 -179.184 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 95.3 mt -111.35 128.89 67.54 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 CA-C-O 121.391 0.615 . . . . 0.0 109.379 179.508 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 35.3 m -113.29 -1.57 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.706 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -179.48 -178.67 48.51 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -142.84 159.45 42.22 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.256 -1.144 . . . . 0.0 109.676 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -154.53 113.0 3.56 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.137 -0.977 . . . . 0.0 109.759 179.496 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 59.97 -141.94 47.57 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.414 -1.075 . . . . 0.0 110.414 179.312 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.44 24.92 1.53 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.572 -0.958 . . . . 0.0 109.324 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -129.75 147.78 51.57 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.545 -0.722 . . . . 0.0 109.087 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -103.94 142.8 33.78 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.465 -0.772 . . . . 0.0 109.607 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -91.69 128.0 37.35 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 14.2 pt -129.89 154.02 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.296 -0.878 . . . . 0.0 109.391 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.413 ' OE1' ' CD2' ' A' ' 53' ' ' HIS . 49.0 tp10 -82.88 110.99 18.36 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.464 -0.772 . . . . 0.0 109.148 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.577 ' O ' ' N ' ' A' ' 51' ' ' GLY . 79.1 t80 -107.35 117.49 34.21 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.398 -0.814 . . . . 0.0 109.464 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt 44.23 -87.44 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.549 -0.72 . . . . 0.0 110.106 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -123.51 -34.0 0.78 Allowed Glycine 0 N--CA 1.497 2.741 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 15.6 p -89.43 169.43 11.39 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.335 -1.097 . . . . 0.0 109.822 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.413 ' CD2' ' OE1' ' A' ' 48' ' ' GLU . 73.2 m80 -96.46 115.63 27.75 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.533 -0.729 . . . . 0.0 109.124 179.645 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.96 153.12 26.56 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.403 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -121.01 138.66 54.06 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.708 -0.877 . . . . 0.0 109.073 179.661 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -136.58 152.59 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.307 -0.87 . . . . 0.0 109.495 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.658 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -75.03 147.26 40.86 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.523 -0.736 . . . . 0.0 110.65 -179.363 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -70.98 -14.11 62.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.431 -0.793 . . . . 0.0 109.444 179.187 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -65.47 -37.9 88.2 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.447 -0.783 . . . . 0.0 110.292 -179.222 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.519 ' C ' HD12 ' A' ' 61' ' ' ILE . 74.1 m-85 -96.81 -7.55 33.35 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.24 -0.912 . . . . 0.0 110.397 -179.068 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.519 HD12 ' C ' ' A' ' 60' ' ' TYR . 1.5 mp -108.17 129.08 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.062 0 O-C-N 121.366 -0.834 . . . . 0.0 108.931 -179.502 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.566 ' NZ ' ' CB ' ' A' ' 8' ' ' ASN . 26.7 pttm -145.86 -178.81 6.3 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.201 -0.937 . . . . 0.0 109.708 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 43.2 t0 60.73 46.67 8.82 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.609 -0.682 . . . . 0.0 109.368 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt -75.56 131.37 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.02 179.667 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.8 mtpm? -107.32 146.01 32.09 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.443 -0.786 . . . . 0.0 110.144 -179.198 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -73.03 149.62 43.08 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.587 -0.696 . . . . 0.0 110.033 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 50.1 tp10 -60.65 -81.13 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.474 -0.766 . . . . 0.0 109.755 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.2 m -84.16 132.76 30.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.183 -0.948 . . . . 0.0 110.271 -179.242 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.539 HD12 ' N ' ' A' ' 69' ' ' LEU . 8.9 mp -88.14 -2.31 58.53 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.517 -0.74 . . . . 0.0 109.442 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -77.0 135.04 38.67 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.28 -0.887 . . . . 0.0 109.992 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.502 ' C ' ' H ' ' A' ' 73' ' ' HIS . 97.8 m-70 -104.87 13.44 31.17 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.555 -0.716 . . . . 0.0 109.079 179.584 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 54.88 4.81 0.08 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.771 -0.581 . . . . 0.0 109.911 -179.581 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.502 ' H ' ' C ' ' A' ' 71' ' ' HIS . 62.0 t-80 -142.18 116.48 9.53 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.279 -0.888 . . . . 0.0 109.399 179.62 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' HIS . . . . . 0.472 ' NE2' ' OXT' ' A' ' 76' ' ' HIS . 84.4 t60 -166.94 85.12 0.26 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.229 -0.92 . . . . 0.0 109.043 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' HIS . . . . . 0.428 ' O ' ' O ' ' A' ' 76' ' ' HIS . 59.5 t-80 -65.86 -43.06 89.51 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.515 -0.741 . . . . 0.0 109.963 -179.47 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' HIS . . . . . 0.472 ' OXT' ' NE2' ' A' ' 74' ' ' HIS . 63.3 t-80 . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 118.064 -0.97 . . . . 0.0 109.901 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.1 tm-20 -89.11 133.05 34.53 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.375 -0.828 . . . . 0.0 110.026 -179.356 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.3 mppt? -137.04 151.88 49.44 Favored 'General case' 0 N--CA 1.494 1.76 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.326 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 68.9 p -122.74 137.68 54.84 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.621 -0.674 . . . . 0.0 109.765 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -119.49 131.09 8.81 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 5.6 mm -86.87 122.53 38.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.411 -1.052 . . . . 0.0 109.431 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 80.7 t -79.13 131.46 34.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.449 -0.782 . . . . 0.0 110.071 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 96.2 m-20 -121.48 101.77 7.83 Favored 'General case' 0 N--CA 1.497 1.925 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 29.4 m -139.98 160.95 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.425 -0.797 . . . . 0.0 110.025 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 80.6 p -81.63 -11.65 59.02 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.0 p -149.07 -70.21 0.21 Allowed 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.455 -0.778 . . . . 0.0 109.267 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 98.6 p -153.95 168.89 24.89 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.904 . . . . 0.0 110.116 -179.598 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.7 tp -115.47 131.03 57.06 Favored 'General case' 0 N--CA 1.498 1.925 0 CA-C-O 121.479 0.657 . . . . 0.0 109.495 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -83.92 135.25 34.55 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.484 -0.76 . . . . 0.0 110.196 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 87.3 t -90.36 131.74 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.478 -0.764 . . . . 0.0 109.218 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.602 HH21 ' N ' ' A' ' 57' ' ' ALA . 87.5 mtm180 -105.55 133.89 49.56 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.493 -0.754 . . . . 0.0 110.187 -179.601 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -67.53 -46.76 71.86 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.561 -0.712 . . . . 0.0 109.673 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.52 178.68 30.23 Favored Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.182 -1.167 . . . . 0.0 110.182 -179.311 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -92.95 21.28 5.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.616 -0.932 . . . . 0.0 108.681 179.536 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.1 m -79.59 165.2 23.18 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.543 -0.723 . . . . 0.0 110.407 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.7 m -63.19 -46.17 88.34 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.691 -0.631 . . . . 0.0 109.976 -179.83 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.8 m -129.44 71.13 1.43 Allowed 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.484 -0.76 . . . . 0.0 109.014 -179.553 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.46 -180.0 7.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.639 -0.663 . . . . 0.0 110.136 -179.545 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -67.05 133.12 49.26 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.617 0.723 . . . . 0.0 110.389 -179.453 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 74.8 t -81.15 129.19 37.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.482 -0.762 . . . . 0.0 109.536 179.696 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.407 HD12 ' CD2' ' A' ' 49' ' ' TYR . 41.1 pt -109.99 -5.09 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.723 -0.611 . . . . 0.0 109.489 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.09 177.39 38.15 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.489 -1.339 . . . . 0.0 110.284 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -132.23 155.71 47.78 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.73 -0.865 . . . . 0.0 109.397 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.6 mt -123.55 150.3 44.18 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-O 121.456 0.646 . . . . 0.0 109.801 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.4 m -71.82 152.54 42.59 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 121.522 0.677 . . . . 0.0 110.195 -179.537 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.451 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -68.07 162.83 48.61 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 56.46 5.0 0.17 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.979 -0.719 . . . . 0.0 109.854 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.451 ' H ' ' C ' ' A' ' 31' ' ' GLY . 35.3 m -81.26 137.1 35.85 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.898 . . . . 0.0 110.138 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -84.96 139.88 31.49 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.498 -0.751 . . . . 0.0 110.176 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 19.8 m -127.0 132.16 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.625 -0.672 . . . . 0.0 109.403 179.562 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 44.5 m -65.67 128.21 35.03 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.725 -0.609 . . . . 0.0 110.047 -179.496 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 97.1 mt -115.55 125.13 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 CA-C-O 121.391 0.615 . . . . 0.0 109.631 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.61 HG23 ' N ' ' A' ' 39' ' ' GLY . 34.6 m -112.96 -47.88 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 179.39 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.61 ' N ' HG23 ' A' ' 38' ' ' VAL . . . -95.06 162.58 23.95 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -142.01 125.63 16.85 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.494 -1.003 . . . . 0.0 109.298 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.518 ' O ' ' N ' ' A' ' 43' ' ' ALA . 83.1 tt0 -114.91 142.95 45.89 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.674 ' O ' ' HB2' ' A' ' 43' ' ' ALA . . . -65.71 59.52 0.13 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.487 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.674 ' HB2' ' O ' ' A' ' 42' ' ' GLY . . . 160.58 -31.7 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.711 -0.876 . . . . 0.0 108.715 179.707 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -134.68 160.91 36.67 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.534 -0.729 . . . . 0.0 110.204 -178.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.7 m-85 -114.13 140.25 48.67 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.589 -0.694 . . . . 0.0 109.688 179.679 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -90.68 129.95 36.73 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 -179.743 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.9 pt -127.9 157.04 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 CA-C-O 121.571 0.701 . . . . 0.0 110.1 -179.685 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -86.93 93.98 9.47 Favored 'General case' 0 N--CA 1.49 1.561 0 CA-C-O 121.431 0.634 . . . . 0.0 109.927 -179.485 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.407 ' CD2' HD12 ' A' ' 26' ' ' ILE . 91.5 t80 -86.89 140.07 30.0 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.399 -0.813 . . . . 0.0 109.467 179.771 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.8 tttm -54.63 100.53 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.422 -0.799 . . . . 0.0 110.05 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 124.51 -33.94 3.63 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 20.7 t -171.11 -168.58 0.66 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.214 -1.168 . . . . 0.0 109.942 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 5.9 m170 -100.69 120.16 39.66 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.519 -0.738 . . . . 0.0 109.641 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.09 161.37 20.85 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -118.09 147.06 43.64 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.737 -0.86 . . . . 0.0 109.626 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.2 m -139.27 153.32 24.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.699 -0.626 . . . . 0.0 109.794 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.602 ' N ' HH21 ' A' ' 16' ' ' ARG . . . -73.68 141.34 46.44 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.574 -0.704 . . . . 0.0 110.59 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -64.61 -12.25 43.65 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.681 -0.637 . . . . 0.0 110.016 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 45.1 tp10 -68.87 -35.97 77.54 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -0.9 . . . . 0.0 110.546 -179.228 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -93.52 2.25 56.48 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.103 -0.998 . . . . 0.0 110.147 -178.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.8 mm -105.67 128.91 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.483 -0.761 . . . . 0.0 109.616 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -143.63 157.09 44.67 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.56 -0.712 . . . . 0.0 109.993 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 37.5 t0 64.39 45.68 3.7 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.615 0.721 . . . . 0.0 109.675 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 97.1 mt -67.83 147.12 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.68 -0.638 . . . . 0.0 110.071 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -80.61 140.19 35.86 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.433 -0.792 . . . . 0.0 110.548 -178.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -62.57 145.21 54.96 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.46 0.648 . . . . 0.0 110.746 -179.377 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.522 ' CD ' ' H ' ' A' ' 67' ' ' GLU . 0.0 OUTLIER -132.19 -83.66 0.49 Allowed 'General case' 0 N--CA 1.498 1.927 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.881 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.514 ' H ' ' CD ' ' A' ' 67' ' ' GLU . 7.9 p -167.66 131.76 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.47 -0.768 . . . . 0.0 109.787 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.577 HD12 ' N ' ' A' ' 69' ' ' LEU . 9.3 mp -79.27 141.62 36.9 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.517 -0.74 . . . . 0.0 110.41 -179.447 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.44 ' O ' ' CD2' ' A' ' 72' ' ' HIS . 96.7 mt-10 55.37 103.11 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 CA-C-O 121.662 0.744 . . . . 0.0 110.181 179.612 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 26.9 p-80 -75.22 -11.34 60.05 Favored 'General case' 0 N--CA 1.487 1.416 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.694 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.44 ' CD2' ' O ' ' A' ' 70' ' ' GLU . 70.4 m-70 60.96 99.02 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 CA-C-O 121.463 0.649 . . . . 0.0 109.943 179.509 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 17.0 p-80 -81.57 1.37 34.03 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 44.9 p-80 -149.24 163.37 37.86 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.233 -0.917 . . . . 0.0 110.026 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 -113.81 139.03 49.48 Favored 'General case' 0 N--CA 1.493 1.692 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.766 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 83.9 t60 . . . . . 0 N--CA 1.489 1.497 0 CA-C-O 117.847 -1.073 . . . . 0.0 109.043 -179.981 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -67.81 137.54 55.44 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.764 0.792 . . . . 0.0 110.423 -179.208 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 52.4 mtmt -137.66 152.93 49.82 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.53 -0.732 . . . . 0.0 109.253 179.584 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 50.6 p -122.8 124.54 43.55 Favored 'General case' 0 N--CA 1.496 1.872 0 CA-C-O 121.829 0.823 . . . . 0.0 109.357 179.52 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -101.78 133.69 11.45 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 -179.365 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 34.4 mm -84.29 126.62 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.7 -0.882 . . . . 0.0 110.009 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.1 t -82.89 98.6 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.376 -0.827 . . . . 0.0 109.317 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -101.47 107.24 18.49 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.508 -0.745 . . . . 0.0 109.889 -179.603 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 m -141.09 144.3 26.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.299 -0.876 . . . . 0.0 109.575 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 27.5 t -66.97 -13.78 62.19 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-O 121.44 0.638 . . . . 0.0 109.497 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.484 ' OG ' ' N ' ' A' ' 12' ' ' SER . 91.1 p -141.3 -103.84 0.14 Allowed 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.161 -0.962 . . . . 0.0 110.231 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.484 ' N ' ' OG ' ' A' ' 11' ' ' SER . 57.8 m -127.49 157.38 40.24 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.464 -0.773 . . . . 0.0 110.191 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 36.5 tp -113.39 128.81 56.58 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 121.723 0.773 . . . . 0.0 109.875 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.9 m-20 -85.07 150.8 24.61 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.479 0.657 . . . . 0.0 110.025 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.4 t -104.41 129.94 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.423 -0.798 . . . . 0.0 109.276 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -105.28 132.81 51.01 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.546 0.688 . . . . 0.0 109.816 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -71.23 -37.22 72.01 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-O 121.819 0.818 . . . . 0.0 109.433 179.635 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -100.73 179.44 29.02 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -179.392 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -94.31 -1.44 53.87 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.193 -1.18 . . . . 0.0 108.825 179.393 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.9 m -83.36 149.82 26.48 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.312 -0.867 . . . . 0.0 110.196 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 97.7 m -65.0 -44.33 89.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.415 -0.803 . . . . 0.0 110.078 179.489 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 76.5 p -78.49 16.66 0.78 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.078 -1.014 . . . . 0.0 109.529 -179.448 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.8 m -63.64 149.65 46.03 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.212 -0.93 . . . . 0.0 110.251 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -70.96 138.25 49.86 Favored 'General case' 0 N--CA 1.488 1.47 0 CA-C-O 121.981 0.895 . . . . 0.0 110.528 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 75.0 t -87.37 130.17 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 CA-C-O 121.697 0.761 . . . . 0.0 109.925 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 37.4 pt -103.61 -4.57 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.007 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.91 -163.96 36.48 Favored Glycine 0 N--CA 1.493 2.451 0 C-N-CA 119.497 -1.335 . . . . 0.0 110.434 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 95.3 p -156.6 163.03 39.81 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.469 -1.019 . . . . 0.0 109.663 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 89.7 mt -124.79 150.86 45.87 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-O 121.694 0.759 . . . . 0.0 109.903 -179.601 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 12.3 p -76.19 164.72 25.81 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.062 0.934 . . . . 0.0 111.038 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.23 152.81 43.48 Favored Glycine 0 N--CA 1.489 2.222 0 CA-C-O 122.105 0.836 . . . . 0.0 111.665 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 67.1 t30 57.89 32.19 21.6 Favored 'General case' 0 N--CA 1.494 1.744 0 CA-C-O 121.635 0.731 . . . . 0.0 110.147 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 24.6 m -89.98 126.95 35.93 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.154 -0.966 . . . . 0.0 109.539 179.044 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -82.77 133.17 35.15 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.337 -0.852 . . . . 0.0 109.624 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.0 m -125.85 133.62 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 CA-C-O 121.791 0.805 . . . . 0.0 110.03 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 85.5 m -80.37 127.53 32.49 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.413 0.625 . . . . 0.0 109.78 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.8 mt -105.41 126.72 60.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 CA-C-O 121.466 0.65 . . . . 0.0 109.602 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 18.5 m -112.68 -1.97 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.56 177.82 45.75 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.613 -1.279 . . . . 0.0 110.364 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -141.72 159.63 41.83 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.356 -1.084 . . . . 0.0 109.871 -179.786 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -154.32 109.42 3.11 Favored 'General case' 0 N--CA 1.489 1.497 0 CA-C-O 121.684 0.754 . . . . 0.0 109.158 179.37 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.34 -137.47 45.0 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.06 23.28 1.26 Allowed 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.458 -1.024 . . . . 0.0 108.979 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -130.44 145.3 51.8 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.415 -0.803 . . . . 0.0 109.79 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.4 m-85 -108.5 139.66 42.94 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.611 0.719 . . . . 0.0 109.41 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -90.65 129.95 36.71 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.558 -0.714 . . . . 0.0 109.304 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.7 pt -129.03 153.53 38.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 CA-C-O 121.708 0.765 . . . . 0.0 109.804 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -81.02 99.66 8.56 Favored 'General case' 0 N--CA 1.49 1.531 0 CA-C-O 121.674 0.75 . . . . 0.0 109.857 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.404 ' CD2' ' N ' ' A' ' 51' ' ' GLY . 88.0 t80 -81.2 144.13 31.83 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.559 -0.713 . . . . 0.0 110.021 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 51.9 mtmt -46.85 -47.22 21.26 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.461 -0.775 . . . . 0.0 110.144 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.404 ' N ' ' CD2' ' A' ' 49' ' ' TYR . . . -69.34 -39.93 80.81 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 179.797 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 21.4 m -171.62 -110.78 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.152 -1.205 . . . . 0.0 109.325 -179.536 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 73.2 m80 -127.56 112.56 15.04 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-O 121.801 0.81 . . . . 0.0 109.352 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.84 154.29 19.94 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 -179.681 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -120.87 139.96 52.45 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.606 -0.938 . . . . 0.0 109.712 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.2 m -135.96 152.55 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.55 -0.719 . . . . 0.0 109.195 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 149.8 37.93 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-O 121.861 0.839 . . . . 0.0 110.667 -179.528 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 62.2 pttt -65.8 -15.43 62.87 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.57 0.7 . . . . 0.0 109.977 179.4 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.443 ' OE2' ' CE2' ' A' ' 60' ' ' TYR . 14.4 pt-20 -67.28 -35.73 80.1 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.243 -0.911 . . . . 0.0 110.199 -179.563 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.443 ' CE2' ' OE2' ' A' ' 59' ' ' GLU . 54.9 m-85 -90.79 -1.69 57.84 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.07 -1.019 . . . . 0.0 109.26 -179.407 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 39.3 mm -110.86 131.72 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.397 -0.815 . . . . 0.0 109.428 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.486 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 63.8 tttp -130.45 158.05 40.96 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.486 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 11.7 t0 79.81 -59.02 0.35 Allowed 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.393 0.616 . . . . 0.0 109.529 179.518 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.414 ' O ' HG22 ' A' ' 64' ' ' ILE . 82.1 mt 43.77 65.91 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 CA-C-O 121.741 0.782 . . . . 0.0 109.268 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 38.0 ttmt -142.55 144.45 32.92 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.258 -0.901 . . . . 0.0 110.065 -179.16 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.478 ' OD1' ' N ' ' A' ' 67' ' ' GLU . 68.1 t0 -63.04 137.63 58.32 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 121.787 0.803 . . . . 0.0 110.316 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.478 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 20.3 pt-20 -50.95 143.35 10.34 Favored 'General case' 0 N--CA 1.494 1.745 0 CA-C-O 121.589 0.709 . . . . 0.0 110.569 -179.489 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 6.9 m -103.25 131.08 52.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 CA-C-O 121.739 0.781 . . . . 0.0 110.266 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.595 HD12 ' N ' ' A' ' 69' ' ' LEU . 9.2 mp -76.39 149.29 36.94 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.773 0.797 . . . . 0.0 110.235 -179.7 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -44.97 146.39 0.82 Allowed 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.951 0.881 . . . . 0.0 110.858 -179.407 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -72.85 127.25 31.99 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.694 0.759 . . . . 0.0 110.735 -179.412 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.499 ' CG ' ' N ' ' A' ' 73' ' ' HIS . 27.5 t-80 -160.59 172.78 16.55 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.559 -0.713 . . . . 0.0 109.539 179.767 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.499 ' N ' ' CG ' ' A' ' 72' ' ' HIS . 95.1 m-70 -61.52 -36.87 81.76 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.433 -0.792 . . . . 0.0 109.639 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 58.6 t-80 -65.07 -39.32 93.06 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.207 -0.933 . . . . 0.0 109.379 179.692 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 24.9 t-80 -69.44 130.02 41.35 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.889 . . . . 0.0 109.919 -179.457 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 . . . . . 0 C--N 1.302 -1.475 0 CA-C-O 118.102 -0.951 . . . . 0.0 109.634 179.985 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 63.2 mttp . . . . . 0 N--CA 1.494 1.771 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 22.9 p -117.61 121.87 42.07 Favored 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.831 0.825 . . . . 0.0 109.631 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -102.03 137.64 13.45 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 27.8 mm -87.11 123.21 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.539 -0.977 . . . . 0.0 109.53 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 33' ' ' THR . 70.5 t -74.36 134.08 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.509 -0.744 . . . . 0.0 110.13 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 47.0 t30 -128.53 101.31 6.12 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.6 -0.687 . . . . 0.0 109.401 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 24.5 m -136.71 160.58 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.397 -0.814 . . . . 0.0 109.709 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 99.9 p -84.16 -10.37 57.81 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.498 0.666 . . . . 0.0 109.604 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 62.5 p -147.4 -66.79 0.26 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.13 -0.981 . . . . 0.0 109.503 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.5 p -157.52 165.73 34.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.237 -0.915 . . . . 0.0 109.414 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.0 tp -113.44 130.18 56.37 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 121.672 0.749 . . . . 0.0 109.822 -179.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -85.78 145.84 27.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.518 -0.739 . . . . 0.0 109.678 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.7 t -111.51 130.97 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.483 ' NE ' ' O ' ' A' ' 21' ' ' THR . 84.6 mtt85 -111.14 146.36 36.99 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.788 0.804 . . . . 0.0 109.76 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -88.19 -16.59 32.9 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.458 ' O ' ' CD2' ' A' ' 55' ' ' TYR . . . -96.66 -130.92 6.69 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -152.21 -5.58 0.23 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -1.11 . . . . 0.0 108.581 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 8.5 p -82.38 172.33 13.19 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.354 -0.841 . . . . 0.0 110.761 -179.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.483 ' O ' ' NE ' ' A' ' 16' ' ' ARG . 52.3 p -66.13 -31.21 71.93 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.603 -0.685 . . . . 0.0 110.219 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 38.0 m -138.39 58.71 1.66 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.029 -1.044 . . . . 0.0 108.896 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.5 m -77.69 -79.1 0.12 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.406 -0.809 . . . . 0.0 109.719 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -157.03 112.97 2.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.073 -1.017 . . . . 0.0 109.792 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.0 t -80.67 129.45 37.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.347 -0.846 . . . . 0.0 109.589 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.4 pt -111.16 -5.58 11.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.554 -0.717 . . . . 0.0 109.126 179.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 164.89 -157.98 30.62 Favored Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.189 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.0 p -153.88 164.7 37.96 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.163 -1.198 . . . . 0.0 109.721 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 94.7 mt -126.64 151.56 47.87 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.671 0.748 . . . . 0.0 109.571 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' OG1' ' A' ' 33' ' ' THR . 29.7 t -71.18 160.7 32.38 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-O 121.91 0.862 . . . . 0.0 110.598 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.459 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.54 160.23 49.72 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 57.87 4.09 0.26 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.957 -0.731 . . . . 0.0 109.754 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.459 ' H ' ' C ' ' A' ' 31' ' ' GLY . 86.0 m -70.36 135.94 49.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.22 -0.925 . . . . 0.0 110.275 179.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 10.2 mtpm? -83.59 140.56 32.15 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.577 -0.702 . . . . 0.0 110.251 -179.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.2 m -126.73 130.88 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.619 -0.676 . . . . 0.0 109.341 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 p -79.83 129.31 34.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.537 -0.727 . . . . 0.0 109.719 -179.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 97.0 mt -112.24 129.38 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 CA-C-O 121.482 0.658 . . . . 0.0 109.358 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.2 m -110.18 -2.51 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.01 177.92 47.9 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.307 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.437 ' CD ' ' N ' ' A' ' 41' ' ' GLU . 9.9 tm-20 -133.09 155.4 49.3 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.423 -1.045 . . . . 0.0 109.402 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.437 ' N ' ' CD ' ' A' ' 40' ' ' GLU . 48.6 tp10 -156.31 115.76 3.52 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.493 -0.754 . . . . 0.0 109.149 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 63.68 -142.9 47.32 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.95 20.2 5.04 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.418 -1.048 . . . . 0.0 109.022 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -130.19 150.82 51.27 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.483 -0.761 . . . . 0.0 109.656 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -102.94 140.6 37.01 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.67 0.747 . . . . 0.0 109.988 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -91.16 130.39 37.05 Favored 'General case' 0 N--CA 1.487 1.425 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.2 pt -128.72 157.15 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 CA-C-O 121.766 0.793 . . . . 0.0 110.199 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -82.08 97.3 8.09 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.594 0.711 . . . . 0.0 109.48 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -85.18 144.85 27.91 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.365 -0.834 . . . . 0.0 109.825 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -66.76 100.62 0.72 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.493 -0.754 . . . . 0.0 110.154 -179.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 116.87 -23.4 10.08 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 109.187 -1.565 . . . . 0.0 109.187 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 10.8 t -169.08 -156.08 0.15 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.065 -1.256 . . . . 0.0 110.101 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -108.49 122.77 47.74 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.706 0.765 . . . . 0.0 109.716 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.41 148.76 19.28 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.458 ' CD2' ' O ' ' A' ' 18' ' ' GLY . 87.9 m-85 -127.16 132.27 50.55 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.669 -0.901 . . . . 0.0 109.238 179.306 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.8 m -138.19 153.45 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.396 -0.815 . . . . 0.0 109.923 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.07 151.23 40.22 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-O 121.574 0.702 . . . . 0.0 110.849 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -67.25 -20.34 65.65 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.526 -0.734 . . . . 0.0 110.548 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -65.38 -32.9 74.78 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.213 -0.93 . . . . 0.0 110.565 -178.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -87.91 1.45 54.01 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.854 -1.154 . . . . 0.0 109.396 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 37.8 mm -108.51 127.25 65.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.411 -0.806 . . . . 0.0 109.346 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 37.5 ttpt -140.58 150.43 43.63 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.815 0.817 . . . . 0.0 110.385 -179.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 54.39 72.3 0.47 Allowed 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.72 0.771 . . . . 0.0 110.254 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.9 mt . . . . . 0 N--CA 1.491 1.607 0 O-C-N 121.287 -0.883 . . . . 0.0 109.402 179.574 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt . . . . . 0 N--CA 1.496 1.826 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 17.4 p -118.36 116.44 26.74 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.513 0.673 . . . . 0.0 109.206 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -93.55 125.62 8.3 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.677 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.7 mp -81.08 124.5 38.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.295 -1.121 . . . . 0.0 109.58 -179.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 76.6 t -77.78 132.67 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.343 -0.848 . . . . 0.0 109.956 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -126.92 98.22 5.26 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.5 m -137.23 158.92 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.58 -0.7 . . . . 0.0 109.616 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.9 m -86.06 -12.57 49.79 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.551 -0.718 . . . . 0.0 109.357 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 71.4 m -133.31 -79.51 0.48 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.462 -0.774 . . . . 0.0 109.204 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.3 p -158.29 165.1 35.62 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.173 -0.954 . . . . 0.0 109.725 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 34.0 tp -112.8 131.58 55.63 Favored 'General case' 0 N--CA 1.498 1.963 0 CA-C-O 121.545 0.688 . . . . 0.0 109.561 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -92.17 143.69 26.17 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.503 -0.748 . . . . 0.0 110.063 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 71.1 t -92.57 132.02 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.479 -0.763 . . . . 0.0 109.122 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -102.16 130.53 48.81 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.395 -0.816 . . . . 0.0 110.102 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -70.41 -41.55 72.8 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.719 -0.613 . . . . 0.0 109.821 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.45 ' H ' ' HB2' ' A' ' 23' ' ' SER . . . -105.7 -171.62 23.65 Favored Glycine 0 N--CA 1.497 2.766 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.106 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.05 57.99 0.76 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.699 -0.883 . . . . 0.0 109.124 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 40.7 t -161.33 154.9 21.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.244 -0.91 . . . . 0.0 109.821 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 75.2 p -66.15 -33.09 74.99 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.627 -0.67 . . . . 0.0 109.806 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 47.1 t -79.07 9.18 4.64 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.195 -0.94 . . . . 0.0 108.979 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.45 ' HB2' ' H ' ' A' ' 18' ' ' GLY . 94.2 p -69.36 159.46 33.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.492 -0.755 . . . . 0.0 110.427 -179.304 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -84.16 138.68 32.87 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.471 -0.768 . . . . 0.0 110.837 -179.198 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.0 t -89.69 130.99 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.541 -0.724 . . . . 0.0 109.792 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.41 HD12 ' CE2' ' A' ' 49' ' ' TYR . 36.8 pt -102.8 -6.59 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.574 -0.703 . . . . 0.0 109.177 179.428 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 169.22 -179.83 41.62 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 119.489 -1.339 . . . . 0.0 110.05 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 63.1 m -133.95 157.03 47.07 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.643 -0.916 . . . . 0.0 109.445 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.1 mt -122.59 148.96 44.61 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 121.544 0.687 . . . . 0.0 109.705 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.0 m -71.18 150.2 45.59 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-O 121.705 0.764 . . . . 0.0 110.519 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.543 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -64.13 163.33 34.45 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 111.099 -0.801 . . . . 0.0 111.099 -179.275 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 37.6 t-20 66.74 -19.64 0.11 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.942 -0.74 . . . . 0.0 110.135 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.543 ' H ' ' C ' ' A' ' 31' ' ' GLY . 33.0 m -67.31 136.4 54.8 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.047 -1.033 . . . . 0.0 110.209 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -90.42 148.81 22.55 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.502 -0.749 . . . . 0.0 109.605 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.5 m -123.51 131.53 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 CA-C-O 121.579 0.704 . . . . 0.0 109.188 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 28.5 m -66.63 130.5 43.39 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.86 -0.525 . . . . 0.0 110.025 -179.166 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.0 mt -110.53 129.78 65.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 19.0 m -112.92 -0.12 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -179.61 -179.31 48.76 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.43 -1.367 . . . . 0.0 110.307 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -139.87 154.08 47.19 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.462 -1.023 . . . . 0.0 109.75 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -153.98 109.05 3.13 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -0.854 . . . . 0.0 109.402 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 59.14 -142.22 46.74 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -83.2 17.85 1.91 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.487 -1.008 . . . . 0.0 109.278 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -129.83 145.57 51.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.615 -0.678 . . . . 0.0 109.514 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 50.4 m-85 -107.68 147.69 30.38 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.605 0.716 . . . . 0.0 109.833 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -90.84 139.29 30.88 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.537 -0.727 . . . . 0.0 109.044 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.4 pt -134.45 158.45 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 CA-C-O 121.665 0.745 . . . . 0.0 110.519 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -84.22 93.59 8.22 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.674 -0.641 . . . . 0.0 109.426 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.41 ' CE2' HD12 ' A' ' 26' ' ' ILE . 82.4 t80 -98.37 135.31 40.14 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.358 -0.839 . . . . 0.0 109.278 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.9 ttpt -49.77 106.72 0.12 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.383 -0.823 . . . . 0.0 110.568 -179.162 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 123.31 -51.76 0.79 Allowed Glycine 0 N--CA 1.496 2.647 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 179.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 22.8 p -158.86 -166.2 1.81 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.132 -1.216 . . . . 0.0 110.124 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 78.3 m80 -90.41 116.87 28.68 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.366 -0.834 . . . . 0.0 109.865 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -86.29 160.75 33.57 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -123.96 136.36 54.26 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.665 -0.903 . . . . 0.0 109.423 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.8 m -136.81 137.24 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.506 -0.746 . . . . 0.0 109.337 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.97 143.67 57.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.599 -0.688 . . . . 0.0 110.632 -179.216 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.9 pttt -62.01 -13.35 24.92 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.544 -0.722 . . . . 0.0 109.422 179.377 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -68.25 -31.0 70.17 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.434 -0.791 . . . . 0.0 110.95 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.402 ' C ' HD12 ' A' ' 61' ' ' ILE . 61.2 m-85 -93.1 -11.05 33.87 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.792 -1.192 . . . . 0.0 109.769 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.533 ' N ' HD12 ' A' ' 61' ' ' ILE . 1.4 mp -94.73 131.63 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.361 -0.837 . . . . 0.0 109.207 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.471 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 65.8 tttm -135.43 155.41 50.59 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.653 -0.655 . . . . 0.0 109.828 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.471 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 11.7 t0 79.39 -66.78 0.17 Allowed 'General case' 0 N--CA 1.495 1.799 0 CA-C-O 121.268 0.556 . . . . 0.0 109.535 179.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 91.5 mt . . . . . 0 N--CA 1.488 1.463 0 O-C-N 121.634 -0.666 . . . . 0.0 109.488 -179.442 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.8 mttt . . . . . 0 N--CA 1.493 1.685 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -114.46 126.61 55.16 Favored 'General case' 0 N--CA 1.498 1.975 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.31 140.75 15.2 Favored Glycine 0 N--CA 1.497 2.754 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 23.7 mm -94.33 116.33 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.364 -1.08 . . . . 0.0 108.904 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.3 t -80.35 132.63 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.376 -0.828 . . . . 0.0 109.99 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.6 t30 -132.99 106.9 7.94 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.428 -0.795 . . . . 0.0 109.34 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 11' ' ' SER . 19.6 m -151.65 -12.87 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.416 ' H ' ' H ' ' A' ' 9' ' ' VAL . 24.0 p 43.87 17.79 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.724 -0.61 . . . . 0.0 109.729 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.525 ' N ' ' O ' ' A' ' 9' ' ' VAL . 23.7 m -151.55 35.85 0.57 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.1 t 60.63 145.31 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.793 -0.567 . . . . 0.0 110.437 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 35.9 tp -116.16 133.13 56.36 Favored 'General case' 0 N--CA 1.503 2.209 0 CA-C-O 121.572 0.701 . . . . 0.0 109.613 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 18.9 p30 -80.65 137.34 36.33 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.429 -0.794 . . . . 0.0 109.62 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 73.7 t -90.95 131.25 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.361 -0.837 . . . . 0.0 108.84 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 96.7 mtt-85 -95.9 138.81 33.0 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.001 . . . . 0.0 109.981 -179.123 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 50.4 tp10 -67.5 -43.67 80.31 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.424 -0.797 . . . . 0.0 109.777 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.43 ' H ' ' HB2' ' A' ' 23' ' ' SER . . . -119.52 -166.6 13.4 Favored Glycine 0 N--CA 1.499 2.856 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 -178.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.69 56.03 0.88 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.62 -0.929 . . . . 0.0 109.225 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 28.8 t -152.8 151.09 30.05 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.264 -0.898 . . . . 0.0 109.725 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 41.7 p -68.06 -23.12 64.92 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.394 -0.816 . . . . 0.0 109.438 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 86.1 p -83.65 -0.48 50.83 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.423 -0.798 . . . . 0.0 109.429 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.43 ' HB2' ' H ' ' A' ' 18' ' ' GLY . 99.8 p -64.84 159.42 22.61 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.222 -0.924 . . . . 0.0 110.387 -179.323 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 22.6 pttp -92.6 140.18 29.81 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.49 -0.756 . . . . 0.0 110.407 -179.458 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 22.6 t -86.69 129.81 37.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.383 -0.823 . . . . 0.0 109.909 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 36.3 pt -102.39 -7.4 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.512 -0.743 . . . . 0.0 109.157 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.77 -162.81 35.22 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 24.8 p -152.78 164.04 38.57 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.299 -1.118 . . . . 0.0 109.433 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.3 mt -124.26 148.48 47.35 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.546 -0.721 . . . . 0.0 109.39 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.9 t -69.94 152.02 44.95 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.493 -0.755 . . . . 0.0 110.622 -179.016 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.46 160.55 32.24 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 12.3 m120 57.31 33.22 22.99 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.653 -0.91 . . . . 0.0 109.563 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 35.1 m -105.02 137.02 43.41 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.57 -0.706 . . . . 0.0 109.832 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -79.76 140.32 36.95 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 109.057 -0.719 . . . . 0.0 109.057 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.8 m -126.77 130.5 71.53 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.416 -0.803 . . . . 0.0 109.397 179.565 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 54.6 m -72.84 126.39 29.81 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.41 -0.806 . . . . 0.0 109.628 -179.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 93.1 mt -107.33 126.71 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.639 -0.663 . . . . 0.0 109.65 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 30.9 m -111.13 -3.26 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 177.21 -174.14 46.78 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -141.05 155.16 46.21 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.323 -1.104 . . . . 0.0 109.441 179.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -151.27 112.06 4.25 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 109.598 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.461 ' O ' ' NZ ' ' A' ' 58' ' ' LYS . . . 61.92 -144.93 49.19 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.501 ' C ' ' HZ2' ' A' ' 58' ' ' LYS . . . -84.36 24.96 0.91 Allowed 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.657 -0.908 . . . . 0.0 109.384 -179.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 -131.58 152.68 50.59 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.602 -0.686 . . . . 0.0 109.341 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 9.1 m-85 -103.16 139.08 39.12 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.413 -0.804 . . . . 0.0 108.855 179.592 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.535 ' HZ2' ' HB3' ' A' ' 53' ' ' HIS . 63.5 tttp -90.71 129.72 36.78 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 33.3 pt -130.72 154.47 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.483 -0.761 . . . . 0.0 109.588 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -83.22 100.3 10.5 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.455 -0.778 . . . . 0.0 109.341 -179.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -83.64 147.1 27.9 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.351 -0.843 . . . . 0.0 109.797 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 8.0 mtmp? -62.21 102.96 0.34 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.267 -0.895 . . . . 0.0 110.861 -179.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 101.63 -10.28 57.5 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 179.106 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 50.4 m -168.29 -166.09 0.67 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.861 -1.376 . . . . 0.0 110.035 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.535 ' HB3' ' HZ2' ' A' ' 46' ' ' LYS . 96.9 m-70 -110.28 115.92 30.55 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.52 -0.737 . . . . 0.0 109.085 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.2 152.08 21.07 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.371 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -126.55 137.79 53.39 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.639 -0.918 . . . . 0.0 109.021 179.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.3 m -135.59 139.56 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.339 -0.85 . . . . 0.0 109.753 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.574 ' HB1' ' OE1' ' A' ' 59' ' ' GLU . . . -68.09 149.58 49.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.575 -0.703 . . . . 0.0 110.593 -179.378 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.501 ' HZ2' ' C ' ' A' ' 43' ' ' ALA . 64.2 mttp -62.23 -33.73 75.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.463 -0.773 . . . . 0.0 109.772 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.574 ' OE1' ' HB1' ' A' ' 57' ' ' ALA . 58.7 mp0 -55.1 -30.98 60.84 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.354 -0.841 . . . . 0.0 110.086 -178.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.478 ' CD2' ' HB3' ' A' ' 57' ' ' ALA . 40.0 m-85 -92.84 -3.98 53.73 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.966 -1.084 . . . . 0.0 109.353 -179.631 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.1 mm -114.46 129.18 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 121.541 -0.724 . . . . 0.0 109.516 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.577 ' O ' ' N ' ' A' ' 64' ' ' ILE . 21.7 ptmt -141.14 -174.16 3.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.418 -0.801 . . . . 0.0 109.581 179.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.458 ' O ' ' O ' ' A' ' 64' ' ' ILE . 91.1 m-20 56.69 -75.48 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.577 ' N ' ' O ' ' A' ' 62' ' ' LYS . 97.7 mt . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.393 0.616 . . . . 0.0 110.01 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.5 mtmp? . . . . . 0 N--CA 1.492 1.642 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 62.0 p -121.35 125.21 46.42 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.567 -0.708 . . . . 0.0 109.464 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -102.86 137.32 13.34 Favored Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.4 mm -95.5 120.07 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.275 -1.133 . . . . 0.0 109.449 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 74.1 t -75.67 134.2 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.566 -0.709 . . . . 0.0 110.321 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' A' ' 60' ' ' TYR . 3.6 p-10 -138.72 99.74 3.88 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.437 -0.789 . . . . 0.0 109.385 179.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 5.7 m -134.98 135.73 52.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.577 -0.702 . . . . 0.0 109.682 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 78.2 p -62.52 -40.49 96.94 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.614 -0.679 . . . . 0.0 109.638 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 68.9 m -101.8 -79.19 0.52 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.447 -0.783 . . . . 0.0 109.877 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 45.5 m -161.51 167.06 26.13 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.334 -0.854 . . . . 0.0 109.596 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 38.6 tp -116.95 130.17 56.53 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.64 -0.662 . . . . 0.0 109.789 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 9.2 m120 -91.16 142.29 27.89 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.397 -0.814 . . . . 0.0 109.686 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 96.3 t -88.89 128.08 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.324 -0.86 . . . . 0.0 109.21 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.758 HH21 ' H ' ' A' ' 20' ' ' SER . 67.5 mtp180 -107.52 133.16 52.39 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.549 -0.719 . . . . 0.0 109.962 -179.357 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.3 pt-20 -70.7 -35.01 72.55 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.488 -0.757 . . . . 0.0 109.879 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -120.95 -148.8 8.05 Favored Glycine 0 N--CA 1.498 2.774 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 -178.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -147.27 75.05 1.36 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.574 -0.957 . . . . 0.0 108.834 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.758 ' H ' HH21 ' A' ' 16' ' ' ARG . 15.2 m -141.85 44.95 1.7 Allowed 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.633 ' N ' ' NH2' ' A' ' 16' ' ' ARG . 59.0 p 50.37 -84.81 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.769 0 CA-C-O 121.319 0.58 . . . . 0.0 110.471 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.527 ' N ' ' O ' ' A' ' 20' ' ' SER . 23.0 t -71.39 44.4 0.09 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.354 -0.841 . . . . 0.0 109.002 -179.45 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.43 ' H ' ' C ' ' A' ' 21' ' ' THR . 15.4 p -78.58 165.22 23.94 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.355 -0.84 . . . . 0.0 110.411 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -77.3 138.54 39.42 Favored 'General case' 0 N--CA 1.488 1.473 0 CA-C-O 121.721 0.772 . . . . 0.0 110.637 -179.583 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 76.5 t -93.49 129.9 43.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 39.4 pt -109.19 -7.1 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.6 -0.687 . . . . 0.0 109.556 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 179.12 -173.53 45.65 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 119.287 -1.435 . . . . 0.0 110.349 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 54.8 m -144.0 154.06 42.87 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.405 -1.056 . . . . 0.0 109.789 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.7 mt -124.89 148.78 48.12 Favored 'General case' 0 N--CA 1.497 1.884 0 CA-C-O 121.546 0.689 . . . . 0.0 109.63 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 90.6 p -79.08 165.06 23.78 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 121.72 0.772 . . . . 0.0 110.854 -179.148 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -65.78 155.27 50.4 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 12.0 m120 57.41 31.59 20.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.73 -0.865 . . . . 0.0 109.86 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 37.0 m -91.73 129.94 37.61 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.216 -0.928 . . . . 0.0 109.835 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -80.11 133.33 36.08 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.514 -0.741 . . . . 0.0 109.639 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 m -128.1 133.29 67.4 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.303 -0.873 . . . . 0.0 110.037 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 21.6 m -81.56 131.23 35.27 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.685 -0.634 . . . . 0.0 109.451 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 91.1 mt -104.91 126.0 59.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.593 -0.692 . . . . 0.0 109.785 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 15.8 m -109.66 -1.43 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.46 -177.79 48.42 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -142.23 160.84 39.45 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.342 -1.093 . . . . 0.0 109.631 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -152.84 112.57 3.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.241 -0.912 . . . . 0.0 109.546 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.22 -135.16 47.88 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.82 25.91 1.94 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.462 -1.022 . . . . 0.0 109.006 -179.456 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 65.3 m-85 -132.4 151.33 51.92 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.685 -0.634 . . . . 0.0 109.452 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 31.5 m-85 -107.84 139.49 42.35 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.528 0.68 . . . . 0.0 109.894 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -92.42 132.63 36.61 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 36.7 pt -128.4 156.88 40.9 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.556 -0.715 . . . . 0.0 110.205 -179.638 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -82.15 97.56 8.27 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.66 -0.65 . . . . 0.0 109.483 -179.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.418 ' H ' ' HA ' ' A' ' 53' ' ' HIS . 90.0 t80 -85.49 161.46 19.36 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.525 -0.734 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.411 ' N ' ' CG ' ' A' ' 49' ' ' TYR . 98.6 mttt -70.91 107.81 4.22 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.415 -0.803 . . . . 0.0 110.267 -179.543 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 98.84 -14.46 61.64 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 81.0 p -169.46 -161.61 0.3 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.942 -1.328 . . . . 0.0 110.145 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.418 ' HA ' ' H ' ' A' ' 49' ' ' TYR . 77.4 m80 -116.43 121.47 41.98 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.628 -0.67 . . . . 0.0 109.571 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.84 163.57 30.84 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.597 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 81.9 m-85 -132.23 137.35 47.52 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.62 -0.929 . . . . 0.0 109.431 179.507 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 30.2 m -138.73 156.49 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.916 0 O-C-N 121.518 -0.739 . . . . 0.0 109.82 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.86 145.54 42.69 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.508 -0.745 . . . . 0.0 110.314 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 10.3 ptmm? -68.71 -13.79 62.6 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.597 -0.69 . . . . 0.0 110.064 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -67.21 -35.99 80.77 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.195 -0.941 . . . . 0.0 110.149 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.424 ' O ' ' OD1' ' A' ' 8' ' ' ASN . 75.7 m-85 -92.14 1.33 57.27 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.079 -1.013 . . . . 0.0 109.602 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.0 mm -113.68 125.49 70.96 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.561 -0.712 . . . . 0.0 109.601 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -142.42 169.83 16.85 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.477 -0.765 . . . . 0.0 109.856 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 47.9 t0 62.28 52.38 3.14 Favored 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.575 0.703 . . . . 0.0 109.787 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt . . . . . 0 N--CA 1.488 1.466 0 O-C-N 121.463 -0.773 . . . . 0.0 109.188 179.571 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 64.5 mttp . . . . . 0 N--CA 1.494 1.77 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 10.1 p -122.86 114.45 20.5 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.506 -0.746 . . . . 0.0 109.315 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -97.3 141.42 15.6 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.4 mm -94.71 119.48 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.381 -1.07 . . . . 0.0 109.225 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.3 t -79.04 125.1 38.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.305 -0.872 . . . . 0.0 109.774 -179.478 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.4 t30 -105.52 94.95 5.48 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.453 -0.779 . . . . 0.0 109.387 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.616 HG22 ' H ' ' A' ' 11' ' ' SER . 2.2 p -144.42 135.49 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.361 -0.837 . . . . 0.0 109.174 179.474 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 77.3 p -84.71 -13.73 50.51 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.558 -0.714 . . . . 0.0 109.562 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.616 ' H ' HG22 ' A' ' 9' ' ' VAL . 66.3 m -117.44 -89.26 0.59 Allowed 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.463 -0.773 . . . . 0.0 109.841 -179.686 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.9 p -158.58 163.51 36.93 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.914 -1.116 . . . . 0.0 109.751 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 40.2 tp -120.52 131.21 54.59 Favored 'General case' 0 N--CA 1.498 1.968 0 CA-C-O 121.666 0.746 . . . . 0.0 109.626 179.74 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -87.04 146.61 26.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.457 -0.777 . . . . 0.0 109.82 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 74.3 t -104.98 129.0 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.455 -0.778 . . . . 0.0 109.125 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.67 HH22 ' N ' ' A' ' 57' ' ' ALA . 0.6 OUTLIER -107.87 138.71 43.64 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.655 0.741 . . . . 0.0 109.372 -179.617 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -93.3 -21.84 19.34 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.554 -0.716 . . . . 0.0 109.35 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.493 ' C ' ' H ' ' A' ' 20' ' ' SER . . . -101.97 7.52 55.05 Favored Glycine 0 N--CA 1.497 2.748 0 N-CA-C 108.897 -1.681 . . . . 0.0 108.897 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . 56.83 3.97 0.15 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.478 -1.013 . . . . 0.0 109.392 -179.44 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.493 ' H ' ' C ' ' A' ' 18' ' ' GLY . 7.6 m -80.87 156.81 25.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.316 -0.865 . . . . 0.0 110.327 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.456 ' O ' ' CB ' ' A' ' 22' ' ' SER . 43.1 p -61.29 101.53 0.17 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.531 -0.731 . . . . 0.0 110.171 -179.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.456 ' CB ' ' O ' ' A' ' 21' ' ' THR . 0.7 OUTLIER 79.06 27.65 0.41 Allowed 'General case' 0 N--CA 1.496 1.852 0 CA-C-O 121.639 0.733 . . . . 0.0 109.519 179.587 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.42 ' O ' ' O ' ' A' ' 22' ' ' SER . 0.2 OUTLIER -56.64 -159.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.915 0.864 . . . . 0.0 110.763 -179.747 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 38.1 ttmt -64.32 128.6 36.51 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.616 0.722 . . . . 0.0 109.785 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 91.1 t -92.14 115.26 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 CA-C-O 121.58 0.705 . . . . 0.0 109.277 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.9 pt -103.66 -3.98 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.57 -163.11 36.73 Favored Glycine 0 N--CA 1.488 2.15 0 C-N-CA 119.405 -1.378 . . . . 0.0 110.53 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.5 p -154.02 163.54 39.91 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.311 -1.111 . . . . 0.0 109.221 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.2 mt -124.63 146.39 49.11 Favored 'General case' 0 N--CA 1.497 1.9 0 CA-C-O 121.725 0.774 . . . . 0.0 110.013 -179.477 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.412 ' C ' ' HG1' ' A' ' 33' ' ' THR . 12.9 m -83.32 162.12 21.21 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-O 121.837 0.827 . . . . 0.0 110.404 -179.533 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.478 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -65.45 158.35 46.35 Favored Glycine 0 N--CA 1.49 2.296 0 CA-C-O 121.817 0.676 . . . . 0.0 111.583 -179.467 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 59.43 0.04 0.19 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.966 -0.726 . . . . 0.0 110.032 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.478 ' H ' ' C ' ' A' ' 31' ' ' GLY . 30.2 m -72.09 140.88 49.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.244 -0.91 . . . . 0.0 110.505 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -87.41 144.74 26.6 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.528 -0.733 . . . . 0.0 109.592 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.6 m -125.87 132.1 71.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 121.456 -0.777 . . . . 0.0 109.96 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 26.6 m -73.11 104.06 4.06 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.68 -0.637 . . . . 0.0 109.362 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.3 mt -101.73 131.1 50.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.553 0.692 . . . . 0.0 109.521 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.612 HG23 ' N ' ' A' ' 39' ' ' GLY . 23.8 m -140.32 -46.51 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.612 ' N ' HG23 ' A' ' 38' ' ' VAL . . . -95.41 164.74 24.59 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -179.338 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.447 ' CD ' ' N ' ' A' ' 41' ' ' GLU . 15.8 tm-20 -135.28 146.0 48.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.369 -1.077 . . . . 0.0 109.594 179.63 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.447 ' N ' ' CD ' ' A' ' 40' ' ' GLU . 84.4 tt0 -153.57 109.1 3.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.458 -0.776 . . . . 0.0 109.408 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.401 ' C ' ' H ' ' A' ' 44' ' ' PHE . . . 48.58 -142.28 8.76 Favored Glycine 0 N--CA 1.494 2.509 0 CA-C-O 121.967 0.759 . . . . 0.0 111.269 179.175 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -81.9 28.51 0.42 Allowed 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.435 -1.038 . . . . 0.0 108.738 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.401 ' H ' ' C ' ' A' ' 42' ' ' GLY . 91.0 m-85 -134.01 140.22 46.56 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.516 -0.74 . . . . 0.0 109.137 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -100.7 142.81 31.64 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.495 -0.753 . . . . 0.0 109.276 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.615 ' HZ3' ' CG ' ' A' ' 53' ' ' HIS . 65.1 tttm -90.45 129.03 36.68 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -179.582 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.0 pt -126.57 152.24 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 CA-C-O 121.699 0.761 . . . . 0.0 110.164 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -84.39 92.2 7.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.511 -0.743 . . . . 0.0 109.658 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -79.3 142.11 36.43 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.331 -0.856 . . . . 0.0 110.134 -179.504 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -58.18 96.46 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.547 -0.721 . . . . 0.0 110.408 -179.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 123.19 -35.83 3.25 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 67.8 p -158.96 -162.96 1.15 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.986 -1.302 . . . . 0.0 109.759 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.615 ' CG ' ' HZ3' ' A' ' 46' ' ' LYS . 97.5 m-70 -106.31 118.26 36.18 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.492 -0.755 . . . . 0.0 109.347 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.15 162.39 22.8 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -126.54 136.56 52.73 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.526 -0.985 . . . . 0.0 109.514 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.8 m -133.67 137.15 53.21 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 CA-C-O 121.477 0.656 . . . . 0.0 109.619 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.67 ' N ' HH22 ' A' ' 16' ' ' ARG . . . -68.85 147.21 52.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.395 -0.816 . . . . 0.0 110.352 -179.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.4 mtmp? -63.8 -9.03 12.51 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.567 -0.708 . . . . 0.0 109.736 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -68.83 -35.99 77.64 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.108 -0.995 . . . . 0.0 110.096 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -92.96 4.99 53.0 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.052 -1.03 . . . . 0.0 109.203 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 44.8 mm -103.88 129.16 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.39 -0.819 . . . . 0.0 109.513 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 26.2 ttpp -149.88 157.34 43.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.306 -0.872 . . . . 0.0 110.439 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 55.81 52.97 9.98 Favored 'General case' 0 N--CA 1.49 1.57 0 CA-C-O 121.59 0.709 . . . . 0.0 109.498 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt . . . . . 0 N--CA 1.489 1.487 0 O-C-N 121.497 -0.752 . . . . 0.0 109.554 179.904 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.4 mttm . . . . . 0 N--CA 1.494 1.754 0 N-CA-C 109.592 -0.521 . . . . 0.0 109.592 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 67.2 p -134.22 152.32 51.76 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.569 -0.707 . . . . 0.0 109.476 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -135.1 128.67 4.83 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.75 ' N ' HD12 ' A' ' 6' ' ' ILE . 2.0 mp -81.99 124.52 39.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.669 -0.901 . . . . 0.0 109.579 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 91.8 t -85.33 116.75 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.506 -0.746 . . . . 0.0 109.732 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.403 HD22 ' HD3' ' A' ' 62' ' ' LYS . 98.0 m-20 -110.19 107.38 17.15 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.521 -0.737 . . . . 0.0 109.663 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 14.9 m -139.33 156.72 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.386 -0.821 . . . . 0.0 109.616 179.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 82.0 p -73.18 -13.81 61.23 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.502 ' OG ' ' N ' ' A' ' 12' ' ' SER . 77.0 p -152.95 -118.61 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.327 -0.858 . . . . 0.0 110.096 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.502 ' N ' ' OG ' ' A' ' 11' ' ' SER . 21.5 m -101.37 161.26 13.75 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.382 -0.824 . . . . 0.0 110.246 -178.835 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 61.6 tp -120.99 133.4 55.27 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.632 0.729 . . . . 0.0 109.653 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -88.95 129.46 35.62 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.633 -0.667 . . . . 0.0 109.866 179.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 80.7 t -89.89 132.56 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.423 -0.798 . . . . 0.0 109.23 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -101.69 134.08 45.39 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.421 -0.799 . . . . 0.0 110.533 -178.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 11.4 tm-20 -69.21 -43.18 74.61 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.315 0.578 . . . . 0.0 109.548 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -101.42 -178.48 28.59 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -178.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -93.24 -2.22 55.34 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.591 -0.947 . . . . 0.0 109.365 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.7 m -82.37 150.79 26.97 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.187 -0.946 . . . . 0.0 110.368 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.458 ' C ' ' H ' ' A' ' 23' ' ' SER . 19.0 m -64.91 -45.4 86.05 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.501 -0.75 . . . . 0.0 109.534 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 8.7 t -77.24 24.39 0.18 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.607 -0.683 . . . . 0.0 109.161 -179.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.458 ' H ' ' C ' ' A' ' 21' ' ' THR . 14.8 m -71.18 151.14 44.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.477 -0.764 . . . . 0.0 110.291 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -73.37 136.65 44.39 Favored 'General case' 0 N--CA 1.491 1.582 0 CA-C-O 121.789 0.804 . . . . 0.0 110.995 -179.181 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 82.2 t -85.62 131.58 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 CA-C-O 121.372 0.605 . . . . 0.0 109.822 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.403 HG13 ' N ' ' A' ' 27' ' ' GLY . 8.4 pt -125.33 -44.31 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.722 -0.611 . . . . 0.0 109.378 179.779 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.403 ' N ' HG13 ' A' ' 26' ' ' ILE . . . -101.29 171.89 22.71 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 -178.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.8 p -158.42 155.58 28.86 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.583 -0.951 . . . . 0.0 109.55 179.072 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 91.9 mt -133.92 150.57 51.32 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.452 -0.78 . . . . 0.0 109.72 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.9 t -82.11 -1.53 49.02 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.497 ' C ' ' H ' ' A' ' 33' ' ' THR . . . 97.83 164.83 31.52 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.272 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.0 m120 52.78 5.22 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.746 -0.855 . . . . 0.0 110.014 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.497 ' H ' ' C ' ' A' ' 31' ' ' GLY . 24.9 m -78.9 141.44 37.61 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.101 -0.999 . . . . 0.0 110.312 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -88.74 132.99 34.37 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.643 -0.661 . . . . 0.0 109.493 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.7 m -124.12 133.79 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 CA-C-O 121.785 0.802 . . . . 0.0 109.854 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 5.8 p -76.8 133.92 39.25 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.722 -0.611 . . . . 0.0 110.141 -179.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.0 mt -111.54 128.9 67.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 121.448 0.642 . . . . 0.0 109.362 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 29.7 m -111.21 -3.34 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -174.99 175.92 47.1 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.662 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -136.51 153.44 51.02 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.667 -0.902 . . . . 0.0 109.46 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -155.11 113.19 3.45 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.195 -0.94 . . . . 0.0 109.996 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 57.48 -137.52 49.38 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 178.695 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.9 24.2 2.86 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.602 -0.94 . . . . 0.0 109.073 -179.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -133.2 147.54 52.01 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.576 -0.702 . . . . 0.0 109.571 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 24.9 m-85 -106.35 147.93 28.65 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.559 -0.713 . . . . 0.0 109.782 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -95.53 124.9 39.79 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 13.8 pt -131.51 154.26 40.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 CA-C-O 121.762 0.791 . . . . 0.0 110.217 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -90.89 106.29 18.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.695 -0.628 . . . . 0.0 109.958 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 88.7 t80 -112.45 115.37 28.57 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.572 0.701 . . . . 0.0 109.172 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.1 mmtp 52.27 31.07 8.73 Favored 'General case' 0 N--CA 1.493 1.689 0 CA-C-O 121.3 0.571 . . . . 0.0 110.193 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 85.64 -11.22 62.27 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 178.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 38.4 t -90.2 170.05 10.62 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.25 -1.147 . . . . 0.0 110.203 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -100.28 93.41 5.67 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.429 -0.794 . . . . 0.0 109.231 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.26 136.1 12.73 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.696 -1.361 . . . . 0.0 109.696 -179.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -112.95 138.58 49.59 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.689 -0.889 . . . . 0.0 109.562 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.1 m -135.89 156.13 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.544 -0.723 . . . . 0.0 109.997 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.548 ' HB3' ' CE2' ' A' ' 60' ' ' TYR . . . -69.21 152.06 45.55 Favored 'General case' 0 N--CA 1.491 1.588 0 CA-C-O 121.76 0.791 . . . . 0.0 110.767 -179.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 60' ' ' TYR . 47.9 mtmt -63.41 -38.69 92.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.698 -0.626 . . . . 0.0 109.49 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -49.64 -7.42 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.401 -0.812 . . . . 0.0 110.222 -179.382 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.548 ' CE2' ' HB3' ' A' ' 57' ' ' ALA . 59.0 m-85 -105.26 -25.05 12.59 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.289 -0.882 . . . . 0.0 109.236 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.629 ' N ' HD12 ' A' ' 61' ' ' ILE . 1.5 mp -89.13 129.09 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.365 -0.835 . . . . 0.0 109.828 -179.51 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.403 ' HD3' HD22 ' A' ' 8' ' ' ASN . 65.2 tttm -146.37 152.55 39.27 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.546 -0.721 . . . . 0.0 109.857 179.228 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 57.47 57.11 4.55 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.496 0.665 . . . . 0.0 109.803 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.9 mt . . . . . 0 N--CA 1.489 1.48 0 O-C-N 121.382 -0.824 . . . . 0.0 109.533 179.902 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 62.9 mttp . . . . . 0 N--CA 1.497 1.88 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.0 p -126.8 126.65 43.76 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.519 -0.738 . . . . 0.0 109.23 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . 0.459 ' C ' HD12 ' A' ' 6' ' ' ILE . . . -94.32 130.58 10.36 Favored Glycine 0 N--CA 1.495 2.611 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.694 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.5 mp -93.64 120.5 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.294 -1.121 . . . . 0.0 109.392 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 70.7 t -76.34 132.91 32.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.427 -0.796 . . . . 0.0 109.335 179.47 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -134.87 85.82 2.21 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.439 -0.788 . . . . 0.0 109.246 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.3 m -130.73 132.97 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.578 -0.701 . . . . 0.0 109.52 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 46.7 m -62.42 -41.56 98.79 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.453 -0.779 . . . . 0.0 109.907 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.42 ' OG ' ' N ' ' A' ' 12' ' ' SER . 77.6 p -91.81 -82.09 0.32 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.216 -0.928 . . . . 0.0 109.628 -179.399 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.42 ' N ' ' OG ' ' A' ' 11' ' ' SER . 43.1 t -165.98 167.25 16.76 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.383 -0.823 . . . . 0.0 109.111 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 51.0 tp -119.87 132.45 55.57 Favored 'General case' 0 N--CA 1.498 1.97 0 CA-C-O 121.595 0.712 . . . . 0.0 109.61 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -91.28 152.79 20.34 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.628 -0.67 . . . . 0.0 109.858 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.3 t -103.41 131.02 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.702 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 92.1 mtm-85 -110.5 134.69 52.13 Favored 'General case' 0 N--CA 1.492 1.664 0 CA-C-O 121.689 0.757 . . . . 0.0 110.178 -179.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -70.91 -36.4 72.68 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.716 -0.615 . . . . 0.0 109.487 179.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.54 -175.88 31.21 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -179.191 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -109.24 24.48 13.05 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.6 -0.941 . . . . 0.0 108.723 179.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.462 ' OG ' ' OG ' ' A' ' 23' ' ' SER . 6.4 p -83.84 171.49 13.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 110.201 -179.524 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 15.9 m -62.72 -43.51 98.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.53 -0.731 . . . . 0.0 109.417 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.8 p -136.12 66.18 1.5 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.457 -0.777 . . . . 0.0 108.956 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.462 ' OG ' ' OG ' ' A' ' 20' ' ' SER . 1.9 m -77.26 -178.08 4.92 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.866 0.841 . . . . 0.0 110.353 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -63.67 139.14 58.74 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.663 0.744 . . . . 0.0 110.656 -179.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 65.6 t -98.27 124.95 51.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.439 -0.788 . . . . 0.0 108.924 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 40.1 pt -104.65 -4.1 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.61 -0.681 . . . . 0.0 109.272 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.81 -168.22 41.23 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.191 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 40.3 t -153.87 154.61 34.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.51 -0.994 . . . . 0.0 109.353 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.7 mt -123.67 151.39 43.14 Favored 'General case' 0 N--CA 1.497 1.923 0 CA-C-O 121.566 0.698 . . . . 0.0 109.652 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.7 t -79.17 166.62 22.02 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.627 0.727 . . . . 0.0 110.606 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -64.79 158.55 44.12 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -179.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 66.8 m-20 57.39 32.94 22.57 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.711 -0.876 . . . . 0.0 109.685 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.2 m -94.53 129.07 41.48 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.281 -0.887 . . . . 0.0 109.456 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -82.92 132.82 35.14 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.426 -0.796 . . . . 0.0 109.822 -179.735 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 m -127.23 134.52 65.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 O-C-N 121.535 -0.728 . . . . 0.0 109.498 179.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 33.6 m -78.49 129.31 34.73 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.462 -0.774 . . . . 0.0 109.732 -179.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.3 mt -106.7 126.03 62.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.593 -0.692 . . . . 0.0 109.612 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 28.5 m -118.77 8.48 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.03 174.47 45.89 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -135.28 155.64 50.3 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.372 -1.075 . . . . 0.0 109.904 -179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.417 ' O ' ' O ' ' A' ' 44' ' ' PHE . 76.3 mm-40 -138.86 153.65 48.34 Favored 'General case' 0 N--CA 1.494 1.73 0 CA-C-O 121.435 0.636 . . . . 0.0 109.759 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.663 ' O ' ' HB3' ' A' ' 43' ' ' ALA . . . -64.36 108.02 2.09 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.124 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.663 ' HB3' ' O ' ' A' ' 42' ' ' GLY . . . 80.67 4.03 1.69 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.663 -0.904 . . . . 0.0 109.151 179.488 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.417 ' O ' ' O ' ' A' ' 41' ' ' GLU . 95.6 m-85 -149.39 159.6 44.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 109.736 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -118.25 147.45 43.41 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.435 ' HZ2' ' HB3' ' A' ' 53' ' ' HIS . 0.1 OUTLIER -91.6 118.1 30.32 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 179.674 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.6 pt -126.57 153.13 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 CA-C-O 121.644 0.735 . . . . 0.0 109.702 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -86.06 118.2 25.38 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.531 -0.731 . . . . 0.0 109.61 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.55 ' O ' ' N ' ' A' ' 51' ' ' GLY . 89.6 t80 -111.58 121.7 45.86 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.554 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.418 ' C ' ' O ' ' A' ' 49' ' ' TYR . 37.3 ttpt 39.52 -90.38 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.261 0.553 . . . . 0.0 110.311 -179.669 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -130.2 -22.64 1.09 Allowed Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.914 -1.675 . . . . 0.0 108.914 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 22.5 m -91.19 163.41 14.27 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.217 -1.167 . . . . 0.0 110.532 -179.355 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.435 ' HB3' ' HZ2' ' A' ' 46' ' ' LYS . 56.9 m170 -83.37 113.12 20.52 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.382 -0.824 . . . . 0.0 109.357 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.64 141.95 15.83 Favored Glycine 0 N--CA 1.495 2.576 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -120.81 139.54 52.99 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.672 -0.899 . . . . 0.0 109.427 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.4 m -132.57 137.83 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.662 -0.649 . . . . 0.0 109.525 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.702 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -61.48 143.72 55.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.548 -0.72 . . . . 0.0 110.805 -179.02 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -66.76 -12.31 58.22 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.505 -0.747 . . . . 0.0 109.899 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 47.3 tp10 -67.15 -36.54 82.06 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.169 -0.957 . . . . 0.0 110.256 -179.494 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -95.62 -5.03 43.39 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.173 -0.955 . . . . 0.0 109.842 -178.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 36.5 mm -110.22 128.94 66.07 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 O-C-N 121.511 -0.743 . . . . 0.0 109.37 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.43 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 21.2 ptmt -140.45 173.23 11.7 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.546 -0.721 . . . . 0.0 110.266 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.43 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 14.7 t0 77.36 -72.21 0.1 Allowed 'General case' 0 N--CA 1.495 1.781 0 CA-C-O 121.114 0.483 . . . . 0.0 109.748 179.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 27.3 mt . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.624 -0.673 . . . . 0.0 109.332 -179.651 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt . . . . . 0 N--CA 1.496 1.828 0 CA-C-O 121.633 0.73 . . . . 0.0 109.889 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 44.1 p -115.72 121.78 43.52 Favored 'General case' 0 N--CA 1.499 1.987 0 CA-C-O 121.833 0.825 . . . . 0.0 109.79 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -100.79 142.27 15.73 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.594 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 22.6 mm -92.69 120.89 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 CA-C-O 121.684 0.754 . . . . 0.0 109.378 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.2 t -80.58 105.03 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 CA-C-O 121.668 0.746 . . . . 0.0 109.59 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -99.43 103.88 15.7 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-O 121.747 0.784 . . . . 0.0 109.61 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 26.8 m -137.93 160.58 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 CA-C-O 121.727 0.775 . . . . 0.0 109.918 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 88.0 p -85.73 -12.83 50.15 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.0 m -142.1 -76.01 0.28 Allowed 'General case' 0 N--CA 1.497 1.884 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 25.9 p -155.81 166.56 33.12 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.518 -0.739 . . . . 0.0 109.735 -179.385 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.8 tp -114.18 133.1 55.83 Favored 'General case' 0 N--CA 1.496 1.849 0 CA-C-O 121.841 0.829 . . . . 0.0 110.34 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -91.29 142.3 27.85 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-O 121.719 0.771 . . . . 0.0 109.991 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.9 t -99.11 129.51 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 CA-C-O 121.634 0.731 . . . . 0.0 109.662 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.7 mtt85 -92.87 153.44 18.82 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 121.793 0.806 . . . . 0.0 110.049 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -64.68 -44.37 90.58 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 19' ' ' ALA . . . -157.88 102.92 0.22 Allowed Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.614 ' H ' ' CB ' ' A' ' 55' ' ' TYR . . . 38.8 -114.51 0.14 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 122.001 -0.705 . . . . 0.0 110.292 179.476 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 19' ' ' ALA . 4.9 m 56.35 152.53 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 121.8 0.81 . . . . 0.0 110.508 179.678 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 97.8 m -67.82 -45.5 74.53 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.822 -0.549 . . . . 0.0 109.907 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 39.5 p -153.05 61.05 0.78 Allowed 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 121.836 0.827 . . . . 0.0 109.222 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 5.2 p -75.04 -171.38 1.34 Allowed 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.76 0.79 . . . . 0.0 110.634 179.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt -66.29 142.91 57.5 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-O 121.743 0.782 . . . . 0.0 110.411 -178.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 68.4 t -98.52 127.31 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 CA-C-O 121.732 0.777 . . . . 0.0 109.305 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 27.8 pt -103.26 -4.12 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 173.34 -173.9 45.86 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 24.1 p -154.35 161.69 41.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.81 -0.818 . . . . 0.0 109.711 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.8 mt -126.99 151.49 48.51 Favored 'General case' 0 N--CA 1.499 2.007 0 CA-C-O 121.947 0.879 . . . . 0.0 109.984 -179.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.412 ' O ' ' OG1' ' A' ' 33' ' ' THR . 84.1 p -72.7 165.87 23.94 Favored 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 121.812 0.815 . . . . 0.0 110.261 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.479 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.85 165.02 45.63 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 56.33 2.88 0.09 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 122.335 -0.509 . . . . 0.0 110.116 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.479 ' H ' ' C ' ' A' ' 31' ' ' GLY . 47.5 m -71.24 136.14 47.83 Favored 'General case' 0 N--CA 1.496 1.851 0 CA-C-O 121.916 0.865 . . . . 0.0 110.391 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -88.9 143.04 27.15 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.34 0.591 . . . . 0.0 109.866 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 35.4 m -126.26 130.46 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 CA-C-O 121.821 0.82 . . . . 0.0 110.08 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 82.7 m -80.01 125.7 30.11 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.517 0.675 . . . . 0.0 109.739 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.6 mt -104.87 128.09 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 CA-C-O 121.554 0.693 . . . . 0.0 109.83 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.8 m -123.92 7.5 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.488 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.04 169.6 42.75 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -129.84 152.77 48.95 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.789 -0.83 . . . . 0.0 109.553 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 53.3 tp10 -153.29 108.33 3.19 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.936 0.874 . . . . 0.0 110.068 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 49.73 -138.14 20.1 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 178.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -84.67 20.3 1.79 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 122.005 -0.703 . . . . 0.0 109.226 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -128.35 151.0 49.85 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-O 121.688 0.756 . . . . 0.0 109.582 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 51.9 m-85 -102.98 141.87 35.04 Favored 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.945 0.878 . . . . 0.0 109.968 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.566 ' NZ ' ' CD2' ' A' ' 53' ' ' HIS . 65.4 tttm -94.29 122.53 36.93 Favored 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.493 0.663 . . . . 0.0 109.384 -179.505 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 34.6 pt -129.25 154.99 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 CA-C-O 121.806 0.813 . . . . 0.0 110.316 179.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -83.45 114.4 21.44 Favored 'General case' 0 N--CA 1.494 1.73 0 CA-C-O 121.568 0.699 . . . . 0.0 109.915 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.569 ' O ' ' N ' ' A' ' 51' ' ' GLY . 86.1 t80 -106.28 114.85 29.22 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.694 0.759 . . . . 0.0 109.588 179.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.1 mttp 40.96 -87.54 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.754 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.105 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -115.63 -39.38 0.92 Allowed Glycine 0 N--CA 1.495 2.58 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 16.7 p -89.54 169.37 11.41 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.804 -0.821 . . . . 0.0 110.45 -179.184 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.566 ' CD2' ' NZ ' ' A' ' 46' ' ' LYS . 73.2 m80 -96.52 111.19 23.4 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.914 0.864 . . . . 0.0 109.952 -179.61 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.64 144.08 23.97 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.614 ' CB ' ' H ' ' A' ' 19' ' ' ALA . 75.8 m-85 -119.63 135.76 54.67 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-O 121.751 0.786 . . . . 0.0 109.515 179.346 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 20.1 m -137.38 156.12 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 CA-C-O 121.913 0.863 . . . . 0.0 110.318 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.07 154.36 33.42 Favored 'General case' 0 N--CA 1.492 1.667 0 CA-C-O 121.681 0.753 . . . . 0.0 110.107 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -69.67 -17.6 63.5 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.529 ' OE2' ' CE2' ' A' ' 60' ' ' TYR . 9.7 pt-20 -65.0 -34.92 79.58 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.786 -0.572 . . . . 0.0 109.893 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.529 ' CE2' ' OE2' ' A' ' 59' ' ' GLU . 66.8 m-85 -91.98 -10.16 40.33 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.451 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 36.0 mm -110.46 120.73 61.94 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.121 0 CA-C-O 121.847 0.832 . . . . 0.0 110.021 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -149.72 173.47 13.67 Favored 'General case' 0 N--CA 1.494 1.734 0 CA-C-O 121.616 0.722 . . . . 0.0 110.21 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 57.6 47.98 15.01 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 121.353 0.596 . . . . 0.0 109.405 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt . . . . . 0 N--CA 1.495 1.788 0 CA-C-O 121.699 0.762 . . . . 0.0 110.055 -179.647 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.5 mttt . . . . . 0 N--CA 1.496 1.83 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 70.4 p -127.73 131.14 49.73 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.524 -0.735 . . . . 0.0 109.144 179.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -120.02 135.18 10.91 Favored Glycine 0 N--CA 1.5 2.918 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.757 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.9 mp -86.72 129.02 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.434 -1.039 . . . . 0.0 109.675 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.3 t -82.13 104.8 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.181 -0.949 . . . . 0.0 109.665 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -108.29 106.45 16.61 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.481 -0.762 . . . . 0.0 109.054 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 27.7 m -138.47 162.4 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.27 -0.894 . . . . 0.0 110.016 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 t -61.99 -43.57 98.55 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.55 -0.719 . . . . 0.0 109.46 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 12' ' ' SER . 70.5 m -161.09 108.9 1.52 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.006 -1.059 . . . . 0.0 110.262 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 11' ' ' SER . 22.7 t 54.0 159.19 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.849 0.833 . . . . 0.0 111.509 179.126 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 35.1 tp -133.22 133.03 42.19 Favored 'General case' 0 N--CA 1.498 1.971 0 CA-C-O 121.485 0.66 . . . . 0.0 109.652 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 46.0 p-10 -80.69 141.81 34.52 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.391 -0.818 . . . . 0.0 109.914 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 78.2 t -93.45 133.12 35.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.201 -0.937 . . . . 0.0 109.666 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -102.38 130.54 49.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.384 -0.823 . . . . 0.0 109.909 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -73.75 -41.31 62.67 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.468 -0.77 . . . . 0.0 109.763 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.479 ' O ' ' CG ' ' A' ' 55' ' ' TYR . . . -95.93 -129.42 5.96 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.934 -1.266 . . . . 0.0 109.934 -179.111 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -137.13 -12.85 1.63 Allowed 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.519 -0.989 . . . . 0.0 109.073 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 12.0 m -72.72 152.36 41.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.198 -0.939 . . . . 0.0 110.688 -179.094 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.7 m -63.15 -46.08 88.87 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.376 -0.828 . . . . 0.0 109.34 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 58.7 m -88.75 34.74 0.77 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.152 -0.967 . . . . 0.0 108.604 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.2 p -73.78 161.95 29.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.405 -0.81 . . . . 0.0 110.376 -179.2 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -66.28 136.11 55.37 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.348 -0.845 . . . . 0.0 110.299 -179.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 53.4 t -100.72 127.98 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.416 -0.802 . . . . 0.0 109.355 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.5 pt -101.11 -3.07 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.04 -164.22 37.6 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.458 -1.353 . . . . 0.0 110.325 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 40.4 t -155.31 158.87 39.43 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.268 -1.136 . . . . 0.0 109.373 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.0 mt -122.96 149.96 43.59 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.508 -0.745 . . . . 0.0 109.769 -179.693 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 29.6 t -69.23 154.62 41.75 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-O 121.834 0.826 . . . . 0.0 111.02 -178.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.46 157.25 37.53 Favored Glycine 0 N--CA 1.492 2.413 0 O-C-N 121.637 -0.664 . . . . 0.0 111.475 -179.418 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.3 t-20 58.75 33.88 23.37 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.809 -0.818 . . . . 0.0 109.741 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.7 m -97.02 129.52 44.46 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.314 -0.866 . . . . 0.0 109.594 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 54.1 tttp -79.8 131.13 35.82 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.352 -0.843 . . . . 0.0 109.344 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 21.6 m -128.77 136.6 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.392 -0.817 . . . . 0.0 109.697 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 18.8 m -80.99 129.46 34.54 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.613 -0.679 . . . . 0.0 109.586 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.6 mt -110.45 129.56 65.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.686 -0.633 . . . . 0.0 109.446 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.583 HG23 ' N ' ' A' ' 39' ' ' GLY . 24.4 m -128.62 -49.37 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.583 ' N ' HG23 ' A' ' 38' ' ' VAL . . . -91.57 166.84 30.64 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 -179.112 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -139.0 146.87 41.42 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.337 -1.096 . . . . 0.0 109.559 179.572 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.5 tm-20 -154.31 110.02 3.19 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.321 -0.862 . . . . 0.0 109.07 179.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 53.13 -138.82 34.79 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 111.044 -0.822 . . . . 0.0 111.044 179.186 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.02 10.65 13.57 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.366 -1.079 . . . . 0.0 109.113 -179.411 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -111.62 144.45 40.85 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.502 -0.748 . . . . 0.0 109.447 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 47.2 m-85 -104.03 141.33 36.38 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.544 -0.723 . . . . 0.0 109.702 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -90.28 137.91 31.96 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.266 -0.897 . . . . 0.0 108.751 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 17.3 pt -127.81 154.38 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.0 0 O-C-N 121.468 -0.77 . . . . 0.0 110.087 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 50.8 tp10 -82.95 106.87 15.13 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.532 ' O ' ' N ' ' A' ' 51' ' ' GLY . 80.1 t80 -109.21 124.69 51.27 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.52 -0.737 . . . . 0.0 110.134 -179.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.443 ' C ' ' O ' ' A' ' 49' ' ' TYR . 67.8 mttm 33.62 -88.97 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.103 0.478 . . . . 0.0 111.246 179.504 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -119.83 -29.3 1.71 Allowed Glycine 0 N--CA 1.498 2.807 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 -179.251 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 66.6 m -100.58 176.86 5.18 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.088 -1.242 . . . . 0.0 110.478 -179.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -107.68 119.91 40.75 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.527 -0.733 . . . . 0.0 109.682 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.7 159.03 25.56 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.479 ' CG ' ' O ' ' A' ' 18' ' ' GLY . 91.0 m-85 -115.98 137.32 52.22 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.444 -1.033 . . . . 0.0 109.64 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.8 m -136.11 137.19 48.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.627 -0.671 . . . . 0.0 109.431 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.32 148.08 51.25 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.498 -0.751 . . . . 0.0 110.611 -179.278 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.3 ptpm? -62.84 -16.55 58.92 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.376 -0.827 . . . . 0.0 109.368 179.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -67.58 -35.84 79.77 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.292 -0.88 . . . . 0.0 109.89 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -92.34 -5.02 53.01 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.018 -1.051 . . . . 0.0 109.236 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 36.7 mm -112.11 123.87 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 121.374 -0.829 . . . . 0.0 109.21 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 20.5 ptmt -141.63 171.17 14.43 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.479 -0.763 . . . . 0.0 110.068 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 58.72 40.86 22.73 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-O 121.477 0.656 . . . . 0.0 109.487 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt . . . . . 0 N--CA 1.493 1.708 0 O-C-N 121.285 -0.884 . . . . 0.0 110.042 -179.95 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 99.1 mttt . . . . . 0 N--CA 1.497 1.923 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.448 ' CB ' ' HZ1' ' A' ' 34' ' ' LYS . 59.2 p -128.41 124.78 37.14 Favored 'General case' 0 N--CA 1.497 1.893 0 CA-C-O 121.643 0.735 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . 0.454 ' C ' HD12 ' A' ' 6' ' ' ILE . . . -99.91 137.25 13.15 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -179.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.776 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.8 mp -93.95 119.16 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.536 -0.979 . . . . 0.0 109.673 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 71.9 t -79.09 133.2 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 CA-C-O 121.494 0.664 . . . . 0.0 109.791 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.533 ' CB ' ' NZ ' ' A' ' 62' ' ' LYS . 46.1 t30 -140.34 106.98 5.33 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.404 -0.81 . . . . 0.0 109.648 -179.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 m -138.3 151.68 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.603 -0.686 . . . . 0.0 109.634 179.8 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 73.5 m -72.26 -42.9 65.06 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 121.477 0.656 . . . . 0.0 109.828 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 69.0 m -103.85 -76.67 0.59 Allowed 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.446 -0.784 . . . . 0.0 109.625 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 41.2 t -160.03 168.27 25.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.325 -0.86 . . . . 0.0 109.687 -179.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 41.8 tp -116.58 130.21 56.62 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 121.592 0.71 . . . . 0.0 109.984 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -91.92 138.38 31.59 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.771 0.796 . . . . 0.0 110.158 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.3 t -89.5 130.01 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 CA-C-O 121.497 0.665 . . . . 0.0 109.802 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.425 ' NH1' HG23 ' A' ' 25' ' ' VAL . 38.4 mmt180 -107.67 131.15 54.71 Favored 'General case' 0 N--CA 1.496 1.835 0 CA-C-O 121.872 0.844 . . . . 0.0 109.565 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -71.22 -40.18 71.27 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-O 121.532 0.682 . . . . 0.0 109.549 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.502 ' N ' ' OG ' ' A' ' 23' ' ' SER . . . -93.69 177.09 37.07 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.34 39.51 0.87 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.501 -0.999 . . . . 0.0 109.104 179.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.9 p -151.91 154.88 36.97 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.398 -0.814 . . . . 0.0 109.686 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.404 ' O ' ' CZ ' ' A' ' 16' ' ' ARG . 60.5 p -71.29 -28.03 63.84 Favored 'General case' 0 N--CA 1.493 1.724 0 CA-C-O 121.675 0.75 . . . . 0.0 109.379 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 91.9 p -82.35 -3.71 55.94 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.502 ' OG ' ' N ' ' A' ' 18' ' ' GLY . 24.0 t -51.73 -97.08 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.619 -0.675 . . . . 0.0 110.188 -179.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.33 131.58 1.2 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.311 -0.868 . . . . 0.0 110.011 -179.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.425 HG23 ' NH1' ' A' ' 16' ' ' ARG . 84.2 t -81.67 132.17 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.73 -0.606 . . . . 0.0 109.939 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 45.0 pt -117.6 -10.28 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.69 -175.01 45.23 Favored Glycine 0 N--CA 1.494 2.554 0 C-N-CA 119.402 -1.38 . . . . 0.0 110.252 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 65.8 m -133.04 156.18 47.84 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.714 -0.874 . . . . 0.0 109.814 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 92.2 mt -122.9 147.91 46.04 Favored 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.83 0.824 . . . . 0.0 109.941 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.6 t -74.77 157.85 34.5 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-O 121.937 0.875 . . . . 0.0 110.63 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -66.6 156.52 51.04 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 11.5 m120 57.36 33.09 22.8 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 122.075 -0.662 . . . . 0.0 109.461 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 43.3 m -94.42 125.07 38.84 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.843 0.83 . . . . 0.0 110.331 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.448 ' HZ1' ' CB ' ' A' ' 4' ' ' THR . 63.3 tttp -79.24 132.14 36.4 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-O 121.306 0.574 . . . . 0.0 109.677 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.1 m -129.5 134.13 64.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 121.804 0.811 . . . . 0.0 109.763 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 52.7 m -79.09 127.63 32.25 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-O 121.6 0.714 . . . . 0.0 109.901 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.7 mt -102.76 124.2 56.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 CA-C-O 121.499 0.666 . . . . 0.0 109.508 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.76 -0.8 9.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.3 176.31 46.0 Favored Glycine 0 N--CA 1.494 2.551 0 C-N-CA 119.681 -1.247 . . . . 0.0 110.538 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -143.94 155.3 44.01 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.65 -0.912 . . . . 0.0 109.475 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -153.27 107.28 3.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.456 -0.777 . . . . 0.0 109.78 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.3 -135.96 49.75 Favored Glycine 0 N--CA 1.493 2.493 0 CA-C-O 121.98 0.766 . . . . 0.0 111.626 178.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -88.28 28.19 1.12 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.554 -0.968 . . . . 0.0 109.122 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -136.11 150.26 49.03 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.641 -0.662 . . . . 0.0 109.58 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.626 ' CZ ' ' NZ ' ' A' ' 58' ' ' LYS . 12.5 m-85 -107.17 146.04 31.82 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-O 121.882 0.849 . . . . 0.0 109.925 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -98.67 124.77 43.69 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.7 pt -129.73 157.79 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 121.651 0.738 . . . . 0.0 110.187 -179.77 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -87.5 101.79 13.95 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.43 0.634 . . . . 0.0 109.811 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.8 t80 -109.85 118.64 37.03 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-O 121.618 0.723 . . . . 0.0 109.45 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.6 mmtt 51.43 29.8 5.6 Favored 'General case' 0 N--CA 1.492 1.668 0 CA-C-O 121.763 0.792 . . . . 0.0 109.754 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.97 -23.45 23.55 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 179.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.3 m -86.53 165.34 16.31 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.281 -1.129 . . . . 0.0 110.576 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -94.51 101.63 13.54 Favored 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 121.73 0.776 . . . . 0.0 109.667 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.1 147.93 19.9 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -115.51 134.08 55.42 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.699 -0.883 . . . . 0.0 109.425 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.6 m -136.14 139.58 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 CA-C-O 121.573 0.702 . . . . 0.0 109.902 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.53 144.71 55.75 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.889 0.852 . . . . 0.0 110.387 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.626 ' NZ ' ' CZ ' ' A' ' 45' ' ' TYR . 67.1 mttm -63.74 -36.84 85.19 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-O 121.421 0.629 . . . . 0.0 110.468 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -46.83 -16.34 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.238 -0.914 . . . . 0.0 110.675 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.45 ' N ' ' O ' ' A' ' 58' ' ' LYS . 36.1 m-85 -108.37 -30.65 8.2 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.162 -0.961 . . . . 0.0 109.132 179.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.627 ' N ' HD12 ' A' ' 61' ' ' ILE . 1.5 mp -93.54 123.22 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.424 -0.798 . . . . 0.0 109.741 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.533 ' NZ ' ' CB ' ' A' ' 8' ' ' ASN . 26.6 pttm -148.78 174.73 11.89 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.585 0.707 . . . . 0.0 109.952 179.527 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.551 ' O ' HD13 ' A' ' 6' ' ' ILE . 97.5 m-20 58.11 51.28 8.87 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-O 121.68 0.752 . . . . 0.0 109.765 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.411 HD11 ' CE2' ' A' ' 45' ' ' TYR . 96.9 mt . . . . . 0 N--CA 1.494 1.757 0 O-C-N 121.51 -0.744 . . . . 0.0 109.722 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt . . . . . 0 N--CA 1.495 1.825 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 46.9 p -115.13 123.13 48.16 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.679 -0.638 . . . . 0.0 109.372 -179.673 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -96.04 131.45 10.66 Favored Glycine 0 N--CA 1.496 2.674 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.585 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.4 mp -80.81 126.41 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.332 -1.099 . . . . 0.0 109.251 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.441 HG13 HD22 ' A' ' 13' ' ' LEU . 74.9 t -80.61 132.78 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.542 -0.724 . . . . 0.0 109.645 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 24.2 t-20 -131.24 103.41 6.46 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.547 -0.721 . . . . 0.0 109.271 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 27.9 m -135.46 156.45 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.492 -0.755 . . . . 0.0 109.434 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 95.6 p -83.7 -10.96 57.8 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.488 -0.758 . . . . 0.0 109.3 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.501 ' OG ' ' N ' ' A' ' 12' ' ' SER . 86.4 p -138.37 -73.1 0.4 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.359 -0.838 . . . . 0.0 109.154 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.501 ' N ' ' OG ' ' A' ' 11' ' ' SER . 31.9 p -158.71 165.04 35.29 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.369 -0.832 . . . . 0.0 109.249 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.441 HD22 HG13 ' A' ' 7' ' ' VAL . 44.9 tp -113.83 131.47 56.23 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.482 -0.761 . . . . 0.0 109.028 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -91.07 146.43 23.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.406 -0.809 . . . . 0.0 109.885 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 65.1 t -99.3 130.1 48.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.504 ' NH1' ' O ' ' A' ' 21' ' ' THR . 93.0 mtt-85 -110.97 136.85 49.36 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.587 -0.695 . . . . 0.0 109.95 -179.346 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.5 ' OE2' HD13 ' A' ' 26' ' ' ILE . 66.3 mm-40 -80.58 -35.73 33.84 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.453 -0.779 . . . . 0.0 109.655 179.592 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -95.57 177.17 34.4 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.68 -5.42 42.31 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.402 -1.058 . . . . 0.0 109.083 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 33.5 t -86.16 153.67 21.89 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -0.852 . . . . 0.0 109.951 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.504 ' O ' ' NH1' ' A' ' 16' ' ' ARG . 15.3 m -63.67 -44.77 92.79 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.433 -0.792 . . . . 0.0 109.725 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 76.7 p -73.11 17.83 0.12 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.212 -0.93 . . . . 0.0 109.408 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.487 ' H ' ' C ' ' A' ' 21' ' ' THR . 17.3 m -64.65 149.22 49.4 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.239 -0.913 . . . . 0.0 109.788 -179.723 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 24.9 pttm -70.79 143.53 51.14 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.395 -0.815 . . . . 0.0 110.367 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 55.6 t -103.24 131.28 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.528 -0.732 . . . . 0.0 109.641 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.5 HD13 ' OE2' ' A' ' 17' ' ' GLU . 24.7 pt -99.01 -6.58 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.441 -0.787 . . . . 0.0 109.538 179.712 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.3 -159.81 33.27 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.8 m -152.92 167.11 30.23 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.436 -1.037 . . . . 0.0 109.571 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.9 mt -127.23 153.89 45.53 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.525 -0.734 . . . . 0.0 109.576 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.6 p -73.25 162.08 29.79 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.505 -0.747 . . . . 0.0 110.721 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.537 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -69.07 163.71 50.6 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -179.509 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 35.2 t-20 65.45 -13.95 0.12 Allowed 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.81 -0.818 . . . . 0.0 110.012 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.537 ' H ' ' C ' ' A' ' 31' ' ' GLY . 38.2 m -67.83 133.7 49.64 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.055 -1.028 . . . . 0.0 109.503 179.568 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.405 ' H ' ' HG2' ' A' ' 34' ' ' LYS . 19.5 pttp -93.81 146.57 23.78 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.353 -0.842 . . . . 0.0 109.651 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.1 m -122.86 131.46 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.618 -0.677 . . . . 0.0 109.424 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 33.6 m -66.13 128.85 37.73 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.526 -0.733 . . . . 0.0 110.352 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 94.2 mt -107.95 127.81 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.399 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 17.1 m -111.57 -1.06 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 O-C-N 121.567 -0.708 . . . . 0.0 109.468 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 178.75 -175.27 47.25 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -140.69 153.63 46.03 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.369 -1.077 . . . . 0.0 109.432 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 47.9 tp10 -151.64 112.06 4.15 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.326 -0.859 . . . . 0.0 109.506 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.96 -143.35 48.58 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.63 17.2 3.41 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.635 -0.92 . . . . 0.0 109.874 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -127.21 148.1 50.2 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.415 -0.803 . . . . 0.0 109.34 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -98.99 147.42 25.03 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.432 -0.792 . . . . 0.0 109.734 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -96.37 126.79 41.81 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.6 pt -128.95 156.36 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.503 -0.748 . . . . 0.0 109.952 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -90.27 117.69 29.2 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.488 -0.757 . . . . 0.0 109.418 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.537 ' O ' ' N ' ' A' ' 51' ' ' GLY . 53.1 t80 -106.49 101.96 11.39 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.551 -0.718 . . . . 0.0 109.358 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 7.7 mtmp? 43.51 -88.69 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.59 -0.693 . . . . 0.0 110.655 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.537 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -128.39 42.61 1.42 Allowed Glycine 0 N--CA 1.501 2.993 0 N-CA-C 109.784 -1.327 . . . . 0.0 109.784 -179.329 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 93.9 p -161.43 163.59 30.38 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.196 -1.179 . . . . 0.0 109.172 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -94.91 111.18 22.99 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.22 -0.925 . . . . 0.0 109.559 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.11 150.22 19.56 Favored Glycine 0 N--CA 1.494 2.546 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -128.41 139.6 52.28 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.627 -0.925 . . . . 0.0 109.473 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 28.8 m -136.19 156.21 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.436 -0.79 . . . . 0.0 109.826 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 147.18 39.49 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.484 -0.76 . . . . 0.0 110.465 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -69.18 -12.53 61.76 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.485 -0.76 . . . . 0.0 109.593 179.456 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -67.88 -35.27 78.22 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.22 -0.925 . . . . 0.0 110.499 -179.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.541 ' C ' HD12 ' A' ' 61' ' ' ILE . 19.8 m-85 -94.35 -4.49 48.47 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.906 -1.121 . . . . 0.0 110.336 -179.17 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.541 HD12 ' C ' ' A' ' 60' ' ' TYR . 1.6 mp -107.82 130.6 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.237 -0.914 . . . . 0.0 108.88 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.563 ' O ' ' N ' ' A' ' 64' ' ' ILE . 64.3 pttt -142.34 -168.11 2.65 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.478 -0.764 . . . . 0.0 109.077 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 56.26 -75.16 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 CA-C-O 120.986 0.422 . . . . 0.0 110.262 179.655 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.563 ' N ' ' O ' ' A' ' 62' ' ' LYS . 90.3 mt . . . . . 0 N--CA 1.491 1.62 0 O-C-N 121.445 -0.785 . . . . 0.0 109.369 -179.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.498 1.936 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 42.5 p -107.22 114.93 29.29 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.777 0.798 . . . . 0.0 109.289 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.45 136.2 12.57 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.523 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.771 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.8 mp -86.38 120.84 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.568 -0.96 . . . . 0.0 109.445 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 99.5 t -82.58 104.35 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 CA-C-O 121.581 0.705 . . . . 0.0 109.354 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 -102.26 103.79 14.29 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.51 -0.744 . . . . 0.0 109.762 -179.57 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 34.7 m -137.46 164.05 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.57 -0.706 . . . . 0.0 109.832 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 79.8 p -63.25 -39.88 95.85 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.348 0.594 . . . . 0.0 109.755 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.442 ' O ' ' O ' ' A' ' 12' ' ' SER . 29.6 p -163.89 109.16 1.04 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.94 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.442 ' O ' ' O ' ' A' ' 11' ' ' SER . 1.4 m 52.48 166.82 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 CA-C-O 121.938 0.875 . . . . 0.0 111.156 179.634 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 37.1 tp -139.46 131.53 27.96 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.583 0.706 . . . . 0.0 109.853 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -79.52 141.86 36.29 Favored 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.516 0.674 . . . . 0.0 109.933 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 75.3 t -98.78 130.62 47.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.54 -0.725 . . . . 0.0 109.718 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.509 ' NE ' ' O ' ' A' ' 21' ' ' THR . 85.1 mtt85 -103.58 134.09 47.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.468 -0.77 . . . . 0.0 109.73 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.1 tm-20 -71.58 -38.98 70.85 Favored 'General case' 0 N--CA 1.491 1.575 0 CA-C-O 121.596 0.713 . . . . 0.0 109.617 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -90.96 173.66 38.2 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.123 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -90.36 5.35 47.71 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.367 -1.079 . . . . 0.0 109.385 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.438 ' CB ' ' HG ' ' A' ' 23' ' ' SER . 7.2 p -78.66 166.64 22.28 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.319 -0.863 . . . . 0.0 110.38 -179.389 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.509 ' O ' ' NE ' ' A' ' 16' ' ' ARG . 0.7 OUTLIER -69.85 -20.71 63.4 Favored 'General case' 0 N--CA 1.491 1.596 0 CA-C-O 121.509 0.671 . . . . 0.0 109.664 179.807 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.7 t -151.11 63.76 0.9 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.009 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.438 ' HG ' ' CB ' ' A' ' 20' ' ' SER . 18.1 m -75.13 -79.42 0.09 Allowed 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.636 0.732 . . . . 0.0 109.447 179.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -160.56 121.17 2.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.218 -0.926 . . . . 0.0 109.935 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 75.7 t -74.97 129.3 36.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.496 0.665 . . . . 0.0 109.623 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 34.8 pt -119.6 -10.22 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.483 0.658 . . . . 0.0 109.24 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 179.47 -168.73 39.47 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.633 -1.27 . . . . 0.0 110.163 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 39.4 t -154.31 154.5 33.47 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.576 -0.955 . . . . 0.0 109.831 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.0 mt -122.71 150.56 42.57 Favored 'General case' 0 N--CA 1.495 1.806 0 CA-C-O 121.622 0.725 . . . . 0.0 109.544 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 17.1 m -69.45 151.31 46.24 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.851 0.834 . . . . 0.0 110.354 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.403 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.2 166.04 41.91 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 57.11 8.52 0.54 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 122.012 -0.699 . . . . 0.0 109.575 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.403 ' H ' ' C ' ' A' ' 31' ' ' GLY . 34.6 m -88.47 134.33 33.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.44 -0.788 . . . . 0.0 110.243 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -78.14 146.66 34.98 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.641 -0.662 . . . . 0.0 110.094 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.7 m -126.33 132.58 70.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 CA-C-O 121.621 0.724 . . . . 0.0 109.567 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 39.6 m -65.12 128.89 37.65 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.547 0.689 . . . . 0.0 110.116 -179.509 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 5.4 mm -102.8 125.2 57.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 CA-C-O 121.442 0.639 . . . . 0.0 109.426 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 6.3 m -122.11 -11.83 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.55 -173.81 45.6 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.544 -1.312 . . . . 0.0 110.659 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -148.56 163.15 38.09 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.577 -0.955 . . . . 0.0 109.827 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -156.08 114.06 3.33 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.504 -0.748 . . . . 0.0 109.503 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 61.17 -136.5 48.14 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 179.582 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.418 ' C ' ' HZ2' ' A' ' 58' ' ' LYS . . . -92.34 28.91 1.8 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.527 -0.984 . . . . 0.0 108.719 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -134.5 150.35 50.78 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.621 -0.674 . . . . 0.0 109.435 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -105.37 139.63 39.7 Favored 'General case' 0 N--CA 1.493 1.715 0 CA-C-O 121.798 0.809 . . . . 0.0 109.703 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -96.86 129.19 44.33 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.9 pt -129.29 164.22 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 CA-C-O 121.727 0.775 . . . . 0.0 110.212 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -77.72 99.75 5.97 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-O 121.619 0.723 . . . . 0.0 109.94 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -90.36 134.77 34.1 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.515 -0.741 . . . . 0.0 109.484 179.521 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 56.6 mtpt -52.1 97.8 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.452 0.644 . . . . 0.0 110.422 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 121.46 -35.58 3.56 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 23.4 p -163.31 -153.96 0.26 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.141 -1.211 . . . . 0.0 110.076 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -106.4 118.6 37.08 Favored 'General case' 0 N--CA 1.496 1.835 0 CA-C-O 121.698 0.761 . . . . 0.0 109.999 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.83 145.55 17.67 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -115.86 136.86 52.64 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.807 -0.819 . . . . 0.0 109.781 179.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.6 m -138.09 154.57 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 CA-C-O 121.425 0.631 . . . . 0.0 109.679 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.5 ' HB3' ' CD2' ' A' ' 60' ' ' TYR . . . -72.97 149.52 43.27 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.845 0.831 . . . . 0.0 110.899 -179.492 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.418 ' HZ2' ' C ' ' A' ' 43' ' ' ALA . 57.1 mttp -63.1 -34.5 77.73 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.486 0.66 . . . . 0.0 109.99 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -53.67 -30.12 41.87 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.418 -0.801 . . . . 0.0 110.111 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.5 ' CD2' ' HB3' ' A' ' 57' ' ' ALA . 36.5 m-85 -90.03 -2.22 58.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.989 -1.069 . . . . 0.0 109.236 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.0 mm -107.64 127.41 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 CA-C-O 121.796 0.807 . . . . 0.0 109.854 -179.788 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -141.22 150.72 43.04 Favored 'General case' 0 N--CA 1.49 1.563 0 CA-C-O 121.77 0.795 . . . . 0.0 110.133 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.1 t0 56.62 59.5 3.54 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 121.652 0.739 . . . . 0.0 109.965 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 97.2 mt . . . . . 0 N--CA 1.488 1.47 0 O-C-N 121.409 -0.807 . . . . 0.0 109.505 179.804 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt . . . . . 0 N--CA 1.496 1.829 0 CA-C-O 121.12 0.486 . . . . 0.0 109.762 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.8 p -116.21 118.32 32.49 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.556 -0.715 . . . . 0.0 109.367 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -105.52 131.5 10.68 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 -179.351 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.749 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.7 mp -84.91 126.04 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.41 -1.053 . . . . 0.0 109.477 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 74.0 t -75.2 129.03 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 O-C-N 121.318 -0.864 . . . . 0.0 109.938 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 65.0 t-20 -120.38 102.61 8.59 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.1 m -137.09 160.75 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.455 -0.778 . . . . 0.0 109.826 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 87.3 p -82.8 -13.09 56.88 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.524 -0.735 . . . . 0.0 109.266 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.7 m -145.69 -69.41 0.28 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.277 -0.889 . . . . 0.0 109.297 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 58.3 m -156.84 168.86 26.19 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.062 -1.024 . . . . 0.0 109.825 -179.564 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 49.8 tp -116.46 129.76 56.39 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-O 121.656 0.741 . . . . 0.0 109.838 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . 0.436 ' O ' ' OD1' ' A' ' 14' ' ' ASN . 15.1 p30 -89.1 122.12 32.1 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.433 -0.792 . . . . 0.0 109.778 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.0 t -76.49 153.54 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.364 -0.835 . . . . 0.0 109.864 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.562 HH22 ' HB2' ' A' ' 57' ' ' ALA . 88.9 mtm180 -128.54 136.47 50.8 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.567 -0.708 . . . . 0.0 109.809 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 12.6 tm-20 -69.95 -38.8 76.23 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.548 -0.72 . . . . 0.0 109.138 179.464 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -104.78 -178.86 24.6 Favored Glycine 0 N--CA 1.496 2.652 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 -179.236 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -94.5 -0.88 54.32 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.493 -1.004 . . . . 0.0 108.569 179.261 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.2 m -84.69 151.53 24.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.307 -0.871 . . . . 0.0 110.022 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 59.0 p -68.96 -29.08 67.23 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.55 -0.719 . . . . 0.0 109.612 179.421 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 96.7 p -85.65 7.47 23.25 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.278 -0.889 . . . . 0.0 109.257 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.0 t -62.42 146.44 51.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.434 -0.791 . . . . 0.0 110.759 -179.278 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -68.77 137.45 54.02 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-O 121.723 0.773 . . . . 0.0 110.954 -179.339 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 69.9 t -80.37 131.59 33.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 121.595 -0.691 . . . . 0.0 110.049 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 23.1 pt -102.21 -4.27 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.507 -0.746 . . . . 0.0 109.029 179.518 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 161.72 -177.09 38.12 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.483 -1.342 . . . . 0.0 109.959 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 57.8 m -132.91 159.55 39.58 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.47 -1.018 . . . . 0.0 109.732 -179.674 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.536 HD21 ' CE1' ' A' ' 49' ' ' TYR . 95.9 mt -120.07 149.55 42.0 Favored 'General case' 0 N--CA 1.496 1.87 0 CA-C-O 121.661 0.743 . . . . 0.0 109.884 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.8 m -74.24 161.42 29.95 Favored 'General case' 0 N--CA 1.489 1.488 0 CA-C-O 121.863 0.839 . . . . 0.0 110.739 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -63.09 149.41 49.79 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 111.339 -0.704 . . . . 0.0 111.339 -179.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.9 m-20 57.09 32.93 22.53 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.792 -0.828 . . . . 0.0 109.73 179.709 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 25.3 m -90.77 126.63 36.06 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.241 -0.912 . . . . 0.0 109.772 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.5 ttmt -80.3 132.89 35.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.428 -0.795 . . . . 0.0 109.716 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.1 m -124.03 131.96 72.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.579 -0.701 . . . . 0.0 109.734 179.794 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 61.1 m -80.04 128.21 33.21 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-O 121.426 0.631 . . . . 0.0 109.979 -179.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.7 mt -97.37 124.68 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.56 -0.712 . . . . 0.0 109.875 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 34.4 m -110.18 -0.84 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.477 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -175.2 178.01 47.01 Favored Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.637 -1.268 . . . . 0.0 110.2 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -142.74 153.58 43.45 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.08 -1.247 . . . . 0.0 109.527 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.408 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 12.9 tm-20 -151.9 107.6 3.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.47 179.367 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.37 -137.39 45.19 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 179.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -84.64 26.01 0.85 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.437 -1.037 . . . . 0.0 109.098 -179.341 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -132.02 145.19 51.29 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.559 -0.713 . . . . 0.0 109.412 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -106.95 139.46 41.31 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.615 0.722 . . . . 0.0 109.455 179.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -93.09 130.44 38.71 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.557 -0.714 . . . . 0.0 109.174 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 37.2 pt -131.26 154.22 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.611 -0.681 . . . . 0.0 110.044 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -90.86 96.57 10.7 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.519 -0.738 . . . . 0.0 109.127 179.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.536 ' CE1' HD21 ' A' ' 29' ' ' LEU . 73.4 t80 -107.33 123.54 48.49 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.507 -0.746 . . . . 0.0 109.953 -179.728 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 74.3 tttt 51.49 34.54 12.44 Favored 'General case' 0 N--CA 1.493 1.678 0 CA-C-O 121.292 0.568 . . . . 0.0 109.944 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.41 -11.84 11.84 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 178.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 26.4 t -91.84 174.02 7.55 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.256 -1.144 . . . . 0.0 110.333 -179.513 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -97.37 101.53 13.09 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.36 -0.837 . . . . 0.0 109.639 -179.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.26 137.79 13.52 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -119.73 137.39 53.97 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.411 -1.052 . . . . 0.0 109.585 179.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.2 m -139.45 154.76 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.276 -0.89 . . . . 0.0 109.822 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.562 ' HB2' HH22 ' A' ' 16' ' ' ARG . . . -73.83 146.98 43.76 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.406 -0.809 . . . . 0.0 110.584 -179.762 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -66.21 -11.37 49.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.62 -0.675 . . . . 0.0 109.682 179.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -67.35 -34.57 77.59 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.222 -0.924 . . . . 0.0 109.779 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -90.71 3.3 54.64 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.209 -0.932 . . . . 0.0 109.487 -179.197 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 38.3 mm -103.47 129.68 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.346 -0.846 . . . . 0.0 109.939 -179.52 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -146.24 154.91 42.26 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.42 -0.8 . . . . 0.0 109.912 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.6 t0 63.11 52.8 2.43 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 121.555 0.693 . . . . 0.0 109.42 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt . . . . . 0 N--CA 1.487 1.392 0 O-C-N 121.524 -0.735 . . . . 0.0 109.649 -179.834 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt . . . . . 0 N--CA 1.495 1.776 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 70.2 p -132.16 133.55 44.37 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.576 -0.703 . . . . 0.0 109.643 -179.539 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -121.61 131.71 8.66 Favored Glycine 0 N--CA 1.499 2.876 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.751 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.8 mp -86.35 127.65 40.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.075 -1.25 . . . . 0.0 110.005 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 71.5 t -75.61 131.09 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 110.186 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.6 t-20 -123.74 108.23 12.3 Favored 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.52 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' A' ' 11' ' ' SER . 29.3 m -152.96 -19.47 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 179.618 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.8 t 67.97 -52.84 0.52 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.79 -0.569 . . . . 0.0 109.677 -179.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.448 ' N ' ' O ' ' A' ' 9' ' ' VAL . 74.0 m -77.92 -79.41 0.12 Allowed 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.382 -0.824 . . . . 0.0 109.751 -179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 31.2 t -168.45 156.06 7.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.43 -0.794 . . . . 0.0 109.332 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 49.5 tp -123.58 130.28 52.43 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.56 -0.713 . . . . 0.0 109.317 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -84.16 154.48 23.08 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.361 -0.837 . . . . 0.0 109.79 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 54.4 t -105.95 130.14 57.97 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.445 -0.784 . . . . 0.0 109.276 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.723 HH21 ' N ' ' A' ' 20' ' ' SER . 42.4 mtp180 -104.64 128.05 52.57 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.476 -0.765 . . . . 0.0 109.699 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -72.06 -43.16 65.35 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.479 -0.763 . . . . 0.0 109.612 179.68 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -100.32 -175.48 30.1 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.125 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.488 ' C ' HH21 ' A' ' 16' ' ' ARG . . . -97.01 39.59 1.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.505 -0.997 . . . . 0.0 108.944 179.589 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.723 ' N ' HH21 ' A' ' 16' ' ' ARG . 33.0 t -131.86 149.87 52.32 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.554 -0.716 . . . . 0.0 109.72 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 53.1 p -65.11 -31.27 72.39 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.507 -0.746 . . . . 0.0 109.64 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 96.6 p -86.55 13.34 8.63 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.262 -0.899 . . . . 0.0 108.993 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.9 m -62.2 151.13 36.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.442 -0.786 . . . . 0.0 110.442 -179.209 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 17.7 ttmm -64.97 136.83 57.27 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.503 -0.748 . . . . 0.0 110.941 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 97.4 t -90.86 116.73 32.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.3 pt -103.73 -4.76 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.514 -0.741 . . . . 0.0 109.699 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -178.69 -175.5 45.81 Favored Glycine 0 N--CA 1.49 2.253 0 C-N-CA 119.316 -1.421 . . . . 0.0 110.615 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.9 p -158.55 166.1 32.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.558 -0.966 . . . . 0.0 109.004 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.3 mt -123.21 153.92 39.45 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.446 -0.784 . . . . 0.0 109.926 -179.552 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.5 m -80.53 -3.54 50.53 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.663 -0.648 . . . . 0.0 109.334 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.488 ' C ' ' H ' ' A' ' 33' ' ' THR . . . 95.19 164.27 34.91 Favored Glycine 0 N--CA 1.498 2.772 0 O-C-N 121.304 -0.872 . . . . 0.0 111.031 178.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 55.7 2.37 0.07 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.753 -0.851 . . . . 0.0 110.033 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.488 ' H ' ' C ' ' A' ' 31' ' ' GLY . 54.0 m -85.01 133.1 34.26 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.122 -0.986 . . . . 0.0 109.578 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 8.3 ttpm? -80.4 136.79 36.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.341 -0.849 . . . . 0.0 109.964 -179.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.9 m -121.24 130.6 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 CA-C-O 121.506 0.669 . . . . 0.0 109.298 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 53.9 m -73.48 133.12 43.58 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.629 -0.669 . . . . 0.0 110.092 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 97.6 mt -109.66 127.7 66.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 CA-C-O 121.362 0.601 . . . . 0.0 109.491 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.54 -1.12 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.42 176.08 45.44 Favored Glycine 0 N--CA 1.49 2.289 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.244 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 -140.13 153.14 46.59 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.346 -1.091 . . . . 0.0 109.828 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.413 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 12.5 tm-20 -151.08 106.93 3.4 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.229 -0.919 . . . . 0.0 109.385 179.71 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 58.82 -138.69 49.23 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.214 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -83.45 5.05 25.13 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.594 -0.945 . . . . 0.0 109.271 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.448 ' CE1' ' NH1' ' A' ' 16' ' ' ARG . 96.6 m-85 -114.5 141.76 47.28 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.69 -0.631 . . . . 0.0 109.539 -179.636 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -107.86 150.72 26.69 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.664 -0.648 . . . . 0.0 109.666 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.5 mtpm? -91.35 139.16 30.99 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.501 -0.749 . . . . 0.0 109.024 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 38.8 pt -134.05 149.82 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.515 -0.741 . . . . 0.0 109.852 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -86.8 95.03 9.71 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.372 -0.83 . . . . 0.0 108.919 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 84.0 t80 -104.6 116.07 31.44 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.382 -0.824 . . . . 0.0 109.196 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 49.2 tttm 52.39 32.19 10.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.614 -0.679 . . . . 0.0 109.695 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 88.36 -20.92 27.71 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 87.2 p -83.3 166.18 18.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.237 -1.155 . . . . 0.0 110.228 -179.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 61.9 m170 -101.62 95.72 6.63 Favored 'General case' 0 N--CA 1.495 1.788 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -88.19 162.9 32.62 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 -179.163 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -122.18 138.02 54.62 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.768 -0.843 . . . . 0.0 109.227 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 20.7 m -137.29 153.61 29.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.333 -0.854 . . . . 0.0 109.647 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.01 139.77 46.87 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.509 -0.744 . . . . 0.0 110.274 -179.475 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -69.2 -12.43 61.67 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.37 -0.831 . . . . 0.0 109.604 179.336 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -63.09 -32.14 73.45 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.44 -0.788 . . . . 0.0 110.353 -179.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -99.17 5.91 46.61 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 109.828 -179.37 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.5 mm -105.18 128.59 58.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.934 0 O-C-N 121.296 -0.877 . . . . 0.0 109.515 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -141.65 164.29 30.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.466 -0.771 . . . . 0.0 110.17 -179.39 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 56.32 52.03 10.71 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.191 0.519 . . . . 0.0 110.137 179.714 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt . . . . . 0 N--CA 1.489 1.493 0 O-C-N 121.249 -0.907 . . . . 0.0 109.319 179.352 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 64.3 mttp . . . . . 0 N--CA 1.495 1.79 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 52.8 p -131.55 115.02 15.58 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.619 0.724 . . . . 0.0 109.363 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . 0.455 ' C ' HD12 ' A' ' 6' ' ' ILE . . . -91.18 137.65 13.94 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 -179.491 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.698 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.5 mp -92.22 122.22 43.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.618 -0.931 . . . . 0.0 109.398 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.0 t -78.22 132.46 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 O-C-N 121.512 -0.743 . . . . 0.0 110.045 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.6 t-20 -137.72 110.16 7.45 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.519 -0.738 . . . . 0.0 109.351 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.3 m -144.62 149.89 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.394 -0.816 . . . . 0.0 109.607 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 39.8 t -63.66 -43.85 95.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.546 -0.721 . . . . 0.0 110.05 179.837 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 24.6 t -109.43 -76.15 0.62 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.555 -0.715 . . . . 0.0 110.09 -179.204 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 92.1 p -156.73 165.54 35.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 -179.244 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.3 tp -115.17 128.28 56.09 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.761 0.791 . . . . 0.0 109.952 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -84.16 149.9 25.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.586 -0.696 . . . . 0.0 110.055 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.0 t -99.91 131.23 47.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.318 -0.864 . . . . 0.0 109.261 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.432 ' CZ ' ' O ' ' A' ' 21' ' ' THR . 99.7 mtt180 -103.84 135.25 45.74 Favored 'General case' 0 N--CA 1.494 1.758 0 CA-C-O 121.777 0.799 . . . . 0.0 110.099 -179.282 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 46.5 tp10 -70.87 -45.33 64.59 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.554 0.693 . . . . 0.0 109.508 179.715 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.08 172.93 26.01 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 -179.303 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -91.59 11.22 24.96 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.472 -1.016 . . . . 0.0 108.727 179.391 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.1 m -73.87 170.86 14.48 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.333 -0.855 . . . . 0.0 110.305 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.432 ' O ' ' CZ ' ' A' ' 16' ' ' ARG . 18.3 m -62.94 -44.82 95.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.576 -0.702 . . . . 0.0 109.996 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.3 t -131.12 71.12 1.46 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.352 -0.843 . . . . 0.0 109.235 -179.648 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.7 t -83.14 176.66 9.03 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-O 121.659 0.742 . . . . 0.0 110.419 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 65.7 tttm -63.72 133.76 54.12 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-O 121.797 0.808 . . . . 0.0 110.569 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 67.0 t -97.62 128.91 48.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.515 -0.74 . . . . 0.0 109.413 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 39.8 pt -105.19 -4.44 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.673 -0.642 . . . . 0.0 109.342 179.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.91 -156.84 27.36 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.368 -1.396 . . . . 0.0 110.491 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 92.9 p -157.43 164.92 36.96 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.425 -1.044 . . . . 0.0 109.515 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.404 HD21 ' CE1' ' A' ' 49' ' ' TYR . 97.4 mt -126.65 148.69 49.79 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.746 0.784 . . . . 0.0 110.021 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 19.4 m -73.59 156.6 37.9 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-O 121.807 0.813 . . . . 0.0 110.55 -179.4 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.17 156.19 38.09 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 65.3 t30 58.14 33.9 23.63 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.688 -0.889 . . . . 0.0 109.873 179.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 24.1 m -97.55 132.39 43.27 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.333 -0.855 . . . . 0.0 109.761 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -80.93 128.73 34.01 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.525 -0.734 . . . . 0.0 110.096 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.8 m -128.24 134.19 65.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.589 -0.694 . . . . 0.0 109.504 179.466 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 34.4 m -82.27 124.98 30.44 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.486 -0.758 . . . . 0.0 109.426 -179.662 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.8 mt -99.41 136.15 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 CA-C-O 121.608 0.718 . . . . 0.0 110.433 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 34.1 m -110.44 -6.93 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 165.79 -174.67 41.49 Favored Glycine 0 N--CA 1.489 2.189 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.359 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -140.91 147.2 38.5 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.459 -1.024 . . . . 0.0 109.205 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.513 ' N ' ' OE1' ' A' ' 41' ' ' GLU . 56.9 mp0 -145.87 120.67 9.91 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.29 -0.881 . . . . 0.0 110.153 -179.454 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.654 ' O ' ' HB3' ' A' ' 43' ' ' ALA . . . 70.19 31.08 69.13 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.654 ' HB3' ' O ' ' A' ' 42' ' ' GLY . . . 77.4 11.03 2.28 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.524 -0.986 . . . . 0.0 109.136 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.464 ' CD2' ' O ' ' A' ' 42' ' ' GLY . 99.2 m-85 -114.03 131.6 56.3 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.653 -0.654 . . . . 0.0 109.319 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -79.47 139.71 37.54 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.615 -0.678 . . . . 0.0 109.963 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -100.56 120.05 39.44 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.495 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.5 pt -125.07 161.63 28.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 CA-C-O 121.748 0.785 . . . . 0.0 110.45 -179.076 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.474 ' CD ' ' H ' ' A' ' 48' ' ' GLU . 0.0 OUTLIER -90.17 124.31 34.72 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.269 0.557 . . . . 0.0 109.649 -179.588 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.404 ' CE1' HD21 ' A' ' 29' ' ' LEU . 81.9 t80 -132.99 120.82 21.88 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.459 -0.776 . . . . 0.0 109.861 179.611 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 76.5 tttt 39.03 47.38 1.26 Allowed 'General case' 0 N--CA 1.496 1.846 0 CA-C-O 121.687 0.756 . . . . 0.0 110.427 179.424 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 86.3 -50.67 4.28 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 179.615 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 16.7 m -74.46 145.16 43.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -1.132 . . . . 0.0 110.51 -179.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -83.94 120.54 26.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.393 -0.817 . . . . 0.0 109.915 -179.665 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.12 148.45 18.99 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -115.23 142.68 46.34 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.689 -0.889 . . . . 0.0 109.846 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.4 m -140.94 153.6 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.491 -0.756 . . . . 0.0 109.525 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.85 140.23 43.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.408 -0.808 . . . . 0.0 110.247 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 7.2 ptmm? -65.45 -9.23 23.82 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.516 -0.74 . . . . 0.0 109.744 179.615 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.53 -21.09 62.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.797 . . . . 0.0 110.164 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.489 ' C ' HD12 ' A' ' 61' ' ' ILE . 65.5 m-85 -104.97 -23.26 13.0 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.268 -0.895 . . . . 0.0 109.582 -179.435 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.668 ' N ' HD12 ' A' ' 61' ' ' ILE . 1.6 mp -97.07 130.87 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.26 -0.9 . . . . 0.0 109.841 -179.706 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.473 ' O ' ' N ' ' A' ' 64' ' ' ILE . 23.0 pttp -134.98 -165.35 1.66 Allowed 'General case' 0 N--CA 1.494 1.739 0 CA-C-O 121.474 0.654 . . . . 0.0 109.697 179.579 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 59.17 -78.27 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.771 0 CA-C-O 121.151 0.5 . . . . 0.0 109.986 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.473 ' N ' ' O ' ' A' ' 62' ' ' LYS . 97.2 mt . . . . . 0 N--CA 1.493 1.684 0 CA-C-O 121.44 0.638 . . . . 0.0 109.842 -179.35 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.8 mttt . . . . . 0 N--CA 1.496 1.854 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 25.7 p -123.57 128.61 49.98 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.519 -0.738 . . . . 0.0 109.682 -179.474 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.97 129.87 9.82 Favored Glycine 0 N--CA 1.497 2.746 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.676 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.6 mp -80.14 126.3 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.185 -1.185 . . . . 0.0 109.292 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.2 t -81.74 131.62 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.274 -0.891 . . . . 0.0 110.186 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.2 m120 -120.2 100.07 6.97 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.476 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.7 m -141.01 136.27 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.875 0 O-C-N 121.302 -0.874 . . . . 0.0 109.577 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 t -61.99 -44.86 95.85 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.576 -0.702 . . . . 0.0 109.707 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 68.0 m -99.3 -79.72 0.48 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.557 -0.715 . . . . 0.0 109.456 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 59.9 m -158.92 172.29 18.48 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.359 -0.838 . . . . 0.0 109.389 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.0 tp -116.27 131.48 56.93 Favored 'General case' 0 N--CA 1.5 2.055 0 CA-C-O 121.479 0.657 . . . . 0.0 109.516 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.5 p30 -90.86 153.86 19.9 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.393 -0.817 . . . . 0.0 109.655 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 53.7 t -105.3 130.28 56.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.39 -0.819 . . . . 0.0 108.842 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.489 HH22 ' H ' ' A' ' 57' ' ' ALA . 91.0 mtm-85 -112.11 137.94 49.47 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.533 -0.729 . . . . 0.0 109.502 -179.538 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 69.8 mm-40 -86.48 -29.35 22.83 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.463 -0.773 . . . . 0.0 109.193 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -98.46 148.39 18.85 Favored Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.701 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -82.63 73.17 9.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.313 -1.11 . . . . 0.0 109.325 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.1 m -159.15 -169.43 2.65 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.127 -0.983 . . . . 0.0 109.55 179.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 65.9 p -80.71 101.56 9.36 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.277 -0.889 . . . . 0.0 109.785 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.6 t 56.6 52.36 9.86 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.77 -0.582 . . . . 0.0 109.854 179.398 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 77.9 p -62.31 -42.97 99.81 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.301 -0.875 . . . . 0.0 109.313 179.551 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 33.2 ttpt -170.6 115.94 0.48 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.262 -0.899 . . . . 0.0 109.443 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.3 t -90.45 130.22 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.527 -0.733 . . . . 0.0 109.737 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.9 pt -117.37 -11.63 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.32 -162.54 31.36 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.187 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 36.9 t -155.44 168.49 26.95 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.321 -1.105 . . . . 0.0 109.868 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 95.2 mt -127.3 152.74 47.04 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.607 -0.683 . . . . 0.0 109.721 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.6 m -71.4 152.95 42.66 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.609 -0.682 . . . . 0.0 110.368 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -61.86 160.45 29.91 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 -179.176 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 64.4 t30 62.06 4.92 1.29 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.941 -0.741 . . . . 0.0 109.874 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 66.7 m -82.74 130.81 35.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.077 -1.014 . . . . 0.0 109.958 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -86.81 147.46 25.81 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.316 -0.865 . . . . 0.0 109.576 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.3 m -123.34 132.97 70.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.431 -0.793 . . . . 0.0 109.458 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 36.2 m -69.92 130.68 42.87 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.744 -0.598 . . . . 0.0 110.065 -179.352 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.2 mt -109.34 129.17 64.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 29.3 m -120.59 5.24 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 179.591 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.68 177.4 45.25 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 119.531 -1.318 . . . . 0.0 110.463 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -126.69 153.74 45.04 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.676 -0.896 . . . . 0.0 109.247 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 8.1 tm-20 -151.03 93.47 1.93 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.158 -0.963 . . . . 0.0 109.892 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 51.97 -133.27 36.82 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 178.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.81 25.38 1.11 Allowed 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.623 -0.928 . . . . 0.0 108.941 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -138.07 134.62 34.95 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.691 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 44.7 m-85 -89.08 144.89 25.82 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.18 -0.95 . . . . 0.0 109.803 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -90.88 129.49 36.92 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.444 -0.785 . . . . 0.0 109.031 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 39.2 pt -128.46 154.26 39.01 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.592 -0.693 . . . . 0.0 110.06 -179.699 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -87.52 93.74 9.51 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.518 -0.739 . . . . 0.0 109.099 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -92.92 152.74 19.2 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.232 -0.917 . . . . 0.0 110.009 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 41.2 tttp -55.46 119.87 6.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.332 -0.855 . . . . 0.0 110.462 -179.37 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 104.4 -46.3 1.2 Allowed Glycine 0 N--CA 1.496 2.66 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.665 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 95.9 p -163.34 177.92 8.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.121 -1.223 . . . . 0.0 109.953 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -81.08 119.74 23.93 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.2 -0.937 . . . . 0.0 109.452 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.72 165.49 32.17 Favored Glycine 0 N--CA 1.496 2.697 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 -179.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -123.42 138.22 54.64 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.762 -0.846 . . . . 0.0 109.455 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.1 m -137.35 140.76 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.535 -0.728 . . . . 0.0 109.534 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.489 ' H ' HH22 ' A' ' 16' ' ' ARG . . . -68.41 151.0 47.47 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.517 -0.739 . . . . 0.0 110.794 -179.291 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 45.3 mtmt -62.6 -28.91 70.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.573 -0.704 . . . . 0.0 109.184 179.49 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -58.95 -34.43 71.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.474 -0.766 . . . . 0.0 110.418 -178.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -89.73 -1.99 58.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.019 -1.051 . . . . 0.0 109.466 -179.345 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 43.7 mm -112.59 130.29 66.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.616 -0.678 . . . . 0.0 109.828 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -136.47 142.17 43.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.65 -0.656 . . . . 0.0 109.694 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 44.6 t0 62.43 77.99 0.31 Allowed 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.296 0.57 . . . . 0.0 109.899 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 82.2 mt . . . . . 0 N--CA 1.491 1.623 0 O-C-N 121.457 -0.777 . . . . 0.0 109.158 179.716 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.495 1.782 0 CA-C-O 121.292 0.568 . . . . 0.0 109.786 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 69.3 p -117.05 113.96 23.07 Favored 'General case' 0 N--CA 1.498 1.973 0 CA-C-O 121.898 0.856 . . . . 0.0 110.038 -179.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -103.06 130.73 10.35 Favored Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.4 mm -87.53 127.66 40.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.901 -0.764 . . . . 0.0 109.957 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.2 t -71.93 130.56 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 CA-C-O 121.467 0.651 . . . . 0.0 109.725 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.413 ' OD1' ' NZ ' ' A' ' 62' ' ' LYS . 56.0 t30 -123.39 101.93 7.62 Favored 'General case' 0 N--CA 1.497 1.894 0 CA-C-O 121.311 0.577 . . . . 0.0 109.642 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 30.5 m -148.18 158.19 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 121.611 0.719 . . . . 0.0 110.146 179.001 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 58.6 m -87.94 -16.81 32.81 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.859 -0.525 . . . . 0.0 109.976 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 12' ' ' SER . 66.4 m -155.38 87.79 1.12 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.422 -0.799 . . . . 0.0 110.326 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 11' ' ' SER . 1.3 m 46.73 -179.99 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 CA-C-O 121.724 0.773 . . . . 0.0 110.99 178.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 37.8 tp -144.59 130.55 19.34 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.681 0.753 . . . . 0.0 109.846 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -83.31 132.37 35.02 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-O 121.721 0.772 . . . . 0.0 110.053 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 86.7 t -81.18 131.99 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 CA-C-O 121.708 0.766 . . . . 0.0 109.73 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.594 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 93.5 mtm-85 -106.42 135.15 48.42 Favored 'General case' 0 N--CA 1.493 1.688 0 CA-C-O 121.762 0.791 . . . . 0.0 109.897 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.513 ' N ' ' OG ' ' A' ' 23' ' ' SER . 82.8 tt0 -99.52 77.4 2.09 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.645 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.38 170.89 16.7 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 179.413 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -88.66 4.87 45.63 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.7 -0.882 . . . . 0.0 109.199 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.3 m -74.68 155.94 37.2 Favored 'General case' 0 N--CA 1.495 1.779 0 CA-C-O 121.637 0.732 . . . . 0.0 109.966 179.753 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 51.0 p -66.77 -29.97 70.06 Favored 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.7 t -136.59 68.32 1.43 Allowed 'General case' 0 N--CA 1.497 1.893 0 CA-C-O 121.429 0.633 . . . . 0.0 109.443 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 17' ' ' GLU . 5.1 p -82.83 176.79 9.03 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.805 0.812 . . . . 0.0 110.6 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -58.5 130.85 48.75 Favored 'General case' 0 N--CA 1.491 1.58 0 CA-C-O 121.991 0.901 . . . . 0.0 111.11 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.4 t -84.31 129.18 38.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 42.1 pt -115.87 -6.39 11.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 168.83 -166.05 39.36 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.996 -1.097 . . . . 0.0 110.66 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 47.4 t -151.84 153.82 34.97 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.825 -0.809 . . . . 0.0 109.935 -179.748 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.0 mt -123.26 149.76 44.35 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.794 0.807 . . . . 0.0 109.65 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 23.4 p -74.73 160.61 30.53 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.752 0.787 . . . . 0.0 110.451 -179.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -68.62 155.72 53.36 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 58.15 34.69 24.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 122.046 -0.679 . . . . 0.0 109.889 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 53.2 m -102.4 127.16 49.53 Favored 'General case' 0 N--CA 1.498 1.949 0 CA-C-O 121.968 0.889 . . . . 0.0 109.936 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.6 ttpt -77.0 130.33 37.32 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.535 0.684 . . . . 0.0 109.881 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.2 m -129.96 130.89 66.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 CA-C-O 121.75 0.786 . . . . 0.0 109.674 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 11.1 p -77.19 134.29 38.68 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.455 0.645 . . . . 0.0 109.879 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.5 mt -106.23 127.64 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 CA-C-O 121.481 0.658 . . . . 0.0 109.473 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -112.05 -1.06 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.99 171.85 44.72 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.789 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 10.0 tm-20 -137.96 146.65 43.44 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.848 -0.795 . . . . 0.0 109.935 -179.499 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 68.7 mm-40 -144.05 109.4 5.11 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-O 121.97 0.891 . . . . 0.0 109.851 179.706 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.12 -135.11 47.73 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.464 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.36 30.52 0.98 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.765 -0.844 . . . . 0.0 108.746 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -134.49 143.42 47.47 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-O 121.531 0.681 . . . . 0.0 109.821 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -108.82 140.46 42.23 Favored 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.898 0.856 . . . . 0.0 109.59 179.342 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 51.1 mtmt -93.59 143.97 25.81 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.686 0.755 . . . . 0.0 109.717 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 41.5 pt -132.94 152.37 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 CA-C-O 121.646 0.736 . . . . 0.0 110.056 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -75.46 93.78 3.02 Favored 'General case' 0 N--CA 1.489 1.506 0 CA-C-O 121.42 0.629 . . . . 0.0 109.787 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -108.78 142.39 39.4 Favored 'General case' 0 N--CA 1.491 1.611 0 CA-C-O 121.828 0.823 . . . . 0.0 109.589 179.624 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 18.5 ptmt -55.03 119.63 5.73 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 121.845 0.831 . . . . 0.0 110.318 -179.697 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.432 ' O ' ' OG ' ' A' ' 52' ' ' SER . . . 110.63 -47.98 0.98 Allowed Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.286 -1.525 . . . . 0.0 109.286 179.58 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.432 ' OG ' ' O ' ' A' ' 51' ' ' GLY . 24.7 m -167.77 -162.44 0.44 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.739 -0.859 . . . . 0.0 110.386 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -100.11 120.2 39.5 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.832 0.825 . . . . 0.0 109.926 -179.157 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -83.03 145.24 23.24 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -108.54 137.33 46.67 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.615 0.721 . . . . 0.0 109.703 179.724 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.6 m -140.67 143.99 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 CA-C-O 121.735 0.779 . . . . 0.0 110.237 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.594 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -66.66 146.76 54.12 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.64 0.734 . . . . 0.0 110.329 -179.716 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 48.3 mtmt -62.94 -34.4 77.4 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 121.318 0.58 . . . . 0.0 109.468 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -51.47 -33.79 32.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.851 -0.53 . . . . 0.0 110.169 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.428 ' CD2' ' HB3' ' A' ' 57' ' ' ALA . 37.9 m-85 -89.57 0.7 56.74 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.567 -0.708 . . . . 0.0 109.831 -179.367 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 5.6 mm -108.84 125.95 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 CA-C-O 121.685 0.755 . . . . 0.0 110.215 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.413 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 64.0 pttt -145.92 163.49 34.97 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.757 0.789 . . . . 0.0 110.536 -179.741 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 57.94 55.02 5.6 Favored 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 121.444 0.64 . . . . 0.0 109.614 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt . . . . . 0 N--CA 1.489 1.481 0 CA-C-O 121.646 0.736 . . . . 0.0 109.554 -179.837 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt . . . . . 0 N--CA 1.479 1.013 1 N-CA-C 99.335 -4.32 . . . . 0.0 99.335 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.06 135.32 29.05 Favored 'General case' 0 N--CA 1.506 2.357 0 C-N-CA 114.944 -2.702 . . . . 0.0 116.574 -173.512 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -105.02 135.82 12.77 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 106.493 -2.643 . . . . 0.0 106.493 177.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 37.1 mm -97.91 121.67 48.7 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.191 -1.182 . . . . 0.0 108.444 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 76.4 t -80.88 132.34 31.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.248 -0.907 . . . . 0.0 109.619 -179.089 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.892 HD22 ' HZ1' ' A' ' 62' ' ' LYS . 43.9 t-20 -144.91 108.38 4.63 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.245 -0.909 . . . . 0.0 109.216 179.753 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 28.5 m -135.84 162.25 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.169 -0.957 . . . . 0.0 110.168 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.6 t -61.65 -43.15 99.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.549 -0.72 . . . . 0.0 110.017 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 57.9 m -123.75 -90.63 0.56 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.432 -0.792 . . . . 0.0 110.245 -179.387 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.9 m -129.71 157.32 42.48 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.539 -0.726 . . . . 0.0 109.771 -179.258 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.9 tp -114.01 130.9 56.51 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.454 -0.778 . . . . 0.0 109.009 179.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -88.29 144.7 26.27 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.421 -0.8 . . . . 0.0 109.614 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 70.8 t -92.35 131.32 39.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.28 -0.888 . . . . 0.0 108.901 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.658 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 84.4 mtm-85 -107.61 136.39 47.45 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.472 -0.767 . . . . 0.0 109.572 -179.464 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -93.48 90.12 6.57 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.162 -0.961 . . . . 0.0 110.049 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 130.16 -174.09 19.7 Favored Glycine 0 N--CA 1.499 2.841 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 179.289 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -105.01 31.19 4.99 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.574 -0.957 . . . . 0.0 109.22 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 36.0 m -134.02 148.87 51.15 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.363 -0.836 . . . . 0.0 109.674 -179.794 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 40.2 p -67.78 -30.87 70.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.302 -0.874 . . . . 0.0 110.285 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 35.9 t -75.5 7.22 3.81 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.273 -0.892 . . . . 0.0 109.605 -179.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.8 m -65.17 148.95 50.77 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.363 -0.835 . . . . 0.0 110.091 -179.43 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -71.46 142.86 50.21 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.488 -0.757 . . . . 0.0 110.343 -179.578 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 20.4 t -85.64 128.32 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.449 -0.782 . . . . 0.0 109.293 179.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 23.9 pt -107.7 -2.89 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 121.312 -0.867 . . . . 0.0 109.908 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.13 178.87 39.23 Favored Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.007 179.662 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -134.23 153.42 51.86 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.542 -0.975 . . . . 0.0 109.248 179.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 91.7 mt -123.98 146.4 48.53 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 121.321 -0.862 . . . . 0.0 109.497 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 28.0 t -79.75 163.53 24.4 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.435 -0.791 . . . . 0.0 110.635 -179.07 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -66.03 161.7 43.83 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.524 -1.031 . . . . 0.0 110.524 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 54.75 31.96 16.51 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.578 -0.954 . . . . 0.0 109.595 -179.762 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.2 m -100.09 126.25 46.29 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.432 -0.793 . . . . 0.0 108.957 179.609 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -79.49 132.2 36.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.32 -0.862 . . . . 0.0 109.501 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 14.9 m -127.03 131.86 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.394 -0.816 . . . . 0.0 108.991 179.451 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 45.9 p -75.4 134.45 40.92 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-O 121.243 0.545 . . . . 0.0 109.87 -179.184 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 95.3 mt -111.35 128.89 67.54 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 CA-C-O 121.391 0.615 . . . . 0.0 109.379 179.508 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 35.3 m -113.29 -1.57 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.706 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -179.48 -178.67 48.51 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -142.84 159.45 42.22 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.256 -1.144 . . . . 0.0 109.676 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -154.53 113.0 3.56 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.137 -0.977 . . . . 0.0 109.759 179.496 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 59.97 -141.94 47.57 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.414 -1.075 . . . . 0.0 110.414 179.312 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.44 24.92 1.53 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.572 -0.958 . . . . 0.0 109.324 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -129.75 147.78 51.57 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.545 -0.722 . . . . 0.0 109.087 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -103.94 142.8 33.78 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.465 -0.772 . . . . 0.0 109.607 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -91.69 128.0 37.35 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 14.2 pt -129.89 154.02 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.296 -0.878 . . . . 0.0 109.391 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.413 ' OE1' ' CD2' ' A' ' 53' ' ' HIS . 49.0 tp10 -82.88 110.99 18.36 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.464 -0.772 . . . . 0.0 109.148 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.577 ' O ' ' N ' ' A' ' 51' ' ' GLY . 79.1 t80 -107.35 117.49 34.21 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.398 -0.814 . . . . 0.0 109.464 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt 44.23 -87.44 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.549 -0.72 . . . . 0.0 110.106 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -123.51 -34.0 0.78 Allowed Glycine 0 N--CA 1.497 2.741 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 15.6 p -89.43 169.43 11.39 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.335 -1.097 . . . . 0.0 109.822 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.413 ' CD2' ' OE1' ' A' ' 48' ' ' GLU . 73.2 m80 -96.46 115.63 27.75 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.533 -0.729 . . . . 0.0 109.124 179.645 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.96 153.12 26.56 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -121.01 138.66 54.06 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.708 -0.877 . . . . 0.0 109.073 179.661 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -136.58 152.59 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.307 -0.87 . . . . 0.0 109.495 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.658 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -75.03 147.26 40.86 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.523 -0.736 . . . . 0.0 110.65 -179.363 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -70.98 -14.11 62.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.431 -0.793 . . . . 0.0 109.444 179.187 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -65.47 -37.9 88.2 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.447 -0.783 . . . . 0.0 110.292 -179.222 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.519 ' C ' HD12 ' A' ' 61' ' ' ILE . 74.1 m-85 -96.81 -7.55 33.35 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.24 -0.912 . . . . 0.0 110.397 -179.068 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.519 HD12 ' C ' ' A' ' 60' ' ' TYR . 1.5 mp -108.17 129.08 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.062 0 O-C-N 121.366 -0.834 . . . . 0.0 108.931 -179.502 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.892 ' HZ1' HD22 ' A' ' 8' ' ' ASN . 26.7 pttm -145.86 -178.81 6.3 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.201 -0.937 . . . . 0.0 109.708 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 43.2 t0 60.73 46.67 8.82 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.609 -0.682 . . . . 0.0 109.368 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt . . . . . 0 N--CA 1.489 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.02 179.667 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.3 mppt? . . . . . 0 N--CA 1.494 1.76 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 68.9 p -122.74 137.68 54.84 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.621 -0.674 . . . . 0.0 109.765 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -119.49 131.09 8.81 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 5.6 mm -86.87 122.53 38.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.411 -1.052 . . . . 0.0 109.431 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 80.7 t -79.13 131.46 34.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.449 -0.782 . . . . 0.0 110.071 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 96.2 m-20 -121.48 101.77 7.83 Favored 'General case' 0 N--CA 1.497 1.925 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 29.4 m -139.98 160.95 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.425 -0.797 . . . . 0.0 110.025 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 80.6 p -81.63 -11.65 59.02 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.0 p -149.07 -70.21 0.21 Allowed 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.455 -0.778 . . . . 0.0 109.267 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 98.6 p -153.95 168.89 24.89 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.904 . . . . 0.0 110.116 -179.598 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.7 tp -115.47 131.03 57.06 Favored 'General case' 0 N--CA 1.498 1.925 0 CA-C-O 121.479 0.657 . . . . 0.0 109.495 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -83.92 135.25 34.55 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.484 -0.76 . . . . 0.0 110.196 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 87.3 t -90.36 131.74 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.478 -0.764 . . . . 0.0 109.218 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.602 HH21 ' N ' ' A' ' 57' ' ' ALA . 87.5 mtm180 -105.55 133.89 49.56 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.493 -0.754 . . . . 0.0 110.187 -179.601 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -67.53 -46.76 71.86 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.561 -0.712 . . . . 0.0 109.673 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.52 178.68 30.23 Favored Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.182 -1.167 . . . . 0.0 110.182 -179.311 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -92.95 21.28 5.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.616 -0.932 . . . . 0.0 108.681 179.536 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.1 m -79.59 165.2 23.18 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.543 -0.723 . . . . 0.0 110.407 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.7 m -63.19 -46.17 88.34 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.691 -0.631 . . . . 0.0 109.976 -179.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.8 m -129.44 71.13 1.43 Allowed 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.484 -0.76 . . . . 0.0 109.014 -179.553 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.46 -180.0 7.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.639 -0.663 . . . . 0.0 110.136 -179.545 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -67.05 133.12 49.26 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.617 0.723 . . . . 0.0 110.389 -179.453 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 74.8 t -81.15 129.19 37.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.482 -0.762 . . . . 0.0 109.536 179.696 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.407 HD12 ' CD2' ' A' ' 49' ' ' TYR . 41.1 pt -109.99 -5.09 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.723 -0.611 . . . . 0.0 109.489 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.09 177.39 38.15 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.489 -1.339 . . . . 0.0 110.284 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -132.23 155.71 47.78 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.73 -0.865 . . . . 0.0 109.397 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.6 mt -123.55 150.3 44.18 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-O 121.456 0.646 . . . . 0.0 109.801 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.4 m -71.82 152.54 42.59 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 121.522 0.677 . . . . 0.0 110.195 -179.537 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.451 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -68.07 162.83 48.61 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 11.8 m120 56.46 5.0 0.17 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.979 -0.719 . . . . 0.0 109.854 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.451 ' H ' ' C ' ' A' ' 31' ' ' GLY . 35.3 m -81.26 137.1 35.85 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.898 . . . . 0.0 110.138 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -84.96 139.88 31.49 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.498 -0.751 . . . . 0.0 110.176 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 19.8 m -127.0 132.16 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.625 -0.672 . . . . 0.0 109.403 179.562 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 44.5 m -65.67 128.21 35.03 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.725 -0.609 . . . . 0.0 110.047 -179.496 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 97.1 mt -115.55 125.13 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 CA-C-O 121.391 0.615 . . . . 0.0 109.631 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.61 HG23 ' N ' ' A' ' 39' ' ' GLY . 34.6 m -112.96 -47.88 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 179.39 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.61 ' N ' HG23 ' A' ' 38' ' ' VAL . . . -95.06 162.58 23.95 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -142.01 125.63 16.85 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.494 -1.003 . . . . 0.0 109.298 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.518 ' O ' ' N ' ' A' ' 43' ' ' ALA . 83.1 tt0 -114.91 142.95 45.89 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.674 ' O ' ' HB2' ' A' ' 43' ' ' ALA . . . -65.71 59.52 0.13 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.487 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.674 ' HB2' ' O ' ' A' ' 42' ' ' GLY . . . 160.58 -31.7 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.711 -0.876 . . . . 0.0 108.715 179.707 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -134.68 160.91 36.67 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.534 -0.729 . . . . 0.0 110.204 -178.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.7 m-85 -114.13 140.25 48.67 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.589 -0.694 . . . . 0.0 109.688 179.679 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -90.68 129.95 36.73 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 -179.743 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.9 pt -127.9 157.04 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 CA-C-O 121.571 0.701 . . . . 0.0 110.1 -179.685 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -86.93 93.98 9.47 Favored 'General case' 0 N--CA 1.49 1.561 0 CA-C-O 121.431 0.634 . . . . 0.0 109.927 -179.485 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.407 ' CD2' HD12 ' A' ' 26' ' ' ILE . 91.5 t80 -86.89 140.07 30.0 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.399 -0.813 . . . . 0.0 109.467 179.771 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.8 tttm -54.63 100.53 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.422 -0.799 . . . . 0.0 110.05 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 124.51 -33.94 3.63 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 20.7 t -171.11 -168.58 0.66 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.214 -1.168 . . . . 0.0 109.942 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 5.9 m170 -100.69 120.16 39.66 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.519 -0.738 . . . . 0.0 109.641 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.09 161.37 20.85 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -118.09 147.06 43.64 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.737 -0.86 . . . . 0.0 109.626 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.2 m -139.27 153.32 24.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.699 -0.626 . . . . 0.0 109.794 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.602 ' N ' HH21 ' A' ' 16' ' ' ARG . . . -73.68 141.34 46.44 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.574 -0.704 . . . . 0.0 110.59 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -64.61 -12.25 43.65 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.681 -0.637 . . . . 0.0 110.016 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 45.1 tp10 -68.87 -35.97 77.54 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -0.9 . . . . 0.0 110.546 -179.228 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -93.52 2.25 56.48 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.103 -0.998 . . . . 0.0 110.147 -178.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.8 mm -105.67 128.91 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.483 -0.761 . . . . 0.0 109.616 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -143.63 157.09 44.67 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.56 -0.712 . . . . 0.0 109.993 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 37.5 t0 64.39 45.68 3.7 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.615 0.721 . . . . 0.0 109.675 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 97.1 mt . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.68 -0.638 . . . . 0.0 110.071 179.916 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 52.4 mtmt . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 50.6 p -122.8 124.54 43.55 Favored 'General case' 0 N--CA 1.496 1.872 0 CA-C-O 121.829 0.823 . . . . 0.0 109.357 179.52 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -101.78 133.69 11.45 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 -179.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 34.4 mm -84.29 126.62 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.7 -0.882 . . . . 0.0 110.009 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.1 t -82.89 98.6 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.376 -0.827 . . . . 0.0 109.317 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -101.47 107.24 18.49 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.508 -0.745 . . . . 0.0 109.889 -179.603 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 m -141.09 144.3 26.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.299 -0.876 . . . . 0.0 109.575 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 27.5 t -66.97 -13.78 62.19 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-O 121.44 0.638 . . . . 0.0 109.497 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.484 ' OG ' ' N ' ' A' ' 12' ' ' SER . 91.1 p -141.3 -103.84 0.14 Allowed 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.161 -0.962 . . . . 0.0 110.231 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.484 ' N ' ' OG ' ' A' ' 11' ' ' SER . 57.8 m -127.49 157.38 40.24 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.464 -0.773 . . . . 0.0 110.191 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 36.5 tp -113.39 128.81 56.58 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 121.723 0.773 . . . . 0.0 109.875 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.9 m-20 -85.07 150.8 24.61 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.479 0.657 . . . . 0.0 110.025 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.4 t -104.41 129.94 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.423 -0.798 . . . . 0.0 109.276 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -105.28 132.81 51.01 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.546 0.688 . . . . 0.0 109.816 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -71.23 -37.22 72.01 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-O 121.819 0.818 . . . . 0.0 109.433 179.635 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -100.73 179.44 29.02 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -179.392 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -94.31 -1.44 53.87 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.193 -1.18 . . . . 0.0 108.825 179.393 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.9 m -83.36 149.82 26.48 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.312 -0.867 . . . . 0.0 110.196 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 97.7 m -65.0 -44.33 89.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.415 -0.803 . . . . 0.0 110.078 179.489 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 76.5 p -78.49 16.66 0.78 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.078 -1.014 . . . . 0.0 109.529 -179.448 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.8 m -63.64 149.65 46.03 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.212 -0.93 . . . . 0.0 110.251 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -70.96 138.25 49.86 Favored 'General case' 0 N--CA 1.488 1.47 0 CA-C-O 121.981 0.895 . . . . 0.0 110.528 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 75.0 t -87.37 130.17 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 CA-C-O 121.697 0.761 . . . . 0.0 109.925 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 37.4 pt -103.61 -4.57 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.007 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.91 -163.96 36.48 Favored Glycine 0 N--CA 1.493 2.451 0 C-N-CA 119.497 -1.335 . . . . 0.0 110.434 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 95.3 p -156.6 163.03 39.81 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.469 -1.019 . . . . 0.0 109.663 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 89.7 mt -124.79 150.86 45.87 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-O 121.694 0.759 . . . . 0.0 109.903 -179.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 12.3 p -76.19 164.72 25.81 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.062 0.934 . . . . 0.0 111.038 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.23 152.81 43.48 Favored Glycine 0 N--CA 1.489 2.222 0 CA-C-O 122.105 0.836 . . . . 0.0 111.665 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 67.1 t30 57.89 32.19 21.6 Favored 'General case' 0 N--CA 1.494 1.744 0 CA-C-O 121.635 0.731 . . . . 0.0 110.147 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 24.6 m -89.98 126.95 35.93 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.154 -0.966 . . . . 0.0 109.539 179.044 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -82.77 133.17 35.15 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.337 -0.852 . . . . 0.0 109.624 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.0 m -125.85 133.62 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 CA-C-O 121.791 0.805 . . . . 0.0 110.03 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 85.5 m -80.37 127.53 32.49 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.413 0.625 . . . . 0.0 109.78 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.8 mt -105.41 126.72 60.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 CA-C-O 121.466 0.65 . . . . 0.0 109.602 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 18.5 m -112.68 -1.97 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.56 177.82 45.75 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.613 -1.279 . . . . 0.0 110.364 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -141.72 159.63 41.83 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.356 -1.084 . . . . 0.0 109.871 -179.786 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -154.32 109.42 3.11 Favored 'General case' 0 N--CA 1.489 1.497 0 CA-C-O 121.684 0.754 . . . . 0.0 109.158 179.37 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.34 -137.47 45.0 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.06 23.28 1.26 Allowed 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.458 -1.024 . . . . 0.0 108.979 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -130.44 145.3 51.8 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.415 -0.803 . . . . 0.0 109.79 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.4 m-85 -108.5 139.66 42.94 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.611 0.719 . . . . 0.0 109.41 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -90.65 129.95 36.71 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.558 -0.714 . . . . 0.0 109.304 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.7 pt -129.03 153.53 38.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 CA-C-O 121.708 0.765 . . . . 0.0 109.804 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -81.02 99.66 8.56 Favored 'General case' 0 N--CA 1.49 1.531 0 CA-C-O 121.674 0.75 . . . . 0.0 109.857 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.404 ' CD2' ' N ' ' A' ' 51' ' ' GLY . 88.0 t80 -81.2 144.13 31.83 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.559 -0.713 . . . . 0.0 110.021 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 51.9 mtmt -46.85 -47.22 21.26 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.461 -0.775 . . . . 0.0 110.144 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.404 ' N ' ' CD2' ' A' ' 49' ' ' TYR . . . -69.34 -39.93 80.81 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 179.797 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 21.4 m -171.62 -110.78 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.152 -1.205 . . . . 0.0 109.325 -179.536 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 73.2 m80 -127.56 112.56 15.04 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-O 121.801 0.81 . . . . 0.0 109.352 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.84 154.29 19.94 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 -179.681 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -120.87 139.96 52.45 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.606 -0.938 . . . . 0.0 109.712 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.2 m -135.96 152.55 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.55 -0.719 . . . . 0.0 109.195 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 149.8 37.93 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-O 121.861 0.839 . . . . 0.0 110.667 -179.528 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 62.2 pttt -65.8 -15.43 62.87 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.57 0.7 . . . . 0.0 109.977 179.4 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.443 ' OE2' ' CE2' ' A' ' 60' ' ' TYR . 14.4 pt-20 -67.28 -35.73 80.1 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.243 -0.911 . . . . 0.0 110.199 -179.563 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.443 ' CE2' ' OE2' ' A' ' 59' ' ' GLU . 54.9 m-85 -90.79 -1.69 57.84 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.07 -1.019 . . . . 0.0 109.26 -179.407 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 39.3 mm -110.86 131.72 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.397 -0.815 . . . . 0.0 109.428 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.486 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 63.8 tttp -130.45 158.05 40.96 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.486 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 11.7 t0 79.81 -59.02 0.35 Allowed 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.393 0.616 . . . . 0.0 109.529 179.518 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.414 ' O ' HG22 ' A' ' 64' ' ' ILE . 82.1 mt . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.741 0.782 . . . . 0.0 109.268 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.677 0.751 . . . . 0.0 109.393 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -70.82 151.21 45.03 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.356 -0.84 . . . . 0.0 110.076 -179.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -127.01 144.2 51.09 Favored 'General case' 0 N--CA 1.494 1.771 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 22.9 p -117.61 121.87 42.07 Favored 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.831 0.825 . . . . 0.0 109.631 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -102.03 137.64 13.45 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 27.8 mm -87.11 123.21 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.539 -0.977 . . . . 0.0 109.53 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 33' ' ' THR . 70.5 t -74.36 134.08 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.509 -0.744 . . . . 0.0 110.13 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 47.0 t30 -128.53 101.31 6.12 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.6 -0.687 . . . . 0.0 109.401 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 24.5 m -136.71 160.58 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.397 -0.814 . . . . 0.0 109.709 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 99.9 p -84.16 -10.37 57.81 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.498 0.666 . . . . 0.0 109.604 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 62.5 p -147.4 -66.79 0.26 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.13 -0.981 . . . . 0.0 109.503 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.5 p -157.52 165.73 34.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.237 -0.915 . . . . 0.0 109.414 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.0 tp -113.44 130.18 56.37 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 121.672 0.749 . . . . 0.0 109.822 -179.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -85.78 145.84 27.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.518 -0.739 . . . . 0.0 109.678 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.7 t -111.51 130.97 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.483 ' NE ' ' O ' ' A' ' 21' ' ' THR . 84.6 mtt85 -111.14 146.36 36.99 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.788 0.804 . . . . 0.0 109.76 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -88.19 -16.59 32.9 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.458 ' O ' ' CD2' ' A' ' 55' ' ' TYR . . . -96.66 -130.92 6.69 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -152.21 -5.58 0.23 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.313 -1.11 . . . . 0.0 108.581 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 8.5 p -82.38 172.33 13.19 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.354 -0.841 . . . . 0.0 110.761 -179.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.483 ' O ' ' NE ' ' A' ' 16' ' ' ARG . 52.3 p -66.13 -31.21 71.93 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.603 -0.685 . . . . 0.0 110.219 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 38.0 m -138.39 58.71 1.66 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.029 -1.044 . . . . 0.0 108.896 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.5 m -77.69 -79.1 0.12 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.406 -0.809 . . . . 0.0 109.719 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -157.03 112.97 2.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.073 -1.017 . . . . 0.0 109.792 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.0 t -80.67 129.45 37.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.347 -0.846 . . . . 0.0 109.589 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.4 pt -111.16 -5.58 11.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.554 -0.717 . . . . 0.0 109.126 179.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 164.89 -157.98 30.62 Favored Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.189 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.0 p -153.88 164.7 37.96 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.163 -1.198 . . . . 0.0 109.721 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 94.7 mt -126.64 151.56 47.87 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.671 0.748 . . . . 0.0 109.571 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.422 ' O ' ' OG1' ' A' ' 33' ' ' THR . 29.7 t -71.18 160.7 32.38 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-O 121.91 0.862 . . . . 0.0 110.598 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.459 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.54 160.23 49.72 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 57.87 4.09 0.26 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.957 -0.731 . . . . 0.0 109.754 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.459 ' H ' ' C ' ' A' ' 31' ' ' GLY . 86.0 m -70.36 135.94 49.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.22 -0.925 . . . . 0.0 110.275 179.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 10.2 mtpm? -83.59 140.56 32.15 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.577 -0.702 . . . . 0.0 110.251 -179.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.2 m -126.73 130.88 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.619 -0.676 . . . . 0.0 109.341 179.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 p -79.83 129.31 34.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.537 -0.727 . . . . 0.0 109.719 -179.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 97.0 mt -112.24 129.38 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 CA-C-O 121.482 0.658 . . . . 0.0 109.358 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.2 m -110.18 -2.51 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.01 177.92 47.9 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.307 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.437 ' CD ' ' N ' ' A' ' 41' ' ' GLU . 9.9 tm-20 -133.09 155.4 49.3 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.423 -1.045 . . . . 0.0 109.402 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.437 ' N ' ' CD ' ' A' ' 40' ' ' GLU . 48.6 tp10 -156.31 115.76 3.52 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.493 -0.754 . . . . 0.0 109.149 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 63.68 -142.9 47.32 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.95 20.2 5.04 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.418 -1.048 . . . . 0.0 109.022 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -130.19 150.82 51.27 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.483 -0.761 . . . . 0.0 109.656 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -102.94 140.6 37.01 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.67 0.747 . . . . 0.0 109.988 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -91.16 130.39 37.05 Favored 'General case' 0 N--CA 1.487 1.425 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.2 pt -128.72 157.15 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 CA-C-O 121.766 0.793 . . . . 0.0 110.199 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -82.08 97.3 8.09 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.594 0.711 . . . . 0.0 109.48 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -85.18 144.85 27.91 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.365 -0.834 . . . . 0.0 109.825 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -66.76 100.62 0.72 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.493 -0.754 . . . . 0.0 110.154 -179.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 116.87 -23.4 10.08 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 109.187 -1.565 . . . . 0.0 109.187 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 10.8 t -169.08 -156.08 0.15 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.065 -1.256 . . . . 0.0 110.101 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -108.49 122.77 47.74 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.706 0.765 . . . . 0.0 109.716 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.41 148.76 19.28 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.458 ' CD2' ' O ' ' A' ' 18' ' ' GLY . 87.9 m-85 -127.16 132.27 50.55 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.669 -0.901 . . . . 0.0 109.238 179.306 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.8 m -138.19 153.45 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.396 -0.815 . . . . 0.0 109.923 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.07 151.23 40.22 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-O 121.574 0.702 . . . . 0.0 110.849 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -67.25 -20.34 65.65 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.526 -0.734 . . . . 0.0 110.548 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -65.38 -32.9 74.78 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.213 -0.93 . . . . 0.0 110.565 -178.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -87.91 1.45 54.01 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.854 -1.154 . . . . 0.0 109.396 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 37.8 mm -108.51 127.25 65.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.411 -0.806 . . . . 0.0 109.346 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 37.5 ttpt -140.58 150.43 43.63 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.815 0.817 . . . . 0.0 110.385 -179.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 54.39 72.3 0.47 Allowed 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.72 0.771 . . . . 0.0 110.254 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.9 mt -90.46 115.14 29.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.287 -0.883 . . . . 0.0 109.402 179.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -142.21 149.79 40.13 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.352 -0.842 . . . . 0.0 110.004 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -67.44 141.76 56.89 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 121.644 0.735 . . . . 0.0 110.357 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -166.84 76.81 0.18 Allowed 'General case' 0 N--CA 1.487 1.384 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.428 ' O ' HG12 ' A' ' 68' ' ' VAL . 46.9 t -94.93 -7.87 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.193 -0.942 . . . . 0.0 109.257 -179.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 60.2 mt 60.27 120.22 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.884 0 CA-C-O 122.045 0.926 . . . . 0.0 110.791 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -61.1 148.51 40.22 Favored 'General case' 0 N--CA 1.489 1.522 0 CA-C-O 121.875 0.845 . . . . 0.0 110.575 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.509 ' ND1' ' N ' ' A' ' 72' ' ' HIS . 57.4 t-80 -66.88 170.93 5.9 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-O 121.952 0.882 . . . . 0.0 111.028 -179.387 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.509 ' N ' ' ND1' ' A' ' 71' ' ' HIS . 84.6 t60 53.26 81.02 0.1 Allowed 'General case' 0 N--CA 1.488 1.455 0 CA-C-O 121.956 0.884 . . . . 0.0 109.547 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -67.11 -38.18 85.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.493 -0.755 . . . . 0.0 109.594 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . 0.456 ' O ' ' NE2' ' A' ' 72' ' ' HIS . 63.0 t-80 -57.87 123.27 15.2 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.29 -0.881 . . . . 0.0 110.284 -179.167 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -81.76 129.97 34.91 Favored 'General case' 0 N--CA 1.488 1.446 0 CA-C-O 121.746 0.784 . . . . 0.0 110.007 -179.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 62.2 m170 . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.018 -0.992 . . . . 0.0 109.987 179.761 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -73.12 150.31 42.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.402 -0.811 . . . . 0.0 110.301 -179.424 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -119.22 151.14 38.89 Favored 'General case' 0 N--CA 1.496 1.826 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 17.4 p -118.36 116.44 26.74 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.513 0.673 . . . . 0.0 109.206 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -93.55 125.62 8.3 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.677 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.7 mp -81.08 124.5 38.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.295 -1.121 . . . . 0.0 109.58 -179.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 76.6 t -77.78 132.67 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.343 -0.848 . . . . 0.0 109.956 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -126.92 98.22 5.26 Favored 'General case' 0 N--CA 1.498 1.928 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.5 m -137.23 158.92 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.58 -0.7 . . . . 0.0 109.616 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.9 m -86.06 -12.57 49.79 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.551 -0.718 . . . . 0.0 109.357 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 71.4 m -133.31 -79.51 0.48 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.462 -0.774 . . . . 0.0 109.204 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.3 p -158.29 165.1 35.62 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.173 -0.954 . . . . 0.0 109.725 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 34.0 tp -112.8 131.58 55.63 Favored 'General case' 0 N--CA 1.498 1.963 0 CA-C-O 121.545 0.688 . . . . 0.0 109.561 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -92.17 143.69 26.17 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.503 -0.748 . . . . 0.0 110.063 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 71.1 t -92.57 132.02 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.479 -0.763 . . . . 0.0 109.122 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -102.16 130.53 48.81 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.395 -0.816 . . . . 0.0 110.102 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -70.41 -41.55 72.8 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.719 -0.613 . . . . 0.0 109.821 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.45 ' H ' ' HB2' ' A' ' 23' ' ' SER . . . -105.7 -171.62 23.65 Favored Glycine 0 N--CA 1.497 2.766 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.106 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.05 57.99 0.76 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.699 -0.883 . . . . 0.0 109.124 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 40.7 t -161.33 154.9 21.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.244 -0.91 . . . . 0.0 109.821 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 75.2 p -66.15 -33.09 74.99 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.627 -0.67 . . . . 0.0 109.806 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 47.1 t -79.07 9.18 4.64 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.195 -0.94 . . . . 0.0 108.979 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.45 ' HB2' ' H ' ' A' ' 18' ' ' GLY . 94.2 p -69.36 159.46 33.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.492 -0.755 . . . . 0.0 110.427 -179.304 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -84.16 138.68 32.87 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.471 -0.768 . . . . 0.0 110.837 -179.198 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.0 t -89.69 130.99 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.541 -0.724 . . . . 0.0 109.792 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.41 HD12 ' CE2' ' A' ' 49' ' ' TYR . 36.8 pt -102.8 -6.59 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.574 -0.703 . . . . 0.0 109.177 179.428 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 169.22 -179.83 41.62 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 119.489 -1.339 . . . . 0.0 110.05 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 63.1 m -133.95 157.03 47.07 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.643 -0.916 . . . . 0.0 109.445 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.1 mt -122.59 148.96 44.61 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 121.544 0.687 . . . . 0.0 109.705 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.0 m -71.18 150.2 45.59 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-O 121.705 0.764 . . . . 0.0 110.519 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.543 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -64.13 163.33 34.45 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 111.099 -0.801 . . . . 0.0 111.099 -179.275 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 37.6 t-20 66.74 -19.64 0.11 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.942 -0.74 . . . . 0.0 110.135 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.543 ' H ' ' C ' ' A' ' 31' ' ' GLY . 33.0 m -67.31 136.4 54.8 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.047 -1.033 . . . . 0.0 110.209 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -90.42 148.81 22.55 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.502 -0.749 . . . . 0.0 109.605 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.5 m -123.51 131.53 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 CA-C-O 121.579 0.704 . . . . 0.0 109.188 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 28.5 m -66.63 130.5 43.39 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.86 -0.525 . . . . 0.0 110.025 -179.166 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.0 mt -110.53 129.78 65.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 19.0 m -112.92 -0.12 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -179.61 -179.31 48.76 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.43 -1.367 . . . . 0.0 110.307 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -139.87 154.08 47.19 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.462 -1.023 . . . . 0.0 109.75 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -153.98 109.05 3.13 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -0.854 . . . . 0.0 109.402 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 59.14 -142.22 46.74 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -83.2 17.85 1.91 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.487 -1.008 . . . . 0.0 109.278 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -129.83 145.57 51.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.615 -0.678 . . . . 0.0 109.514 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 50.4 m-85 -107.68 147.69 30.38 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.605 0.716 . . . . 0.0 109.833 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -90.84 139.29 30.88 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.537 -0.727 . . . . 0.0 109.044 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.4 pt -134.45 158.45 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 CA-C-O 121.665 0.745 . . . . 0.0 110.519 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -84.22 93.59 8.22 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.674 -0.641 . . . . 0.0 109.426 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.41 ' CE2' HD12 ' A' ' 26' ' ' ILE . 82.4 t80 -98.37 135.31 40.14 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.358 -0.839 . . . . 0.0 109.278 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.9 ttpt -49.77 106.72 0.12 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.383 -0.823 . . . . 0.0 110.568 -179.162 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 123.31 -51.76 0.79 Allowed Glycine 0 N--CA 1.496 2.647 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 179.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 22.8 p -158.86 -166.2 1.81 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.132 -1.216 . . . . 0.0 110.124 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 78.3 m80 -90.41 116.87 28.68 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.366 -0.834 . . . . 0.0 109.865 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -86.29 160.75 33.57 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -123.96 136.36 54.26 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.665 -0.903 . . . . 0.0 109.423 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.8 m -136.81 137.24 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.506 -0.746 . . . . 0.0 109.337 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.97 143.67 57.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.599 -0.688 . . . . 0.0 110.632 -179.216 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.9 pttt -62.01 -13.35 24.92 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.544 -0.722 . . . . 0.0 109.422 179.377 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -68.25 -31.0 70.17 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.434 -0.791 . . . . 0.0 110.95 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.402 ' C ' HD12 ' A' ' 61' ' ' ILE . 61.2 m-85 -93.1 -11.05 33.87 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.792 -1.192 . . . . 0.0 109.769 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.533 ' N ' HD12 ' A' ' 61' ' ' ILE . 1.4 mp -94.73 131.63 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.361 -0.837 . . . . 0.0 109.207 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.471 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 65.8 tttm -135.43 155.41 50.59 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.653 -0.655 . . . . 0.0 109.828 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.471 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 11.7 t0 79.39 -66.78 0.17 Allowed 'General case' 0 N--CA 1.495 1.799 0 CA-C-O 121.268 0.556 . . . . 0.0 109.535 179.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 91.5 mt 56.46 83.95 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.634 -0.666 . . . . 0.0 109.488 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -142.16 152.29 43.05 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.533 -0.729 . . . . 0.0 109.826 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -79.34 110.01 14.22 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.422 -0.799 . . . . 0.0 109.674 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 49.6 tp10 -87.55 143.18 27.33 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.357 -0.839 . . . . 0.0 109.739 -179.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 27.9 m -75.84 144.9 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.452 -0.78 . . . . 0.0 110.159 -179.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.536 ' N ' HD12 ' A' ' 69' ' ' LEU . 10.8 mp -84.0 -4.27 58.62 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.292 -0.88 . . . . 0.0 109.022 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 10.8 tm-20 -100.72 120.83 40.66 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.334 -0.854 . . . . 0.0 109.793 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -155.85 48.89 0.51 Allowed 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.373 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.609 ' NE2' ' CE1' ' A' ' 73' ' ' HIS . 6.9 t-80 -148.52 145.9 28.09 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.373 -0.829 . . . . 0.0 109.722 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.609 ' CE1' ' NE2' ' A' ' 72' ' ' HIS . 5.8 p-80 -72.36 -14.08 61.63 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.594 -0.691 . . . . 0.0 109.457 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 13.8 m80 -132.21 144.21 50.48 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.446 -0.784 . . . . 0.0 109.573 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -87.91 140.73 29.21 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.594 -0.691 . . . . 0.0 110.394 -179.588 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 . . . . . 0 N--CA 1.493 1.696 0 CA-C-O 118.081 -0.962 . . . . 0.0 110.021 179.849 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.464 ' O ' ' O ' ' A' ' 1' ' ' ALA . 50.7 mt-10 57.5 144.94 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 121.581 0.705 . . . . 0.0 110.372 -179.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -139.19 154.62 48.08 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.431 -0.793 . . . . 0.0 109.133 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -114.46 126.61 55.16 Favored 'General case' 0 N--CA 1.498 1.975 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.31 140.75 15.2 Favored Glycine 0 N--CA 1.497 2.754 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 23.7 mm -94.33 116.33 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.364 -1.08 . . . . 0.0 108.904 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.3 t -80.35 132.63 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.376 -0.828 . . . . 0.0 109.99 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.6 t30 -132.99 106.9 7.94 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.428 -0.795 . . . . 0.0 109.34 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 11' ' ' SER . 19.6 m -151.65 -12.87 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.416 ' H ' ' H ' ' A' ' 9' ' ' VAL . 24.0 p 43.87 17.79 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.724 -0.61 . . . . 0.0 109.729 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.525 ' N ' ' O ' ' A' ' 9' ' ' VAL . 23.7 m -151.55 35.85 0.57 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.1 t 60.63 145.31 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.793 -0.567 . . . . 0.0 110.437 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 35.9 tp -116.16 133.13 56.36 Favored 'General case' 0 N--CA 1.503 2.209 0 CA-C-O 121.572 0.701 . . . . 0.0 109.613 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 18.9 p30 -80.65 137.34 36.33 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.429 -0.794 . . . . 0.0 109.62 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 73.7 t -90.95 131.25 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.361 -0.837 . . . . 0.0 108.84 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 96.7 mtt-85 -95.9 138.81 33.0 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.001 . . . . 0.0 109.981 -179.123 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 50.4 tp10 -67.5 -43.67 80.31 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.424 -0.797 . . . . 0.0 109.777 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.43 ' H ' ' HB2' ' A' ' 23' ' ' SER . . . -119.52 -166.6 13.4 Favored Glycine 0 N--CA 1.499 2.856 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 -178.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.69 56.03 0.88 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.62 -0.929 . . . . 0.0 109.225 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 28.8 t -152.8 151.09 30.05 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.264 -0.898 . . . . 0.0 109.725 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 41.7 p -68.06 -23.12 64.92 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.394 -0.816 . . . . 0.0 109.438 179.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 86.1 p -83.65 -0.48 50.83 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.423 -0.798 . . . . 0.0 109.429 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.43 ' HB2' ' H ' ' A' ' 18' ' ' GLY . 99.8 p -64.84 159.42 22.61 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.222 -0.924 . . . . 0.0 110.387 -179.323 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 22.6 pttp -92.6 140.18 29.81 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.49 -0.756 . . . . 0.0 110.407 -179.458 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 22.6 t -86.69 129.81 37.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.383 -0.823 . . . . 0.0 109.909 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 36.3 pt -102.39 -7.4 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.512 -0.743 . . . . 0.0 109.157 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.77 -162.81 35.22 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 24.8 p -152.78 164.04 38.57 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.299 -1.118 . . . . 0.0 109.433 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.3 mt -124.26 148.48 47.35 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.546 -0.721 . . . . 0.0 109.39 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.9 t -69.94 152.02 44.95 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.493 -0.755 . . . . 0.0 110.622 -179.016 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.46 160.55 32.24 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 12.3 m120 57.31 33.22 22.99 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.653 -0.91 . . . . 0.0 109.563 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 35.1 m -105.02 137.02 43.41 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.57 -0.706 . . . . 0.0 109.832 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -79.76 140.32 36.95 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 109.057 -0.719 . . . . 0.0 109.057 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.8 m -126.77 130.5 71.53 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.416 -0.803 . . . . 0.0 109.397 179.565 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 54.6 m -72.84 126.39 29.81 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.41 -0.806 . . . . 0.0 109.628 -179.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 93.1 mt -107.33 126.71 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.639 -0.663 . . . . 0.0 109.65 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 30.9 m -111.13 -3.26 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 177.21 -174.14 46.78 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -141.05 155.16 46.21 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.323 -1.104 . . . . 0.0 109.441 179.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -151.27 112.06 4.25 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 109.598 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.461 ' O ' ' NZ ' ' A' ' 58' ' ' LYS . . . 61.92 -144.93 49.19 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.501 ' C ' ' HZ2' ' A' ' 58' ' ' LYS . . . -84.36 24.96 0.91 Allowed 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.657 -0.908 . . . . 0.0 109.384 -179.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 -131.58 152.68 50.59 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.602 -0.686 . . . . 0.0 109.341 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 9.1 m-85 -103.16 139.08 39.12 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.413 -0.804 . . . . 0.0 108.855 179.592 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.535 ' HZ2' ' HB3' ' A' ' 53' ' ' HIS . 63.5 tttp -90.71 129.72 36.78 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 33.3 pt -130.72 154.47 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.483 -0.761 . . . . 0.0 109.588 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -83.22 100.3 10.5 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.455 -0.778 . . . . 0.0 109.341 -179.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -83.64 147.1 27.9 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.351 -0.843 . . . . 0.0 109.797 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 8.0 mtmp? -62.21 102.96 0.34 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.267 -0.895 . . . . 0.0 110.861 -179.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 101.63 -10.28 57.5 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 179.106 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 50.4 m -168.29 -166.09 0.67 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.861 -1.376 . . . . 0.0 110.035 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.535 ' HB3' ' HZ2' ' A' ' 46' ' ' LYS . 96.9 m-70 -110.28 115.92 30.55 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.52 -0.737 . . . . 0.0 109.085 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.2 152.08 21.07 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.371 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -126.55 137.79 53.39 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.639 -0.918 . . . . 0.0 109.021 179.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.3 m -135.59 139.56 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.339 -0.85 . . . . 0.0 109.753 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.574 ' HB1' ' OE1' ' A' ' 59' ' ' GLU . . . -68.09 149.58 49.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.575 -0.703 . . . . 0.0 110.593 -179.378 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.501 ' HZ2' ' C ' ' A' ' 43' ' ' ALA . 64.2 mttp -62.23 -33.73 75.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.463 -0.773 . . . . 0.0 109.772 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.574 ' OE1' ' HB1' ' A' ' 57' ' ' ALA . 58.7 mp0 -55.1 -30.98 60.84 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.354 -0.841 . . . . 0.0 110.086 -178.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.478 ' CD2' ' HB3' ' A' ' 57' ' ' ALA . 40.0 m-85 -92.84 -3.98 53.73 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.966 -1.084 . . . . 0.0 109.353 -179.631 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.1 mm -114.46 129.18 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 121.541 -0.724 . . . . 0.0 109.516 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.577 ' O ' ' N ' ' A' ' 64' ' ' ILE . 21.7 ptmt -141.14 -174.16 3.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.418 -0.801 . . . . 0.0 109.581 179.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.458 ' O ' ' O ' ' A' ' 64' ' ' ILE . 91.1 m-20 56.69 -75.48 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.577 ' N ' ' O ' ' A' ' 62' ' ' LYS . 97.7 mt 57.71 150.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 CA-C-O 121.393 0.616 . . . . 0.0 110.01 -179.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -117.52 108.71 15.83 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.619 -0.676 . . . . 0.0 109.473 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -88.87 113.71 24.71 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.335 -0.853 . . . . 0.0 109.309 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -87.61 -2.11 58.4 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.231 -0.918 . . . . 0.0 109.234 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.414 ' O ' HG13 ' A' ' 68' ' ' VAL . 3.4 p -155.84 114.89 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.344 -0.847 . . . . 0.0 109.36 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 88.5 mt -80.41 141.39 35.36 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.324 -0.86 . . . . 0.0 110.159 -179.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.481 ' C ' ' H ' ' A' ' 72' ' ' HIS . 96.0 mt-10 -84.09 162.34 20.34 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.385 -0.822 . . . . 0.0 110.669 -179.317 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 28.8 t60 66.43 -8.51 0.37 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.812 -0.555 . . . . 0.0 109.889 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.481 ' H ' ' C ' ' A' ' 70' ' ' GLU . 74.8 m80 -89.31 -7.62 54.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.223 -0.923 . . . . 0.0 109.045 179.523 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 74.2 m80 -71.4 142.61 50.31 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.428 -0.795 . . . . 0.0 110.036 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . 0.582 ' CD2' ' H ' ' A' ' 74' ' ' HIS . 0.2 OUTLIER -132.99 89.65 2.65 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.419 -0.801 . . . . 0.0 109.171 179.577 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 86.4 t60 40.03 86.35 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.947 0 CA-C-O 121.379 0.609 . . . . 0.0 110.318 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 61.1 t-80 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.644 179.764 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.449 0.642 . . . . 0.0 109.625 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -80.48 126.69 31.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.258 -0.901 . . . . 0.0 110.214 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.5 mtmp? -143.13 157.74 44.24 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.512 -0.742 . . . . 0.0 109.051 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 62.0 p -121.35 125.21 46.42 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.567 -0.708 . . . . 0.0 109.464 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -102.86 137.32 13.34 Favored Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.4 mm -95.5 120.07 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.275 -1.133 . . . . 0.0 109.449 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 74.1 t -75.67 134.2 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.566 -0.709 . . . . 0.0 110.321 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' A' ' 60' ' ' TYR . 3.6 p-10 -138.72 99.74 3.88 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.437 -0.789 . . . . 0.0 109.385 179.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 5.7 m -134.98 135.73 52.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.577 -0.702 . . . . 0.0 109.682 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 78.2 p -62.52 -40.49 96.94 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.614 -0.679 . . . . 0.0 109.638 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 68.9 m -101.8 -79.19 0.52 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.447 -0.783 . . . . 0.0 109.877 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 45.5 m -161.51 167.06 26.13 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.334 -0.854 . . . . 0.0 109.596 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 38.6 tp -116.95 130.17 56.53 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.64 -0.662 . . . . 0.0 109.789 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 9.2 m120 -91.16 142.29 27.89 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.397 -0.814 . . . . 0.0 109.686 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 96.3 t -88.89 128.08 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.324 -0.86 . . . . 0.0 109.21 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.758 HH21 ' H ' ' A' ' 20' ' ' SER . 67.5 mtp180 -107.52 133.16 52.39 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.549 -0.719 . . . . 0.0 109.962 -179.357 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.3 pt-20 -70.7 -35.01 72.55 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.488 -0.757 . . . . 0.0 109.879 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -120.95 -148.8 8.05 Favored Glycine 0 N--CA 1.498 2.774 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 -178.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -147.27 75.05 1.36 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.574 -0.957 . . . . 0.0 108.834 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.758 ' H ' HH21 ' A' ' 16' ' ' ARG . 15.2 m -141.85 44.95 1.7 Allowed 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.633 ' N ' ' NH2' ' A' ' 16' ' ' ARG . 59.0 p 50.37 -84.81 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.769 0 CA-C-O 121.319 0.58 . . . . 0.0 110.471 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.527 ' N ' ' O ' ' A' ' 20' ' ' SER . 23.0 t -71.39 44.4 0.09 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.354 -0.841 . . . . 0.0 109.002 -179.45 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.43 ' H ' ' C ' ' A' ' 21' ' ' THR . 15.4 p -78.58 165.22 23.94 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.355 -0.84 . . . . 0.0 110.411 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -77.3 138.54 39.42 Favored 'General case' 0 N--CA 1.488 1.473 0 CA-C-O 121.721 0.772 . . . . 0.0 110.637 -179.583 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 76.5 t -93.49 129.9 43.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 39.4 pt -109.19 -7.1 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.6 -0.687 . . . . 0.0 109.556 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 179.12 -173.53 45.65 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 119.287 -1.435 . . . . 0.0 110.349 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 54.8 m -144.0 154.06 42.87 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.405 -1.056 . . . . 0.0 109.789 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.7 mt -124.89 148.78 48.12 Favored 'General case' 0 N--CA 1.497 1.884 0 CA-C-O 121.546 0.689 . . . . 0.0 109.63 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 90.6 p -79.08 165.06 23.78 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 121.72 0.772 . . . . 0.0 110.854 -179.148 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -65.78 155.27 50.4 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 12.0 m120 57.41 31.59 20.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.73 -0.865 . . . . 0.0 109.86 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 37.0 m -91.73 129.94 37.61 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.216 -0.928 . . . . 0.0 109.835 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -80.11 133.33 36.08 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.514 -0.741 . . . . 0.0 109.639 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 m -128.1 133.29 67.4 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.303 -0.873 . . . . 0.0 110.037 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 21.6 m -81.56 131.23 35.27 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.685 -0.634 . . . . 0.0 109.451 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 91.1 mt -104.91 126.0 59.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.593 -0.692 . . . . 0.0 109.785 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 15.8 m -109.66 -1.43 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.46 -177.79 48.42 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -142.23 160.84 39.45 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.342 -1.093 . . . . 0.0 109.631 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -152.84 112.57 3.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.241 -0.912 . . . . 0.0 109.546 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.22 -135.16 47.88 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.82 25.91 1.94 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.462 -1.022 . . . . 0.0 109.006 -179.456 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 65.3 m-85 -132.4 151.33 51.92 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.685 -0.634 . . . . 0.0 109.452 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 31.5 m-85 -107.84 139.49 42.35 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.528 0.68 . . . . 0.0 109.894 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -92.42 132.63 36.61 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 36.7 pt -128.4 156.88 40.9 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.556 -0.715 . . . . 0.0 110.205 -179.638 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -82.15 97.56 8.27 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.66 -0.65 . . . . 0.0 109.483 -179.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.418 ' H ' ' HA ' ' A' ' 53' ' ' HIS . 90.0 t80 -85.49 161.46 19.36 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.525 -0.734 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.411 ' N ' ' CG ' ' A' ' 49' ' ' TYR . 98.6 mttt -70.91 107.81 4.22 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.415 -0.803 . . . . 0.0 110.267 -179.543 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 98.84 -14.46 61.64 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 81.0 p -169.46 -161.61 0.3 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.942 -1.328 . . . . 0.0 110.145 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.418 ' HA ' ' H ' ' A' ' 49' ' ' TYR . 77.4 m80 -116.43 121.47 41.98 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.628 -0.67 . . . . 0.0 109.571 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.84 163.57 30.84 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.597 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 81.9 m-85 -132.23 137.35 47.52 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.62 -0.929 . . . . 0.0 109.431 179.507 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 30.2 m -138.73 156.49 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.916 0 O-C-N 121.518 -0.739 . . . . 0.0 109.82 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.86 145.54 42.69 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.508 -0.745 . . . . 0.0 110.314 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 10.3 ptmm? -68.71 -13.79 62.6 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.597 -0.69 . . . . 0.0 110.064 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -67.21 -35.99 80.77 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.195 -0.941 . . . . 0.0 110.149 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.424 ' O ' ' OD1' ' A' ' 8' ' ' ASN . 75.7 m-85 -92.14 1.33 57.27 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.079 -1.013 . . . . 0.0 109.602 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.0 mm -113.68 125.49 70.96 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.561 -0.712 . . . . 0.0 109.601 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -142.42 169.83 16.85 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.477 -0.765 . . . . 0.0 109.856 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 47.9 t0 62.28 52.38 3.14 Favored 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.575 0.703 . . . . 0.0 109.787 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt -74.62 131.04 35.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.463 -0.773 . . . . 0.0 109.188 179.571 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -114.0 134.37 54.89 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.547 -0.72 . . . . 0.0 110.038 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.411 ' OD1' ' O ' ' A' ' 66' ' ' ASP . 43.3 p-10 -104.28 125.76 50.81 Favored 'General case' 0 N--CA 1.494 1.727 0 CA-C-O 121.472 0.653 . . . . 0.0 109.461 179.71 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.551 ' N ' ' OE1' ' A' ' 67' ' ' GLU . 56.8 mp0 -98.97 -16.36 18.77 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 16.8 m -94.06 140.13 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.335 -0.853 . . . . 0.0 110.274 -179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.573 ' N ' HD12 ' A' ' 69' ' ' LEU . 10.6 mp -85.08 -1.41 56.82 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 52.96 -90.6 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.391 -0.818 . . . . 0.0 110.205 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.448 ' N ' ' O ' ' A' ' 69' ' ' LEU . 44.6 m80 -143.14 153.3 42.74 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.188 -0.945 . . . . 0.0 109.646 -179.148 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.442 ' CG ' ' N ' ' A' ' 73' ' ' HIS . 86.3 t60 -78.14 162.34 26.7 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.561 -0.712 . . . . 0.0 110.622 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.442 ' N ' ' CG ' ' A' ' 72' ' ' HIS . 75.4 m80 -70.58 132.58 45.7 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.454 -0.779 . . . . 0.0 110.492 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 51.6 p-80 -84.94 -14.13 48.59 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.512 -0.742 . . . . 0.0 109.337 179.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 74.8 m80 -66.0 -39.76 90.56 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.345 -0.847 . . . . 0.0 109.242 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 75.0 m-70 . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 118.076 -0.964 . . . . 0.0 109.558 -179.674 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -65.05 134.17 53.25 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.434 -0.791 . . . . 0.0 110.02 -179.507 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -137.33 149.98 47.41 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.421 -0.799 . . . . 0.0 109.285 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 10.1 p -122.86 114.45 20.5 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.506 -0.746 . . . . 0.0 109.315 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -97.3 141.42 15.6 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.4 mm -94.71 119.48 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.381 -1.07 . . . . 0.0 109.225 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.3 t -79.04 125.1 38.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.305 -0.872 . . . . 0.0 109.774 -179.478 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.4 t30 -105.52 94.95 5.48 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.453 -0.779 . . . . 0.0 109.387 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.616 HG22 ' H ' ' A' ' 11' ' ' SER . 2.2 p -144.42 135.49 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.361 -0.837 . . . . 0.0 109.174 179.474 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 77.3 p -84.71 -13.73 50.51 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.558 -0.714 . . . . 0.0 109.562 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.616 ' H ' HG22 ' A' ' 9' ' ' VAL . 66.3 m -117.44 -89.26 0.59 Allowed 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.463 -0.773 . . . . 0.0 109.841 -179.686 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.9 p -158.58 163.51 36.93 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.914 -1.116 . . . . 0.0 109.751 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 40.2 tp -120.52 131.21 54.59 Favored 'General case' 0 N--CA 1.498 1.968 0 CA-C-O 121.666 0.746 . . . . 0.0 109.626 179.74 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 -87.04 146.61 26.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.457 -0.777 . . . . 0.0 109.82 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 74.3 t -104.98 129.0 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.455 -0.778 . . . . 0.0 109.125 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.67 HH22 ' N ' ' A' ' 57' ' ' ALA . 0.6 OUTLIER -107.87 138.71 43.64 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.655 0.741 . . . . 0.0 109.372 -179.617 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -93.3 -21.84 19.34 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.554 -0.716 . . . . 0.0 109.35 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.493 ' C ' ' H ' ' A' ' 20' ' ' SER . . . -101.97 7.52 55.05 Favored Glycine 0 N--CA 1.497 2.748 0 N-CA-C 108.897 -1.681 . . . . 0.0 108.897 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . 56.83 3.97 0.15 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.478 -1.013 . . . . 0.0 109.392 -179.44 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.493 ' H ' ' C ' ' A' ' 18' ' ' GLY . 7.6 m -80.87 156.81 25.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.316 -0.865 . . . . 0.0 110.327 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.456 ' O ' ' CB ' ' A' ' 22' ' ' SER . 43.1 p -61.29 101.53 0.17 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.531 -0.731 . . . . 0.0 110.171 -179.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.456 ' CB ' ' O ' ' A' ' 21' ' ' THR . 0.7 OUTLIER 79.06 27.65 0.41 Allowed 'General case' 0 N--CA 1.496 1.852 0 CA-C-O 121.639 0.733 . . . . 0.0 109.519 179.587 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.42 ' O ' ' O ' ' A' ' 22' ' ' SER . 0.2 OUTLIER -56.64 -159.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.915 0.864 . . . . 0.0 110.763 -179.747 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 38.1 ttmt -64.32 128.6 36.51 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.616 0.722 . . . . 0.0 109.785 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 91.1 t -92.14 115.26 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 CA-C-O 121.58 0.705 . . . . 0.0 109.277 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.9 pt -103.66 -3.98 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.57 -163.11 36.73 Favored Glycine 0 N--CA 1.488 2.15 0 C-N-CA 119.405 -1.378 . . . . 0.0 110.53 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.5 p -154.02 163.54 39.91 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.311 -1.111 . . . . 0.0 109.221 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.2 mt -124.63 146.39 49.11 Favored 'General case' 0 N--CA 1.497 1.9 0 CA-C-O 121.725 0.774 . . . . 0.0 110.013 -179.477 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.412 ' C ' ' HG1' ' A' ' 33' ' ' THR . 12.9 m -83.32 162.12 21.21 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-O 121.837 0.827 . . . . 0.0 110.404 -179.533 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.478 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -65.45 158.35 46.35 Favored Glycine 0 N--CA 1.49 2.296 0 CA-C-O 121.817 0.676 . . . . 0.0 111.583 -179.467 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 59.43 0.04 0.19 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.966 -0.726 . . . . 0.0 110.032 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.478 ' H ' ' C ' ' A' ' 31' ' ' GLY . 30.2 m -72.09 140.88 49.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.244 -0.91 . . . . 0.0 110.505 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -87.41 144.74 26.6 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.528 -0.733 . . . . 0.0 109.592 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.6 m -125.87 132.1 71.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 121.456 -0.777 . . . . 0.0 109.96 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 26.6 m -73.11 104.06 4.06 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.68 -0.637 . . . . 0.0 109.362 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.3 mt -101.73 131.1 50.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.553 0.692 . . . . 0.0 109.521 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.612 HG23 ' N ' ' A' ' 39' ' ' GLY . 23.8 m -140.32 -46.51 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.612 ' N ' HG23 ' A' ' 38' ' ' VAL . . . -95.41 164.74 24.59 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -179.338 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.447 ' CD ' ' N ' ' A' ' 41' ' ' GLU . 15.8 tm-20 -135.28 146.0 48.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.369 -1.077 . . . . 0.0 109.594 179.63 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.447 ' N ' ' CD ' ' A' ' 40' ' ' GLU . 84.4 tt0 -153.57 109.1 3.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.458 -0.776 . . . . 0.0 109.408 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.401 ' C ' ' H ' ' A' ' 44' ' ' PHE . . . 48.58 -142.28 8.76 Favored Glycine 0 N--CA 1.494 2.509 0 CA-C-O 121.967 0.759 . . . . 0.0 111.269 179.175 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -81.9 28.51 0.42 Allowed 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.435 -1.038 . . . . 0.0 108.738 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.401 ' H ' ' C ' ' A' ' 42' ' ' GLY . 91.0 m-85 -134.01 140.22 46.56 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.516 -0.74 . . . . 0.0 109.137 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 29.0 m-85 -100.7 142.81 31.64 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.495 -0.753 . . . . 0.0 109.276 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.615 ' HZ3' ' CG ' ' A' ' 53' ' ' HIS . 65.1 tttm -90.45 129.03 36.68 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -179.582 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.0 pt -126.57 152.24 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 CA-C-O 121.699 0.761 . . . . 0.0 110.164 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -84.39 92.2 7.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.511 -0.743 . . . . 0.0 109.658 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -79.3 142.11 36.43 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.331 -0.856 . . . . 0.0 110.134 -179.504 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -58.18 96.46 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.547 -0.721 . . . . 0.0 110.408 -179.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 123.19 -35.83 3.25 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 67.8 p -158.96 -162.96 1.15 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.986 -1.302 . . . . 0.0 109.759 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.615 ' CG ' ' HZ3' ' A' ' 46' ' ' LYS . 97.5 m-70 -106.31 118.26 36.18 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.492 -0.755 . . . . 0.0 109.347 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.15 162.39 22.8 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -126.54 136.56 52.73 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.526 -0.985 . . . . 0.0 109.514 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.8 m -133.67 137.15 53.21 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 CA-C-O 121.477 0.656 . . . . 0.0 109.619 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.67 ' N ' HH22 ' A' ' 16' ' ' ARG . . . -68.85 147.21 52.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.395 -0.816 . . . . 0.0 110.352 -179.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.4 mtmp? -63.8 -9.03 12.51 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.567 -0.708 . . . . 0.0 109.736 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -68.83 -35.99 77.64 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.108 -0.995 . . . . 0.0 110.096 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -92.96 4.99 53.0 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.052 -1.03 . . . . 0.0 109.203 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 44.8 mm -103.88 129.16 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.39 -0.819 . . . . 0.0 109.513 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 26.2 ttpp -149.88 157.34 43.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.306 -0.872 . . . . 0.0 110.439 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 55.81 52.97 9.98 Favored 'General case' 0 N--CA 1.49 1.57 0 CA-C-O 121.59 0.709 . . . . 0.0 109.498 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt -69.9 130.8 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.497 -0.752 . . . . 0.0 109.554 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 18.2 tptm -133.05 137.54 46.47 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.815 0.817 . . . . 0.0 110.173 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -89.33 114.63 26.06 Favored 'General case' 0 N--CA 1.488 1.461 0 CA-C-O 121.694 0.759 . . . . 0.0 109.744 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -56.43 156.27 6.2 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.699 0.762 . . . . 0.0 110.844 -179.241 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 4.9 t 62.1 77.83 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.77 0.795 . . . . 0.0 109.639 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.454 ' H ' HD23 ' A' ' 69' ' ' LEU . 0.1 OUTLIER -85.08 157.3 20.75 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 121.773 0.797 . . . . 0.0 110.064 -179.243 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 73.5 mm-40 -59.98 140.61 56.64 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 121.729 0.776 . . . . 0.0 110.435 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.411 ' O ' ' O ' ' A' ' 72' ' ' HIS . 59.2 t-80 -80.64 -15.13 57.35 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 179.38 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.411 ' O ' ' O ' ' A' ' 71' ' ' HIS . 96.9 m-70 54.45 106.21 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.662 0.744 . . . . 0.0 110.174 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -148.4 159.08 44.38 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.114 -0.991 . . . . 0.0 109.562 179.645 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -102.82 133.26 48.18 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.301 -0.875 . . . . 0.0 110.217 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 58.6 t-80 -66.12 -42.86 88.58 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.475 -0.766 . . . . 0.0 109.797 179.69 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 67.5 m-70 . . . . . 0 N--CA 1.495 1.788 0 CA-C-O 118.198 -0.906 . . . . 0.0 109.947 -179.538 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -74.17 152.42 39.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.486 -0.758 . . . . 0.0 110.192 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -112.0 156.92 21.37 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.694 -0.629 . . . . 0.0 109.592 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 67.2 p -134.22 152.32 51.76 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.569 -0.707 . . . . 0.0 109.476 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -135.1 128.67 4.83 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.75 ' N ' HD12 ' A' ' 6' ' ' ILE . 2.0 mp -81.99 124.52 39.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.669 -0.901 . . . . 0.0 109.579 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 91.8 t -85.33 116.75 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.506 -0.746 . . . . 0.0 109.732 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.403 HD22 ' HD3' ' A' ' 62' ' ' LYS . 98.0 m-20 -110.19 107.38 17.15 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.521 -0.737 . . . . 0.0 109.663 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 14.9 m -139.33 156.72 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.386 -0.821 . . . . 0.0 109.616 179.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 82.0 p -73.18 -13.81 61.23 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.502 ' OG ' ' N ' ' A' ' 12' ' ' SER . 77.0 p -152.95 -118.61 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.327 -0.858 . . . . 0.0 110.096 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.502 ' N ' ' OG ' ' A' ' 11' ' ' SER . 21.5 m -101.37 161.26 13.75 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.382 -0.824 . . . . 0.0 110.246 -178.835 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 61.6 tp -120.99 133.4 55.27 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.632 0.729 . . . . 0.0 109.653 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -88.95 129.46 35.62 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.633 -0.667 . . . . 0.0 109.866 179.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 80.7 t -89.89 132.56 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.423 -0.798 . . . . 0.0 109.23 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -101.69 134.08 45.39 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.421 -0.799 . . . . 0.0 110.533 -178.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 11.4 tm-20 -69.21 -43.18 74.61 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.315 0.578 . . . . 0.0 109.548 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -101.42 -178.48 28.59 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -178.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -93.24 -2.22 55.34 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.591 -0.947 . . . . 0.0 109.365 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.7 m -82.37 150.79 26.97 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.187 -0.946 . . . . 0.0 110.368 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.458 ' C ' ' H ' ' A' ' 23' ' ' SER . 19.0 m -64.91 -45.4 86.05 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.501 -0.75 . . . . 0.0 109.534 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 8.7 t -77.24 24.39 0.18 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.607 -0.683 . . . . 0.0 109.161 -179.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.458 ' H ' ' C ' ' A' ' 21' ' ' THR . 14.8 m -71.18 151.14 44.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.477 -0.764 . . . . 0.0 110.291 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -73.37 136.65 44.39 Favored 'General case' 0 N--CA 1.491 1.582 0 CA-C-O 121.789 0.804 . . . . 0.0 110.995 -179.181 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 82.2 t -85.62 131.58 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 CA-C-O 121.372 0.605 . . . . 0.0 109.822 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.403 HG13 ' N ' ' A' ' 27' ' ' GLY . 8.4 pt -125.33 -44.31 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.722 -0.611 . . . . 0.0 109.378 179.779 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.403 ' N ' HG13 ' A' ' 26' ' ' ILE . . . -101.29 171.89 22.71 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 -178.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.8 p -158.42 155.58 28.86 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.583 -0.951 . . . . 0.0 109.55 179.072 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 91.9 mt -133.92 150.57 51.32 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.452 -0.78 . . . . 0.0 109.72 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.9 t -82.11 -1.53 49.02 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.497 ' C ' ' H ' ' A' ' 33' ' ' THR . . . 97.83 164.83 31.52 Favored Glycine 0 N--CA 1.496 2.665 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.272 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.0 m120 52.78 5.22 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.746 -0.855 . . . . 0.0 110.014 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.497 ' H ' ' C ' ' A' ' 31' ' ' GLY . 24.9 m -78.9 141.44 37.61 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.101 -0.999 . . . . 0.0 110.312 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -88.74 132.99 34.37 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.643 -0.661 . . . . 0.0 109.493 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.7 m -124.12 133.79 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 CA-C-O 121.785 0.802 . . . . 0.0 109.854 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 5.8 p -76.8 133.92 39.25 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.722 -0.611 . . . . 0.0 110.141 -179.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.0 mt -111.54 128.9 67.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 121.448 0.642 . . . . 0.0 109.362 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 29.7 m -111.21 -3.34 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -174.99 175.92 47.1 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.662 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -136.51 153.44 51.02 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.667 -0.902 . . . . 0.0 109.46 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -155.11 113.19 3.45 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.195 -0.94 . . . . 0.0 109.996 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 57.48 -137.52 49.38 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 178.695 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.9 24.2 2.86 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.602 -0.94 . . . . 0.0 109.073 -179.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -133.2 147.54 52.01 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.576 -0.702 . . . . 0.0 109.571 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 24.9 m-85 -106.35 147.93 28.65 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.559 -0.713 . . . . 0.0 109.782 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -95.53 124.9 39.79 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 13.8 pt -131.51 154.26 40.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 CA-C-O 121.762 0.791 . . . . 0.0 110.217 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -90.89 106.29 18.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.695 -0.628 . . . . 0.0 109.958 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 88.7 t80 -112.45 115.37 28.57 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.572 0.701 . . . . 0.0 109.172 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.1 mmtp 52.27 31.07 8.73 Favored 'General case' 0 N--CA 1.493 1.689 0 CA-C-O 121.3 0.571 . . . . 0.0 110.193 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 85.64 -11.22 62.27 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 178.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 38.4 t -90.2 170.05 10.62 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.25 -1.147 . . . . 0.0 110.203 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -100.28 93.41 5.67 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.429 -0.794 . . . . 0.0 109.231 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.26 136.1 12.73 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.696 -1.361 . . . . 0.0 109.696 -179.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -112.95 138.58 49.59 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.689 -0.889 . . . . 0.0 109.562 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.1 m -135.89 156.13 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.544 -0.723 . . . . 0.0 109.997 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.548 ' HB3' ' CE2' ' A' ' 60' ' ' TYR . . . -69.21 152.06 45.55 Favored 'General case' 0 N--CA 1.491 1.588 0 CA-C-O 121.76 0.791 . . . . 0.0 110.767 -179.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.525 ' O ' ' N ' ' A' ' 60' ' ' TYR . 47.9 mtmt -63.41 -38.69 92.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.698 -0.626 . . . . 0.0 109.49 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -49.64 -7.42 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.401 -0.812 . . . . 0.0 110.222 -179.382 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.548 ' CE2' ' HB3' ' A' ' 57' ' ' ALA . 59.0 m-85 -105.26 -25.05 12.59 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.289 -0.882 . . . . 0.0 109.236 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.629 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.5 mp -89.13 129.09 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.365 -0.835 . . . . 0.0 109.828 -179.51 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.403 ' HD3' HD22 ' A' ' 8' ' ' ASN . 65.2 tttm -146.37 152.55 39.27 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.546 -0.721 . . . . 0.0 109.857 179.228 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 57.47 57.11 4.55 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.496 0.665 . . . . 0.0 109.803 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.9 mt -70.73 131.7 34.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.382 -0.824 . . . . 0.0 109.533 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -130.71 139.9 50.32 Favored 'General case' 0 N--CA 1.494 1.755 0 CA-C-O 121.511 0.672 . . . . 0.0 109.346 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 41.0 p-10 -93.46 116.21 28.74 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.467 -0.771 . . . . 0.0 110.428 -179.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.428 ' OE2' ' O ' ' A' ' 69' ' ' LEU . 4.7 tm-20 54.56 95.93 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 CA-C-O 121.644 0.735 . . . . 0.0 110.114 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.453 ' O ' ' O ' ' A' ' 69' ' ' LEU . 14.8 t -87.32 104.81 14.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.51 -0.744 . . . . 0.0 110.119 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.469 HD12 ' N ' ' A' ' 69' ' ' LEU . 10.7 mp 55.85 148.28 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 122.045 0.926 . . . . 0.0 111.076 179.196 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 14.7 tm-20 -155.86 114.37 3.43 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.41 -0.806 . . . . 0.0 109.404 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 7.8 p80 -77.68 119.7 21.58 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.549 -0.719 . . . . 0.0 109.866 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 28.5 p80 -100.26 -10.13 21.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.502 -0.749 . . . . 0.0 109.023 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -65.96 -36.74 84.17 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.526 -0.734 . . . . 0.0 109.327 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . 0.592 ' CD2' ' CE1' ' A' ' 75' ' ' HIS . 79.1 t60 -60.03 -44.16 94.83 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.454 -0.779 . . . . 0.0 109.655 -179.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.592 ' CE1' ' CD2' ' A' ' 74' ' ' HIS . 26.1 m170 -144.69 142.7 30.27 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.314 -0.866 . . . . 0.0 109.84 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . 0.521 ' O ' ' CG ' ' A' ' 76' ' ' HIS . 54.2 p-80 . . . . . 0 N--CA 1.489 1.479 0 CA-C-O 118.081 -0.962 . . . . 0.0 109.724 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.432 ' O ' ' O ' ' A' ' 1' ' ' ALA . 79.8 tt0 58.35 121.49 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.389 0.614 . . . . 0.0 110.27 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -136.44 155.74 49.58 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.494 -0.754 . . . . 0.0 109.283 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.0 p -126.8 126.65 43.76 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.519 -0.738 . . . . 0.0 109.23 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.459 ' C ' HD12 ' A' ' 6' ' ' ILE . . . -94.32 130.58 10.36 Favored Glycine 0 N--CA 1.495 2.611 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.694 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.5 mp -93.64 120.5 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.294 -1.121 . . . . 0.0 109.392 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 70.7 t -76.34 132.91 32.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.427 -0.796 . . . . 0.0 109.335 179.47 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -134.87 85.82 2.21 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.439 -0.788 . . . . 0.0 109.246 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.3 m -130.73 132.97 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.578 -0.701 . . . . 0.0 109.52 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 46.7 m -62.42 -41.56 98.79 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.453 -0.779 . . . . 0.0 109.907 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.42 ' OG ' ' N ' ' A' ' 12' ' ' SER . 77.6 p -91.81 -82.09 0.32 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.216 -0.928 . . . . 0.0 109.628 -179.399 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.42 ' N ' ' OG ' ' A' ' 11' ' ' SER . 43.1 t -165.98 167.25 16.76 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.383 -0.823 . . . . 0.0 109.111 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 51.0 tp -119.87 132.45 55.57 Favored 'General case' 0 N--CA 1.498 1.97 0 CA-C-O 121.595 0.712 . . . . 0.0 109.61 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -91.28 152.79 20.34 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.628 -0.67 . . . . 0.0 109.858 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 51.3 t -103.41 131.02 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.702 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 92.1 mtm-85 -110.5 134.69 52.13 Favored 'General case' 0 N--CA 1.492 1.664 0 CA-C-O 121.689 0.757 . . . . 0.0 110.178 -179.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -70.91 -36.4 72.68 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.716 -0.615 . . . . 0.0 109.487 179.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.54 -175.88 31.21 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -179.191 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -109.24 24.48 13.05 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.6 -0.941 . . . . 0.0 108.723 179.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.462 ' OG ' ' OG ' ' A' ' 23' ' ' SER . 6.4 p -83.84 171.49 13.06 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 110.201 -179.524 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 15.9 m -62.72 -43.51 98.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.53 -0.731 . . . . 0.0 109.417 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.8 p -136.12 66.18 1.5 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.457 -0.777 . . . . 0.0 108.956 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.462 ' OG ' ' OG ' ' A' ' 20' ' ' SER . 1.9 m -77.26 -178.08 4.92 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.866 0.841 . . . . 0.0 110.353 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -63.67 139.14 58.74 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.663 0.744 . . . . 0.0 110.656 -179.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 65.6 t -98.27 124.95 51.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.439 -0.788 . . . . 0.0 108.924 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 40.1 pt -104.65 -4.1 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.61 -0.681 . . . . 0.0 109.272 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.81 -168.22 41.23 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.191 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 40.3 t -153.87 154.61 34.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.51 -0.994 . . . . 0.0 109.353 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.7 mt -123.67 151.39 43.14 Favored 'General case' 0 N--CA 1.497 1.923 0 CA-C-O 121.566 0.698 . . . . 0.0 109.652 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.7 t -79.17 166.62 22.02 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.627 0.727 . . . . 0.0 110.606 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -64.79 158.55 44.12 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -179.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 66.8 m-20 57.39 32.94 22.57 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.711 -0.876 . . . . 0.0 109.685 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.2 m -94.53 129.07 41.48 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.281 -0.887 . . . . 0.0 109.456 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -82.92 132.82 35.14 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.426 -0.796 . . . . 0.0 109.822 -179.735 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 m -127.23 134.52 65.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 O-C-N 121.535 -0.728 . . . . 0.0 109.498 179.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 33.6 m -78.49 129.31 34.73 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.462 -0.774 . . . . 0.0 109.732 -179.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.3 mt -106.7 126.03 62.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.593 -0.692 . . . . 0.0 109.612 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 28.5 m -118.77 8.48 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.03 174.47 45.89 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -135.28 155.64 50.3 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.372 -1.075 . . . . 0.0 109.904 -179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.417 ' O ' ' O ' ' A' ' 44' ' ' PHE . 76.3 mm-40 -138.86 153.65 48.34 Favored 'General case' 0 N--CA 1.494 1.73 0 CA-C-O 121.435 0.636 . . . . 0.0 109.759 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.663 ' O ' ' HB3' ' A' ' 43' ' ' ALA . . . -64.36 108.02 2.09 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.124 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.663 ' HB3' ' O ' ' A' ' 42' ' ' GLY . . . 80.67 4.03 1.69 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.663 -0.904 . . . . 0.0 109.151 179.488 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.417 ' O ' ' O ' ' A' ' 41' ' ' GLU . 95.6 m-85 -149.39 159.6 44.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 109.736 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -118.25 147.45 43.41 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.435 ' HZ2' ' HB3' ' A' ' 53' ' ' HIS . 0.1 OUTLIER -91.6 118.1 30.32 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 179.674 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.6 pt -126.57 153.13 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 CA-C-O 121.644 0.735 . . . . 0.0 109.702 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -86.06 118.2 25.38 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.531 -0.731 . . . . 0.0 109.61 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.55 ' O ' ' N ' ' A' ' 51' ' ' GLY . 89.6 t80 -111.58 121.7 45.86 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.554 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.418 ' C ' ' O ' ' A' ' 49' ' ' TYR . 37.3 ttpt 39.52 -90.38 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.261 0.553 . . . . 0.0 110.311 -179.669 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -130.2 -22.64 1.09 Allowed Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.914 -1.675 . . . . 0.0 108.914 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 22.5 m -91.19 163.41 14.27 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.217 -1.167 . . . . 0.0 110.532 -179.355 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.435 ' HB3' ' HZ2' ' A' ' 46' ' ' LYS . 56.9 m170 -83.37 113.12 20.52 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.382 -0.824 . . . . 0.0 109.357 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.64 141.95 15.83 Favored Glycine 0 N--CA 1.495 2.576 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -120.81 139.54 52.99 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.672 -0.899 . . . . 0.0 109.427 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.4 m -132.57 137.83 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.662 -0.649 . . . . 0.0 109.525 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.702 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -61.48 143.72 55.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.548 -0.72 . . . . 0.0 110.805 -179.02 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -66.76 -12.31 58.22 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.505 -0.747 . . . . 0.0 109.899 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 47.3 tp10 -67.15 -36.54 82.06 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.169 -0.957 . . . . 0.0 110.256 -179.494 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -95.62 -5.03 43.39 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.173 -0.955 . . . . 0.0 109.842 -178.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 36.5 mm -110.22 128.94 66.07 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 O-C-N 121.511 -0.743 . . . . 0.0 109.37 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.43 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 21.2 ptmt -140.45 173.23 11.7 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.546 -0.721 . . . . 0.0 110.266 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.43 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 14.7 t0 77.36 -72.21 0.1 Allowed 'General case' 0 N--CA 1.495 1.781 0 CA-C-O 121.114 0.483 . . . . 0.0 109.748 179.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 27.3 mt 62.04 59.59 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.624 -0.673 . . . . 0.0 109.332 -179.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -142.89 135.68 27.89 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.509 -0.744 . . . . 0.0 109.587 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.438 ' OD1' ' N ' ' A' ' 67' ' ' GLU . 67.9 t0 -67.68 134.22 50.72 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.465 -0.772 . . . . 0.0 109.926 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.438 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 98.0 mt-10 -72.56 95.64 1.85 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.35 -0.844 . . . . 0.0 109.829 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 14.6 m -122.0 131.43 73.15 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 O-C-N 121.653 -0.655 . . . . 0.0 109.489 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.565 HD22 ' N ' ' A' ' 69' ' ' LEU . 3.8 mm? -78.31 142.76 37.53 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.513 -0.742 . . . . 0.0 110.341 -179.264 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -157.12 110.61 2.59 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 73.6 m80 -76.02 -73.54 0.26 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.579 -0.701 . . . . 0.0 109.806 -179.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -82.5 132.69 35.2 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.271 -0.893 . . . . 0.0 110.14 -179.218 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.537 ' O ' ' CG ' ' A' ' 74' ' ' HIS . 92.6 m-70 -67.33 -39.09 85.79 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.431 -0.793 . . . . 0.0 109.494 179.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . 0.537 ' CG ' ' O ' ' A' ' 73' ' ' HIS . 98.0 m-70 -158.49 -126.36 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.261 -0.899 . . . . 0.0 110.023 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -66.41 -39.31 88.93 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.538 -0.726 . . . . 0.0 109.605 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 92.4 m-70 . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.147 -0.97 . . . . 0.0 109.71 -179.871 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.54 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 57.4 mp0 -81.41 148.98 29.03 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 121.979 0.895 . . . . 0.0 110.462 -179.522 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt -132.21 153.13 50.9 Favored 'General case' 0 N--CA 1.496 1.828 0 CA-C-O 121.633 0.73 . . . . 0.0 109.889 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 44.1 p -115.72 121.78 43.52 Favored 'General case' 0 N--CA 1.499 1.987 0 CA-C-O 121.833 0.825 . . . . 0.0 109.79 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -100.79 142.27 15.73 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.594 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 22.6 mm -92.69 120.89 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 CA-C-O 121.684 0.754 . . . . 0.0 109.378 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 83.2 t -80.58 105.03 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 CA-C-O 121.668 0.746 . . . . 0.0 109.59 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -99.43 103.88 15.7 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-O 121.747 0.784 . . . . 0.0 109.61 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 26.8 m -137.93 160.58 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 CA-C-O 121.727 0.775 . . . . 0.0 109.918 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 88.0 p -85.73 -12.83 50.15 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.0 m -142.1 -76.01 0.28 Allowed 'General case' 0 N--CA 1.497 1.884 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 25.9 p -155.81 166.56 33.12 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.518 -0.739 . . . . 0.0 109.735 -179.385 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.8 tp -114.18 133.1 55.83 Favored 'General case' 0 N--CA 1.496 1.849 0 CA-C-O 121.841 0.829 . . . . 0.0 110.34 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -91.29 142.3 27.85 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-O 121.719 0.771 . . . . 0.0 109.991 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.9 t -99.11 129.51 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 CA-C-O 121.634 0.731 . . . . 0.0 109.662 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.7 mtt85 -92.87 153.44 18.82 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 121.793 0.806 . . . . 0.0 110.049 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -64.68 -44.37 90.58 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 19' ' ' ALA . . . -157.88 102.92 0.22 Allowed Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.614 ' H ' ' CB ' ' A' ' 55' ' ' TYR . . . 38.8 -114.51 0.14 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 122.001 -0.705 . . . . 0.0 110.292 179.476 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 19' ' ' ALA . 4.9 m 56.35 152.53 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 121.8 0.81 . . . . 0.0 110.508 179.678 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 97.8 m -67.82 -45.5 74.53 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.822 -0.549 . . . . 0.0 109.907 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 39.5 p -153.05 61.05 0.78 Allowed 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 121.836 0.827 . . . . 0.0 109.222 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 5.2 p -75.04 -171.38 1.34 Allowed 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.76 0.79 . . . . 0.0 110.634 179.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt -66.29 142.91 57.5 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-O 121.743 0.782 . . . . 0.0 110.411 -178.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 68.4 t -98.52 127.31 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 CA-C-O 121.732 0.777 . . . . 0.0 109.305 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 27.8 pt -103.26 -4.12 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 173.34 -173.9 45.86 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 24.1 p -154.35 161.69 41.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.81 -0.818 . . . . 0.0 109.711 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 90.8 mt -126.99 151.49 48.51 Favored 'General case' 0 N--CA 1.499 2.007 0 CA-C-O 121.947 0.879 . . . . 0.0 109.984 -179.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.412 ' O ' ' OG1' ' A' ' 33' ' ' THR . 84.1 p -72.7 165.87 23.94 Favored 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 121.812 0.815 . . . . 0.0 110.261 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.479 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.85 165.02 45.63 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 56.33 2.88 0.09 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 122.335 -0.509 . . . . 0.0 110.116 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.479 ' H ' ' C ' ' A' ' 31' ' ' GLY . 47.5 m -71.24 136.14 47.83 Favored 'General case' 0 N--CA 1.496 1.851 0 CA-C-O 121.916 0.865 . . . . 0.0 110.391 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -88.9 143.04 27.15 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.34 0.591 . . . . 0.0 109.866 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 35.4 m -126.26 130.46 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 CA-C-O 121.821 0.82 . . . . 0.0 110.08 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 82.7 m -80.01 125.7 30.11 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.517 0.675 . . . . 0.0 109.739 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 90.6 mt -104.87 128.09 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 CA-C-O 121.554 0.693 . . . . 0.0 109.83 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.8 m -123.92 7.5 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.488 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.04 169.6 42.75 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -129.84 152.77 48.95 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.789 -0.83 . . . . 0.0 109.553 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 53.3 tp10 -153.29 108.33 3.19 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.936 0.874 . . . . 0.0 110.068 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 49.73 -138.14 20.1 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 178.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -84.67 20.3 1.79 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 122.005 -0.703 . . . . 0.0 109.226 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -128.35 151.0 49.85 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-O 121.688 0.756 . . . . 0.0 109.582 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 51.9 m-85 -102.98 141.87 35.04 Favored 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.945 0.878 . . . . 0.0 109.968 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.566 ' NZ ' ' CD2' ' A' ' 53' ' ' HIS . 65.4 tttm -94.29 122.53 36.93 Favored 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.493 0.663 . . . . 0.0 109.384 -179.505 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 34.6 pt -129.25 154.99 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 CA-C-O 121.806 0.813 . . . . 0.0 110.316 179.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -83.45 114.4 21.44 Favored 'General case' 0 N--CA 1.494 1.73 0 CA-C-O 121.568 0.699 . . . . 0.0 109.915 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.569 ' O ' ' N ' ' A' ' 51' ' ' GLY . 86.1 t80 -106.28 114.85 29.22 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.694 0.759 . . . . 0.0 109.588 179.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.1 mttp 40.96 -87.54 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.754 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.105 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -115.63 -39.38 0.92 Allowed Glycine 0 N--CA 1.495 2.58 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 16.7 p -89.54 169.37 11.41 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.804 -0.821 . . . . 0.0 110.45 -179.184 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.566 ' CD2' ' NZ ' ' A' ' 46' ' ' LYS . 73.2 m80 -96.52 111.19 23.4 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.914 0.864 . . . . 0.0 109.952 -179.61 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.64 144.08 23.97 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.614 ' CB ' ' H ' ' A' ' 19' ' ' ALA . 75.8 m-85 -119.63 135.76 54.67 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-O 121.751 0.786 . . . . 0.0 109.515 179.346 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 20.1 m -137.38 156.12 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 CA-C-O 121.913 0.863 . . . . 0.0 110.318 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.07 154.36 33.42 Favored 'General case' 0 N--CA 1.492 1.667 0 CA-C-O 121.681 0.753 . . . . 0.0 110.107 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -69.67 -17.6 63.5 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.529 ' OE2' ' CE2' ' A' ' 60' ' ' TYR . 9.7 pt-20 -65.0 -34.92 79.58 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.786 -0.572 . . . . 0.0 109.893 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.529 ' CE2' ' OE2' ' A' ' 59' ' ' GLU . 66.8 m-85 -91.98 -10.16 40.33 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.451 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 36.0 mm -110.46 120.73 61.94 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.121 0 CA-C-O 121.847 0.832 . . . . 0.0 110.021 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.0 ptpt -149.72 173.47 13.67 Favored 'General case' 0 N--CA 1.494 1.734 0 CA-C-O 121.616 0.722 . . . . 0.0 110.21 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 57.6 47.98 15.01 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-O 121.353 0.596 . . . . 0.0 109.405 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt -72.0 129.91 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 CA-C-O 121.699 0.762 . . . . 0.0 110.055 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -103.61 140.59 37.35 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-O 121.924 0.869 . . . . 0.0 110.148 -179.018 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -97.66 113.53 25.29 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.703 0.764 . . . . 0.0 109.697 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.532 ' N ' ' OE1' ' A' ' 67' ' ' GLU . 57.3 mp0 -84.2 -6.48 59.41 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 75.0 t -84.34 134.29 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 CA-C-O 121.704 0.764 . . . . 0.0 110.21 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 65.4 mt -64.57 134.74 55.0 Favored 'General case' 0 N--CA 1.495 1.791 0 CA-C-O 121.814 0.816 . . . . 0.0 110.088 -179.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -74.11 141.88 45.61 Favored 'General case' 0 N--CA 1.491 1.603 0 CA-C-O 121.695 0.76 . . . . 0.0 110.207 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.409 ' CD2' ' O ' ' A' ' 72' ' ' HIS . 85.9 t60 -71.76 149.81 45.02 Favored 'General case' 0 N--CA 1.491 1.594 0 CA-C-O 121.777 0.799 . . . . 0.0 110.464 -179.302 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.409 ' O ' ' CD2' ' A' ' 71' ' ' HIS . 99.3 m-70 -70.05 138.91 52.51 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.773 0.797 . . . . 0.0 110.553 -179.308 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 46.62 77.0 0.09 Allowed 'General case' 0 N--CA 1.491 1.576 0 CA-C-O 121.575 0.703 . . . . 0.0 109.496 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -62.27 -42.9 99.74 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -147.08 140.07 25.17 Favored 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 121.884 0.85 . . . . 0.0 109.885 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 47.1 p-80 . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 118.135 -0.936 . . . . 0.0 109.325 179.687 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.685 0 CA-C-O 121.624 0.726 . . . . 0.0 110.303 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.427 ' OE1' ' OE1' ' A' ' 67' ' ' GLU . 96.9 mt-10 -66.12 142.22 57.84 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.288 -0.882 . . . . 0.0 110.512 -179.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -136.48 151.34 49.35 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.535 -0.728 . . . . 0.0 109.478 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 70.4 p -127.73 131.14 49.73 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.524 -0.735 . . . . 0.0 109.144 179.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -120.02 135.18 10.91 Favored Glycine 0 N--CA 1.5 2.918 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.757 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.9 mp -86.72 129.02 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.434 -1.039 . . . . 0.0 109.675 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.3 t -82.13 104.8 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.181 -0.949 . . . . 0.0 109.665 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -108.29 106.45 16.61 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.481 -0.762 . . . . 0.0 109.054 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 27.7 m -138.47 162.4 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.27 -0.894 . . . . 0.0 110.016 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 t -61.99 -43.57 98.55 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.55 -0.719 . . . . 0.0 109.46 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 12' ' ' SER . 70.5 m -161.09 108.9 1.52 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.006 -1.059 . . . . 0.0 110.262 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 11' ' ' SER . 22.7 t 54.0 159.19 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.849 0.833 . . . . 0.0 111.509 179.126 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 35.1 tp -133.22 133.03 42.19 Favored 'General case' 0 N--CA 1.498 1.971 0 CA-C-O 121.485 0.66 . . . . 0.0 109.652 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 46.0 p-10 -80.69 141.81 34.52 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.391 -0.818 . . . . 0.0 109.914 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 78.2 t -93.45 133.12 35.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.201 -0.937 . . . . 0.0 109.666 -179.395 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -102.38 130.54 49.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.384 -0.823 . . . . 0.0 109.909 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -73.75 -41.31 62.67 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.468 -0.77 . . . . 0.0 109.763 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.479 ' O ' ' CG ' ' A' ' 55' ' ' TYR . . . -95.93 -129.42 5.96 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.934 -1.266 . . . . 0.0 109.934 -179.111 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -137.13 -12.85 1.63 Allowed 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.519 -0.989 . . . . 0.0 109.073 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 12.0 m -72.72 152.36 41.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.198 -0.939 . . . . 0.0 110.688 -179.094 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.7 m -63.15 -46.08 88.87 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.376 -0.828 . . . . 0.0 109.34 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 58.7 m -88.75 34.74 0.77 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.152 -0.967 . . . . 0.0 108.604 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.2 p -73.78 161.95 29.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.405 -0.81 . . . . 0.0 110.376 -179.2 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -66.28 136.11 55.37 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.348 -0.845 . . . . 0.0 110.299 -179.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 53.4 t -100.72 127.98 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.416 -0.802 . . . . 0.0 109.355 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.5 pt -101.11 -3.07 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.04 -164.22 37.6 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.458 -1.353 . . . . 0.0 110.325 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 40.4 t -155.31 158.87 39.43 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.268 -1.136 . . . . 0.0 109.373 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.0 mt -122.96 149.96 43.59 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.508 -0.745 . . . . 0.0 109.769 -179.693 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 29.6 t -69.23 154.62 41.75 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-O 121.834 0.826 . . . . 0.0 111.02 -178.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.46 157.25 37.53 Favored Glycine 0 N--CA 1.492 2.413 0 O-C-N 121.637 -0.664 . . . . 0.0 111.475 -179.418 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 14.3 t-20 58.75 33.88 23.37 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.809 -0.818 . . . . 0.0 109.741 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.7 m -97.02 129.52 44.46 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.314 -0.866 . . . . 0.0 109.594 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 54.1 tttp -79.8 131.13 35.82 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.352 -0.843 . . . . 0.0 109.344 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 21.6 m -128.77 136.6 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.392 -0.817 . . . . 0.0 109.697 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 18.8 m -80.99 129.46 34.54 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.613 -0.679 . . . . 0.0 109.586 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.6 mt -110.45 129.56 65.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.686 -0.633 . . . . 0.0 109.446 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.583 HG23 ' N ' ' A' ' 39' ' ' GLY . 24.4 m -128.62 -49.37 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.583 ' N ' HG23 ' A' ' 38' ' ' VAL . . . -91.57 166.84 30.64 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 -179.112 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -139.0 146.87 41.42 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.337 -1.096 . . . . 0.0 109.559 179.572 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.5 tm-20 -154.31 110.02 3.19 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.321 -0.862 . . . . 0.0 109.07 179.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 53.13 -138.82 34.79 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 111.044 -0.822 . . . . 0.0 111.044 179.186 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.02 10.65 13.57 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.366 -1.079 . . . . 0.0 109.113 -179.411 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -111.62 144.45 40.85 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.502 -0.748 . . . . 0.0 109.447 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 47.2 m-85 -104.03 141.33 36.38 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.544 -0.723 . . . . 0.0 109.702 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.6 ttmt -90.28 137.91 31.96 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.266 -0.897 . . . . 0.0 108.751 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 17.3 pt -127.81 154.38 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.0 0 O-C-N 121.468 -0.77 . . . . 0.0 110.087 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 50.8 tp10 -82.95 106.87 15.13 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.532 ' O ' ' N ' ' A' ' 51' ' ' GLY . 80.1 t80 -109.21 124.69 51.27 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.52 -0.737 . . . . 0.0 110.134 -179.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.443 ' C ' ' O ' ' A' ' 49' ' ' TYR . 67.8 mttm 33.62 -88.97 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 CA-C-O 121.103 0.478 . . . . 0.0 111.246 179.504 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -119.83 -29.3 1.71 Allowed Glycine 0 N--CA 1.498 2.807 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 -179.251 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 66.6 m -100.58 176.86 5.18 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.088 -1.242 . . . . 0.0 110.478 -179.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -107.68 119.91 40.75 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.527 -0.733 . . . . 0.0 109.682 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.7 159.03 25.56 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.479 ' CG ' ' O ' ' A' ' 18' ' ' GLY . 91.0 m-85 -115.98 137.32 52.22 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.444 -1.033 . . . . 0.0 109.64 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 9.8 m -136.11 137.19 48.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.627 -0.671 . . . . 0.0 109.431 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.32 148.08 51.25 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.498 -0.751 . . . . 0.0 110.611 -179.278 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.3 ptpm? -62.84 -16.55 58.92 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.376 -0.827 . . . . 0.0 109.368 179.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -67.58 -35.84 79.77 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.292 -0.88 . . . . 0.0 109.89 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -92.34 -5.02 53.01 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.018 -1.051 . . . . 0.0 109.236 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 36.7 mm -112.11 123.87 68.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 121.374 -0.829 . . . . 0.0 109.21 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 20.5 ptmt -141.63 171.17 14.43 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.479 -0.763 . . . . 0.0 110.068 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 58.72 40.86 22.73 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-O 121.477 0.656 . . . . 0.0 109.487 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt -75.8 129.87 36.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.285 -0.884 . . . . 0.0 110.042 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.9 mtpt -135.42 147.13 48.88 Favored 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 121.752 0.787 . . . . 0.0 110.215 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 65.1 t0 -82.92 122.19 27.94 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.565 -0.709 . . . . 0.0 110.251 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.427 ' OE1' ' OE1' ' A' ' 2' ' ' GLU . 96.2 mt-10 -47.43 152.15 0.68 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.263 -0.898 . . . . 0.0 110.76 -179.535 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.415 HG23 ' O ' ' A' ' 68' ' ' VAL . 19.5 m -66.62 130.56 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 CA-C-O 121.881 0.848 . . . . 0.0 110.56 -179.093 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.426 ' O ' ' O ' ' A' ' 70' ' ' GLU . 5.6 tp -104.11 -18.6 14.47 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.426 ' O ' ' O ' ' A' ' 69' ' ' LEU . 73.8 mm-40 58.28 119.45 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.923 0 CA-C-O 121.925 0.869 . . . . 0.0 110.467 -179.736 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.423 ' O ' ' O ' ' A' ' 72' ' ' HIS . 96.7 m-70 -74.65 147.92 41.12 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.609 0.718 . . . . 0.0 110.82 -179.463 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.423 ' O ' ' O ' ' A' ' 71' ' ' HIS . 71.1 m80 58.61 123.42 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.779 0 CA-C-O 121.713 0.768 . . . . 0.0 110.418 179.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 58.8 t-80 -79.99 106.33 11.93 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.486 -0.759 . . . . 0.0 109.926 -179.704 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 78.3 m80 -151.86 64.05 0.85 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 179.497 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -61.97 -42.04 98.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.397 -0.814 . . . . 0.0 109.221 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 33.9 p-80 . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 117.945 -1.026 . . . . 0.0 109.699 -179.711 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.448 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.527 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 56.2 mp0 44.02 97.47 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.668 0.747 . . . . 0.0 110.205 179.819 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -119.62 154.95 33.22 Favored 'General case' 0 N--CA 1.497 1.923 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.448 ' CB ' ' HZ1' ' A' ' 34' ' ' LYS . 59.2 p -128.41 124.78 37.14 Favored 'General case' 0 N--CA 1.497 1.893 0 CA-C-O 121.643 0.735 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.454 ' C ' HD12 ' A' ' 6' ' ' ILE . . . -99.91 137.25 13.15 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -179.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.776 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.8 mp -93.95 119.16 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.536 -0.979 . . . . 0.0 109.673 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 71.9 t -79.09 133.2 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 CA-C-O 121.494 0.664 . . . . 0.0 109.791 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.533 ' CB ' ' NZ ' ' A' ' 62' ' ' LYS . 46.1 t30 -140.34 106.98 5.33 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.404 -0.81 . . . . 0.0 109.648 -179.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 m -138.3 151.68 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.603 -0.686 . . . . 0.0 109.634 179.8 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 73.5 m -72.26 -42.9 65.06 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 121.477 0.656 . . . . 0.0 109.828 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 69.0 m -103.85 -76.67 0.59 Allowed 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.446 -0.784 . . . . 0.0 109.625 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 41.2 t -160.03 168.27 25.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.325 -0.86 . . . . 0.0 109.687 -179.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 41.8 tp -116.58 130.21 56.62 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 121.592 0.71 . . . . 0.0 109.984 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -91.92 138.38 31.59 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.771 0.796 . . . . 0.0 110.158 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.3 t -89.5 130.01 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 CA-C-O 121.497 0.665 . . . . 0.0 109.802 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.425 ' NH1' HG23 ' A' ' 25' ' ' VAL . 38.4 mmt180 -107.67 131.15 54.71 Favored 'General case' 0 N--CA 1.496 1.835 0 CA-C-O 121.872 0.844 . . . . 0.0 109.565 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 52.1 tp10 -71.22 -40.18 71.27 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-O 121.532 0.682 . . . . 0.0 109.549 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.502 ' N ' ' OG ' ' A' ' 23' ' ' SER . . . -93.69 177.09 37.07 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.34 39.51 0.87 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.501 -0.999 . . . . 0.0 109.104 179.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.9 p -151.91 154.88 36.97 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.398 -0.814 . . . . 0.0 109.686 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.404 ' O ' ' CZ ' ' A' ' 16' ' ' ARG . 60.5 p -71.29 -28.03 63.84 Favored 'General case' 0 N--CA 1.493 1.724 0 CA-C-O 121.675 0.75 . . . . 0.0 109.379 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 91.9 p -82.35 -3.71 55.94 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.502 ' OG ' ' N ' ' A' ' 18' ' ' GLY . 24.0 t -51.73 -97.08 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.619 -0.675 . . . . 0.0 110.188 -179.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.33 131.58 1.2 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.311 -0.868 . . . . 0.0 110.011 -179.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.425 HG23 ' NH1' ' A' ' 16' ' ' ARG . 84.2 t -81.67 132.17 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.73 -0.606 . . . . 0.0 109.939 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 45.0 pt -117.6 -10.28 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.69 -175.01 45.23 Favored Glycine 0 N--CA 1.494 2.554 0 C-N-CA 119.402 -1.38 . . . . 0.0 110.252 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 65.8 m -133.04 156.18 47.84 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.714 -0.874 . . . . 0.0 109.814 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 92.2 mt -122.9 147.91 46.04 Favored 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.83 0.824 . . . . 0.0 109.941 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.6 t -74.77 157.85 34.5 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-O 121.937 0.875 . . . . 0.0 110.63 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -66.6 156.52 51.04 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 11.5 m120 57.36 33.09 22.8 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 122.075 -0.662 . . . . 0.0 109.461 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 43.3 m -94.42 125.07 38.84 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.843 0.83 . . . . 0.0 110.331 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.448 ' HZ1' ' CB ' ' A' ' 4' ' ' THR . 63.3 tttp -79.24 132.14 36.4 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-O 121.306 0.574 . . . . 0.0 109.677 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.1 m -129.5 134.13 64.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 121.804 0.811 . . . . 0.0 109.763 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 52.7 m -79.09 127.63 32.25 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-O 121.6 0.714 . . . . 0.0 109.901 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.7 mt -102.76 124.2 56.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 CA-C-O 121.499 0.666 . . . . 0.0 109.508 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.76 -0.8 9.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.3 176.31 46.0 Favored Glycine 0 N--CA 1.494 2.551 0 C-N-CA 119.681 -1.247 . . . . 0.0 110.538 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -143.94 155.3 44.01 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.65 -0.912 . . . . 0.0 109.475 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -153.27 107.28 3.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.456 -0.777 . . . . 0.0 109.78 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.3 -135.96 49.75 Favored Glycine 0 N--CA 1.493 2.493 0 CA-C-O 121.98 0.766 . . . . 0.0 111.626 178.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -88.28 28.19 1.12 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.554 -0.968 . . . . 0.0 109.122 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -136.11 150.26 49.03 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.641 -0.662 . . . . 0.0 109.58 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.626 ' CZ ' ' NZ ' ' A' ' 58' ' ' LYS . 12.5 m-85 -107.17 146.04 31.82 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-O 121.882 0.849 . . . . 0.0 109.925 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -98.67 124.77 43.69 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.7 pt -129.73 157.79 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 121.651 0.738 . . . . 0.0 110.187 -179.77 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -87.5 101.79 13.95 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.43 0.634 . . . . 0.0 109.811 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.8 t80 -109.85 118.64 37.03 Favored 'General case' 0 N--CA 1.495 1.807 0 CA-C-O 121.618 0.723 . . . . 0.0 109.45 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.6 mmtt 51.43 29.8 5.6 Favored 'General case' 0 N--CA 1.492 1.668 0 CA-C-O 121.763 0.792 . . . . 0.0 109.754 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.97 -23.45 23.55 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 179.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.3 m -86.53 165.34 16.31 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.281 -1.129 . . . . 0.0 110.576 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -94.51 101.63 13.54 Favored 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 121.73 0.776 . . . . 0.0 109.667 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.1 147.93 19.9 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -115.51 134.08 55.42 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.699 -0.883 . . . . 0.0 109.425 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 12.6 m -136.14 139.58 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 CA-C-O 121.573 0.702 . . . . 0.0 109.902 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.53 144.71 55.75 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.889 0.852 . . . . 0.0 110.387 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.626 ' NZ ' ' CZ ' ' A' ' 45' ' ' TYR . 67.1 mttm -63.74 -36.84 85.19 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-O 121.421 0.629 . . . . 0.0 110.468 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -46.83 -16.34 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.238 -0.914 . . . . 0.0 110.675 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.45 ' N ' ' O ' ' A' ' 58' ' ' LYS . 36.1 m-85 -108.37 -30.65 8.2 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.162 -0.961 . . . . 0.0 109.132 179.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.627 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.5 mp -93.54 123.22 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.424 -0.798 . . . . 0.0 109.741 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.533 ' NZ ' ' CB ' ' A' ' 8' ' ' ASN . 26.6 pttm -148.78 174.73 11.89 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.585 0.707 . . . . 0.0 109.952 179.527 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.551 ' O ' HD13 ' A' ' 6' ' ' ILE . 97.5 m-20 58.11 51.28 8.87 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-O 121.68 0.752 . . . . 0.0 109.765 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.411 HD11 ' CE2' ' A' ' 45' ' ' TYR . 96.9 mt -71.08 133.53 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.51 -0.744 . . . . 0.0 109.722 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 15.0 ttmm -112.87 132.25 55.37 Favored 'General case' 0 N--CA 1.496 1.825 0 CA-C-O 121.841 0.829 . . . . 0.0 110.258 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -85.91 117.68 24.92 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.739 0.78 . . . . 0.0 109.672 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -60.31 135.73 57.82 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.846 0.832 . . . . 0.0 110.117 -179.583 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.456 HG13 ' O ' ' A' ' 68' ' ' VAL . 9.0 p -99.45 125.44 53.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 CA-C-O 121.673 0.749 . . . . 0.0 109.581 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 87.0 mt -93.42 -5.23 49.81 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.542 -0.724 . . . . 0.0 109.116 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.427 ' H ' HG22 ' A' ' 68' ' ' VAL . 97.8 mt-10 -59.23 136.01 57.83 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.309 -0.869 . . . . 0.0 110.051 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 86.6 t60 -67.17 -40.41 86.59 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.75 0.786 . . . . 0.0 109.506 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -68.25 145.53 54.18 Favored 'General case' 0 N--CA 1.49 1.531 0 CA-C-O 121.677 0.751 . . . . 0.0 110.156 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.531 ' O ' ' CG ' ' A' ' 74' ' ' HIS . 59.4 t-80 -132.95 164.53 26.74 Favored 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.576 0.703 . . . . 0.0 109.811 -179.565 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . 0.531 ' CG ' ' O ' ' A' ' 73' ' ' HIS . 18.7 p80 41.7 -158.98 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.579 0.705 . . . . 0.0 110.589 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.443 ' N ' ' ND1' ' A' ' 74' ' ' HIS . 99.1 m-70 -138.88 147.66 42.66 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.422 -0.799 . . . . 0.0 110.072 -179.139 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . 0.455 ' O ' ' CG ' ' A' ' 76' ' ' HIS . 85.8 t60 . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 118.145 -0.931 . . . . 0.0 109.065 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -69.48 140.51 54.02 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.342 -0.849 . . . . 0.0 110.265 -179.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt -137.42 153.28 50.16 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.482 -0.761 . . . . 0.0 109.384 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 46.9 p -115.13 123.13 48.16 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.679 -0.638 . . . . 0.0 109.372 -179.673 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -96.04 131.45 10.66 Favored Glycine 0 N--CA 1.496 2.674 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.585 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.4 mp -80.81 126.41 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.332 -1.099 . . . . 0.0 109.251 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.441 HG13 HD22 ' A' ' 13' ' ' LEU . 74.9 t -80.61 132.78 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.542 -0.724 . . . . 0.0 109.645 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 24.2 t-20 -131.24 103.41 6.46 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.547 -0.721 . . . . 0.0 109.271 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 27.9 m -135.46 156.45 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.492 -0.755 . . . . 0.0 109.434 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 95.6 p -83.7 -10.96 57.8 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.488 -0.758 . . . . 0.0 109.3 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.501 ' OG ' ' N ' ' A' ' 12' ' ' SER . 86.4 p -138.37 -73.1 0.4 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.359 -0.838 . . . . 0.0 109.154 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.501 ' N ' ' OG ' ' A' ' 11' ' ' SER . 31.9 p -158.71 165.04 35.29 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.369 -0.832 . . . . 0.0 109.249 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.441 HD22 HG13 ' A' ' 7' ' ' VAL . 44.9 tp -113.83 131.47 56.23 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.482 -0.761 . . . . 0.0 109.028 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -91.07 146.43 23.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.406 -0.809 . . . . 0.0 109.885 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 65.1 t -99.3 130.1 48.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.504 ' NH1' ' O ' ' A' ' 21' ' ' THR . 93.0 mtt-85 -110.97 136.85 49.36 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.587 -0.695 . . . . 0.0 109.95 -179.346 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.5 ' OE2' HD13 ' A' ' 26' ' ' ILE . 66.3 mm-40 -80.58 -35.73 33.84 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.453 -0.779 . . . . 0.0 109.655 179.592 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -95.57 177.17 34.4 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.68 -5.42 42.31 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.402 -1.058 . . . . 0.0 109.083 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 33.5 t -86.16 153.67 21.89 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -0.852 . . . . 0.0 109.951 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.504 ' O ' ' NH1' ' A' ' 16' ' ' ARG . 15.3 m -63.67 -44.77 92.79 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.433 -0.792 . . . . 0.0 109.725 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 76.7 p -73.11 17.83 0.12 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.212 -0.93 . . . . 0.0 109.408 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.487 ' H ' ' C ' ' A' ' 21' ' ' THR . 17.3 m -64.65 149.22 49.4 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.239 -0.913 . . . . 0.0 109.788 -179.723 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 24.9 pttm -70.79 143.53 51.14 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.395 -0.815 . . . . 0.0 110.367 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 55.6 t -103.24 131.28 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.528 -0.732 . . . . 0.0 109.641 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.5 HD13 ' OE2' ' A' ' 17' ' ' GLU . 24.7 pt -99.01 -6.58 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.441 -0.787 . . . . 0.0 109.538 179.712 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.3 -159.81 33.27 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.8 m -152.92 167.11 30.23 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.436 -1.037 . . . . 0.0 109.571 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.9 mt -127.23 153.89 45.53 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.525 -0.734 . . . . 0.0 109.576 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.6 p -73.25 162.08 29.79 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.505 -0.747 . . . . 0.0 110.721 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.537 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -69.07 163.71 50.6 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -179.509 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 35.2 t-20 65.45 -13.95 0.12 Allowed 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.81 -0.818 . . . . 0.0 110.012 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.537 ' H ' ' C ' ' A' ' 31' ' ' GLY . 38.2 m -67.83 133.7 49.64 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.055 -1.028 . . . . 0.0 109.503 179.568 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.405 ' H ' ' HG2' ' A' ' 34' ' ' LYS . 19.5 pttp -93.81 146.57 23.78 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.353 -0.842 . . . . 0.0 109.651 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.1 m -122.86 131.46 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.618 -0.677 . . . . 0.0 109.424 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 33.6 m -66.13 128.85 37.73 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.526 -0.733 . . . . 0.0 110.352 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 94.2 mt -107.95 127.81 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.399 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 17.1 m -111.57 -1.06 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 O-C-N 121.567 -0.708 . . . . 0.0 109.468 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 178.75 -175.27 47.25 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -140.69 153.63 46.03 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.369 -1.077 . . . . 0.0 109.432 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 47.9 tp10 -151.64 112.06 4.15 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.326 -0.859 . . . . 0.0 109.506 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.96 -143.35 48.58 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.63 17.2 3.41 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.635 -0.92 . . . . 0.0 109.874 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -127.21 148.1 50.2 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.415 -0.803 . . . . 0.0 109.34 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -98.99 147.42 25.03 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.432 -0.792 . . . . 0.0 109.734 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -96.37 126.79 41.81 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.6 pt -128.95 156.36 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.503 -0.748 . . . . 0.0 109.952 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -90.27 117.69 29.2 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.488 -0.757 . . . . 0.0 109.418 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.537 ' O ' ' N ' ' A' ' 51' ' ' GLY . 53.1 t80 -106.49 101.96 11.39 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.551 -0.718 . . . . 0.0 109.358 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 7.7 mtmp? 43.51 -88.69 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.59 -0.693 . . . . 0.0 110.655 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.537 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -128.39 42.61 1.42 Allowed Glycine 0 N--CA 1.501 2.993 0 N-CA-C 109.784 -1.327 . . . . 0.0 109.784 -179.329 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 93.9 p -161.43 163.59 30.38 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.196 -1.179 . . . . 0.0 109.172 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -94.91 111.18 22.99 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.22 -0.925 . . . . 0.0 109.559 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.11 150.22 19.56 Favored Glycine 0 N--CA 1.494 2.546 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -128.41 139.6 52.28 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.627 -0.925 . . . . 0.0 109.473 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 28.8 m -136.19 156.21 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.436 -0.79 . . . . 0.0 109.826 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 147.18 39.49 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.484 -0.76 . . . . 0.0 110.465 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -69.18 -12.53 61.76 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.485 -0.76 . . . . 0.0 109.593 179.456 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -67.88 -35.27 78.22 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.22 -0.925 . . . . 0.0 110.499 -179.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.541 ' C ' HD12 ' A' ' 61' ' ' ILE . 19.8 m-85 -94.35 -4.49 48.47 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.906 -1.121 . . . . 0.0 110.336 -179.17 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.541 HD12 ' C ' ' A' ' 60' ' ' TYR . 1.6 mp -107.82 130.6 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.237 -0.914 . . . . 0.0 108.88 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.563 ' O ' ' N ' ' A' ' 64' ' ' ILE . 64.3 pttt -142.34 -168.11 2.65 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.478 -0.764 . . . . 0.0 109.077 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 56.26 -75.16 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 CA-C-O 120.986 0.422 . . . . 0.0 110.262 179.655 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.563 ' N ' ' O ' ' A' ' 62' ' ' LYS . 90.3 mt 57.49 81.08 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.445 -0.785 . . . . 0.0 109.369 -179.667 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -139.15 154.74 48.14 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.518 -0.739 . . . . 0.0 109.359 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -81.19 108.4 14.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.298 -0.876 . . . . 0.0 109.813 -179.527 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -103.67 -10.74 18.14 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.476 -0.765 . . . . 0.0 109.157 179.556 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.6 t -92.16 -21.19 6.37 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.239 -0.913 . . . . 0.0 109.396 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 70' ' ' GLU . 86.6 mt -89.91 137.49 32.3 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.357 -0.839 . . . . 0.0 109.917 -179.627 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.421 ' C ' ' O ' ' A' ' 69' ' ' LEU . 15.0 pt-20 35.16 -150.99 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.971 0 CA-C-O 121.661 0.743 . . . . 0.0 111.504 179.146 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 69.8 t60 54.82 92.29 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.392 -0.818 . . . . 0.0 109.451 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.571 ' O ' ' N ' ' A' ' 74' ' ' HIS . 59.0 t-80 -70.14 105.87 3.08 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.455 -0.778 . . . . 0.0 110.063 -179.718 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.601 ' ND1' ' ND1' ' A' ' 74' ' ' HIS . 62.4 t-80 51.3 -80.12 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.65 -0.656 . . . . 0.0 110.814 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . 0.601 ' ND1' ' ND1' ' A' ' 73' ' ' HIS . 21.2 p-80 -146.99 168.44 21.5 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.922 -1.111 . . . . 0.0 109.635 -179.293 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.524 ' CD2' ' H ' ' A' ' 75' ' ' HIS . 5.9 p80 -66.06 141.08 58.27 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.448 -0.782 . . . . 0.0 110.348 -179.177 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.5 m-70 . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 118.151 -0.928 . . . . 0.0 109.97 179.622 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.665 0.745 . . . . 0.0 109.938 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -71.74 155.28 40.63 Favored 'General case' 0 N--CA 1.491 1.583 0 CA-C-O 121.543 0.687 . . . . 0.0 110.237 -179.503 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.445 ' H ' ' HB ' ' A' ' 37' ' ' ILE . 68.6 mttm -136.54 154.9 50.58 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.486 -0.758 . . . . 0.0 109.566 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 42.5 p -107.22 114.93 29.29 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.777 0.798 . . . . 0.0 109.289 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.45 136.2 12.57 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.523 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.771 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.8 mp -86.38 120.84 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.568 -0.96 . . . . 0.0 109.445 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 99.5 t -82.58 104.35 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 CA-C-O 121.581 0.705 . . . . 0.0 109.354 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 -102.26 103.79 14.29 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.51 -0.744 . . . . 0.0 109.762 -179.57 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 34.7 m -137.46 164.05 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.57 -0.706 . . . . 0.0 109.832 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 79.8 p -63.25 -39.88 95.85 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.348 0.594 . . . . 0.0 109.755 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.442 ' O ' ' O ' ' A' ' 12' ' ' SER . 29.6 p -163.89 109.16 1.04 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.94 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.442 ' O ' ' O ' ' A' ' 11' ' ' SER . 1.4 m 52.48 166.82 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 CA-C-O 121.938 0.875 . . . . 0.0 111.156 179.634 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 37.1 tp -139.46 131.53 27.96 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.583 0.706 . . . . 0.0 109.853 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -79.52 141.86 36.29 Favored 'General case' 0 N--CA 1.489 1.493 0 CA-C-O 121.516 0.674 . . . . 0.0 109.933 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 75.3 t -98.78 130.62 47.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.54 -0.725 . . . . 0.0 109.718 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.509 ' NE ' ' O ' ' A' ' 21' ' ' THR . 85.1 mtt85 -103.58 134.09 47.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.468 -0.77 . . . . 0.0 109.73 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.1 tm-20 -71.58 -38.98 70.85 Favored 'General case' 0 N--CA 1.491 1.575 0 CA-C-O 121.596 0.713 . . . . 0.0 109.617 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -90.96 173.66 38.2 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.123 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -90.36 5.35 47.71 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.367 -1.079 . . . . 0.0 109.385 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.438 ' CB ' ' HG ' ' A' ' 23' ' ' SER . 7.2 p -78.66 166.64 22.28 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.319 -0.863 . . . . 0.0 110.38 -179.389 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.509 ' O ' ' NE ' ' A' ' 16' ' ' ARG . 0.7 OUTLIER -69.85 -20.71 63.4 Favored 'General case' 0 N--CA 1.491 1.596 0 CA-C-O 121.509 0.671 . . . . 0.0 109.664 179.807 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.7 t -151.11 63.76 0.9 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.009 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.438 ' HG ' ' CB ' ' A' ' 20' ' ' SER . 18.1 m -75.13 -79.42 0.09 Allowed 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.636 0.732 . . . . 0.0 109.447 179.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -160.56 121.17 2.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.218 -0.926 . . . . 0.0 109.935 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 75.7 t -74.97 129.3 36.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.496 0.665 . . . . 0.0 109.623 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 34.8 pt -119.6 -10.22 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.483 0.658 . . . . 0.0 109.24 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 179.47 -168.73 39.47 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.633 -1.27 . . . . 0.0 110.163 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 39.4 t -154.31 154.5 33.47 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.576 -0.955 . . . . 0.0 109.831 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.0 mt -122.71 150.56 42.57 Favored 'General case' 0 N--CA 1.495 1.806 0 CA-C-O 121.622 0.725 . . . . 0.0 109.544 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 17.1 m -69.45 151.31 46.24 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.851 0.834 . . . . 0.0 110.354 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.403 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -67.2 166.04 41.91 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 57.11 8.52 0.54 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 122.012 -0.699 . . . . 0.0 109.575 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.403 ' H ' ' C ' ' A' ' 31' ' ' GLY . 34.6 m -88.47 134.33 33.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.44 -0.788 . . . . 0.0 110.243 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -78.14 146.66 34.98 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.641 -0.662 . . . . 0.0 110.094 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.7 m -126.33 132.58 70.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 CA-C-O 121.621 0.724 . . . . 0.0 109.567 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 39.6 m -65.12 128.89 37.65 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.547 0.689 . . . . 0.0 110.116 -179.509 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.445 ' HB ' ' H ' ' A' ' 3' ' ' LYS . 5.4 mm -102.8 125.2 57.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 CA-C-O 121.442 0.639 . . . . 0.0 109.426 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 6.3 m -122.11 -11.83 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 179.55 -173.81 45.6 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.544 -1.312 . . . . 0.0 110.659 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -148.56 163.15 38.09 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.577 -0.955 . . . . 0.0 109.827 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -156.08 114.06 3.33 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.504 -0.748 . . . . 0.0 109.503 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 61.17 -136.5 48.14 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 179.582 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.418 ' C ' ' HZ2' ' A' ' 58' ' ' LYS . . . -92.34 28.91 1.8 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.527 -0.984 . . . . 0.0 108.719 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -134.5 150.35 50.78 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.621 -0.674 . . . . 0.0 109.435 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -105.37 139.63 39.7 Favored 'General case' 0 N--CA 1.493 1.715 0 CA-C-O 121.798 0.809 . . . . 0.0 109.703 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -96.86 129.19 44.33 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.9 pt -129.29 164.22 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 CA-C-O 121.727 0.775 . . . . 0.0 110.212 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -77.72 99.75 5.97 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-O 121.619 0.723 . . . . 0.0 109.94 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -90.36 134.77 34.1 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.515 -0.741 . . . . 0.0 109.484 179.521 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 56.6 mtpt -52.1 97.8 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.452 0.644 . . . . 0.0 110.422 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 121.46 -35.58 3.56 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 23.4 p -163.31 -153.96 0.26 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.141 -1.211 . . . . 0.0 110.076 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -106.4 118.6 37.08 Favored 'General case' 0 N--CA 1.496 1.835 0 CA-C-O 121.698 0.761 . . . . 0.0 109.999 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.83 145.55 17.67 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -115.86 136.86 52.64 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.807 -0.819 . . . . 0.0 109.781 179.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.6 m -138.09 154.57 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 CA-C-O 121.425 0.631 . . . . 0.0 109.679 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.5 ' HB3' ' CD2' ' A' ' 60' ' ' TYR . . . -72.97 149.52 43.27 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.845 0.831 . . . . 0.0 110.899 -179.492 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.418 ' HZ2' ' C ' ' A' ' 43' ' ' ALA . 57.1 mttp -63.1 -34.5 77.73 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.486 0.66 . . . . 0.0 109.99 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -53.67 -30.12 41.87 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.418 -0.801 . . . . 0.0 110.111 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.5 ' CD2' ' HB3' ' A' ' 57' ' ' ALA . 36.5 m-85 -90.03 -2.22 58.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.989 -1.069 . . . . 0.0 109.236 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.0 mm -107.64 127.41 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 CA-C-O 121.796 0.807 . . . . 0.0 109.854 -179.788 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -141.22 150.72 43.04 Favored 'General case' 0 N--CA 1.49 1.563 0 CA-C-O 121.77 0.795 . . . . 0.0 110.133 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.1 t0 56.62 59.5 3.54 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-O 121.652 0.739 . . . . 0.0 109.965 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 97.2 mt -75.4 98.63 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.409 -0.807 . . . . 0.0 109.505 179.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -141.85 155.95 45.54 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.608 0.718 . . . . 0.0 109.988 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -83.88 112.58 20.26 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -76.9 98.8 5.0 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.479 -0.763 . . . . 0.0 109.822 -179.47 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.2 m -152.37 -8.31 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -90.88 152.65 20.66 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.383 -0.823 . . . . 0.0 110.332 -179.706 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -57.37 152.29 14.57 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.699 0.761 . . . . 0.0 110.796 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 36.1 p-80 -148.02 165.33 31.07 Favored 'General case' 0 N--CA 1.491 1.622 0 CA-C-O 121.733 0.778 . . . . 0.0 110.279 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 84.9 t60 43.25 92.55 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.721 0 CA-C-O 121.94 0.876 . . . . 0.0 110.058 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 55.6 p-80 -72.3 128.57 36.05 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-O 121.495 0.664 . . . . 0.0 110.173 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . 0.466 ' O ' ' CG ' ' A' ' 74' ' ' HIS . 55.1 p-80 -103.07 112.53 25.41 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.52 -0.738 . . . . 0.0 109.666 -179.778 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 75.0 m80 -144.0 148.65 35.55 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.553 -0.717 . . . . 0.0 109.935 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.211 -0.9 . . . . 0.0 109.827 179.678 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.431 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 1' ' ' ALA . 97.3 mt-10 56.16 114.23 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.539 0.685 . . . . 0.0 110.33 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -132.85 151.0 52.1 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.596 -0.69 . . . . 0.0 109.762 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.8 p -116.21 118.32 32.49 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.556 -0.715 . . . . 0.0 109.367 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -105.52 131.5 10.68 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 -179.351 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.749 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.7 mp -84.91 126.04 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.41 -1.053 . . . . 0.0 109.477 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 74.0 t -75.2 129.03 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 O-C-N 121.318 -0.864 . . . . 0.0 109.938 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 65.0 t-20 -120.38 102.61 8.59 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.1 m -137.09 160.75 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.455 -0.778 . . . . 0.0 109.826 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 87.3 p -82.8 -13.09 56.88 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.524 -0.735 . . . . 0.0 109.266 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.7 m -145.69 -69.41 0.28 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.277 -0.889 . . . . 0.0 109.297 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 58.3 m -156.84 168.86 26.19 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.062 -1.024 . . . . 0.0 109.825 -179.564 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 49.8 tp -116.46 129.76 56.39 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-O 121.656 0.741 . . . . 0.0 109.838 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . 0.436 ' O ' ' OD1' ' A' ' 14' ' ' ASN . 15.1 p30 -89.1 122.12 32.1 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.433 -0.792 . . . . 0.0 109.778 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 61.0 t -76.49 153.54 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.364 -0.835 . . . . 0.0 109.864 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.562 HH22 ' HB2' ' A' ' 57' ' ' ALA . 88.9 mtm180 -128.54 136.47 50.8 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.567 -0.708 . . . . 0.0 109.809 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 12.6 tm-20 -69.95 -38.8 76.23 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.548 -0.72 . . . . 0.0 109.138 179.464 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -104.78 -178.86 24.6 Favored Glycine 0 N--CA 1.496 2.652 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 -179.236 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -94.5 -0.88 54.32 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.493 -1.004 . . . . 0.0 108.569 179.261 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.2 m -84.69 151.53 24.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.307 -0.871 . . . . 0.0 110.022 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 59.0 p -68.96 -29.08 67.23 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.55 -0.719 . . . . 0.0 109.612 179.421 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 96.7 p -85.65 7.47 23.25 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.278 -0.889 . . . . 0.0 109.257 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.0 t -62.42 146.44 51.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.434 -0.791 . . . . 0.0 110.759 -179.278 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -68.77 137.45 54.02 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-O 121.723 0.773 . . . . 0.0 110.954 -179.339 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 69.9 t -80.37 131.59 33.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 121.595 -0.691 . . . . 0.0 110.049 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 23.1 pt -102.21 -4.27 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.507 -0.746 . . . . 0.0 109.029 179.518 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 161.72 -177.09 38.12 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.483 -1.342 . . . . 0.0 109.959 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 57.8 m -132.91 159.55 39.58 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.47 -1.018 . . . . 0.0 109.732 -179.674 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.536 HD21 ' CE1' ' A' ' 49' ' ' TYR . 95.9 mt -120.07 149.55 42.0 Favored 'General case' 0 N--CA 1.496 1.87 0 CA-C-O 121.661 0.743 . . . . 0.0 109.884 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.8 m -74.24 161.42 29.95 Favored 'General case' 0 N--CA 1.489 1.488 0 CA-C-O 121.863 0.839 . . . . 0.0 110.739 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -63.09 149.41 49.79 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 111.339 -0.704 . . . . 0.0 111.339 -179.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.9 m-20 57.09 32.93 22.53 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.792 -0.828 . . . . 0.0 109.73 179.709 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 25.3 m -90.77 126.63 36.06 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.241 -0.912 . . . . 0.0 109.772 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.5 ttmt -80.3 132.89 35.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.428 -0.795 . . . . 0.0 109.716 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.1 m -124.03 131.96 72.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.579 -0.701 . . . . 0.0 109.734 179.794 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 61.1 m -80.04 128.21 33.21 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-O 121.426 0.631 . . . . 0.0 109.979 -179.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.7 mt -97.37 124.68 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.56 -0.712 . . . . 0.0 109.875 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 34.4 m -110.18 -0.84 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.477 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -175.2 178.01 47.01 Favored Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.637 -1.268 . . . . 0.0 110.2 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -142.74 153.58 43.45 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.08 -1.247 . . . . 0.0 109.527 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.408 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 12.9 tm-20 -151.9 107.6 3.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.47 179.367 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.37 -137.39 45.19 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 179.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -84.64 26.01 0.85 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.437 -1.037 . . . . 0.0 109.098 -179.341 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -132.02 145.19 51.29 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.559 -0.713 . . . . 0.0 109.412 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -106.95 139.46 41.31 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.615 0.722 . . . . 0.0 109.455 179.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -93.09 130.44 38.71 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.557 -0.714 . . . . 0.0 109.174 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 37.2 pt -131.26 154.22 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.611 -0.681 . . . . 0.0 110.044 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -90.86 96.57 10.7 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.519 -0.738 . . . . 0.0 109.127 179.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.536 ' CE1' HD21 ' A' ' 29' ' ' LEU . 73.4 t80 -107.33 123.54 48.49 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.507 -0.746 . . . . 0.0 109.953 -179.728 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 74.3 tttt 51.49 34.54 12.44 Favored 'General case' 0 N--CA 1.493 1.678 0 CA-C-O 121.292 0.568 . . . . 0.0 109.944 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.41 -11.84 11.84 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 178.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 26.4 t -91.84 174.02 7.55 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.256 -1.144 . . . . 0.0 110.333 -179.513 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -97.37 101.53 13.09 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.36 -0.837 . . . . 0.0 109.639 -179.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.26 137.79 13.52 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -119.73 137.39 53.97 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.411 -1.052 . . . . 0.0 109.585 179.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.2 m -139.45 154.76 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.276 -0.89 . . . . 0.0 109.822 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.562 ' HB2' HH22 ' A' ' 16' ' ' ARG . . . -73.83 146.98 43.76 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.406 -0.809 . . . . 0.0 110.584 -179.762 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -66.21 -11.37 49.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.62 -0.675 . . . . 0.0 109.682 179.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -67.35 -34.57 77.59 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.222 -0.924 . . . . 0.0 109.779 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -90.71 3.3 54.64 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.209 -0.932 . . . . 0.0 109.487 -179.197 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 38.3 mm -103.47 129.68 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.346 -0.846 . . . . 0.0 109.939 -179.52 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -146.24 154.91 42.26 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.42 -0.8 . . . . 0.0 109.912 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.6 t0 63.11 52.8 2.43 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 121.555 0.693 . . . . 0.0 109.42 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt -78.09 123.37 34.78 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 121.524 -0.735 . . . . 0.0 109.649 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 19.2 tptm -140.43 142.61 35.39 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.35 -0.844 . . . . 0.0 109.742 179.734 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.526 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 1.9 m-20 -85.14 118.29 24.61 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.414 -0.804 . . . . 0.0 110.29 -179.516 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.428 ' O ' ' O ' ' A' ' 68' ' ' VAL . 97.5 mt-10 -94.86 -14.5 24.51 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 179.365 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.624 HG12 ' N ' ' A' ' 69' ' ' LEU . 43.5 t 52.01 169.28 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 CA-C-O 121.884 0.849 . . . . 0.0 110.889 179.345 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.624 ' N ' HG12 ' A' ' 68' ' ' VAL . 4.2 tt -68.58 105.14 2.15 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.381 -0.824 . . . . 0.0 109.781 -179.13 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.406 ' C ' ' O ' ' A' ' 69' ' ' LEU . 93.3 mt-10 40.28 85.45 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.85 0 CA-C-O 121.623 0.725 . . . . 0.0 110.471 179.581 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.405 ' ND1' ' N ' ' A' ' 71' ' ' HIS . 0.0 OUTLIER -90.76 164.45 14.1 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.449 -0.782 . . . . 0.0 109.923 -179.731 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.479 ' CD2' ' N ' ' A' ' 72' ' ' HIS . 2.8 p80 -146.89 133.43 19.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.07 179.49 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.495 ' C ' ' H ' ' A' ' 75' ' ' HIS . 95.9 m-70 -112.44 109.01 18.36 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.433 -0.792 . . . . 0.0 109.626 -179.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . 0.472 ' ND1' ' O ' ' A' ' 74' ' ' HIS . 60.9 t-80 53.62 6.04 0.07 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.626 -0.672 . . . . 0.0 109.762 -179.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.495 ' H ' ' C ' ' A' ' 73' ' ' HIS . 81.0 t60 -89.88 135.79 33.42 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.239 -0.913 . . . . 0.0 109.746 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 86.3 t60 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.156 -179.635 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.488 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -75.86 137.29 40.35 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.48 -0.763 . . . . 0.0 110.343 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt -130.29 145.96 51.83 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 70.2 p -132.16 133.55 44.37 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.576 -0.703 . . . . 0.0 109.643 -179.539 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -121.61 131.71 8.66 Favored Glycine 0 N--CA 1.499 2.876 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.751 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.8 mp -86.35 127.65 40.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.075 -1.25 . . . . 0.0 110.005 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 71.5 t -75.61 131.09 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 110.186 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.6 t-20 -123.74 108.23 12.3 Favored 'General case' 0 N--CA 1.497 1.905 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.52 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' A' ' 11' ' ' SER . 29.3 m -152.96 -19.47 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 179.618 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.8 t 67.97 -52.84 0.52 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.79 -0.569 . . . . 0.0 109.677 -179.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.448 ' N ' ' O ' ' A' ' 9' ' ' VAL . 74.0 m -77.92 -79.41 0.12 Allowed 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.382 -0.824 . . . . 0.0 109.751 -179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 31.2 t -168.45 156.06 7.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.43 -0.794 . . . . 0.0 109.332 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 49.5 tp -123.58 130.28 52.43 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.56 -0.713 . . . . 0.0 109.317 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -84.16 154.48 23.08 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.361 -0.837 . . . . 0.0 109.79 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 54.4 t -105.95 130.14 57.97 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.445 -0.784 . . . . 0.0 109.276 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.723 HH21 ' N ' ' A' ' 20' ' ' SER . 42.4 mtp180 -104.64 128.05 52.57 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.476 -0.765 . . . . 0.0 109.699 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -72.06 -43.16 65.35 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.479 -0.763 . . . . 0.0 109.612 179.68 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -100.32 -175.48 30.1 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.125 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.488 ' C ' HH21 ' A' ' 16' ' ' ARG . . . -97.01 39.59 1.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.505 -0.997 . . . . 0.0 108.944 179.589 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.723 ' N ' HH21 ' A' ' 16' ' ' ARG . 33.0 t -131.86 149.87 52.32 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.554 -0.716 . . . . 0.0 109.72 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 53.1 p -65.11 -31.27 72.39 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.507 -0.746 . . . . 0.0 109.64 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 96.6 p -86.55 13.34 8.63 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.262 -0.899 . . . . 0.0 108.993 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.9 m -62.2 151.13 36.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.442 -0.786 . . . . 0.0 110.442 -179.209 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 17.7 ttmm -64.97 136.83 57.27 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.503 -0.748 . . . . 0.0 110.941 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 97.4 t -90.86 116.73 32.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 38.3 pt -103.73 -4.76 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.514 -0.741 . . . . 0.0 109.699 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -178.69 -175.5 45.81 Favored Glycine 0 N--CA 1.49 2.253 0 C-N-CA 119.316 -1.421 . . . . 0.0 110.615 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.9 p -158.55 166.1 32.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.558 -0.966 . . . . 0.0 109.004 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 86.3 mt -123.21 153.92 39.45 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.446 -0.784 . . . . 0.0 109.926 -179.552 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 73.5 m -80.53 -3.54 50.53 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.663 -0.648 . . . . 0.0 109.334 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.488 ' C ' ' H ' ' A' ' 33' ' ' THR . . . 95.19 164.27 34.91 Favored Glycine 0 N--CA 1.498 2.772 0 O-C-N 121.304 -0.872 . . . . 0.0 111.031 178.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 55.7 2.37 0.07 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.753 -0.851 . . . . 0.0 110.033 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.488 ' H ' ' C ' ' A' ' 31' ' ' GLY . 54.0 m -85.01 133.1 34.26 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.122 -0.986 . . . . 0.0 109.578 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 8.3 ttpm? -80.4 136.79 36.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.341 -0.849 . . . . 0.0 109.964 -179.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.9 m -121.24 130.6 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 CA-C-O 121.506 0.669 . . . . 0.0 109.298 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 53.9 m -73.48 133.12 43.58 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.629 -0.669 . . . . 0.0 110.092 -179.511 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 97.6 mt -109.66 127.7 66.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 CA-C-O 121.362 0.601 . . . . 0.0 109.491 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -111.54 -1.12 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.42 176.08 45.44 Favored Glycine 0 N--CA 1.49 2.289 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.244 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 -140.13 153.14 46.59 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.346 -1.091 . . . . 0.0 109.828 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.413 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 12.5 tm-20 -151.08 106.93 3.4 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.229 -0.919 . . . . 0.0 109.385 179.71 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 58.82 -138.69 49.23 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.214 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -83.45 5.05 25.13 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.594 -0.945 . . . . 0.0 109.271 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.448 ' CE1' ' NH1' ' A' ' 16' ' ' ARG . 96.6 m-85 -114.5 141.76 47.28 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.69 -0.631 . . . . 0.0 109.539 -179.636 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -107.86 150.72 26.69 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.664 -0.648 . . . . 0.0 109.666 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.5 mtpm? -91.35 139.16 30.99 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.501 -0.749 . . . . 0.0 109.024 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 38.8 pt -134.05 149.82 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.515 -0.741 . . . . 0.0 109.852 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -86.8 95.03 9.71 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.372 -0.83 . . . . 0.0 108.919 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 84.0 t80 -104.6 116.07 31.44 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.382 -0.824 . . . . 0.0 109.196 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 49.2 tttm 52.39 32.19 10.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.614 -0.679 . . . . 0.0 109.695 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 88.36 -20.92 27.71 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 87.2 p -83.3 166.18 18.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.237 -1.155 . . . . 0.0 110.228 -179.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 61.9 m170 -101.62 95.72 6.63 Favored 'General case' 0 N--CA 1.495 1.788 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -88.19 162.9 32.62 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 -179.163 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -122.18 138.02 54.62 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.768 -0.843 . . . . 0.0 109.227 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 20.7 m -137.29 153.61 29.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.333 -0.854 . . . . 0.0 109.647 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.01 139.77 46.87 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.509 -0.744 . . . . 0.0 110.274 -179.475 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -69.2 -12.43 61.67 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.37 -0.831 . . . . 0.0 109.604 179.336 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -63.09 -32.14 73.45 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.44 -0.788 . . . . 0.0 110.353 -179.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -99.17 5.91 46.61 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 109.828 -179.37 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.5 mm -105.18 128.59 58.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.934 0 O-C-N 121.296 -0.877 . . . . 0.0 109.515 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -141.65 164.29 30.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.466 -0.771 . . . . 0.0 110.17 -179.39 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 56.32 52.03 10.71 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.191 0.519 . . . . 0.0 110.137 179.714 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt -79.43 122.08 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.249 -0.907 . . . . 0.0 109.319 179.352 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.9 ptpp? -142.85 150.72 40.26 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.288 -0.882 . . . . 0.0 109.885 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -69.27 140.54 54.45 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.502 -0.749 . . . . 0.0 110.351 -179.406 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.445 ' O ' ' O ' ' A' ' 68' ' ' VAL . 39.9 tp10 -80.08 61.91 4.09 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.333 -0.854 . . . . 0.0 109.365 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.445 ' O ' ' O ' ' A' ' 67' ' ' GLU . 5.3 t 58.55 127.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 CA-C-O 121.654 0.74 . . . . 0.0 110.731 179.807 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 83.6 mt -72.31 142.31 48.84 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.459 -0.776 . . . . 0.0 109.551 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -156.79 86.04 0.98 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.355 -0.841 . . . . 0.0 108.902 179.665 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 59.9 m170 42.09 90.29 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.652 -0.655 . . . . 0.0 110.108 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 9.3 p80 -67.76 138.4 56.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.352 -0.843 . . . . 0.0 110.074 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -74.51 132.36 41.79 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.3 -0.875 . . . . 0.0 110.433 -179.313 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 81.4 t60 -152.0 139.51 19.6 Favored 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.549 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 97.8 m-70 -106.67 136.5 46.37 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.344 -0.847 . . . . 0.0 109.858 -179.531 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 76.2 m80 . . . . . 0 N--CA 1.488 1.47 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.658 179.942 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.639 0.733 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.621 ' H ' ' CD ' ' A' ' 2' ' ' GLU . 1.0 OUTLIER -86.88 154.16 21.06 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.397 -0.814 . . . . 0.0 110.133 -179.401 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -123.4 157.14 34.04 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.729 -0.607 . . . . 0.0 109.496 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 52.8 p -131.55 115.02 15.58 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.619 0.724 . . . . 0.0 109.363 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.455 ' C ' HD12 ' A' ' 6' ' ' ILE . . . -91.18 137.65 13.94 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 -179.491 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.698 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.5 mp -92.22 122.22 43.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.618 -0.931 . . . . 0.0 109.398 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.0 t -78.22 132.46 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 O-C-N 121.512 -0.743 . . . . 0.0 110.045 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.6 t-20 -137.72 110.16 7.45 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.519 -0.738 . . . . 0.0 109.351 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.3 m -144.62 149.89 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.394 -0.816 . . . . 0.0 109.607 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 39.8 t -63.66 -43.85 95.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.546 -0.721 . . . . 0.0 110.05 179.837 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 24.6 t -109.43 -76.15 0.62 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.555 -0.715 . . . . 0.0 110.09 -179.204 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 92.1 p -156.73 165.54 35.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 -179.244 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.3 tp -115.17 128.28 56.09 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.761 0.791 . . . . 0.0 109.952 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -84.16 149.9 25.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.586 -0.696 . . . . 0.0 110.055 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.0 t -99.91 131.23 47.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.318 -0.864 . . . . 0.0 109.261 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.432 ' CZ ' ' O ' ' A' ' 21' ' ' THR . 99.7 mtt180 -103.84 135.25 45.74 Favored 'General case' 0 N--CA 1.494 1.758 0 CA-C-O 121.777 0.799 . . . . 0.0 110.099 -179.282 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 46.5 tp10 -70.87 -45.33 64.59 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.554 0.693 . . . . 0.0 109.508 179.715 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.08 172.93 26.01 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 -179.303 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -91.59 11.22 24.96 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.472 -1.016 . . . . 0.0 108.727 179.391 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.1 m -73.87 170.86 14.48 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.333 -0.855 . . . . 0.0 110.305 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.432 ' O ' ' CZ ' ' A' ' 16' ' ' ARG . 18.3 m -62.94 -44.82 95.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.576 -0.702 . . . . 0.0 109.996 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.3 t -131.12 71.12 1.46 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.352 -0.843 . . . . 0.0 109.235 -179.648 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.7 t -83.14 176.66 9.03 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-O 121.659 0.742 . . . . 0.0 110.419 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 65.7 tttm -63.72 133.76 54.12 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-O 121.797 0.808 . . . . 0.0 110.569 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 67.0 t -97.62 128.91 48.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.515 -0.74 . . . . 0.0 109.413 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 39.8 pt -105.19 -4.44 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.673 -0.642 . . . . 0.0 109.342 179.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 170.91 -156.84 27.36 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.368 -1.396 . . . . 0.0 110.491 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 92.9 p -157.43 164.92 36.96 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.425 -1.044 . . . . 0.0 109.515 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.404 HD21 ' CE1' ' A' ' 49' ' ' TYR . 97.4 mt -126.65 148.69 49.79 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-O 121.746 0.784 . . . . 0.0 110.021 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 19.4 m -73.59 156.6 37.9 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-O 121.807 0.813 . . . . 0.0 110.55 -179.4 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.17 156.19 38.09 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 65.3 t30 58.14 33.9 23.63 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.688 -0.889 . . . . 0.0 109.873 179.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 24.1 m -97.55 132.39 43.27 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.333 -0.855 . . . . 0.0 109.761 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -80.93 128.73 34.01 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.525 -0.734 . . . . 0.0 110.096 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.8 m -128.24 134.19 65.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.589 -0.694 . . . . 0.0 109.504 179.466 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 34.4 m -82.27 124.98 30.44 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.486 -0.758 . . . . 0.0 109.426 -179.662 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.8 mt -99.41 136.15 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 CA-C-O 121.608 0.718 . . . . 0.0 110.433 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 34.1 m -110.44 -6.93 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 165.79 -174.67 41.49 Favored Glycine 0 N--CA 1.489 2.189 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.359 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -140.91 147.2 38.5 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.459 -1.024 . . . . 0.0 109.205 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.513 ' N ' ' OE1' ' A' ' 41' ' ' GLU . 56.9 mp0 -145.87 120.67 9.91 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.29 -0.881 . . . . 0.0 110.153 -179.454 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.654 ' O ' ' HB3' ' A' ' 43' ' ' ALA . . . 70.19 31.08 69.13 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.654 ' HB3' ' O ' ' A' ' 42' ' ' GLY . . . 77.4 11.03 2.28 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.524 -0.986 . . . . 0.0 109.136 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.464 ' CD2' ' O ' ' A' ' 42' ' ' GLY . 99.2 m-85 -114.03 131.6 56.3 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.653 -0.654 . . . . 0.0 109.319 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -79.47 139.71 37.54 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.615 -0.678 . . . . 0.0 109.963 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -100.56 120.05 39.44 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.495 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.5 pt -125.07 161.63 28.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 CA-C-O 121.748 0.785 . . . . 0.0 110.45 -179.076 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.474 ' CD ' ' H ' ' A' ' 48' ' ' GLU . 0.0 OUTLIER -90.17 124.31 34.72 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 121.269 0.557 . . . . 0.0 109.649 -179.588 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.404 ' CE1' HD21 ' A' ' 29' ' ' LEU . 81.9 t80 -132.99 120.82 21.88 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.459 -0.776 . . . . 0.0 109.861 179.611 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 76.5 tttt 39.03 47.38 1.26 Allowed 'General case' 0 N--CA 1.496 1.846 0 CA-C-O 121.687 0.756 . . . . 0.0 110.427 179.424 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 86.3 -50.67 4.28 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 179.615 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 16.7 m -74.46 145.16 43.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -1.132 . . . . 0.0 110.51 -179.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -83.94 120.54 26.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.393 -0.817 . . . . 0.0 109.915 -179.665 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.12 148.45 18.99 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -115.23 142.68 46.34 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.689 -0.889 . . . . 0.0 109.846 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.4 m -140.94 153.6 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.491 -0.756 . . . . 0.0 109.525 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.85 140.23 43.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.408 -0.808 . . . . 0.0 110.247 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 7.2 ptmm? -65.45 -9.23 23.82 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.516 -0.74 . . . . 0.0 109.744 179.615 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.53 -21.09 62.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.797 . . . . 0.0 110.164 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.489 ' C ' HD12 ' A' ' 61' ' ' ILE . 65.5 m-85 -104.97 -23.26 13.0 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.268 -0.895 . . . . 0.0 109.582 -179.435 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.668 ' N ' HD12 ' A' ' 61' ' ' ILE . 1.6 mp -97.07 130.87 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.26 -0.9 . . . . 0.0 109.841 -179.706 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.473 ' O ' ' N ' ' A' ' 64' ' ' ILE . 23.0 pttp -134.98 -165.35 1.66 Allowed 'General case' 0 N--CA 1.494 1.739 0 CA-C-O 121.474 0.654 . . . . 0.0 109.697 179.579 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 59.17 -78.27 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.771 0 CA-C-O 121.151 0.5 . . . . 0.0 109.986 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.473 ' N ' ' O ' ' A' ' 62' ' ' LYS . 97.2 mt 57.42 87.63 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 CA-C-O 121.44 0.638 . . . . 0.0 109.842 -179.35 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 63.3 tttp -139.56 133.61 31.02 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.379 -0.826 . . . . 0.0 109.752 179.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.407 ' OD1' ' O ' ' A' ' 66' ' ' ASP . 40.9 p-10 -67.12 122.82 18.65 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 121.577 0.703 . . . . 0.0 110.183 -179.759 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 32.6 tp10 -99.18 -13.77 19.6 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.417 -0.802 . . . . 0.0 109.061 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.418 ' C ' HD12 ' A' ' 69' ' ' LEU . 11.2 t -88.9 99.38 9.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.231 -0.918 . . . . 0.0 109.487 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.562 ' N ' HD12 ' A' ' 69' ' ' LEU . 10.4 mp -100.13 11.47 39.28 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.516 -0.74 . . . . 0.0 109.17 -179.685 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 71.8 mm-40 57.66 92.87 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.673 0.749 . . . . 0.0 109.86 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 34.6 p80 -68.44 140.21 55.75 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 121.711 0.767 . . . . 0.0 110.736 -179.425 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.625 ' CE1' ' NE2' ' A' ' 73' ' ' HIS . 14.2 t-160 -159.24 -29.23 0.07 Allowed 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.405 -0.809 . . . . 0.0 109.306 179.209 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.625 ' NE2' ' CE1' ' A' ' 72' ' ' HIS . 95.9 m-70 -150.97 159.86 44.3 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.092 -1.005 . . . . 0.0 110.302 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 32.6 p-80 -151.5 162.16 41.45 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.265 -0.897 . . . . 0.0 109.945 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 35.1 p-80 -136.61 89.57 2.47 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.462 -0.773 . . . . 0.0 109.564 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 . . . . . 0 N--CA 1.493 1.725 0 CA-C-O 118.119 -0.944 . . . . 0.0 110.355 179.685 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -66.96 137.38 56.48 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.422 -0.799 . . . . 0.0 110.386 -179.493 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -136.69 151.35 49.16 Favored 'General case' 0 N--CA 1.496 1.854 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.654 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.419 ' OG1' ' O ' ' A' ' 65' ' ' LYS . 25.7 p -123.57 128.61 49.98 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.519 -0.738 . . . . 0.0 109.682 -179.474 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -107.97 129.87 9.82 Favored Glycine 0 N--CA 1.497 2.746 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.676 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.6 mp -80.14 126.3 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.185 -1.185 . . . . 0.0 109.292 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.2 t -81.74 131.62 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.274 -0.891 . . . . 0.0 110.186 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.2 m120 -120.2 100.07 6.97 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 179.476 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.7 m -141.01 136.27 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.875 0 O-C-N 121.302 -0.874 . . . . 0.0 109.577 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 t -61.99 -44.86 95.85 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.576 -0.702 . . . . 0.0 109.707 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 68.0 m -99.3 -79.72 0.48 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.557 -0.715 . . . . 0.0 109.456 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 59.9 m -158.92 172.29 18.48 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.359 -0.838 . . . . 0.0 109.389 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.0 tp -116.27 131.48 56.93 Favored 'General case' 0 N--CA 1.5 2.055 0 CA-C-O 121.479 0.657 . . . . 0.0 109.516 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 26.5 p30 -90.86 153.86 19.9 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.393 -0.817 . . . . 0.0 109.655 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 53.7 t -105.3 130.28 56.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.39 -0.819 . . . . 0.0 108.842 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.489 HH22 ' H ' ' A' ' 57' ' ' ALA . 91.0 mtm-85 -112.11 137.94 49.47 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.533 -0.729 . . . . 0.0 109.502 -179.538 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 69.8 mm-40 -86.48 -29.35 22.83 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.463 -0.773 . . . . 0.0 109.193 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -98.46 148.39 18.85 Favored Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.701 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -82.63 73.17 9.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.313 -1.11 . . . . 0.0 109.325 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.1 m -159.15 -169.43 2.65 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.127 -0.983 . . . . 0.0 109.55 179.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 65.9 p -80.71 101.56 9.36 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.277 -0.889 . . . . 0.0 109.785 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.6 t 56.6 52.36 9.86 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.77 -0.582 . . . . 0.0 109.854 179.398 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 77.9 p -62.31 -42.97 99.81 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.301 -0.875 . . . . 0.0 109.313 179.551 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 33.2 ttpt -170.6 115.94 0.48 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.262 -0.899 . . . . 0.0 109.443 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.3 t -90.45 130.22 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.527 -0.733 . . . . 0.0 109.737 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.9 pt -117.37 -11.63 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.32 -162.54 31.36 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.187 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 36.9 t -155.44 168.49 26.95 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.321 -1.105 . . . . 0.0 109.868 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 95.2 mt -127.3 152.74 47.04 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.607 -0.683 . . . . 0.0 109.721 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.6 m -71.4 152.95 42.66 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.609 -0.682 . . . . 0.0 110.368 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -61.86 160.45 29.91 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 -179.176 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 64.4 t30 62.06 4.92 1.29 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.941 -0.741 . . . . 0.0 109.874 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 66.7 m -82.74 130.81 35.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.077 -1.014 . . . . 0.0 109.958 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -86.81 147.46 25.81 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.316 -0.865 . . . . 0.0 109.576 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.3 m -123.34 132.97 70.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.431 -0.793 . . . . 0.0 109.458 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 36.2 m -69.92 130.68 42.87 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.744 -0.598 . . . . 0.0 110.065 -179.352 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.2 mt -109.34 129.17 64.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 29.3 m -120.59 5.24 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 179.591 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.68 177.4 45.25 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 119.531 -1.318 . . . . 0.0 110.463 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -126.69 153.74 45.04 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.676 -0.896 . . . . 0.0 109.247 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' A' ' 41' ' ' GLU . 8.1 tm-20 -151.03 93.47 1.93 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.158 -0.963 . . . . 0.0 109.892 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 51.97 -133.27 36.82 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 178.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.81 25.38 1.11 Allowed 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.623 -0.928 . . . . 0.0 108.941 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -138.07 134.62 34.95 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.691 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 44.7 m-85 -89.08 144.89 25.82 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.18 -0.95 . . . . 0.0 109.803 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -90.88 129.49 36.92 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.444 -0.785 . . . . 0.0 109.031 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 39.2 pt -128.46 154.26 39.01 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.592 -0.693 . . . . 0.0 110.06 -179.699 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -87.52 93.74 9.51 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.518 -0.739 . . . . 0.0 109.099 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -92.92 152.74 19.2 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.232 -0.917 . . . . 0.0 110.009 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 41.2 tttp -55.46 119.87 6.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.332 -0.855 . . . . 0.0 110.462 -179.37 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 104.4 -46.3 1.2 Allowed Glycine 0 N--CA 1.496 2.66 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.665 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 95.9 p -163.34 177.92 8.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.121 -1.223 . . . . 0.0 109.953 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -81.08 119.74 23.93 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.2 -0.937 . . . . 0.0 109.452 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.72 165.49 32.17 Favored Glycine 0 N--CA 1.496 2.697 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 -179.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -123.42 138.22 54.64 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.762 -0.846 . . . . 0.0 109.455 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.1 m -137.35 140.76 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.535 -0.728 . . . . 0.0 109.534 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.489 ' H ' HH22 ' A' ' 16' ' ' ARG . . . -68.41 151.0 47.47 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.517 -0.739 . . . . 0.0 110.794 -179.291 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 45.3 mtmt -62.6 -28.91 70.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.573 -0.704 . . . . 0.0 109.184 179.49 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -58.95 -34.43 71.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.474 -0.766 . . . . 0.0 110.418 -178.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -89.73 -1.99 58.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.019 -1.051 . . . . 0.0 109.466 -179.345 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 43.7 mm -112.59 130.29 66.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.616 -0.678 . . . . 0.0 109.828 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -136.47 142.17 43.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.65 -0.656 . . . . 0.0 109.694 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 44.6 t0 62.43 77.99 0.31 Allowed 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.296 0.57 . . . . 0.0 109.899 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 82.2 mt -81.95 77.68 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.457 -0.777 . . . . 0.0 109.158 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.419 ' O ' ' OG1' ' A' ' 4' ' ' THR . 63.9 mttp -143.08 157.58 44.4 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.297 -0.877 . . . . 0.0 109.723 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -86.24 109.48 18.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.451 -0.78 . . . . 0.0 109.33 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 45.6 tp10 -90.21 -77.35 0.4 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.331 -0.856 . . . . 0.0 109.48 -179.722 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 13.7 p -172.29 152.83 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.297 -0.877 . . . . 0.0 109.767 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 78.7 mt -66.49 145.0 56.14 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.356 -0.84 . . . . 0.0 110.346 -179.163 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -55.18 136.88 48.11 Favored 'General case' 0 N--CA 1.491 1.581 0 CA-C-O 121.565 0.698 . . . . 0.0 110.332 -179.244 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.617 ' CD2' ' H ' ' A' ' 73' ' ' HIS . 49.0 t60 -80.77 165.11 22.21 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.452 -0.78 . . . . 0.0 110.438 -179.539 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.501 ' N ' ' CG ' ' A' ' 71' ' ' HIS . 76.5 m80 -65.8 -39.93 91.41 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.581 -0.699 . . . . 0.0 109.812 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.617 ' H ' ' CD2' ' A' ' 71' ' ' HIS . 80.3 m80 -105.18 137.63 42.65 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.446 -0.784 . . . . 0.0 109.775 -179.335 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 62.4 m170 -48.48 172.13 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.668 0 CA-C-O 121.788 0.804 . . . . 0.0 111.473 -178.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 47.5 p-80 -59.38 -41.3 89.01 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.645 -0.659 . . . . 0.0 109.741 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 56.8 t-80 . . . . . 0 N--CA 1.488 1.469 0 CA-C-O 117.916 -1.04 . . . . 0.0 109.248 179.939 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.431 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.486 0 CA-C-O 121.542 0.686 . . . . 0.0 110.01 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 1' ' ' ALA . 44.7 tt0 58.76 147.47 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 CA-C-O 121.577 0.703 . . . . 0.0 110.138 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.49 ' NZ ' ' OD1' ' A' ' 66' ' ' ASP . 68.6 mttm -137.56 151.64 48.59 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.759 -0.588 . . . . 0.0 109.786 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 69.3 p -117.05 113.96 23.07 Favored 'General case' 0 N--CA 1.498 1.973 0 CA-C-O 121.898 0.856 . . . . 0.0 110.038 -179.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -103.06 130.73 10.35 Favored Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.4 mm -87.53 127.66 40.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.901 -0.764 . . . . 0.0 109.957 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.2 t -71.93 130.56 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 CA-C-O 121.467 0.651 . . . . 0.0 109.725 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.413 ' OD1' ' NZ ' ' A' ' 62' ' ' LYS . 56.0 t30 -123.39 101.93 7.62 Favored 'General case' 0 N--CA 1.497 1.894 0 CA-C-O 121.311 0.577 . . . . 0.0 109.642 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 30.5 m -148.18 158.19 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 121.611 0.719 . . . . 0.0 110.146 179.001 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 58.6 m -87.94 -16.81 32.81 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.859 -0.525 . . . . 0.0 109.976 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 12' ' ' SER . 66.4 m -155.38 87.79 1.12 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.422 -0.799 . . . . 0.0 110.326 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.433 ' O ' ' O ' ' A' ' 11' ' ' SER . 1.3 m 46.73 -179.99 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 CA-C-O 121.724 0.773 . . . . 0.0 110.99 178.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 37.8 tp -144.59 130.55 19.34 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.681 0.753 . . . . 0.0 109.846 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -83.31 132.37 35.02 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-O 121.721 0.772 . . . . 0.0 110.053 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 86.7 t -81.18 131.99 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 CA-C-O 121.708 0.766 . . . . 0.0 109.73 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.594 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 93.5 mtm-85 -106.42 135.15 48.42 Favored 'General case' 0 N--CA 1.493 1.688 0 CA-C-O 121.762 0.791 . . . . 0.0 109.897 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.513 ' N ' ' OG ' ' A' ' 23' ' ' SER . 82.8 tt0 -99.52 77.4 2.09 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.645 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.38 170.89 16.7 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 179.413 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -88.66 4.87 45.63 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.7 -0.882 . . . . 0.0 109.199 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.3 m -74.68 155.94 37.2 Favored 'General case' 0 N--CA 1.495 1.779 0 CA-C-O 121.637 0.732 . . . . 0.0 109.966 179.753 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 51.0 p -66.77 -29.97 70.06 Favored 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.7 t -136.59 68.32 1.43 Allowed 'General case' 0 N--CA 1.497 1.893 0 CA-C-O 121.429 0.633 . . . . 0.0 109.443 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 17' ' ' GLU . 5.1 p -82.83 176.79 9.03 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.805 0.812 . . . . 0.0 110.6 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -58.5 130.85 48.75 Favored 'General case' 0 N--CA 1.491 1.58 0 CA-C-O 121.991 0.901 . . . . 0.0 111.11 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.4 t -84.31 129.18 38.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 42.1 pt -115.87 -6.39 11.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 168.83 -166.05 39.36 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.996 -1.097 . . . . 0.0 110.66 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 47.4 t -151.84 153.82 34.97 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.825 -0.809 . . . . 0.0 109.935 -179.748 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.0 mt -123.26 149.76 44.35 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.794 0.807 . . . . 0.0 109.65 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 23.4 p -74.73 160.61 30.53 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.752 0.787 . . . . 0.0 110.451 -179.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -68.62 155.72 53.36 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 58.15 34.69 24.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 122.046 -0.679 . . . . 0.0 109.889 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 53.2 m -102.4 127.16 49.53 Favored 'General case' 0 N--CA 1.498 1.949 0 CA-C-O 121.968 0.889 . . . . 0.0 109.936 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.6 ttpt -77.0 130.33 37.32 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.535 0.684 . . . . 0.0 109.881 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.2 m -129.96 130.89 66.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 CA-C-O 121.75 0.786 . . . . 0.0 109.674 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 11.1 p -77.19 134.29 38.68 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.455 0.645 . . . . 0.0 109.879 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 96.5 mt -106.23 127.64 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 CA-C-O 121.481 0.658 . . . . 0.0 109.473 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 27.1 m -112.05 -1.06 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -172.99 171.85 44.72 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.789 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 10.0 tm-20 -137.96 146.65 43.44 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.848 -0.795 . . . . 0.0 109.935 -179.499 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 68.7 mm-40 -144.05 109.4 5.11 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-O 121.97 0.891 . . . . 0.0 109.851 179.706 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.12 -135.11 47.73 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.464 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.36 30.52 0.98 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.765 -0.844 . . . . 0.0 108.746 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -134.49 143.42 47.47 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-O 121.531 0.681 . . . . 0.0 109.821 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -108.82 140.46 42.23 Favored 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.898 0.856 . . . . 0.0 109.59 179.342 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 51.1 mtmt -93.59 143.97 25.81 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.686 0.755 . . . . 0.0 109.717 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 41.5 pt -132.94 152.37 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 CA-C-O 121.646 0.736 . . . . 0.0 110.056 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -75.46 93.78 3.02 Favored 'General case' 0 N--CA 1.489 1.506 0 CA-C-O 121.42 0.629 . . . . 0.0 109.787 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -108.78 142.39 39.4 Favored 'General case' 0 N--CA 1.491 1.611 0 CA-C-O 121.828 0.823 . . . . 0.0 109.589 179.624 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 18.5 ptmt -55.03 119.63 5.73 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 121.845 0.831 . . . . 0.0 110.318 -179.697 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.432 ' O ' ' OG ' ' A' ' 52' ' ' SER . . . 110.63 -47.98 0.98 Allowed Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.286 -1.525 . . . . 0.0 109.286 179.58 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.432 ' OG ' ' O ' ' A' ' 51' ' ' GLY . 24.7 m -167.77 -162.44 0.44 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.739 -0.859 . . . . 0.0 110.386 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -100.11 120.2 39.5 Favored 'General case' 0 N--CA 1.497 1.898 0 CA-C-O 121.832 0.825 . . . . 0.0 109.926 -179.157 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -83.03 145.24 23.24 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -108.54 137.33 46.67 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.615 0.721 . . . . 0.0 109.703 179.724 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 15.6 m -140.67 143.99 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 CA-C-O 121.735 0.779 . . . . 0.0 110.237 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.594 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -66.66 146.76 54.12 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-O 121.64 0.734 . . . . 0.0 110.329 -179.716 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 48.3 mtmt -62.94 -34.4 77.4 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 121.318 0.58 . . . . 0.0 109.468 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -51.47 -33.79 32.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.851 -0.53 . . . . 0.0 110.169 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.428 ' CD2' ' HB3' ' A' ' 57' ' ' ALA . 37.9 m-85 -89.57 0.7 56.74 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.567 -0.708 . . . . 0.0 109.831 -179.367 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 5.6 mm -108.84 125.95 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 CA-C-O 121.685 0.755 . . . . 0.0 110.215 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.413 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 64.0 pttt -145.92 163.49 34.97 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.757 0.789 . . . . 0.0 110.536 -179.741 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 57.94 55.02 5.6 Favored 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 121.444 0.64 . . . . 0.0 109.614 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.6 mt -76.02 126.23 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 CA-C-O 121.646 0.736 . . . . 0.0 109.554 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -129.32 145.81 51.31 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.726 0.774 . . . . 0.0 110.169 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.49 ' OD1' ' NZ ' ' A' ' 3' ' ' LYS . 85.5 m-20 -89.89 105.76 18.02 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.705 -0.479 . . . . 0.0 109.705 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.452 ' C ' ' O ' ' A' ' 66' ' ' ASP . 52.3 tp10 34.09 79.25 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 CA-C-O 121.277 0.561 . . . . 0.0 110.153 179.615 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.568 ' O ' HG13 ' A' ' 68' ' ' VAL . 7.5 p -104.99 114.48 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 CA-C-O 121.618 0.723 . . . . 0.0 109.951 -179.481 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.496 HD22 ' N ' ' A' ' 69' ' ' LEU . 4.0 mm? -97.6 -6.62 32.97 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.684 -0.635 . . . . 0.0 109.414 179.56 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 52.5 tp10 57.9 78.18 0.25 Allowed 'General case' 0 N--CA 1.491 1.622 0 CA-C-O 121.689 0.757 . . . . 0.0 109.764 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 72.3 m80 -81.21 145.48 30.96 Favored 'General case' 0 N--CA 1.488 1.472 0 CA-C-O 121.76 0.791 . . . . 0.0 110.123 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 79.8 m80 39.82 83.28 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.634 0 CA-C-O 121.712 0.767 . . . . 0.0 110.057 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 54.0 p-80 -86.57 -16.15 37.71 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 61.6 t-80 -66.35 -44.72 82.46 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.829 -0.544 . . . . 0.0 109.54 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -79.47 142.67 35.65 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-O 121.793 0.806 . . . . 0.0 110.267 -179.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . 0.536 ' CD2' ' H ' ' A' ' 76' ' ' HIS . 4.9 p80 . . . . . 0 N--CA 1.489 1.478 0 CA-C-O 117.844 -1.074 . . . . 0.0 109.686 -179.623 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.41 0 CA-C-O 122.109 0.957 . . . . 0.0 108.566 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -158.18 102.48 1.78 Allowed 'General case' 0 C--N 1.29 -1.996 0 CA-C-O 122.417 1.103 . . . . 0.0 109.868 179.258 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -113.63 156.36 23.83 Favored 'General case' 0 C--N 1.282 -2.357 1 N-CA-C 99.335 -4.32 . . . . 0.0 99.335 174.36 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.06 135.32 29.05 Favored 'General case' 0 N--CA 1.506 2.357 0 C-N-CA 114.944 -2.702 . . . . 0.0 116.574 -173.512 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -105.02 135.82 12.77 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 106.493 -2.643 . . . . 0.0 106.493 177.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 37.1 mm -97.91 121.67 48.7 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.191 -1.182 . . . . 0.0 108.444 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 76.4 t -80.88 132.34 31.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.248 -0.907 . . . . 0.0 109.619 -179.089 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.892 HD22 ' HZ1' ' A' ' 62' ' ' LYS . 43.9 t-20 -144.91 108.38 4.63 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.245 -0.909 . . . . 0.0 109.216 179.753 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 28.5 m -135.84 162.25 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.169 -0.957 . . . . 0.0 110.168 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.6 t -61.65 -43.15 99.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.549 -0.72 . . . . 0.0 110.017 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 57.9 m -123.75 -90.63 0.56 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.432 -0.792 . . . . 0.0 110.245 -179.387 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.9 m -129.71 157.32 42.48 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.539 -0.726 . . . . 0.0 109.771 -179.258 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.9 tp -114.01 130.9 56.51 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.454 -0.778 . . . . 0.0 109.009 179.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -88.29 144.7 26.27 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.421 -0.8 . . . . 0.0 109.614 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 70.8 t -92.35 131.32 39.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.28 -0.888 . . . . 0.0 108.901 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.658 ' NH2' ' H ' ' A' ' 57' ' ' ALA . 84.4 mtm-85 -107.61 136.39 47.45 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.472 -0.767 . . . . 0.0 109.572 -179.464 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -93.48 90.12 6.57 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.162 -0.961 . . . . 0.0 110.049 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 130.16 -174.09 19.7 Favored Glycine 0 N--CA 1.499 2.841 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 179.289 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -105.01 31.19 4.99 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.574 -0.957 . . . . 0.0 109.22 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 36.0 m -134.02 148.87 51.15 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.363 -0.836 . . . . 0.0 109.674 -179.794 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 40.2 p -67.78 -30.87 70.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.302 -0.874 . . . . 0.0 110.285 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 35.9 t -75.5 7.22 3.81 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.273 -0.892 . . . . 0.0 109.605 -179.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.8 m -65.17 148.95 50.77 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.363 -0.835 . . . . 0.0 110.091 -179.43 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -71.46 142.86 50.21 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.488 -0.757 . . . . 0.0 110.343 -179.578 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 20.4 t -85.64 128.32 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.449 -0.782 . . . . 0.0 109.293 179.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 23.9 pt -107.7 -2.89 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 121.312 -0.867 . . . . 0.0 109.908 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.13 178.87 39.23 Favored Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.007 179.662 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -134.23 153.42 51.86 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.542 -0.975 . . . . 0.0 109.248 179.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 91.7 mt -123.98 146.4 48.53 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 121.321 -0.862 . . . . 0.0 109.497 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 28.0 t -79.75 163.53 24.4 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.435 -0.791 . . . . 0.0 110.635 -179.07 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -66.03 161.7 43.83 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.524 -1.031 . . . . 0.0 110.524 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 99.6 m-20 54.75 31.96 16.51 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.578 -0.954 . . . . 0.0 109.595 -179.762 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.2 m -100.09 126.25 46.29 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.432 -0.793 . . . . 0.0 108.957 179.609 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -79.49 132.2 36.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.32 -0.862 . . . . 0.0 109.501 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 14.9 m -127.03 131.86 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.394 -0.816 . . . . 0.0 108.991 179.451 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 45.9 p -75.4 134.45 40.92 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-O 121.243 0.545 . . . . 0.0 109.87 -179.184 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 95.3 mt -111.35 128.89 67.54 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 CA-C-O 121.391 0.615 . . . . 0.0 109.379 179.508 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 35.3 m -113.29 -1.57 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.706 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -179.48 -178.67 48.51 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -142.84 159.45 42.22 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.256 -1.144 . . . . 0.0 109.676 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -154.53 113.0 3.56 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.137 -0.977 . . . . 0.0 109.759 179.496 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 59.97 -141.94 47.57 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.414 -1.075 . . . . 0.0 110.414 179.312 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.44 24.92 1.53 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.572 -0.958 . . . . 0.0 109.324 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -129.75 147.78 51.57 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.545 -0.722 . . . . 0.0 109.087 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -103.94 142.8 33.78 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.465 -0.772 . . . . 0.0 109.607 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -91.69 128.0 37.35 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 14.2 pt -129.89 154.02 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.296 -0.878 . . . . 0.0 109.391 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.413 ' OE1' ' CD2' ' A' ' 53' ' ' HIS . 49.0 tp10 -82.88 110.99 18.36 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.464 -0.772 . . . . 0.0 109.148 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.577 ' O ' ' N ' ' A' ' 51' ' ' GLY . 79.1 t80 -107.35 117.49 34.21 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.398 -0.814 . . . . 0.0 109.464 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt 44.23 -87.44 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.549 -0.72 . . . . 0.0 110.106 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 49' ' ' TYR . . . -123.51 -34.0 0.78 Allowed Glycine 0 N--CA 1.497 2.741 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 15.6 p -89.43 169.43 11.39 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.335 -1.097 . . . . 0.0 109.822 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.413 ' CD2' ' OE1' ' A' ' 48' ' ' GLU . 73.2 m80 -96.46 115.63 27.75 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.533 -0.729 . . . . 0.0 109.124 179.645 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.96 153.12 26.56 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -121.01 138.66 54.06 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.708 -0.877 . . . . 0.0 109.073 179.661 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -136.58 152.59 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.307 -0.87 . . . . 0.0 109.495 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.658 ' H ' ' NH2' ' A' ' 16' ' ' ARG . . . -75.03 147.26 40.86 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.523 -0.736 . . . . 0.0 110.65 -179.363 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -70.98 -14.11 62.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.431 -0.793 . . . . 0.0 109.444 179.187 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -65.47 -37.9 88.2 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.447 -0.783 . . . . 0.0 110.292 -179.222 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.519 ' C ' HD12 ' A' ' 61' ' ' ILE . 74.1 m-85 -96.81 -7.55 33.35 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.24 -0.912 . . . . 0.0 110.397 -179.068 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.519 HD12 ' C ' ' A' ' 60' ' ' TYR . 1.5 mp -108.17 129.08 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.062 0 O-C-N 121.366 -0.834 . . . . 0.0 108.931 -179.502 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.892 ' HZ1' HD22 ' A' ' 8' ' ' ASN . 26.7 pttm -145.86 -178.81 6.3 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.201 -0.937 . . . . 0.0 109.708 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 43.2 t0 60.73 46.67 8.82 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.609 -0.682 . . . . 0.0 109.368 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.7 mt -75.56 131.37 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.02 179.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.8 mtpm? -107.32 146.01 32.09 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.443 -0.786 . . . . 0.0 110.144 -179.198 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -73.03 149.62 43.08 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.587 -0.696 . . . . 0.0 110.033 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 50.1 tp10 -60.65 -81.13 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.474 -0.766 . . . . 0.0 109.755 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.2 m -84.16 132.76 30.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.183 -0.948 . . . . 0.0 110.271 -179.242 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.539 ' N ' HD12 ' A' ' 69' ' ' LEU . 8.9 mp -88.14 -2.31 58.53 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.517 -0.74 . . . . 0.0 109.442 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -77.0 135.04 38.67 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.28 -0.887 . . . . 0.0 109.992 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.502 ' C ' ' H ' ' A' ' 73' ' ' HIS . 97.8 m-70 -104.87 13.44 31.17 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.555 -0.716 . . . . 0.0 109.079 179.584 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 54.88 4.81 0.08 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.771 -0.581 . . . . 0.0 109.911 -179.581 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.502 ' H ' ' C ' ' A' ' 71' ' ' HIS . 62.0 t-80 -142.18 116.48 9.53 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.279 -0.888 . . . . 0.0 109.399 179.62 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . 0.472 ' NE2' ' OXT' ' A' ' 76' ' ' HIS . 84.4 t60 -166.94 85.12 0.26 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.229 -0.92 . . . . 0.0 109.043 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.428 ' O ' ' O ' ' A' ' 76' ' ' HIS . 59.5 t-80 -65.86 -43.06 89.51 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.515 -0.741 . . . . 0.0 109.963 -179.47 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . 0.472 ' OXT' ' NE2' ' A' ' 74' ' ' HIS . 63.3 t-80 . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 118.064 -0.97 . . . . 0.0 109.901 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.1 tm-20 -89.11 133.05 34.53 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.375 -0.828 . . . . 0.0 110.026 -179.356 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.3 mppt? -137.04 151.88 49.44 Favored 'General case' 0 N--CA 1.494 1.76 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.326 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 68.9 p -122.74 137.68 54.84 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.621 -0.674 . . . . 0.0 109.765 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -119.49 131.09 8.81 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 5.6 mm -86.87 122.53 38.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.411 -1.052 . . . . 0.0 109.431 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 80.7 t -79.13 131.46 34.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.449 -0.782 . . . . 0.0 110.071 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 96.2 m-20 -121.48 101.77 7.83 Favored 'General case' 0 N--CA 1.497 1.925 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 29.4 m -139.98 160.95 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.425 -0.797 . . . . 0.0 110.025 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 80.6 p -81.63 -11.65 59.02 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.0 p -149.07 -70.21 0.21 Allowed 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.455 -0.778 . . . . 0.0 109.267 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 98.6 p -153.95 168.89 24.89 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.904 . . . . 0.0 110.116 -179.598 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 44.7 tp -115.47 131.03 57.06 Favored 'General case' 0 N--CA 1.498 1.925 0 CA-C-O 121.479 0.657 . . . . 0.0 109.495 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -83.92 135.25 34.55 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.484 -0.76 . . . . 0.0 110.196 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 87.3 t -90.36 131.74 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.478 -0.764 . . . . 0.0 109.218 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.602 HH21 ' N ' ' A' ' 57' ' ' ALA . 87.5 mtm180 -105.55 133.89 49.56 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.493 -0.754 . . . . 0.0 110.187 -179.601 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -67.53 -46.76 71.86 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.561 -0.712 . . . . 0.0 109.673 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.52 178.68 30.23 Favored Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.182 -1.167 . . . . 0.0 110.182 -179.311 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -92.95 21.28 5.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.616 -0.932 . . . . 0.0 108.681 179.536 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.1 m -79.59 165.2 23.18 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.543 -0.723 . . . . 0.0 110.407 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.7 m -63.19 -46.17 88.34 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.691 -0.631 . . . . 0.0 109.976 -179.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.8 m -129.44 71.13 1.43 Allowed 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.484 -0.76 . . . . 0.0 109.014 -179.553 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.46 -180.0 7.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.639 -0.663 . . . . 0.0 110.136 -179.545 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -67.05 133.12 49.26 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.617 0.723 . . . . 0.0 110.389 -179.453 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 74.8 t -81.15 129.19 37.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.482 -0.762 . . . . 0.0 109.536 179.696 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.407 HD12 ' CD2' ' A' ' 49' ' ' TYR . 41.1 pt -109.99 -5.09 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.723 -0.611 . . . . 0.0 109.489 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.09 177.39 38.15 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.489 -1.339 . . . . 0.0 110.284 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -132.23 155.71 47.78 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.73 -0.865 . . . . 0.0 109.397 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 88.6 mt -123.55 150.3 44.18 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-O 121.456 0.646 . . . . 0.0 109.801 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.4 m -71.82 152.54 42.59 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 121.522 0.677 . . . . 0.0 110.195 -179.537 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.451 ' C ' ' H ' ' A' ' 33' ' ' THR . . . -68.07 162.83 48.61 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 11.8 m120 56.46 5.0 0.17 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.979 -0.719 . . . . 0.0 109.854 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.451 ' H ' ' C ' ' A' ' 31' ' ' GLY . 35.3 m -81.26 137.1 35.85 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.264 -0.898 . . . . 0.0 110.138 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -84.96 139.88 31.49 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.498 -0.751 . . . . 0.0 110.176 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 19.8 m -127.0 132.16 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.625 -0.672 . . . . 0.0 109.403 179.562 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 44.5 m -65.67 128.21 35.03 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.725 -0.609 . . . . 0.0 110.047 -179.496 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 97.1 mt -115.55 125.13 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 CA-C-O 121.391 0.615 . . . . 0.0 109.631 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.61 HG23 ' N ' ' A' ' 39' ' ' GLY . 34.6 m -112.96 -47.88 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 179.39 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.61 ' N ' HG23 ' A' ' 38' ' ' VAL . . . -95.06 162.58 23.95 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -142.01 125.63 16.85 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.494 -1.003 . . . . 0.0 109.298 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.518 ' O ' ' N ' ' A' ' 43' ' ' ALA . 83.1 tt0 -114.91 142.95 45.89 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.674 ' O ' ' HB2' ' A' ' 43' ' ' ALA . . . -65.71 59.52 0.13 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.487 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.674 ' HB2' ' O ' ' A' ' 42' ' ' GLY . . . 160.58 -31.7 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.711 -0.876 . . . . 0.0 108.715 179.707 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -134.68 160.91 36.67 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.534 -0.729 . . . . 0.0 110.204 -178.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.7 m-85 -114.13 140.25 48.67 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.589 -0.694 . . . . 0.0 109.688 179.679 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -90.68 129.95 36.73 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 -179.743 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.9 pt -127.9 157.04 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 CA-C-O 121.571 0.701 . . . . 0.0 110.1 -179.685 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -86.93 93.98 9.47 Favored 'General case' 0 N--CA 1.49 1.561 0 CA-C-O 121.431 0.634 . . . . 0.0 109.927 -179.485 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.407 ' CD2' HD12 ' A' ' 26' ' ' ILE . 91.5 t80 -86.89 140.07 30.0 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.399 -0.813 . . . . 0.0 109.467 179.771 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.8 tttm -54.63 100.53 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.422 -0.799 . . . . 0.0 110.05 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 124.51 -33.94 3.63 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 20.7 t -171.11 -168.58 0.66 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.214 -1.168 . . . . 0.0 109.942 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 5.9 m170 -100.69 120.16 39.66 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.519 -0.738 . . . . 0.0 109.641 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.09 161.37 20.85 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -118.09 147.06 43.64 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.737 -0.86 . . . . 0.0 109.626 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.2 m -139.27 153.32 24.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.699 -0.626 . . . . 0.0 109.794 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.602 ' N ' HH21 ' A' ' 16' ' ' ARG . . . -73.68 141.34 46.44 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.574 -0.704 . . . . 0.0 110.59 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -64.61 -12.25 43.65 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.681 -0.637 . . . . 0.0 110.016 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 45.1 tp10 -68.87 -35.97 77.54 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -0.9 . . . . 0.0 110.546 -179.228 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -93.52 2.25 56.48 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.103 -0.998 . . . . 0.0 110.147 -178.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 42.8 mm -105.67 128.91 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.483 -0.761 . . . . 0.0 109.616 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -143.63 157.09 44.67 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.56 -0.712 . . . . 0.0 109.993 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 37.5 t0 64.39 45.68 3.7 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.615 0.721 . . . . 0.0 109.675 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 97.1 mt -67.83 147.12 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.68 -0.638 . . . . 0.0 110.071 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -80.61 140.19 35.86 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.433 -0.792 . . . . 0.0 110.548 -178.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -62.57 145.21 54.96 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.46 0.648 . . . . 0.0 110.746 -179.377 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.522 ' H ' ' CD ' ' A' ' 67' ' ' GLU . 0.0 OUTLIER -132.19 -83.66 0.49 Allowed 'General case' 0 N--CA 1.498 1.927 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.881 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.514 ' H ' ' CD ' ' A' ' 67' ' ' GLU . 7.9 p -167.66 131.76 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.47 -0.768 . . . . 0.0 109.787 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.577 ' N ' HD12 ' A' ' 69' ' ' LEU . 9.3 mp -79.27 141.62 36.9 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.517 -0.74 . . . . 0.0 110.41 -179.447 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.44 ' O ' ' CD2' ' A' ' 72' ' ' HIS . 96.7 mt-10 55.37 103.11 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 CA-C-O 121.662 0.744 . . . . 0.0 110.181 179.612 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 26.9 p-80 -75.22 -11.34 60.05 Favored 'General case' 0 N--CA 1.487 1.416 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.694 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.44 ' CD2' ' O ' ' A' ' 70' ' ' GLU . 70.4 m-70 60.96 99.02 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 CA-C-O 121.463 0.649 . . . . 0.0 109.943 179.509 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.532 ' CD2' ' H ' ' A' ' 73' ' ' HIS . 8.2 p80 -81.57 1.37 34.03 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . 0.519 ' ND1' ' CE1' ' A' ' 73' ' ' HIS . 44.9 p-80 -149.24 163.37 37.86 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.233 -0.917 . . . . 0.0 110.026 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 -113.81 139.03 49.48 Favored 'General case' 0 N--CA 1.493 1.692 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 83.9 t60 . . . . . 0 N--CA 1.489 1.497 0 CA-C-O 117.847 -1.073 . . . . 0.0 109.043 -179.981 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -67.81 137.54 55.44 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.764 0.792 . . . . 0.0 110.423 -179.208 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 52.4 mtmt -137.66 152.93 49.82 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.53 -0.732 . . . . 0.0 109.253 179.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 50.6 p -122.8 124.54 43.55 Favored 'General case' 0 N--CA 1.496 1.872 0 CA-C-O 121.829 0.823 . . . . 0.0 109.357 179.52 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -101.78 133.69 11.45 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 -179.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 34.4 mm -84.29 126.62 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.7 -0.882 . . . . 0.0 110.009 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 73.1 t -82.89 98.6 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.376 -0.827 . . . . 0.0 109.317 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -101.47 107.24 18.49 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.508 -0.745 . . . . 0.0 109.889 -179.603 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 m -141.09 144.3 26.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.299 -0.876 . . . . 0.0 109.575 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 27.5 t -66.97 -13.78 62.19 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-O 121.44 0.638 . . . . 0.0 109.497 179.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.484 ' OG ' ' N ' ' A' ' 12' ' ' SER . 91.1 p -141.3 -103.84 0.14 Allowed 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.161 -0.962 . . . . 0.0 110.231 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.484 ' N ' ' OG ' ' A' ' 11' ' ' SER . 57.8 m -127.49 157.38 40.24 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.464 -0.773 . . . . 0.0 110.191 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 36.5 tp -113.39 128.81 56.58 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 121.723 0.773 . . . . 0.0 109.875 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 99.9 m-20 -85.07 150.8 24.61 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.479 0.657 . . . . 0.0 110.025 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.4 t -104.41 129.94 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.423 -0.798 . . . . 0.0 109.276 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -105.28 132.81 51.01 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.546 0.688 . . . . 0.0 109.816 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -71.23 -37.22 72.01 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-O 121.819 0.818 . . . . 0.0 109.433 179.635 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -100.73 179.44 29.02 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -179.392 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -94.31 -1.44 53.87 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.193 -1.18 . . . . 0.0 108.825 179.393 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.9 m -83.36 149.82 26.48 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.312 -0.867 . . . . 0.0 110.196 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 97.7 m -65.0 -44.33 89.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.415 -0.803 . . . . 0.0 110.078 179.489 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 76.5 p -78.49 16.66 0.78 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.078 -1.014 . . . . 0.0 109.529 -179.448 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.8 m -63.64 149.65 46.03 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.212 -0.93 . . . . 0.0 110.251 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -70.96 138.25 49.86 Favored 'General case' 0 N--CA 1.488 1.47 0 CA-C-O 121.981 0.895 . . . . 0.0 110.528 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 75.0 t -87.37 130.17 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 CA-C-O 121.697 0.761 . . . . 0.0 109.925 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 37.4 pt -103.61 -4.57 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.007 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 171.91 -163.96 36.48 Favored Glycine 0 N--CA 1.493 2.451 0 C-N-CA 119.497 -1.335 . . . . 0.0 110.434 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 95.3 p -156.6 163.03 39.81 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.469 -1.019 . . . . 0.0 109.663 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 89.7 mt -124.79 150.86 45.87 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-O 121.694 0.759 . . . . 0.0 109.903 -179.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 12.3 p -76.19 164.72 25.81 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.062 0.934 . . . . 0.0 111.038 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.23 152.81 43.48 Favored Glycine 0 N--CA 1.489 2.222 0 CA-C-O 122.105 0.836 . . . . 0.0 111.665 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 67.1 t30 57.89 32.19 21.6 Favored 'General case' 0 N--CA 1.494 1.744 0 CA-C-O 121.635 0.731 . . . . 0.0 110.147 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 24.6 m -89.98 126.95 35.93 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.154 -0.966 . . . . 0.0 109.539 179.044 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -82.77 133.17 35.15 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.337 -0.852 . . . . 0.0 109.624 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.0 m -125.85 133.62 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 CA-C-O 121.791 0.805 . . . . 0.0 110.03 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 85.5 m -80.37 127.53 32.49 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.413 0.625 . . . . 0.0 109.78 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 92.8 mt -105.41 126.72 60.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 CA-C-O 121.466 0.65 . . . . 0.0 109.602 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 18.5 m -112.68 -1.97 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.56 177.82 45.75 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.613 -1.279 . . . . 0.0 110.364 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -141.72 159.63 41.83 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.356 -1.084 . . . . 0.0 109.871 -179.786 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -154.32 109.42 3.11 Favored 'General case' 0 N--CA 1.489 1.497 0 CA-C-O 121.684 0.754 . . . . 0.0 109.158 179.37 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.34 -137.47 45.0 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -85.06 23.28 1.26 Allowed 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.458 -1.024 . . . . 0.0 108.979 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -130.44 145.3 51.8 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.415 -0.803 . . . . 0.0 109.79 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.4 m-85 -108.5 139.66 42.94 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.611 0.719 . . . . 0.0 109.41 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -90.65 129.95 36.71 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.558 -0.714 . . . . 0.0 109.304 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.7 pt -129.03 153.53 38.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 CA-C-O 121.708 0.765 . . . . 0.0 109.804 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -81.02 99.66 8.56 Favored 'General case' 0 N--CA 1.49 1.531 0 CA-C-O 121.674 0.75 . . . . 0.0 109.857 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.404 ' CD2' ' N ' ' A' ' 51' ' ' GLY . 88.0 t80 -81.2 144.13 31.83 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.559 -0.713 . . . . 0.0 110.021 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 51.9 mtmt -46.85 -47.22 21.26 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.461 -0.775 . . . . 0.0 110.144 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.404 ' N ' ' CD2' ' A' ' 49' ' ' TYR . . . -69.34 -39.93 80.81 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 179.797 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 21.4 m -171.62 -110.78 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.152 -1.205 . . . . 0.0 109.325 -179.536 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 73.2 m80 -127.56 112.56 15.04 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-O 121.801 0.81 . . . . 0.0 109.352 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.84 154.29 19.94 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 -179.681 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -120.87 139.96 52.45 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.606 -0.938 . . . . 0.0 109.712 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.2 m -135.96 152.55 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.55 -0.719 . . . . 0.0 109.195 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 149.8 37.93 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-O 121.861 0.839 . . . . 0.0 110.667 -179.528 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 62.2 pttt -65.8 -15.43 62.87 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.57 0.7 . . . . 0.0 109.977 179.4 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.443 ' OE2' ' CE2' ' A' ' 60' ' ' TYR . 14.4 pt-20 -67.28 -35.73 80.1 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.243 -0.911 . . . . 0.0 110.199 -179.563 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.443 ' CE2' ' OE2' ' A' ' 59' ' ' GLU . 54.9 m-85 -90.79 -1.69 57.84 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.07 -1.019 . . . . 0.0 109.26 -179.407 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 39.3 mm -110.86 131.72 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.397 -0.815 . . . . 0.0 109.428 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.486 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 63.8 tttp -130.45 158.05 40.96 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.486 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 11.7 t0 79.81 -59.02 0.35 Allowed 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.393 0.616 . . . . 0.0 109.529 179.518 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.414 ' O ' HG22 ' A' ' 64' ' ' ILE . 82.1 mt 43.77 65.91 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 CA-C-O 121.741 0.782 . . . . 0.0 109.268 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 38.0 ttmt -142.55 144.45 32.92 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.258 -0.901 . . . . 0.0 110.065 -179.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.478 ' OD1' ' N ' ' A' ' 67' ' ' GLU . 68.1 t0 -63.04 137.63 58.32 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 121.787 0.803 . . . . 0.0 110.316 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.478 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 20.3 pt-20 -50.95 143.35 10.34 Favored 'General case' 0 N--CA 1.494 1.745 0 CA-C-O 121.589 0.709 . . . . 0.0 110.569 -179.489 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 6.9 m -103.25 131.08 52.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 CA-C-O 121.739 0.781 . . . . 0.0 110.266 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.595 ' N ' HD12 ' A' ' 69' ' ' LEU . 9.2 mp -76.39 149.29 36.94 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.773 0.797 . . . . 0.0 110.235 -179.7 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -44.97 146.39 0.82 Allowed 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.951 0.881 . . . . 0.0 110.858 -179.407 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -72.85 127.25 31.99 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.694 0.759 . . . . 0.0 110.735 -179.412 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.499 ' CG ' ' N ' ' A' ' 73' ' ' HIS . 80.9 t60 -160.59 172.78 16.55 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.559 -0.713 . . . . 0.0 109.539 179.767 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.499 ' N ' ' CG ' ' A' ' 72' ' ' HIS . 95.1 m-70 -61.52 -36.87 81.76 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.433 -0.792 . . . . 0.0 109.639 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 58.6 t-80 -65.07 -39.32 93.06 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.207 -0.933 . . . . 0.0 109.379 179.692 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 24.9 t-80 -69.44 130.02 41.35 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.889 . . . . 0.0 109.919 -179.457 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 . . . . . 0 C--N 1.302 -1.475 0 CA-C-O 118.102 -0.951 . . . . 0.0 109.634 179.985 . . . . . . . . 0 0 . 1 stop_ save_